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1 Abstract 
The human genome comprises approximately 20,000-25,000 genes. The genes 
known to be involved in Alzheimer’s disease (AD) are the amyloid precursor protein 
(AβPP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (APOE). 
However, which additional genes are involved in its etiology is a controversial topic. 
C99, the C-terminal cleavage product of AβPP is the direct, in vivo occurring, 
precursor of Aβ-peptides. It is proteolytically processed, resulting in the generation of 
several Aβ-peptides. In contrast to the form with 40 amino acids (Aβ40), which is 
regarded as the physiological form, the variant with 42 amino acids (Aβ42) is thought 
to be the pathogenic form triggering the pathophysiological cascade in AD. In order 
to produce different Aβ42 and Aβ40 levels, the Aβ precursors C99I45F and C99V50F 
(two C99 mutants, known to generate different amounts of Aβ42 and Aβ40) were 
overexpressed in human neuroblastoma cells. This resulted, due to varying 
intracellular cleavage by γ-secretase, in different Aβ42 and Aβ40 levels accompanied 
by the generation of their respective APP intracellular domains (AICDs). The goal of 
this thesis was to obtain information about effects of the different C99 cleavage 
products. Therefore different C99 mutants were overexpressed in the human 
neuroblastoma cell line SH-SY5Y resulting in different Aβ42/Aβ40 levels and a 
genome-wide transcriptomic (Affymetrix) and proteomic response of these cells was 
monitored. As was expected, many genes previously reported to be associated with 
AD were found to be differentially expressed. Importantly, further genes, not yet 
linked to AD, have been identified and new cross-talk between genes/proteins has 
been suggested. The genes assumed to play a predominant role in response to 
altered C99 cleavage products are indicated in brackets and full gene names are to 
be found in Chapter 10, Abbreviations. In this thesis, it was demonstrated that an 
increased Aβ42/Aβ40 ratio, but not a decreased Aβ42/Aβ40 ratio, induced upregulation 
of the retinoic acid binding protein CRABP1 on the transcript level and on the protein 
level. This, in turn, reduced the responsiveness of SH-SY5Y cells to retinoic acid, 
which reduced their differentiation potential. Knockdown of the increased CRABP1 
levels by siRNA rescued the differentiation potential of these cells. These findings, in 
conjunction with known functional properties of CRABP1, suggest that up-regulated 
CRABP1 might, possibly also in vivo, prevent the terminal differentiation of neural 
precursor cells into functional neurons (disturbed neurogenesis). Furthermore, the 
phosphorylation status of proteins was determined providing further insights into 
signal transduction pathways. The IGF2/IGF1R/PKC together with the PI3K/AKT 
survival pathway was found to be inversely regulated by an altered Aβ42/Aβ40 ratio 
(IGF2, IGFBP5, PKC, AKT1). The chromosomal locus 11p15.5 was identified as a 
hot spot: an increased Aβ42/Aβ40 ratio, in contrast to a decreased one, down-
regulated the IGF2-H19 imprinted region (chr.11p15.5) indicating that imprinting may 
play a role in AD. In consequence of an increased Aβ42/Aβ40 ratio, GSK3β was 
hyperphosphorylated on the activating site Y216, and tau441 showed stronger 
phosphorylation on S199/S202, two sites reported to turn tau, upon phosphorylation, 
into a protein with possible toxic properties. APLP2 was found to be up-regulated as 
a consequence of an increased Aβ42/Aβ40 ratio, whereas APLP1 was up-regulated in 
response to a decreased Aβ42/Aβ40 ratio, indicating inverse Aβ-dependent regulation 
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of APLP1/2 expression. In response to an increased Aβ42/Aβ40 ratio, expression 
levels of a set of genes were altered in such a way that a tendency towards faster 
blood coagulation and reduced fibrinolysis could be recognized on the transcript level 
(PLAT, TFPI2, FGB, SERPINF1, SERPINE2). This view is supported by observations 
in AD patients who have a greater risk of strokes and diminished cerebral perfusion. 
As Aβ-inducible candidate kinases possibly involved in tau-phosphorylation, DYRK1, 
CDKL1, CDKL5, CDK6, DCAMKL1, ERK1 and PFKP were identified due to their 
altered expression levels (or phosphorylation status for ERK1). Indeed, previous 
studies demonstrated that Aβ42 induces tau hyperphosphorylation in animal models.  
PFKP, which plays a key role in glycolysis, was found to be dysregulated in 
consequence of a changed Aβ42/Aβ40 ratio and could possibly reflect disturbed 
regulation of glucose and ATP metabolism in brains of AD patients. A potential 
function was assigned to the hitherto uncharacterized KIAA0125, namely to be a 
counter player of neurogenin 2, which was co-regulated with C99 and neuronatin. 
Furthermore, the following areas were distinctly affected by a changed Aβ42/Aβ40 
ratio (for most genes determined on the transcript level and for some additionally on 
the protein level): Copper transport/metabolism with special regard to ATP7A, several 
(metallo) proteases (ADAMTS9, ADAMTS3, MMP8, PREP, ECEL1, CTSD, 
PRSS12), metalloprotease inhibitors (TIMP3, TIMP1), extracellular matrix proteins or 
related enzymes thereof (RELN, COL4A1, COL4A2, HS3ST2), cytoskeletal proteins 
(ACTA2, ACTN1), mitochondrial respiratory chain components (NDUFB9), 
cytochromes (b-561 and b-245), dopamine, serotonin and glutamate -metabolism 
with special regard to DDC, HMP19 and GAD1. Effects of BDNF (non-catalytic 
isoform of TRKB), membrane fusion of neurotransmitter containing vesicles (STX3A, 
SYN2), Ca2+ influx (AMPA2), acetylcholine receptors (CHRNA7), Notch signaling 
(DNER, TLE1, TLE2, JAG1, CUTL2), TGFβ signaling (TGFB2, TGFBR2, BAMBI, 
BMP7), WNT signaling (DKK2, DKK4), G protein signaling (RGS4) and ERK/MEK 
signaling (ERK1, MEK1). Growth cone guidance, synaptogenesis and dendritic 
branching are expected to be impaired as consequence of an increased Aβ42/Aβ40 
ratio but improved as a result of a decreased one (SEMA3A, SEMA3C, L1CAM, PTN, 
SLIT1). Further genes involved in the following areas were distinctly influenced by a 
changed Aβ42/Aβ40 ratio: Glutamate/ammonia metabolism (GLUL, GLS), urea cycle 
(ASS), cell cycle regulation (CCND1, CDKN1A), glucocorticoid regulated kinase 
(SGK), receptors (PTGER2, EGFR, AMPA2, AMPA3, GRM7, GRM8c, GLRB, 
GABRB3), long term potentiation (CREB1), axonal transport (DNCLI2), angiogenesis 
(HGF, VEGF), T-cell receptors and connected transcription factors (T-cell receptor α 
and δ locus, GATA3), lipoprotein associated proteins or adaptor proteins hereof 
(LRP4, PDZK1), vesicular transport of organelles and microtubule association (VMP), 
transcription factors (PBX1, SHOX2) and stress-related factors (ADRB1). Taken 
together, the identified genes, proteins and pathways have given new and deeper 
insight into the effects of different C99 cleavage products and they have provided 
new hypotheses for the pathological mechanisms of AD. Furthermore they are 
possible candidates for genetic risk factors and may be helpful in explaining the 
mechanisms of non-genetic risk factors. The gene expression pattern, specific for an 
increased Aβ42/Aβ40 ratio, could be useful, together with clinical data, for the 
diagnosis of AD. Finally, some of the identified transcripts, proteins and pathways 
might turn out to be suitable drug targets.     
  Zusammenfassung 
 
 
3
2 Zusammenfassung 
Das humane Genom umfasst ca. 20.000-25.000 Gene. Die Gene, für die eine 
Beteiligung an der Alzheimer Krankheit (AK) bekannt ist, sind das Amyloid Precursor 
Protein (AβPP), Presenilin 1 (PS1), Presenilin 2 (PS2) und Apolipoprotein E (APOE). 
Es wird kontrovers diskutiert, welche weiteren Gene an der Ätiologie der AK beteiligt 
sind. C99, das C-terminale Spaltprodukt von AβPP, ist das direkte, in vivo 
vorkommende Vorläufer-Protein der Aβ-peptide. Es wird proteolytisch prozessiert, 
wobei verschiedene Aβ-peptide gebildet werden. Im Gegensatz zu der Form mit 40 
Aminosäuren (Aβ40), die als physiologische Aβ-Form betrachtet wird, glaubt man von 
der Variante mit 42 Aminosäuren (Aβ42), dass es sich um die pathogene Form 
handelt, welche die pathophysiologische Kaskade der AK auslöst. Um verschiedene 
Aβ42 und Aβ40 Mengen zu bilden, wurden die Aβ-Vorläufer C99I45F und C99V50F 
(zwei C99-Mutanten, die dafür bekannt sind, verschiedene Aβ42 und Aβ40 Mengen zu 
bilden) in humanen Neuroblastomzellen überexprimiert. Daraus resultierten, in Folge 
variierender intrazellulärer Spaltung durch die γ-Sekretase, unterschiedliche Aβ42- 
und Aβ40-Mengen und die miteinhergehende Bildung der entsprechenden 
intrazellulären Domänen (AICD). Das Ziel dieser Arbeit war es, neue Einsichten in 
die pathologischen Mechanismen der AK als Konsequenz der veränderten C99-
Spaltprodukte zu erhalten. Deshalb wurde die Reaktion der humanen 
Neuroblastomzellinie SH-SY5Y auf verschiedene, überexprimierende Aβ42/Aβ40 
Mengen genomweit auf Transkriptom-Ebene (Affymetrix) und auf Proteom-Ebene 
untersucht. Wie zu erwarten war, wurde eine Vielzahl von Genen als differentiell 
exprimiert identifiziert, die zuvor in anderen Studien als AK-assoziiert gefunden 
wurden. Entscheidend war jedoch die Entdeckung weiterer Gene, für die bisher noch 
keine Verbindung zur AK hergestellt wurde. Hierdurch wurden neue 
Wechselwirkungen („Cross-Talk“) zwischen Genen/Proteinen ersichtlich. Die Gene, 
für die eine vorherrschende Rolle als Antwort auf veränderte C99 Spaltprodukte 
angenommen wird, sind in Klammern angegeben und deren vollständige Gennamen 
sind in Kapitel 10, Abkürzungsverzeichnis, zu finden. In dieser Arbeit wurde gezeigt, 
dass das Retinsäure-bindende Protein CRABP1 in Folge eines erhöhten, jedoch 
nicht in Folge eines erniedrigten Aβ42/Aβ40-Verhältnisses, auf Transkript- und 
Proteinebene heraufreguliert wurde. Dies wiederum erniedrigte die Ansprechbarkeit 
der SH-SY5Y Zellen auf Retinsäure, wodurch deren Differenzierungspotential 
reduziert wurde. „Knockdown“ des heraufregulierten CRABP1 stellte das 
Differenzierungspotential dieser Zellen wieder her. Diese Entdeckung, in Verbindung 
mit den bisher bekannten funktionellen Eigenschaften von CRABP1, könnte 
möglicherweise auch in vivo ein wichtiger Mechanismus sein, bei dem CRABP1 die 
terminale Differenzierung von neuralen Vorläuferzellen in  funktionelle Neuronen 
verhindern könnte (gestörte Neurogenese). Weiterhin wurde der 
Phosphorylierungsstatus von Proteinen bestimmt, wodurch weitere Einsichten in 
Signaltransduktionswege ersichtlich wurden. Der IGF2/IGF1R/PKC- zusammen mit 
dem PI3K/AKT-Signaltrans-duktionsweg wurde durch ein verändertes Aβ42/Aβ40-
Verhältnis invers reguliert (IGF2, IGFBP5, PKC, AKT1). Der chromosomale Lokus 
11p15.5 wurde als „hot spot” identifiziert: ein erhöhtes Aβ42/Aβ40-Verhältnis, im 
Gegensatz zu einem erniedrigten, regulierte die „IGF2-H19 imprinted region“ 
(chr.11p15.5) herunter, was darauf hindeutet, dass genomische Prägung (Imprinting) 
bei der AK eine Rolle spielen könnte. In Folge eines erhöhten Aβ42/Aβ40-
Verhältnisses wurde GSK3β an der aktivierenden Stelle Y216 hyperphosphoryliert 
und Tau441 zeigte stärkere Phosphorylierung an S199/S202 zwei Stellen, von denen 
angenommen wird, Tau durch Phosphorylierung, in ein Protein mit evtl. toxischen 
Eigenschaften zu überführen. APLP2 wurde in Folge eines erhöhten Aβ42/Aβ40-
Verhältnisses heraufreguliert, wohingegen APLP1 in Folge eines erniedrigten 
Aβ42/Aβ40-Verhältnisses heraufreguliert wurde, was auf eine inverse, Aβ-abhängige 
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Regulation von APLP1/2 hindeutet. Als Antwort auf ein erhöhtes Aβ42/Aβ40-Verhältnis 
änderte sich die Expression einer Gruppe von Genen so, dass eine Tendenz zu 
schnellerer Blutgerinnung, bei gleichzeitig verlangsamter Fibrinolyse (PLAT, TFPI2, 
FGB, SERPINF1, SERPINE2) auf Transkriptebene zu erkennen war. Diese 
Sichtweise wird durch Beobachtungen an Alzheimer Patienten unterstützt, die ein 
größeres Risiko für Schlaganfälle und verminderte cerebrale Durchblutung 
aufweisen. Als Aβ-induzierbare Kandidaten für Kinasen, die Tau phosphorylieren 
könnten, wurden DYRK1, CDKL1, CDKL5, CDK6, DCAMKL1, ERK1 und PFKP 
identifiziert, für die veränderte Expressionswerte (oder ein veränderter 
Phosphorylierungsstatus für ERK1) gefunden wurden. In der Tat haben 
vorhergehende Studien gezeigt, dass Aβ42 Tau-Hyperphosphorylierung in 
Tiermodellen induziert. PFKP, ein Schlüsselenzym der Glykolyse, wurde in Folge 
eines veränderten Aβ42/Aβ40-Verhältnisses unterschiedlich reguliert und könnte 
möglicherweise einen gestörten Glukose- und ATP-Metabolismus in Gehirnen von 
AK-Patienten widerspiegeln. Dem bisher uncharakterisierten KIAA0125 wurde die 
mögliche Funktion zugewiesen, ein Gegenspieler von Neurogenin 2 zu sein, welches 
mit C99 und Neuronatin als gemeinsam reguliert identifiziert wurde. Weiterhin 
wurden folgende Bereiche durch ein verändertes Aβ42/Aβ40-Verhältnis deutlich 
beeinflusst (für die meisten Gene auf Transkriptebene bestimmt und für manche 
zusätzlich auf Proteinebene): Kupfertransport/Kupferstoffwechsel mit speziellem 
Hinblick auf ATP7A, verschiedene (Metallo)proteasen (ADAMTS9, ADAMTS3, 
MMP8, PREP, ECEL1, CTSD, PRSS12),  Metalloproteaseinhibitoren (TIMP3, 
TIMP1), extrazelluläre Matrixproteine oder hiermit verwandte Enzyme (RELN, 
COL4A1, COL4A2, HS3ST2), Proteine des Zytoskeletts (ACTA2, ACTN1), 
Komponenten der mitochondrialen Atmungskette (NDUFB9), Zytochrome (b-561 und 
b-245), Dopamin-, Serotonin- und Glutamatstoffwechsel mit spezieller Hinsicht auf 
DDC, HMP19 and GAD1. Effekte durch BDNF (nicht-katalytische TRKB-Isoform), 
Membranfusionen von Neurotransmitter-enthaltenden Vesikeln (STX3A, SYN2), 
Ca2+-Einstrom (AMPA2), Azetylcholinrezeptoren (CHRNA7), Notch-Signalweg 
(DNER, TLE1, TLE2, JAG1, CUTL2), TGFβ-Signalweg (TGFB2, TGFBR2, BAMBI, 
BMP7), WNT-Signalweg (DKK2, DKK4), G-Protein-Signalweg (RGS4) und 
ERK/MEK-Signalweg (ERK1, MEK1). Die Orientierung axonaler Wachstumskegel, 
die Synaptogenese und die Tendenz dendritische Verzweigungen zu bilden, waren 
auf Transkriptebene in Folge eines erhöhten Aβ42/Aβ40-Verhältnisses vermindert, 
aber als Resultat eines erniedrigten Aβ42/Aβ40-Verhältnisses verstärkt (SEMA3A, 
SEMA3C, L1CAM, PTN, SLIT1). Deutlich beeinflusst durch ein verändertes 
Aβ42/Aβ40-Verhältnis waren Gene, die an folgenden Bereichen beteiligt waren: 
Glutamat/Ammoniak Stoffwechsel (GLUL, GLS), Harnstoff-Zyklus (ASS), 
Zellzyklusregulation (CCND1, CDKN1A),  Glukokortikoid regulierte Kinase (SGK), 
Rezeptoren (PTGER2, EGFR, AMPA2, AMPA3, GRM7, GRM8c, GLRB, GABRB3), 
Langzeitpotenzierung (CREB1), axonaler Transport (DNCLI2), Angiogenese (HGF, 
VEGF), T-Zellrezeptoren und assoziierte Transkriptionsfaktoren (T-Zellrezeptor α und 
δ Lokus, GATA3), Lipoprotein-assoziierte Proteine oder Adapterproteine hiervon 
(LRP4, PDZK1), vesikulärer Organellen Transport und Mikrotubuli Assoziation 
(VMP), Transkriptionsfaktoren (PBX1, SHOX2) und stressverwandte Faktoren 
(ADRB1). Zusammengefasst haben die identifizierten Gene, Proteine und Signal-
transduktionswege neue und tiefere Einblicke in die Effekte veränderter C99-
Spaltprodukte gewährt and stellen neue Hypothesen für die pathologischen 
Mechanismen der Alzheimer Krankheit  zur Verfügung. Weiterhin sind sie mögliche 
Kandidaten für genetische Risikofaktoren und könnten dabei hilfreich sein, 
Mechanismen nicht-genetischer Risikofaktoren zu erklären. Das für ein erhöhtes 
Aβ42/Aβ40-Verhältnis spezifische Genexpressionsmuster könnte, zusammen mit 
klinischen Daten, für die Diagnose der AK nützlich sein. Letztendlich könnten sich 
einige der identifizierten Transkripte, Proteine und Signalwege als geeignete 
Angriffsstellen für Medikamente erweisen.                                 ………………………..                     
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3 Introduction 
3.1 Overview 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly 
population. Alois Alzheimer, a German physician, was the first to link brain pathology 
with cognitive dysfunction of his patients [1]. AD is a progressive neurodegenerative 
disorder with a long preclinical phase that can take several decades. It is manifested 
by cognitive and memory deterioration, a variety of neuropsychiatric symptoms and 
behavioral disturbances [2]. One of the most important risk factors is the age of the 
patients. Apart from the less frequent early onset of the disease, which can start from 
<65 years of age, most of the patients manifest symptoms over 65 years (late onset 
Alzheimer’s disease, LOAD). With the increasing longevity of our population, it is 
assumed that AD will approach epidemic proportions in the future with no cure yet 
available. Its prevalence rises dramatically with age. Its prevalence approximately 
doubles every five years for those between 65 and 85 years of age, representing 5-
10% of the population over 65 years of age and more than 20% over age 80. One 
hallmark of AD are extracellular deposits (amyloid plaques found in the patients’ 
brains), consisting, apart from other proteins, of amyloid β-peptides. These peptides, 
of about 40 amino acids in length, are derived from cleavage of the amyloid 
precursor protein (APP), a transmembrane protein [3]. The proportion of two major 
amyloid β-peptides, Aβ40 and Aβ42 is approximately 90% to 10% in the amyloid 
plaques, however, the less abundant Aβ42 is regarded as the critical component for 
the progression of the disease. Aβ42 differs from Aβ40 by two amino acids (isoleucine 
and alanine). Mc Laurin and co-workers examined the folding properties of Aβ42 and 
Aβ40. At pH 6.0 and in the presence of phosphatidylinositol vesicles, both Aβ42 and 
Aβ40 adopted an amyloidogenic β-structure. In contrast, at neutral pH only Aβ42 
folded into a β-structure in the presence of phosphatidylinositol vesicles [4]. Anti-
parallel β-structures contribute to reduce the water-solubility of proteins. 
AD is a genetically heterogeneous disorder because mutations and polymorphisms 
occur in multiple genes and might  together contribute to the disease. Moreover, non-
genetic factors are involved [5]. Early onset familial AD is caused by rare and highly 
penetrant mutations which manifest in an autosomal dominant fashion, whereas late 
onset (>65 years of age) AD proceeds from common polymorphisms with relatively 
low penetrance but high prevalence [6]. In addition to APOE, a well established risk 
factor for AD, which is localized on chromosome 19, linkage has been found on other 
chromosomes. During the last years many new candidate genes have been found in 
genetic and biochemical approaches. The number of chromosomal regions, 
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assumed to be associated with AD, has grown. The genetic risk of a complex 
disease such as AD may be determined by the combined effects of numerous loci, 
some of which may produce only minor contributions to the overall risk. Linkage and 
association studies suggested candidate genes on nearly all chromosomes 
according to the overview at www.alzforum.org. The fact that nearly all chromosomes 
appear to be affected questions the accuracy of linkage and association studies. To 
narrow down putative candidate genes, more attention should be drawn onto the lod 
score. Most of the previously described chromosomal regions do not exceed the 
commonly accepted lod score of 3.0 for significant linkage and therefore true linkage 
is questionable. Recently, systematic meta-analyses were performed for each 
polymorphism with available genotype data [7]. 
Mutations in APP, PS1 and PS2 cause the autosomal dominant form of early onset 
AD. The APOE ε4 allele has been associated with an increased risk of developing 
both early and late onset AD [8, 9]. These genes are assumed to be responsible for 
approximately 50% of the genetic background of the disease, suggesting that further 
susceptibility genes exist.  
APP is a ubiquitous protein found in all cell types of all species, suggesting a basic 
and important role: APP-family members were suggested to be involved in neuronal 
development, a crosstalk to Notch has been observed and Numb was identified as a 
potential target for APP-family members [10]. Furthermore, Soba and colleagues 
provided evidence that homo- and heterocomplexes of APP/APLPs promote trans-
cellular adhesion in vivo and that APLP2 is required for cell-cell adhesion in mouse 
embryonic fibroblasts [11]. A neurotrophic function for APP and secreted APP 
(sAPP) is often discussed [12]. Therefore, a loss of function of APP rather than a 
gain of toxic function of Aβ could also be a possible hypothesis to explain the 
stimulation of tau pathology and neurodegeneration. APP-C-terminal fragments 
(APP-CTFs) decrease unexpectedly during the course of AD and are well correlated 
with the progression of tau pathology [12]. This decrease could be explained by 
these observations: Firstly, loss of APP-C-terminal fragments (CTFs) could result 
from a modification of secretase activities, and especially from an activation of γ-
secretase, and therefore a transformation of APP-CTFs into γ-CTFs and other 
smaller fragments. Secondly, targeting of APP in subcellular compartments might be 
dysregulated. Furthermore, proteasomal degradation of APP-CTFs could be involved 
[13]. Beta, alpha and gamma-stubs were also significantly decreased in the brain 
tissue of patients having an inherited form of AD linked to mutations of PS1. An 
important role of the gamma stub, also named AICD (APP intracellular domain), as a 
gene regulator could explain its involvement in the disease if these fragments are 
lacking [14]. 
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Aβ is a normal product of cellular metabolism throughout life and circulates as a 
soluble peptide in biological fluids. It is secreted by neural and non-neural cells and 
also primary neurons from fetal brain produce Aβ [15]. Aβ is also present in the 
cerebrospinal fluid and plasma of normal humans [16, 17]. It was hypothesized that 
chronically enhanced production and/or decreased clearance of soluble, diffusible Aβ 
could lead to the gradual precipitation of aggregated non-diffusible Aβ in the form of 
spherical plaques and vascular deposits in AD and Down’s syndrome. In cerebro 
spinal fluid (CSF) decreases in the level of Aβ42 correlated with the presence of AD 
and might be diagnostically meaningful [18]. Aβ42 is the more fibrillogenic Aβ species, 
whereas Aβ40 is the physiological and more abundantly secreted Aβ [19]. 
APOE is likely to be involved in the transport or clearance of Aβ. The fact that all four 
known AD genes (APP, PS1, PS2, APOE) implicate Aβ, and that APOE implicates 
fibrillogenesis directly provides support for the hypothesis that Aβ accumulation is 
central to the disease. There are three human APOE alleles. The three common 
isoforms of the APOE gene on chromosome 19q13.2 are encoded by alleles ε2, ε3 
and ε4. The APOE ε4-allele is considerably over-represented in AD subjects 
(approximately 40% versus 15% in the general population). It was observed that 
ApoE2 prevented the development of fibrillar plaques in transgenic mice. However,  
the protective ε2-allele can only be found in 2% of all AD cases, compared to 10% in 
the general population. The absence or presence of one or two ε4-alleles was found 
to correlate in a dose-dependent manner with the relative density of amyloid plaques 
[20]. The mean age of onset of AD is less than 70 years among the ε4/ε4 population, 
but over 90 years for the ε2/ε3 population. 
The APOE gene is the only robustly replicated risk factor for the common form of AD 
with onset after 65 years of age. Twin studies found a concordance rate for AD 
among monozygotic twins to be 78%, indicating a strong genetic influence [21]. More 
than 95% of AD cases are sporadic with onset after 65 years of age. 25 different AD-
associated mutations in the APP gene have been published (including the 
duplications of the APP locus), which affect more than 71 families with the age-of-
onset ranging between 30 and 65 years (http://www.molgen.ua.ac.be/AD.Mutations/). 
The most frequent pathological APP-mutation is the V717I substitution, which is 
found in approximately 50% of APP-linked families. Some of these APP-mutations 
are related to hereditary cerebral hemorrhage with amyloid (congophilic) angiopathy 
(HCHWAD) [22, 23]. 
Although Aβ is the major constituent of the amyloid deposits, there are other 
components such as P-component [24], APOE [25], APOJ [26], proteoglycans [27], 
lysosomal proteinases [28, 29] and the proteinases inhibitors α1-antichymotrypsin 
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[30], α1-antitrypsin [31], α2-macroglobulin [32, 33] and cystatin C [34-38]. These 
components could also contribute to (or prevent when regarded as a counter 
regulation in order to get rid of deposits) the development of AD. 
Vascular risk factors, such as hypertension and hypercholesterolemia, may play an 
important role in the development of AD. Since neurodegenerative processes of AD 
might begin 20 to 30 years before manifestation of dementia it is crucial to identify 
early risk factors. Antihypertensive medication may protect against AD [39-41]. High 
serum cholesterol in middle age increases the risk of late-life AD [42]. Using statins 
as cholesterol reducing drugs has been shown to significantly reduce rates of AD 
[43-45]. Studies revealed that using simvastatin decreased Aβ levels in the CSF and 
slowed the progression of AD [46]. Participants with elevated systolic blood pressure 
(BP, ≥ 160 mmHg) or high serum cholesterol (≥ 6.5 mmol/l) in middle age had a 
significantly higher risk of AD in later life, even after normalisation for age, body mass 
index, education, vascular events, smoking status and alcohol consumption, than 
those with normal systolic BP or serum cholesterol. Both risk factors in middle age 
together had a significantly higher risk of developing AD than those with either of the 
risk factors alone. Diastolic blood pressure in middle age had no significant effect on 
the risk of AD. Presence of the APOE ε4 allele, which is involved in cholesterol 
metabolism, is the most important genetic risk factor for AD. The APOE ε4 allele is 
an independent risk factor for AD, even after adjustment for midlife vascular risk 
factors and other confounders. Similarly, elevated midlife cholesterol level and 
systolic BP were independent risk factors for AD, even after adjustment for APOE 
genotype and other confounding factors. APOE has a central role in lipid metabolism 
and the APOE ε4 allele is associated with increased serum cholesterol levels. The 
APOE ε4 allele is also associated with an adverse prognosis in other diseases of the 
brain in the elderly, such as stroke and brain trauma. Thus, the APOE ε4 allele is not 
specific for AD and there is some evidence that the risk related with the APOE ε4 
allele could be reduced or modified by interventions to treatable risk factors. Some 
recent studies have suggested that the APOE ε4 allele is a significant risk factor for 
AD only among hypertensive individuals who have not used antihypertensive drugs 
[47]. Searching susceptibility genes for AD has turned out to be complicated, as it is 
known for all other diseases with complex inheritance, due to combined effects of 
numerous trait loci. Microarray techniques are promising tools in order to unravel the 
complex interplay of numerous genes. Population based studies of patients that 
subsequently developed AD show a significant decrease in plasma cholesterol levels 
preceding development of cognitive symptoms [48], potentially obscuring the past 
effects of higher cholesterol levels earlier in life. Finally, subjects with the highest 
levels of plasma cholesterol generally die at younger ages from cardiovascular 
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events and are lost from the sample of elderly subjects, introducing a “survivorship 
effect” into the population. It is therefore important that a relationship between AD 
and cholesterolemia in human subjects is established at the neuropathological level 
during the early stages of amyloid accumulation and before development of cognitive 
symptoms later in life. Furthermore, autopsy of human brains showed a strong 
association between total plasma cholesterol levels and presence of early amyloid 
deposits in a young subgroup of subjects (40-55 years).  
3.2 Proteolytic processing of the amyloid precursor protein 
(APP) and activation of transcription 
Proteolytic processing of APP plays a central role in AD (Fig. 3.1). Due to variable 
APP processing, several β-amyloid peptides are generated. In contrast to the form 
with 40 amino acids, the variant with 42 amino acids has a higher tendency to form 
protease resistant aggregates and is thought to be the pathogenic form triggering the 
pathophysiological cascade in AD (amyloidogenic pathway; APP can also be 
processed at the α-site, which precludes Aβ-generation and is therefore called the 
non-amyloidogenic pathway). APP is cleaved by β-secretase within its ectodomain 
resulting in generation of the C-terminal fragment C99, which is further cleaved within 
its transmembrane domain by the γ-secretase complex (presumably sequentially) 
first at the ε-, than at the ζ-cleavage site and finally at the γ-cleavage site (the ζ-
cleavage site is located between the γ-cleavage and ε-cleavage site). Due to variable 
processing by the γ-secretase complex, cleavage at the γ-cleavage site generates 
Aβ42 and Aβ40 and the AICD50-99 and AICD49-99 [49, 50]. Cleavage at the ε-cleavage 
site occurs at Aβ49 [51] and cleavage at the ζ-cleavage site at Aβ46 (APP717 
mutation site=London mutation) [52]. Proceeding from the carboxyl terminus toward 
the N-terminus, the cleavages generate successively shorter Aβ peptides, from 49/48 
to 46/45, to 43/40 and 42 [53].  
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Figure 3.1 Model of proteolytic processing of C99 by γ-secretase. While knowledge of Aβ42 and  
Aβ40 generation is well established, knowledge of the AICD is limited by its inherent quick degradation 
and hence difficulties in its detection. C99 is generated as a result of APP cleavage by β-secretase 
(not shown) and undergoes further cleavage by γ-secretase. On the one hand Aβ40 is generated and 
accompanied by the generation of the APP C-terminal fragment AICD50-99 [49]. This process is 
regarded as non-pathogenic. In contrast to this, due to varying processing by γ-secretase, the less 
abundant Aβ42 is also generated, accompanied by generation of AICD49-99. This process is regarded as 
pathogenic (pathogenic effects are assumed to be mediated by Aβ42, while effects of the AICD49-99 
have not been well investigated yet). A link between the production of Aβ42 and the AICD49-99 was 
suggested [50]. It has been shown that equimolar amounts of Aβ and AICD are produced [49]. *Gene 
expression could also be triggered by the as yet unidentified AICD57 and AICD59, the two species 
which should theoretically remain after cleavage of Aβ42 and Aβ40 from the precursor C99. 
Furthermore, it has to be taken into consideration that the AICDs themselves are cleaved and that 
their cleavage products may also induce or repress gene expression. 
How transcription is activated/repressed after APP-processing is a controversial 
issue. The question of whether the AICD, like the Notch intracellular domain, is 
involved in nuclear signaling is highly controversial  [14, 54, 55] and, apart from the 
AICD as the transcription-activating peptide, other mechanisms are imaginable:  
intracellular Aβ, even if present in only tiny amounts, could trigger transcription via 
cross-talk with other proteins, or secreted Aβ could influence transcription by docking 
from outside of the cell to transmembrane receptors and transduce a signal to the 
nucleus. Moreover, AICD fragments, derived after cleavage, might activate or 
repress transcription. 
A suggested function of the AICD is the formation of a complex together with Fe65 
and TIP60, a histone-acetyl-transferase, translocation to the nucleus (after cytosolic 
degradation of the AICD). APP may anchor Fe65 in the cytosol, while the release of 
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AICD from APP by γ-cleavage may allow the AICD-Fe65 complex to translocate to 
the nucleus where it  may act as a transcription factor [55, 56]. 
Some reports suggest that the AICD regulates the expression of KAI1, glycogen 
synthase kinase-3β, neprilysin and APP. However, no consistent effects on the 
expression levels of these genes were found in cells and tissues by using gamma-
secretase inhibitors or by genetic deficiencies in the gamma-secretase complex. 
Furthermore, it was demonstrated that Fe65, an important AICD-binding protein, 
transactivates a wide variety of different promoters independent of AICD co-
expression. It was concluded that the four previously proposed target genes are at 
best indirectly and weakly influenced by APP processing [54]. This is supported by a 
gene expression profiling study of the human neuroblastoma cell line SHEP-SF 
transfected with a tetracycline-inducible system, in which no differential expression 
was observed for KAI1 and glycogen synthase kinase-3 beta in response to AICD 
overexpression [57]. 
JNK (c-Jun N-terminal kinase)-interacting protein 1 (JIP1) may promote transcription 
different from the mechanism mediated by Fe65 [58]. Many proteins have been 
described to interact with the NPTY motif of APP: Disabled-1 (Dab1) [59]. Shc [60, 
61], JIP1 [62], X11 [63] and FE65 [64-67]. It has been reported that a transcriptionally 
active complex of APP with Fe65 and histone acetyltransferase can be formed [55]. 
Tarr et al. identified Shc A and Shc C, PTB containing adaptor proteins cross-talking 
with cellular differentiation and survival pathways, as APP interacting proteins [68]. 
The FE65s (FE65, FE65L1, and FE65L2) are a family of multidomain adaptor 
proteins that form multiprotein complexes with a range of functions. FE65 is brain-
enriched, whereas FE65L1 and FE65L2 are more widely expressed. All three 
members contain two PTB domains and a WW domain. Through the PTB2 domain, 
they all interact with the AICD of APP and can alter APP processing [69]. 
There is in vivo evidence of transcriptional activation of the KAI1 gene by a complex 
consisting of the C-terminal cleavage product of APP, Fe65 and TIP60, which 
corroborates the function of APP in nuclear signaling [70], although there is some 
controversy in regard to nuclear translocation of the AICD [14, 71, 72]. 
It was shown that a caspase-mediated cleavage releases the last 31 amino acids 
from the C-terminus of APP. This C31 peptide causes apoptosis in cultured cells and 
can be found in brain samples from AD patients but not in samples from control 
brains. Daniel Lu, Edward Koo and colleagues reported that the 31 amino-acid 
peptide from the C-terminus of APP could be involved in AD neuronal death, maybe 
in conjunction with Aβ. Their results indicate that both caspase-8 and caspase-9 
cleave APP to form the C31 peptide, which is cytotoxic to cultured cells. They also 
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determined that the previously demonstrated cytotoxicity of the C100 peptide is 
dependent on that final 31-amino-acid fragment. Finally, in AD brains, but not in 
control tissue, they found evidence of intracytoplasmic APP cleavage (presumed to 
be caspase-mediated) and activation of caspase-9 [73]. 
3.3 The amyloid cascade hypothesis 
Genetic analysis of kindred with AD has pointed to Aβ as the initiating molecule in 
the development of the disease. Biochemical work on APP processing revealed that 
all pathogenic mutations altered processing in such a way that Aβ42 was more likely 
to be produced. Such genetic and biochemical data together suggested that Aβ42 
accumulation was the primary event in the pathogenesis of AD. These data together 
led to the formulation of the amyloid cascade hypothesis (Fig. 3.2). 
 
 
Figure 3.2  Pathophysiological cascade in Alzheimer’s disease. Figure was taken and modified 
from “Alzheimer’s Disease and Related Disorders” (Agneta Nordberg). 
Soluble Aβ, secreted in vitro, forms SDS-insoluble oligomers [74]. These Aβ 
oligomers secreted by cells cause neuronal dysfunction in vivo [75, 76] and it was 
demonstrated that they are more neurotoxic than Aβ fibrils [77]. The soluble and 
diffusible Aβ oligomers were identified as the actual trigger of AD pathogenesis. Aβ is 
produced under normal conditions but in brain tissue it is immediately sequestered or 
Accumulation of soluble Aβ42 
(Aβ oligomers) 
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rapidly catabolized. When this Aβ removal mechanism is overwhelmed by 
overproduction, as in Down’s syndrome, or by impaired removal, Aβ deposition and 
plaque formation start. The Aβ species associated with AD form oligomers more 
quickly, are more toxic to neurons and produce more severe membrane damage 
than the Aβ species associated with normal brain aging. The combination of different 
Aβ species leads to differently conformed Aβ soluble aggregates that exhibit a large 
spectrum of toxicity. 
There is a large body of evidence that Aβ42, but not Aβ40, triggers the 
pathophysiological cascade in AD. Some recent publications discuss whether the 
ratio of Aβ40 to Aβ42 is responsible for triggering this cascade [78]. Furthermore, it 
turned out that Aβ was derived from the transmembranous part of the type 1 integral 
membrane protein APP after cleavage by proteases. Research on HCHWAD 
revealed further  associations between  Aβ  deposition  in cerebral  blood vessels 
and  mutations at the APP locus  coding for  the middle of the Aβ part of the molecule 
[23]. Since mutations in the APP locus have been shown to be responsible for only a 
very small percentage of AD familial cases  it was obvious that other genes had to be 
involved; linkage studies in  families who had an onset age from approximately 30-40  
years revealed a locus on chromosome 14 [79]. Further work identified the presenilin 
1 gene on chromosome 14. Genetic analysis of pedigrees of Russian-German origin 
revealed a further locus on chromosome 1, which was shown to correspond to 
presenilin 2, a presenilin 1 homologue [80]. In the presenilin 2 gene a small number 
of mutations which cause AD have also been found. While APP/PS transgenic mice 
generate amyloid plaques they develop no tangle pathology and only little cell loss. 
Data on amyloid plaque pathology relate directly only to the early onset familial forms 
of the disease, a direct connection to late onset (>65 years of age) cases is less 
clear. The fact that APP/PS transgenic animals do not develop either tangles or cell 
loss has questioned the accuracy of the amyloid cascade hypothesis. However, the 
fact that a perfect animal model for AD does not exist must also be considered. 
Furthermore, data obtained from transgenic animals are not directly transferable to 
humans. 
These observations support the hypothesis that Aβ is crucial for the initiation of the 
disease: 
Adverse effects were recognized after the injection of 20 µl of picomolar solutions of 
Aβ oligomers into the cerebral ventricles of young rats, for instance disorientation in 
the Morris water maze [81]. Amyloid deposited in the cerebrovasculature of 
transgenic mice (APP: E693Q) consists predominantly of Aβ1-40. Cross-breeding 
such mice with mice expressing a PS1 variant that increases Aβ1-42 production 
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resulted in early (starting at 3 months of age) accumulation of brain-parenchymal 
amyloid plaques and reduced cerebral amyloid angiopathy [82]. Thus, similarly to 
humans, the main component of blood vessels amyloid is Aβ1-40. Increasing the 
Aβ42/Aβ40 ratio favours parenchymal amyloid deposition with higher Aβ1-42 content. 
The presence of a mechanism rapidly binding or breaking down Aβ42, for instance by 
extracellular proteases (neprylisin, IDE, plasmin, etc.) was suggested [83-85].  
The APP gene, located on chromosome 21q21, consists of 19 exons that are 
alternatively spliced into eight mRNA forms. Several mutations in the APP gene have 
been discovered. Although the APP mutations account for less than 0.1% of all AD 
cases, they result in complete penetrance leading to AD between the fourth to 
seventh decades of life [86]. Although the mutations in the APP-gene in several 
familial AD (FAD) pedigrees were expected to alter quantitative Aβ production by a 
changed β-secretase or γ-secretase cleavage only in the K670N/M671L double 
mutation, secreted peptide amounts were affected. This mutation is located 
aminoterminally to Aβ and was found in a Swedish kindred [87]. Cultured cells 
expressing mutated APP secrete higher levels of Aβ compared to cells expressing 
the normal sequence [88]. Aβ42 contains two more hydrophobic residues (isoleucine, 
alanine) than the Aβ40 form, making Aβ42 more fibrillogenic and enhances 
aggregation [89]. Insufficient proteolytic removal of Aβ by proteases such as 
neprilysin, endothelin-converting enzymes, insulin-degrading enzyme, angiotensin-
converting enzyme, the plasmin system and matrix metalloproteases, also has been 
proposed as a mechanism that leads to Aβ accumulation in the brain. 
While it is clear that familial Alzheimer’s disease (FAD) mutations in APP result in 
increased Aβ deposition, it is unclear whether the deposition itself is pathogenic. 
Apart from the view that deposited Aβ is neurotoxic, more recently it has been 
suggested that the neurodegeneration observed in AD is caused by either soluble 
oligomers of Aβ, the build up of C-terminal fragments of APP or abnormal signaling 
by the intracellular domain of APP [90, 91]. 
The so-called Swedish mutation, located at the N-terminus of Aβ, results in an APP 
molecule that is a better substrate for β-site APP cleaving enzyme1 (BACE1) 
resulting in higher levels of Aβ [87]. In contrast FAD mutations located between 
APP714 and APP723 result in altered cleavage by γ-secretase [92]. The amounts of 
the different Aβ species (Aβ37- Aβ43) vary with each mutation [93]. Interestingly a 
common feature of all mutations causing AD seems to be an increase in Aβ42. Five 
mutations have been reported within the Aβ sequence at residues APP692-694. 
These mutations are often associated with cerebral hemorrhage rather than AD [94]. 
Unlike humans, transgenic mice with these mutations do not develop obvious 
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neurodegeneration or neurofibrillary tangles. However, Aβ42 overexpression primarily 
leads to parenchymal Aβ deposition (such as that observed in AD), whereas Aβ40 
overexpression leads to Aβ deposition primarily in the cerebral vessels [82]. APP 
mutations, which result in higher levels of both Aβ40 and Aβ42 lead to both pathologies 
[95], while mutations, like APPV717F, lead to parenchymal Aβ deposition [96] and 
APPA692G leads to Aβ deposition in the cerebral vessels [82].  
Analysis of families suffering from dementia and Parkinson’s disease revealed 
linkage to chromosome 17, at the chromosomal locus where the tau gene is 
localized. Especially intronic mutations which influence the alternate splicing of exon 
10 lead to heavy deposits of mutant tau, which in turn lead to tangle formation and 
neurodegeneration but not to amyloid deposition. This information makes it probable 
that  Aβ is upstream of tau dysfunction and tau dysfunction and tangle formation is 
proximal to cell death. Mice with the tau-P301L-transgene, under the control of the 
prion promoter, develop tangle formation and cell death in the spinal cord and 
midbrain. However, when these mice were crossed with APP transgenic mice, 
enhanced  tangle formation and degeneration occurred in the cortex and midbrain. 
The production of α-synuclein, a component of Lewy bodies, which are characteristic 
for Parkinson’s disease (PD), is enhanced  by crossing α-synuclein transgenic mice 
with APP transgenic mice.  
Brains of 22 subjects with Down’s syndrome (DS) were examined for the presence of 
soluble Aβ42. Soluble Aβ42 was detected in half of the fetal brains and in all postnatal 
cases, even in the young cases (from 4 days up to 14 years old) where diffuse 
amyloid plaques had not yet formed. Soluble Aβ1-40 and Aβx-40 were not detected in 
any of the Down’s syndrome cases examined [97]. From this study it was concluded 
that the overproduction of total Aβ42 is due to APP overexpression in Down’s 
syndrome and that the initial seeding of Aβ42 may begin more than a decade before 
amyloid fibrils are formed. Nearly all middle-aged DS patients develop AD pathology 
[98]. However, DS individuals with partial trisomy 21, who are not trisomic for the 
APP gene, do not develop AD neuropathology. AD pathology in Down’s syndrome is 
associated with three copies of the APP gene [99].  
The presence of Aβ in patients suffering from Mild Cognitive Impairment (MCI), as 
well as a decrease of Aβx-42 in the CSF [100] is an important  marker of incipient AD. 
The amyloid cascade hypothesis is a controversial one and the following features are 
not in line with it (However, it should be borne in mind that data from mice are not 
always directly transferable to humans): 
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In cognitively intact individuals, aging of the brain is very often associated with Aβ 
deposition but not with neurofibrillary tangles (NFT), suggesting that in these 
individuals Aβ accumulation does not produce neuronal damage [101]. Transgenic 
mice expressing APP have age-related neurological deficits in the absence of 
plaques (however, in these studies soluble Aβ was not tested for pathogenic effects) 
or neurodegenerative changes [102]. A 56 kDa soluble complex of Aβ, called Aβ 56, 
in the brains of the Tg2576 mouse model of AD impairs memory in the absence of 
amyloidosis or neuronal loss [81]. 
Tau pathology is more closely related to cognitive impairment than is Aβ. Moreover, 
tau pathology can be found in the hippocampal area without Aβ deposits [99]. 
3.4 Aβ, tau and the connection in between 
Neurofibrillary tangles, one pathological hallmark of AD, are composed of the highly 
phosphorylated microtubule-associated protein tau. Tau is involved in the assembly 
and stabilization of microtubules (MTs). The affinity of tau for MT is actively regulated 
by phosphorylation and by changes in the ratio of its isoforms, containing either three 
or four MT binding domains (tau-3R, tau-4R) [103, 104]. Electron microscopy 
revealed that the substructure of these tangles were paired helical (twisted) filaments 
[105]. Tangles contain 10-20 nm paired helical filaments (PHF). Phosphorylated tau 
was recognized as the major, if not the only, component of PHF [106]. 
Neurofibrillary tangles appear in the entorhinal cortex of 20 % of people with an 
average age of 25 years. At the age of 50 years 50% of the people are affected and 
at 75 years all people are affected. The extent varies greatly among individuals. 
Since 100% of patients have a tau pathology at the age of 75 years, tau pathology 
can be regarded as an inevitable degenerating process that occurs in the human 
brain. On the other hand, the brains of non-demented centenarians have been 
analyzed and a few of these patients had only a very mild entorhinal tauopathy, 
demonstrating the absence of a direct link with aging. Tau pathology is more closely 
related to cognitive impairment than Aβ is, but the presence of Aβ in patients 
suffering from Mild Cognitive Impairment, as well as a decrease of Aβ x-42 in the 
CSF is an important marker of incipient AD. Spreading of tau is likely to start in a 
specific vulnerable neuronal population (presumably in layer II of the entorhinal 
formation in AD). Then this local tauopathy will destabilize the connected neuronal 
populations. This degenerating process will extend, as a kind of domino effect, to 
other neuronal populations along a neuron-to neuron propagation phenomenon. It is 
not surprising that tau pathology is well correlated with cognitive impairment, since it 
shows the neurodegenerative process and its extent. Aβx-42 aggregates are 
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observed at the early stages of tau pathology in non-demented patients and all along 
AD pathology. During the progression of the disease, Aβx-42 aggregates increase in 
quantity in close parallel to the extension of tau pathology. Tau pathology can be 
found in the hippocampal area without  Aβ deposits. In contrast to this the extension 
of tau pathology in polymodal association areas was systematically found in the 
presence of Aβ deposits, as if these Aβ species were necessary to stimulate the 
progression of tau pathology.  
Tau is a phosphoprotein and even normal adult tau is phosphorylated to some 
degree. Many kinases are able to generate phosphorylation sites on tau proteins in 
vitro. Among the most promising candidates are GSK-3β and cdk5. Tau 
phosphorylation modulates its binding to microtubules [107] and its ability to stabilize 
them. Hyperphosphorylated tau species do not bind well to microtubules and this 
decreased biological function would cause a “loss of function” in affected neurons. 
Phosphorylation of tau could favour the aggregation of tau in PHF. Soluble or 
oligomeric forms of phosphorylated tau could also be toxic by themselves, leading to 
a “toxic gain of function”. On the other hand, tau phosphorylation/aggregation might 
also be a protective response of neurons submitted to various damaging influences. 
According to the amyloid cascade hypothesis, tau-phosphorylation is a downstream 
event of amyloid accumulation. However, it was unexpectedly observed that animals 
developing Aβ amyloid deposits did not develop NFT, including animals also 
expressing a human wild-type tau protein. On the other hand, in double transgenic 
(mutant tau and APP) animals, neurofibrillary degeneration was observed. Tau 
contains of six isoforms [108]. PHF can also be found in entorhinal and hippocampal 
regions in patients aged over 75 years who are non-demented. Since 100% of 
people at the age of over 75 have neurofibrillary tangles, means that tau pathology is 
an inevitable degenerating process that occurs in the human brain. At the age of 25, 
20% of people show tau pathology. NFT formation in the entorhinal cortex precedes 
Aβ-deposition, whereas NFTs appear in the limbic and neocortical areas only after 
Aβ-deposition [109]. Presumably NFT formation in the entorhinal cortex develops as 
a result of normal brain aging and only in the disease state of AD does it spread into 
limbic and neocortical areas. 
In human SH-SY5Y cells, tau has been shown to be hyperphosphorylated at several 
of the same sites as in AD brains. As in AD, the hyperphosphorylated tau 
accumulated in the cultured cells and did not bind to microtubules [110]. Inhibition of 
protein phosphatase 2A (PP2A) and protein phosphatase 1 (PP1) activities by 
okadaic acid up-regulated the activities of MAPK and CDK5 and resulted in abnormal 
hyperphosphorylation of tau, a decrease in stable microtubules, and an increase in 
cell death. It was shown in vitro that protein phosphatase 2A and 2B 
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dephosphorylated neurofibrillary tangles/PHF and stimulated assembly of tubulin into 
microtubules. The state of phosphorylation of a phosphoprotein is a function of the 
balance between the activities of protein kinases and phosphatases that regulates its 
phosphorylation. Tau, which is phosphorylated at more than 30 serine/threonine 
residues in AD [111], is a substrate for several protein kinases. Among these kinases 
there are:  
 
• glycogen-synthase kinase-3 (GSK-3) 
• cyclin-dependent protein kinase 5 (CDK5) 
• protein kinase A (PKA) 
• calcium-calmodulin-dependent protein kinase-II (CaMKII) 
• mitogen-activated protein kinase ERK1/2 
• stress-activated protein kinases 
 
It has been shown that phosphorylation of tau by non-proline-dependent protein 
kinases PKA, PKC, CaMKII, and casein-kinase 1 (CK1) primed it for subsequent 
phosphorylation by proline directed protein kinases (PDPK) cdk5 and and GSK3. 
Ser262 and Thr231 are the two major sites at which phosphorylation inhibits the 
binding of tau to microtubules [112]. 
Among the involved phosphatases there are for instance:  
• protein phosphatase 2A (PP2A) 
• protein phosphatase 1 (PP1) 
 
PP2A also regulates the activities of several kinases in the brain: 
• CaMKII  
• PKA  
• MAP kinase kinase (MEK1/2) 
• Extracellular regulated kinase (ERK1/2) 
• P70S6 kinase  
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PP1 activity is mainly regulated by inhibitor-1 (I-1) [113]. I-1 and DARPP32 
(dopamine and cAMP-regulated phosphoprotein of a molecular weight of 32.000) are 
activated on phosphorylation by protein kinase A and inactivated at basal calcium 
levels by PP2A. Thus, inhibition of PP2A activity would keep I-1 and DARPP32 in an 
active form and thereby result in a decrease in PP1 activity.  
PP2A is inhibited by I1PP2a (cytosolic protein, synonyms: putative and 
histocompatibility leukocyte antigen class II-associated protein (PHAP1), 
mapmodulin, pp32, LANP) and  I2 PP2a (nuclear protein, synonyms: TAF1β, PHAP2) 
[114]. Other conditions also influence tau phosphorylation: phosphorylation depends 
on whether tau contains three or four repeat domains (conserved sequence repeats) 
and whether it contains zero, one or two N-terminal inserts [115]. Tau can also be 
abnormally glycosylated, which can promote tau phosphorylation. 
Hyperphosphorylation of tau at the level of 4-6 moles phosphate/mole of the protein 
induces the toxic property. Not all of the 30 phosphorylation sites may be involved in 
converting normal tau into a toxic molecule. The following phosphorylation sites are 
among the critical ones to convert tau into a protein with toxic properties: 
S199/202/205, T212, T231/S235, S262/356 and S404 [116].  
Glycogen synthase kinase (GSK-3β) was first identified from the microtubule fraction 
of bovine brain. It can phosphorylate tau in vivo. GSK-3 was identified as a calcium- 
and cyclic nucleotide-independent kinase of glycogen synthase, which is a rate 
limiting enzyme for glycogen biosynthesis and a substrate for several kinases. GSK-
3α and GSK-3β are encoded by different genes but they share 85% homology [117]. 
GSK-3β consists of  482 amino acids and has a molecular weight of 47 kDa. Its 
promoter has putative binding sites for: AP1, AP2, c-Myb, Cre, MZF1, Sp1 and Tst1. 
GSK-3β is expressed in all tissues, its levels are highest in the brain. GSK-3β has 
also been detected in mitochondria and in nuclei [118]. The GSK-3β homolog in 
Drosophila, shaggy, is involved not only in glycogen homeostasis but also in cellular 
signaling cascades. GSK-3β activity is regulated by Ser9 (inhibitory site) 
phosphorylation for instance by protein kinase A (PKA), protein kinase B (PKB, 
synonym: AKT), protein kinase C (PKC), p90Rsk and p70S6kinase [119]. Cell 
survival signals activate PKA, PKB, and PKC, thereby deactivating GSK-3β. Thus, 
GSK-3β is activated in response to reduced cell survival signals, such as the 
reduction of growth factors. GSK-3β is able to phosphorylate many substrates and is 
part of several cellular events including metabolism, signaling and transcription [119]. 
GSK-3 is categorized as a proline-directed kinase. Most GSK-3β targets are 
phosphorylated by another kinase before they can be phosphorylated by GSK-3β. 
GSK-3β is the major tau kinase in vivo [120-125]. 4 moles of phosphate can be 
incorporated into each mole of tau. Tau is phosphorylated by GSK-3β at Ser199, 
  Introduction 
 
 
20
Thr231,Ser396 and Ser413 [126], Ser 202/Thr205, Ser396/Ser404 and Ser235 [127]. 
There is evidence that in total 15 sites are phosphorylated by GSK-3β. Among these 
only Ser400, Ser404 and Ser413 are non-proline-directed sites. To test whether 
GSK-3β is activated by Aβ, neuronal death was induced in rat hippocampal cultures 
by introducing Aβ to the cultures. It was found that GSK-3β was activated 
approximately two-fold over controls, and that the activation induced 
hyperphosphorylation of tau and that these events preceded neuronal cell death 
[128]. Aβ was found to inhibit phosphatidylinositol-3 (PI3K) kinase and this in turn 
resulted in activation of GSK-3β. In hippocampal cultures, treatment of Aβ resulted in 
cytoplasmic accumulation of the secreted form of  APP. Inhibiting GSK-3β prevented 
this accumulation [129]. APP is metabolized during its transport from the 
endoplasmic reticulum (ER) to the synaptic regions [130]. When axonal transport is 
impaired, APP becomes trapped between the Golgi and synaptic regions. Thus 
trapped, it is metabolized, prematurely releasing the secreted form of APP into the 
cytoplasm. From these results it was concluded that axonal transport is disrupted by 
GSK-3β. Disruption of axonal transport could be caused by microtubule 
destabilization resulting from hyperphosphorylation of tau or by kinesin, a motor 
protein which is a substrate of GSK-3β. Pathways leading to cell death may be 
influenced by Aβ accumulation, for instance by increasing intracellular Ca2+ levels, 
induction of reactive oxygen species or other mechanisms. Ser422 of tau cannot be 
phosphorylated by GSK-3β, suggesting there are further kinases involved in 
phosphorylation of tau, since Ser422 was found to be phosphorylated in AD brains.  
Ser422 of tau can be phosphorylated by c-Jun N-terminal kinase (JNK). 
Hyperphosphorylation of tau by GSK-3β and JNK was shown to induce NFT 
formation. Recently it was reported that GSK-3β can phosphorylate mitogen-
activated protein kinase /ERK kinase kinase (MEKK) and consequently activate JNK.  
Thus, Aβ might activate JNK indirectly through activation of GSK-3β [131]. Kinesin, a 
substrate of GSK-3β, loses its ability to bind to the cargo protein of vesicles after it is 
phosphorylated by GSK-3β, impairing axonal transport.  
Cyclic AMP response element binding protein (CREB), which is a further substrate of 
GSK-3β, modulates the gene expression of promoters containing cyclic AMP 
response elements [132]. CREB is involved in processes like long-term memory and 
the maintenance of synaptic plasticity. CREB is activated when it is phosphorylated 
at Ser133 by PKA. However, after phosphorylation of CREB at  Ser133,  GSK-3β 
recognizes this phosphorylation and phosphorylates CREB at Ser129, which inhibits 
CREB’s transcriptional activity. Thus, the cell’s ability to produce long term 
potentiation (LTP), and in consequence memory formation, is reduced.  
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LiCl, a known inhibitor of GSK-3β, protected neurons from neurotoxic influences 
(nerve growth factor deprivation, glutamate exitoxicity and Aβ-neurotoxicity in rat 
hippocampal neurons [133]. Thus GSK-3β might be involved in neuronal death. The 
anti-apoptotic protein BCL-2 is a target of CREB. Since CREB is a substrate of GSK-
3β, GSK-3β can influence BCL-2 via CREB. When GSK-3β is activated, it can 
phosphorylate CREB (previously, CREB has to be phosphorylated at SER133, for 
instance by PKA) and induce BCL-2 expression.  
A PS1 mutation was found in frontotemporal dementia patients. This mutation can 
activate GSK-3β [134]. GSK-3 inhibition may be a potential therapy for AD, because 
it may inhibit both Aβ-generation and Aβ-induced pathophysiological events in AD 
models.  
3.5 Genes associated with Alzheimer's disease 
In addition to APOE, the only currently established genetic risk factor for AD, linkage 
has been found on chromosome 12. Other linkage and association studies 
suggested, with less consistent results, candidate genes on chromosome 1, 2, 3, 4, 
5, 6, 9, 10, 11, 12, 14, 15, 19 , 21 and the X-chromosome. Recently, systematic 
meta-analyses were performed for each polymorphism with available genotype data. 
In addition to identifying the epsilon4 allele of APOE and related effects, over a 
dozen potential Alzheimer disease susceptibility genes were pinpointed (ACE, 
CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM 
and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-
1.38 for risk alleles and 0.92-0.67 for protective alleles) [7]. At www.alzforum.org an 
effort was made to select the most promising candidate genes, which are updated 
regularly (Table 3.1):  
 
1.  APOE (ε2/3/4) apolipoprotein E (ε2/3/4)  
2.  GAB2 GRB2-associated binding protein 2  
3.  CHRNB2 cholinergic receptor, nicotinic, beta 2 (neuronal) 
4.  CH25H cholesterol 25-hydroxylase  
5.  PGBD1 piggy Bac transposable element derived 1  
6.  LMNA lamin A/C  
7.  MAPT microtubule-associated protein tau   
8.  PCK1 phosphoenolpyruvate carboxykinase 1 (soluble)  
9.  TFAM transcription factor A, mitochondrial  
10. CST3    cystatin C 
11.  ACE angiotensin I converting enzyme (peptidyl-dipeptidase A) 1  
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12.  SORCS1 sortilin-related VPS10 domain containing receptor 1   
13.  hCG2039140 [predicted by Celera Genome Assembly]   
14.  GALP galanin-like peptide precursor   
15.  SORL1 Sortilin-related receptor 
16.  TNK1 tyrosine kinase, non-receptor, 1  
17.  GWA_14q32.13 protein unknown 
18.  IL1B interleukin 1, beta  
19.  TF transferrin  
20.  LOC651924 similar to Ubiquitin-like 1-activating enzyme E1B  
21.  GWA_7p15.2 protein unknown 
22.  LOC439999 similar to ribosomal protein S3a  
23.  DAPK1 death-associated protein kinase 1   
24.  GAPDHS 
glyceraldehyde-3-phosphate dehydrogenase, 
spermatogenic  
25.  PRNP prion protein 
26.  MYH13 myosin, heavy chain 13, skeletal muscle  
27.  MTHFR 5,10-methylenetetrahydrofolate reductase (NADPH)   
28.  BDNF brain-derived neurotrophic factor  
Table 3.1 Top candidate genes assumed to be involved in the pathogenesis of AD 
(www.alzforum.org, February 2008).  
‘Suggestive’ linkage according to Lander & Kruglyak was observed using several 
programme packages including USERM13, FASTLINK and GENEHUNTER-PLUS. 
Multipoint lod scores and two-point lod scores give an estimation how significant a 
result is. Lod scores above 3.0 are usually regarded as significant. One of the 
identified regions, on chromosome 19q13, fulfillls Lander & Kruglyak’s criteria of 
“highly significant“ linkage. This is presumably caused by the nearby APOE locus, 
localized in the same chromosomal region. Further suggestive linkage has been 
reported for a region between 10q22 and 10q26 close to the insulin degrading 
enzyme (IDE). The chromosomal region 9q21-22 has also been found in linkage 
analyses and an association with AD on this chromosome has been reported for the 
very low density lipoprotein receptor (VLDL-R). Three chromosomal regions are of 
particular interest because of their proximity to proposed AD candidate genes (1q23, 
11q25) or established AD genes (14q22). The linkage region on chromosome 1q23 
lies within 3 Mb of the nicastrin gene, which is part of the γ-secretase complex which 
liberates Aβ from APP. The beta-secretase cleavage enzyme (BACE) is a further 
candidate gene and is located approximately 20 Mb upstream of the region 11q25. 
The strong linkage signal on chromosome 14q22 lies within 20 Mb of the presenilin 1 
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gene (14q24.3), which is responsible for the majority of all early-onset familial AD 
cases. Families with AD-causing PSEN1 mutations have an average onset age of 
about 45 years. Recently new PSEN1 mutations were found causing an onset age of 
60 years or older. 
Genetic and environmental factors contribute to the pathogenesis of AD which is 
characterized, apart from other features, by amyloid accumulation, tau 
hyperphosphorylation, inflammation, apoptosis and oxidative stress. Some of the 
genetic and environmental risk factors are high age, a history of AD cases in the 
family, apolipoproteine E ε4 allele, high blood pressure, glucose intolerance, high 
homocysteine, low vitamine B12, B6 and folate levels, smoking, hypothyreosis, low 
level of education and others. Protective factors might be use of estrogens, 
antioxidants, anti-inflammatory agents, statins, apolipoproteine E ε2 allele, high level 
of education, physical exercise, a supporting social network. Mutations in APP, PS1 
and PS2 cause the autosomal dominant form of early onset AD. The APOE ε4 allele 
has been associated with an increased risk of developing both early and late onset 
AD. These genes are assumed to be responsible for approximately 50% of the 
genetic background of the disease, suggesting that further susceptibility genes exist. 
Fine mapping of chromosomal susceptibility regions using single nucleotide 
polymorphism (SNP) have been used to identify candidate genes in the most 
promising targets. Among many other candidate genes, which can be found on the 
web site www.alzforum.org, polymorphisms in the myeloperoxidase (MPO)-and 
alpha-2-macroglobulin (A2M)-gene have been detected in Finnish AD patients.  In 
order to find new susceptibility loci for late onset AD, a linkage disequilibrium 
analysis was performed in a Finnish population [135, 136]. Forty-seven patients with 
late-onset AD and 51 age-matched control subjects were chosen from the same 
geographic area in eastern Finland, where the population is descendent mainly from 
a small group of original founders. These subjects were initially genotyped with 366 
polymorphic microsatellite markers and a follow-up analysis was performed with 
additional microsatellite markers for those chromosome loci found to be associated 
with AD. This analysis revealed 8 chromosomal loci where more than one 
microsatellite marker was associated with AD: 1p36.12, 2p22.2, 3q28, 4p13, 10p13, 
13q12, 18q12.1 and 19p13.3. Genes in close proximity to these loci will provide 
targets for future genetic and functional studies of AD.  
Mutations in the PS1 gene, located on chromosome 14q24.3, account for 18-50% of 
all early onset AD cases and lead to the onset of the disease ranging from 16 to 65 
years [137]. 155 different PS1 mutations (most of them are missense substitutions) 
have been found in more than 315 AD families (http://www.molgen.ua.ac.be/ADMu 
tations/). The most frequent PS1 mutation is G206A observed in 18 unrelated 
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Caribbean Hispanic families [138].  
PS2 is located on chromosome 1q31-q42. In contrast to PS1, mutations of the PS2 
gene are rare and associated with a later age of onset [139]. 10 different PS2 
mutations have been reported in 18 families with age of onset ranging between 40 
and 85 years (http://www.molgen.ua.ac.be/ADMutations/). 
Mutations in the PS1-and PS2 genes cause the overproduction of Aβ42. In addition to 
APP processing, PS1 and PS2 are essential for the proteolytic cleavage of several 
other proteins including Notch.  
The strongest support for linkage has been described for chromosomes 10 and 12. 
The identified regions are rather broad (>30Mb). Whether true linkage for the 
following genes really exists is questionable, since LOD scores are quite small 
(approximately up to 1.2): VR22 (α-3-catenin; CTNNA3, α-T-catenin), IDE (insulin 
degrading enzyme), CH25H (cholesterol 25-hydroxylase), plasminogen activator 
urokinase (PLAU), Glutathione S-Transferase Omega1 (GSTO1). Higher LOD scores 
(approximately up to 4.0) have been found for M6PR (mannose-6-phosphate 
receptor), A2M (α2-macroglobulin), and LRP1 (lipoprotein receptor-related protein 1, 
α2-macroglobulin receptor A2MR, APOE receptor). Recently glyceraldehyde-3-
phosphate dehydrogenase (GAPD) and pregnancy zone protein (a homologue of 
A2M) have been discussed as candidate genes. Since in linkage studies relatively 
broad chromosomal regions are identified, it is probable that genes (further genes 
identified within this region) that have not yet been considered may play a crucial 
role. In recent years many genes have been reported to be associated with AD 
(http://www.alzforum.org/re/com/Alzforum) but none of these have shown the same 
replicable association like the one between AD and the APOE ε4-allele. 
Some of the APP mutations are close to the α-secretase cleavage site (for instance 
the following mutations: Dutch APP693, Flemish APP692, Arctic E693G, Italian 
E693K and Iowa D694N). Alpha-secretase cleavage prevents the generation of  Aβ. 
Thus, these mutations confirmed the expected change of the fibrillogenic potential of 
the generated Aβ species. This was strong support for the belief that APP is central 
in the disease mechanism. Cerebrovascular amyloid deposits are mainly composed 
of Aβ40, the less fibrillogenic Aβ form. 
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3.6 Selection of normalization algorithms 
 
For further information about the Affymetrix Match/Mismatch system and background 
calculation etc. refer to Chapter 12.4, Mathematical background. 
Microarray analysis provides the ability to measure several thousands of transcripts 
in parallel with the advantage of giving insight into the interplay between genes. 
Here, approximately 40,000 transcripts (the human genome comprises 20,000-
25,000 genes), were analyzed. Analyzing so much data in parallel requires a certain 
normalization strategy.  
Normalization of data is necessary to make it possible to compare the output of 
microarrays. Even if all conditions for sample preparation and hybridization are kept 
constant as good as possible, there is an inevitable extent of variation of the 
conditions. Due to variations in sample preparation, reagents, different lot-numbers 
of used kits, quality of Chips and many more, the output of microarrays will vary. To 
equalize these differences a suitable normalization strategy is necessary.  
There are several normalization strategies available, all of which can strongly 
influence the detection of transcripts. Some algorithms use Affymetrix’s ‘perfect 
match signals’ and ‘mismatch signals’, for instance the Probe Logarithmic Intensity 
Error Estimate (PLIER) algorithm, others only use ‘perfect match signals’ (GC-RMA). 
Background correction using mismatch signals has shown to improve accuracy but 
worsen precision. GC-RMA and PLIER algorithms provided the best balance of 
accuracy and precision [140], PLIER appeared to be superior to other algorithms in 
avoiding false positives with poorly performing probe sets [141]. The variability in 
performance of probe set algorithms is more dependent on assumptions regarding 
‘background’, than on calculations of ‘signal’. It was argued that ‘background’ is an 
enormously complex variable that can only be vaguely quantified, and thus the 
optimal probe set algorithm will vary from project to project [141]. It has to be taken 
into consideration that raw data should be calculated with more than one 
normalization algorithm and with a certain filtering strategy. Data have to be filtered 
in such a way that also certain hidden data, for instance false-negatives (differentially 
expressed data not to be realized as differentially expressed due to an insufficient 
filtering strategy) are discovered. It is necessary to use more than one algorithm in 
order to pinpoint the highest number of truly differentially expressed genes (Fig. 3.3). 
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Normalisation algorithms
True
biological
values
MAS 5
GC-RMA PLIER  
 
Figure 3.3 Diagram showing unknown, truly differentially expressed genes (true values, red 
circle) and hypothetical intersection with normalization algorithms. An algorithm finding 100% of 
true values does not exist for very big datasets, for instance when the whole genome, like here, is 
analyzed. In order to find the highest number of truly differentially expressed genes, a combination of 
three algorithms was used. Each algorithm has advantages and disadvantages concerning accuracy 
and precision. Some algorithms are known to detect nearly a similar set of genes. Here however, a 
combination of algorithms was chosen, to detect the highest number of truly differentially expressed 
genes, neglecting a big overlap. Some genes are detected by all 3 algorithms, others by two or by 
one. A few genes might be left which are not detected by any of these 3 algorithms. The genes found 
by only one algorithm should not be regarded as less important as the ones detected by two or three 
algorithms. The intersection in this Figure is hypothetical and provides a rough estimate of detected 
genes.  
 
It was shown that the overlap of data using 6 different algorithms was only 27 to 36% 
[142] or 60-70% when 3 algorithms were compared [143, 144]. MAS 5 usually 
generates higher signal variability for low expressed genes and similar detection 
sensitivity at higher expression levels. It is important to remember that the numerical 
outputs for signal intensity are complex patterns of hybridization across numerous 
oligonucleotides, representing both specific (PM) and non-specific (MM) signals, in 
addition to local background signal from non-probe surfaces. RMA (Robust Multiple 
Array Analysis) uses probeset information across several microarrays to determine 
specific signal from background or non-specific hybridization, while MAS 5 analyzes 
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one array at a time. Here, four normalization strategies are shown that were used for 
the calculation of the data presented in this thesis: 
Scale factor: This factor is used to make different intensities (measured 
fluorescence intensities derived from phycoerytrin-labeled targets) comparable. 
Different intensities are related to a common target intensity. Hybridization of a 
sample of bad RNA-quality (or bad hybridization conditions or low amounts of cRNA) 
will result in low intensities. This in turn results in an increased scale factor, because 
all measured intensities have to be multiplied by this factor to reach the same target 
intensity. Good RNA-quality usually results in high intensities. This in turn reduces 
the scale factor, because only a small factor is necessary to reach the same target 
intensity. The absolute values for the scale factor for each Chip should be lower than 
3.0. The relative values for the scale factor should not differ more than three-fold 
from Chip to Chip, otherwise the bias in the data becomes too big. A scale factor of 
approximately 1.0 is regarded as optimal. For these reasons the scale factor is a 
rough estimate of sample quality. Chips with a scale factor bigger than 3 should be 
omitted from data analysis according to Affymetrix.  
GC-RMA (Robust Multichip Averaging, regarding GC content) 
This algorithm was introduced by Wu et al. [145, 146] and has a special background 
correction step. The goal behind its design was to reduce the bias caused by not 
subtracting MM (MisMatches) in the RMA algorithm. The GC-RMA algorithm uses a 
rather technical procedure to reduce this bias and is based on the fact that the non-
specific affinity of a probe is related to its base sequence. The algorithm computes a 
background value to be subtracted from each probe using its base sequence and 
leaves the MM unconsidered.  
PLIER (Probe Logarithmic Intensity Error Estimate): This algorithm has been 
shown to be the most stringent with the lowest likelihood for false positives in poorly 
performing probe sets [141]. The results presented by Seo et al. indicate that the 
new dynamic weighting and error model for PLIER signal calculation is effective in 
reducing the influence of noise. The PLIER method produces an improved signal by 
accounting for experimentally observed patterns in probe behavior and handling 
error.  
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Resulting benefits include:  
• Higher reproducibility of signal (lower coefficient of variation) without loss of 
accuracy. 
• Higher sensitivity to changes in abundance of targets near background. 
• Dynamic estimation of the most informative features in an experiment to 
determine signal. 
PLIER produces a more accurate probe set signal by utilizing inherent probe feature 
response values, empirical probe performance, and handling error appropriately 
across low and high expressors. Feature response is calculated using experimental 
data across multiple arrays. PLIER also utilizes an error model that assumes error is 
proportional to the raw intensity, rather than to the background adjusted intensity. 
This ensures that the error model can adjust appropriately for relatively low and high 
abundance of target nucleic acids. 
MAS 5: Ordinary name for a frequently used algorithm implemented in the MAS 5.0 
software (Affymetrix). The expression values are calculated according to the ‘one-
step Tukey’s biweight algorithm’. This is a method for calculating cumulative probe 
set signal values. It is important to note that the MAS 5 algorithm occurs on a Chip-
by-Chip basis and is not applied across an entire set of chips. The signal value is 
calculated from the combined, background-adjusted PM and MM values of the 
probes in the probe set. It represents the amount of transcript in the solution. The 
signal is calculated as follows:  
• Cell intensities are pre-processed for global background.  
• An ideal mismatch value is calculated and subtracted to adjust the PM 
intensity.  
• The adjusted PM intensities are log-transformed to stabilize the variance.  
• The biweight estimator is used to provide a robust mean of the resulting 
values. Signal is output as the antilog of the resulting value.  
• Finally, the signal is scaled using a trimmed mean.  
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3.7 MIAME standards 
MIAME (Minimal Information About A Microarray Experiment) is the minimal 
information about a microarray experiment that is necessary to make it 
understandable for other researchers and to enable them to share the data and to 
repeat the experiment. The records of a certain experiment should be provided so 
that the data can be fully understood and the experiment fully reproduced by other 
researchers. MIAME is regarded as a guideline rather than a strict rule that has to be 
followed. However, MIAME has become the standard for many microarray software 
packages and databases, so it is highly recommended that the recorded data of the 
experiments are compliant with MIAME. MIAME is arranged into two broad areas: 
array design description and experiment description. Experiment description is 
further subdivided into: Experimental design, sample preparations and labelings, 
hybridization procedures, parameters and description of the data itself, together with 
any information about normalization or transformation of the data. Further details are 
described in Brazma et al. (2001) [147]. The microarray experiments in this thesis 
were carried out following MIAME guidelines. 
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3.8 Flow diagram of sample preparation and hybridization  
 
 
 
Figure 3.4 Flow diagram of sample preparation and hybridization. Total-RNA, extracted from 
cells, was reverse transcribed into cDNA, in vitro transcribed (and biotin-labeled) into cRNA. After 
fragmentation, cRNA was labelled with streptavidin-phycoerythrin and hybridized onto Gene Chips®.  
Gene Chips® were washed, scanned and data analysis was subsequently performed (Figure taken 
from www.Affymetrix.com). 
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3.9 Significance level, cut-off for fold change and 
normalization  
The selection of a ‘suitable’ significance level in combination with a ‘suitable’ 
threshold for the fold change of expression is crucial for microarray experiments. The 
commonly accepted p-value of 0.05 might, especially if a large amount of data is 
analyzed in parallel, not be stringent enough, if one wants to rule out any false-
positive data. This problem is known as the problem of ‘multiplicity of testing’. On the 
other hand, the number of obtained up and down-regulated genes could become too 
small if the selected threshold for the p-value is <0.05. Moreover, it has to be 
considered that the number of obtained genes depends crucially on the normalization 
algorithm used. To circumvent such problems and to obtain the most useful data the 
following strategy was used: 
All the data were calculated with at least three different normalization algorithms 
(PLIER, GC-RMA, MAS 5). The thresholds for the p-values were finally adjusted to 
p<0.05 (PLIER), to p<0.005 (GC-RMA) and to p<0.05 (MAS 5). Fold changes >2-fold 
or >3-fold were regarded as biologically meaningful (strongly depending on the 
algorithm used). However, it should be emphasized that smaller fold changes were 
also regarded to be important, for instance when weakly expressed genes, like 
transcription factors, were analyzed. There is no real agreement on which fold 
change is ‘biologically meaningful’, therefore, several combinations of fold changes 
and p-values were initially used to filter genes. Finally a combination thereof was 
chosen which best balanced accuracy and precision. Selected genes were confirmed 
by real-time PCR and proteomics. In parallel, no threshold for the fold change was 
fixed; instead, a fixed number of the most up or down-regulated genes was selected 
(for instance the 20 most down-regulated genes with a p-value <0.05). This approach 
is more applicable for some data sets, because there is no agreement on a ‘suitable’ 
cut-off for the fold change. Moreover, fold changes for relatively highly expressed 
genes, like the ones for structural proteins, do not have the same meaning as 
identical fold changes for weakly expressed genes, like transcription factors. In other 
words, the absolute intensity values have also to be considered whenever fold 
changes (relative intensity values) are calculated. 
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3.10 Software 
Apart from standard software, like Excel (Microsoft) and others, the following 
software was used for data analysis: 
• Microarray Suite 5.0 (Affymetrix) 
• Gene Chip Operating Software (GCOS) 1.2 (Affymetrix) 
• Data Mining Tool (Affymetrix) 
• Array Assist  3.3 (Stratagene) 
• Pathway Assist  3.0 (Stratagene) 
• Pathway Architect 3.0.1 (Stratagene) 
• Ingenuity Pathway Analysis (Ingenuity Systems)  
• Language R (open source software) 1
                                            
1 The open source software R (http://www.r-project.org) has revolutionized the statistical data analysis for most 
bioscience disciplines. The required time to learn the R software is well invested, since the R environment covers 
an unmatched spectrum of statistical tools including an efficient programming language for automating time-
consuming analysis routines. The fully integrated BioConductor project contains many additional R packages, in 
particular for the analysis of functional transcriptomics and microarray data. Due to their popularity, R and 
BioConductor are continuously updated and extended with the latest analysis tools that are available in the 
different research fields. The R environment is completely free and runs on all common operating systems.  
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4 The aim of this Ph.D. thesis 
There is a large body of evidence showing that Aβ42, in contrast to Aβ40, triggers a 
chain of harmful events in the development of AD. In order to elucidate the different 
mechanisms of Aβ42 and Aβ40 action, expression profiles of both Aβ42 and Aβ40- 
overexpressing human neuroblastoma cells should be performed. In order to produce 
different Aβ42 and Aβ40 levels, the Aβ precursors C99I45F and C99V50F (two C99 
mutants, known to generate different amounts of Aβ42 and Aβ40, due to their point 
mutations) should be overexpressed in human neuroblastoma cells. This should 
result, due to varying intracellular cleavage by γ-secretase, in different Aβ42 and Aβ40 
levels accompanied by the generation of their respective APP intracellular domains 
(AICDs) [49, 50]. The overall goal of this thesis was to obtain information about 
effects of the different C99 cleavage products. Whenever in this thesis the term 
“Aβ42/Aβ40 ratio” is used for reasons of simplicity, it also implies all further possible 
C99 cleavage products generated by γ-secretase. Human neuroblastoma cells 
should be stably transfected with constructs bearing point mutations that increase or 
decrease the Aβ42/Aβ40 ratio. Whole genome gene expression profiles (Affymetrix 
Gene Chip Technology™) of these cells were planned to be performed and to be 
compared to each other. A proteomic approach to the same cells should be 
compared with the transcriptomic approach. Overlapping transcripts/proteins should 
be further characterized. The function of promising candidates was intended to be 
elucidated by RNA interference. Therefore, CRABP1, which turned out to be up-
regulated in consequence of an increased Aβ42/Aβ40 ratio, both on the transcript and 
protein-level, should be knocked down in order to evaluate its effect on the 
differentiation behavior of the cells. Pharmacological treatments with retinoic acid 
should provide further insights into the reactions of the cells. For elucidating signal 
transduction pathways, I intended to determine the phosphorylation status of 
interesting proteins belonging to those pathways, which I had previously determined 
by gene expression profiling.  
 
The specific goals were to: 
• Identify genes that are differentially expressed by Aβ42 and Aβ40 
overexpression. 
• Identify genes that are inversely regulated by Aβ42 and Aβ40 overexpression. 
• Validate important genes by quantitative real-time PCR. 
• Identify signal transduction pathways affected by Aβ42 and Aβ40. 
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• Identify molecular functions affected by Aβ42 and Aβ40. 
• Identify chromosomal susceptibility regions which might be associated with 
AD. 
• Analyze the phosphorylation status of proteins in consequence of Aβ42 and 
Aβ40 overexpression. 
• Compare transcriptomic and proteomic data in order to obtain new insights 
into the pathological mechanisms of AD. 
• Identify candidate genes for kinases phosphorylating the microtubule-
associated protein tau. 
• Identify the most suitable algorithm for microarray analysis. 
• Discover specific gene/protein functions. 
• Establish models for the genes/proteins assumed to play predominant roles in 
response to altered Aβ42 and Aβ40 levels.  
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5 Results 
5.1 Preface 
The main goal of this thesis was to obtain information about how the different Aβ42 
and Aβ40 levels differ from each other in regard to their effect on gene expression. To 
generate different Aβ42 and Aβ40 levels, two C99 mutants were overexpressed in 
human neuroblastoma cells utilizing their ability to strongly shift the Aβ42/Aβ40 ratio in 
either direction, as previously demonstrated in detail [148, 149] and also shown in 
this thesis. C99I45F and C99V50F had opposite effects on the Aβ species 
generated: C99I45F is mainly processed to Aβ42, resulting in a dramatic increase of 
the secreted Aβ42/Aβ40 levels, whereas C99V50F is mainly processed to Aβ40. Since, 
due to a point mutation, the constructs expressed peptides only differing in a single 
amino acid outside the Aβ domain (at position 45 or 50, C99I45F and C99V50F 
respectively) compared to the wild type construct (C99WT), they were ideal for gene 
expression profiling, and potential technical variation influencing gene expression 
could be minimized. C99 is cleaved by γ-secretase resulting on the one hand in the 
release of Aβ42 and Aβ40 and on the other hand in the release of different AICD 
species. In the two C99 mutants (C99I45F and C99V50F) a strong shift in the 
amount of generated Aβ42 and Aβ40 levels was observed resulting from varying 
cleavage by γ-secretase. This is assumed to inherently be accompanied by 
production of two AICDs differing in length [49]. It has been shown that in cells 
overexpressing Aβ42 more AICD49-99 is produced than in cells overexpressing Aβ40 in 
which more AICD50-99 is produced [49, 50]. AICD57 and AICD59, the two species which 
should theoretically be left over after cleavage of Aβ42 and Aβ40 from the precursor 
C99, have not yet been unambiguously identified [150].   
Furthermore, the effects of C99-overexpression (C99WT versus mock) were 
evaluated and served as a control. The comparison C99I45F versus C99WT in this 
thesis is indicated by an increased Aβ42/Aβ40 ratio (Aβ42/Aβ40↑) whereas the 
comparison C99V50F versus C99WT is indicated by a decreased Aβ42/Aβ40 ratio 
(Aβ42/Aβ40↓).  
The observed alterations in gene expression may be triggered by Aβ42/Aβ40 or their 
respective AICDs (or cleavage products thereof, for instance through cleavage by 
caspases [151]). For reasons of simplicity the term “changed Aβ42/Aβ40 ratio” is used 
in this thesis but it also implies a change of the AICDs and all further possible C99 
cleavage products. It is assumed, even though no experimental evidence is provided 
here that the AICDs change similarly to Aβ42 and Aβ40. Currently, we are 
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investigating this issue together with our collaboration partner Stefan Lichtenthaler.  
Genome-wide analyses, phosphorylation screenings and functional assays were 
performed. These data were supported by a proteomic approach and real-time PCR 
data. Data from all approaches were combined to identify affected signal transduction 
pathways (Fig. 5.1). 
5.2 Flow chart of experimental steps 
 
What makes Aβ42  putative pathogenic compared to the physiological Aβ40 ?
Hypothesis: Aβ42 overexpression in human
neuroblastoma cells results in a gene
expression profile distinctly different
from that of Aβ40 overexpression
(accompanied by overexpression of
different AICDs)
Experimental design
* Quality control
Cell culture
*
RNA extraction
*
Labeling of RNA 
and hybridization 
on Chip
*
Data analysis
Transfection of SH-SY5Y cells with pCEP vectors
containing sequences encoding C99WT and C99 
mutants. Overexpressed C99 is intracellularly
cleaved resulting in different amounts of Aβ42
and Aβ40 in the mutants
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Data analysis
Normalisation
PLIERMAS 5 GC-RMA
Data filtering
Reintegration of data
Pathway analysis
Real-time PCR
and proteomics
Functional
assays
Phosphorylation
screening
Data filtering Data filtering
 
 
Figure 5.1 Flow diagram showing experimental steps from setting up the experimental design 
to the final data analysis. 
 
5.3 Cloning and expression of APP-fragments (C99 wildtype 
and -mutants) 
To analyze altered Aβ expression in a controlled manner, C99-overexpression 
constructs encoding the C-terminal part of AβPP (C99) were used, together with an 
N-terminal signal peptide [148, 149]. This peptide is correctly cleaved by signal 
peptidase and thus is identical to the AβPP-derived C99, the ultimate precursor for 
Aβ generation. C99 is processed by γ-secretase in the same manner as AβPP-
derived C99, making it an ideal substrate to study γ-secretase function or its 
cleavage products Aβ42 and Aβ40 without the influence of β-secretase. Since, due to 
a point mutation, the constructs express peptides only differing in a single amino acid 
outside the Aβ domain (at position 45 or 50, C99I45F and C99V50F respectively) 
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compared to the wild type construct (C99WT), they were ideal for gene expression 
profiling, enabling me to minimize potential technical variation influencing gene 
expression. 
Single independent clones of the human neuroblastoma cell line SH-SY5Y, 
overexpressing C99, were selected and checked for Aβ42 and Aβ40-expression. 
SH-SY5Y cells were stably transfected with constructs coding for the AβPP C-
terminal fragment C99WT and also for constructs bearing the point mutations 
C99I45F and C99V50F and the vector only (negative control) (Fig. 5.2). 2 
 
 
Figure 5.2 SH-SY5Y cells were stably transfected with a pCEP-vector containing the AβPP C-
terminal fragment C99WT, and constructs bearing the point mutations C99I45F and C99V50F. 
The same cell line was transfected with an empty vector (negative control). Eight clones (clone 1-3 for 
C99WT, clone 1-3 for C99I45F and clone 1-2 for C99V50F) with approximately similar expression 
levels and C99V50F clone 3, showing stronger expression, were selected and us ed for transcriptome 
and proteome analysis. Apart from analyzing the complete set of 3 clones, data analysis for the 
transcriptomic approach was also performed by excluding clone 3 (C99V50F), resulting in no 
significant difference compared with the triplicates. 
The purpose for using these mutations was their ability to strongly shift the Aβ42/Aβ40 
ratio in either direction, as previously demonstrated in detail [148]. This was 
confirmed here (Fig. 5.3). 
C99 mutants expressed different amounts of Aβ42 and Aβ40 
Overexpressed C99 is processed resulting in different amounts of Aβ42 and Aβ40 in 
the corresponding cell clones. To verify this, one clone of each triplicate was checked 
for the appropriate expression (Fig. 5.3). 
 
 
                                            
2 Western-blot was performed in collaboration with my colleague Kamran Honarnejad. 
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Figure 5.3 Western blot showing secreted Aβ42 and Aβ40. Aβ42 and Aβ40 were immunoprecipitated 
from conditioned media of the human neuroblastoma cell line SH-SY5Y, overexpressing C99, using 
the G2-11 antibody, specific for Aβ42 and G2-10, specific for Aβ40. Both Aβ species were detected by 
Western blotting using antibody W02. C99 is intracellularly cleaved, generating different amounts of 
Aβ42 and Aβ40 in mutant C99I45F and C99V50F. Mutant C99I45F expresses more Aβ42 than Aβ40, 
whereas C99V50F expresses more Aβ40 than Aβ42. 
As expected and described in detail [148, 149] C99I45F and C99V50F had opposite 
effects on the Aβ species generated: C99I45F is mainly processed to Aβ42, resulting 
in a dramatic increase of the secreted Aβ42/Aβ40 levels (relative ratio approximately 
20.4 compared to the Aβ42/Aβ40 ratio in C99WT); C99V50F is mainly processed to 
Aβ40 (relative ratio approximately 0.3 compared to C99WT) [148]. 
5.4 Transcriptomics 
5.4.1 Preface 
In a genome-wide approach in SH-SY5Y human neuroblastoma cells, both mutants 
(C99I45F and C99V50F) were compared to each other and compared to C99WT with 
the goal of obtaining information about the effects triggered by an increased 
(C99I45F) or decreased (C99V50F) Aβ42/Aβ40 ratio. Furthermore, the effects 
mediated by C99 were determined by comparing C99WT to a mock-control.  
5.4.2 Quality control 
Refer to Chapter 12.5, Supplementary Information. 
5.4.3 C99 as an internal control. The APP gene (overexpressed 
C99 respectively) was detected among the top up-
regulated genes 
The fold changes of the data were calculated (C99WT versus vector control) and 
were plotted against the scanned intensity values (derived from hybridization of 
target-RNA to the probes on the Chip). In Figure 5.4 B another set of triplicates for 
C99WT was used compared to Figure 5.4 A: Comparable distributions of the 
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transcripts in Figure A and B show consistency of the data, especially for strongly 
differentially expressed genes. C99 here served as an internal positive control for 
overexpressed C99, which was detected by the probe on the Chip, originally 
designed for detecting APP (probes selected by Affymetrix are usually taken from the 
3’ end and so able to detect the C-terminal fragment of APP). The analysis of another 
comparison (C99WT versus C99I45F) in which C99 was expected to be present in 
similar amounts showed that C99 was not differentially expressed. However, it has 
been reported that the AICD regulates the transcription of its own precursor [152] and 
consequently upregulation of endogenous APP cannot be excluded completely.  
 
A  
 
 
B 
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Figure 5.4 Graphs show up and down-regulated genes. Each dot represents one transcript 
(calculated with the Data Mining Tool, Affymetrix). A) A set of three single clones (corresponding to 
three replicates) for C99WT were used for Chip analysis; the mean of these replicates was used to 
calculate the fold change compared to the mock control. B) One clone (C99WT) used in Fig. A was 
combined with two other C99WT clones (clone 4 and 5, see Fig. 5.2). The position of the transcripts 
indicates the fold change (y-axis) and the intensity (x-axis). Encircled transcripts showed similar 
positions in Fig. A and B. Comparable distributions of the transcripts in Figure A and B showed 
consistency of the data especially for strongly differentially expressed genes (red encircled transcript: 
neuronatin, green: neurogenin 2, blue: C99). 
Performing data analysis with different sets of clones provided more information and 
a deeper insight into the spectrum of differentially expressed genes. C99 here served 
as an internal positive control for overexpressed C99. C99 is among the strongest 
up-regulated genes, reflecting the overexpression compared to the vector control 
(relative values). Furthermore, it is among the transcripts showing strong intensity 
values (absolute values), which was expected due to high abundance caused by 
overexpression.  
 5.4.4 Genes identified using different algorithms and software  
The same set of raw data was analyzed with three different algorithms to obtain as 
much significant information as possible: 
 
• PLIER algorithm (Array Assist, Stratagene) 
• GC-RMA algorithm (Language R, Bioconductor) 
• MAS 5 algorithm (one-step Tukey’s biweight algorithm) (Array Assist, 
Stratagene) 
 
Refer to Chapter 12.2, Supplementary Information, for gene lists analyzed with 
PLIER, GC-RMA and MAS 5.  
Volcano plots were created with Array Assist, using the PLIER algorithm for 
normalization. Graphs show differentially expressed genes plotted against the p-
value. Approximately 40,000 transcripts were analyzed.  
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Volcano plots showing differentially expressed genes plotted against the p-
value 
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Figure 5.5 Volcano plots showing differentially expressed genes (logarithmic scale to the base 
2) plotted against the p-value. Graph A: C99I45F/C99WT1 (increased Aβ42/Aβ40 ratio), Graph B: 
C99V50F/C99WT1 (decreased Aβ42/Aβ40 ratio). Data were calculated with the PLIER algorithm. The 
PLIER algorithm appeared to be superior to other algorithms in avoiding false positives with poorly 
performing probe sets [141]. The threshold was set to p<0.05 (n=3) and log ratio>1 (fold change>2) 
(lower left and right highlighted rectangle). A log2 ratio=0 corresponds to a fold change of 1 (not 
differentially expressed); a log2 ratio<0 means downregulation; a log2 ratio>0 means upregulation. 
The adjustment of a threshold for statistical and biological significance has to be regarded with care 
when a huge amount of data (here 44,000 data points corresponding to approximately 40,000 
transcripts) are analyzed. Also data with p-values bigger than 0.05 or fold changes smaller than 2.0 
may be biologically meaningful. Red colored CRABP1 and PREP were also found (along with others: 
INA, NEFL, NEF3 etc.) in a proteomic approach among the 20 most up-regulated proteins.The 
proteomic approach was performed blind by an independent laboratory of the University of Göttingen, 
Germany. For fold changes of expression, p-values (page S1-S11) and gene annotations (page S40-
S65) refer to Chapters 12.2 and 12.3, Supplementary Information.  
5.5 Transcriptomics compared to proteomics 
5.5.1  Preface 
The proteomic approach was performed to get information about differences on the 
protein level, because dysregulation on the transcript level does not necessarily 
mean that such a dysregulation also occurs on the protein level. Furthermore, genes 
from the transcriptomic approach overlapping with proteins from the proteomic 
approach validated each other increasing the reliability of the data.  
5.5.2 CRABP1 (cellular retinoic acid binding protein 1) and 
further genes associated with retinoic acid  
5.5.2.1 CRABP1 was differentially expressed both on the 
transcript level and on the protein level 
The transcriptomic and proteomic responses to an altered Aβ42/Aβ40 ratio in human 
neuroblastoma cells were studied. An increased or decreased Aβ42/Aβ40 ratio 
revealed differentially expressed transcripts, of which the 60 most up-regulated were 
used here. For the corresponding proteomic approach the 20 most up-regulated 
proteins were selected to validate altered protein expression. Only the overlap of 
transcriptomic and proteomic data was used for further analysis (Fig. 5.6).  
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CRABP1 was up-regulated exclusively in the mutant cell line with an increased 
Aβ42/Aβ40 ratio 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Differentially expressed transcripts and proteins. Comparison of C99I45F or C99V50F 
versus C99WT revealed differentially expressed transcripts, of which each of the 60 most up-regulated 
were used here. The 20 most up-regulated proteins each were selected for the corresponding 
proteomic approach. An intersection of the transcriptomic and proteomic data was subsequently 
performed. Only the intersection of both approaches (4 transcripts and proteins respectively) was used 
for further analysis. Out of these 4, only CRABP1 was up-regulated in C99I45F, whereas no 
differential expression was found in C99V50F (both mutants compared to C99WT). The remaining 3 
transcripts and proteins were differentially expressed in both mutants. The proteomic approach was 
performed blind by an independent laboratory. The term “differentially expressed” was applied when 
the fold change exceeded a threshold of ≥1.9 either on the transcript or the protein level. 
Three single independent clones each from C99WT, C99I45F and C99V50F (Fig. 
5.2) were used for transcriptomic and proteomic analyses (mock-transfected cells as 
negative control): 
For transcriptomics whole genome HG-U133 A and B Chips were used. Replicates 
were prepared and hybridized on different days and were derived from different 
independent clones. Data analysis was performed by calculating the means of three 
independent single clones.  
 
  Results 
 
 
45
For proteomics three clones each from C99WT, C99I45F and C99V50F were pooled, 
then proteins were extracted, CyDye labeled and analyzed by two-dimensional 
differential fluorescence intensity gel electrophoresis (2D-DIGE, Fig. 5.7). Up-
regulated proteins were identified by mass spectrometry [153]. 
 
 
Figure 5.7 2D-PAGE of CyDye-labeled proteins, extracted from SH-SY5Y cells. C99I45F and 
C99V50F were compared with C99WT. Differentially expressed proteins, evaluated by intensity of 
merged colors (Cy5, Cy3), were identified by mass spectrometry. Arrows indicate CRABP1. The 
proteomic approach was performed in collaboration with Dr. Peter Brechlin, Prof. Dr. Markus Otto (2D-
PAGE, University of Göttingen) and Dr. Olaf Jahn (mass spectrometry, Max Planck Institute for 
Experimental Medicine, Göttingen). 
Data analysis (transcriptomics and proteomics): For testing significance, analysis of 
variance (ANOVA) was performed for C99WT, C99I45F and C99V50F. For direct 
comparison of the two mutants (C99I45F and C99V50F) an unpaired t-test was 
performed. For further analysis, only the intersection of the transcriptomic and 
proteomic approach was used, increasing the reliability of the data.  
Immunocytochemistry confirmed the results of the transcriptomic and proteomic 
approach: CRABP1 was up-regulated in the mutant with an increased Aβ42/Aβ40 ratio 
(Fig. 5.8).  
 
 
 
 
 
Figure 5.8 Immunocytochemistry of human neuroblastoma cells (SH-SY5Y). CRABP1 
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expression was detected with an anti-CRABP1 antibody (see Materials and Methods) . A) Mutant 
C99I45F showed strong CRABP1 staining. B) Mutant C99V50F showed only a weak signal close 
to background staining. 
5.5.2.2 CRABP1 was up-regulated in mutant C99I45F (Aβ42/Aβ40↑) only, 
whereas mutant C99V50F (Aβ42/Aβ40↓) showed no differential 
expression of CRABP1 
 
Name Fold change 
(Transcript- 
omics) 
C99I45F/ 
C99WT  
Fold change 
(Proteomics) 
C99I45F/ 
C99WT 
Fold change 
(Transcript- 
omics) 
C99V50F/ 
C99WT 
Fold change 
(Proteomics) 
C99V50F/ 
C99WT  
P-value 
(Transcript- 
omics)  
P-value 
(Prote-
omics)  
CRABP1 
NEF3 
NEFL 
INA 
2.7 
2.6 
2.2 
1.8 
2.6 
3.1 
2.3 
1.8 
1.3 
2.3 
2.2 
1.6 
-1.1 
2.7 
2.5 
1.9 
0.123 
0.038 
0.032 
0.056 
0.032 
0.01 
0.004 
0.002 
Table 5.1 Comparisons of both mutants with C99WT. The overlay of transcriptomics and 
proteomics revealed four differentially expressed transcripts and proteins respectively. Out of 
these four, only CRABP1 was differentially expressed in C99I45F whereas C99V50F showed no 
differential expression of CRABP1 (compared to C99WT). Analysis of variance (One-Way ANOVA) 
was performed for C99WT, C99I45F and C99V50F. Cellular retinoic acid binding protein 1 (NCBI 
accession number of the protein identified by proteomics: gi|48146151); NEF3, Neurofilament 3 
(gi|67678152); NEFL, Neurofilament, light polypeptide 68kDa (gi|105990539); INA, Internexin neuronal 
intermediate filament protein, alpha (gi|14249342). 
CRABP1 was the second most up-regulated protein of the whole proteome and the 
second most up-regulated transcript of approximately 20,000 tested transcripts when 
only Chip A was considered (22,283 probe sets).  
 
Direct comparison of both mutants revealed CRABP1 as up-regulated in C99I45F 
compared to C99V50F. In contrast to this, neurofilaments were not differentially 
expressed. This comparison revealed an effect mediated by a changed Aβ42/Aβ40 
ratio, because both mutants expressed inverse levels of Aβ42 and Aβ40 respectively 
(Table 5.2).  
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Direct comparison between the two mutants (C99I45F versus C99V50F) showed 
CRABP1 as up-regulated in mutant C99I45F (Aβ42/Aβ40↑) whereas 
neurofilaments were not differentially expressed. 
 
Name Fold change 
(Transcriptomics) 
C99I45F/C99V50F 
Fold change 
(Proteomics) 
C99I45F/C99V50F 
P-value 
(Transcriptomics) 
P-value 
(Proteomics) 
CRABP1 
NEF3 
NEFL 
INA 
2.3 
1.1 
1.1 
1.1 
2.8 
-1.1 
-1.1 
-1.1 
0.188 
0.790 
0.640 
0.679 
0.059 
0.56 
0.51 
0.24 
Table 5.2 Direct comparison of C99I45F and C99V50F; C99V50F was the baseline 
experiment) revealed effects mediated by an altered Aβ42/Aβ40 ratio for CRABP1 by a 
fold change distinctly deviating from 1.0, and an effect mediated by C99 for NEF3, 
NEFL and INA by a fold change close to 1.0, because C99 was expressed 
approximately equally in both mutants. Significance was determined by performing an 
unpaired t-test for the direct comparison of both mutants. As to be expected, p-values 
were high for not differentially expressed genes [154, 155]. 
NEF3, NEFL and INA were not differentially expressed. I regard this unaltered 
expression of neurofilaments as mediated by C99, since C99 was expressed in 
similar amounts in both mutants and hence a comparison between these two 
mutants resulted in a fold change close to 1.0 (not differentially expressed). 
Comparison of SH-SY5Y cells transfected with the C99WT encoding construct 
versus SH-SY5Y cells transfected with the empty vector (mock) provides information 
about the effects mediated by C99 (Table 5.3).  
5.5.2.3 CRABP1 was not differentially expressed in 
consequence of C99-overexpression in contrast to 
neurofilaments 
 
Name Fold change 
(Transcriptomics) 
C99WT/mock 
Fold change  
(Proteomics) 
C99WT/mock 
P-value 
(Transcriptomics)  
P-value 
(Proteomics) 
CRABP1 
NEF3 
NEFL 
INA 
1.0 
-3.4 
-3.0 
-1.9 
1.4 
-1.8 
-1.3 
-1.3 
0.979 
0.024 
0.039 
0.069 
0.042 
0.086 
0.11 
0.029 
Table 5.3 Comparison between C99WT and mock-transfected cells revealed effects mediated 
by C99. NEF3, NEFL, INA were down-regulated in consequence of C99-overexpression. CRABP1 
was not differentially expressed (cut-off for differential expression ≥ 1.9 on the transcript or protein 
level respectively).  
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Neurofilaments (NEF3, NEFL, INA) were down-regulated in consequence of C99-
overexpression. CRABP1 was not differentially expressed, supporting the view that 
C99 is not responsible for CRABP1 dysregulation. 
 
Differential expression of CRABP1 was confirmed by real-time PCR 
Expression of CRABP1 was measured by quantitative real-time PCR with cyclophilin 
A as endogenous normalization control. Measurements reflect the mean of three 
independent clones, measured in triplicate. The fold change for CRABP1 of mutant 
C99I45F (Aβ42/Aβ40↑) compared to C99WT was 4.1 (stdev fold change: +/-2.3). In contrast 
to this, CRABP1 was only up-regulated 1.7 fold (stdev fold change: +/-0.8) in C99V50F 
compared to C99WT (Aβ42/Aβ40↓) and was up-regulated 1.3 fold (stdev fold change: +/-
0.8) in C99WT compared to mock-transfected cells. 
5.5.2.4 Increased Aβ42/Aβ40 ratio up-regulated CRABP1 and 
made cells less sensitive to all-trans retinoic acid 
CRABP1 is involved in RA-metabolism and transport [156] and I found it to be up-
regulated in consequence of an increased Aβ42/Aβ40 ratio. This raised the question of 
whether cells with an increased Aβ42/Aβ40 ratio show altered responses to RA 
treatment. SH-SY5Y cells were stably transfected with the constructs increasing or 
lowering the Aβ42/Aβ40 ratio (Fig. 5.2 and 5.3). These cells were treated with 0.1-1000 
nM RA in the absence or presence of serum. After 6 days, differentiation was 
evaluated by observing the length and number of outgrowing protrusions by phase 
contrast microscopy (Fig. 5.9, 1A and 1B). 
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Figure 5.9 Phase contrast images showing living human neuroblastoma cells (SH-SY5Y), 
grown on collagen coated glass cover slips and treated with 1 nM RA. Differentiation was 
evaluated by the number, shape and length of outgrowing protrusions. 1A) C99I45F 
(Aβ42/Aβ40↑). 2A) C99V50F (Aβ42/Aβ40↓). Differentiation was evaluated after RA-treatment for 6 days. 
Both cultures were 50% confluent when RA was added (day zero). C99I45F reached 90-100% 
confluency after 4-6 days without any signs of differentiation, whereas C99V50F did not exceed more 
than 60-70% confluency (after 6-10 days) and showed strong differentiation. C99I45F was also 
evaluated at 60-70% of confluency showing no signs of differentiation (data not shown), thus strong 
confluency of C99I45F (shown here) does not conceal putative signs of differentiation. B) C99I45F 
(Aβ42/Aβ40↑). 30 nM siRNA was admi nistered to the cells for 24 h in combination with a treatment of 1 
nM RA for 2.5 days. After 2.5 days, the effects of >50% knockdown of CRABP1 (2B) was compared to 
a nonsense sequence (negative control, 2A). C) C99I45F, same conditions as in B) except that RA 
was administered for 4 days. Differentiation was evaluated after 4 days. Knockdown of CRABP1 (2C) 
was compared to a nonsense sequence (negative control, 1C). D) C99I45F, same conditions as in C, 
but with another preparation from the same experiment as in C. B) and C) show preparations from 
different experiments. Experiments were repeated three times with consistent results. See Chapter 
12.7 (page S88, Fig. 12.4), Suppl. Information, for an enlarged picture of fig 5.9 D). 
Furthermore, the cell shape and number of cells were evaluated. 1 nM RA was 
selected for the subsequent functional validation and C99I45F-transfected cells were 
treated with 1 nM RA for 6 days (Fig. 5.9, 1A). No signs of differentiation were 
observed, irrespective of the cell confluency and duration of RA-treatment (cells were 
checked daily by light microscopy up to 10 days). In contrast to this, the cells 
expressing C99V50F (Fig. 5.9, 2A) showed differentiation at 1 nM RA treatment for 6 
days: the cells were approximately 30-60% confluent and did not reach 100% 
confluency after 10 days. Cells had an average of 2-4 protrusions. This differentiation 
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was observed from 0.1-10 nM RA, which approximately corresponds to physiological 
plasma concentrations [157, 158]. At concentrations ≥100 nM RA, differentiation 
could also be observed for the C99I45F transfected cell line. 
5.5.2.5 CRABP1 knockdown rescued the differentiation potential 
of Aβ42 overexpressing human neuroblastoma cells after 
RA treatment 
If an increased Aβ42/Aβ40 exerts the diminished differentiation behavior via CRABP1, 
a CRABP1 knockdown in C99I45F-transfected cells should rescue this effect. 30 nM 
siRNA was administered to C99I45F-transfected SH-SY5Y cells for 24h in 
combination with a treatment of 0.1-1000 nM (1 nM shown in Fig. 5.9) for 2.5-4 days 
in the absence (data not shown) or presence of serum. Serum withdrawal can mimic 
differentiation (“pseudo differentiation”) and was therefore excluded from further 
analysis. A >50% knockdown of CRABP1 was detected by quantitative real-time 
PCR (p=0.0002, n=3). Differentiation was evaluated after 2.5 days and 4 days. 
Knockdown of CRABP1 in combination with 1 nM RA (Fig. 5.9, 2B-2D) resulted in a 
strong change of cell shape, whereas transfection with a nonsense sequence, 
combined with 1 nM RA (negative control, Fig. 5.9, 1B-1D) did not alter the shape of 
the cells. The strongest differentiation was observed at 1 nM RA. No differentiation 
could be observed for treatment with siRNA but without RA, or treatment with 1 nM 
RA but without siRNA (data not shown). After CRABP1 knockdown and RA-
treatment, the cells were approximately 30-80% confluent (Fig. 5.9, 2B-2D) and did 
not reach 100% confluency after 10 days. The extent of interconnections between 
cells was clearly increased (Fig. 5.9, 2D) compared to the negative control (Fig. 5.9, 
1D).  
5.5.2.6 Three further genes, associated with RA-metabolism 
were differentially expressed in consequence of a 
changed Aβ42/Aβ40 ratio and may have influenced the 
effects mediated by RA 
Three further genes may influence the effects mediated by RA. Chip analysis 
revealed the following differential expression: Cytochrome P450 family 26 subfamily 
B polypeptide 1 (Cyp26B1), a RA-metabolizing enzyme [156], was found to be up-
regulated 1.8 fold (p=0.01, n=3) in C99I45F (Aβ42/Aβ40↑), whereas C99V50F 
(Aβ42/Aβ40↓) showed no differential expression (compared to C99WT). Direct 
comparison of both mutants (C99I45F/C99V50F) revealed a 2.6 fold upregulation for 
Cyp26B1 in mutant C99I45F (p=0.02, n=3). RAR-related orphan receptor B (RORB) 
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was down-regulated 2.0-fold (p=0.049, n=3) in C99V50F (compared to C99WT), 
whereas it was not differentially expressed in C99I45F. RA receptor beta (RARB) 
was not differentially regulated in C99V50F, whereas it was up-regulated 1.4 fold 
(p=0.05, n=3) in C99I45F (compared to C99WT). 
5.5.2.7 Further genes, located on chromosomal regions adjacent 
to CRABP1 (15q24), were differentially expressed 
CRABP1 is located on the same chromosomal locus (15q24) as alpha polypeptide 3, 
4 and 5 of the nicotinic cholinergic receptor and cytochrome P450, subfamily XIA 
(cholesterol side chain cleavage, Cyp11A1). Linkage of the chromosomal locus 
15q24 to AD is explainable by the presence of alpha polypeptide 3, 4 and 5 of the 
nicotinic cholinergic receptor. However, this linkage actually could also be based on 
CRABP1, located on the same chromosomal locus. CRABP1 is in close 
chromosomal proximity to the γ-aminobutyric acid (GABA) A receptor, beta 3 
(chr15q11.2-q12), which I found to be 2.6 fold up-regulated (p=0.03, n=3) in mutant 
C99I45F, whereas it was not differentially expressed in C99V50F (compared to 
C99WT). Furthermore, I found the insulin-like growth factor 1 receptor (IGF1R) 
(15q25-q26) 1.8 fold up-regulated (p=0.28, n=3) in mutant C99I45F whereas it was 
not differentially expressed in C99V50F (compared to C99WT).  
5.5.3 Further overlapping transcripts/proteins 
5.5.3.1 Preface 
Using less stringent criteria (for instance using an increased number of 
transcripts/proteins to be overlaid) for transcriptomics and proteomics revealed the 
following genes and proteins as differentially expressed. The 20 most up and down-
regulated proteins were compared with the 100 most (for PREP the 200 most) up 
and down-regulated transcripts (p<0.05). P-values were calculated from three 
independent experiments for the transcriptomic approach (each experiment with a 
different clone, so that the probability of clonal effects was minimized); although p-
values are not yet determined for the proteomic approach (but will be calculated prior 
to publication as a paper), and could turn out to exceed the generally accepted level 
of significance (p-value=0.05), the results are assumed to be reliable because two 
different technologies (transcriptomics and proteomics) validated each other and 
were carried out in two independent laboratories (transcriptomics: University of 
Heidelberg, Germany; proteomics: University of Göttingen, Germany). The probability 
that among a relatively small number of proteins analyzed by proteomics (20 most 
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up-regulated and 20 most down-regulated proteins) an overlap can be found with the 
most dysregulated transcripts just by chance is very low.  
5.5.3.2 PREP (prolyl endopeptidase) 
 
• C99I45F/C99WT (Aβ42/Aβ40↑): 1.6 fold up-regulated, p=0.0025 
(transcriptomics), 1.2 fold up-regulated (proteomics) 
• C99V50F/C99WT (Aβ42/Aβ40↓): 1,1 fold down-regulated, p=0.41 
(transcriptomics, as to be expected p-values were high for not differentially 
expressed genes), 1.2 fold down-regulated (proteomics). 
• C99I45F/C99V50F (direct comparison between the two mutants): 2.2 fold up-
regulated , p=0.0075 (transcriptomics), 1.4 fold up-regulated (proteomics). 
 
5.5.3.3 T-cell receptor, α and δ locus 
 
• C99WT/mock (C99↑): α-locus: 5.0 fold down-regulated, p=0.02490 
(transcriptomics), α and δ loci of the T-cell receptor were among the 20 most 
dysregulated proteins (proteomics). 
• C99I45F/C99WT (Aβ42/Aβ40↑): α-locus: 5.0 fold up-regulated, p=0.00219 
(transcriptomics), δ-locus: 4.0 fold up-regulated, p=0.02572 (transcriptomics), 
α and δ loci of the T-cell receptor were among the 20 most dysregulated 
proteins (proteomics). 
• C99V50F/C99WT (Aβ42/Aβ40↓): α-locus: 6.3 fold up-regulated 0.00132 
(transcriptomics), α and δ loci of the T-cell receptor were among the 20 most 
dysregulated proteins (proteomics). 
 
5.5.3.4 VGF (VGF nerve growth factor inducible) 
 
• C99I45F/WT (Aβ42/Aβ40↑): not differentially expressed 
• C99V50F/WT (Aβ42/Aβ40↓): 2.0 fold up-regulated (transcriptomics), VGF was 
among the 20 most dysregulated proteins (proteomics). 
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5.5.3.5 NADH dehydrogenase (ubiquinone)  
NDUFB9 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 22kDa) was 
differentially expressed on the transcript level: 
 
• C99I45F/WT (Aβ42/Aβ40↑): 1.3 fold up-regulated, p=0.063 (transcriptomics) 
• C99V50F/WT (Aβ42/Aβ40↓): 2.3 fold down-regulated, p=0.132 (transcriptomics) 
 
On the protein level the ubiquinone precursor was detected: 
 
• The NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa, precursor  
was identified among the 20 most dysregulated proteins (proteomics). 
 
5.5.3.6 DNCLI2 (dynein cytoplasmic light intermediate 
polypeptide 2)  
• C99I45F/WT (Aβ42/Aβ40↑): 1.5 fold down-regulated p=0.0066 (transcriptomics) 
• DNCLI2 was among the 20 most dysregulated proteins (proteomics). 
• C99V50F/WT (Aβ42/Aβ40↓): not differentially expressed 
5.6 Inversely regulated genes 
5.6.1 Preface 
Genes regulated in this manner are regarded in particular as specific for a changed 
Aβ42/Aβ40 ratio, because the direction of regulation (which is inverse for Aβ42/Aβ40↑ 
and for Aβ42/Aβ40↓) point to a process expected to depend on the ratio itself: More 
Aβ42 /less Aβ40 has the opposite effect (on the direction of gene regulation) as more 
Aβ40 /less Aβ42. If the ratio itself (increased ratio) up-regulated a certain gene, then 
the same gene should be found among the most down-regulated ones (and vice 
versa) for an inverted (decreased ratio). Indeed such genes could be found. 
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5.6.2 Genes up-regulated in mutant C99I45F versus C99WT 
(Aβ42/Aβ40↑) and at the same time down-regulated in 
mutant C99V50F versus C99WT (Aβ42/Aβ40↓)  
Most up-regulated genes (C99I45F versus C99WT(Aβ42/Aβ40↑)) which were 
simultaneously the most down-regulated ones according to the comparison C99V50F 
versus C99WT (Aβ42/Aβ40↓): 
Inversely regulated genes were identified by calculating the differences (∆ fold 
change) of the fold changes, derived from the comparisons of C99I45F versus 
C99WT1 and C99V50F versus C99WT1. ∆ fold changes were sorted descendingly. 
The cut off ∆ fold change  was set to ≥2.5 (below ∆ fold change=2.5, differential 
expression here was questionable, because at least one value was close to 1.0 and 
thus not differentially expressed). 
 
Table 5.4 Most up-regulated genes (C99I45F versus C99WT(Aβ42/Aβ40↑)) which 
were at the same time the most down-regulated ones according to the 
comparison C99V50F versus C99WT 
Probe set 
ID 
Gene 
Symbol 
Gene name p-
value 
fold 
change 
C99I45F/ 
C99WT1 
p-
value 
fold  
change 
C99V50/ 
C99WT1 
∆ fold 
change 
Chro
mo- 
somal 
loca-
tion 
226814_at ADAMTS9 a disintegrin-like 
and 
metalloprotease  
(reprolysin type) 
with 
thrombospondin  
type 1 motif  9 
0.003 2.0 0.066 -5.0 7.0 chr3p
14.3-
p14.2 
225627_s
_at 
KIAA1573 KIAA1573 
protein 
0.044 1.6 0.149 -2.7 4.3 chr1p
31.3 
225990_at BOC brother of CDO 0.081 1.6 0.072 -2.5 4.2 chr3q
13.2 
225081_s
_at 
RAM2 transcription 
factor RAM2 
0.160 1.4 0.157 -2.6 4,0 chr7p
15.3 
221796_at NTRK2 neurotrophic 
tyrosine kinase 
receptor type 2, 
non-catalytic 
isoform 
0.023 2.2 0.086 -1.7 3.9 chr9q
22.1 
229831_at CNTN3 contactin 3  
(plasmacytoma 
 associated) 
0.176 2.3 0.163 -1.6 3.8 chr3p
26 
228978_at LOC44045
0 
LOC440450 0.083 1.6 0.003 -2.2 3.8 chr17
q23.2 
223721_s
_at 
DNAJC12 DnaJ (Hsp40)  
homolog  
0.036 1.7 0.170 -2.0 3.7 chr10
q22.1 
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subfamily  
C  member 12 
228053_s
_at 
C9orf105 chromosome 9  
open reading 
frame 105 
0.074 1.3 0.168 -2.3 3.6 chr9p
13.1 
221795_at NTRK2 neurotrophic 
tyrosine 
 kinase  receptor  
type 2, non-
catalytic isoform 
0.193 1.9 0.058 -1.7 3.6 chr9q
22.1 
222992_s
_at 
NDUFB9 NADH 
dehydrogenase 
(ubiquinone) 1  
Beta subcomplex  
9  22kDa 
0.063 1.3 0.132 -2.3 3.6 chr8q
13.3 
228080_at LOC14390
3 
layilin 0.149 1.6 0.182 -2.0 3.6 chr11
q23.1 
229400_at HOXD10 homeo box D10 0.065 1.6 0.128 -2.0 3.6 chr2q
31.1 
241872_at DKFZp761
D221 
Hypothetical 
protein 
DKFZp761D221 
0.032 1.8 0.191 -1.8 3.6 chr1p
31.2 
221933_at NLGN4X neuroligin 4  X-
linked 
0.030 1.9 0.149 -1.5 3.4 chrXp
22.32-
p22.3
1 
236308_at LOC28587
8 
hypothetical 
protein 
LOC285878 
0.081 1.9 0.151 -1.5 3.4 chr7p
11.2 
237563_s
_at 
LOC44073
1 
LOC440731 0.052 1.5 0.117 -1.8 3.3 chr1q
42.2 
234472_at GALNT13 UDP-N-acetyl-
alpha-D-
galactosamine: 
polypeptide N-
acetylgalactosa
minyltransferase 
13 (GalNAc-T13)
0.084 1.5 0.167 -1.8 3.2 chr2q
23.3-
q24.1 
219697_at HS3ST2 heparan sulfate 
(glucosamine) 3-
O-
sulfotransferase 
2 
0.012 1.7 0.137 -1.5 3.2 chr16
p12 
224407_s
_at 
MASK Mst3 and SOK1-
related kinase /// 
Mst3 and SOK1-
related kinase 
0.026 1.3 0.142 -1.8 3.1 chrXq
26.2 
209238_at STX3A syntaxin 3A 0.159 1.4 0.044 -1.8 3.1 chr11
q12.1 
225626_at PAG phosphoprotein 
associated with 
glycosphingolipid
-enriched 
microdomains 
0.037 1.5 0.078 -1.6 3.1 chr8q
21.13 
210123_s
_at 
CHRNA7  cholinergic 
receptor  
nicotinic alpha  
polypeptide 7  
0.061 1.8 0.152 -1.3 3.0 chr15
q14 /// 
chr15
q13.1 
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203640_at MBNL2 muscleblind-like 
2 (Drosophila) 
0.037 1.5 0.126 -1.5 3.0 chr13
q32.1 
205151_s
_at 
KIAA0644 KIAA0644 gene 
product 
0.107 1.4 0.145 -1.5 2.9 chr7p
15.1 
205150_s
_at 
KIAA0644 KIAA0644 gene 
product 
0.127 1.4 0.195 -1.5 2.9 chr7p
15.1 
214680_at NTRK2 neurotrophic 
tyrosine kinase  
receptor  type 2, 
non-catalytic 
isoform 
0.062 1.6 0.165 -1.3 2.9 chr9q
22.1 
205380_at PDZK1 PDZ domain 
containing 1 
0.115 1.3 0.058 -1.6 2.9 chr1q
21 
212148_at PBX1 Pre-B-cell 
leukemia 
transcription 
factor 1 
0.121 1.3 0.143 -1.6 2.9 chr1q
23 
223734_at OSAP ovary-specific 
acidic protein 
0.117 1.3 0.187 -1.5 2.8 chr4q
31.1 
213068_at DPT dermatopontin 0.167 1.3 0.106 -1.4 2.7 chr1q
12-
q23 
219501_at FLJ10094 hypothetical 
protein 
FLJ10094 
0.073 1.3 0.111 -1.4 2.7 chr13
q14.1
1 
216985_s
_at 
STX3A syntaxin 3A  3 0.130 1.3 0.072 -1.4 2.7 chr11
q12.1 
210247_at SYN2 synapsin II 0.072 1.3 0.102 -1.3 2.6 chr3p
25 
216268_s
_at 
JAG1 jagged 1 (Alagille 
syndrome) 
0.095 1.3 0.187 -1.3 2.6 chr20
p12.1-
p11.2
3 
Table 5.4 Most up-regulated genes (C99I45F versus C99WT(Aβ42/Aβ40↑)) which were at the same 
time the most down-regulated ones according to the comparison C99V50F versus C99WT 
(Aβ42/Aβ40↓). ∆ fold change indicates the extent of differential expression between both mutants. For 
gene annotations see Chapter 12.3 (pages S66-S70), Supplementary Information. 
Syntaxin 3 
Syntaxin 3 was of special interest, due to its involvement in neurotransmitter release. 
Syntaxin 3a together with its splice product syntaxin 3b were found to be inversely 
regulated. 
C99I45F versus C99WT (Aβ42/Aβ40↑) C99V50F versus C99WT (Aβ42/Aβ40↓) 
Syntaxin 3a up-regulated Syntaxin 3a down-regulated 
Syntaxin 3b up-regulated Syntaxin 3b down-regulated 
                                            
3 Erroneously named (by Affymetrix) syntaxin 3A (216985_s_at) is a spliced form of syntaxin 3A and its correct 
name is syntaxin 3B. Syntaxin 3B is identical to syntaxin 3A but lacks 37 amino acid residues, from amino acid 
226 to amino acid 262. 
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Table 5.5 Syntaxin 3a and its splice product syntaxin 3b were inversely regulated in both 
mutants. Syntaxin 3a/b were up-regulated in consequence of an increased Aβ42/Aβ40 ratio, whereas 
they were down-regulated in consequence of a decreased Aβ42/Aβ40 ratio. The fact that both isoforms 
(3a and 3b) were regulated in the same direction, to the same extent and belong to the transcripts with 
high absolute values (highly abundant transcripts), strongly increases the reliability of a real differential 
expression of syntaxin 3.  
Intriguingly, we (together with our colleague Laura Busia) also found Syntaxin 3 to be 
among the most significantly down-regulated genes in embryonic mouse fibroblasts 
in consequence of PS2 knockdown with siRNA. In this approach Aβ levels may be 
speculated to be decreased. This is in line with the observation of syntaxin 3 down-
regulation in mutant C99V50 compared to C99WT (Aβ42/Aβ40↓) and argues for an 
effect mediated by a decreased Aβ42 expression. If a decreased Aβ42 level exerts this 
effect, then an increased Aβ42 level should regulate syntaxin3a in the opposite 
direction. Indeed, this appears to be true, because it was found to be up-regulated for 
an increased Aβ42/Aβ40 ratio. 
5.6.3 Genes down-regulated in mutant C99I45F versus C99WT 
(Aβ42/Aβ40↑) and at the same time up-regulated in mutant 
C99V50F versus C99WT (Aβ42/Aβ40↓) 
Most down-regulated genes (C99I45F versus C99WT (Aβ42/Aβ40↑)), which were 
simultaneously most up-regulated for the comparison C99V50F versus C99WT 
(Aβ42/Aβ40↓):  
Inversely regulated genes were identified by calculating the differences (∆ fold 
change) of the fold changes, derived from the comparisons C99I45F versus C99 
WT1 and C99V50F versus C99 WT1. ∆ fold changes were sorted descending. The 
cut off ∆ fold change was set to ≥2.5 (below ∆ fold change=2.5, differential expression 
here was questionable, because at least one value was close to 1.0 and thus not 
differentially expressed). 
 
probe set 
ID 
Gene 
symbol 
Gene 
 name 
p-value 
C99I45F/ 
C99WT1
Fold 
change 
C99I45F/ 
C99WT1
p-value 
C99V50F/ 
C99WT1 
Fold 
change 
C99V50F/ 
C99WT1 
∆ fold 
change 
Chromo
somal 
location
209604_s_
at 
GATA3 GATA 
binding 
protein 3 
0.1625 -2.7 0.0780 1.2 3.9 chr10p1
5 
210135_s_
at 
SHOX2 short stature 
homeobox 2 
0.1886 -2.1 0.0023 1.2 3.3 chr3q25-
q26.1 
209164_s_
at 
CYB561 cytochrome 
b-561 
0.0602 -1.9 0.0884 1.3 3.2 chr17q1
1-qter 
209163_at CYB561 cytochrome 0.0736 -1.8 0.0651 1.3 3.1 chr17q1
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b-561 1-qter 
210816_s_
at 
CYB561 cytochrome 
b-561 
0.0343 -1.6 0.0951 1.3 2.9 chr17q1
1-qter 
217200_x_
at 
CYB561 cytochrome 
b-561 
0.0370 -1.7 0.1908 1.2 2.9 chr17q1
1-qter 
210134_x_
at 
SHOX2 short stature 
homeobox 2 
0.1240 -1.4 0.1722 1.1 2.5 chr3q25-
q26.1 
Table 5.6 Most down-regulated genes (C99I45F versus C99WT (Aβ42/Aβ40↑)) which were at the 
same time the most up-regulated ones according to the comparison C99V50F versus C99WT 
(Aβ42/Aβ40↓). ∆ fold change indicates the extent of differential expression between both mutants. 
TFPI2, which belongs to the strongest differentially expressed genes, is not listed here, because of a 
rather high p-value which is beyond a threshold of 0.05. Nevertheless, it should be taken into 
consideration that TFPI2 was detected by two independent probe sets as down-regulated (C99I45F 
versus C99WT), but strongly up-regulated in C99V50F versus C99WT, also detected by two 
independent probe sets and a p-value <0.05 (compare with Fig. 5.5). 
For gene annotations see Chapter 12.3.3 (pages S66-S70), Supplementary 
Information. 
5.7 Increased Aβ42/Aβ40 ratio down-regulated the imprinted 
region IGF2-H19 on chromosome 11p15.5 
Among the strongest down-regulated genes, as a consequence of an increased 
Aβ42/Aβ40 ratio, were the following four genes, all of which are known to be regulated 
by imprinting. All are localized on the same chromosomal locus and were down-
regulated to the same extent (IGF2, p=0.05, fold change= -2.6; CDKN1C, p= 0,06, 
fold change=-1.98; putative IGF2 associated protein, p=0.1, fold change=-1.84; H19, 
p=0.21, fold change=-2.0). Detection of transcripts by several probe sets make down-
regulation highly reliable: downregulation was confirmed by 2 different probe sets for 
IGF2, by 2 different probe sets for H19, by 3 different probe sets for CDKN1C and by 
1 probe set for putative IGF2 associated protein. 
 
Gene symbol Gene name Chromosomal locus Silencing 
IGF2 
insulin-like growth factor 2 
(somatomedin A) chr11p15.5 imprinted gene 
H19 
H19  imprinted maternally 
expressed untranslated mRNA chr11p15.5 imprinted gene 
CDKN1C 
cyclin-dependent kinase 
inhibitor 1C (p57, Kip2) chr11p15.5 imprinted gene 
LOC492304 
putative IGF2 associated 
protein chr11p15.5 imprinted gene  
Table 5.7 Genes, known to be regulated by imprinting localized on the same chromosomal 
locus (chr.11p15.5) and down-regulated to the same extent. 
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In contrast to this, a decreased Aβ42/Aβ40 ratio did not result in dysregulation of the 
previously described genes. The fact that cathepsin D, one of the top candidate 
genes for AD, is localized on the same locus (chr.11p15.5) make this region a top 
candidate region for AD. Cathepsin D was among the 10 most down-regulated genes 
as a result of a decreased Aβ42/Aβ40 ratio (C99V50F/C99WT1, p=0.09, fold change= 
-2.9). Cathepsin D, located 230 kb from H19, is among a set of candidate imprinted 
genes in mice [159]. 
5.8 Phosphorylation status of proteins and total protein 
amounts in consequence of an altered Aβ42/Aβ40 ratio 
detected by high throughput immunoblotting  
5.8.1 Immunoblots 
High throughput immunoblotting was performed using Kinetworks™, a screening 
procedure from the Canadian company Kinexus. Antibodies directed against 
phosphorylated proteins were extensively tested for specificity by Kinexus. Out of 
3000 commercially available antibodies, Kinexus selected approximately the 650 
most potent and specific ones for their phosphorylation screening. The KinetworksTM 
analysis has been specially optimized to reveal band shifts in signaling proteins on 
SDS-PAGE gels that may arise from their phosphorylation. A high-resolution scanner 
was used by Kinexus to detect chemoluminescence. The relative abundance of each 
detected immunoreactive protein was quantified: The intensities of the enhanced 
chemoluminescence (ECL) signals were quantified (counts per minute) from the 
multiple immunoblots. 
At first the KPSS-9.0 Phospho-Site Neurobiology screen was used to pre-select 
interesting proteins. For further detailed analysis the KCPS-1.0 custom screens were 
used twice. 
The phosphorylation status of proteins extracted from the human neuroblastoma cell 
line SH-SY5Y, transfected with mutant C99I45F (Aβ42/Aβ40↑), C99V50F (Aβ42/Aβ40↓), 
and C99WT was checked by Western-blotting. C99WT served as a reference (base-
line experiment). Subsequently, relative (to C99WT) percentage of phosphorylation 
was calculated (by densitometry of the bands and normalized to a set of 
normalization controls). These data were compared to each other, providing insights 
into differentially phosphorylated proteins. For some proteins the total protein 
expression was measured using a pan-specific (directed against phosphorylated and 
non-phosphorylated binding sites) antibody. This provides the possibility to 
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discriminate between a real change in the phosphorylation status and a change in 
total protein expression of the corresponding protein. For the remaining proteins, a 
change in the phosphorylation status was observed, however, total protein 
expression was not tested by Western-blotting. Gen expression data (transcript-level) 
for these proteins provide limited estimations of how these proteins are regulated (the 
protein-levels for many proteins, measured by a proteomic approach, were mostly 
consistent with mRNA-levels). For these proteins it can be concluded that a 
difference in the phosphorylation status exists or that a difference in total protein 
expression exists, which might simulate hyper/hypo-phosphorylation. However, 
differences in total protein expression were not probable (but cannot be totally 
excluded, due to putative regulatory processes on the protein-level, like proteasomal 
degradation and others), since m-RNA levels were monitored by gene expression 
data showing no altered transcript expression, if not indicated elsewhere. Further 
validation of total protein expression will provide further insights into the 
phosphorylation status. According to Kinexus, only differences of expression or 
phosphorylation of >25% (between two samples) can be regarded as a real change 
in expression or phosphorylation. Only proteins showing a distinct difference of 
expression or phosphorylation between C99WT and C99-mutants compared to each 
other (after normalization) were selected for further analysis (see diagrams below). 
Apart from a change of expression or phosphorylation (relative values between two 
samples presented in %), absolute values (band intensities of one sample) have to 
be taken into account, to evaluate data reliability. 
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KPSS-9.0 - Phospho-Site Neurobiology screen: 
A 
C99WT: 
 
 
B 
C99I45F: 
 
Figure 5.10 Immunoblots of proteins from SH-SY5Y cells. Phospho-
specific antibodies were used to determine the phosphorylation 
status. A) Cells transfected with C99WT and B) Cells transfected with 
C99I45F. 
 
 
Example: 
FAK shows less 
phosphorylation 
in C99I45F than 
in C99WT 
(normalisation 
not considered 
here) 
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NORMALIZED 
COUNTS PER 
MINUTE 
LANE BAND 
FULL NAME OF PROTEIN  
[EPITOPE] ABBREVIATION C99WT C99I45F
2 1 
MAPK/ERK protein-serine kinase 1 
(MKK1) [T385] MEK1 5635 5928 
4 1 Protein-serine kinase C delta [S664] PKCd 6421 3195 
5 1 
cAMP response element binding 
protein 1 [S129+S133] CREB1 606 342 
6 1 
Protein-serine kinase C epsilon 
[S729] PKCe 627 622 
6 3 
Microtubule-associated protein tau 
[S720] (55) Tau 509 257 
7 1 
Focal adhesion protein-tyrosine 
kinase [S722] FAK 4864 3048 
9 3 
Microtubule-associated protein tau 
[S515/S518] (46) Tau 2650 4241 
9 4 
MAPK/ERK protein-serine kinase 1 
(MKK1) [S297] MEK1 1490 2188 
10 2 Protein-serine kinase C eta [S674] PKCh 5885 1972 
11 3 
Protein-serine kinase C gamma 
[T514] PKCg 7009 4135 
11 4 
MAPK/ERK protein-serine kinase 1 
(MKK1) [T291] MEK1 5028 5832 
12 3 
G protein-coupled receptor-serine 
kinase 2 (BARK1) [S670] (70) GRK2 652 744 
13 2 
Microtubule-associated protein tau 
[S515] (63) Tau 742 1028 
13 3 
Microtubule-associated protein tau 
[S515] (46) Tau 446 971 
13 4 
Microtubule-associated protein tau 
[S515] (44) Tau 1175 2541 
14 3 
Extracellular regulated protein-serine 
kinase 1 (p44 MAP kinase) 
[T202+Y204] Erk1 929 1503 
15 2 
Microtubule-associated protein tau 
[S712] (46) Tau 677 942 
15 3 
Microtubule-associated protein tau 
[S712] (44) Tau 789 2213 
16 3 Protein-serine kinase C eta [T655] PKCh 3631 1369 
16 5 
cAMP-dependent protein-serine 
kinase catalytic subunit beta [S338] PKA Cb 16110 12100 
17 1 
Protein-serine kinase B alpha (Akt1) 
[S473] PKBa (Akt1) 1401 1008 
18 1 
Protein-serine kinase C beta 2 
[T641] PKCb2 1917 1104 
18 2 
Glycogen synthase-serine kinase 3 
alpha [Y279] (44) GSK3a 4069 9008 
18 3 
Glycogen synthase-serine kinase 3 
beta [Y216] (39) GSK3b 4365 7390 
19 3 
Microtubule-associated protein tau 
[S518] (46) Tau 2550 5662 
20 5 
cAMP-dependent protein-serine 
kinase catalytic subunit alpha/beta 
[T197] PKA Ca/b 5858 7168 
Reprobed* Reprobed* Protein-serine kinase C beta 1/2 
[T500] PKCb1/2 324 146 
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Table 5.8 The phosphorylation status of proteins extracted from the human neuroblastoma cell 
line SH-SY5Y, transfected with mutant C99I45F (Aβ42/Aβ40↑) and C99WT was checked by 
Western-blotting using phospho-specific antibodies. C99WT served as a reference (base-line 
experiment). Subsequently, relative (to C99WT) percentage of phosphorylation was calculated. * Due 
to problems with immunoblotting, the sample C99WT and C99I45F had to be reprobed with an 
antibody for protein-serine kinase C beta 1/2 [T500]. 
KPSS-9.0 - Phospho-Site Neurobiology screen: 
A 
C99WT: 
 
 
B 
C99V50F: 
 
Figure 5.11 Immunoblots of proteins from SH-SY5Y cells. Phospho-
specific antibodies were used to determine the phosphorylation 
status. A) Cells transfected with C99WT and B) Cells transfected with 
C99V50F. 
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Table 5.9 The phosphorylation status of proteins extracted from the human neuroblastoma cell 
line SH-SY5Y, transfected with mutant C99V50F (Aβ42/Aβ40↓) and C99WT was checked by 
Western-blotting using phospho-specific antibodies. C99WT served as a reference (base-line 
experiment). Subsequently, relative (to C99WT) percentage of phosphorylation was calculated. 
 
 
 
 
NORMALIZED 
COUNTS PER 
MINUTE 
LANE BAND FULL NAME OF PROTEIN [EPITOPE] ABBREVIATION C99WT C99V50F
2 1 
MAPK/ERK protein-serine kinase 1 
(MKK1) [T385] MEK1 9367 7195 
4 1 Protein-serine kinase C delta [S664] PKCd 2533 5086 
6 2 Protein-serine kinase C epsilon [S729] PKCe 621 1077 
7 2 Protein-serine kinase C gamma [T514] PKCg 2122 3563 
7 3 
MAPK/ERK protein-serine kinase 1 
(MKK1) [T291] MEK1 3078 2229 
8 1 Protein-serine kinase C beta 1/2 [T500] PKCb1/2 731 1148 
9 3 
Microtubule-associated protein tau 
[S515/S518] (46) Tau 4006 3784 
9 4 
MAPK/ERK protein-serine kinase 1 
(MKK1) [S297] MEK1 3486 2390 
10 1 Protein-serine kinase C eta [S674] PKCh 2433 4848 
11 2 
Focal adhesion protein-tyrosine kinase 
[S722] FAK 2386 2473 
12 3 
G protein-coupled receptor-serine kinase 
2 (BARK1) [S670] (70) GRK2 448 277 
13 2 
Microtubule-associated protein tau [S720] 
(46) Tau 1412 1255 
13 3 
Microtubule-associated protein tau [S720] 
(44) Tau 2138 2499 
15 2 
Microtubule-associated protein tau [S712] 
(46) Tau 4636 5918 
15 3 
Microtubule-associated protein tau [S712] 
(44) Tau 4884 6751 
16 2 Protein-serine kinase C eta [T655] PKCh 990 2667 
16 4 
cAMP-dependent protein-serine kinase 
catalytic subunit beta [S338] PKA Cb 13301 13079 
17 1 
Protein-serine kinase B alpha (Akt1) 
[S473] PKBa (Akt1) 1113 889 
18 1 Protein-serine kinase C beta 2 [T641] PKCb2 867 1866 
20 1 Protein-serine kinase C gamma [T655] PKCg 2009 3224 
20 4 
cAMP-dependent protein-serine kinase 
catalytic subunit alpha/beta [T197] PKA Ca/b 1712 2107 
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KCPS-1.0 custom screen: 
A 
C99WT: 
 
 
B 
C99I45F: 
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C 
C99V50F: 
 
 
Figure 5.12 Immunoblots of proteins from SH-SY5Y cells. Pan-specific 
and phospho-specific antibodies were used to determine the 
phosphorylation status. A) Cells transfected with C99WT and B) Cells 
transfected with C99I45F and C) Cells transfected with C99V50F. 
NORMALIZED COUNTS PER MINUTE 
LANE BAND 
FULL NAME OF 
PROTEIN [EPITOPE] ABBREVIATION C99WT C99I45F C99V50F 
6 1 
Protein-serine kinase 
C alpha/beta 2 
[T638/T641] 
PKCa/b2 
[T638/T641] 1928 2254 3530 
7 1 
Glycogen synthase-
serine kinase 3 alpha, 
pan-specific GSK3a 1836 1906 2235 
7 2 
Glycogen synthase-
serine kinase 3 beta, 
pan-specific GSK3b 723 894 1126 
8 2 
Protein-serine kinase 
C gamma [T514] PKCg 3822 3176 4776 
11 1 
Protein-serine kinase 
C delta [S664] PKCd 3132 3460 5099 
12 1 
Glycogen synthase-
serine kinase 3 alpha 
[Y279] GSK3a 2741 2590 3282 
14 2 
cAMP-dependent 
protein-serine kinase 
catalytic subunit beta 
[S338] PKA Cb 8662 4891 6923 
15 1 
Protein-serine kinase 
C eta [S674] PKCh 2255 1550 3439 
16 1 
Serum/glucocorticoid 
regulated kinase 3, SGK3  966 612 941 
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pan-specific 
18 2 
Protein-serine kinase 
C delta, pan-specific PKCd 1506 2271 1064 
Table 5.10 The total protein expression level and phosphorylation status of proteins extracted 
from the human neuroblastoma cell line SH-SY5Y, transfected with mutant C99I45F 
(Aβ42/Aβ40↑), C99V50F (Aβ42/Aβ40↓) and C99WT was checked by Western-blotting using pan-
specific and phospho-specific antibodies. C99WT served as a reference (base-line experiment). 
Subsequently, relative (to C99WT) percentage of phosphorylation was calculated. 
A 
C99WT: 
 
B 
C99I45F: 
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C 
C99V50F: 
 
Figure 5.13 Immunoblots of proteins from SH-SY5Y cells. Pan-specific 
and phospho-specific antibodies were used to determine the 
phosphorylation status. A) Cells transfected with C99WT and B) Cells 
transfected with C99I45F and C) Cells transfected with C99V50F. 
NORMALIZED COUNTS PER 
MINUTE 
LANE BAND 
FULL NAME OF PROTEIN  
[EPITOPE] ABBREVIATION C99WT C99I45F C99V50F 
3 1 
Protein-serine kinase C 
alpha/beta 2 [T638/T641] PKCa/b2 1516 746 2092 
4 4 
Microtubule-associated 
protein tau [S515] (46) Tau 343 524 797 
5 1 
Protein-serine kinase C delta 
[S664] PKCd 2331 1723 4497 
6 3 
Microtubule-associated 
protein tau [S515+S518] (46) Tau 602 1927 1606 
7 1 
Protein-serine kinase C eta 
[T655] PKCh 595 679 1077 
9 1 
Superoxide dismutase 1, pan-
specific SOD (Cu/Zn) 4761 7110 3570 
11 2 
cAMP-dependent protein-
serine kinase catalytic subunit 
beta [S338] PKA Cb 3958 4055 3720 
12 1 
Serine/threonine-protein 
kinase DCAMKL1, pan-
specific CPG16/CaMK VI 57 130 51 
14 1 
Serum/glucocorticoid 
regulated kinase 3, pan-
specific SGK3  1481 794 768 
18 1 
Cyclin D1 (PRAD1), pan-
specific Cyclin D1 11253 7990 10013 
19 1 
Glycogen synthase-serine 
kinase 3 alpha, pan-specific GSK3a 521 385 224 
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Phosphorylation of PKC α/β 2 on 
threonine 638/threonine 641
+38%
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 threonine 500
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19 2 
Glycogen synthase-serine 
kinase 3 beta, pan-specific GSK3b 210 149 78 
Table 5.11 The total protein expression level and phosphorylation status of proteins extracted 
from the human neuroblastoma cell line SH-SY5Y, transfected with mutant C99I45F 
(Aβ42/Aβ40↑), C99V50F (Aβ42/Aβ40↓) and C99WT was checked by Western-blotting using pan-
specific and phospho-specific antibodies. C99WT served as a reference (base-line experiment). 
Subsequently, relative (to C99WT) percentage of phosphorylation was calculated. 
5.8.2 Quantification and graphical presentation of previously 
shown immunoblots 
Immunoblots were performed in triplicates, duplicates or single experiments. Since a 
large number of proteins was examined, it was not possible to perform any 
experiments in triplicates for financial reasons. So triplicates were restricted to those 
proteins that were expected to reveal the most useful information.   
 
Protein kinase C β 1/2: 
 
 
 
 
Figure 5.14 Protein kinase C β 1/2 showed 
weaker phosphorylation on threonine 500 
in mutant C99I45F compared to C99V50F 
and C99WT. 
 
Protein kinase C α/β 2: 
 
 
 
 
Figure 5.15 Protein kinase C α/β 2 showed 
weaker phosphorylation on threonine 
638/641 in mutant C99I45F compared to 
C99V50F. 
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Phosphorylation of PKC β 2 on 
threonine 641
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Protein kinase C β 2: 
 
 
 
 
 
Figure 5.16 Protein kinase C β2 showed 
weaker phosphorylation on threonine 641 
in mutant C99I45F compared to C99V50F 
and C99WT. 
 
Protein kinase C δ: 
 
 
 
 
 
Figure 5.17 Protein kinase C δ showed 
weaker phosphorylation on serine 664 in 
mutant C99I45F compared to C99V50F and 
C99WT (n=3, p=0.007). 
 
Protein kinase C ε: 
 
 
 
Figure 5.18 Protein kinase C ε showed 
weaker phosphorylation on serine 729 in 
mutant C99I45F compared to C99V50F. 
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Protein kinase C η:  
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Figure 5.19 Protein kinase C η showed weaker phosphorylation on threonine 655 and on 
serine 674 in mutant C99I45F compared to C99V50F. 
Protein kinase C γ: 
 
 
 
 
 
Figure 5.20 Protein kinase C γ showed weaker 
phosphorylation on threonine 514 in mutant 
C99I45F compared to C99V50F and to C99WT. 
GSK3α:  
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Figure 5.21 Expression of total-GSK3α (left Figure) and phosphorylation on tyrosine 279 (right 
Figure). Total GSK3α was not more strongly expressed in mutant C99I45F and C99V50F than in 
C99WT, but showed hyper-phosphorylation on tyrosine 279 in mutant C99I45F compared to C99V50F 
and C99WT. Due to a change in the antibody-panel of Kinexus, it was not possible to repeat the 
experiment with the same (anti-GSK3α tyrosine 279) antibody. Another anti-GSK3α tyrosine 279 
antibody, provided by Kinexus, did not allow reproducing the previous results. Further replicates, with 
diverse antibodies recognizing the same phosphorylation-site, are necessary to clarify this issue. 
 
GSK3 β : 
 
 
 
 
 
 
 
 
 
Figure 5.22 Total GSK3β expression and phosphorylation on tyrosine 216. Total GSK3β was 
approximately equally expressed in mutant C99I45F, C99V50F and in C99WT (diagram on the left), 
but showed hyperphosphorylation on tyrosine 216 in mutant C99I45F compared to C99WT and 
hypophosphorylation on tyrosine 216 in mutant C99V50F compared to C99WT. In addition direct 
comparison of both mutants showed stronger phosphorylation on tyrosine 216 in mutant C99I45F 
compared to C99V50F (diagram on the right). 
Tau: 
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Figure 5.23 Tau showed stronger phosphorylation on serine 515♦ and 518♦ in mutant C99I45F 
compared to C99WT. Stronger phosphorylation detected by an antibody recognizing both serine 515 
and 518 (diagram on page 72) was confirmed by two specific antibodies recognizing either serine 518 
(corresponding to serine 202 of tau isoform 2=tau441, diagram on the left) or serine 515 (corresponding 
to serine 199 of tau isoform 2, diagram on the right). *Different splice forms of tau, detected with the 
same antibody. 
 
 
 
 
 
Figure 5.24 Tau showed stronger phosphorylation 
on serine 712♦ (corresponding to serine 396 of tau 
isoform 2=tau441) in mutant C99I45F compared to 
C99WT and a weak tendency towards a stronger 
phosphorylation compared to C99V50F.  
CREB1: 
 
 
Figure 5.25 CREB1 appeared to be less 
phosphorylated on serine 129 and 133 in mutant 
C99I45F compared to C99WT. Microarray data 
revealed that CREB1 was among the most 20 down-
regulated transcripts (C99I45F versus C99WT1).  
                                            
 
♦ Numbering refers to the full length (unspliced) form of tau 
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DCAMKL1: 
 
 
 
Figure 5.26 DCAMKL1 was more strongly expressed 
in mutant C99I45F compared to C99WT and 
C99V50F. 
 
Serum/glucocorticoid regulated kinase 3 (SGK3):  
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Figure 5.27 SGK3 was more weakly expressed in mutant C99I45F compared to C99WT (Figure 
on the left). This was corroborated by microarray data in which SGK was down-regulated on the 
transcript-level (C99I45F versus C99WT1). Interestingly SGK was among the 16 most up-regulated 
transcripts in mutant C99V50F compared to C99WT (shown by micoarray analysis). This inverse 
regulation indicates that SGK was regulated by a changed Aβ42/Aβ40 ratio. 
Superoxide dismutase 1 (SOD1): 
 
 
 
Figure 5.28 SOD1 was more strongly expressed in 
mutant C99I45F whereas it was more weakly 
expressed in mutant C99V50F (compared to 
C99WT).  
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FAK: 
 
 
 
 
 
 
Figure 5.29 Focal adhesion protein-tyrosine kinase 
(FAK) showed weaker phosphorylation on serine 
722 in mutant C99I45F compared to C99WT and 
C99V50F. 
 
ERK1 : 
 
 
 
 
 
Figure 5.30 ERK1 showed stronger phosphorylation 
on threonine 202/tyrosine 204  in mutant C99I45F 
compared to C99WT.  
 
MEK1: 
 
 
 
 
Figure 5.31 MEK1 showed stronger phosphorylation 
on threonine 385 in mutant C99I45F compared to 
C99V50F. 
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Figure 5.32 MEK1 showed stronger phosphorylation on serine 297 in mutant C99I45F and 
weaker phosphorylation in mutant C99V50F compared to C99WT (Figure on the left). The same 
might be true, although less evident, for threonine 291 (Figure on the right).   
Cyclin D1: 
 
 
 
 
 
Figure 5.33 Cyclin D1 was more weakly 
expressed  in mutant C99I45F compared to 
C99WT and C99V50F.  
 
PKA β: 
  
 
Figure 5.34 PKAβ (Protein kinase A β) showed 
weaker phosphorylation on serine 338 in 
mutant C99I45F compared to C99WT. Direct 
comparison of both mutants showed weaker 
phosphorylation on serine 338 in mutant 
C99I45F compared to mutant C99V50F. 
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5.9 Models 
5.9.1 Preface 
Data derived from the transcriptomic approach and from the output of the 
phosphorylation status were used for pathway analysis. Moreover, some genes were 
validated on the protein level by immunoblotting. Analysis was performed with 
Pathway Architect™ (Stratagene).  
 
not differentially expressed 
 
  up-regulated transcript  
 
down-regulated transcript 
 
   
  activation 
inhibited activation 
 
inhibition 
inhibited inhibition 
 
 P↑ hyperphosphorylation♣ 
 P↓ hypophosphorylation♣ 
 
                                            
♣ For proteins whose total protein expression was not tested and thus an apparent 
hypo/hyperphosphorylation (tested with phospho-specific antibodies by immuno-blotting) may be a 
result of altered protein levels rather than a real change in the phosphorylation status, the term 
“showed weaker or stronger phosphorylation” was used instead of  “hypo/hyperphosphorylation”. 
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 5.9.2 Model: Downregulation of IGF2/IGF1R/PKC and PI3K/AKT 
signaling by an increased Aβ42/Aβ40 ratio 
 
A     Aβ42/Aβ40↑ 
 
 
 
P↓
P↑
P↓ 
P↑
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B     Aβ42/Aβ40↓ 
 
Figure 5.35 IGF2/IGF1R/PKC and PI3K/AKT signaling are influenced by an altered Aβ42/Aβ40  
ratio. Crucial differentially expressed genes were selected and integrated into the Pathway 
Architect software (Stratagene). By a complex filtering procedure this pathway was created in 
which all transcripts/proteins (except for DDC) were found to be connected in a network. Only 
direct bindings (gray faint lines) are shown for simplicity. A Figure with all interconnectivities can 
be found in the Supplementary Information (Chapter 12.6, Fig. 12.3, page S87). Crucial activating 
or inhibiting interactions are illustrated (black bold lines). For most of the shown 
transcripts/proteins there is more than one localization (for instance transcription factors, here 
shown in the nucleus, are also localized in the cytoplasm). See Table 5.12 after this Figure legend 
(page 83), for fold changes, p-values and gene names. 
P↑
P↓
P↑ 
P↓
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A) An increased Aβ42/Aβ40 ratio down-regulates IGF2/IGF1R/PKC and PI3K/AKT signaling. 
A plethora of inhibiting/activating molecules converge towards PI3K and AKT. PI3K/AKT activating 
molecules like IGF2 were significantly down-regulated (4.0 fold down-regulated, determined by 
real-time PCR). This downregulation was corroborated by the simultaneous downregulation of 
H19 and may have been triggered by imprinting (IGF2-H19 imprinted region on chromosome 
11p15.5). The insulin-like growth factor 2 (IGF2) is essential for development; bioavailable IGF2 is 
tightly regulated by 6 related IGFBPs of which IGFBP5 is the most conserved. Up-regulated 
IGFBP5 binds IGF2 directly with a high association rate and is expected to reduce unbound levels 
of IGF2 [161]. IGF2 is known to exert its effects by binding to the IGF1 Receptor4 (IGF2 may also 
bind to the IGF2 Receptor which acts as a signaling antagonist preventing IGF2 responses; the 
IGF2 Receptor specifically binds IGF2 but is devoid of signal transduction capability, and its 
primary function with respect to IGF action is as a clearance receptor that can modulate the 
bioavailability of extracellular IGF2) [164]. Although the IGF1 Receptor is regarded as the main 
receptor for IGF2 action, it has been discovered that IGF2 also binds to the insulin receptor [165, 
166] and important information can be expected from further study of this binding (binding 
competition between IGF2 and insulin to the insulin receptor may be of importance). Direct 
bindings between IGF2 and VIP, VIP and NPY, NPY and ATP7A are known. This builds up an 
axis starting from IGF2 and ending up in ATP7A. IGF2 might thus influence copper transport via 
ATP7A. It can be speculated that APLP2 influences this pathway via VIP because interactions 
between APLP2 and VIP have been reported and VIP was strongly increased in brains of a 
Down’s syndrome mouse model [167] (NPY was insignificantly (p=0.569) down-regulated); thus 
APLP2 could influence copper homeostasis by affecting the IGF2/VIP/NPY/ATP7A axis. The 
effects of BDNF, known to activate this pathway via NTRK2 (synonym: TrkB) [160], are expected 
to be reduced because the non-catalytic isoform of NTRK2 was strongly up-regulated. 
Consequently the catalytic isoform (not up-regulated) is expected to compete with the non-
catalytic isoform for BDNF binding so that less BDNF is expected to be available for pathway 
activation.  Down-regulated HGF and ITGB5 target PI3K (PIK3CA: catalytic subunit of PI3K, PI3K: 
phosphoinositide-3-kinase) and may further contribute to downregulation of PI3K/AKT signaling. 
TIMP1 and TIMP3, two metallopeptidase inhibitors, may target different metallopeptidases, 
because of their inverse regulation. TIMPs (synonym: collagenase inhibitors) are natural inhibitors 
of the matrix metalloproteinases (MMPs), a group of peptidases involved in degradation of the 
extracellular matrix. Transcription of TIMPs is highly inducible in response to many cytokines and 
hormones. TIMP1 is located within intron 6 of the synapsin I gene and is transcribed in the 
opposite direction. TIMP genes and synapsin genes are interlocked: SYN1-TIMP1, SYN2-TIMP4 
and SYN3 with TIMP3. Interestingly differential expression was found for synapsins together with 
TIMPs. Thus proteolytic cleavage (TIMPs are protease inhibitors) and neurotransmitter release 
(mediated by synapsins) are expected to interact and play a crucial role in Aβ induced cellular 
processes. TIMP3 has specifically been shown to inhibit the actions of ADAM10 and ADAM17 
[168, 169], two APP α-secretases [170]. Very recently it has been demonstrated that TIMP3 
immunoreactivity is increased in AD brains [171] and that TIMP3 treatment reduces α-cleavage of 
APP and promotes β-cleavage, with significant increases in Aβ production [169]. The authors 
emphasized that there is a striking increase in TIMP3 in AD brains (but not in other tested 
neurodegenerative diseases) which raises the possibility that TIMP3 contributes to the elevated 
Aβ levels in AD, making its inhibition a potential target for therapeutic approaches to reducing Aβ. 
It may be speculated that up-regulated TIMP3, apart from α-secretase inhibition, also inhibits the 
metalloprotease MMP8 (MMP8: Aβ42/Aβ40↑: p=0.00219, fold change= -5.0; Aβ42/Aβ40↓: not 
differentially expressed). MMP8, a collagenase, may be involved in plaque formation. Collagenous 
Alzheimer amyloid plaque component/collagen XXV (CLAC) [172] was observed in brains from 
subjects with AD. CLAC is derived from a type II transmembrane collagen protein [173]. VEGF 
might exert its influence on PI3K/AKT signaling via direct binding to CTNNB1 (β-catenin) or via 
diverse other molecules, since VEGF is currently the gene/protein with the most known 
                                            
4 Interestingly, IGF1R/EGFR heterodimerization has been reported in epithelial cancers. Stimulation of 
head and neck cancer cells with either IGF or EGF resulted in IGF1R and EGFR heterodimerization, 
but only IGF caused activating phosphorylation of both receptors [162]. Insulin receptor (IR) and 
insulin-like growth factor I receptor (IGF1R) are both from the same subgroup of receptor tyrosine 
kinases that exist as covalently bound receptor dimers at the cell surface. For both IR and IGF-IR, the 
most described forms are homodimer receptors. However, hybrid receptors consisting of one-half IR 
and one-half IGF-IR are also present at the cell surface [163]. 
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interconnectivities to other molecules (only for AKT1 more interconnectivities have been reported). 
VEGF is the protein with strongest known angiogenic effects and it is also involved in 
neurodegeneration. Even if here (Aβ42/Aβ40↑) only weakly (fold change=-1.3) and insignificantly 
(0.2343) down-regulated it may, synergistically with down-regulated HGF (also a well-known 
promoter of angiogenesis), reduce vascularisation [174]; (this effect may be supported by 
upregulation of flj13710, an uncharacterized gene, 37% similarity to ADAMTS1 precursor, found in 
the cluster analysis as significantly up-regulated for Aβ42/Aβ40↑ but not for Aβ42/Aβ40↓, which is 
assumed to have angiogenic inhibitor activity). Low VEGF levels cause neurodegeneration in part 
by impairing neural tissue perfusion. Perfusion deficits have also been documented, apart from 
AD, in other neurodegenerative disorders like amyotrophic lateral sclerosis (ALS ) and Huntington 
disease. Mice with reduced VEGF levels develop motoneuron degeneration [175]. DOPA 
decarboxylase (DDC) is an enzyme synthesizing 2 important neurotransmitters, dopamine and 
serotonin. DDC catalyzes the decarboxylation of dihydroxyphenylalanine (dopa) to dopamine, and 
hydroxytryptophan to serotonin. Downregulation of DDC in consequence of an increased 
Aβ42/Aβ40 ratio (but no differential expression for Aβ42/Aβ40↓) argues for decreased dopamine and 
serotonin levels (for Aβ42/Aβ40↑). The up-regulated EGFR might play a crucial role in the regulation 
of PI3K/AKT signaling due to its direct bindings to IGF2, CCND1, PLCG1 and NUMB. Crosstalk 
between the IGF1R and the EGFR has often been described [176]. The EGFR directly binds to 
IGF2, PLCG1, NUMB and CCND1 making it a putative key factor in this pathway. Mutations in the 
mouse Col4a1 gene, encoding procollagen type IV alpha 1, predisposes both newborn and adult 
mice to intracerebral hemorrhage [177] and cause perinatal cerebral hemorrhage and 
porencephaly [178]. Col4a1 gene transcription is mediated by TGF-β [179]. This is in line with the 
later mentioned (see discussion) activation of TGF-β signaling in response to an increased 
Aβ42/Aβ40 ratio. PRKCD, normally known to inhibit GSK3β, was hypophosphorylated, so its 
inhibiting influence on GSK3β is expected to be diminished. Inhibiting action of PTEN onto PIP3 
(PIP3 is a substrate of PI3K, not shown here) may further contribute to inactivation of PI3K/AKT 
signaling. Furthermore, AKT1 received inhibiting input via the IGF2/IGF1R/PIK3CA axis. 
Consequently AKT1 was found to be less phosphorylated, resulting in less inhibition of GSK3β. 
AKT1 (synonym: protein kinase B) as well as protein kinase A and C (known inhibitors of GSK3β), 
all of which showed a decreased phosphorylation status compared to C99WT, are expected to 
exert reduced kinase activity and consequently contribute to GSK3β activation. Especially protein 
kinase C, for which a very strong and most reliable (shown for many subunits, many different 
phosphorylation sites, partially demonstrated with n=3 independent experiments) differential 
phosphorylation status has been demonstrated, is expected to contribute to downregulation of 
PI3K/AKT signaling. PKC and AKT1 (presumably in concert with proteinkinase A) may 
synergistically activate GSK3β (due to reduced inhibitory effects), and due to the very strong 
inverse phosphorylation, PKC could have the stronger effect on GSK3β (apart from this, cross-talk 
from Wnt-signaling, in which GSK3β is a pivotal protein, may be expected). In this study, GSK3β 
was found to be activated by hyperphosphorylation on tyrosine 216. This in turn enables GSK3β 
to phosphorylate tau (synonym: MAPT). Indeed, tau showed stronger phosphorylation on serine 
199/202 (numbering refers to tau isoform 2), two sites reported to convert tau into a molecule with 
toxic properties [116]. GSK3β phosphorylates the cell cycle regulators ß-catenin, cyclin D1, cyclin 
E, p21CIP1 and c-Myc, leading to their ubiquitin-dependent destruction. GSK3β phosphorylates 
cyclin D1 on Thr286 and induces its rapid turnover [118]. Indeed, cyclinD1 was found to be down-
regulated on the transcript and on the protein-level. Cyclins function as regulators of CDK kinases. 
Cyclin D1 forms a complex with and functions as a regulatory subunit of CDK4 and CDK6, whose 
activity is required for cell cycle G1/S transition. Brisken et al. found that IGF2 induced cyclin D1 
protein expression in mouse mammary epithelial cultures [180]. Downregulation of cyclin D1, 
which is also a target gene of Wnt-signaling, is in line with the previously mentioned 
downregulation (off-state) of the Wnt-signaling pathway. Cyclin D1 became predominantly 
cytoplasmic as primary cortical progenitor cells underwent cell cycle withdrawal and terminal 
differentiation whereas it efficiently entered the nucleus of proliferating progenitor cells [181]. 
GATA3 is a transcriptional activator which binds to the enhancer of the T-cell receptor alpha and 
delta genes [187]. Interestingly the expression of the T-cell receptor genes was significantly down-
regulated in consequence of C99 overexpression (C99WT/mock), while both increased and 
decreased Aβ42/Aβ40 ratios resulted in strong and significant upregulation of these genes. Since 
this cannot be a consequence of GATA3 dysregulation (if so, T-cell receptors would be expected 
to be down-regulated for Aβ42/Aβ40↑, because GATA3 was down-regulated here), GATA3 
downregulation is rather assumed to be a consequence than the cause of differential T-cell 
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receptor expression, which maybe limits its own expression by GATA3 downregulation (negative 
feedback loop). The transcription factor ETS1 regulates the transcription of matrix 
metalloproteinase (MMP) genes and tissue inhibitors of metalloproteinases (TIMPs), the activities 
of which regulate matrix degradation and the migration of endothelial cells [188]. Up-regulated 
ETS1 might thus participate in regulating the differential expression of TIMP1, TIMP3 and MMP8 
(Aβ42/Aβ40↑). This view is corroborated by the fact that these 3 proteins (together with ETS1) were 
not differentially expressed for a decreased Aβ42/Aβ40 ratio. Foxo3A can be assumed to be 
activated (for Aβ42/Aβ40↑) because two effects derived from AKT1 and SGK, known to directly 
inhibit FoxoA, were expected to be inhibited (AKT1 showed less phoshorylation and thus was 
expected to be less active, total SGK3 was lower expressed in C99I45F than in C99WT (shown by 
immunoblotting) and consequently its inhibiting actions were expected to be diminished compared 
to Aβ42/Aβ40↓ where SGK was demonstrated to be up-regulated on the transcript level and where 
hyperphosphorylated AKT1 was able to inhibit Foxo3A.  
B) A decreased Aβ42/Aβ40 ratio up-regulates IGF2/IGF1R/PKC and PI3K/AKT signaling. 
Compared to an increased Aβ42/Aβ40 ratio IGF2 was not down-regulated for a decreased 
Aβ42/Aβ40 ratio, so no inactivating effect was derived from IGF2. The effect of BDNF, known to 
activate this pathway via NTRK2 (synonym: TrkB), is expected to be increased because the non-
catalytic isoform of NTRK2 was down-regulated. Since the catalytic isoform (not dysregulated) is 
expected to compete with the non-catalytic isoform for BDNF binding, more BDNF is expected to 
be available for pathway activation. IGFBP5 binds IGF2 directly and may, due to its 
downregulation, increase unbound levels of IGF2. Thus, although not up-regulated on the 
transcript level, a higher IGF2 protein level may be expected. The IGF2/VIP/NPY/ATP7A axis may 
influence copper transport via downregulation of ATP7A. Numb is a Notch antagonist, it functions 
during asymmetric cell division to determine alternative cell fates. Numb upregulation indicates 
downregulation of Notch signaling. Distinct Notch isoforms inhibit proliferation of stem cells and 
promote neuronal differentiation [189]. Thus, a stronger tendency towards neuronal differentiation 
for Aβ42/Aβ40↓ may be expected. This view is supported by CDK6 down-regulation: CyclinD1 was 
found to be up-regulated. Cyclins function as regulators of CDK kinases. Cyclin D1 forms a 
complex with and functions as a regulatory subunit of CDK4 and CDK6, whose activity is required 
for cell cycle G1/S transition. Apart from its role in cell cycle progression, a new role for CDK6 has 
recently been described in differentiation [182]. Exit from the cell cycle is a necessary step in 
terminal differentiation and may be triggered by down-regulation of CDK6. It was shown that 
CDK6 blocks differentiation [183]. CDK6 expression must be reduced to allow proper osteoblast 
and osteoclast differentiation; enforced CDK6 expression blocked differentiation of mouse embryo 
fibroblasts, and CDK6 expression in primary astrocytes favored the expression of progenitor cell 
markers [183-186]. Strong and significant down-regulation of CDK6 (validated by three different 
probe sets, not shown in Fig. 5.35) for Aβ42/Aβ40↓ (but not for Aβ42/Aβ40↑) argues for an enhanced 
tendency of mutant C99V50F (Aβ42/Aβ40↓) to differentiate. PRKCD was hyperphosphorylated, so 
its inhibitory influence on GSK3β can be expected to be enhanced. Furthermore, AKT1 can be 
expected to not receive inhibiting input via the IGF2/IGF1R/PIK3CA axis (because IGF2 signaling 
is not down-regulated, in contrast to Aβ42/Aβ40↑). Consequently, AKT1 was found to be stronger 
phosphorylated, resulting in stronger inhibition of GSK3β (AKT1 is known to inhibit GSK3β). 
GSK3β can be expected to be less active by hypophosphorylation on tyrosine 216. This in turn 
inhibits the kinase activity of GSK3β to phosphorylate tau (synonym: MAPT). Indeed, tau was 
found to be less phosphorylated (in mutant C99V50F) on serine 396 (numbering refers to tau 
isoform 2, phosphorylation of this site is reported to convert tau into a protein with toxic properties 
[116]) when directly compared to mutant C99I45F. GSK3β is known to inhibit Cyclin D1 (CCND1) 
by phosphorylation. This is in concert with upregulation of CCND1 on the transcript level. IGFBP5, 
known to reduce free IGF2 levels, may, by its downregulation provide more free IGF2 on the 
protein level. Increased IGF2 levels have been demonstrated to induce CCND1 expression [180]. 
Foxo3A can be assumed to be less active because of the inhibiting effects derived from activated 
AKT1 and up-regulated SGK. 
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Table 5.12 Differentially expressed transcripts or differentially phosphorylated 
proteins found in the PI3K/AKT pathway and interconnected pathways (only 
differential expression is shown here. For a change in the phosphorylation 
status see Chapter 5.8, pages 59-76). 
Gene 
symbol 
Name fold 
change  
C99I45F/ 
C99WT 
p- 
value 
fold 
change 
C99V50F/
C99WT 
p- 
value 
Connecti-
vities 
Ranking 
of 
connecti-
vities 
NTRK2 neurotrophic  
tyrosine kinase, 
receptor, type 2 
(non-catalytic 
isoform) 
2.2 0.0231 -1.7 0.0581 303 26. 
IGFBP5 insulin-like growth 
factor binding  
protein 5 
1.9 0.0905 -1.7 0.1694 428 20. 
ETS1 v-ets 
erythroblastosis 
virus E26  
oncogene 
 homolog 1 (avian) 
1.9 0.0876 - - 611 17. 
IGF1R insulin-like growth 
factor 1 receptor 
1.8 0.2803 - - 603 18. 
VIP vasoactive intestinal 
peptide 
1.8 0.0361 - - 2450 4. 
EGFR epidermal growth 
factor receptor 
(erythroblastic 
leukemia viral  
(v-erb-b) oncogene 
homolog, avian) 
1.8 0.0733 - - 3574 3. 
TIMP3 TIMP 
metallopeptidase 
inhibitor 3  
1.7 0.0263 - - 231 28. 
COL4A1 collagen, type IV, 
alpha 1 
1.6 0.1167 - - 214 29. 
APLP2 amyloid beta (A4) 
precursor-like 
protein 2 
1.5 0.0080 - - 1065 15. 
COL4A2 collagen, type IV, 
alpha 2 
1.5 0.1163 - - 28 35. 
ATP7A ATPase, Cu++ 
transporting, alpha 
polypeptide 
(Menkes syndrome) 
1.5 0.0222 -2.0 0.0621 484 19. 
VEGF vascular endothelial 
growth factor 
-1.3 0.2343 - - 4281 2. 
CCND1 cyclin D1 (PRAD1: 
parathyroid 
adenomatosis 1) 
-1.4 0.1325 1.5 0.0249 2267 6. 
ITGB5 integrin, beta 5 -2.0 0.0477 -1.7 0.2 34 34. 
H19 H19, imprinted 
maternally 
expressed 
-2.1 0.2135 - - 111 32. 
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untranslated 
mRNA 
DDC dopa decarboxylase 
(aromatic L-amino 
acid decarboxylase) 
-2.1 0.1295 - - 123 31. 
IGF2 insulin-like growth 
factor 2 
(somatomedin A) 
-2.6 (-4.0 
by real-
time PCR, 
standard 
error fold 
change=1.55)
0.0522 -1.7 (-1.2 
by real-
time 
PCR, 
standard 
error fold 
change=0.2) 
0.2 2351 5. 
GATA3 GATA binding 
protein 3 
-2.7 0.1625 - - 290 27. 
HGF hepatocyte growth 
factor (hepapoietin 
A; scatter factor) 
-3.0 0.1571 - - 2166 7. 
TIMP1 TIMP 
metallopeptidase 
inhibitor 1 
-3.5 0.1275 - - 1203 12. 
PTEN phosphatase and 
tensin homolog  
4.0 0.02572   902 16. 
PRKCD protein kinase C, 
delta 
- - - - 1286 10. 
PPARD peroxisome 
proliferative 
activated receptor, 
delta 
- - - - 396 22. 
PLCG1 phospholipase C, 
gamma 1 
- - - - 1249 11. 
NUMB numb homolog 
(Drosophila) 
- - 3.2 0.00749 65 33. 
SGK serum/glucocorticoid 
regulated kinase 
- - 1.9 0.0291 369 23. 
PIK3CA 
(subunit 
of PI3K) 
phosphoinositide-3-
kinase, catalytic, 
alpha polypeptide 
- - - - 201 30. 
NPY neuropeptide Y - - -1.4 0.1161 1840 8. 
MAPT microtubule-
associated protein 
tau 
- - - - 304 25. 
GSK3B glycogen synthase 
kinase 3 beta 
- - - - 1120 13. 
GSK3A glycogen synthase 
kinase 3 alpha 
- - - - 397 21. 
FOXO3A forkhead box O3A - - - - 322 24. 
CTNNB1 catenin (cadherin-
associated protein), 
beta 1, 88kDa 
- - - - 1114 14. 
BDNF brain-derived 
neurotrophic factor 
- - - - 1757 9. 
AKT1 v-akt murine 
thymoma viral 
oncogene homolog1 
- - - - 6459 1. 
Table 5.12 Differentially expressed transcripts or differentially phosphorylated proteins for the 
comparisons C99I45F/C99WT (Aβ42/Aβ40↑) and C99V50F/C99WT (Aβ42/Aβ40↓) found in the 
PI3K/AKT pathway and interconnected pathways.  
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5.9.3 Model: Increased Aβ42/Aβ40 ratio is expected to reduce the 
ATP level and to induce phosphofructokinase upregulation 
 
    Aβ42/Aβ40↑ 
 
  
IGF2 signaling ↓                 GSK3β ↑ 
 
 
    Glucose  ↓                  Glycogen synthase ↓ 
 
 
        ATP ↓        
 
 
Phosphofructokinase ↑                   Tau 
 
Figure 5.36 Hypothetical model: Low glucose and ATP levels as pacemakers for dysregulation 
of glycolytic enzymes. Parallel effects of insulin-like growth factor 2 (IGF2) and insulin on glucose 
metabolism have been described: IGF2 and insulin stimulate the glucose uptake and incorporation 
into glycogen and stimulate the activity of glycogen synthase [190]. Here, due to downregulation of 
IGF2 signaling (which has also been described in the brain of Alzheimer patients [191]), glucose 
uptake by the cells is expected to be impaired. Thus, intracellular glucose cannot be replenished due 
to down-regulated IGF2 signaling and is followed by low intracellular glucose levels. In consequence 
there is no feed forward production of ATP. A low ATP level (high AMP level) is the best known 
inductor for phosphofructokinase (ATP inhibits, AMP induces phosphofructokinase; upregulation of 
phosphofructokinase is a typical indicator for reduced energy levels). Phosphofructokinase is the most 
important regulatory enzyme of glycolysis. If phosphofructokinase turns out to be a possible kinase for 
tau phosphorylation, then tau phosphorylation would be inherently caused by low glucose/ATP levels. 
While possibly resulting in higher ATP levels, up-regulated phosphofructokinase (Aβ42/Aβ40↑: 2.1 fold 
up-regulated, p=0.0023, but not differentially expressed for Aβ42/Aβ40↓) may contribute to reduce 
glucose levels. Inhibited glycogen synthase by phosphorylation through GSK3β can be regarded as an 
‘attempt’ (self-regulated by feedback loops) of the cells to restore sufficient glucose/ATP levels by 
down-regulating glycogen synthesis. Phosphofructokinase generates fructose 1,6 bisphosphate from 
fructose 6-phosphate. There is also the possibility that an increased Aβ42/Aβ40 ratio directly up-
regulates phosphofructokinase (not mediated by IGF2 signaling, glucose and ATP).  
?
+
- 
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5.9.4 Model: Transcriptional control of blood coagulation and 
fibrinolysis is influenced by an altered Aβ42/Aβ40 ratio 
 
A     Aβ42/Aβ40↑ 
 
  
Blood coagulation ↑     (Fibrinolysis↓) 
 
 
 
 
 
 
*
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B     Aβ42/Aβ40↓ 
 
 
Blood coagulation ↓      Fibrinolysis ↑ 
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Figure 5.37 Transcriptional control of blood coagulation and fibrinolysis is influenced by an 
altered Aβ42/Aβ40 ratio.  A) An increased Aβ42/Aβ40 ratio results  in upregulation of F12 and FGB, well-
known factors for the activation of blood clotting (up-regulated FGF1 may also contribute to blood 
clotting, see Chapter 6.12, page 156). Moreover, inhibitors of blood clotting, like TFPI2, are down-
regulated. Both factors might synergistically enhance blood coagulation in consequence of an 
increased Aβ42/Aβ40 ratio. Serpin E2 affects both, blood coagulation and fibrinolysis. Interestingly, in 
presence of collagen 4 (Col4A1, Col4A2), serpin E2 has a much stronger tendency to affect blood 
coagulation than fibrinolysis (see discussion, Chapter 6.12). In presence of collagen 4, serpin E2 (if 
expression is increased, which is not the case here) tends to inhibit thrombin and thus coagulation. 
However, here, this inhibiting effect may be abolished by serpin E2 downregulation. This might result 
in increased blood clotting. HGF was found to inhibit thrombin-dependent platelet aggregation. Thus, 
down-regulation of HGF might support platelet aggregation and in consequence blood clotting. The 
function of the uncharacterized VWCD1 is not well understood, but it may influence transcription (via 
XAB2, *XAB2 could be regarded as weakly up-regulated, 1.3 fold, p=0.104) in concert with F2R. 
Increased intracellular Ca2+ levels, a well studied consequence of increased Aβ42 levels and a hallmark 
of AD, may contribute to enhance blood coagulation (for instance after disruption of cells and release 
of Ca2+ into the extracellular space and uptake into adjacent blood vessels). 
B) A decreased Aβ42/Aβ40 ratio results in upregulation of TFPI2 (inhibitor of blood clotting), so blood 
clotting might be inhibited and downregulation of the thrombin receptor F2R and F2RL3 (thrombin 
receptor-like 3), may further reduce the tendency towards coagulation. In parallel to this, strong down-
regulation of serpin F1, an anti-plasmin, might result in higher plasmin levels, which in turn accelerates 
fibrinolysis. One of the most prominent activators of fibrinolysis (and a candidate gene for AD 
according to the Alzforum database, www.alzforum.org) is PLAT (plasminogen activator, tissue). Due 
to its upregulation enhanced fibrinolysis may be expected.  
Table 5.13 Differentially expressed transcripts found in blood coagulation and 
fibrinolysis 
Gene symbol Name 
fold change 
C99I45F/C99WT p-value 
fold change 
C99V50F/C99WT p-value 
- Angiostatin - - - - 
- calcium ion 
presumably 
increased levels ♦ - 
presumably 
decreased levels ♦ - 
COL4A1 
collagen, type IV, 
alpha 1 1.6 0.1167 
not differentially 
expressed■ - 
COL4A2 
collagen, type IV, 
alpha 2 1.5 0.1163 
not differentially 
expressed■ - 
F12 
coagulation factor 
XII (Hageman 
factor) 1.3 0.036 
not differentially 
expressed■ - 
F2R 
coagulation factor 
II (thrombin) 
receptor - - -1.2 0.0266 
F2RL1 
coagulation factor 
II (thrombin) 
receptor-like 1 
not differentially 
expressed■ - 
not differentially 
expressed■ - 
F2RL3 
coagulation factor 
II (thrombin) 
receptor-like 3 
not differentially 
expressed■ - -3.2 0.04742 
- factor vii - - - - 
- Factor XIIa 1.3 0.0723 - - 
FGB 
fibrinogen beta 
chain 2.5 0.0161 - - 
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FGF1 
fibroblast growth 
factor 1 (acidic) 1.6 0.0036 - - 
- fibrinopeptide a - - - - 
- glu-plasminogen - - - - 
- glycosaminoglycan - - - - 
- Heparan sulfate - - - - 
HGF 
hepatocyte growth 
factor (hepapoietin 
A; scatter factor) -3.0 0.157 - - 
PLAT 
plasminogen 
activator, tissue 
not differentially 
expressed■ - 2.1 0.0047 
SERPINE2 
serpin peptidase 
inhibitor, clade E, 
member 2 -2.3 0.174 
not differentially 
expressed■ - 
SERPINF1 
serpin peptidase 
inhibitor, clade F 
(alpha-2 
antiplasmin), 
member 1 
not differentially 
expressed■ - -3.1 0.00362 
TFPI2 
tissue factor 
pathway inhibitor 2 -3.1 0.365* 2.6 0.027 
- thrombin - - - - 
VWCD1 
von Willebrand 
factor type A and 
cache domain 
containing 1 1.6 0.044 -2.7 0.149 
XAB2 
XPA binding 
protein 2 1.3 0.104 
not differentially 
expressed■ - 
Table 5.13 Differentially expressed transcripts found in blood coagulation and fibrinolysis. 
Hyphen (-): no information available because not regulated on the transcript level but derived from the 
cells' metabolism or because not probed on the microarray. 
♦ see Chapter 6.36, page 201, for further explanation 
■ the term "not differentially expressed" was used when fold changes were close to 1.0 (0.9-1.1) or 
exceeded a threshold of p>0.2 
*TFPI2 could be regarded as not differentially expressed due to its high p-value (for the comparison 
C99I45F/C99WT). It is listed here despite the high p-value, because it was detected as down-
regulated with more than one probe set, increasing the probability of a true downregulation. In contrast 
to this, TFPI2 was significantly up-regulated for C99V50F/C99WT.  
5.10 Candidates for tau or GSK3 phosphorylation 
5.10.1 Preface 
The state of phosphorylation of a phosphoprotein is a function of the balance 
between the activities of protein kinases and phosphatases that regulates its 
phosphorylation. Tau, which is phosphorylated at more than 30 serine/threonine 
residues in AD [111, 192], is a substrate for several protein kinases. Not all of the 30 
phosphorylation sites may be involved in converting normal tau into a toxic molecule. 
Hyperphosphorylation of tau at the level of 4-6 moles phosphate/mole of the protein 
induces the toxic property. 
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GSK3β is able to phosphorylate many substrates and is part of several cellular 
events including metabolism, signaling and transcription [119]. GSK-3β is the major 
tau kinase in vivo [120-125]. There is evidence that in total 15 sites are phos-
phorylated by GSK3β. GSK3β itself can also be phosphorylated/dephosphorylated by 
several kinases/phosphatases. This is crucial for its functional state. For these 
reasons candidate kinases/phosphatases for tau and GSK3β were identified. 
5.10.2 Kinases 
Even if activation of kinases is often regulated on the protein level (for instance by 
phosphorylation) kinases are also regulated on the transcript level. Here, only 
kinases showing distinctly stronger expression for Aβ42/Aβ40↑ than for Aβ42/Aβ40↓ 
were selected. 
differentially expressed kinases 
Aβ42/Aβ40↑ Aβ42/Aβ40↓ 
Gene 
symbol Name p-value 
Fold 
change p-value 
Fold 
change 
Chromoso-
mal location
GRK5 
G protein-coupled 
receptor kinase 5 0.0167 2.0 - - 
chr10q24-
qter 
PFKP 
phosphofructokinase  
platelet 0.00230 2.1 - - 
chr10p15.3-
p15.2 
RPS6KA5 
ribosomal protein S6 
kinase, 90kDa, 
polypeptide 5 
- - 
0.018 -1.2 
chr14q31-
q32.1 
PHKG1 
phosphorylase 
kinase  gamma 1 
(muscle) 
- - 
0.0441 -1.3 chr7p12-q21
PKN2 Protein kinase N2 - - 0.0215 -1.4 chr1p22.2 
CDK6 
cyclin-dependent 
kinase 6 - - 0.00749 -3.2 chr7q21-q22
CDKL5 
cyclin-dependent 
kinase-like 5 0.02490 4.0 - - chrXp22 
CDKL1 
cyclin-dependent 
kinase-like 1 
(CDC2-related 
kinase) 0.01613 2.5 - - chr14q21.3 
DYRK1A 
Dual-specificity 
tyrosine-(Y)-
phosphorylation 
regulated kinase 
1A 
- - 
0.03517 -6.3 
chr21q22.13 
(according 
to 
Affymetrix) 
chr21q22.22 
(according 
to other 
sources)  
Table 5.14 Differentially expressed genes encoding kinases as candidates that could 
phosphorylate tau or GSK3 
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A further kinase, DCAMKL1 (doublecortin and CaM kinase-like 1), was up-regulated 
for Aβ42/Aβ40↑ and slightly down-regulated for Aβ42/Aβ40↓ on the protein level, shown 
by immunoblotting. DCAMKL1 might be a further candidate for tau or GSK3 
phosphorylation. Moreover ERK1 showed stronger phosphorylation on threonine 202 
and tyrosine 204 (two activating sites, making ERK1 a further possible candidate 
kinase for tau or GSK3 phosphorylation) in consequence of an increased Aβ42/Aβ40 
ratio. However, no data are available for a decreased Aβ42/Aβ40 ratio.  
5.10.3 Phosphatases 
Here, the focus was on phosphatases showing weaker expression (except for 
PPP2R2C which showed stronger expression) for Aβ42/Aβ40↑ than for Aβ42/Aβ40↓. 
differentially expressed phosphatases 
(or their subunits) 
Aβ42/Aβ40↑ Aβ42/Aβ40↓ 
Gene 
symbol Name p-value 
Fold 
change p-value 
Fold 
change 
Chromosomal 
location 
  
protein 
phosphatase 
2A, regulatory 
subunit B' (PR 
53) - - 0.0069 1.2 chr9q34 
PPP2R2C 
protein 
phosphatase 2 
(formerly 2A)  
regulatory 
subunit B (PR 
52) gamma 
isoform 0.0201 2.4 - - chr4p16.1 
PHACTR2 
Phosphatase 
and actin 
regulator 2 0.02572 -3.2 
- - 
chr6q24.2 
Table 5.15 Differentially expressed genes encoding phosphatases as candidates that could 
dephosphorylate tau or GSK3. PPP2R4, PPP2R2C were differentially expressed and are important 
regulatory subunits for protein phosphatase 2A. PHACTR2 is a family member of proteins that binds 
protein phosphatase 1 and cytoplasmic actin; it may play a role in regulation of the actin cytoskeleton. 
5.11 Genes co-regulated with APLP1 and APLP2 
APP is a member of a larger gene family including amyloid precursor-like proteins 
APLP1 and APLP2. Mice deficient in the nervous system-specific APLP1 protein 
showed a postnatal growth deficit as the only obvious abnormality. In contrast to this 
minor phenotype, APLP2(-/-)/APLP1(-/-) and APLP2(-/-)/APP(-/-) mice die early 
postnatally. Surprisingly, APLP1(-/-)/APP(-/-) mice were viable, apparently normal, 
and showed no compensatory upregulation of APLP2 expression. These data 
indicate a key physiological role for APLP2. This view gains further support by the 
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observation that APLP1(-/-)/APP(-/-)/APLP2(+/-) mice die early postnatally [193]. In 
order to shed light on the redundancy between APLP2 and both other family 
members, co-regulated genes (which are speculated as having an important 
common function) to APLP1 and APLP2 were identified. 
APLP2 appeared among the most up-regulated genes from the comparison C99I45F 
versus C99WT (Aβ42/Aβ40↑), whereas APLP1 appeared among the most up-
regulated genes from the comparison C99V50F versus C99WT (Aβ42/Aβ40↓). The 
genes found in close vicinity (and thus co-regulated) with APLP2 and APLP1 (if gene 
lists were compared in which genes were sorted according to fold changes), were: 
 
• Catenin (cadherin-associated protein) α 2 (CTNNA2), chr2p12-p11.1 
• Neural cell adhesion molecule 1 (NCAM1), chr11q23.1 
• Actinin  alpha 1 (ACTN1), chr14q22-q24 
• Rho GTPase activating protein 26 (ARHGAP26), chr5q31 
• KIAA1102, chr4p13 
 
5.12 Identification of altered signal transduction pathways 
and molecular functions 
5.12.1 Preface  
PANTHER (Protein Analysis Through Evolutionary Relationships, Applied 
Biosystems) is a classification system for genes and proteins. It delivers information 
about the under or over-representation of transcripts in certain pathways or provides 
information about which molecular functions are under or over-represented. It is 
crucial to evaluate these data with special regard to the kind of data integrated (most 
up or down-regulated transcripts, number of integrated transcripts etc.). Most 
important was to find a suitable number of transcripts which reflects a balance 
between acceptable sensitivity (all affected pathways should be discovered, so the 
number of integrated transcripts should not be too small) and specificity (only strong 
up or downregulation is likely to be meaningful, therefore, the number of transcripts 
should not be too big, otherwise weakly dysregulated transcripts could possibly falsify 
the results). Here in this analysis, PANTHER delivers information about the 
representation of transcripts in certain pathways which must not be mixed up with the 
extent of up and downregulation: The most up and down-regulated genes were 
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integrated into PANTHER. (For pathway analysis making use of the extent of up and 
downregulation, see Fig. 5.35 (pages 78, 79), Fig. 5.37 (page 86) and Fig. 12.3 
(page S87), which were created with Pathway Architect; for this, the gene expression 
values of up and down-regulated genes were used). Using both approaches 
together, over/under-representation and the extent of up and downregulation (gene 
expression values), provides more reliable information than one approach alone.  
 
When a certain pathway is meant to be evaluated for activation or inhibition, there 
are crucial considerations, which must be seen in the whole context: 
• Were the integrated data the most up or down-regulated ones? 
• Do the transcripts that were found to be differentially expressed have inhibitory 
or activating functions within the pathway? 
• What was the cut-off for the p-value? 
• How big was the fold change of the integrated data? 
• How many transcripts were integrated? 
Due to similarities of names of integrated gene symbols and ‘matching’ gene names, 
PANTHER very occasionally erroneously recognizes genes to be affected, so 
PANTHER’s analysis was manually checked and corrected. 
5.12.2 Over and under-representation of transcripts in signal 
transduction and metabolic pathways 
The two mutants C99I45F and C99V50F were compared to C99WT. Differentially 
represented pathways might be key regulators in the pathogenesis of AD.  
 
Top fifty up-regulated transcripts 
The top fifty up-regulated transcripts, selected by using the Array Assist software and 
the PLIER algorithm, derived from the comparisons C99I45F versus C99WT and 
C99V50F versus C99WT (p<0.05, n=3), were integrated into the PANTHER™ gene 
and protein classification system. 
Out of 130 tested signal transduction and metabolic pathways, 43 pathways were 
differentially represented (data not shown) in consequence of a changed Aβ42/Aβ40 
ratio. These 43 pathways, in turn, were used for further analysis. The distribution of 
transcripts into these pathways was examined and those pathways, which showed 
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the strongest difference in the number of transcripts, were selected. The most 
differentially represented pathways were these 7:  
 
Transcripts 
Pathways 
C99V50F versus C99WT 
(Aβ42/Aβ40↓): 
C99I45F versus C99WT 
(Aβ42/Aβ40↑) : 
∆ Number 
of transcripts
Wnt signaling 
pathway 
• cyclin D1 
CCND1 
• catenin (cadherin-
associated protein), alpha 
2 
CTNNA2 
• protein kinase C, alpha 
PRKCA 
 
– 3 
Apoptosis signaling 
pathway 
• cAMP responsive element 
modulator 
CREM 
• protein kinase C, alpha 
PRKCA 
• B-cell CLL/lymphoma 2 
BCL2 
– 3 
Endothelin signaling 
pathway 
 
• protein kinase C, alpha 
PRKCA 
• endothelin converting 
enzyme-like 1 
ECEL1 
– 2 
Interleukin signaling 
pathway 
 
• forkhead box C1 
FOXC1 
• cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) 
CDKN1A 
  
– 2 
PDGF signaling 
pathway 
 
• protein kinase C, alpha 
PRKCA 
• FEV (ETS oncogene 
family) 
FEV 
• Rho GTPase activating 
protein 26 
ARHGAP26 GRAF-
RELATED  
• Rho GTPase 
activating protein 26 
ARHGAP26 GRAF-
RELATED  
  2 
PI3K kinase pathway 
 
• forkhead box C1 
FOXC1 
• cyclin D1 
CCND1 
  
– 2 
TGF-beta signaling 
pathway 
 
• jun D proto-oncogene 
JUND 
• forkhead box C1 
FOXC1 
• BMP and activin 
• bone morphogenetic 
protein 7 (osteogenic 
protein 1) 
BMP7 
  
2 
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membrane-bound inhibitor 
homolog (Xenopus laevis) 
BAMBI 
  
Table 5.16 PANTHER™ gene and protein classification system: The analysis of the fifty most 
up-regulated transcripts from the comparison C99V50F/C99WT and C99I45F/C99WT (p<0.05, 
n=3) revealed these 7 most differentially represented pathways. 
The remaining pathways differed only in one transcript. Nevertheless, it cannot be 
concluded that they are unimportant, because the single transcript might fulfill 
important functions, like having a key position within a pathway, cross-talk to other 
pathways etc. An example for this was: 
 
 
The total difference in transcripts here is one, but different transcripts are affected (in 
the upper example). Especially if they fulfilll contrary functions in the cell (e.g. 
inhibitory/activating when both mutants are compared), this might be an important 
pathway. Hence, the pathways differing only in one transcript were examined 
manually and, if regarded as important, they were taken into account and listed in 
this thesis. 
 
The twenty most down-regulated transcripts 
The twenty most down-regulated transcripts, selected by the Array Assist software 
and the PLIER algorithm, derived from the comparisons C99I45F versus C99WT and 
C99V50F versus C99WT (p<0.05, n=3), were integrated into the PANTHER™ gene 
and protein classification system. 
 
Transcripts 
Pathways 
C99V50F versus C99WT 
(Aβ42/Aβ40↓): 
C99I45F versus C99WT 
(Aβ42/Aβ40↑) : 
∆ Number 
of transcripts 
Inflammation 
mediated by 
chemokine and 
cytokine signaling 
pathway 
 
• jun D proto-oncogene 
JUND 
• protein kinase C, alpha 
PRKCA 
• doublecortin and 
CaMkinase-like 1 
DCAMKL1 
• G protein-coupled 
receptor kinase 5 
GRK5 
• tenascin C 
(hexabrachion) 
TNC 
  
 
1 
Axon guidance 
mediated by 
semaphorins 
 
• collapsin response 
mediator protein 1 
CRMP1 
 
– 1 
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Out of 130 tested signal transduction and metabolic pathways, 21 pathways were 
differentially represented (data not shown) in consequence of a changed Aβ42/Aβ40 
ratio. Out of these 21 pathways, the strongest difference in the number of transcripts 
(∆ transcripts), and hence the most differentially represented pathways were these 3: 
 
Transcripts 
Pathways 
C99V50F versus C99WT 
(Aβ42/Aβ40↓): 
C99I45F versus C99WT 
(Aβ42/Aβ40↑) : 
∆ Number 
of transcripts 
Alzheimer 
disease-amyloid 
secretase 
pathway 
 
• protein kinase N2 
PKN2 
• cholinergic receptor, 
muscarinic 3 
CHRM3 5 
– 2 
Angiogenesis 
 
• ephrin-B2 
EFNB2 
• transcription factor 7-
like 2 (T-cell specific, 
HMG-box) 
TCF7L2 
– 2 
Endothelin 
signaling 
pathway 
 
• adenylate cyclase 1 
(brain) 
ADCY1 
• protein kinase N2 
PKN2 
– 2 
Table 5.17 PANTHER™ gene and protein classification system: The analysis of the twenty 
most down-regulated transcripts from C99I45F/C99WT and C99V50F/C99WT (p<0.05, n=3) 
revealed these 3 most differentially represented pathways. 
5.12.3 Over and under-representation of transcripts involved in 
certain molecular functions 
The same data set used in 5.12.2 was integrated into PANTHER in order to obtain 
information about affected molecular functions.  
Top fifty up-regulated transcripts 
Out of 254 tested molecular functions, 52 were differentially represented (data not 
shown) in consequence of a changed Aβ42/Aβ40 ratio: 
Out of these molecular functions, the strongest difference in the number of transcripts 
(∆ transcripts), and hence, the most differentially represented, were these: 
 
 
                                            
5 In a less stringent (p<0.075 instead of < 0.05) analysis, CHRM3 appeared also as down-regulated in mutant 
C99I45F, so ∆ Number of transcripts was finally = 1, which makes a real differential representation of this pathway 
less probable. 
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Transcripts 
Molecular 
functions 
C99V50F versus C99WT 
(Aβ42/Aβ40↓): 
C99I45F versus C99WT 
(Aβ42/Aβ40↑) : 
∆ Number 
of 
transcripts 
Receptors • (slit homolog 1 
(Drosophila) 
SLIT1)6 
• prostaglandin E receptor 
2 (subtype EP2), 53kDa 
PTGER2 
• delta/Notch-like EGF repeat 
containing 
DNER 
• gamma-aminobutyric acid 
(GABA) A receptor, beta 3 
GABRB3 
• G protein-coupled receptor 
64 
GPR64 
• glutamate receptor, 
ionotropic, AMPA 2 
GRIA2 
• neurotrophic tyrosine 
kinase, receptor, type 2 
NTRK2, non-catalytic 
isoform 
• odz, odd Oz/ten-m homolog 
4 (Drosophila) 
ODZ4 
• protease, serine, 12 
(neurotrypsin, motopsin) 
PRSS12 
• protein tyrosine 
phosphatase, receptor type, 
M 
PTPRM 
7 
Other 
transcription 
factors 
• jun D proto-oncogene 
JUND 
• inhibitor of DNA binding 
4, dominant negative 
helix-loop-helix protein 
ID4 
• forkhead box C1 
FOXC1 
• FEV (ETS oncogene 
family) 
FEV 
– 4 
Actin binding 
cytoskeletal 
proteins 
• tropomodulin 1 
TMOD1 
• spectrin, beta, non-
erythrocytic 1 
SPTBN1 
• ectodermal-neural cortex 
(with BTB-like domain) 
ENC1 
• catenin (cadherin-
associated protein), alpha 
2 
CTNNA2 
• actinin, alpha 1 
• ectodermal-neural cortex 
(with BTB-like domain) 
ENC1 
• troponin C type 1 (slow) 
TNNC1 
3 
                                            
6 Slit1 was erroneously recognized as a receptor by PANTHER analysis. Correctly, it is a secreted 
protein involved in axon guidance. 
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ACTN1 
Non-motor actin 
binding proteins 
• spectrin, beta, non-
erythrocytic 1 
SPTBN1 
• ectodermal-neural cortex 
(with BTB-like domain) 
ENC1 
• catenin (cadherin-
associated protein), alpha 
2 
CTNNA2 
• actinin, alpha 1 
ACTN1 
• ectodermal-neural cortex 
(with BTB-like domain) 
ENC1 
3 
Nucleic acid 
binding 
• single-stranded DNA 
binding protein 2 
SSBP2 
• REV3-like, catalytic 
subunit of DNA 
polymerase zeta (yeast) 
REV3L 
• jun D proto-oncogene 
JUND 
• forkhead box C1 
FOXC1 
• cAMP responsive 
element modulator 
CREM 
• ELAV (embryonic lethal, 
abnormal vision, 
Drosophila)-like 4 (Hu 
antigen D) 
ELAVL4 
• Scm-like with four mbt 
domains 2 
SFMBT2 3 
Transcription 
factors 
• jun D proto-oncogene 
JUND 
• inhibitor of DNA binding 
4, dominant negative 
helix-loop-helix protein 
ID4 
• forkhead box C1 
FOXC1 
• FEV (ETS oncogene 
family) 
FEV 
• cAMP responsive 
element modulator 
CREM 
• delta/Notch-like EGF repeat 
containing 
DNER 
• Scm-like with four mbt 
domains 2 
SFMBT2 
3 
Ion channels 
– 
• glutamate receptor, 
ionotropic, AMPA 2 
GRIA2 
• gamma-aminobutyric acid 
(GABA) A receptor, beta 3 
GABRB3 
• calcium channel, voltage-
dependent, L type, alpha 
1D subunit 
CACNA1D 
3 
Membrane-
bound signaling 
molecules 
– 
• sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3C 
SEMA3C 
• odz, odd Oz/ten-m homolog 
4 (Drosophila) 
3 
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ODZ4 
• delta/Notch-like EGF repeat 
containing 
DNER 
Other receptors 
– 
• protein tyrosine 
phosphatase, receptor type, 
M 
PTPRM 
• protease, serine, 12 
(neurotrypsin, motopsin) 
PRSS12 
• protein tyrosine 
phosphatase, receptor type, 
M 
PTPRM 
3 
Signaling 
molecules 
• VGF nerve growth factor 
inducible 
VGF 
• FEV (ETS oncogene 
family) 
FEV 
• B-cell CLL/lymphoma 2 
BCL2 
• bone morphogenetic protein 
7 (osteogenic protein 1) 
BMP7 
• delta/Notch-like EGF repeat 
containing 
DNER 
• neuroligin 4, X-linked 
NLGN4X 
• odz, odd Oz/ten-m homolog 
4 (Drosophila) 
ODZ4 
• sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3C 
SEMA3C 
• vasoactive intestinal peptide 
VIP 
3 
Protein kinases • tribbles homolog 2 
(Drosophila) 
TRIB2 
• serum/glucocorticoid 
regulated kinase 
SGK 
• protein kinase C, alpha 
PRKCA 
• polo-like kinase 2 
(Drosophila) 
PLK2 
• doublecortin and CaM 
kinase-like 1 
DCAMKL1 
• neurotrophic tyrosine 
kinase, receptor, type 2 
NTRK2, non-catalytic 
isoform 
• G protein-coupled receptor 
kinase 5 
GRK5 
• polo-like kinase 2 
(Drosophila) 
PLK2 
2 
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Cytoskeletal 
proteins 
• tropomodulin 1 
TMOD1 
• spectrin, beta, non-
erythrocytic 1 
SPTBN1 
• neurofilament, medium 
polypeptide 150kDa 
NEFM 
• neurofilament, light 
polypeptide 68kDa 
NEFL 
• ectodermal-neural cortex 
(with BTB-like domain) 
ENC1 
• doublecortin and CaM 
kinase-like 1 
DCAMKL1 
• catenin (cadherin-
associated protein), alpha 
2 
CTNNA2 
• actinin, alpha 1 
ACTN1 
• dynein, cytoplasmic 1, 
intermediate chain 1 
DYNC1I1 
• ectodermal-neural cortex 
(with BTB-like domain) 
ENC1 
• neurofilament, light 
polypeptide 68kDa 
NEFL 
• neurofilament, medium 
polypeptide 150kDa 
NEFM 
• septin 9 
SEPT9 
• troponin C type 1 (slow) 
TNNC1 
2 
Hydrolases • phosphodiesterase 2A, 
cGMP-stimulated 
PDE2A 
• collapsin response 
mediator protein 1 
CRMP1 
– 2 
Kinase 
modulators 
• cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) 
CDKN1A 
• cyclin D1 
CCND1 
– 2 
Non-receptor 
serine/threonine 
protein kinases 
• protein kinase C, alpha 
PRKCA 
• serum/glucocorticoid 
regulated kinase 
SGK 
• polo-like kinase 2 
(Drosophila) 
PLK2 
• doublecortin and CaM 
kinase-like 1 
DCAMKL1 
• polo-like kinase 2 
(Drosophila) 
PLK2 
• G protein-coupled receptor 
kinase 5 
GRK5 2 
Ligand-gated ion 
channels 
 
 
– 
 
• glutamate receptor, 
ionotropic, AMPA 2 
GRIA2 
• gamma-aminobutyric acid 
(GABA) A receptor, beta 3 
GABRB3 
2 
Other signaling 
molecules 
• B-cell CLL/lymphoma 2 
BCL2 
• FEV (ETS oncogene 
family) 
FEV 
• bone morphogenetic protein 
7 (osteogenic protein 1) 
BMP7 
• neuroligin 4, X-linked 
NLGN4X 
• odz, odd Oz/ten-m homolog 
2 
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4 (Drosophila) 
ODZ4 
• sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3C 
SEMA3C 
Oxidoreductases 
– 
• ubiquinol-cytochrome c 
reductase, Rieske iron-
sulfur polypeptide 1 
UQCRFS1 
• cytochrome P450, family 
26, subfamily B, polypeptide 
1 
CYP26B1 
2 
Phosphatases 
– 
• protein phosphatase 2 
(formerly 2A), regulatory 
subunit B (PR 52), gamma 
isoform 
PPP2R2C 
• protein tyrosine 
phosphatase, receptor type, 
M 
PTPRM 
2 
Protein 
phosphatases 
– 
• protein phosphatase 2 
(formerly 2A), regulatory 
subunit B (PR 52), gamma 
isoform 
PPP2R2C 
• protein tyrosine 
phosphatase, receptor type, 
M 
PTPRM 
2 
Table 5.18 PANTHER™ gene and protein classification system: The analysis of the fifty most 
up-regulated transcripts from the comparisons C99V50F/C99WT and C99I45F/C99WT (p<0.05, 
n=3) revealed these differentially represented molecular functions. 
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The total difference of the following transcripts was one, but different transcripts were 
affected. Especially if they fulfilll contrary functions in the cell (e.g. 
inhibitory/activating), these molecular functions might play an important role: 
 
 
Transcripts 
Molecular 
functions 
C99V50F versus C99WT 
(Aβ42/Aβ40↓): 
C99I45F versus C99WT 
(Aβ42/Aβ40↑) : 
∆ 
Number 
of 
transcrip
ts 
Kinases • tribbles homolog 2 
(Drosophila) 
TRIB2 
• serum/glucocorticoid 
regulated kinase 
SGK 
• protein kinase C, alpha 
PRKCA 
• polo-like kinase 2 
(Drosophila) 
PLK2 
• doublecortin and CaM 
kinase-like 1 
DCAMKL1 
• G protein-coupled receptor 
kinase 5 
GRK5 
• neurotrophic tyrosine 
kinase, receptor, type 2 
NTRK2, non-catalytic 
isoform 
• phosphofructokinase, 
platelet 
PFKP 
• polo-like kinase 2 
(Drosophila) 
PLK2 
1 
Select calcium 
binding proteins 
• protein kinase C, alpha 
PRKCA 
• sarcoglycan, epsilon 
SGCE 
• troponin C type 1 (slow) 
TNNC1 1 
Proteases • endothelin converting 
enzyme-like 1 
ECEL1 
• ADAM metallopeptidase 
with thrombospondin type 1 
motif, 9 
ADAMTS9 
• protease, serine, 12 
(neurotrypsin, motopsin) 
PRSS12 
1 
 
 
The twenty most down-regulated transcripts 
Out of 254 tested molecular functions, 47 (data not shown) were differentially 
represented in consequence of a changed Aβ42/Aβ40 ratio. Out of these molecular 
functions, the strongest difference in the number of transcripts (∆ transcripts), and 
hence, most differentially represented, were these: 
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Transcripts 
Molecular 
function 
C99V50F versus C99WT 
(Aβ42/Aβ40↓): 
C99I45F versus C99WT 
(Aβ42/Aβ40↑) : 
∆ Number 
of 
transcripts 
Receptors • transferrin receptor (p90, 
CD71) 
TFRC 
• cholinergic receptor, 
muscarinic 3 
CHRM3 
• G protein-coupled receptor 
176 
GPR176 
• RAR-related orphan 
receptor B 
RORB 
• integrin, beta 5 
ITGB5 
 
3 
G-protein 
coupled 
receptors 
• cholinergic receptor, 
muscarinic 3 
CHRM3 
• G protein-coupled receptor 
176 
GPR176 
– 2 
Kinases • protein kinase N2 
PKN2 
• cyclin-dependent kinase 6 
CDK6 
– 2 
Non-receptor 
serine/threon
ine protein 
kinases 
• protein kinase N2 
PKN2 
• cyclin-dependent kinase 6 
CDK6 
– 2 
Protein 
kinases 
• protein kinase N2 
PKN2 
• cyclin-dependent kinase 6 
CDK6 
– 2 
Nucleic acid 
binding 
• transcription factor 4 
TCF4 
• prospero-related homeobox 
1 
PROX1 
• neurogenin 2 
NEUROG2 
• v-myc myelocytomatosis 
viral related oncogene, 
neuroblastoma derived 
(avian) 
MYCN 
• transcription factor 7-like 2 
(T-cell specific, HMG-box) 
TCF7L2 
• RAR-related orphan 
receptor B 
RORB 
• heart and neural crest 
derivatives expressed 1 
HAND1 
• cAMP responsive element 
binding protein 1 
CREB1 
• ribosomal protein S2 
RPS2 
• nuclear receptor coactivator 6 
NCOA6 
• endothelial PAS domain 
protein 1 
EPAS1 
• homeobox A7 
HOXA7 
• poly(A) binding protein, 
cytoplasmic 1 
PABPC1 
• ELAV (embryonic lethal, 
abnormal vision, Drosophila)-
like 1 (Hu antigen R) 
ELAVL1 
2 
Other – • matrix Gla protein 2 
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signaling 
molecules 
MGP 
• golgi apparatus protein 1 
GLG1 
Select 
regulatory 
molecules 
• serpin peptidase inhibitor, 
clade F (alpha-2 
antiplasmin, pigment 
epithelium derived factor), 
member 1 
SERPINF1 
• protein kinase C substrate 
80K-H 
PRKCSH 
• dynein, cytoplasmic 1, light 
intermediate chain 2 
DYNC1LI2 
• regulator of G-protein 
signaling 4 
RGS4 
2 
Transferases 
– 
• tetratricopeptide repeat 
domain 5 
TTC5 
• COX10 homolog, cytochrome 
c oxidase assembly protein, 
heme A: farnesyltransferase 
(yeast) 
COX10 
2 
Table 5.19 PANTHER™ gene and protein classification system: The analysis of the twenty most 
down-regulated transcripts from the comparisons C99V50F/C99WT and C99I45F/C99WT 
(p<0.05, n=3) revealed these differentially represented molecular functions. 
The total difference in the following transcripts was one, but different transcripts were 
affected. Especially if they have contrary functions in the cell (e.g. inhibitory/activating 
when both mutants are compared), they could fulfill important functions: 
 
Transcripts 
Molecular 
function 
C99V50F versus C99WT 
(Aβ42/Aβ40↓): 
C99I45F versus C99WT 
(Aβ42/Aβ40↑) : 
∆ Number 
of transcripts
CREB 
transcription 
factor 
– 
cAMP responsive element binding 
protein 1 
CREB1 
1 
Protease 
inhibitor 
• serpin peptidase inhibitor, 
clade F (alpha-2 antiplasmin, 
pigment epithelium derived 
factor), member 1 
SERPINF1 
– 1 
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5.13 Cluster analysis 
Hierarchical clustering is used to group genes according to common properties, for 
instance their expression level. With this information one can gain insight into 
relationships between genes or their proteins. Certain expression patterns represent 
common regulatory processes and can be a sign of putative functional relationships 
(interaction partners, inhibition, activation etc.). However, coincidence of clusters with 
similar expression patterns cannot be completely excluded. Here, genes were 
clustered hierarchically.7 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.38 Hierarchical clustering according to gene expression values. Gene expression 
values of three independent replicates of C99WT and C99-mutants were clustered in order to 
obtain information about expression patterns in wildtype and mutants. C99WT1 was used as a 
baseline experiment, set to 1 (100%=white) and hence, unchanged expression levels appear as 
white rectangles. Blue rectangles represent down-regulated genes, red rectangles represent up-
regulated genes. Three main clusters were identified (1, 2, 3). Here, hierarchical clustering was 
used. Genes were clustered with the Manhattan metric as distance between the centered 
expression profiles and complete linkage as distance between the clusters. GC-RMA normalized 
m-RNA levels were used.  
                                            
7 Cluster analysis was performed in cooperation with our collaboration partner Carina Ittrich from the DKFZ 
(German Cancer Research Center, Biostatistics Group).  
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See Chapter 12.3.4 (pages S71-S75), Supplementary Information, for gene 
annotations.  
In order to extract maximum information out of the data, data analysis was performed 
in parallel with another set of triplicates for C99WT (here named C99WT2: C99WT 
clone 1 was combined with C99WT clone 4 and 5, refer to Fig. 5.2, page 38) and 
used as a baseline experiment. This procedure revealed further genes and 
expression patterns (Fig. 5.39). See also annotations for clustered genes, Chapter 
12.3.4 (pages S73-S75), Supplementary Information: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.39 Hierarchical clustering according to gene expression values. Gene expression 
values of three independent replicates of C99WT and C99-mutants were clustered in order 
to obtain information about expression patterns in wildtype and mutants. C99WT2 (clone 1, 4 
and 5, see Fig. 5.2, page 38) was used as a baseline experiment. Using a different set of replicates 
for the baseline experiment provides further information about affected genes and provides insight 
into variability from clone to clone. Two main clusters were identified. 
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In order to utilize maximum information out of the data, data derived from C99WT1, 
C99WT2, C99 mutants and the mock control was used providing information about 
overall gene regulation. 
This procedure revealed a hitherto unknown relationship between neurogenin 2 and 
the uncharacterized KIAA0125. Interestingly both genes were the most strongly 
differentially expressed genes, and secondly, they were inversely regulated in all 
measured cell clones.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.40 Hierarchical clustering according to gene expression values. Gene expression 
values of three independent replicates of C99WT1, C99WT2, C99-mutants and mock transfected 
cells were clustered in order to obtain information about expression patterns. This procedure revealed 
a so far unknown relationship between neurogenin 2 (Neurog2) and the until now uncharacterized 
KIAA0125: Neurogenin 2 and KIAA0125 were inversely regulated. Here, no baseline experiment was 
defined. Instead, for each probe set the mean was calculated over all Chips and was subtracted from 
every single value (centering of data). 
Interestingly, KIAA0125 (chr14q32.33) is localized close to the PS1 locus 
(chr14q24.3). There might be a functional relationship between PS1, KIAA0125 and 
neurogenin 2. 
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5.14 Quantitative real-time PCR 
5.14.1 Preface 
The advantage of using microarrays to measure thousands of transcripts in parallel is 
accompanied by a certain imprecision of the measurements. Calculated fold changes 
for microarray experiments can vary greatly depending on the used normalisation 
algorithms. Quantitative real-time PCR is a suitable tool to verify microarray data and 
provide more precise results. The fold changes determined by real-time PCR better 
reflect true expression levels and hence was used here to validate microarray data. 
To obtain reliable results, measurements need to be normalized, thus a normalisation 
control was selected out of ten different normalisation controls and used for all 
measurements. All fold changes determined by real-time PCR validated the 
microarray data. As to be expected [194] microarray data calculated with the PLIER 
algoritm slightly underestimated true fold changes of expression (as determined by 
real-time PCR).  
5.14.2 Normalisation 
These 10 candidate controls were used to select a suitable endogenous control for 
normalisation:   
 
• Acidic ribosomal protein 
• β-actin 
• CyclophilinA 
• Glyceraldehyde-3-phosphate dehydrogenase 
• Phosphoglycerokinase 
• β2-Microglobulin 
• β-Glucuronidase 
• Hypoxanthine ribosyl transferase 
• Transcription factor IID, TATA binding protein 
• Transferrin receptor 
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Efficiency of endogenous control (cyclophilin A) 
amplification for Assays-on-Demand™
y = -3,4181x + 24,023
R2 = 0,9997
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Suitable controls were those providing equal and high expression in all tested cell 
clones. Cyclophilin A, β-actin and acidic ribosomal protein turned out to be suitable 
for normalisation. Detailed analysis of these 3 normalisation controls, in turn, showed 
that cyclophilin A was insignificantly more favorable than the other two, due to equal 
expression in all cell clones. Thus, cyclophilin A was chosen as the normalisation 
control. 
5.14.3 Relative quantification with the ∆∆CT Method 
 
Validation of an equal amplification efficiency of the genes of interest and the 
endogenous control for Assays-on-Demand™ 
For the ∆∆CT –Method to be valid, the efficiency of the target amplification and the 
efficiency of the reference amplification must be approximately equal. A suitable 
method to assess this, is to look at how ∆CT varies with template dilution. As an 
example, the amplification efficiencies of the endogenous control and two target 
genes (sema3c and ecel1) are shown (Fig. 5.41, A-C). Furthermore, the amplification 
efficiencies of endogenous control and one target gene were directly compared to 
assess equal efficiencies (Fig. 5.42).  
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Figure 5.41 A-C Diagrams show cDNA amplification 
determined by measuring the threshold cycle (CT) at 
different input cDNA amounts by real-time PCR. For 
calculating the amplification efficiencies (E) the equation used 
was: E=10 (-1/slope) -1. 
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Equal efficiency of target and endogenous control 
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Figure 5.42 Input cDNA is plotted against the differences (∆CT) of 
the CT values between gene of interest and reference. If the 
efficiencies of the two amplicons are approximately equal, the slope 
tends towards zero and should be <0.1. 
The amplification efficiencies of target (gene of interest) and reference were found to 
be equal and close to 100% (90%-110%) in all tested assays. Apart from this, 
Applied Biosystems guarantees the same efficiencies of target and reference 
amplification for all Assays-on Demand™ when measuring at a range from 1-100 ng 
cDNA) so the ∆∆CT Method could be used for calculating fold changes of gene 
expression. Apart from this, efficiency curves delivered information about the range in 
which reliable measurements were possible: It turned out that it was possible to 
measure from 0.01-100 ng input cDNA for high and medium abundant transcripts 
and from 1-100 ng for low abundant transcripts. Finally 50 ng was chosen to be sure 
to measure in a linear range (at th is amount one is able to detect low abundant 
transcripts while inhibition by overexcess of cDNA can be excluded). 
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5.14.4 Direct comparison of data derived from oligonucleotide 
microarrays and quantitative real-time PCR 
 
Oligonucleotide microarrays 
 C99V50F/C99WT1 C99I45F/C99WT1 C99I45F/C99V50F C99WT1/mock 
 Fold change p-value 
Fold 
change p-value 
Fold 
change p-value 
Fold 
change p-value 
AMPA2 not differentially expressed 6.5 0.033 4.8 0.025 
not differentially 
expressed 
CRABP1 not differentially expressed 2.7 0.116 2.3 0.188 
not differentially 
expressed 
ECEL1 
 
1.9 
 
0.037 not differentially expressed -4.0 0.137 -2.0 0.3238 
Glutamate 
Receptor 
8c 
not differentially 
expressed 1.5 0.247 -2.6 0.198 
not differentially 
expressed 
HGF not differentially expressed -3.0 0.157 -2.5 0.219 
not differentially 
expressed 
IGF2 not differentially expressed -2.6 0.05 -3.8 0.082 1.9 0.1030 
PTPRN2 1.6 0.095 1.8 0.041 1.9 0.027 not differentially expressed 
Sema3c not differentially expressed 1.8 0.032 2.6 0.027 
not differentially 
expressed 
TrkB, different splice products: 
214680_at 
(non-
catalytic 
isoform) 
-1.3 0.165 1.6 0.062 2.8 0.030 1.6 0.0721 
221796_at 
(non-
catalytic 
isoform) 
-1.7 0.086 2.2 0.023 5.4 0.013 3.3 0.0111 
221795_at
(non-
catalytic 
isoform) 
-1.7 0.058 1.9 0.193 5.2 0.047 2.7 0.0038 
207152_at 
(catalytic 
isoform) 
not differentially 
expressed 
not differentially 
expressed 1.4 0.142 
not differentially 
expressed 
Table 5.20 Selected genes from whole genome microarray experiments. Data were derived from 
three independent experiments. All replicates (n=3) were performed at different days and from 
independent single clones. Data were normalized with the PLIER algorithm. The complete coding 
sequence of TrkB (NTRK2) consists of 24 exons (207152_at, longest isoform, contains the 
carboxyterminal catalytic domain (exon 20-24) and the carboxyterminal phospholipase C γ binding site 
(exon 23-24). The non-catalytic isoforms of TrkB end after exon 16, so that they lack both the catalytic 
domain and the phospholipase C γ binding site. All (non-catalytic and catalytic isoforms) transcripts 
were sufficiently abundant (absolute values) to ensure reliable results. (The direct comparison of both 
mutants (C99I45F/C99V50F) and the comparison C99WT1/mock are shown here to give an 
impression of their regulation but are not shown by Real-Time PCR). 
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Quantitative Real-Time PCR 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Figure 5.43 Differentially expressed genes validated by Real-Time PCR. Columns 
represent the mean of the fold change of three independent single clones. Each clone was 
measured once and the mean was calculated from three clones (n=3). Thus biological clone 
to clone variation is not concealed and can be seen from error bars representing the S.E.M. 
(standard error of the mean).  
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Data derived from Real-Time PCR showed agreement with microarray data in all 
tested cell clones. Real-Time PCR delivers more precise data than the microarray 
analysis (in which thousands of transcript are measured in parallel) due to the 
concentration onto one transcript.  
5.15 “Chromeron-Effect” on chromosomal loci 1q23 and 1p36 
Equally regulated genes, localized on the same chromosomal locus may have 
important functional relations. Such a regulation, resembling the “Operon” in 
prokaryotes, was named “Chromeron” in eukaryotes [195, 196]. I observed this effect 
for the chromosomal loci 1q23 and 1p36:  
 
Gene Name Gene Symbol 
C99I45F versus 
C99WT 
(Aβ42/Aβ40↑) Chromosomal locus 
neural cell adhesion 
molecule 1 NCAM1 1.7 fold up-regulated 1q23 
regulator of G-protein 
signaling 7 RGS7 1.5 fold up-regulated 1q23 
(regulator of G-protein 
signaling 4) (RGS4) 
(2.7 fold down-
regulated) (1q23) 
kinesin family 
member 1B Kif1B 1.6 fold up-regulated 1p36 
neuroblastoma  
suppression of 
tumorigenicity 1 NBL1 1.7 fold up-regulated 1p36 
Table 5.21 “Chromeron-Effect” on chromosomal loci 1q23 and 1p36 (n=3, p<0.05 for all listed 
genes). Equally regulated NCAM1 and RGS7 show the chromeron effect on chromosome 1q23. Kif1B 
and NBL1 show this effect on chromosome 1p36. RGS4, localized on 1q23, was one of the most 
downregulated genes (C99I45F versus C99WT) and is discussed as a top candidate gene for 
schizophrenia.  
Further genes that are regulated in the same direction and to the same extent (co-
regulated genes), but are localized on different chromosomal regions were: 
 
APLP2 (1.6 fold up-regulated in C99I45F versus C99WT, chr11q23-q25|11q24), α-
catenin (1.8 fold up-regulated in C99I45F versus C99WT, chr2p12), PREP (1.5 fold 
up-regulated in C99I45F versus C99WT, chr6q22), Sema3c (1.8 fold up-regulated in 
C99I45F versus C99WT, chr7q21). 
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5.16 Agreement of differentially expressed genes with genes 
found in linkage and association studies 
Two genes or markers that are so close together on a chromosome that they are 
rarely separated by recombination are said to be linked. Linkage analysis is a 
statistical method for detecting linkage between a disease and markers of known 
location by following their inheritance in families. Two genes that are near each other 
on the same chromosome are said to be linked. If one gene is inherited, the 
probability is high that the other one will also be inherited. Linkage usually means 
that a gene contributing partially or completely to the phenotype (a genetic disease, 
for instance) maps in the vicinity of the markers. The tendency of certain genes to be 
inherited together due to their physical proximity on the chromosome provides 
important information. This information (chromosomal loci identified by linkage 
analysis) was compared to the identified susceptibility loci identified here in this 
thesis. Genes identified in overlapping loci (identified by linkage analysis and gene 
expression profiling in consequence of altered Aβ42/Aβ40 ratios) are expected to 
provide more promising candidates for AD than one approach alone.  
Chromosomal regions of most differentially expressed genes (as a result of a 
changed Aβ42/Aβ40 ratio) were selected and compared with chromosomal regions 
identified in linkage analyses (lod score>2). Only overlapping results are shown here. 
This procedure was used in order to narrow down important candidate genes.  
Gene Symbol Gene Name 
Differentially 
expressed 
in these 
compared clones 
Fold 
change p-value 
Chromosomal  
location, 
lod score > 2 
RGS4   
regulator of 
G-protein 
signaling 4 C99I45F/C99WT1 
>3- fold 
down -
regulated <0.005 chr1q23.3 
LPAL2   
LPAL2   
Lipoprotein, 
Lp(a)-like 2 C99I45F/C99WT1 
>3- fold 
down -
regulated <0.005 chr6q26-q27 
FGF21  
FGF21  
fibroblast 
growth factor 
21 C99I45F/C99WT2 
>3- fold 
down -
regulated <0.005 
chr19q13.1-
qter 
NTRK2 
neurotrophic 
tyrosine 
kinase, 
receptor, type 
2 (non-
catalytic 
isoform) C99I45F/C99V50F 
>3-fold up-
regulated <0.005 chr9q22.1 
NTRK2 
neurotrophic 
tyrosine 
kinase, 
receptor, type C99I45F/C99WT2 
>3-fold up-
regulated <0.005 chr9q22.1 
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2 (non-
catalytic 
isoform) 
DPT dermatopontin C99I45F/C99V50F 
>3-fold up-
regulated <0.005 chr1q12-q23 
DPT dermatopontin C99I45F/C99WT2 
>2-fold up-
regulated <0.005 chr1q12-q23 
ITPR2 
inositol 1,4,5-
trisphosphate 
receptor, type 
2 C99I45F/C99V50F 
>3-fold up-
regulated <0.005 chr12p11 
Table 5.22 Overlap of chromosomal regions, identified by localization of differentially 
expressed genes (identified in this thesis), with chromosomal susceptibility loci identified by 
linkage analysis. Chromosomal loci, in which the most strongly differentially expressed genes were 
found, were compared to chromosomal loci in which relatively strong (lod score >2) linkage to AD was 
found. Lod (logarithm of the odds) score 2 is a rather stringent cut-off for true linkage. Data were 
derived from calculation with several algorithms.  
The same procedure was used for the following genes and linkage was also found 
for these regions, but with a lod score <2.0, reducing the reliability of true linkage 
compared to lod scores>2.0:  
Gene 
Symbol Gene Name 
Differentially 
expressed 
in these compared 
clones 
Fold 
change p-value 
Chromosomal 
location 
WNT9A    
Wingless-type MMTV 
integration site family, 
member 9A C99V50F/C99WT1 
>3-fold up-
regulated <0.005 chr1q42 
WNT9A    
Wingless-type MMTV 
integration site family, 
member 9A C99I45F/C99V50F 
>3-fold 
down-
regulated <0.005 chr1q42 
GRM7   
glutamate receptor, 
metabotropic 7 C99I45F/C99WT2 
>3-fold up-
regulated <0.005 chr3p26 
ENPP5   
ectonucleotide 
pyrophosphatase/phos
phodiesterase 5 
(putative function) C99I45F/C99WT1 
>3-fold 
down-
regulated <0.005 
chr 6p21.1-
p11.2 
PAX2    paired box gene 2 C99V50F/C99WT1 
>3-fold up-
regulated <0.005 chr 10q24 
ADRB1   
adrenergic, beta-1-, 
receptor C99V50F/C99WT1 
>3-fold up-
regulated <0.005 chr 10q24-q26 
ADRB1   
adrenergic, beta-1-, 
receptor C99V50F/C99WT2 
>3-fold up-
regulated <0.005 chr 10q24-q26 
ADRB1   
adrenergic, beta-1-, 
receptor C99I45F/C99V50F 
>3-fold 
down-
regulated <0.005 chr 10q24-q26 
CMKLR1 
chemokine-like 
receptor 1 C99I45F/C99WT1 
>3-fold 
down-
regulated <0.005 chr 12q24.1 
CUTL2 cut-like 2 (Drosophila) C99I45F/C99WT2 
>3-fold up-
regulated <0.005 
chr 12q24.11-
q24.12 
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FLT1   
Fms-related tyrosine 
kinase 1 (vascular 
endothelial growth 
factor/vascular 
permeability factor 
receptor) , spliced form C99V50F/C99WT1 
>3-fold up-
regulated <0.005 chr13q12 
TC9  
tetratricopeptide repeat 
domain 9 C99I45F/C99WT1 
>3-fold up-
regulated <0.005 chr14q24.2 
TTC9  
tetratricopeptide repeat 
domain 9 C99I45F/C99WT2 
>3-fold up-
regulated <0.005 chr14q24.2 
CYP2B6   
cytochrome P450, 
family 2, subfamily B, 
polypeptide 6 C99I45F/C99V50F 
>3-fold up-
regulated <0.005 chr19q13.2 
NCR1   
natural cytotoxicity 
triggering receptor 1 C99I45F/C99V50F 
>3-fold up-
regulated <0.005 chr19q13.42 
GRIA3  
glutamate receptor, 
ionotropic, AMPA 3 C99I45F/C99WT2 
>3- fold 
down -
regulated <0.005 chrXq25-q26 
Table 5.23 Overlap of chromosomal regions, identified by localization of differentially 
expressed genes (identified in this thesis), with chromosomal susceptibility loci identified by 
linkage analysis. Chromosomal loci, in which strong differentially expressed genes were found, were 
compared to chromosomal loci in which linkage (lod score <2.0) was found. Data were derived from 
calculation with several algorithms.  
Genetic association studies are performed to determine whether a genetic variant is 
associated with a disease or trait: if association is present, a particular allele, 
genotype or haplotype of (a) polymorphism(s) will be seen more often than expected 
by chance in an individual carrying the trait. Thus, a person carrying one or two 
copies of a high-risk variant is at an increased risk of developing the associated 
disease or having the associated trait. Genetic association is the occurrence together 
in a population, more often than can be readily explained by chance, of two or more 
traits of which at least one is known to be genetic. This can be between phenotypes, 
e.g. visible characteristics such as height or eye colour, between a phenotype and a 
genetic polymorphism, such as a single nucleotide polymorphism, or between two 
genetic polymorphisms.  
Linkage disequilibrium (LD) is a term used in the study of population genetics for the 
non-random association of alleles at two or more loci, not necessarily on the same 
chromosome. It is not the same as linkage, which describes the phenomenon 
whereby two or more loci on a chromosome have reduced recombination between 
them because of their physical proximity to each other. LD describes a situation in 
which some combinations of alleles or genetic markers occur more or less frequently 
in a population than would be expected from a random formation of haplotypes from 
alleles based on their frequencies. 
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In order to find new susceptibility loci for late onset AD a linkage disequilibrium 
analysis was performed in a Finnish population [135, 136]. Forty-seven patients with 
late-onset AD and 51 age-matched control subjects were chosen from the same 
geographic area in eastern Finland, where the population is descended mainly from a 
small group of original founders. These subjects were initially genotyped with 366 
polymorphic microsatellite markers and a follow-up analysis was performed with 
additional microsatellite markers for those chromosome loci found to be associated 
with AD. This analysis revealed 8 chromosomal loci where more than one 
microsatellite marker was associated with AD: 1p36.12, 2p22.2, 3q28, 4p13, 10p13, 
13q12, 18q12.1 and 19p13.3. Genes in close proximity to these loci (Table 5.24) will 
provide targets for future genetic and functional studies of AD.  
 
Gene 
Symbol Gene Name 
Differentially 
expressed in these 
compared clones 
Fold 
change p-value 
Chromosomal 
location 
NBL1 
neuroblastoma, 
suppression of 
tumorigenicity 1 C99I45F/C99WT1 
2.6 fold 
up-
regulated 0.00002 
chr1p36.13-
p36.11 
KIAA1026 KIAA1026 protein C99I45F/C99WT1 
1.7 fold 
up-
regulated 0.0021 chr1p36.21 
KIF1B kinesin family member 1B C99I45F/C99WT1 
1.6 fold 
up-
regulated 0.0371 chr1p36.2 
VAMP3 
vesicle-associated 
membrane protein 3 
(cellubrevin) C99I45F/C99WT1 
1.1 fold 
down-
regulated 0.0327 chr1p36.23 
NPPA 
natriuretic peptide 
precursor A C99V50F/C99WT1 
1.3 fold 
up-
regulated 0.0488 chr1p36.21 
NPD014 NPD014 protein C99V50F/C99WT2 
1.2 fold 
up-
regulated 0.0163 
chr1p36.13-
p35.1 
KIAA1102 KIAA1102 protein C99I45F/C99WT1 
2.1 fold 
up-
regulated 0.0038 chr4p13 
CCDC3 
coiled-coil domain 
containing 3 C99I45F/C99WT1 
2.5 fold 
up-
regulated 0.01613 chr10p13 
TLE2 
transducin-like enhancer 
of split 2 (E(sp1) homolog, 
Drosophila) C99I45F/C99WT1 
2.8 fold 
down-
regulated 0.00253 chr19p13.3 
EML4 
echinoderm microtubule 
associated protein like 4 C99V50F/C99WT1 
1.6 fold 
up-
regulated 0.0224 chr2p22-p21 
SOS1 
Son of sevenless 
homolog 1 (Drosophila) C99V50F/C99WT1 
4.0 fold 
down-
regulated 0.02572 chr2p22-p21 
SLC14A2 Solute carrier family 14 C99I45F/C99WT1 5.0 fold 0.00219 chr18q12.1 
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(urea transporter), 
member 2 
up-
regulated 
SLC14A2 
Solute carrier family 14 
(urea transporter), 
member 2 C99V50F/C99WT1 
4.0 fold 
up-
regulated 0.02572 chr18q12.1 
Table 5.24 Overlap of chromosomal regions, identified by localization of differentially 
expressed genes (identified in this thesis) with chromosomal susceptibility loci identified by 
genotyping and subsequent use of microsatellite markers (publications of other working 
groups). Chromosomal loci, in which strongly differentially expressed genes were found, were 
compared to chromosomal susceptibility loci identified in a Finnish population. No overlap was found 
for chromosomal region 3q28. 
5.17 Agreement of differentially expressed genes with genes 
of the “Alzforum database”  
The Alzforum database, containing candidate genes for AD, is updated regularly and 
thus varies with time. For this reason, here only a small selection of genes is shown: 
Gene lists presented in Chapter 12.2 (Supplementary Information) can be compared 
with the gene list presented at www.alzforum.org from time to time in order to identify 
further candidate genes.  
Gene Name Gene Symbol 
Differentially 
expressed 
in these compared 
clones 
Fold change p-value 
CD14 CD14 C99I45F/C99WT1 >3-fold down-
regulated 
<0.005 
CD14 CD14 C99V50F/C99WT1 >3-fold up-regulated <0.005 
neurotrophic 
tyrosine kinase, 
receptor, type 2 
(non-catalytic 
isoform) 
NTRK2 C99I45F/C99WT2 >3-fold up-regulated <0.005 
plasminogen 
activator, tissue 
 
PLAT C99V50F/C99WT1 >2-fold up-regulated <0.005 
Table 5.25 Genes found to be differentially expressed as a result of a changed Aβ42/Aβ40 ratio, 
were compared to putative candidate genes presented at www.alzforum.org. Only overlapping 
genes are listed here. Data were derived from calculation with several algorithms. 
5.18 Intersection of genes identified in this thesis as a 
consequence of an altered Aβ42/Aβ40 ratio and genes 
identified as a result of PS1/PS2 knockdown in murine 
embryonic fibroblasts 
Differentially expressed genes derived from the comparison C99I45F/C99WT 
(Aβ42/Aβ40↑) and C99V50F/C99WT (Aβ42/Aβ40↓) in human neuroblastoma cells were 
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compared with differentially expressed genes from embryonic mouse fibroblasts in 
which presenilin 1 and  presenilin 2 were knocked down by siRNA (carried out by my 
colleague Laura Busia; data are available in her Master thesis). Here, the 100 most 
up and down-regulated transcripts in either datasets were compared. Both 
approaches have one common mechanism, namely the processing by the γ-
secretase complex. If processing by by the γ-secretase complex is the pivotal 
common step, genes dependent on this process should be identified in both 
approaches. Indeed I found such genes by overlaying both datasets: 
 
Gene symbol Name 
ACTA2 actin, alpha 2, smooth muscle, aorta 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
COL4A1 collagen type IV α 1  
CRABP1 cellular retinoic acid binding protein 1 
DKK2 dickkopf homolog 2 (Xenopus laevis) 
FBN1 fibrillin 1 (Marfan syndrome) 
RELN Reelin  
SEMA3A 
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
semaphorin 3A 
STX3 syntaxin 3 
USP18 ubiquitin specific protease 18 
Table 5.26 Genes, found to be differentially expressed as a result of a changed Aβ42/Aβ40 ratio 
(identified in this thesis) were compared with genes identified as a result of PS1/PS2 
knockdown in embryonic mouse fibroblasts. Only overlapping genes are listed here.  
5.19 Intersection of genes identified in this thesis as a 
consequence of an altered Aβ42/Aβ40 ratio and genes 
identified in response to AICD overexpression in human 
neuroblastoma cells 
Differentially expressed genes derived from the comparison C99I45F/C99WT 
(Aβ42/Aβ40↑) and C99V50F/C99WT (Aβ42/Aβ40↓) in the human neuroblastoma cell line 
SH-SY5Y (identified in this thesis) were compared with differentially expressed genes 
in the human neuroblastoma cell line SHEP-SF overexpressing the AICD identified 
by Müller et al. [57].  
Here, the 100 most up and down-regulated transcripts (identified in this thesis) were 
compared with the genes presented in the dissertation by Thorsten Müller (University 
of Münster, Germany, 2005).  A selection of overlapping genes is shown in Table 
5.27. 
  Results 
 
 
121
Gene symbol Name 
ACTA2   α2-actin, smooth muscle, aorta   
PTN pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) 
PROX1 prospero-related homeobox 1 
DOCK4   dedicator of cytokinesis 4   
TFPI2 tissue factor pathway inhibitor 2 
Table 5.27 Genes, found to be differentially expressed as a result of changed C99 cleavage 
products (identified in this thesis) were compared with genes identified as a result of AICD 
overexpression. A selection of overlapping genes is listed here.  
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6 Discussion 
6.1 Preface 
There is a large body of evidence showing that Aβ42, in contrast to Aβ40, triggers a 
chain of harmful events in the development of AD [19, 197]. Most of the scientific 
community generally agrees on the hypothesis that Aβ42 triggers or is causally 
involved in the malfunction of AD. However, the mechanism of how Aβ42 acts is 
unclear. It has been demonstrated that Aβ42 and Aβ40 have opposing effects on 
amyloid deposition. It has been shown that Aβ42 promotes amyloid deposition, 
whereas Aβ40 inhibits it [78]. Aβ40 seems to have protective properties and it was 
suggested that selective increases in Aβ40 levels may actually reduce the risk for 
development of AD. Moreover it was suggested that the Aβ42/Aβ40 ratio, not total Aβ 
levels, controls amyloid deposition in transgenic mice [78]. To shed light on this 
issue, gene expression profilings of human neuroblastoma cells were performed in 
the presence of altered Aβ42/Aβ40 levels. One big advantage of human cells, in 
contrast to neurons from mice or other species, is that obtained data can be better 
compared to linkage and association studies from affected families suffering from 
AD. Furthermore, signal transduction and metabolic pathways differ between species 
and elucidation of the mechanism for AD feasible for mice is not necessarily 
beneficial to humans. The question of how transcription is activated was not directly 
addressed in this thesis. There is growing evidence that the APP intracellular domain 
(AICD) is involved in nuclear signaling. Fe65 has been shown to stabilize the 
intracellular domains of γ-secretase cleaved APP, APLP1 and APLP2, which, 
together with Fe65, are localized to the nuclear compartment [198, 199]. The analogy 
of APP processing to Notch receptor signaling suggested a possible function for the 
AICD in nuclear signaling [200, 201]. Nuclear signaling of the AICD is assumed to be 
regulated by the APP-adaptor proteins Fe65, Jip1b and X11α, as well as the nuclear 
docking protein Tip60.  
 
C99 is cleaved by γ-secretase, resulting on the one hand in the release of Aβ42 and 
Aβ40 and on the other hand in the release of two AICD species (AICD49-99 and 
AICD50-99) [49]. So the observed alterations in gene expression may be triggered by 
Aβ or the AICD (or cleavage products thereof for instance through cleavage by 
caspases [151]). Further research distinguishing AICD effects from Aβ effects is 
necessary. Some publications about these issues already exist with the inherent 
problems of external Aβ supply [197, 202, 203]. Here, however, Aβ expression was 
analyzed in a controlled manner: C99-overexpressing constructs encoding the C-
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terminal part of AβPP (C99), together with an N-terminal signal peptide were used. 
This peptide is correctly cleaved by signal peptidase and thus is identical to the 
AβPP-derived C99, the ultimate precursor for Aβ generation. C99 is processed by γ-
secretase in the same manner as AβPP-derived C99, making it an ideal substrate to 
study γ-secretase function or its cleavage products Aβ42 and Aβ40 without influence of 
β-secretase. C99 cleavage by γ-secretase results in Aβ42 and Aβ40 production and is 
inherently accompanied by production of two AICDs differing in length [49]. A link 
between the production of Aβ42 and the AICD49-99 has been suggested [50]. It has 
been shown that equimolar amounts of Aβ and AICD are produced [49]. Gene 
expression could also be triggered by the as yet unidentified AICD57 and AICD59, the 
two species which should theoretically be left after cleavage of Aβ42 and Aβ40 from 
the precursor C99. Furthermore, it has to be taken into consideration that the AICDs 
themselves are cleaved and that their cleavage products may also induce or repress 
gene expression. 
Comparing our datasets with gene expression profiles from human neuroblastoma 
cells overexpressing the AICD alone (Müller et al. 2007 [57]) may indicate that some 
of the observed changes in gene expression are partially triggered by the AICD (or 
cleavage products thereof). This can be concluded from the significant overlap of 
identified genes by Müller et al. and genes identified here in this thesis. Further 
support for this view comes from the work of my colleague Laura Busia who identified 
genes in consequence of presenilin 1 and presenilin 2 knockdown by siRNA in 
murine embryonic fibroblasts (a big overlap of genes with the genes presented here 
in this thesis and with the genes identified by Müller et al. was observed). Processing 
by γ-secretase is expected to be influenced, with the consequence of changed 
Aβ42/Aβ40 and AICD levels. If gene expression is triggered by the AICD, overlapping 
genes should be found with the genes identified by Müller et al.. Therefore, I 
compared this dataset with the genes identified by Müller et al. and indeed found an 
overlap of genes that is bigger than can be expected by chance (a selection of such 
genes is shown in Chapter 5.19, pages 120-121). The overlap of genes from our 
approaches (changed Aβ42/Aβ40 and AICD levels in human neuroblastoma cells and 
PS1/PS2 knockdown in murine embryonic fibroblasts) was bigger, if compared to 
identified genes by Müller et al. in which the AICD was inducibly overexpressed in a 
human neoblastoma cell line (and compared to the same non-induced cell line), than 
a comparison between our identified genes with several gene expression studies 
about Aβ42 treated cells [197, 204]. However, it has to be taken into consideration 
that treating cells with Aβ42 may be more artificial than our approach in which Aβ42 is 
generated from a precursor. KAI1, which was shown to be induced by the AICD 
[152], was significantly differentially expressed in our PS1/PS2 knockdown approach. 
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However, it is noteworthy that AICD-regulated genes may be a subset of a much 
larger group of genes controlled by γ-secretase processing. 
Whenever the term “Aβ42/Aβ40 ratio” is used in this thesis for reasons of simplicity, it 
also implies the corresponding AICDs [49, 50] and all possible further C99 cleavage 
products.  
Apart from relative values (equal to fold changes derived from the comparison 
between two groups) the absolute values from one group (absolute expression 
levels) have to be taken into consideration: The genes discussed in this thesis were 
checked for sufficiently high absolute values. However, there is no real agreement on 
what “sufficiently high” means. Also weakly expressed genes can be of relevance, if 
they belong to a group of genes which are generally weakly expressed, like for 
instance transcription factors. The absolute expression values of the genes were 
checked, but not necessarily intentionally excluded from analysis if they were below a 
certain threshhold. Instead, genes with very low absolute values were explicitly 
mentioned in the text. Furthermore, it has to be taken into consideration that absolute 
values (as well as relative values) strongly depend on the algorithm used to calculate 
the data.  
The terms “differentially expressed and up/down-regulated” refer to data derived from 
microarray analysis. If they were derived from real-time PCR, immunoblotting, 
immunocytochemistry, this was explicitly mentioned in the text.  
Among big datasets derived from microarray analysis there is usually a portion of 
data which are so-called “false-positives” (genes that are not differentially expressed, 
but erroneously appear so). To restrict the number of false positives, while avoiding a 
too stringent cut-off, which would also remove genes with biologically relevant 
information, a balance for the stringency should be found. This was done by 
adjusting the threshold for the p-value to 0.05 (MAS 5 algorithm), 0.05 (PLIER 
algorithm) and 0.005 (GC-RMA algorithm). Nevertheless, differentially expressed 
genes with p-values slightly greater than 0.05 were also partially included into the 
data analysis, otherwise possible important biological effects would have been 
overlooked. The often used technique of strictly excluding such data (without any 
regard to their biological relevance) is a convenient way to make data analysis more 
simple (because a smaller data set has to be handled), but increases the risk of not 
recognizing crucial biological relationships. This is particularly true for signal 
transduction pathways in which many proteins (or their encoding genes) are 
components of a certain pathway: The probability that some of these proteins 
(genes) exceed the general accepted cut-off for significance (p=0.05) is high; 
excluding such data from the beginning may conceal that this pathway is actually 
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affected.  
Among big datasets derived from microarray analysis, the differentially expressed 
genes are usually a mixture of direct (primary) effects and indirect (secondary) 
effects derived from the original trigger (the trigger can be for instance an 
overexpressed protein, a knocked down gene etc.). Primary effects are caused 
directly by the trigger (overexpression of the trigger A leads to dysregulation of gene 
B). Secondary effects are caused by an indirectly dysregulated gene/protein 
(overexpression of the trigger A leads to dysregulation of gene C, via dysregulation of 
gene B). Such secondary effects are inevitable but can be biologically meaningful (for 
instance when gene B codes for a protein that itself has a strong impact on gene 
expression and influences the expression of gene C). A way to restrict such 
secondary effects (even if they cannot be excluded completely) is time-course 
experiments, in which typical “immediate early genes” (together with further directly 
responding  genes, influenced by the trigger) can to some degree be distinguished 
from subsequently responding genes (secondary effects).  
Gene expression profiling studies usually result in the generation of gene lists, in 
which genes can be listed according to their relative expression levels (fold changes), 
p-values or other kind of sorting criteria. Among these listed genes are some that 
specifically respond to the intended trigger (for instance an overexpressed protein 
triggering a pathological effect) and thus provide important information about the 
pathological mechanism. However, a subset of the listed genes, whose size is 
unknown, is differentially expressed in consequence of unspecific effects (these are, 
for instance, epiphenomena, not connected to the pathological mechanism). In order 
to control these unspecific effects as much as possible, a mock control (cells 
transfected with an empty vector) was used to recognize such effects. C99WT 
overexpression was compared to the mock control (dataset I) providing information 
about C99 effects. On the other hand the two mutants C99I45F (increased Aβ42/Aβ40 
ratio) and C99V50F (decreased Aβ42/Aβ40 ratio) were compared with C99WT 
(dataset II and III). Finally all three datasets (I, II and III) were compared to each 
other to identify specific effects (specific especially for the AD-typical increased 
Aβ42/Aβ40 ratio). Taking advantage of the knowledge about the amounts of generated 
Aβ42/Aβ40 (C99I45F>C99WT>C99V50F) allowed to some degree the distinguishing 
between effects of different Aβ42/Aβ40 amounts. Of special interest were those genes 
which were among the most up-regulated ones for dataset II and in parallel among 
the most down-regulated ones for dataset III and vice versa. These genes in 
particular were expected to be influenced by inverse levels of Aβ42/Aβ40. 
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It has to be taken into consideration that a small portion of Aβ42/Aβ40 (C99 
respectively) was also present in the cells, which was endogenously generated from 
the APP-locus (untransfected cells) with the disadvantage that expression values 
cannot go below endogenous levels (in contrast to APP knockout approaches). C99 
was overexpressed approximately 10-fold (compared to endogenous C99 levels). 
This overexpression affected the comparison C99WT/mock. I regarded a 10-fold 
overexpression as sufficient to recognize important biological effects while it might 
not have been too high to cause a significant bias in the data due to unphysiological 
high C99 concentrations. For the comparisons C99I45F/C99WT and 
C99V50F/C99WT, C99-levels themselves were not expected to have an influence on 
gene expression, because all cells to be compared contained matched C99 
expression levels. It was previously demonstrated [148, 149] and shown in this thesis 
that C99I45F and C99V50F express inverse Aβ42/Aβ40 levels. Secreted Aβ42/Aβ40 
levels were 20-fold higher in C99I45F than in C99WT and intracellular Aβ42/Aβ40 
levels were 1.9-fold higher in C99I45F than in C99WT. In contrast to this, secreted 
Aβ42/Aβ40 was approximately 3-fold lower in C99V50F than in C99WT and 
intracellular Aβ42/Aβ40 was 1.9-fold lower in C99V50F than in C99WT [148]. These 
differences in Aβ42/Aβ40 levels turned out (in this thesis) to be sufficient to see an 
effect on gene expression. Another possible approach would have been an APP 
knockout background where Aβ-expressing cells would have been compared with 
APP-knockout cells in which no endogenous Aβ-levels would have been expected. 
However, this would also have had disadvantages: APP-like proteins could have 
taken over APP-functions which might have caused a bias in the data. Moreover, 
cells from animals, instead from humans, would have been used and precious 
information that can possibly only be recognized in human cells would have been lost 
(for instance, signal transduction pathways differ between species).  
According to what is currently known, the possible mechanisms identified in this 
thesis (synaptic dysfunction, influenced copper transport, change in protease 
(inhibitor) expression, etc.) are in agreement with the assumption that they are 
caused by increased Aβ42. However this does not provide any proof that other 
consequences of the processing of C99I45F and C99V50F mutants (changed Aβ40 
levels, possible changed AICD levels) are not responsible for some of the observed 
effects. Increased Aβ42 levels are usually accompanied by reduced Aβ40 levels. So 
effects of increased Aβ42 could also be caused by reduced Aβ40 levels (and vice 
versa). Moreover, it cannot be ruled out that increased Aβ42 and reduced Aβ40 levels 
act synergistically. For these reasons the term “Aβ42/Aβ40 ratio” is mostly used in this 
thesis and might be more suitable than just speaking about Aβ42 levels. 
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It has to be expected that Aβ42/Aβ40 and the AICDs are similarly produced by 
processing, thus the possibility of effects being mediated by non-Aβ mechanisms is 
rather likely.  
The models presented in this thesis were derived from microarray data and real-time 
PCR and thus reflect changes on the transcript level. For the model “Downregulation 
of IGF2/IGF1R/PKC and PI3K/AKT signaling by an increased Aβ42/Aβ40 ratio”, 
microarray data were supported by data about the phosphorylation status of crucial 
proteins (determined by immunoblotting with phospho-specific antibodies) also 
providing insight into the regulation on the protein-level. The models provide 
information about a changed C99 processing. This is comparable to C99 processing 
in vivo. However, these models are derived from cell culture experiments and are not 
validated in vivo. Thus, further in vivo research is necessary. The models are in line 
with many observations of the brains of AD patients and might reflect the molecular 
basis of some of the pathological mechanisms for which an explanation has been 
missing. The use of human cells in this thesis is an advantage over studies using 
cells from animals: Signal transduction pathways differ partially between mice and 
humans and a cure for AD that works in mice will not necessarily work in humans as 
well. For these reasons data on human cells are important. Moreover, the data in this 
thesis can be better compared with association studies of families suffering from AD 
than data derived from mice.  
6.2 Data analysis with different algorithms 
The use of different algorithms has an extreme impact on the data obtained. In this 
thesis I used three of the most frequently used algorithms (MAS 5, GC-RMA, PLIER), 
with the goal of obtaining complementary information, rather than to obtain a big 
overlap. This procedure increases the probability of getting a maximal amount of 
significant data. I favoured the recently developed PLIER-algorithm for several 
reasons: Most importantly, the intersection of calculated data (transcript level) with 
the data derived from a proteomic approach was the biggest when the data were 
analyzed with the PLIER-algorithm. Moreover, the PLIER-algorithm provides the best 
balance of accuracy and precision [140]. In addition PLIER appeared to be superior 
to other algorithms in avoiding false positives with poorly performing probe sets [141]. 
Furthermore, all genes tested by real-time PCR, which were selected by using the 
PLIER algorithm (9 genes), could be validated by real-time PCR in all cell clones. 
Nevertheless, I emphasize that data derived from the MAS 5 and GC-RMA algorithm 
provide further information that could not be obtained by using the PLIER algorithm. 
In conclusion, the data demonstrates that it is necessary to calculate raw data with 
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more than one algorithm, in order to obtain a maximal amount of information while 
reducing the risk of overlooking important data. This increases the number of 
candidate genes. The identified candidate genes needed to be functionally verified. 
Since verification of all candidate genes was not feasible, due to their large number, 
it cannot be excluded that some of the presented top candidate genes (which were 
not functionally verified) are not associated to any pathological mechanism of AD (but 
possibly appear dysregulated caused by unspecific effects). So further functional 
verification of these genes is necessary. To validate the approach, one candidate 
gene (CRABP1, which was also identified on the protein level through a proteomic 
approach) was selected and examined in detail. This showed that the approach 
identified the genes correctly and consequently essential cellular functions (here 
cellular differentiation). 
6.3 An altered Aβ42/Aβ40 ratio has a strong impact on gene 
expression 
As can be seen from the distribution of differentially expressed genes (volcano plots, 
Fig. 5.5 A, B, page 42) the number of up-regulated genes was bigger than the 
number of down-regulated genes in consequence of an increased Aβ42/Aβ40 ratio 
(Fig. 5.5 A). An inverse distribution could be observed if the ratio was decreased: the 
number of down-regulated genes was bigger than the number of up-regulated genes 
in consequence of a decreased Aβ42/Aβ40 ratio (Fig. 5.5 B). These distributions 
provide hints about the general activation/inhibition of transcription. However, it has 
to be taken into consideration that among the up-regulated genes there might occur 
genes which have inhibiting properties, whereas among the down-regulated genes 
there might occur genes which have activating properties. So it was necessary to 
analyze every strongly differentially expressed gene separately. 
6.4 Retinoic acid, AD and neurogenesis 
6.4.1 Retinoic acid, APOE4, APOE2 
Taking up retinoids, transport, storage and conversion into retinoic acid (RA) is a 
highly regulated process known as the “retinoid cascade” [195]. Retinoid availability 
is influenced by environmental factors and diet. As a nutritional vitamin necessary for 
life but not produced within the body, retinoid must be ingested from plants as beta-
carotene, as preformed retinyl esters, and as retinol from animal origin (liver and fish 
oil). Vitamin A showed anti-amyloidogenic and fibril-destabilizing effects in vitro [205] 
and it was shown that disruption of the retinoid signaling pathway causes a 
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deposition of Aβ in the adult rat brain [206]. RA amounts are determined by the 
supply of retinoids in the food, their transport to the brain and within the cells, and the 
production and removal of the functional end product of the retinoid cascade. 
Diffusion at high-retinyl ester concentrations of retinol into cells of the nervous 
system is enabled by other transporters, including apolipoprotein E (APOE) and 
apolipoprotein D (APOD). The retinyl ester/APOE complex has a crucial impact on 
the transcription of retinoid-regulated target genes. The APOE2 allele clears 
postprandial chylomicron remnants containing retinyl esters more slowly than APOE3 
or APOE4 [207]. As a consequence retinyl esters are more abundant in the presence 
of the APOE2 allele. APOE2 is protective against late onset Alzheimer’s disease 
(LOAD) and has been shown to protect against memory impairment in rats. APOE4 
is strongly associated with an increased risk of AD of both early and late onset AD in 
genetic and clinical trials. APOD expression is regulated by retinoic acid receptor A 
(RARA) and increased in stressed neurons of LOAD patients. It was suggested that 
the increased expression may be the result of a feedback mechanism as a 
consequence of the reduced amounts of retinol in ageing individuals, particularly 
those at risk of LOAD. APOE2, which slowly clears retinyl esters may be a preferred 
carrier of retinol to brain in contrast to APOE4 which rapidly clears retinyl esters and 
preferentially transports low density lipoprotein cholesterol. The RBPs (retinol binding 
proteins) are able to carry retinol alone as well as complexed with transthyretin 
(TTR). TTR is probably the major carrier of retinol bound to RBP from liver stores 
through plasma [209, 210] and across the choroid plexus to the brain [211]. 
6.4.2 Association between AD and RA 
Associations between AD and RA-transport and metabolism are known [196, 212]. It 
was shown that disruption of the retinoid signaling pathway causes a deposition of 
Aβ in the adult rat brain [206]. RA amounts are determined by many regulatory 
proteins, like retinoid binding proteins, retinoid anabolizing and catabolizing enzymes 
[195]. CYP26B1 has been linked to AD and psychosis [213]. One crucial mechanism 
whereby availability of RA is regulated is by binding to CRABP1 (cellular retinoic acid 
binding protein 1). CRABP1 is a protein with a molecular weight of 15.4 kDa, 
localized in the cytoplasm. The gene is strongly conserved in evolution and assumed 
to play an important role in RA-mediated differentiation and proliferation processes. It 
may regulate the access of RA to the nuclear RA receptors (RAR). In the adult brain 
the two main regions of RA signaling are the olfactory bulb and the hippocampus 
[214], both regions are predominantly affected in LOAD [195]. CRABP1 and RA are 
inversely regulated [215]. CRABP1 binds RA and prevents it from entering the 
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nucleus and in cells with low CRABP1 expression RA enters the nucleus and binds 
to RARs [216-218]. An association between CRABP1 and Aβ has not yet been 
established. In this study I demonstrated that an increased Aβ42/Aβ40 ratio resulted in 
CRABP1 upregulation on the transcript and on the protein-level. Furthermore, I 
demonstrated that up-regulated CRABP1 reduced the differentiation potential of SH-
SY5Y cells. C99I45F-transfection of SH-SY5Y cells resulted in differentiation only if 
exposed to 100 nM or more of RA, but the same cell line already showed strong 
differentiation at 1 nM RA when CRABP1 was knocked down by >50%. Therefore, it 
was estimated that a 50% knockdown of CRABP1 makes cells more sensitive to RA 
by a factor of approximately 101-102. The physiological plasma concentration of RA in 
humans is approximately 10 nM and 8.4 pmol/g in the hippocampi of mice [219]. 
Excess of exogenous RA may oversaturate the binding capacities of CRABP1 
allowing the remaining RA to bind to the RARs [220]. This provides an explanation 
for our finding that treatment with an excess of RA (>100 nM) makes no difference in 
the differentiation behavior detectable, but differences are evident at low 
(physiological) levels of RA. CRABP1 transfection of AMC-HN-7 cells results in an 
increased Cyp26-mediated catabolism of RA [156]. This decreases the RA level 
accessible to the nuclear receptors. Indeed I found Cyp26B1 to be up-regulated in 
C99I45F (Aβ42/Aβ40↑), but not in C99V50F (Aβ42/Aβ40↓). RORB (RAR-related orphan 
receptor B) was down-regulated in C99V50F, but not in C99I45F. Furthermore, 
RARB (RA receptor beta) was not differentially regulated in C99V50F, but up-
regulated in C99I45F. These observations might reflect a response of the cells to an 
increased RA-level in C99V50F or a decreased RA-level in C99I45F respectively. An 
inverse regulation of receptors and their ligands is often observed [221]. 
6.4.3 Linkage of the chromosomal locus 15q24 to mental 
retardation 
CRABP1 is located on the same chromosomal locus (15q24) as alpha polypeptide 3, 
4 and 5 of the nicotinic cholinergic receptor (nAChR) and cytochrome P450, 
subfamily XIA (cholesterol side chain cleavage, Cyp11A1). Association of nAChR 
and AD has been described [222]. Moreover, there has been found to be a linkage of 
the chromosomal locus 15q24 to mental retardation [223] and linkage of the flanking 
regions (15q22 and 15q26) to AD [224, 225]. This linkage may be explained by the 
presence of alpha polypeptide 3, 4 and 5 of nAChR or of CRABP1, located on the 
same chromosomal locus.  
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6.4.4  Neurofilaments were inversely regulated by C99 and  
Aβ42, Aβ40 
Downregulation of the neurofilaments NEF3, NEFL and INA was observed as a result 
of C99-overexpression. Interestingly, these three neurofilaments were up-regulated 
in response to Aβ42 and Aβ40-overexpression. This may indicate a role of NEF3, 
NEFL and INA in the axonal “clogging” phenomenon [226-229] observed in neurons 
induced by AβPP or its cleavage products [230]. 
6.4.5  Role of neurogenesis in AD 
Neurogenesis is reported to be enhanced in the hippocampi [231] of patients with AD 
[232] where it may generate cells to replace neurons lost in the disease [233]. The 
effect of AD on neurogenesis could be reproduced in a transgenic mouse model [234] 
in which AβPP mutations lead to increased incorporation of BrdU and expression of 
immature neuronal markers in two neuroproliferative regions: the dentate gyrus and 
the subventricular zone. As neurogenesis is increased in these mice in the absence 
of neuronal loss, it might be triggered by more subtle disease manifestations, for 
example the initital accumulation of the Aβ peptide. In transgenic mice, 
overexpressing familial AD variants of AβPP and/or PS1 dramatically diminished 
survival of newborn neurons 4 weeks after birth [235]. These data hint at an 
increased neurogenesis in AD, but in contrast to this, also point to early detrimental 
events shortly after the neurons are born.  
6.4.6  Sensitive balance between proliferation and differentiation 
is influenced by an altered Aβ42/Aβ40 ratio via CRABP1 
Treating neural stem cells with Aβ increases the total number of neurons in a dose-
dependent manner [236]. In our study neuroblastoma cells were used, which shared 
related proliferation and differentiation properties with neural stem cells. We 
observed increased proliferation of human neuroblastoma cells in consequence of an 
increased Aβ42/Aβ40 ratio via CRABP1 and suggest that this influences neurogenesis 
by promoting proliferation. However, the newly generated neurons may be prevented 
from adopting a functional phenotype, as a consequence of CRABP1 upregulation 
restricting the quantity of RA. This view is supported by a study showing that RA 
induces neurite outgrowth in SH-SY5Y cells [237]. Theoretically, it seems possible 
that CRABP1 knockdown would release the block of terminal differentiation of 
neurons in AD and thus improve the differentiation of neural stem cells into a 
functional phenotype. 
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In summary, it was observed that an increased Aβ42/Aβ40 ratio up-regulated CRABP1, 
reducing the availability of free RA. This resulted in an increased tendency towards 
proliferation, accompanied by a reduced potential to differentiate. This effect could  
be rescued by knocking down CRABP1. It can be speculated that, in vivo, Aβ42 
induces the initial steps in neurogenesis by boosting neuronal precursor cell 
proliferation while preventing the terminal differentiation into mature neurons. This 
scenario may provide an explanation for why there is an increase in neurogenesis in 
AD and at the same time an increased risk of neurodegeneration. 
The ADAM10 gene encodes a membrane-bound disintegrin-metalloproteinase, 
which, after overexpression in an AD mouse model, prevents amyloid pathology and 
improves long term potentiation and memory. RA was identified as an inducer of 
human ADAM10 promoter activity [238]. This finding suggests that pharmacologic 
inhibition of CRABP1, and hence increased availability of RA, may increase the 
expression of the α-secretase ADAM10, with beneficial effects on AD pathology. 
Furthermore, RA has been shown to protect hippocampal neurons from amyloid-beta 
induced neurodegeneration [239]. Elevated CRABP1 levels were detected in the 
cerebrospinal fluid of patients with Moyamoya disease [240]. Moyamoya disease is a 
occlusive disease of the cerebral vasculature, in which the blood supply to the brain 
is affected, resulting in frequent strokes. In an effort to circumvent these blockages, 
the body forms abnormal blood vessels (Moyamoya vessels) to reroute blood flow to 
the brain. 
6.4.7 Overlapping results obtained from different laboratories 
and different technologies increased reliability of the data 
Our results were derived from several independent clones with slightly varying 
expression. Thus clonal effects which can only be observed in a single clone, but not 
in others, can be regarded as minimized. Furthermore, two independent experimental 
approaches, transcriptomics and proteomics, led to highly similar results (CRABP1 
was found to be the second most up-regulated transcript of approximately 20,000 
ones tested on Chip A, and the second most up-regulated protein of the whole 
proteome in consequence of an increased Aβ42/Aβ40 ratio). Transcriptomics and 
proteomics were carried out by two independent laboratories and the time interval 
between these two approaches was nearly three years, minimizing the probability 
that cell culture conditions or preparation procedures caused a bias in our data. The 
genomic approach was performed first and the subsequent proteomic approach was 
performed blind.  
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6.4.8 Target genes of retinoic acid (RA) indicate low levels of RA 
for Aβ42/Aβ40↑, but high levels for Aβ42/Aβ40↓ 
A meta-analysis was performed with the goal of identifying target genes of retinoic 
acid [241]. Therefore, published data from 1191 papers covering 532 genes were 
investigated. I compared the most differentially expressed genes (from the 
comparisons Aβ42/Aβ40↑ and Aβ42/Aβ40↓) with the genes identified by Balmer et al.. 
There were more overlapping genes than could be expected by chance, indicating a 
predominant role for RA. For instance the following genes are induced by RA, 
according to Balmer et al. : PLAT, TGFBR2, ACTA2, BCL2, GAP43, TGFβ2, ITGB5. 
Interestingly, I found the following genes to be down-regulated for Aβ42/Aβ40↑: 
TGFBR2, ITGB5. In contrast to this the following genes were up-regulated for 
Aβ42/Aβ40↓: PLAT, ACTA2, BCL2, GAP43. This is in line with my view that up-
regulated CRABP1 (for Aβ42/Aβ40↑) suppresses the effects of RA.  
6.5 Downregulation of the IGF2/IGF1R/PKC and PI3K/AKT 
survival pathways as a result of an increased Aβ42/Aβ40 
ratio 
It was shown that IGF2 and insulin are normally produced in the central nervous 
system and that their expression levels are markedly reduced in AD. These 
abnormalities were associated with reduced levels of phosphatidylinositol 3-kinase 
and phospho-Akt (activated), increased GSK3β activity and APP-mRNA expression. 
The strikingly reduced central nervous system (CNS) expression of genes encoding 
insulin, IGF1, and IGF2, as well as the insulin and IGF1 receptors, suggested that AD 
may represent a neuro-endocrine disorder that resembles diabetes mellitus. 
Therefore, the name "Type 3 diabetes" was proposed for AD [191]. 
The PI3K/AKT survival pathway is known to be activated by insulin, growth factors, 
integrins and other molecules [242, 243] and crosstalk to IGF2/IGF1R/PKC signaling 
is known [242, 244, 245]. I identified the PI3K/AKT survival pathway and 
IGF2/IGF1R/PKC signaling as down-regulated in consequence of an increased 
Aβ42/Aβ40 ratio. As can be seen from the model (see Fig. 5.35, pages 78-79), the 
PI3K/AKT pathway is activated by different molecules, most of which have been 
found to be down-regulated as a result of an increased Aβ42/Aβ40 ratio 
(C99I45F/C99WT), whereas the same molecules were not regulated or even up-
regulated as a result of a decreased Aβ42/Aβ40 ratio (C99V50F/C99WT): Some of 
these molecules, HGF and several integrins (ITGB5 is a receptor for fibronectin), 
target the PI3-kinase [246-251]. This pathway is known to be especially activated by 
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insulin, IGF1 or IGF2 via the IGF1 receptor [164, 166]. IGF2 was found to activate 
the IGFR1 with an affinity similar to IGF1 [252] and the PI3K/AKT pathway was 
demonstrated to be activated by IGF2 [245]. Increasing insulin-related signals in 
neurons reduces GSK3β activity by improving PI3K/Akt activity  [245]. (Furthermore, 
apoptosis-inducing genes were up-regulated for Aβ42/Aβ40↑, for instance TNFAIP6 
and TRAF5, but not for Aβ42/Aβ40↓). IGF2 was among the 10 most down-regulated 
genes as a result of an increased Aβ42/Aβ40 ratio (C99I45F/C99WT). The fact that 
downregulation of IGF2 was detected by two probe sets validates the 
downregulation. There is a plethora of  further indications of PI3K/AKT 
downregulation not only on the transcript but also on the protein and phosphorylation 
level. From the view of an increased Aβ42/Aβ40 ratio (C99I45F/C99WT), the following 
molecules targeting different steps of the pathway, are assumed to down-regulate it 
synergistically: PTEN was up-regulated and inhibits PIP3 [253, 254]. The effect of 
TrkB, normally known to activate AKT [160, 255, 256], can be assumed to be less 
active by binding of the ligands BDNF and neurotrophins 3, 4, 5 to the strongly up-
regulated non-catalytic isoform of TrkB (a competitive binding of these ligands 
between catalytic and non-catalytic isoforms can be assumed; truncated TrkB 
receptors have been shown to inhibit BDNF-induced neurite outgrowth in vitro [257]). 
In contrast to this, a decreased Aβ42/Aβ40 ratio down-regulated the non-catalytic 
isoform of TrkB. This up and downregulation was validated by detection of the 
transcript for the non-catalytic isoform of TrkB by more than one probe set (see 
information below). Moreover, AKT1 (protein kinase B) showed weaker 
phosphorylation (n=1) for mutant C99I45F than for C99WT.  
I found IGFBP1 up-regulated (increased Aβ42/Aβ40 ratio, C99I45F/C99WT), whereas 
no differential expression was observed for a decreased Aβ42/Aβ40 ratio, 
(C99V50F/C99WT). Unlike insulin, both IGF1 and IGF2 circulate in plasma tightly 
bound to specific binding proteins. Two major forms of IGF-binding proteins have 
been identified in human plasma, a low molecular weight form and a high molecular 
weight form. The low molecular weight IGF-binding protein (IGFBP1) binds both IGF1 
and IGF2 with high affinity [258]. In primary cultures of human fetal hepatocytes 
under hypoxic conditions, IGFBP1 mRNA expression increased 3 to 4-fold compared 
with normoxic controls. Western blot analysis of conditioned medium revealed the 
presence of IGFBP1, IGFBP2, IGFBP3, and IGFBP4. IGFBP1 was the most 
abundant IGFBP in conditioned medium. The authors concluded that hypoxia up-
regulates fetal hepatocyte IGFBP1 mRNA levels and protein [259]. Using loss and 
gain-of-function approaches with zebrafish embryos, Kajimura et al. (2005) 
demonstrated that IGFBP1 mediated hypoxia-induced embryonic growth retardation 
and developmental delay. When tested in vitro with cultured zebrafish embryonic 
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cells, IGFBP1 itself had no mitogenic activity, but it inhibited IGF1 and IGF2-
stimulated cell proliferation by binding to and inhibiting the activities of IGFs [258].  
MBNL2 (muscleblind-like 2 (Drosophila)) was found to be inversely expressed as a 
result of a changed Aβ42/Aβ40 ratio (up-regulated as consequence of an increased 
Aβ42/Aβ40 ratio, C99I45F/C99WT, down-regulated as consequence of a decreased 
Aβ42/Aβ40 ratio, C99V50F/C99WT). MBNL2 is a zinc finger protein that regulates 
alternative splicing of two pre-mRNAs that are misregulated in myotonic dystrophy. It 
was demonstrated that small interfering RNA-mediated downregulation of MBNL2 in 
myoblasts results in abnormal insulin receptor (IR) splicing [260].  
Further clues for altered insulin-signaling are the inversely regulated uncharacterized 
gene KIAA0644. There is a relatively strong similarity (34%) to insulin-like growth 
factor-binding protein complex acid labile chain precursor. KIAA0644 was up-
regulated as a result of an increased Aβ42/Aβ40 ratio, but down-regulated as a result 
of a decreased Aβ42/Aβ40 ratio. KIAA0644 is assumed to be a secreted protein that 
may have an important role in regulating the access of circulating insulin growth 
factors to the tissues. KIAA0644 is assumed (due to similarity to Insulin-like growth 
factor-binding protein complex acid labile chain)  to form a ternary complex of about 
140 to 150 kda with IGF2 and/or IGFBP3 [261]. I speculate that KIAA0644 binds 
IGF2 and keeps it in an inactive state or lowers its ability to bind to the IGF receptor.  
Target genes of the PI3K/AKT-pathway were found to be down-regulated as a result 
of an increased Aβ42/Aβ40 ratio (C99I45F/C99WT), for instance cyclin D1. I observed 
downregulation of cyclin D1 on the transcript level and on the protein level, whereas 
cyclin D1 was up-regulated as a result of a decreased Aβ42/Aβ40 ratio 
(C99V50F/C99WT).  
Finally it can be concluded that a plethora of molecules known to activate the 
PI3K/AKT-pathway are down-regulated and inhibiting effects or missing activation 
converge towards PI3K/PIP3/AKT. Many molecules known to inhibit this pathway 
were up-regulated. Important downstream components of this pathway, known to be 
inhibited by AKT1 (by reduced phosphorylation), like GSK3 (α and β), might be 
activated by downregulation of AKT1. Further components, known to inhibit GSK3 
were also less active (PKC lambda/iota), which further contribute to activation of 
GSK3.  
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6.6 Downregulation of the IGF2-H19 imprinted region on 
chromosome 11p15.5 as a result of an increased 
Aβ42/Aβ40 ratio 
It is intriguing that these genes (IGF2, H19, CDKN1C, LOC492304) known to be 
imprinted (see Chapter 5.7, page 58) were especially prominent among the most 
down-regulated ones. The IGF2 (insulin-like growth factor 2) gene encodes a 
member of the insulin family of polypeptide growth factors that is involved in 
development and growth. It is an imprinted gene and is expressed only from the 
paternally inherited allele. Two alternatively spliced transcript variants encoding the 
same protein have been found for this gene. Symmetric and asymmetric DNA 
methylations in the human IGF2-H19 imprinted region have been detected [262]. 
Enhancers specifically activate IGF2 on the paternal chromosome and H19 on the 
maternal chromosome [263]. Interaction between differentially methylated regions 
partitions the imprinted genes IGF2 and H19 into parent-specific chromatin loops 
[264]. Interaction of IGF2 with multiple plasma proteins has been observed: high 
affinity binding of plasminogen to IGF2 and IGF binding protein 3. Transferrin binds 
insulin-like growth factors and affects binding properties of insulin-like growth factor 
binding protein 3 [380]. 
H19 is an imprinted maternally expressed untranslated mRNA. Mutter et al. found 
that H19 is expressed only from the maternal allele and IGF2 is expressed from the 
paternal allele. The oppositely imprinted genes H19 and IGF2 have been shown to 
be coexpressed in the human androgenetic trophoblast [265]. These results 
demonstrated that a biparental genome may be required for expression of the 
reciprocal IGF2/H19 imprint. In the mouse, the imprinted H19 gene, which encodes 
an untranslated RNA, lies at the end of a cluster of imprinted genes. Leighton et al. 
found that imprinting of the insulin2 (INS2) gene and the IGF2 gene, which lie about 
100 kb upstream of H19, can be disrupted by maternal inheritance of a targeted 
deletion of the H19 gene and its flanking sequence [266]. Pfeifer et al. stated that the 
product of the H19 gene is an untranslated RNA that is expressed exclusively from 
the maternal chromosome during mammalian development. The H19 gene and its 5’-
flanking sequence are required for the genomic imprinting of 2 paternally expressed 
genes in mice, INS2 and IGF2 that lie 90 and 115 kb 5-prime to the H19 gene, 
respectively [267]. Imprinted genes are expressed from only 1 of the parental alleles 
and are marked epigenetically by DNA methylation and histone modifications. The 
paternally expressed gene IGF2 is separated by approximately 100 kb from the 
maternally expressed noncoding gene H19 on mouse distal chromosome 7. 
Differentially methylated regions in IGF2 and H19 contain chromatin boundaries, 
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silencers, and activators, and regulate the reciprocal expression of the 2 genes in a 
methylation-sensitive manner by allowing them exclusive access to a shared set of 
enhancers. Murrell et al. used a GAL4 knock-in approach as well as the chromosome 
conformation capture technique to show that the differentially methylated regions in 
the imprinted genes IGF2 and H19 interact in mice. These interactions are 
genetically regulated and partition maternal and paternal chromatin into distinct 
loops. This generates a simple epigenetic switch for IGF2, through which it moves 
between an active and a silent chromatin domain [264]. It is believed that 
chromosomes interact with each other to regulate transcription in trans. To explore 
systematically the epigenetic dimension of such interactions, Zhao et al. devised a 
strategy termed ‘circular chromosome conformation capture’ (4C). This approach 
enabled high-throughput screening of physical interactions between chromosomes 
without a preconceived idea of the interacting partners. The authors identified 114 
unique sequences from all autosomes, several of which interact primarily with the 
maternally inherited H19 imprinting control region. Imprinted domains were strongly 
overrepresented in the library of 4C sequences, further highlighting the epigenetic 
nature of these interactions. Moreover, Zhao et al. found that the direct interaction 
between differentially methylated regions was linked to epigenetic regulation of 
transcription in trans. They found that the patterns of interactions specific to the 
maternal H19 imprinting control region underwent reprogramming during in vitro 
maturation of embryonic stem cells [268]. 
Hatada and Mukai showed that a mouse homolog of p57(KIP2) is genomically 
imprinted. The paternally inherited allele is transcriptionally repressed and 
methylated. The mouse gene maps to the distal region of chromosome 7, within a 
cluster of imprinted genes, including IGF2 and H19 [269]. Matsuoka et al. 
demonstrated that the p57(KIP2) gene is imprinted in humans as well. It is situated 
500 kb centromeric to the IGF2 gene. The maternal allele is preferentially expressed; 
However, the imprint is not absolute, as the paternal allele is also expressed at low 
levels in most tissues and at levels comparable to the maternal allele in fetal brain 
and some embryonal tumors. It appears to lie in a domain containing other imprinted 
genes [270]. Matsuoka et al. commented that establishment of an imprint may be 
coordinately regulated throughout the entire domain, as suggested by similar tissue-
specific expression and imprinting patterns of IGF2, H19, and p57(KIP2) genes, while 
loss of imprinting may not necessarily affect the entire region [270]. Du et al. 
confirmed the existence of insulators in the differentially methylated region (DMR) of 
the H19 gene and reported 2 insulators in the IGF2 gene. They also found 2 novel 
silencer sequences: one in KvDMR, a region that is thought to contain the promoter 
for the KCNQ1OT1 transcript, and the other in CDKN1C. The authors demonstrated 
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binding of the zinc finger protein CTCF in vitro to all the insulators and sequences 
detected [271]. Using primary human hematopoietic cells and microarray analysis, 
Scandura et al. identified p57 (KIP2) as the only cyclin-dependent kinase inhibitor 
induced by TGF-β. Upregulation of p57 mRNA and protein occurred before TGF-β-
induced G1 cell cycle arrest, required transcription, and was mediated via a highly 
conserved region of the proximal p57 promoter. Upregulation of p57 was essential for 
TGF-β-induced cell cycle arrest in these cells, since 2 different small interfering 
RNAs that prevented p57 upregulation blocked the cytostatic effects of TGF-β on 
hematopoietic cells [272]. The putative insulin-like growth factor 2 associated gene 
(LOC492304) encodes a member of the insulin family of polypeptide growth factors 
that is involved in development and growth. It is an imprinted gene and is expressed 
only from the paternally inherited allele. 
6.7 The non-catalytic TrkB receptor was strongly up-
regulated in response to an increased Aβ42/Aβ40 ratio and 
might have suppressed the effects of neurotrophins on 
cell survival and LTP in a competitive manner 
NTRK2 (synonym:TrkB) is a member of the neurotrophic tyrosine receptor kinase 
(NTRK) family. It is a membrane-bound receptor that, upon neurotrophin binding, 
phosphorylates itself and members of the MAPK pathway. Signaling through this 
kinase leads to cell differentiation. Mutations in its gene have been associated with 
obesity and mood disorders. Alternate transcriptional splice variants encoding 
different isoforms have been found for this gene [273]. TrkB and its ligands influence 
neuronal survival, differentiation, synaptogenesis, and maintenance. Decreased 
BDNF and full-length TrkB expression accompanied by increased truncated TrkB 
expression, as revealed by Western blotting, was observed in the (postmortem) 
frontal cortex of patients with AD. Strong BDNF immunoreactivity was observed in 
dystrophic neurites surrounding senile plaques (postmortem frontal cortex). Moreover 
increased truncated TrkB immunoreactivity was observed in frontal cortex of patients 
with AD [274]. Differential regulation of catalytic and non-catalytic trkB messenger 
RNAs was observed in the rat hippocampus following seizures induced by systemic 
administration of kainate [275]. Hybridization with probes specific for the non-catalytic 
trkB receptor and the catalytic trkB receptor revealed that the increases at four and 
seven days in the molecular layers of the hippocampus reflected an upregulation of 
only the non-catalytic form of the receptor [276]. Truncated TrkB receptors have been 
shown to inhibit BDNF-induced neurite outgrowth in vitro [257]. 
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There is growing evidence suggesting that the naturally occurring truncated TrkB 
receptors have dominant inhibitory effects on brain-derived neurotrophic factor 
signaling [277] and it was suggested that the truncated TrkB receptors negatively 
influence neuron survival by interfering with the function of catalytic TrkB receptors 
[278]. Expression of the catalytic TrkB alone conferred a BDNF survival response 
whereas co-expression of non-catalytic TrkB substantially reduced this response and 
it was suggested that BDNF responsiveness in sensory neurons during development 
is modulated by the relative levels of catalytic and non-catalytic TrkB [273]. BDNF, 
neurotrophin 3 and neurotrophin 4/5 levels in the brain are fine-tuned and kept 
constant. Due to the fact that these neurotrophins do not occur in excess they are 
ideal regulatory molecules which can be controlled by binding to their appropriate 
receptors: There might be competition between the catalytic and non-catalytic 
isoform of the TrkB-receptor for their ligands. In response to an increased Aβ42/Aβ40 
ratio, the non-catalytic isoform of TrkB was found to be strongly up-regulated. The 
up-regulated non-catalytic isoform is supposed to compete with the not differentially 
expressed catalytic isoform for their ligands. Binding of the neurotrophins to the non-
catalytic isoform reduces the amount of them available for binding to the catalytic 
isoform. Thus the signal transduced from the receptor to the nucleus should be 
reduced. Diminished signaling from the TrkB receptor has been demonstrated to 
suppress cell survival and LTP [279-281]. 
In contrast to this, a decreased Aβ42/Aβ40 ratio down-regulated the non-catalytic 
isoform of TrkB (while leaving the catalytic isoform unaffected). The up and 
downregulation of the non-catalytic isoform of TrkB was validated by the detection of 
the transcripts for the non-catalytic isoform of TrkB by three different probe sets (see  
Table 5.20, page 112). 
The effect of TrkB, normally known to activate AKT, can be assumed to be less 
active by binding of the ligands BDNF and neurotrophins 3, 4, 5 to the strongly up-
regulated non-catalytic isoform of TrkB (for an increased Aβ42/Aβ40 ratio; a 
competitive binding of these ligands between catalytic and non-catalytic isoforms can 
be assumed). In contrast to this, a decreased Aβ42/Aβ40 ratio down-regulated the 
non-catalytic isoform of TrkB. This up and downregulation was validated by detection 
of the transcript for the non-catalytic isoform of TrkB by more than one probe set, 
thus increasing the reliability of the data. 
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6.8 Up-regulated ATP7A, a copper transporting ATPase is 
expected to dysregulate copper levels in consequence of 
an increased Aβ42/Aβ40 ratio 
It has been shown that APP modulates copper-induced toxicity and oxidative stress 
in primary neuronal cultures. APP can reduce copper (II) to copper (I) in a cell-free 
system potentially leading to increased oxidative stress in neurons, suggesting APP 
may interact with copper to induce a localized increase in oxidative stress through 
copper (I) production. Substitution of the copper coordinating histidine residues with 
asparagines (APP142-166, H147N, H149N, H151N) abrogates the toxic effects. 
These data support a role for the APP copper-binding domain in APP-mediated 
copper (I) generation and toxicity in primary neurons, a process that has important 
implications for AD and other neurodegenerative disorders [282].  
High concentrations of copper are found in the vicinity of Aβ amyloid deposits in AD. 
It was reported that Cu(II) markedly potentiates the neurotoxicity exhibited by Aβ in 
cell culture. The potentiation of toxicity is greatest for Aβ1-42 > Aβ1-40 >> mouse/rat 
Aβ1-40, corresponding to their relative capacities to reduce Cu(II) to Cu(I), to form 
H2O2 in cell-free assays and to exhibit amyloid pathology [283]. It was shown that 
human Aβ directly produces hydrogen peroxide (H2O2) by a mechanism that involves 
the reduction of metal ions, like Cu(II). These findings indicate that the accumulation 
of Aβ could be a direct source of oxidative stress in AD [284]. 
Copper is essential for human health, however copper imbalance is a key factor in 
the etiology and pathology of several neurodegenerative diseases. The copper-
transporting ATP7A is a key molecule required for the regulation and maintenance of 
mammalian copper homeostasis. Its malfunction leads to the genetically inherited 
disorders, Menkes and Wilson’s diseases, respectively. ATP7A has a dual role in 
cells, namely to provide copper to essential cuproenzymes and to mediate the 
excretion of excess intracellular copper. A unique feature of ATP7A is its ability to 
sense and respond to intracellular copper levels, the latter manifested through their 
copper-regulated trafficking from the transGolgi network to the appropriate cellular 
membrane domain (basolateral or apical, respectively) to eliminate excess copper 
from the cells [285]. Raised copper concentrations result in the trafficking of ATP7A 
to the plasma membrane, where it functions in copper export. 
A role for ATP7A and/or copper in axon outgrowth and synaptogenesis has been 
demonstrated [286]. 
ATP7A exports copper from cells and thus critically contributes to the homeostatic 
control of copper [287]. The trafficking of ATP7A from the trans-Golgi network to 
endocytic vesicles in response to various signals allows the balancing of intracellular 
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copper levels. ATP7A uses the energy of ATP hydrolysis to transport copper from the 
cytosol into the secretory pathway and thus supply the metal for subsequent 
biosynthetic incorporation into various copper-dependent enzymes. The localization 
in the trans-Golgi network (TGN), which is observed for ATP7A under low copper 
conditions, reflects its role in the delivery of copper to copper-dependent enzymes.  
The exporting of copper from the cell requires trafficking of ATP7A from the TGN to 
vesicles. This re-localization occurs in response to copper elevation, hormone 
release, or other signaling and developmental events. The vesicles then fuse with the 
plasma membrane releasing copper into the extracellular space. The regulation of 
intracellular localization of ATP7A represents the key mechanism that determines 
whether the ATP7A performs its homeostatic or biosynthetic function at a given 
moment. The function of ATP7A is to translocate copper across the membrane from 
the cytosol into the lumen of the appropriate intracellular compartment (either TGN or 
vesicles). This copper translocation across the membranes is driven by the 
hydrolysis of ATP. Copper binds to the N-terminal cytosolic sites of ATP7A in the 
reduced Cu(I) form and it is thought that copper is translocated across the membrane 
in that form. This process takes place in the lumen of the trans-Golgi network, i.e. at 
the site of copper release from the transporters. It has previously been reported that 
the biosynthesis of secreted copper containing enzymes, such as SOD1, correlates 
well with the rate of copper incorporation into these proteins (SOD1 was found to be 
up-regulated in consequence of an increased Aβ42/Aβ40 ratio, shown by 
immunoblotting in this thesis). Although the rate of apo-protein production and 
secretion is not affected by copper levels, the amount of holo-protein is greatly 
diminished when copper is limited. The close link between the copper transporter 
activity and the biosynthesis of copper-dependent enzymes is also emphasized by a 
correlation in their expression levels and developmental co-regulation. Trafficking 
(from the TGN to vesicles) may be initiated when the amount of copper transported 
into the secretory pathway exceeds the biosynthetic needs of a cell.  
ATP7A was up-regulated in consequence of an increased Aβ42/Aβ40 ratio (and down-
regulated for a decreased ratio). Further research is necesssary to answer the 
question of whether upregulation of ATP7A is a direct consequence of an increased 
Aβ42/Aβ40 ratio, or an indirect result of increased intracellular copper-levels, or the 
reason for decreased intracellular copper-levels. In the latter case upregulation of 
ATP7A could be pathological and possibly a suitable target for a therapy (knock-
down or pharmacological inhibition of ATP7A could increase copper concentrations 
to normal levels). In the other cases upregulation of ATP7A might be an attempt of 
the cells to expel excess copper from the cells. Copper levels are expected to be 
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decreased in brains of AD patients [288]. This is supported by the observation from 
White and colleagues who observed increased copper levels in mice brains in which 
APP or APLP2 was knocked out [289]. The APP and APLP2 molecules contain metal 
binding sites for copper and zinc. APP reduces copper (II) to copper (I) and this 
activity could promote copper-mediated neurotoxicity [289]. Furthermore it was 
demonstrated that double knockout of APP and APLP2 resulted in significant 
increases in copper accumulation in the primary cortical neurons of mice and 
embryonic fibroblasts. In contrast, over-expression of APP in transgenic mice 
resulted in significantly reduced copper levels in primary cortical neurons [290].  
6.9 Proteases and protease inhibitors 
6.9.1  Preface 
Insufficient proteolytic removal of Aβ by proteases such as neprilysin, endothelin-
converting enzymes, insulin-degrading enzyme, angiotensin-converting enzyme, the 
plasmin system and matrix metalloproteases, has been proposed as a mechanism 
that leads to Aβ accumulation in the brain [83-85]. For this reason proteases and 
their inhibitors were analyzed. 
6.9.2  ADAMTS9 was the most inversely regulated gene in 
response to a changed Aβ42/Aβ40 ratio and it was found to 
be clustered with other proteases 
ADAMTS9 (a disintegrin and metalloproteinase with thrombospondin motifs) belongs 
to the ADAMTS family. Members of this family share several distinct protein modules, 
including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, 
and a thrombospondin type 1 (TS) motif. Members of the ADAMTS family have been 
implicated in the cleavage of proteoglycans, the control of organ shape during 
development, and the inhibition of angiogenesis. ADAMTS9 is a secreted, cell-
surface-binding metalloprotease that cleaves the proteoglycans versican and 
aggrecan and binds Zn2+ ions [291]. Unlike most precursor proteins, the ADAMTS9 
zymogen (pro-ADAMTS9) is resistant to intracellular processing. Instead, pro-
ADAMTS9 is processed by furin at the cell surface. It is suggested that unlike other 
metalloproteases, furin processing of the ADAMTS9 propeptide reduces its catalytic 
activity [292]. Observations suggest that the propeptide is a key functional domain of 
ADAMTS9, mediating an unusual regulatory mechanism that may have evolved to 
ensure maximal activity of this protease at the cell surface. ADAMTS proteins are 
structurally homologous to ADAM proteins, but they also contain at least 1 C-terminal 
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thrombospondin type 1 (TSP1) repeat and are secreted rather than membrane 
bound.  
ADAMTS9 was found to be clustered with other proteases and binding partners for 
APP: Here in this thesis, NBL1 (neuroblastoma  suppression of tumorigenicity 1) was 
found in the same cluster as prolylendopeptidase (PREP) and it is a known binding 
partner for APP (770aa) and ubiquilin-1 (UBQLN1). (UBQLN1 modulates amyloid 
precursor protein trafficking and Aβ secretion). PREP cleaves peptide bonds on the 
C-terminal side of prolyl residues within peptides that are up to approximately 30 
amino acids long. Prolyl endopeptidases have been reported to be involved in the 
maturation and degradation of peptide hormones and neuropeptides. PREP is 
believed to inactivate neuropeptides that are present in the extracellular space. 
Immunocytochemical double-labelling procedures and localization of PREP-
enhanced green fluorescent protein fusion proteins showed that PREP is mainly 
localized to the perinuclear space, and is associated with the microtubulin 
cytoskeleton in human neuroblastoma and glioma cell lines [293]. Disassembly of the 
microtubules by nocodazole treatment disrupts both the fibrillar tubulin and PREP 
labelling. Furthermore, in a two-hybrid screen, PREP was identified as a binding 
partner of tubulin. These findings indicate new functions for PREP in axonal transport 
and/or protein secretion. In brains of young APP transgenic Tg2576 mice, 
hippocampal PREP activity was higher than in wild-type littermates in the pre-plaque 
phase but not in aged mice with beta-amyloid plaque pathology. This "accelerated 
aging" with regard to hippocampal PREP expression in young APP transgenic mice 
might be one factor contributing to the observed cognitive deficits in these mice in the 
pre-plaque phase and could also explain in part the cognition-enhancing effects of 
PREP inhibitors in several experimental paradigms [294]. PREP is a proline-specific 
oligopeptidase with a reported effect on learning and memory in different rat model 
systems. Measuring different second-messenger concentrations revealed an inverse 
correlation between inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] concentration and 
PREP expression. 
6.9.3 Further proteases and protease inhibitors 
The matrix metalloproteinase 8 (MMP8, neutrophil collagenase) was down-regulated 
(Aβ42/Aβ40↑) (p=0.00219, fold change=-5.0), but not differentially expressed when the 
ratio was decreased (Aβ42/Aβ40↓). MMP8 can degrade fibrillar type I, II, and III 
collagens. Collagenous Alzheimer amyloid plaque component collagen XXV (CLAC) 
[172] was observed in the brains of subjects with AD. CLAC is derived from a type II 
transmembrane collagen protein [173]. Downregulation of the collagenase MMP8 
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may contribute to the maintenance of these plaques. 
The tissue inhibitor of metalloproteinase 3 (TIMP3) was up-regulated (Aβ42/Aβ40↑) 
(p=0.0263, fold change=1.7), but not differentially expressed when the ratio was 
decreased. TIMP3 has specifically been shown to inhibit the actions of ADAM10 and 
ADAM17 [168, 169] two APP α-secretases [170]. Very recently it has been 
demonstrated that TIMP3 immunoreactivity is increased in AD brains [171] and  that 
TIMP3 treatment reduces α-cleavage of APP and promotes β-cleavage, with 
significant increases in Aβ production [169]. The authors emphasized that there is a 
striking increase in TIMP3 in AD brains (but not in other neurodegenerative diseases) 
which raises the possibility that TIMP3 contributes to the elevated Aβ levels in AD, 
making its inhibition a potential target for therapeutic approaches to reducing Aβ. It 
may be speculated that up-regulated TIMP3, apart from α-secretase inhibition, also 
inhibits the metalloprotease MMP8. 
A disintegrin-like and metalloprotease (reprolysin ADAMTS3) was down-regulated 
(Aβ42/Aβ40↑, p=0.086, fold change=-2.1), but not differentially expressed when the 
ratio was decreased. ADAMTS3 is the major procollagen II N-propeptidase. 
ADAMTS3 induced procollagen I processing in fibroblasts, suggesting a role in 
procollagen I processing during musculoskeletal development [295]. The fact that 
ADAMTS3 was down-regulated (Aβ42/Aβ40↑) argues for increased collagen II and 
presumably collagen I levels (Aβ42/Aβ40↑). 
ADAM22 was up-regulated (Aβ42/Aβ40↑, p=0.074, fold change=1.7), but not 
differentially expressed when the ratio was decreased. ADAM22 is one of three 
catalytically inactive ADAM family members highly expressed in the brain. ADAM22 
has numerous splice variants and can act to inhibit cell proliferation, however, it has 
been suggested that it also acts as an adhesion protein. 14-3-3 protein members 
have been shown to bind to ADAM22. There might be a role for 14-3-3 proteins in 
targeting ADAM22 to the cell membrane by masking ER retention signals [296]. 
Protease serine 12 (PRSS12, neurotrypsin, motopsin) was up-regulated (Aβ42/Aβ40↑, 
p=0.00486, fold change=2.1) and confirmed by another probe-set (p=0.0008, fold 
change=2.0), but not differentially expressed when Aβ42/Aβ40 was decreased. This 
gene encodes a member of the trypsin family of secreted serine proteases. Studies 
in mice suggest that PRSS12 may be involved in structural reorganizations 
associated with learning and memory and plays a role in neuronal plasticity. Molinari 
et al. studied the temporospatial expression of neurotrypsin by in situ hybridization in 
fetal human brain. Neurotrypsin was expressed from day 44 to 15 weeks of 
gestation. At 15 weeks the highest gene expression was detected in the cortical 
plate, the hippocampal formation, and the tegmental nuclei of the brainstem. In the 
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hippocampal formation, neurotrypsin was expressed in a spatial gradient. Staining 
was moderate in the subiculum and reached very high levels in areas CA3 and CA4 
of the Ammon’s horn. By electron microscopy, neurotrypsin was identified in the 
presynaptic nerve endings of cortical synapses [297].  
TIMP1, previously described as an collagenase inhibitor, was down-regulated 
(Aβ42/Aβ40↑, p=0.127, fold change=-3.5), but not differentially expressed when the 
Aβ42/Aβ40 ration was decreased. The TIMP1 gene is localized on chromosome 
Xp11.3-p11.23. Transcription of this gene is highly inducible in response to many 
cytokines and hormones. The proteins encoded by this gene family are natural 
inhibitors of the matrix metalloproteinases (MMPs), a group of peptidases involved in 
degradation of the extracellular matrix. Transcription of this gene is highly inducible in 
response to many cytokines and hormones. This gene is located within intron 6 of the 
synapsin I gene and is transcribed in the opposite direction. 
Cathepsin D (CTSD), a lysosomal aspartyl protease, was previously mentioned in 
this thesis (because its gene is localized in an imprinted chromosomal region and is 
one of the top candidate genes for AD). It was not differentially expressed for 
Aβ42/Aβ40↑, but it was down-regulated when the Aβ42/Aβ40 was decreased (p=0.09, 
fold change=-2.9). This lysosomal aspartyl protease is composed of a dimer of 
disulfide-linked heavy and light chains, both produced from a single protein 
precursor. Transcription of this gene is initiated from several sites, including one 
which is a start site for an estrogen-regulated transcript. CTSD is a protease, 
localized in lysosomes, and active in intracellular protein breakdown. Mutations in 
this gene are possibly involved in the pathogenesis of Alzheimer disease. The val-58 
allele is significantly overrepresented in demented patients compared with 
nondemented controls. Carriers of the val-58 allele have a 3.1-fold increased risk for 
developing AD than non carriers [298]. 
Endothelin converting enzyme-like 1 (ECEL1) was not differentially expressed for 
Aβ42/Aβ40↑, but was up-regulated for Aβ42/Aβ40↓ (p=0.037, fold change=1.9 
(microarray) and confirmed by the more exact real-time PCR measurement: fold 
change=5.3 (see Fig. 5.43, page 113). The ECEL1 gene encodes a member of the 
neutral endopeptidase (NEP)-related family. It is expressed specifically in the 
nervous system and may contribute to the degradation of peptide hormones and be 
involved in the inactivation of neuronal peptides. It is assumed to bind one zinc ion. In 
cell-based and in vitro models (ECEL1) was characterized as an Aβ-degrading 
enzyme that appears to act intracellularly, thus limiting the amount of Aβ available for 
secretion. To determine the physiological significance of this activity, Aβ levels were 
analyzed in the brains of mice deficient for ECEL1 and the closely related enzyme, 
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ECEL2. Significant increases in the levels of both Aβ40 and Aβ42 were found in the 
brains of these animals when compared with age-matched littermate controls. The 
increase in Aβ levels in the ECEL-deficient mice provided the first direct evidence for 
a physiological role for both ECEL1 and ECEL2 in limiting Aβ accumulation in the 
brain and also provides further insight into the factors involved in Aβ clearance in vivo 
[299]. Since I found it up-regulated for Aβ42/Aβ40↓ it may be assumed that Aβ-
degradation is increased in mutant C99V50F. I observed no upregulation for 
Aβ42/Aβ40↑, so the Aβ-degrading effect can be expected to be missing in mutant 
C99I45F.  
An uncharacterized transcribed locus (expressed sequence tag (EST), detected by 
the probe set 238237_at) may be of interest, since it was found significantly and 
strongly down-regulated (Aβ42/Aβ40↑, p=0.023, fold change=-8.0, calculated with the 
MAS 5 algorithm) but not differentially expressed when the Aβ42/Aβ40 ratio was 
decreased. Interestingly, the comparison C99WT/mock revealed that this transcript 
was strongly up-regulated (C99WT/mock, p=0.014, fold change=12.7). Alignment of 
the EST with sequences from human genomic databases by means of the Basic 
Local Alignment Search Tool (BLAST) showed that it is >98% similar (compared was 
the whole target sequence which is larger than 400 nucleotides) to human ADAM32 
and ADAM28, two disintegrin and metalloproteases. I suggest that the EST, with 
previously unknown function, is identical to ADAM32, ADAM28 or another protease 
with sequence similarity. Furthermore, I suggest that the EST is functionally 
associated to Aβ42/Aβ40 and to C99 (due to extreme differential expression of the EST 
in C99WT and C99I45F).  
The rho and metalloprotease 1 motif GTPase activating protein 26 (ARHGAP26) and 
its splice product were significantly up-regulated for Aβ42/Aβ40↑ (215955_x_at: 
p=0.0074, fold change 1.5; 205068_s_at: p=0.0093, fold change=1.8). Upregulation 
was also found for Aβ42/Aβ40↓ (205068_s_at: p=0.0199, fold change=1.5). The 
comparison C99WT/mock showed significant downregulation of ARHGAP26 
(C99WT/mock, 205068_s_at, p=0.0104, fold change=-2.1 and no differential 
expression for 215955_x_). FAK (tyrosine kinase, component of the integrin signaling 
transduction pathway) binds with its C-terminal domain to the SH3 domain of 
ARHGAP26. ARHGAP26 is known to stimulate the GTPase activity of the GTP-
binding protein RhoA. RhoA is a GTP-binding protein and activation of its GTPase 
activity turns GTP into GDP, thus finally inhibiting RhoA. Since ARHGAP26 was up-
regulated, RhoA is assumed to be inhibited. ARHGAP26 is part of PDGF signaling 
(apart from integrin signaling). Upregulation of ARHGAP26 in both Aβ42/Aβ40↑ and 
Aβ42/Aβ40↓ hints at upregulation of this pathway. This is especially true for 
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Aβ42/Aβ40↓, because here, two further components of this pathway (PKCα and FEV) 
were also significantly up-regulated and supported by strong phosphorylation (shown 
by immuno blotting for PKCα). PKCα was down-regulated for Aβ42/Aβ40↑  and  less 
phosphorylation could be observed questioning whether this pathway is really 
affected (for Aβ42/Aβ40↑). In conclusion, an upregulation of PDGF signaling can be 
expected for Aβ42/Aβ40↓. 
In summary, proteases and protease inhibitors belonged to the most significantly and 
differentially expressed genes in consequence of a changed Aβ42/Aβ40 ratio. 
Especially intriguing is the interplay between the most strongly down-regulated 
proteases and the top up-regulated protease inhibitors (and vice versa) and should 
be one of the major topics of future research. 
6.10 Extracellular matrix proteins like fibronectin-domain 
containing proteins, collagen, heparan sulfate 
proteoglycan and reelin may play a fundamental role in 
gene expression incuced by a changed Aβ42/Aβ40 ratio 
Fibronectins are adhesive proteins. They are filamentous dimers consisting of two 
related peptide chains linked to each other by disulfide bonds. Fibronectins have 
different domains enabling them to bind to cell-surface receptors, collagen, fibrin and 
proteoglycans (heparan sulfate, heparin, hyaluronate etc.) Fibronectin has a module 
that causes adhesion to cells containing the characteristic amino acid sequence Arg-
Gly-Asp-Ser. These residues enable fibonectin to bind to cell surface receptors, 
known as integrins. 
I found fibronectin type III domain containing 3A (FNDC3A), fibronectin type III 
domain containing 6 (FNDC6) [300] significantly down-regulated (for Aβ42/Aβ40↑).  
L1 cell adhesion molecule (L1CAM, on chromosome Xq28), was up-regulated 
(Aβ42/Aβ40↓). L1CAM is a type I membrane protein. The protein encoded by this gene 
is an axonal glycoprotein belonging to the immunoglobulin supergene family. The 
ectodomain, consisting of several immunoglobulin-like domains and fibronectin-like 
repeats (type III).  
Neuronal cell adhesion molecule (NRCAM) was up-regulated (Aβ42/Aβ40↓) and 
contains fibronectin type-III domains and is an ankyrin-binding protein. KIAA0746 
was up-regulated (Aβ42/Aβ40↓). KIAA0746 is a potential type I membrane protein 
which may play a role in Notch signaling. It has 27% similarity with Sel-1 homolog 
precursor (Mus musculus) and  contains 1 fibronectin type-II domain. SEL-1 functions 
as a negative regulator of the LIN-12/GLP-1 Notch-like signaling pathway in C. 
  Discussion 
 
 
148
elegans. 
Brother of CDO (BOC) and contactin 3 plasmacytoma associated (CNTN3) were 
among the most up-regulated genes (Aβ42/Aβ40↑) and in parallel the most 
downregulated ones in mutant C99V50F (Aβ42/Aβ40↓). BOC is a cell surface receptor 
of the immunoglobulin (Ig)/fibronectin type III repeat family involved in myogenic 
differentiation.  
Contactins mediate cell surface interactions during nervous system development. 
CNTN3 contains 4 fibronectin type-III domains and 6 immunoglobulin-like domains. 
Fibronectin leucine rich transmembrane protein 1 (FLRT1) was down-regulated 
(Aβ42/Aβ40↑, p=0.113, fold change=-2.4, derived from the comparison C99I45F/WT2) 
These data indicate a crucial role for fibronectin type III in Aβ-mediated gene 
expression. Moreover, apart from the expected involvement in cell adhesion, it is 
striking that many of these fibronectin-associated genes are involved in axonal 
outgrowth and growth cone guidance. 
Collagens, of which there are at least 19 different varieties, form fibers, fibrils and 
networks. They are quantitatively among the most abundant proteins. Collagens form 
water-insoluble fibers that occur as structural elements of the extracellular matrix. 
I found the following collagens up-regulated in consequence of a decreased 
Aβ42/Aβ40 ratio: collagen, type XII, alpha 1 (COL12A1) (p=0.00653, fold change=8.0), 
collagen, type XXVII, alpha 1 (COL27A1) (p=0.01613, fold change=6.3), collagen, 
type XI (COL11A1) (p=0.00313, fold change=6.3), collagen, type I, alpha (COL1A2), 
(p=0.02322, fold change=5.0). In contrast to this, none of these collagens were 
differentially expressed when the Aβ42/Aβ40 ratio was increased.  
In response to wounding, the expression of amyloid precursor-like protein 2 (APLP2) 
in the basal cells of migrating corneal epithelium is greatly up-regulated. APLP2 has 
been suggested to be involved in wound healing, therefore the migratory response of 
transfected Chinese Hamster Ovary (CHO) cells expressing APLP2 isoforms to a 
variety of extracellular matrix components including laminin, collagen types I, IV, and 
VII, fibronectin, and heparan sulfate proteoglycans (HSPGs) was measured [301]. 
CHO cells overexpressing either of two APLP2 variants, differing in chondroitin 
sulfate  attachment, exhibit a marked increase in chemotaxis toward type IV collagen 
and fibronectin but not to laminin, collagen types I and VII, and HSPGs. APLP2 was 
suggested to contribute to re-epithelialization during wound healing by supporting 
epithelial cell adhesion to fibronectin and collagen IV, thus influencing their capacity 
to migrate over the wound bed. (Furthermore, APLP2 interactions with fibronectin 
and collagen IV appear to be potentiated by the addition of a chondroitin sulfate 
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chain to the core proteins) [301]. This is in line with co-regulation (both up-regulated 
to the same extent) of collagen IV and APLP2 (observed in this thesis) in 
consequence of an increased Aβ42/Aβ40↑ ratio, in contrast to a decreased one, for 
which neither of these proteins were up-regulated. I  have proposed collagen IV (see 
Fig. 5.37) to be involved in blood coagulation. This fits to the previously mentioned 
data by Li et al. [301], because enhanced local blood coagulation is a prerequisite to 
wound healing. 
Collagen type IV α 1 (COL4A1) has been described to influence Aβ levels in  
platelets, but the opposite aspect (Aβ42 influences collagen IV) may also be true, 
because I found COL4A1 up-regulated in response to an increased Aβ42/Aβ40↑ 
(p=0.03, fold change=2.4), but not differentially expressed when the Aβ42/Aβ40 ratio 
was decreased. This could be a vicious circle in which Aβ42 reinforces itself via 
COL4A1 expression. Furthermore, I found COL4A2 up-regulated in response to an 
increased Aβ42/Aβ40↑ (p=0,116, fold change=1.5) and validated by another probe-set, 
but not differentially expressed when the Aβ42/Aβ40 ratio was decreased. 
Type IV collagen is associated with laminin and heparan sulfate proteoglycans to 
form the sheetlike basement membranes that separate epithelium from connective 
tissue. The genes for the alpha-1 and alpha-2 chains of type IV collagen (COL4A1 
and COL4A2) map to the same chromosomal band (13q34) and have a high degree 
of nucleotide homology. Aligning the 2-alpha chains of type IV collagen from the N-
terminus, it was concluded that the alpha-2 chain has 43 more amino acids than the 
alpha-1 chain. Twenty-one of these additional residues form a disulfide-bridged loop 
within the triple helix, which is unique among all known collagens. The 2 subunit 
genes COL4A1 and COL4A2 are transcribed from a common promoter. COL4A2 
encodes one of the six subunits of type IV collagen, the major structural component 
of basement membranes. The C-terminal portion of the protein, known as canstatin, 
is an inhibitor of angiogenesis and tumor growth. Like the other members of the type 
IV collagen gene family, this gene is organized in a head-to-head formation with 
another type IV collagen gene so that each gene pair shares a common promoter. 
Microfibrillar-associated protein 4 (MFAP4), which was down-regulated (Aβ42/Aβ40↓) 
has binding specificities for both collagens and carbohydrates. It is thought to be an 
extracellular matrix protein which is involved in cell adhesion or intercellular 
interactions. Although the precise function of this protein is not known, it has been 
suggested that it could be a Ca2+-dependent adhesive protein that is associated with 
elastin microfibrils in the extracellular matrix. MFAP4 has a fibrinogen-like domain. 
The N-terminus of the protein contains an arg-gly-asp sequence that serves as the 
ligand motif for cell surface receptor integrin. The matrix metalloproteinase 8 
  Discussion 
 
 
150
(MMP8), a collagenase, was down-regulated  (Aβ42/Aβ40↑, p=0.00219, fold change=-
5.0, see discussion about proteases for further information). However, MMP8 was 
not differentially expressed when the ratio was decreased. A disintegrin-like and 
metalloprotease (reprolysin type) with thrombospondin type 1 motif 3 (ADAMTS3) 
was down-regulated (Aβ42/Aβ40↑, p=0.086, fold change=-2.1), however, weakly up-
regulated (Aβ42/Aβ40↓, p=0.23, fold change=1.3). ADAMTS3 is the major procollagen 
II N-propeptidase. 
Tissue inhibitor of metalloproteinase 1 (collagenase inhibitor) (TIMP1) was down-
regulated (Aβ42/Aβ40↑, p=0.127, fold change=-3.5), but not differentially expressed 
when the Aβ42/Aβ40 ration was decreased. The TIMP1 gene belongs to the TIMP 
gene family and is localized on chrXp11.3-p11.23. The proteins encoded by this gene 
family are natural inhibitors of the matrix metalloproteinases (MMPs), a group of 
peptidases involved in degradation of the extracellular matrix. In addition to its 
inhibitory role against most of the known MMPs, the encoded protein is able to 
promote cell proliferation in a wide range of cell types, and may also have an anti-
apoptotic function. Transcription of this gene is highly inducible in response to many 
cytokines and hormones. In addition, the expression from some but not all inactive X 
chromosomes suggests that this gene inactivation is polymorphic in human females. 
This gene is located within intron 6 of the synapsin I gene and is transcribed in the 
opposite direction. 
Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 (HS3ST2) was among the 
most inversely regulated genes: Aβ42/Aβ40↑ (p=0.0116, fold change=1.7) and 
Aβ42/Aβ40↓ (p=0,137, fold change=-1.5). Heparan sulfate biosynthetic enzymes are 
key components in generating a myriad of distinct heparan sulfate structures that 
carry out multiple biological activities. HS3ST2 is a type II integral membrane protein 
and possesses heparan sulfate glucosaminyl 3-O-sulfotransferase activity. The 
HS3ST2 gene is expressed predominantly in the brain and may play a role in the 
nervous system. 
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Heparan sulfate proteoglycan 2 (HSPG2) (perlecan) was up-regulated Aβ42/Aβ40↑ 
(p=0,158, fold change=2, calculated with the MAS 5 algorithm) and not differentially 
expressed for Aβ42/Aβ40 ↓. 
Heparan sulfate proteoglycan 1, (syndecan 2 (SDC2), cell surface-associated, 
fibroglycan) was not differentially expressed for Aβ42/Aβ40↑, but down-regulated for 
Aβ42/Aβ40↓ p=0,116, fold change=1.6, calculated with the MAS 5 algorithm). 
Glypican 3 (GPC3) was not differentially expressed (Aβ42/Aβ40↑), but was among the 
6 most significantly down-regulated genes (calculated with the GC-RMA algorithm) 
when the Aβ42/Aβ40 was decreased (p=0.00089, fold change=-2.5). GPC3 is a cell 
surface heparan sulfate proteoglycan that is composed of a membrane-associated 
protein core substituted with a variable number of heparan sulfate chains. Members 
of the glypican-related integral membrane proteoglycan family (GRIPS) contain a 
core protein anchored to the cytoplasmic membrane via a glycosyl 
phosphatidylinositol linkage. These proteins may play a role in the control of cell 
division and growth regulation. GPC3 may play a role in the modulation of IGF2 
interactions with its receptor and thereby modulate its function. Predicted functional 
partners are IGF2, Insulin precursor, WNT5A, CDKN1C, WNT3A, WNT7B. 
Reelin (RELN) was the third most significantly up-regulated gene (C99I45F/C99WT2, 
Aβ42/Aβ40↑, p=0,031728, fold change=3.3), but was not differentially expressed for 
Aβ42/Aβ40↓. Reelin is up-regulated in the brain and CSF of AD patients [302]. 
Intriguingly, we (together with our colleague Laura Busia) also found reelin to be 
among the most significantly dysregulated genes in embryonic mouse fibroblasts in 
consequence of PS1 knockdown with siRNA.  
The encoded protein resembles extracellular matrix proteins involved in cell adhesion 
[303] thought to control cell-cell interactions critical for cell positioning and neuronal 
migration during brain development. RELN may be involved in schizophrenia, autism, 
bipolar disorder, major depression and in migration defects associated with temporal 
lobe epilepsy. RELN regulates microtubule functions in neurons and neuronal 
migration. RELN is an extracellular matrix serine protease [304] that plays a role in 
layering of neurons in the cerebral cortex and cerebellum and its enzymatic activity is 
important for the modulation of cell adhesion. RELN binds to the extracellular 
domains of lipoprotein receptors VLDLR and APOER2 [305, 306] induces tyrosine 
phosphorylation of Dab1 and modulation of tau phosphorylation [306]. Very recently it 
has been shown that APOER2 and X11 alpha/beta mediate apolipoprotein E-induced 
endocytosis of APP and β-secretase, leading to amyloid-β production [307]. RELN is 
abundantly produced during brain ontogenesis by the Cajal-Retzius cells and other 
pioneer neurons located in the telencephalic marginal zone and by granule cells of 
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the external granular layer of the cerebellum. In adult brains, it is preferentially 
expressed in GABAergic interneurons of prefrontal cortices, temporal cortices, 
hippocampi and glutamatergic granule cells of cerebellum. It is also expressed in 
fetal and adult liver. 
Taken together, collagen IV levels might be increased (for Aβ42/Aβ40↑) through down-
regulation of collagenases and by up-regulation on the transcript level (for 
Aβ42/Aβ40↑). On the other hand, collagen-levels (for type 11α1, 12 α1, 27α1 and type 
1α2) might be increased for Aβ42/Aβ40↓ by upregulation of collagen-coding genes. 
Collagen type IV α may play a crucial role in Aβ induced pathology supported by the 
observation that collagen type IV and fibronectin are present in Alzheimer deposits 
[308]. Furthermore, the data indicate increased generation of heparan sulfate 
proteoglycans as a result of an increased Aβ42/Aβ40 ratio and reduced generation in 
consequence of a decreased Aβ42/Aβ40 rat io. RELN may be involved, by its 
extracellular matrix serine protease activity in the break down of the extracellular 
matrix (for Aβ42/Aβ40↑).  
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6.11 ACTA2 is assumed to be a pivotal protein in gene 
expression induced by altered C99 cleavage products 
ACTA2 (actin, alpha 2, smooth muscle, aorta) is one of six different actin isoforms. 
Actins are highly conserved proteins that are involved in cell motility, structure and 
cell integrity. They are ubiquitous proteins involved in the formation of filaments that 
are major component of the cytoskeleton. Interaction with myosin provides the basis 
of muscular contraction and many aspects of cell motility.  
ACTA2, localized on chromosome chr10q23.3, was the third most strongly up-
regulated gene for Aβ42/Aβ40↓ but it was not differentially expressed for Aβ42/Aβ40↑. It 
was co-regulated with GAP43, PLAT, GDF1 and MAPK8IP2. Co-regulation with 
GAP43 was further supported by the observation that ACTA2 and GAP43 were also 
co-regulated for the comparison C99WT/mock in which both transcripts were found 
to be down-regulated. Intriguingly, we (together with our colleague Laura Busia) also 
found ACTA2 among the most strongly and most significantly up-regulated genes in 
embryonic mouse fibroblasts in consequence of PS1 and PS2 knockdown with 
siRNA. In this approach Aβ levels were expected to be decreased. This is in line with 
the observation of ACTA2 upregulation in mutant C99V50F compared to C99WT 
(Aβ42/Aβ40↓) and argues for an effect mediated by a decreased Aβ42 or increased 
Aβ40 expression or for a change in the corresponding AICD levels. Müller et al. found 
ACTA2 among the most up-regulated genes in consequence of AICD overexpression 
[57]. This argues for an effect mediated by the AICD (or further cleavage products 
hereof). ACTA2 has been described as being involved in vascularisation and 
vascular branching [309, 310, 311]. Furthermore, impaired vascular contractility and 
blood pressure homeostasis in smooth muscle α-actin null mice has been observed 
[312]; The major function of vascular smooth muscle cells is contraction to regulate 
blood pressure and flow [311]. It can be speculated that a decreased Aβ42/Aβ40 up-
regulates ACTA2, a mechanism that might also occur in smooth muscle cells, which 
in turn could lead to improved vascularisation and could regulate blood pressure. 
This positive effect might be missing for an increased Aβ42/Aβ40 ratio where no 
differential ACTA2 expression was observed.  
6.12 Transcriptional control of blood coagulation and 
fibrinolysis was influenced by a changed Aβ42/Aβ40 ratio 
See Model, Fig. 5.37, pages 86-87. Clinical data as well as immunohistochemical 
and electron microscopy data of cerebral cortex and brain microvessels hint at an 
altered regulation of blood coagulation and fibrinolysis in Alzheimer’s patients [313, 
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314]. Here, information is available about the transcriptional control of blood 
coagulation and fibrinolysis, however, blood coagulation and fibrinolysis were not 
tested directly. The tissue factor pathway inhibitor 2 (TFPI2) was significantly 
(p=0.027) up-regulated (fold change=2.6) in consequence of a decreased Aβ42/Aβ40 
ratio (and confirmed by another probe-set), however, it was down-regulated for 
Aβ42/Aβ40↑ (p=0,365, fold change=-3.1); this downregulation was confirmed with 
another probe-set making a real downregulation more probable. Using another set of 
triplicates as a baseline experiment (C99WT2) revealed TFPI2 as the most down-
regulated gene (Aβ42/Aβ40↑, 10-fold down-regulated, p=0,241034). This result was 
also confirmed with another probe set. Direct comparison between both mutants 
(C99I45F/C99V50F) indicated strong downregulation in mutant C99I45F (Aβ42/Aβ40↑, 
p=0.132, fold change=-10.1) and another probe set for detection of TFPI2 delivered 
similar results (Aβ42/Aβ40↑, p=0.158, fold change=-32.0). TFPI2 was the most 
inversely regulated gene (by a changed Aβ42/Aβ40 ratio). Even if TFPI2 does not pass 
the generally accepted cut-off for significant differential expression for Aβ42/Aβ40↑ 
(p<0.05), TFPI2 can be regarded as important, because of the fact that it was the 
most inversely regulated gene and only 3 replicates (n=3) were measured: a few 
outliers (for instance one replicate shows diverse expression compared to the other 
two) could have increased the p-value. It can be assumed that increasing the number 
of replicates would reduce the p-value for this gene. Further measurements with 
further clones (for instance n=6 instead of n=3) may reduce the p-value.   
Tissue factor pathway inhibitor is an important regulator of the extrinsic pathway of 
blood coagulation through its ability to inhibit factor Xa and factor VIIa-tissue factor 
activity. It was originally identified by Siiteri et al. [315] and Butzow et al. [316] as a 
placental glycoprotein that inhibits blood coagulation [317]. After a 22-residue signal 
peptide, the mature TFPI2 protein contains 213 amino acids with 18 cysteines and 2 
canonical N-linked glycosylation sites. The deduced sequence of mature TFPI2 
revealed a short acidic N-terminal region, 3 tandem Kunitz-type domains, and a C-
terminal tail highly enriched in basic amino acids. It may also play a role in the 
regulation of plasmin-mediated matrix remodeling. 
Taken together, there are strong indications that blood coagulation is increased  
(decreased blood flow)  for Aβ42/Aβ40↑, due to downregulation of inhibiting properties 
of TFPI2 onto blood clotting. In vivo, a decreased cerebral blood flow may be 
assumed to be a consequence of an increased Aβ42/Aβ40 ratio. Here, information 
about the transcriptional control of blood coagulation is available. Future research 
should focus on the direct analysis of blood coagulation.   
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The gene plasminogen activator, tissue (PLAT) was not differentially expressed for 
Aβ42/Aβ40↑, but significantly (p=0.0047) up-regulated (fold change=2.1) when the 
Aβ42/Aβ40 was decreased. Even if only shown on the transcript-level in cell culture, 
this points to increased fibrinolysis, and thus augmented blood flow when the 
Aβ42/Aβ40 was decreased. In contrast to this, fibrinogen, B beta polypeptide (FGB) 
was significantly (p=0.01613) up-regulated (Aβ42/Aβ40↑, fold change= 2.5), but no 
differential expression was observed when the Aβ42/Aβ40 was decreased. This 
indicates increased generation of fibrin in consequence of an increased Aβ42/Aβ40.  
A plethora of proteins with fibronectin domains were found to be differentially 
expressed (previosly discussed in this thesis). Fibronectin was shown to enhance 
thrombocyte aggregation, which may further influence blood coagulation or 
fibrinolysis.  
SERPINE2 (synonyms: Nexin plasminogen activator inhibitor type 1, protease nexin I 
(PN1), protease inhibitor 7, glial-derived neurite promoting factor p) was down-
regulated (Aβ42/Aβ40↑). SERPINE2 shares several features with antithrombin III, an 
abundant plasma thrombin inhibitor. Both SERPINE2 and AT-III have high affinities 
for heparin; heparin accelerates their rate of thrombin inhibition  and it is the most 
important physiologic regulator of alpha-thrombin in tissues [318]. SERPINE2 is 
highly expressed and developmentally regulated in the nervous system where it is 
concentrated at neuromuscular junctions and also at central synapses in the 
hippocampus and striatum. Approximately 10% of identified proteins at mammalian 
neuromuscular junctions are serine protease inhibitors, consistent with their central 
role in balancing serine protease activity to develop, maintain, and remodel 
synapses. Pericyte expression of SERPINE2 may provide endogenous anticoagulant 
activity [319]. SERPINE2 in solution forms inhibitory complexes with thrombin or 
urokinase, which have opposing effects on the blood coagulation cascade. An initial 
report provided data supporting the idea that SERPINE2 properties are under the 
influence of collagen type IV. SERPINE2 binds tightly to and is regulated by the 
extracellular matrix. This interaction accelerates the inhibition of thrombin by 
SERPINE2 and blocks urokinase and plasmin inhibition by SERPINE2. Previous 
work showed that heparan sulfate proteoglycan is largely responsible for the 
acceleration of thrombin inhibition by SERPINE2. It has been shown that collagen 
type IV decreased the formation of SDS-stable complexes between urokinase or 
plasmin and SERPINE2 without affecting formation of complexes between thrombin 
and SERPINE2. Other extracellular matrix components (collagen type I, vitronectin, 
fibronectin, and heat-denatured collagen type IV) did not affect complex formation or 
the rate of inhibition of proteases by SERPINE2, indicating that these effects were 
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specific to collagen type IV. Collagen type IV was also copurified with SERPINE2 
from fibroblast-conditioned medium [320]. This has led to the generally accepted idea 
that the primary role of SERPINE2 in the brain is to act as a rapid thrombin inhibition 
mechanism during trauma. Due to the down-regulation of SERPINE2 (for Aβ42/Aβ40↑) 
the inhibiting properties of SERPINE2 on thrombin can be expected to be reduced. In 
consequence thrombin may be more active leading to faster blood coagulation.  
The serine proteinase inhibitor, clade F, member 1 (SERPINF1, α-2 anti-plasmin) 
was the third most significantly down-regulated transcript (Aβ42/Aβ40↓, p=0.00362, 
fold change=-3.1, GC-RMA algorithm), whereas it was not differentially expressed 
when the Aβ42/Aβ40 was increased. Generated fibrin (the end product of blood 
coagulation) can be converted into soluble fragments (fibrinolysis). Plasmin, a 
protease, converts fibrin into soluble fragments by cleavage. SERPINF1 is an anti-
plasmin and it was strongly down-regulated (Aβ42/Aβ40↓). This means that more 
plasmin is expected to be available, which in turn would accelerate fibrinolysis (for e 
decreased Aβ42/Aβ40 ratio).  
Heparin strongly inhibits blood coagulation, for instance by binding to anti-thrombin 
III, factor IXa and Xa. FGF1, a heparin-binding growth factor, was up-regulated for 
Aβ42/Aβ40↑ (p=0.02, fold change=1.6), whereas it was not differentially expressed 
when the Aβ42/Aβ40 was decreased. Superoxide dismutase 1 (SOD1) was reported to 
bind heparin [321] and immunoblotting showed its upregulation for Aβ42/Aβ40↑, but its 
downregulation when the Aβ42/Aβ40 ratio was decreased. I speculate that FGF1 and  
SOD1 could retain heparin by binding it, so that the free level of heparin may be 
reduced. Consequently, it may be no longer available in sufficient amounts to inhibit 
blood coagulation (for Aβ42/Aβ40↑). 
Binding of the weakly, but significantly up-regulated coagulation factor XII (Hageman 
factor; for Aβ42/Aβ40↑, p=0.036, fold change 1.3) to collagens, triggers the intrinsic 
blood coagulation cascade. The Hageman factor was not differentially expressed 
when the Aβ42/Aβ40 was decreased. KIAA1573 was among the most inversely 
regulated genes. It was up-regulated (for Aβ42/Aβ40↑, p=0.044, 1.6 fold), but down-
regulated (p=0.149, -2.7 fold) when the Aβ42/Aβ40 was decreased. KIAA1573 (Von 
Willebrand factor type A and cache domain containing 1), is assumed, due to 
sequence similarity, to be a L-type calcium channel. It contains a VWFA (Von 
Willebrand factor A) domain. Von Willebrand factor mediates thrombocyte 
aggregation to collagen. Ca2+ ions were shown to be a co-factor for local clotting 
(Ca2+ supports triggering the extrinsic clotting cascade) and Ca2+ can be assumed to 
be increased (Aβ42/Aβ40↑, see information about Ca2+-levels, Chapter 6.36, pages 
201-202). Coagulation factor II (thrombin) receptor-like 3 (F2RL3) was down-
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regulated (Aβ42/Aβ40↓, p=0.04742, fold change=-3.2) and coagulation factor II 
(thrombin) receptor was weakly down-regulated (Aβ42/Aβ40↓, p=0.0266, fold 
change=-1.2), whereas no differential expression was observed when the Aβ42/Aβ40 
was increased. I speculate that down-regulated thrombin receptors support the 
downregulation of the blood coagulation cascade (Aβ42/Aβ40↓) and thus increase 
blood flow. Interestingly, the inversely regulated JAG1 (Aβ42/Aβ40↑: up-regulated, 
Aβ42/Aβ40↓: down-regulated) is a type I membrane-protein and contains in its 
extracellular part a von Willebrand factor type C domain. HGF was one of the most 
down-regulated genes (Aβ42/Aβ40↑). At physiological concentrations HGF was found 
to inhibit thrombin-dependent platelet aggregation in a dose- and time-dependent 
manner. These results suggest that circulating HGF may counteract thrombogenesis 
by negatively modulating platelet functions [322]. Thus, down-regulation of HGF 
might support platelet aggregation (for Aβ42/Aβ40↑).  
In summary, there are indications of increased blood coagulation and presumably 
decreased fibrinolysis as a consequence of an increased Aβ42/Aβ40 ratio, while a 
decreased Aβ42/Aβ40 ratio may result in enhanced fibrinolysis, while blood 
coagulation might be reduced. All differentially expressed genes (described in Figure 
5.37, pages 86-89), except for F2R, F2RL3 and VWCD1, code for secreted 
proteins.Theoretically it seems possible that in vivo (in brains of AD patients) an 
increased Aβ42/Aβ40 ratio triggers the release of the previously mentioned factors into 
the extracellular space and into blood vessels, in which a shift towards increased 
blood coagulation and decreased fibrinolysis may take place. Indeed, clinical data on 
blood coagulation and fibrinolysis as well as immunohistochemical and electron 
microscopy data of cerebral cortex and brain microvessels hint at such a regulation in 
Alzheimer’s patients [313, 314]. Such a regulation would result in decreased cerebral 
blood flow and a stronger tendency towards stroke and mental dysfunction.  
Further research directly focusing on blood coagulation and fibrinolysis is necessary 
to demonstrate that the changes, identified here on the transciptional level, hold true.  
Platelets contain both APP and Aβ and may contribute to the perivascular amyloid 
deposition seen in AD [323]. APP is abundantly expressed in the platelet α-granule 
where its role remains unclear. A study described a function for APP in regulating 
human platelet activation. Secreted APP (sAPP) potently inhibited platelet 
aggregation [324]. Secreted APP, which contains a KPI (Kunitz protease inhibitor) 
domain, has been identified as the serine protease inhibitor, protease nexin II (PNII), 
which inhibits the serine protease factor XIa in the blood coagulation cascade [325, 
326]. These studies indicate an association of APP and Aβ with blood coagulation. 
Furthermore, Aβ was detected in human atherosclerotic plaques suggesting a link 
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between Aβ and strokes [327].  
Taken together, previously publications hint at inhibition of blood coagulation by 
secreted APP. Here in this thesis, altered C99 processing accompanied by an 
increased Aβ42/Aβ40 ratio seemed to enhance blood coagulation via its transcriptional 
control.  
6.13 Kinases/phosphatases as possible candidates for tau or 
GSK3 phosphorylation 
6.13.1 Kinases 
See results, Table 5.14 (Chapter 5.10.2, page 90). The state of phosphorylation of a 
phosphoprotein is a function of the balance between the activities of protein kinases 
and phosphatases that regulates its phosphorylation. For these reasons candidate 
kinases/phosphatases for tau and GSK3β were identified. 
Of special interest was CDKL1 (cyclin-dependent kinase-like 1, synonyms: CDC2-
related kinase, p42), due to its location on chromosome chr14q21.3, which is in very 
close vicinity to the presenilin 1 gene (chr14q24). This gene product is a member of a 
large family of CDC2-related serine/threonine protein kinases. CDKL1 is known to 
regulate important transitions in the eukaryotic cell cycle. 
Another top candidate was DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 1A), located on chromosome chr21q22.13, which is directly 
adjacent to the APP locus (chr21q21.2|21q21.3). Song et al. mentioned that DYRK1A 
may be involved in the abnormal neurogenesis found in Down’s syndrome. They 
considered DYRK1A a good candidate to mediate some of the pleiotropic effects of 
Down’s syndrome [328]. DYRK1A is activated by tyrosine phosphorylation in the 
activation loop between subdomains VII and VIII of the catalytic domain. The human 
gene for DYRK1A is located in the "Down’s syndrome critical region" of chromosome 
21 and is therefore a candidate gene for mental retardation in Down syndrome. An 
unusual enzymatic property of Dyrk-related kinases is their ability to catalyze 
tyrosine-directed autophosphorylation as well as phosphorylation of serine/threonine 
residues in exogenous substrates [329]. Using fluorescence in situ hybridization and 
regional mapping data, Song et al. localized the DYRK gene between markers 
D21S336 and D21S337 in the 21q22.2 region [328]. Altafaj et al. generated 
transgenic mice overexpressing the full-length cDNA of DYRK1A. DYRK1A mice 
exhibited delayed craniocaudal maturation with functional consequences in 
neuromotor development. Dyrk1A mice also showed altered motor skill acquisition 
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and hyperactivity, which was maintained to adulthood. In the Morris water maze, 
DYRK1A mice showed a significant impairment in spatial learning and cognitive 
flexibility, indicative of hippocampal and prefrontal cortex dysfunction. In the more 
complex repeated reversal learning paradigm, this defect was specifically related to 
reference memory, whereas working memory was almost unimpaired. The authors 
suggested a causative role of DYRK1A in mental retardation and in motor anomalies 
of Down’s syndrome [330]. 
For both loci (chr14q21.3 and chr21q21.2|21q21.3)  a “Chromeron regulation” [195] 
can be assumed: APP would then be co-regulated with DYRK1A and presenilin 1 
would be co-regulated with CDKL1. Overexpressed APP would be accompanied by 
DYRK1A upregulation (and low expressed APP would be accompanied by DYRK1A 
downregulation). Consequently, as a result of increased APP processing, more Aβ42 
would be produced and at the same time DYRK1A would be increased, which in turn 
could phosphorylate downstream targets like GSK3β or tau. Overexpressed 
presenilin 1 would be accompanied by up-regulated CDKL1. Consequently, as a 
result of changed APP processing (due to overexpressed presenilin 1), more Aβ42 
would be produced while CDKL1 would be increased. CDKL1, in turn, could then 
phosphorylate downstream targets like GSK3β or tau. 
PFKP (phosphofructokinase platelet) catalyzes the irreversible conversion of 
fructose-6-phosphate to fructose-1,6-bisphosphate and is the key regulatory enzyme 
of glycolysis (ADP + D-fructose -1,6-bisphosphate = ATP + D-fructose -6-phosphate). 
PFKP was up-regulated for Aβ42/Aβ40↑, but not differentially expressed for 
Aβ42/Aβ40↓. This form of PFK is called the 'platelet' type because it is the only form 
made by platelets, whereas for instance fibroblasts have more than one form of 
phosphofructokinase. The ‘platelet’ type is abundant in the brain. This allosteric 
enzyme is activated by ADP, AMP, or fructose bisphosphate and is inhibited by ATP 
or citrate. 
Up-regulated PFKP (Aβ42/Aβ40↑, see Model Chapter 5.9.3, Fig. 5.36, page 85) may 
contribute to reduce glucose levels observed in brains of AD patients [331] and its 
induction on the transcript level is in line (PFKP is activated by ADP and AMP, but 
inhibited by ATP) with reduced ATP levels observed in brains of AD patients [332]. 
Phosphofructokinase activity in brains from patients with Alzheimer's disease was 
significantly increased in frontal and temporal cortex when compared with control 
brains [332]. There is a long lasting debate about “metabolic insufficiency“ in AD. 
Since PFKP was found to be up-regulated (for Aβ42/Aβ40↑), this may be a response 
to, rather than the cause of reduced glucose metabolism and could be regarded as 
the attempt of the cells to restore sufficient ATP levels. Another explanation might be 
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reduced glucose levels in the brains of AD patients that triggers upregulation of 
glycolysis by PFKP upregulation. The observation that glucose metabolism is 
reduced in AD brains might rather reflect reduced levels of substrates (as part of the 
glycolysis pathway, reduced feed-forward stimulation) than decreased expression of 
glycolytic enzymes. This would mean that glucose is missing in the brain (possibly 
due to a changed insulin/IGF2 metabolism) resulting in reduced ATP levels 
(increased ADP and AMP levels), which in turn would cause PFKP to produce more 
ATP. Thus, missing glucose/ATP could be inherently connected to GSK3/tau 
phosphorylierung (provided PFKP turns out to be a possible GSK or tau-kinase) via 
PFKP upregulation, so GSK3/tau phosphorylation would be an inherent byproduct of 
reduced glucose/ATP levels. In Tg2576 mice, overexpressing the Swedish mutation 
of APP, reduced PFKP levels were detected [333]. Bigl et al. found increased levels 
in astrocytes localized in frontal and temporal cortex from AD patients compared to 
healthy controls [331] and phosphofructokinase activity in brains from patients with 
Alzheimer's disease was significantly increased in the frontal and temporal cortex 
[332]. 
Further protein kinases were dysregulated for a changed Aβ42/Aβ40 ratio and thus 
possible GSK/tau kinases: 
Cyclin-dependent kinase-like 5 (CDKL5), localized on chrXp22, was up-regulated  for 
Aβ42/Aβ40↑ (p=0.02490, fold change=4.0), but not differentially expressed for 
Aβ42/Aβ40↓. CDKL5 (cyclin-dependent kinase-like 5, synonym: STK9 serine/threonine 
kinase 9). CDKL5 belongs to the ser/thr protein kinase family. Defects in CDKL5 are 
a cause of Rett syndrome. Rett syndrome is an X-linked dominant disease. It is a 
progressive neurologic disorder accompanied by brain atrophy and is one of the most 
common causes of mental retardation in females.  
GRK5 (G protein–coupled receptor kinase 5) plays an important role in 
phosphorylating and regulating the activity of a variety of G protein-coupled 
receptors.  
Rps6ka5 (ribosomal protein S6 kinase, polypeptide 5, synonym: mitogen-and stress-
activated protein kinase1, MSK1). Rps6ka5 is directly activated by MAPK and 
SAPK2/p38, and may mediate activation of CREB [334]. 
PHKG1 (phosphorylase kinase  gamma 1 (muscle)) is a crucial glycogenolytic 
regulatory enzyme. The holoenzymes are composed of 16 subunit proteins 
containing equimolar ratios of 4 subunit types known as alpha, beta, gamma, and 
delta. Skeletal muscles contain the highest amount of phosphorylase kinase 
enzymatic activity, although activity is also observed in the liver, cardiac muscle, 
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brain and several other tissues. PHKG1 was not differentially expressed in C99I45F 
However, it was slightly down-regulated in C99V50F compared to C99WT (p=0.0441, 
fold change=-1.3). This could be a weak sign of sufficient ATP levels for Aβ42/Aβ40↓ 
because glucose generation (to produce ATP) by glycogenolysis may not be needed, 
so the glycogenolytic enzyme PHKG1 is down-regulated. 
PKN2 (protein kinase N2, synonym: PAK2) belongs to the serine/threonine protein 
kinase family. This phospholipid-regulated protein kinase phosphorylates ribosomal 
protein S6 and is activated by lipids, particularly by cardiolipin and to a lesser extent 
by other acidic phospholipids and unsaturated fatty acids. 
CDK6 (cyclin-dependent kinase 6) regulates cell cycle transitions in eukaryotic cells. 
Vulnerable neurons in the AD brain show activation of cell cycle markers [335]. This 
observation is supported by the recent demonstration that hypoxia/ischemia in the 
mouse and rat brain may also result in activation of the cell cycle and DNA replication 
prior to neuronal death [336, 337]. 
DCAMKL1 (synonym: CPG16) is highly expressed in the brain and may mediate 
calcium signaling in neural cells. DCAMKL1 has microtubule polymerizing activity 
that is independent of its protein kinase activity [338]. Overexpression of DCAMKL1 
seems to partially inhibit cAMP-stimulated activity of the transcription factor CREB 
(cAMP response element-binding protein), suggesting its involvement in the down-
regulation of cAMP-induced transcription [339]. 
DCAMKL1 was found up-regulated on the protein-level for Aβ42/Aβ40↑ and slightly 
down-regulated for Aβ42/Aβ40↓, shown by immunobloting (n=1). Thus, it could be a 
possible candidate kinase for GSK3 or tau-phosphorylation. In this regard its 
microtubule polymerizing activity is of special interest and should be a focus in future 
research.  
6.13.2 Phosphatases 
See results, Table 5.15 (Chapter 5.10.3, page 91). Protein phosphatase 2A (PP2A) is 
a serine/ threonine protein phosphatase regulating mainly cell growth and division. It 
comprises three subunits, A, B, and C. All PP2A holoenzymes have a catalytic 
subunit C and a structural scaffolding subunit A in common. These subunits 
assemble with regulatory and targeting B subunits to form functionally distinct 
heterotrimers which are likely to have different functions in the cell [340]. PPP2R4 
(protein phosphatase 2A activator, regulatory subunit 4) belongs to the B' family. This 
gene encodes a specific phosphotyrosyl phosphatase activator of the dimeric form of 
protein phosphatase 2A and might severely affect PP2A activities [341, 342]. 
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Recently it has been suggested to be a peptidyl-prolyl cis/trans-isomerase [343]. The 
B-subunit is involved in enzyme activity and substrate specificity. The B-subunit 
family is of great diversity and is divided into three classes, the B1, B2, and B3 
subfamilies. The putative protein B1 gamma (PPP2R2C) shares 81 and 85% identity 
with B1alpha (PPP2R2A) and B1beta (PPP2R2B), respectively. One remarkable 
characteristic of PPP2R2C is that it is highly expressed in the brain with a 4.7-kb 
transcript while it is nearly undetectable in other tissues [344]. Interestingly, in 
contrast to its significant upregulation (for Aβ42/Aβ40↑), it was significantly (p=0.0198) 
down-regulated (-2.2 fold) in C99WT compared to mock-transfected cells.  
The often cited protein phosphatase 2A (as a candidate for tau dephosphorylation) is 
strongly regulated by its regulatory subunit B [341, 342]. Interestingly , PPP2R4 and 
the more recently discovered PPP2R2C (for which less information is available in the 
literature and in databases) are differentially affected by an altered Aβ42/Aβ40 ratio. 
Further research focusing on these two subunits, with special regard to their 
regulation shown here, may help to gain further insight into the function of PP2A.  
A further phosphatase dysregulated by a changed Aβ42/Aβ40 ratio was PHACTR2 
(Phosphatase and actin regulator 2). PHACTR2 is a family member of proteins that 
binds protein phosphatase 1 and cytoplasmic actin; it may play a role in regulation of 
the actin cytoskeleton. PHACTR2 was -3.2 fold down-regulated (p=0.02572) for 
Aβ42/Aβ40↑ but not differentially expressed for Aβ42/Aβ40↓. This downregulation could 
contribute to increased phosphorylation of tau and GSK3 for Aβ42/Aβ40↑. 
6.14 Changed phosphorylation status of GSK3α/β, tau, 
proteinkinase C and further molecules 
6.14.1 GSK3α and GSK3β 
Signal transduction pathways are especially activated/inhibited by phosphorylation or 
dephosphorylation, thus the phosphorylation status of key molecules was checked. 
Phosphorylation on tyrosine 279 and/or 216 activates GSK3α and GSK3β. GSK3α 
was found to be hyperphosphorylated on tyrosine 279 (n=1) as result of an increased 
Aβ42/Aβ40 ratio, whereas a decreased Aβ42/Aβ40 ratio (C99V50F/C99WT) led to 
hypophosphorylation (n=1) on tyrosine 279. GSK3β was hyperphosphorylated on 
tyrosine 216 (n=3; Aβ42/Aβ40↑, C99I45F/C99WT), whereas a decreased Aβ42/Aβ40 
ratio led to hypophosphorylation (n=3) on tyrosine 279. GSK3 is known to inhibit 
glycogen synthase, cyclin D1, p21. These 3 genes were down-regulated (increased 
Aβ42/Aβ40 ratio, C99I45F/C99WT), and thus in line with GSK3 activation.  
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6.14.2 Tau 
Tau hyperphosphorylation of certain phosphorylation sites is a hallmark of AD and 
consequence of Aβ overproduction. Indeed, I found tau more strongly 
phosphorylated on serine 515 and serine 518 (corresponding to S199 and S202 of 
tau isoform 2=tau441) while it was not differentially expressed on the transcript level 
(Aβ42/Aβ40↑). This was validated by 3 antibodies: one directed against 
phosphorylated serine 515/518, one specifically against phosphorylated serine 515 
and one specifically against phosphorylated serine 518. Serine 712 (corresponding to 
S396 of tau isoform 2=tau441) showed stronger phosphorylation in C99I45F than in 
C99V50F. Further repetitions with other antibodies (directed against serine 712) are 
necessary to validate this result. The following phosphorylation sites are among the 
critical sites to convert tau into a protein with toxic properties: S199/202/205, T212, 
T231/S235, S262/356 and S404 [116]. Furthermore, phosphorylation on T231, S396, 
and S422 promotes self-assembly of tau into filaments. Taken together, serine 199, 
serine 202 and presumably serine 396 showed stronger phosphorylation in 
consequence of an increased Aβ42/Aβ40 ratio than in consequence of a decreased 
Aβ42/Aβ40 ratio. This strong phosphorylation possibly converts  tau into a protein with 
toxic properties. 
6.14.3 Inverse phosphorylation of PKC as a result of a changed 
Aβ42/Aβ40 ratio 
PKC showed a clear difference in the phosphorylation status as a consequence of a 
changed Aβ42/Aβ40 ratio: PKC showed weaker phosphorylation as a result of an 
increased Aβ42/Aβ40 ratio (mutant C99I45F/C99WT), whereas a decreased Aβ42/Aβ40 
ratio (mutant C99V50F/C99WT) led to stronger phosphorylation. This was observed 
for many subunits of PKC: β1/2 (threonine 500, n=1), α/β 2 (threonine 638/ threonine 
641, n=2), ß2 (threonine 641, n=1), δ (serine 664, n=3), η (serine 674, n=2), strongly 
indicating inverse phosphorylation of PKC. Hypophosphorylation for C99I45F 
(Aβ42/Aβ40 ratio↑) at the sites mentioned above is known to decrease activity of PKC.  
PKC, as well as proteinkinases A and B, are reported to inhibit GSK3. For an 
increased Aβ42/Aβ40 ratio, due to the expected reduced activity of PKC, the inhibiting 
effect on GSK3 is expected to be reduced which may contribute to GSK3 activation.  
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6.14.4 Differential phosphorylation of PKB (AKT1), PKA and FAK 
as a result of a changed Aβ42/Aβ40 ratio  
AKT1 showed weaker phosphorylation on serine 473 in mutant C99I45F than in 
C99WT. Hence, in mutant C99I45F the known inhibiting effects from AKT1 onto 
GSK3β might be reduced. This should result in increased GSK3β activity in C99I45F. 
AKT normally activates SGK. SGK was found to be down-regulated on the transcript 
(n=3) and protein level (n=1) and is in agreement with AKT-downregulation (for 
Aβ42/Aβ40 ↑).  
FAK (Focal adhesion protein-tyrosine kinase) is known to activate AKT (via further 
proteins). FAK showed weaker phosphorylation on S722 and is expected to be less 
active (for C99I45F compared to C99WT, Aβ42/Aβ40↑), which might contribute to 
reduced activity of AKT.  
PKAβ (on serine 338) showed weaker phosphorylation in mutant C99I45F than in 
mutant C99V50F which might lead to reduced PKA activity, so that inhibiting effects 
from PKA onto GSK3β might be reduced. This should contribute to increased GSK3β 
activity. 
6.14.5 Probable activation of MAPkinase/ERK signaling due to 
strong phosphorylation of MEK1 and ERK1 in response to 
an increased Aβ42/Aβ40 ratio 
Raf1 or other upstream proteins activate the MAP2 kinases, MEK1 and MEK2 
(MEK1/2). MEK1/2, in turn, activates ERK1/2. The extracellular signal-regulated 
kinases 1 and 2 (ERK1 and ERK2) are pleiotropic mitogen activated serine/threonine 
protein (MAP) kinases with over 160 known substrates, found throughout the cell that 
include other protein kinases, membrane receptors, cytoskeletal proteins, 
downstream effector kinases and transcription factors. ERK1/2 regulates 
proliferation, differentiation, cell cycle processes, and survival, as well as many other 
cell processes. Excessive ERK1/2 activation induces apoptosis. ERK1/2 activate a 
plethora of transcription factors including but not limited to CREB, c-Myc, c-Jun, c-
Fos, and STAT. In response to an increased Aβ42/Aβ40 ratio MEK1 was stronger 
phosphorylated on serine 297, but less phosphorylated on the same site for 
Aβ42/Aβ40↓. The same phosphorylation pattern could be found for threonine 291. 
ERK1 was more strongly phosphorylated on threonine 202 or/and tyrosine 204 in 
mutant C99I45F than in C99WT. This argues for an activation of both MEK1 and 
ERK1. Since ERK1 is a downstream target of MEK1 the whole pathway seems to be 
activated (in response to an increased Aβ42/Aβ40).  
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6.15 APLP1 and APLP2 were differentially affected by a 
changed Aβ42/Aβ40 ratio 
Amyloid precursor-like protein 1 (APLP1) is a membrane-associated glycoprotein 
cleaved by secretases in a manner similar to APP cleavage. This cleavage liberates 
an intracellular cytoplasmic fragment that may act as a transcriptional activator. The 
encoded protein may also play a role in synaptic maturation during cortical 
development. Alternatively spliced transcript variants encoding different isoforms 
have been described. It may play a role in postsynaptic function. APLP1 may interact 
with cellular G-protein signaling pathways. It can regulate neurite outgrowth through 
binding to components of the extracellular matrix such as heparin and collagen I. 
APLP1 is a cell membrane; single-pass type Imembrane protein, C-terminally 
processed in the golgi complex. It is assumed to bind, via its C-terminus, to several 
cytoplasmic proteins, including MAPK8IP1 and DAB1. Binding to DAB1 inhibits its 
serine phosphorylation and it is assumed to interact with CPEB1. It is expressed in 
the cerebral cortex where it is localized to the postsynaptic density. It binds zinc and 
copper in the extracellular domain, zinc-binding increases heparin binding. APLP1 
influences endocytosis and proteolytic processing of the amyloid precursor protein. 
APLP1 influences endocytosis and proteolytic processing of the amyloid precursor 
protein. APLP1 affects the endocytosis of APP and makes more APP available for α-
secretase cleavage [345]. Interaction of APLP1 with the α2A-adrenergic receptor 
increases agonist-mediated inhibition of adenylate cyclase [346]. The proteolytic 
processing of the amyloid precursor protein gene family members APLP1 and APLP2 
involves α, β, γ, and ε-like cleavages; APLP1 processing is modulated by n-
glycosylation [347]. 
The human amyloid precursor-like protein 2 (APLP2) is a a highly conserved single-
pass type I membrane protein. APLP2 may interact with cellular G-protein signaling 
pathways. The intracellular domains of APLP2 interact with the CP2 transcription 
factor in the nucleus and induce glycogen synthase kinase 3β expression [348, 349].  
It has been shown that APP/APLP2-deficient mice die shortly after birth [350]. 
APLP2(-/-)/APLP1(-/-) and APLP2(-/-)/APP(-/-) mice died at an early postnatal stage. 
Surprisingly, APLP1(-/-)/APP(-/-) mice were viable, apparently normal, and showed 
no compensatory upregulation of APLP2 expression. These data indicate a key 
physiological role for APLP2. This view gains further support by the observation that 
APLP1(-/-)/APP(-/-)/APLP2(+/-) mice died early postnatally. However, none of the 
lethal double mutants displayed obvious histopathological abnormalities in the brain 
or any other organ examined. Moreover, cortical neurons from single or combined 
mutant mice showed unaltered survival rates under basal culture conditions and 
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unaltered susceptibility to glutamate excitotoxicity in vitro [193] .  
As a consequence of an increased Aβ42/Aβ40 ratio I found APLP2 significantly (n=3, 
p=0.0179, fold change=1.6) up-regulated, whereas APLP1 was not differentially 
expressed. There is in vivo evidence for increased immunoreactivities of the nuclear 
C-terminal fragments of APLP2 in the brains of AD patients [348]. 
In contrast to this APLP1 was significantly (n=3, p=0.0188, fold change=1.7) up-
regulated as a result of a decreased Aβ42/Aβ40 ratio, whereas APLP2 was not 
differentially expressed. APP was not differentially expressed in either of the mutants 
(compared to C99WT). 
I speculate that upregulation of APLP2 as a consequence of an increased Aβ42/Aβ40 
ratio could either be a putative physiological function of Aβ42 or a survival signal of 
the cells, which are stressed by Aβ42. Furthermore, it can be argued that APLP2 up-
regulation is a counter-reaction of the cell to protect itself from toxic Aβ42. APLP2 has 
been reported to be involved in apoptosis [351]. 
Further characterisation of the promoters of APLP2/APLP1 is necessary to address 
the question of whether Aβ42/Aβ40 directly bind to their promoters (even if only small 
intracellular amounts of Aβ are expected to be available) or if APLP2/APLP1 
expression is triggered via further factors. Glypican 3 was among the genes with 
smallest p-values and so it was significantly down-regulated as a result of a 
decreased Aβ42/Aβ40 ratio. Colocalisation in perinuclear compartments of 
neuroblastoma cells of APLPs and glypicans has been shown [352], so it can be 
speculated that there is a functional relationship between the up-regulated APLP1 
(for Aβ42/Aβ40↓) and the down-regulated cell adhesion molecule glypican 3. Further 
functional interaction partners for APLP1/APLP2 may be the following cell adhesion 
molecules, which were found to be dysregulated in consequence of a changed 
Aβ42/Aβ40 ratio: integrin beta 5, tetraspanin 7, neural cell adhesion molecule 1,  neural 
cell adhesion molecule 2, CD99 antigen, catenin alpha 2, reelin, microfibrillar-
associated protein 4, neurofascin, L1 cell adhesion molecule and neuronal cell 
adhesion molecule. 
6.16 APLP1/APLP2 co-regulated genes 
Genes coding for catenin α 2, NCAM1, ACTN1, Rho GTPase activating protein 26 
and KIAA1102 were found to be co-regulated with APLP1 and APLP2. Since these 
genes were found to be co-regulated with both APP-like genes, a functional 
relationship can be assumed between APP-like genes and these five genes. 
Furthermore, it can be assumed to not be by chance that actinin alpha 1 (ACTN1, 
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chr14q24) is localized on the same chromosomal locus as presenilin 1 (chr14q24). 
There might be a feedback mechanism between presenilin 1 and actinin alpha 1, 
possibly via processing of APLPs/APP or another kind of regulation. 
6.17 Axonal outgrowth, synaptogenesis, neurotransmitter 
release 
Axonal outgrowth, synaptogenesis and neurotransmitter release have been shown to 
be affected in AD [353-355].  
L1CAM (synonym: L1) was found to be up-regulated (Aβ42/Aβ40↓). L1CAM is a cell 
adhesion molecule which plays an important role in nervous system development, 
including neuronal migration and differentiation. L1CAM is involved in neuron-neuron 
adhesion, neurite fasciculation, outgrowth of neurites, etc.. It binds to axonin on 
neurons. Mutations in the gene cause three X-linked neurological syndromes known 
by the acronym CRASH (corpus callosum hypoplasia, retardation, aphasia, spastic 
paraplegia and hydrocephalus). Defects in hydrocephalus due to stenosis of the 
aqueduct of sylvius  are characterized by mental retardation and enlarged brain 
ventricles. Kenwrick et al. reviewed the various functions of L1CAM, including 
guidance of neurite outgrowth in development, neuronal cell migration, axon 
bundling, synaptogenesis, myelination, neuronal cell survival, and long-term 
potentiation [356]. On differentiated neurons L1 is found at regions of contact 
between neighbouring axons and on the growth cones, the structures at the leading 
tip of axons that are responsible for sensing extracellular growth and guidance cues. 
This distribution supports the suggestion from in vitro studies that L1 adhesive inter-
actions may mediate axon bundling (fasciculation) and that L1 acts as a growth cone 
receptor for signals that induce the extension of processes (neurites) from neurons in 
culture.  
Neuronal cell adhesion molecule (NRCAM) was up-regulated (Aβ42/Aβ40↓). This 
ankyrin-binding protein is involved in neuron-neuron adhesion and promotes 
directional signaling during axonal cone growth. This gene is also expressed in non-
neural tissues and may play a general role in cell-cell communication via signaling 
from its intracellular domain to the actin cytoskeleton during directional cell migration. 
Allelic variants of this gene have been associated with autism and vulnerability to 
addiction. 
Contactin 3 (CNTN3) was up-regulated in mutant C99I45F (Aβ42/Aβ40↑) and in 
parallel downregulated in mutant C99V50F (Aβ42/Aβ40↓). Contactins mediate cell 
surface interactions during nervous system development. CNTN3 is assumed to 
have neurite outgrowth-promoting activity. 
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Semaphorin 3C (SEMA3C) was up-regulated (Aβ42/Aβ40↑, p=0.0106, fold 
change=1.9), but not differentially expressed when the Aβ42/Aβ40 was decreased. 
Semaphorins, constitute a family characterized by the presence of a conserved 
semaphorin domain at the N-terminus. SEMA3C may be involved in diverse cell 
survival mechanisms. All glioma cell lines are reported to express SEMA3A and 
SEMA3C and exhibit SEMA3A binding sites. 
SEMA3A was up-regulated, which was confirmed by another probe-set (Aβ42/Aβ40↓, 
p=0.025, fold change=4.0), but not differentially expressed when the Aβ42/Aβ40 was 
increased. Intriguingly, we (together with our colleague Laura Busia) also found 
SEMA3A to be among the most strongly and significantly up-regulated genes in 
embryonic mouse fibroblasts in consequence of PS1 and PS2 knockdown with 
siRNA. In this approach Aβ levels were expected to be decreased. This is in line with 
the observation of SEMA3A upregulation in mutant C99V50F compared to C99WT 
(Aβ42/Aβ40↓) and argues for an effect mediated by decreased Aβ42. 
The SEMA3A gene is a member of the semaphorin family and encodes a protein with 
an Ig-like C2-type (immunoglobulin-like) domain, a PSI domain and a sema domain. 
It is a secreted protein which can function as a chemoattractive agent, stimulating the 
growth of apical dendrites. The protein is vital for normal neuronal pattern 
development. Associations with Alzheimer's disease have been found [357]. 
SEMA3A could serve as a ligand that guides specific growth cones by a motility-
inhibiting mechanism, it binds to the complex neuropilin-1/plexin-1. Polleux et al. 
demonstrated that the growth of apical dendrites toward the pial surface is regulated 
by a diffusible chemoattractant present at high levels near the marginal zone. A 
major component of this signal was SEMA3A. Soluble guanylate cyclase is 
asymmetrically localized to the developing apical dendrite, and is required for the 
chemoattractive effect of SEMA3A. Thus, the asymmetric localization of soluble 
guanylate cyclase confers distinct SEMA3A responses to axons and dendrites. 
Polleux et al. concluded that these observations reveal a mechanism by which a 
single chemotropic signal can pattern both axons and dendrites during development 
[358]. Loss of neuropilin function increases the number of interneurons that migrate 
into the striatum. Marin et al. concluded that their observations reveal a mechanism 
by which neuropilins (semophorin-neuropilin interaction were studied) mediate 
sorting of distinct neuronal populations into different brain structures, and provide 
evidence that, in addition to guiding axons, these receptors also control neuronal 
migration in the central nervous system [359].  
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Growth associated protein 43 (GAP43) has been termed a 'growth' or 'plasticity' 
protein because it is expressed at high levels in neuronal growth cones during 
development and axonal regeneration. GAP43 is considered to be a crucial 
component of an effective regenerative response in the nervous system. GAP43 
binds calmodulin with a greater affinity in the absence of Ca2+ than in its presence. 
Aberrant GAP43 gene expression in Alzheimer's disease has been observed [360]. 
Nuclear receptor subfamily 2, group F, member 1 (NR2F1) was not differentially 
expressed (for Aβ42/Aβ40↑), but up-regulated when the Aβ42/Aβ40 was decreased 
(p=0.064, fold change=1.4). NR2F1, a transcription factor, is an orphan member of 
the nuclear receptor superfamily. It is an important regulator of neurogenesis, cellular 
differentiation and cell migration. NR2F1 is required for proper axonal growth and 
guidance of all major forebrain commissures. Moreover, hippocampal neurons 
lacking NR2F1 have a defect in neurite outgrowth and show an abnormal axonal 
morphology [359] . 
Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1 
(PTN) was not differentially expressed (insignificantly down-regulated, Aβ42/Aβ40↑, 
p=0.69, fold change=-1.2 ), but up-regulated when the Aβ42/Aβ40 ratio was decreased, 
p=0.152, fold change=1.6). PTN is a heparin binding mitogenic protein. It has neurite 
extension activity. PTN is a member of a highly conserved human gene family of 
proteins. It exhibits neurite outgrowth-promoting activity and may play a role in 
nervous tissue development and/or maintenance. Expression of this factor is 
developmentally regulated, increasing in the brain during embryogenesis and 
reaching its maximum expression at the time of birth. In a spinal cord explant system, 
PTN caused increased outgrowth of spinal motor axons and protected spinal motor 
neurons against chronic excitotoxic injury. In neonatal mice, PTN protected facial 
motor neurons against cell death induced by deprivation of growth factors. In adult 
rats, PTN enhanced regeneration of myelinated axons across a graft in transected 
sciatic nerve. Pleiotrophin is a neurotrophic factor for spinal motor neurons [361]. 
HGF was down-regulated (Aβ42/Aβ40↑, p=0.157, fold change=-3.0), but not 
differentially expressed when the Aβ42/Aβ40 was decreased. Two further probe-sets 
confirmed the downregulation, however, with p-values >0.05. 
HGF induces signal transduction through the receptor tyrosine kinase c-Met [362]. It 
activates the urokinase-type plasminogen activator promoter (PLAU) [363] and thus 
accelerates fibrinolysis. Gene transfer of the HGF gene into rat brains improved 
learning and memory in the chronic stage of cerebral infarction; 
immunohistochemical analysis for Cdc42 and synaptophysin in the peri-infarct region 
revealed that HGF enhanced the neurite extension and increased the number of  
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synapses. These data demonstrated that HGF has a pivotal role for the functional 
recovery after cerebral infarction through neuritogenesis and improved 
microcirculation [364]. HGF antagonizes TGF-β1 by stabilizing SMAD transcriptional 
co-repressor TGIF [365]. Human platelets express the HGF receptor (the tyrosine 
kinase encoded by the c-MET gene). At physiological concentrations HGF was found 
to inhibit both glycoprotein α2β3 activation and thrombin-dependent platelet 
aggregation in a dose and time-dependent manner. These results suggest that 
circulating HGF may counteract thrombogenesis by negatively modulating platelet 
functions [322]. Exogenous HGF promoted a highly significant increase in dendritic 
growth and branching of layer 2 pyramidal neurons, whereas deactivation of 
endogenous HGF with function-blocking anti-HGF antibodies caused a marked 
reduction in size and complexity of the dendritic arbors of these neurons. 
Furthermore, pyramidal neurons transfected with an MET dominant-negative mutant 
receptor likewise had much smaller and less complex dendritic arbors than control 
transfected neurons did. These results indicate that HGF plays a role in regulating 
dendritic morphology in the developing cerebral cortex [366]. Expression of c-Met in 
developing rat hippocampus provided evidence for HGF as a neurotrophic factor for 
calbindin D-expressing neurons [367]. It is known that HGF induces in vitro 
expression of vascular endothelial growth factor (VEGF), a key agonist of tumor 
angiogenesis; by contrast, thrombospondin 1 (TSP-1) is a negative regulator of 
angiogenesis. It was shown that, in the very same tumor cells, in addition to inducing 
VEGF expression, HGF down-regulated TSP-1 expression.  
Amyloid beta (A4) precursor-like protein 1 (APLP1) was not differentially expressed 
(for Aβ42/Aβ40↑) but was up-regulated when the Aβ42/Aβ40 was decreased (p=0.0188, 
fold change=1.7). Accumulation of APLP2 and reduction of APLP1 in retinoic acid-
differentiated human neuroblastoma cells has been observed upon curcumin-induced 
neurite retraction [368]. 
Ectodermal-neural cortex (with BTB-like domain) (ENC1) was up-regulated both 
when the Aβ42/Aβ40 ratio was increased (p=0.0079, fold change=2.2) and when the 
Aβ42/Aβ40 ratio was decreased (p=0.0089, fold change=1.7). Kim et al. showed that 
expression of ENC1 induced neuronal process formation, whereas antisense 
treatment inhibited neurite development. Immunoblot analysis showed that ENC1 is a 
nuclear matrix protein and can be phosphorylated and binds to the functionally active 
hypophosphorylated form of the nuclear matrix protein RB1 during neuronal 
differentiation [369]. The fact that ENC1 was up-regulated in consequence of an 
increased Aβ42/Aβ40 ratio as well as a decreased Aβ42/Aβ40 ratio hints at it not being a 
good candidate gene for axonal outgrowth due to a changed Aβ42/Aβ40 ratio.  
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SERPINE2 (synonyms: glial-derived neurite promoting factor p, nexin plasminogen 
activator inhibitor type 1, protease nexin I (PN1), protease inhibitor 7), previously 
mentioned in this thesis as being involved in blood coagulation, was down-regulated 
(Aβ42/Aβ40↑, p=0,174 fold change=-2.3), but not differentially expressed when the 
Aβ42/Aβ40 was decreased. SERPINE2 is highly expressed and developmentally 
regulated in the nervous system where it is concentrated at neuromuscular junctions 
and central synapses in the hippocampus and striatum. Approximately 10% of 
identified proteins at mammalian neuromuscular junctions are, like SERPINE2, 
serine protease inhibitors, consistent with their central role in balancing serine 
protease activity to develop, maintain, and remodel synapses.  
TIMP1, previously described as an collagenase inhibitor, was down-regulated 
(Aβ42/Aβ40↑, p=0.127, fold change=-3.5), but not differentially expressed when the 
Aβ42/Aβ40 ratio was decreased. This gene is located within intron 6 of the synapsin I 
gene and is transcribed in the opposite direction. TIMP1 is mentioned here, because 
of its location within an intron of the synapsin I gene. So there might be a functional 
relationship between synaptogenesis/neurotransmitter release (mediated by 
synapsins) and inhibition of metalloproteases (function of TIMPs). 
SynapsinI (SYN1) could only be found to be significantly down-regulated for the 
comparison C99WT/mock (p=0.00194, fold change= -3.0), but it was not differentially 
expressed when both mutants were compared to the wildtype (C99I45F/C99WT and 
C99V50F/C99WT). This argues, in contrast to the results obtained for synapsinII, for 
an effect mediated by C99 rather than by Aβ42 or Aβ40.  
SynapsinII was among the most inversely regulated genes by an altered Aβ42/Aβ40 
ratio: Aβ42/Aβ40↑, p=0.072, fold change=1,3 ; Aβ42/Aβ40↓, p=0.102, fold change=-1,3. 
These data demonstrated that SynapsinII (SYN2) was regulated by Aβ42/Aβ40. 
Synapsins encode neuronal phosphoproteins which associate with the cytoplasmic 
surface of synaptic vesicles. They are implicated in synaptogenesis and the 
modulation of neurotransmitter release, suggesting a potential role in several 
neuropsychiatric diseases. The synapsins are a family of 4 synaptic vesicle-
associated proteins, synapsins Ia, Ib, IIa, and IIb that have been implicated in 
modulation of neurotransmitter release and in synaptogenesis [370]. They are 
products from alternative splicing of 2 distinct genes, SYN1 and SYN2. SYN2 
encodes a neuron-specific phosphoprotein that selectively binds to small synaptic 
vesicles in the presynaptic nerve terminal. The TIMP4 gene is located within an 
intron of this gene and is transcribed in the opposite direction. Mutations in this gene 
may be associated with abnormal presynaptic function and schizophrenia. Alternative 
splicing of this gene results in two transcripts. SYN2 coats synaptic vesicles, binds to 
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the cytoskeleton, and is believed to function in the regulation of neurotransmitter 
release. Mirnics et al. found that transcripts encoding proteins involved in the 
regulation of presynaptic function were decreased in all subjects with schizophrenia 
[371]. Predicted functional partners (predicted by computational calculations) of 
SYN2 are: TIMP2, 3 and 4. Using a cDNA microarray representing 6794 distinct 
human genes, Ho et al. identified candidate genes whose expression is altered in 
cerebral cortex of cases of early AD; among these was the synaptic vesicle protein 
SYN2, which plays an important role in neurotransmitter release. A selective 
decrease in the expression of the SYN2 splice variants I-III of the a-type isoform was 
found in the entorhinal but not visual cortex characterized by the earliest clinically 
detectable stage of AD. In contrast, Ho et al. found no changes in synapsin splice 
variant II of the b-type isoform. Alteration of synapsin expression at the earliest 
clinical stage of AD may suggest new strategies for improved treatment [372]. 
SLIT1, a human homolog of the Drosophila SLIT gene, encodes a secreted protein, 
which contains conserved protein-protein interaction domains including leucine-rich 
repeats and epidermal growth factor-like motifs. Slit proteins have been shown to 
regulate axon guidance, branching, and neural migration. It was reported that SLIT1 
regulates dendritic development. Slit1 is expressed in the developing cortex, and 
exposure to SLIT1 leads to increased dendritic growth and branching. Conversely, 
inhibition of Slit-Robo interactions (Slit is the ligand and Robo the corresponding 
receptor) by a dominant-negative Robo attenuates dendritic branching. Stimulation of 
neurons transfected with a Met-Robo chimeric receptor with Hepatocyte growth 
factor leads to a robust induction of dendritic growth and branching, suggesting that 
Robo-mediated signaling is sufficient to induce dendritic remodeling. These 
experiments indicated that Slit-Robo interactions may exert a significant influence 
over the specification of cortical neuron morphology by regulating both axon 
guidance and dendritic patterning [373]. SLIT1 was found to be up-regulated for a 
decreased Aβ42/Aβ40 ratio, but not for an increased one.  
In summary, these data strongly indicate inhibited axonal outgrowth in consequence 
of an increased Aβ42/Aβ40 ratio, but a strong tendency to enhanced axonal outgrowth 
in consequence of a decreased Aβ42/Aβ40 ratio. Furthermore, there are signs of 
reduced  dendritic sprouting and synaptogenesis (Aβ42/Aβ40↑) in contrast to promoted 
dendritic sprouting and synaptogenesis for a decreased Aβ42/Aβ40 ratio. The genomic 
localisation of TIMP genes within introns of synapsin genes and its  transcription in 
the opposite direction is interesting. This mechanism may turn out to be crucial, 
because TIMP and synapsin genes belong to the most differentially expressed genes 
in this thesis. 
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6.18 Axonal transport 
Axonal transport has been shown to be affected in AD (reviewed in [374]). 
Dynein cytoplasmic light intermediate polypeptide 2 (DNCLI2) was down-regulated 
(Aβ42/Aβ40↑, p=0.0066, fold change=-1.5). The corresponding protein (DNCLI2) was 
also found to be among the 20 most down-regulated proteins in blind samples 
(proteomic approach: 2D-gel with subsequent mass spectrometry). DNCI2 was not 
differentially expressed when the Aβ42/Aβ40 was decreased. It may play a role in 
regulating interactions between dynein and p150-glued, and the cellular substrates 
for dynein-mediated motility (such as organelles). Downregulation of DNCI2 could 
explain the “clogging phenomenon” in axons, due to aggravated retrograde cargo 
transport. 
Dynein cytoplasmic intermediate polypeptide 1 (DNCI1) was up-regulated 
(Aβ42/Aβ40↑, p=0.0111, fold change=1.8), but not differentially expressed when the 
Aβ42/Aβ40 was decreased. The intermediate chains seem to help dynein bind to the 
dynactin 150 kDa component. It may play a role in mediating the interaction of 
cytoplasmic dynein with membranous organelles and kinetochores. There is 
experimental evidence for an association between DNCI1 and internexin neuronal 
intermediate filament protein, alpha (INA) [375]. INA was found to be among the 20 
most up-regulated and significant (p<0.05) transcripts and proteins (Aβ42/Aβ40↑, 
C99I45F/C99WT) but also when the Aβ42/Aβ40 ratio was decreased 
(C99V50F/C99WT). 
The following kinesin family members were up-regulated (Aβ42/Aβ40↑), but not 
differentially expressed when the Aβ42/Aβ40 was decreased. Kinesin family member 
1A (KIF1A) (p=0.15, fold change=2.2), KIF21A (p=0.074, fold change=1.8), KIF5c 
(p=0.01, fold change=1.7), KIF1B (p=0.0371, fold change=1.6). In contrast to this 
Kinesin 2 (KNS2, 60/70kDa) was not differentially expressed (Aβ42/Aβ40↑), but weakly 
and significantly up-regulated (p=0.027, fold change=1.3) when the Aβ42/Aβ40 was 
decreased. KIF1A is an anterograde motor protein that transports membranous 
organelles along axonal microtubules. Its cargo includes a subset of precursors for 
synaptic vesicles: synaptophysin, synaptotagmin, and Rab3A. The phenotype of 
KIF1A knockout mice includes motor and sensory disturbances, a reduction in the 
density of synaptic vesicles in nerve terminals, and accumulation of vesicles in nerve 
cell bodies [376]. It can be hypothesized that KIF1A may play a critical role in the 
development of axonal neuropathies resulting from impaired axonal transport. 
Kinesin family member 21A (KIF21A). It was demonstrated that mouse KIF21A 
bound strongly to microtubules in the presence of a nonhydrolyzable ATP analog. 
They found that KIF21A accumulated on the proximal side of a sciatic nerve ligation, 
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consistent with KIF21A being a plus end-directed motor protein. Nangaku et al. found 
that mouse KIF1B works as a monomer, having a microtubule plus-end-directed 
motility. Immunocytochemically, KIF1B was colocalized with mitochondria in vivo. A 
subcellular fractionation study showed that KIF1B was concentrated in the 
mitochondrial fraction, and purified KIF1B could transport mitochondria along 
microtubules in vitro. These data suggested that KIF1B works as a monomeric motor 
for anterograde transport of mitochondria. KIF1B up-regulation may be a counter-
regulation ot the cells (due to possible reduced energy in consequence of an 
increased Aβ42/Aβ40 ratio), with the goal of providing more ATP to regions where 
energy is needed. ATP might be involved, which is also suggested by the previously 
discussed KIF21A, which binds strongly to microtubules in the presence of a 
nonhydrolyzable ATP analog [377]. 
Weak upregulation of Kinesin 2 (synonyms: KLC, KLC1, KNS2A) could be 
interpreted as an augmented anterograd axonal transport, in consequence of a 
decreased Aβ42/Aβ40 ratio. 
Prolyl endopeptidase (PREP) was found to be up-regulated on the transcript level 
and on the protein level for Aβ42/Aβ40↑ but not for Aβ42/Aβ40↓. Immunocytochemical 
double-labelling procedures and localization of PREP-enhanced green fluorescent 
protein fusion proteins showed that PREP is mainly localized to the perinuclear 
space, and is associated with the microtubulin cytoskeleton in human neuroblastoma 
and glioma cell lines. Disassembly of the microtubules by nocodazole treatment 
disrupts both the fibrillar tubulin and PREP labelling. Furthermore, in a two-hybrid 
screen, PREP was identified as binding partner of tubulin [293]. These findings 
indicate novel functions for PREP in axonal transport and/or protein secretion. 
Vesicular membrane protein p24 (VMP) was the second most significantly up-
regulated gene (for Aβ42/Aβ40↑, p=0.0055, fold change=2.8), but no differential 
expression was observed for Aβ42/Aβ40↓. VMP contains two putative membrane 
spanning domains and a hydrophilic tail homologous to the microtubule-binding 
domain of MAPs. So it can be speculated that VMP may be associated with 
microtubules through its C-terminus and may play an important role in vesicular 
organelles transport and nerve signals. 
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6.19 Oxidative stress is expected to be increased by up-
regulation of the mitochondrial respiratory chain in 
consequence of an increased Aβ42/Aβ40 ratio  
Accumulation of reactive oxygen species (ROS) results in damage to major 
components of cells: nucleus, mitochondrial DNA, membranes, and cytoplasmic 
proteins. The imbalance between the generation of free radicals and ROS may be 
involved in the pathogenesis of most of the neurodegenerative disorders, including 
AD, as suggested by many authors for many years. The fact that age is a key risk 
factor in AD provides considerable support for the “free radical hypothesis” because 
effects of the attacks by free radicals, particularly those produced by ROS, can 
accumulate over the years [378]. 
The respiratory chain is influenced by a changed Aβ42/Aβ40 ratio. NDUFB9 (NADH 
dehydrogenase (ubiquinone) 1 beta subcomplex) was 1.3 fold up-regulated (p=0.063, 
for Aβ42/Aβ40↑) and in parallel  2.3 fold down-regulated (p=0.132, for Aβ42/Aβ40↓). 
NDUFB9 transfers electrons from NADH to the respiratory chain. The immediate 
electron acceptor for the enzyme is believed to be ubiquinone. NDUFB9 is localized 
in the inner mitochondrial membrane on the matrix side. It transfers electrons to the 
following reaction: NADH + ubiquinone = NAD+ + ubiquinol. 
SDHAL2 (Succinate dehydrogenase complex, subunit A, flavoprotein-like 2, localized 
on chr3q29) was not differentially expressed (for Aβ42/Aβ40↑) but 3.2 fold down-
regulated (p=0.04742, for Aβ42/Aβ40↓). This regulations might reflect a response of 
the cells to reduced ATP levels for Aβ42/Aβ40↑ and sufficient ATP levels for 
Aβ42/Aβ40↓. ADAM11 (a disintegrin and metalloproteinase domain 11) was exactly 
co-regulated (not differentially expressed for Aβ42/Aβ40↑, but down-regulated for 
Aβ42/Aβ40↓, p=0.04742, fold change=-3.2) with SDHAL2. Moreover, ADAM11 is 
located on the same chromosomal locus as tau (chr17q21.3), thus it can be 
speculated that there is a functional relationship between the respiratory chain (ATP-
levels respectively), metalloproteases and tau. Another functional relationship can be 
assumed for the dysregulated transferrin receptor (p90, CD71), localized on the 
same locus as SDHAL2 (chr3q29). The transferrin receptor was not differentially 
expressed (for Aβ42/Aβ40↑) but 1,4  fold down-regulated for Aβ42/Aβ40↓ (p=0.0361). 
Due to the same tendency of regulation on the same chromosomal locus a 
“Chromeron regulation” is probable. Cellular uptake of iron occurs via receptor-
mediated endocytosis of ligand-occupied transferrin receptors into specialized 
endosomes and endosomal acidification leads to iron release. The transferrin 
receptor is required for iron delivery from transferrin to cells. There is a bidirectional 
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relationship between iron metabolism and type 2 diabetes: Iron affects glucose 
metabolism and glucose metabolism influences several iron metabolic pathways. 
Both insulin sensitivity and glucose tolerance are closely associated with serum 
transferrin receptor concentrations [379]. Furthermore, transferrin binds insulin-like 
growth factors and affects binding properties of insulin-like growth factor binding 
protein 3 [380]. 
The above proposed ATP-dependent regulation of components of the respiratory 
chain is supported by the observation of upregulation of UQCRFS1 (ubiquinol-
cytochrome c reductase, Rieske iron-sulfur polypeptide 1, localized at the 
mitochondrial inner membrane) for Aβ42/Aβ40↑, but the lack of differential expression 
for Aβ42/Aβ40↓ (detected by PANTHER analysis in which the 50 most up-regulated 
genes were integrated with a p value <0.05). 
The hypothetical protein FLJ10094 shows strong similarity to hydroquinone (NADH) 
oxidase. Hydroquinone (NADH) oxidase is assumed to be localized at the plasma 
membrane. It probably acts as a terminal oxidase of electron transport from cytosolic 
NAD(P)H via hydroquinones to acceptors at the cell surface. FLJ10094 was up-
regulated for Aβ42/Aβ40↑ (p=0.073, fold change=1.3) and down-regulated for 
Aβ42/Aβ40↓ (p=0.111, fold change=-1.4). 
Taken together, the results indicate an upregulation of the respiratory chain for 
Aβ42/Aβ40↑, but a downregulation for Aβ42/Aβ40↓, which might reflect the attempt of 
the cells to restore sufficient ATP-levels for Aβ42/Aβ40↑. This may be inherently 
connected with increased oxidative stress by the release of reactive oxygen species 
(ROS) like the superoxide radical ( .O2-), the peroxide anion (O22-) or the hydroxy 
radical (.OH). Hydrogen peroxide levels were found to be significantly increased in 
Tg2576 mice when compared with age-matched WT littermates and directly 
correlated with levels of soluble Aβ in Tg2576 mice, suggesting that soluble Aβ may 
be responsible for the production of hydrogen peroxide in AD progression in Tg2576 
mice [381]. In parallel to this, the superoxide dismutase 1 (SOD1) was up-regulated 
for Aβ42/Aβ40↑ (shown by immuno blot, n=1). Intracellular copper levels might be 
decreased (extracellular copper levels could be increased, depending at least in part 
on basal extracellular copper levels) because the copper-transporting ATP7A 
(exports copper from the cells) was increased for Aβ42/Aβ40↑ (p=0.0222, fold 
change=1.5) and decreased for Aβ42/Aβ40↓ (p=0.0621, fold change=-2.0). The driving 
force for these regulatory processes might be low ATP-levels caused by an 
increased Aβ42/Aβ40 ratio.  
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6.20 Strong dysregulation of cytochromes by a changed 
Aβ42/Aβ40 ratio 
The cytochrome b-245, alpha polypeptide (Cyba, synonyms: Nox2, superoxide-
generating NADPH oxidase light chain subunit ) is an essential component of 
NADPH-oxidase (for instance in phagocytes), a membrane-bound enzyme complex 
that generates large quantities of microbicidal superoxide and other oxidants upon 
activation. NADPH oxidase of phagocytic cells is important for the efficient killing and 
digestion of ingested microbes. Cyba is a flavocytochrome containing FAD and the 
NADPH-binding site of the microbicidal oxidase of phagocytes [382]. Cyba was found 
in the plasma membrane, cytosol and granules of neutrophil granulocytes [383, 384], 
but was also suggested to be located in other intracellular structures [385]. 
Jackson et al. reported that activated mouse T-cells deficient in Cyba showed 
enhanced activation of ERK and MEK and diminished expression of phagocyte-type 
NADPH oxidase and that T cell receptor stimulation induces rapid generation of 
reactive oxygen species by an yet unclear mechanism [386].  
The cytochrome b-245, alpha polypeptide was among the most significantly down-
regulated (p=0.00028, fold change=-2.5) genes for Aβ42/Aβ40↑ but was not 
differentially expressed for Aβ42/Aβ40↓. Interestingly the expression (detected on the 
transcript level by microarray analysis and on the protein level by a proteomics 
approach) of the T-cell receptor alpha and delta locus was significantly up-regulated 
in consequence of both increased and decreased Aβ42/Aβ40 ratios. MEK1 and ERK1 
were more strongly phosphorylated in response to an increased Aβ42/Aβ40 ratio 
(compared to a decreased ratio) and thus most probably activated (described 
elsewhere in this thesis). This underlines the observation of Jackson et al. of a 
relationship between T-cells (or T-cell receptors), Cyba and ERK/MEK. 
Cyba downregulation for Aβ42/Aβ40↑ might be a secondary effect of increased Aβ42. I 
suggest that in our approach, Aβ42 overexpression triggers oxidative stress (for 
instance via upregulation of the mitochondrial respiratory chain, discussed in the 
previous Chapter). The cells may counter-regulate this by downregulating the 
superoxide-generating Cyba, so that superoxide radicals do not rise too extremely. 
Cyp561 (cytochrome b561) is a functional ferric reductase presumed to be regulated 
by iron [387]. It is a major transmembrane protein that is found in catecholamine and 
neuropeptide secretory vesicles of the adrenal medulla, pituitary gland, and other 
neuroendocrine tissues. This cytochrome is present in both the small synaptic 
vesicles and the large dense core vesicles (chromaffin granules) of the tissues. Its 
role is to supply reducing equivalents to 2 monooxygenases, dopamine beta-
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hydroxylase in chromaffin granules and monooxygenases in neurosecretory vesicles.  
Cyp561 was among the most significantly down-regulated (p=0.00129, fold change=-
2.8) genes for Aβ42/Aβ40↑ and validated by 4 different probe sets on the microarray, 
but it was not differentially expressed for Aβ42/Aβ40↓. Interestingly, the expression of 
MAOA (monoamine oxidase A) was strongly down-regulated for the comparison 
C99WT1/mock (p=0.02572, fold change=-4.0) and validated by three different probe 
sets on the microarray. In contrast to this MAOA was not found differentially 
expressed for Aβ42/Aβ40↑ and Aβ42/Aβ40↓. Since Cyp561 is a functional ferric 
reductase and down-regulated in consequence of an increased Aβ42/Aβ40 ratio, I 
assume that the reduction of Fe3+ to Fe2+ may be impaired. This could lead to 
abnormal Fe3+ accumulation. Basal ganglia ferritin is increased in AD. Similarly in 
Parkinson’s disease patients’ iron is increased by approximately 35% in the 
substantia nigra, mainly due to a rise in insoluble Fe[III] rather than soluble Fe[II] iron 
[388]. Iron Fe[II] is necessary for the conversion of norepinephrine (noradrenaline) 
into dopamine and serves as a cofactor of tyrosine hydroxylase, thus increasing of 
Fe[III] at the expense of Fe[II] may result in reduced dopamine levels. This is 
supported by the observation of decreased dopa decarboxylase (DDC) levels in 
response to an increased Aβ42/Aβ40 level. Fe3+ induces the deposition of "fibrillar" 
amyloid plaques at neutral pH [389].  
6.21 Enzymes regulating neurotransmitter metabolism were 
strongly affected by a changed Aβ42/Aβ40 ratio on the 
transcriptional level and so might be neurotransmitter 
levels 
Altered Neurotransmitter metabolism has been shown to be involved in AD [390] and 
clinical data hint at changed neurotransmitter levels [391]. Glutamate decarboxylase 
1 (GAD1, brain, 67kDa) was not differentially expressed (for Aβ42/Aβ40↑), but it was 
significantly and strongly up-regulated when the Aβ42/Aβ40 ratio was decreased 
(p=0.0048, fold change=5.0). Interestingly, GAD1 was strongly down-regulated for 
the comparison C99WT/mock (p=0.02572, fold change=-4.0). In conclusion, reduced 
glutamate levels for a decreased Aβ42/Aβ40 ratio can be assumed.  
Glutamate decarboxylase (GAD; L-glutamate-1-carboxylyase; EC 4.1.1.15) catalyzes 
the conversion of glutamate, the major excitatory neurotransmitter, to gamma-
aminobutyric acid (GABA), the major inhibitory neurotransmitter in the vertebral 
central nervous system. The GAD1 gene encodes one of several forms of glutamic 
acid decarboxylase, identified as a major autoantigen in insulin-dependent diabetes. 
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The enzyme encoded is responsible for catalyzing the production of gamma-
aminobutyric acid from L-glutamic acid. A pathogenic role for this enzyme has been 
identified in the human pancreas since it has been identified as an autoantigen and 
an autoreactive T cell target in insulin-dependent diabetes. Alternative splicing of this 
gene results in two products, the predominant 67-kD form and a less-frequent 25-kD 
form. Autoantibodies to insulin and GAD are features of preclinical type 1 diabetes in 
children. For insulin autoantibodies, the antibody affinity and epitope specificity 
predict which children progress to diabetes [392]. 
HMP19 is a D1 dopamine receptor-interacting protein and it was the most up-
regulated gene for the comparison Aβ42/Aβ40↑ (p=0.003, fold change=3.0), however, 
it was also up-regulated when the Aβ42/Aβ40 was decreased (p=0.0139, fold 
change=2.1). 
Dopa decarboxylase (DDC, aromatic L-amino acid decarboxylase) was down-
regulated (Aβ42/Aβ40↑, p=0.00496, fold change=-3.1), but not altered when the 
Aβ42/Aβ40 was decreased. 
DDC catalyzes the decarboxylation of dihydroxyphenylalanine (dopa) to dopamine, 
and hydroxytryptophan to serotonin and tryptophan to tryptamine. Defects in DDC 
are the cause of aadc (aromatic L-amino acid decarboxylase deficiency). Aadc 
deficiency is an inborn error in neurotransmitter metabolism that leads to combined 
serotonin and catecholamine deficiency. It causes developmental and psychomotor 
delay, poor feeding and lethargy. The onset is early in infancy and inheritance is 
autosomal recessive. Dopa decarboxylase (EC 4.1.1.28) is an enzyme implicated in 
2 metabolic pathways, synthesizing 2 important neurotransmitters, dopamine and 
serotonin [393]. Tyrosine is hydroxylated by tyrosine hydroxylase (tyrosine-3-
monooxygenase) to form L-dihydroxyphenylalanine (L-DOPA), which in turn is 
converted into dopamine by DDC. DDC is found in different areas of the brain and is 
particularly abundant in basal ganglia. Dopamine is also produced by DDC in the 
sympathetic nervous system and is the precursor of the catecholaminergic 
hormones, noradrenaline and adrenaline in the adrenal medulla. In the nervous 
system, tryptophan hydroxylase produces 5-OH tryptophan, which is decarboxylated 
by DDC, giving rise to serotonin. DDC is a homodimeric, pyridoxal phosphate-
dependent enzyme.  
Cytochrome b-561 (CYB561, mentioned before in Chapter 6.20) was down-regulated 
(Aβ42/Aβ40↑, p=0.00333, fold change=-2.3). Two spliced isoforms were also among 
the 10 most significantly down-regulated genes (Aβ42/Aβ40↑, CYB561, 209164_s_at: 
p=0.00129, fold change=-2.8 and 210816_s_at, p=0.00018, fold change=-4.8; data 
normalized with the GC-RMA algorithm). Data normalized with the PLIER algorithm 
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resulted in similar results and revealed that these most down-regulated (Aβ42/Aβ40↑) 
transcripts, where in parallel among the most up-regulated ones for the comparison 
Aβ42/Aβ40↓. The fact that CYB561 and two of its spliced isoforms were regulated in 
the same way, moreover, were among the most inversely regulated genes and 
among the most significant ones, make CYB561 a major candidate for Aβ42 induced 
pathology. 
Cytochrome b561 is a major transmembrane protein that is specific to catecholamine 
and neuropeptide secretory vesicles of the adrenal medulla, pituitary gland, and other 
neuroendocrine tissues. This 30-kDa cytochrome is present in both the small 
synaptic vesicles and the large dense core vesicles (chromaffin granules) of the 
tissues. Its role is to supply reducing equivalents to 2 monooxygenases, dopamine 
beta-hydroxylase (dopamine β monooxygenase, copper-dependent !) in chromaffin 
granules and peptidylglycine monooxygenase in neurosecretory vesicles.  The 
cytochrome fulfillls this role by catalyzing the transfer of electrons from a cytoplasmic 
donor, ascorbate, across a phospholipid bilayer to the luminal acceptor, 
semidehydroascorbate, in the interior of the vesicles. The continuously regenerated 
ascorbate within these vesicles is the immediate donor of the monooxygenases 
within the neuroendocrine secretory vesicles. Thus cytochrome b561 is a 
transmembrane electron channel. B561 is assumed to bind 2 heme groups non-
covalently. 
The gene for RAM2, a transcription factor, was up-regulated (Aβ42/Aβ40↑, p=0.160, 
fold change=1.4) and in parallel among the most downregulated genes according to 
the comparison Aβ42/Aβ40↓, p=0.157, fold change -2.6. 
The transcription factor RAM2 (R1/CDCA7L/JPO2) inhibits the Monoamine oxidase A 
(MAOA) promoter and enzymatic activities. MAOA degrades serotonin, 
norepinephrine, and dopamine and produces reactive oxygen that may cause 
neuronal cell death. Using R1 overexpression, R1 small interfering RNA, and a MAO 
A inhibitor, it was found that R1 and MAOA act upstream of cyclin D1 and E2F1. In 
summary, this study demonstrated the functions of MAOA and its repressor R1 in 
apoptotic signaling pathways [394].  
MAOA was only found to be strongly down-regulated for the comparison 
C99WT/mock (p=0.00017, fold change=-6.5, validated by another probe set: 
p=0.00001, fold change=-6.5, also a spliced isoform, 204388_s_at, revealed similar 
results: p=0.00008, fold change=-7.0, calculated with the GC-RMA algorithm), but 
neither for Aβ42/Aβ40↑ nor for Aβ42/Aβ40↓ MAOA dysregulation was observed. This 
indicates increased serotonin, norepinephrine, and dopamine-levels in consequnce 
of C99-overexpression. This effect may get lost after C99-cleavage, because 
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differential expression of MAOA was observed neither for Aβ42/Aβ40↑ nor for 
Aβ42/Aβ40↓. This, in turn, is a sign of both Aβ42 and Aβ40-overexpression, leading to 
reduced serotonin, norepinephrine, and dopamine-levels (compared to C99-
overexpression) due to the “missing effect” of down-regulated MAOA (C99WT/mock). 
Taken together, I conclude that dopamine, serotonin and  tryptamine-levels might be 
reduced due to DDC downregulation in consequence of an increased Aβ42/Aβ40 ratio, 
but not altered when the Aβ42/Aβ40 was decreased. Furthermore, the data indicate 
that the supply of reducing equivalents to 2 monooxygenases like dopamine β-
hydroxylase is reduced due to downregulation (Aβ42/Aβ40↑) of CYB561, and thus the 
conversion of dopamine to norepinephrine (noradrenaline) might be impaired. 
Reduced noradrenaline levels, apart from reduced serotonin and dopamine levels, 
are well-known for causing mood disorders and may explain the often observed 
symptoms of depression in AD. CYB561 downregulation could be a counter-
regulation of the cells to keep up sufficient dopamine levels while accepting reduced 
noradrenaline levels. 
6.22 Changed glutamine synthase and glutaminase 
expression in response to a changed Aβ42/Aβ40 ratio 
6.22.1 Glutamine synthase was down-regulated exclusively in 
consequence of a decreased Aβ42/Aβ40 ratio and is 
assumed to couple ATP synthesis to neurotransmitter 
levels  
Changed glutamate levels have been claimed to be involved in AD [395, 396] 
presumably accompanied by altered ATP levels [397, 398]. The underlying 
mechanism, however is unclear. Here, an explanation is provided by the changed 
expression of glutamine synthase.  
Glutamine synthase (synonym: Glutamate-ammonia ligase, GLUL) catalyzes an 
energetic coupled reaction8: 
Glutamate + NH3 Æ Glutamine +H20    +14 kJ/mol 
This reaction is coupled to: 
                                            
8 Direct transfer of NH3 to glutamate is endergonic and can therefore only take place coupled to an 
exergonic reaction like ATP hydrolysis. In the cell, the reaction is divided into two exergonic steps: 
First, the γ-phosphate residue is transferred from ATP to glutamate and forms an energy-rich mixed 
acid anhhydride. In the second step the phosphate residue from the intermediate is substituted by 
NH3, and glutamine and free phosphate are produced.  
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ATP+ H20 Æ ADP + P      -31 kJ/mol 
 
This results in the following total reaction: 
Glutamate + NH3 + ATP Æ Glutamine+ ADP + P  -17 kJ/mol 
Since GLUL was down-regulated in consequence of a decreased Aβ42/Aβ40 ratio 
(p=0.01613, fold change=-2.5), whereas an increased Aβ42/Aβ40 ratio did not lead to 
differential expression of glutamine synthase, ATP levels may be assumed to be 
increased in mutant C99V50F (due to the downregulation of glutamine synthase  the 
ATP-consuming reaction is expected to be reduced, so that more ATP may be 
available). In parallel the expected increase in glutamate levels may be limited by up-
regulation (Aβ42/Aβ40↓, p=0.0048, fold change=5.0) of glutamate decarboxylase 1 
(GAD1). 
6.22.2 Glutaminase was up-regulated exclusively in response to an 
increased Aβ42/Aβ40 ratio  
Changed glutamate and ammonia levels are neurotoxic in larger amounts [353, 390]. 
The underlying mechanism for increased levels, however is unclear. Here, an 
explanation is provided by changed expression of glutaminase.  
Glutaminase (GLS) hydrolyzes glutamine by desamination so that glutamate and 
ammonia are generated. GLS was up-regulated (n=0.02589, fold change=1.5) in 
response to an increased Aβ42/Aβ40 ratio, whereas a decreased Aβ42/Aβ40 ratio did 
not lead to differential expression of GLS. Due to GLS upregulation more glutamate 
and NH3 are expected to be produced while GAD1 is not up-regulated (Aβ42/Aβ40↑). 
This may contribute to increased glutamate and NH3 levels (for Aβ42/Aβ40↑). 
However, ammonia levels may be restricted by other metabolic reactions (see 
Chapter 6.23).  
6.23 Two enzymes of the urea cycle were affected by a 
changed Aβ42/Aβ40 ratio: argininosuccinate synthase and 
argininosuccinate lyase 
Argininosuccinate synthase (ASS) converts citrulline (mitochondria) into 
argininosuccinate (cytoplasm) in an ATP consuming step. ASS was up-regulated 
(n=0.0047, fold change=2.6, calculated with the GC-RMA algorithm) in response to 
an increased Aβ42/Aβ40 ratio, whereas a decreased Aβ42/Aβ40 ratio did not lead to 
differential expression of ASS. This might contribute to increased ATP consumption 
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and might reduce total ATP levels in mutant C99I45F (Aβ42/Aβ40 ↑). 
Argininosuccinate lyase (ASL) converts argininosuccinate into arginine and fumarate 
in a non-ATP consuming step. ASL was up-regulated (n=0,06 fold change=1.4, 
calculated with the GC-RMA algorithm) in response to an increased Aβ42/Aβ40 ratio, 
and a decreased Aβ42/Aβ40 ratio led to a 1.8 fold upregulation (n=0.032) of ASL. 
ASS upregulation exclusively in response to an increased Aβ42/Aβ40 ratio might drive 
the following reaction circle in the cytoplasm: argininosuccinate (which may play a 
key role here, because it participates in both ASS and ASL-mediated, reactions) Æ 
fumarate Æ malate Æ oxaloacetate Æ aspartate Æ argininosuccinate. The steps 
malate Æ oxaloacetate Æ aspartate are accompanied by glutamate production (from 
2-oxoglutarate and NH4+) and NH4+ consumption (glutamate is also used for 
aspartate production from oxaloacetate). 
In summary it can be speculated that for an increased Aβ42/Aβ40 ratio, ATP levels 
and NH4+ levels could be reduced and glutamate levels could possibly be increased. 
Maybe this can be interpreted as an ‘attempt’ (via feedback loops) of the cells to 
reduce neurotoxic NH4+ levels.  
6.24 Exocytosis 
Neurotransmission has been reported to be influenced  in AD [399] and impaired 
exocytosis was observed [400]. 
I found syntaxin 3A and its splice product syntaxin 3B to be up-regulated as a result 
of an increased Aβ42/Aβ40 ratio. I conclude that the pre-m-RNA of syntaxin 3 is up-
regulated as a result of an increased Aβ42/Aβ40 ratio. Syntaxin 3, in turn, is spliced 
subsequently to generate syntaxin 3B. In contrast to this a decreased Aβ42/Aβ40 ratio 
led to downregulation of both syntaxin 3A and 3B. I regard this as an important 
regulatory mechanism for several reasons: Out of about 40,000 measured transcripts 
the unspliced form (syntaxin 3A) together with the spliced form (syntaxin 3B) were 
inversely regulated as a result of a changed Aβ42/Aβ40 ratio. The probability that this 
strong inverse regulation of the same gene occurs by chance is extremely low ! 
Moreover, both transcripts (syntaxin 3A and its splice product 3B) were regulated in 
the same direction, to the same extent and belong to those with high absolute values 
(highly abundant transcripts), increasing the reliability of the results. Syntaxins (t-
SNAREs) interact with synaptotagmin and are responsible for membrane fusions of 
transmitter containing vesicles. Synaptotagmin XIII was up-regulated in consequence 
of an increased Aβ42/Aβ40 ratio and could possibly be an interaction partner for 
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syntaxin 3A/B9. I speculate that neurotransmitter release is influenced by 
dysregulation of syntaxin 3A/B. 
6.25 New assignment of a functional relationship between 
neurogenin 2 and KIAA0125 
Neurogenin 2 (Ngn2, synonym: Math4A) and the so far completely uncharacterized 
KIAA0125 were the most extremely and inversely regulated genes when genes were 
hierarchically clustered (see Chapter 5.13, Fig. 5.40, page 107) in consequence of a 
decreased Aβ42/Aβ40 ratio: While KIAA0125 was the most up-regulated gene 
(p=0.00142, fold change=5.3, calculated with the GC-RMA algorithm), Ngn2 was the 
most down-regulated one (p=0.00166, fold change=-12.5, calculated with the GC-
RMA algorithm), (KIAA0125 and Ngn2 were not differentially expressed as a result of 
an increased Aβ42/Aβ40 ratio). This pattern was not only seen for a decreased 
Aβ42/Aβ40 ratio but also for the comparison C99/mock. Interestingly, for this 
comparison the expression was inverted: Ngn2 was the second most up-regulated 
gene, whereas KIAA0125 was strongly down-regulated. Most interestingly, Ngn2 was 
co-expressed with C99 (and neuronatin) as revealed by the comparison C99/mock 
while KIAA0125 was co-regulated with APLP1 (and BCL2) as revealed by the 
comparison C99V50F/C99WT1. This argues for an effect associated with C99 and 
APP like proteins respectively. Ngn2 and KIAA0125 respond inversely to decreased 
Aβ42 and/or increased Aβ40 expression (concluded from the observation that a 
decreased Aβ42/Aβ40 ratio strongly influences their expression), while they do not 
respond to increased Aβ42 and/or decreased Aβ40 expression (concluded from the 
observation that an increased Aβ42/Aβ40 ratio does not influence their expression). It 
may be speculated that there is, due to the close chromosomal vicinity, a relationship 
between KIAA0125 (chr.14q32-33) and presenilin 1 (chr.14q24). Ngn2 is a member 
of the neurogenin subfamily of basic helix-loop-helix (bHLH) transcription factor 
genes that play an important role in neurogenesis. During mouse neurogenesis, 
Ngn2 and Ngn1 are expressed in distinct progenitor populations in the central and 
peripheral nervous systems [401]. Yan et al. observed that in the developing chick 
retina, Ngn2 was expressed in a subpopulation of proliferating progenitor cells [402]. 
Scardigli et al. hypothesized that Ngn2 is both responsive to, and a regulator, of 
                                            
9 Affymetrix uses the gene name for target sequences, so the name of splice products can differ from the gene 
name. Unprecisely named syntaxin 3A (216985_s_at) is a spliced form of syntaxin 3A; its correct name is 
syntaxin 3B. Syntaxin 3B is identical to syntaxin 3A but lacks 37 amino acid residues, from amino acid 226 to 
amino acid 262. Syntaxin 3A has one potential target sequence of phosphorylation by cAMP/cGMP-dependent 
protein kinase in Thr-161 and four potential sites of phosphorylation by proteinkinase C at the residues S124, 
T156, S207, and T250, this last one being absent in syntaxin 3B. Syntaxins are involved in vesicle transport to the 
apical plasma membrane. 
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genetic pathways that specify neuronal fates in the ventral spinal cord [403]. It was 
reported that in the developing ventral mesencephalon the proneural gene 
neurogenin 2 is expressed exclusively in the part of the ventricular zone that gives 
rise to the migrating mesencephalic dopamine neuroblasts, but not in the 
differentiated mesencephalic dopamine neurons. It was shown that Ngn2 is involved 
in the generation of mesencephalic dopamine neurons and that the development of 
mesencephalic dopamine neurons is severely compromised in Ngn2-null mutant 
mice. It was reported that proneural genes have an intricate pattern of expression in 
the ventricular zone of the ventral midbrain, where mesencephalic dopaminergic 
neurons are generated. Neurogenin 2 (Ngn2) and Mash1 are expressed in the 
ventral midline, while Ngn1, Ngn2 and Mash1 are co-localized more laterally in the 
ventricular zone. Ngn2 is also expressed in an intermediate zone, immediately 
adjacent to the ventricular zone at the ventral midline. Ngn2 is required for the 
differentiation of ventricular zone progenitors into postmitotic dopaminergic neuron 
precursors in the intermediate zone. It  was concluded that Ngn2 is required for the 
development of midbrain dopaminergic neurons [404]. Ngn2 was immunohisto-
chemically detected in a certain cycling population during G1 phase and was further 
restricted during G2-M phases to the subventricular zone-directed population. Ngn2 
may further be involved in the asymmetric cell divisions of progenitor cells [405]. 
Furthermore, it has been reported that inhibition of proneural bHLH factors, like 
Ngn2, in cortical progenitors promotes the formation of astrocytes [406].  
I assign the following property/function to KIAA0125: Firstly, that KIAA0125 has a 
functional relationship to Ngn2 (KIAA0125 probably acts as an antagonist of Ngn2), 
secondly that KIAA0125 and Ngn2 are dependent on a decreased Aβ42/Aβ40 ratio, 
C99 or/and APLP1, thirdly that KIAA0125 plays a role in neurogenesis (maybe in 
preventing the generation of dopaminergic neurons or it could be involved in inducing 
astrocytosis). 
6.26 Receptors were strongly differentially affected by a 
changed Aβ42/Aβ40 ratio 
The number of dysregulated receptors was greatly affected for the 50 most up-
regulated transcripts (for Aβ42/Aβ40↑). Many more receptors or subunits thereof (8 
receptors; 8 out of 50 is a high proportion for receptors) were up-regulated as a result 
of an increased Aβ42/Aβ40 ratio compared to a decreased Aβ42/Aβ40 ratio: delta/Notch-
like EGF repeat containing (DNER); gamma-aminobutyric acid (GABA) A receptor, 
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beta 3 (GABRB3); G protein-coupled receptor 64 (GPR64); glutamate receptor, 
ionotropic, AMPA 2 (GRIA2); neurotrophic tyrosine kinase, receptor, type 2 (NTRK2, 
non-catalytic isoform); odd Oz/ten-m homolog 4 (Drosophila) (ODZ4); protease 
serine 12 (neurotrypsin, motopsin) (PRSS12) and protein tyrosine phosphatase, 
receptor type, M (PTPRM). In contrast to this, only 1 receptor, the prostaglandin E 
receptor 2, subtype EP2 (PTGER2) was up-regulated for Aβ42/Aβ40↓.  
The difference between the number of up-regulated receptors (8 for Aβ42/Aβ40 ↑ and 
only 1 for Aβ42/Aβ40↓) was 7. This strong difference indicates a regulatory process on 
the receptor/ligand level. Up-regulation of receptors is often found accompanied by 
low-levels of ligands and vice versa [221]. This is a well-known mechanism of the 
cells to keep up the cells’ homeostasis. However, other mechanisms, like feedback 
loops or cross talk between receptors or pathways may also play a role here. 
Among the 20 most down-regulated genes (Aβ42/Aβ40↑), the only affected receptor 
was integrin β 5 (ITGB5): ITGB5 is a type I membrane protein. It is a heterodimer of 
an α and a β subunit. Subunit β-5 associates with α-v integrin; α-v/β-5 is a receptor 
for fibronectin. This is of interest because fibronectin- associated genes were among 
the most differentially expressed genes and the number of them was much higher 
than could be expected by chance. 
ITGB5 downregulation is in agreement with PKC downregulation (shown on the 
transcript and protein-level), because ITGB5 is known to activate PKC. Taken 
together, ITGB5 is a further component playing in concert with many other molecules 
to down-regulate PKC, and hence contribute to the upregulation of GSK3, since PKC 
is known to inhibit GSK3. 
Among the 20 most down-regulated genes (for Aβ42/Aβ40↓) were:  
The transferrin receptor (p90, CD71) (TFRC), the cholinergic receptor, muscarinic 3 
(CHRM3), (CHRM3 was also found down-regulated for an increased Aβ ratio 
(Aβ42/Aβ40↑) when the stringency of significance was reduced from p<0.05 to 
p<0.075, so downregulation of CHRM3 does not appear to be specific for Aβ42), the 
G protein-coupled receptor 176 (GPR176), the RAR-related orphan receptor B 
(RORB). RA is assumed to be the ligand for RORB. Presumably RA is present in 
excess (Aβ42/Aβ40↓), leading to downregulation of its receptor on the transcript-level. 
This is in line with the observation that many RA target genes were found to be 
induced (Aβ42/Aβ40↓), indicating presence of RA. To name a few: PKC, PLAT, 
STRA6, ACTA2, BCL2, p21. 
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Furthermore, I would like to emphasize the involvement of transferrin receptors in 
insulin metabolism, dynein-mediated transport processes and gatekeeper function for 
regulating iron uptake by most cells:  
Cellular uptake of iron occurs via receptor-mediated endocytosis of the ligand-
occupied transferrin receptor into specialized endosomes, endosomal acidification 
leads to iron release. The apotransferrin-receptor complex is then recycled to the cell 
surface with a return to neutral pH and the simultaneous loss of affinity of 
apotransferrin for its receptor. The transferrin receptor is necessary for the 
development of erythrocytes and the nervous system. The relationships between iron 
metabolism and type 2 diabetes are bidirectional: iron affects glucose metabolism 
and glucose metabolism influences several iron metabolic pathways. Both insulin 
sensitivity and glucose tolerance status are significantly linked with serum transferrin 
receptor concentrations [379]. The early endosome is organized into domains to 
ensure the separation of cargo. Activated mitogenic receptors, such as epidermal 
growth factor (EGF) receptor, are concentrated into vesicles enriched for the small 
GTPase Rab5, which progressively exclude nutrient receptors, such as transferrin 
receptor, into neighbouring tubules. These vesicles become enlarged, increase their 
content of intralumenal vesicles as EGF receptor is sorted from the limiting 
membrane, and eventually mature to late endosomes. Maturation is governed by the 
loss of Rab5 and is accompanied by the movement of endosomes along 
microtubules towards the cell centre. It has been shown that EGF relocates to the 
cell center in a dynein-dependent fashion, simultaneously with the sorting away of 
transferrin receptor, although it remains in Rab5-positive early endosomes. When 
dynein function is acutely disrupted, efficient recycling of transferrin from EGF-
containing endosomes is retarded, loss of Rab5 is slowed and endosome 
enlargement is reduced [407]. Transferrin receptor 1 is required for iron delivery from 
transferrin to cells. It was established as a gatekeeper for regulating iron uptake by 
most cells. TFRC is regulated by cellular iron levels through binding of the iron 
regulatory proteins, Irp1 and Irp2, to iron-responsive elements in the 3'-UTR. Down-
regulation of the transferrin receptor for a decreased Aβ42/Aβ40 ratio could be a 
counter-regulation of the cells in response to increased iron availability.  
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6.27 Prostaglandin E receptor 2 was up-regulated exclusively 
by a decreased Aβ42/Aβ40 ratio 
PTGER2 (Prostaglandin E receptor 2, subtype EP2) was up-regulated (p=0.011, fold 
change=1.8) as a consequence of a decreased Aβ42/Aβ40 ratio whereas an increased 
Aβ42/Aβ40 ratio did not differentially express PTGER2.  
The activity of prostaglandin receptors is mediated by G-proteins that stimulate 
adenylate cyclase. The subsequent rise in intracellular cAMP is responsible for the 
relaxing effect of this receptor on smooth muscle. How cyclooxygenase-2 (COX-2) 
and its proinflammatory metabolite prostaglandin E2 (PGE2) enhance colon cancer 
progression remains poorly understood. It has been shown that PGE2 stimulates 
colon cancer cell growth through its heterotrimeric guanine nucleotide-binding protein 
(G protein)-coupled receptor, EP2, by a signaling route that involves the activation of 
phosphoinositide-3-kinase and the protein kinase AKT by free G protein β, γ-subunits 
and the direct association of the G protein alpha subunit with the regulator of G 
protein signaling (RGS) domain of axin. This leads to the deactivation and release of 
glycogen synthase kinase 3 β from its complex with axin, thereby relieving the 
inhibitory phosphorylation of β-catenin and activating its signaling pathway [408]. 
Recent studies suggest a neuroprotective function of the PGE2 EP2 receptor in 
excitotoxic neuronal injury. The function of the EP2 receptor was examined at certain 
time intervals after excitotoxicity in an organotypic hippocampal model of N-methyl-D-
aspartate (NMDA) challenge and in a permanent model of focal forebrain ischemia. 
Activation of EP2 led to significant neuroprotection in hippocampal slices up to 3 
hours after a toxic NMDA stimulus. Genetic deletion of EP2 resulted in a marked 
increase in the number of strokes in the permanent middle cerebral artery occlusion 
model. These findings support further investigation into therapeutic strategies 
targeting the EP2 receptor in stroke [409]. Neuroprotective function of the PGE2 EP2 
receptor was observed in cerebral ischemia [408]. Cyclo-oxygenases (COXs) 
catalyze the first committed step in the synthesis of the prostaglandins PGE(2), 
PGD(2), PGF(2alpha), PGI(2) and thomboxane A(2). Expression and enzymatic 
activity of COX-2, the inducible isoform of COX, are observed in several neurological 
diseases and result in significant neuronal injury. The neurotoxic effect of COX-2 is 
believed to occur through downstream effects of its prostaglandin products. The 
function of PGD(2) and its two receptors DP1 and chemo-attractant receptor-
homologous molecule expressed on Th2 cells (CRTH2) (DP2) was studied in 
neuronal survival. PGD(2) is the most abundant prostaglandin in brain and regulates 
sleep, temperature and nociception. It signals through two distinct G protein-coupled 
receptors, DP1 and DP2 that have opposite effects on cyclic AMP (cAMP) 
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production. Physiological concentrations of PGD(2) potently and unexpectedly 
rescued neurons in paradigms of glutamate toxicity in cultured hippocampal neurons 
and organotypic slices [410].  
Interestingly, the PTGER2 gene (chr.14q22) is located in close proximity to the PS1 
gene (chr.14q24). There could be a (functional) relationship between PTGER2 and 
PS1 (probably via a decreased Aβ42/Aβ40 ratio).  
6.28 Nicotinic acetylcholine receptor α7 was inversely 
regulated by a changed Aβ42/Aβ40 ratio 
The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of 
ligand-gated ion (Na+, K+, Ca2+) channels that mediate fast signal transmission at 
synapses. The protein encoded by this gene forms a homo-oligomeric channel, 
displays marked permeability to calcium ions and is a major component of brain 
nicotinic receptors that are blocked by, and highly sensitive to, α-bungarotoxin. Once 
this receptor binds acetylcholine, it undergoes an extensive change in conformation 
that affects all subunits and leads to opening of an ion-conducting channel across the 
plasma membrane. This gene (encoding nicotinic acetylcholine receptor α7) is 
located in a region identified as a major susceptibility locus for juvenile myoclonic 
epilepsy and schizophrenia. Aβ1-42 interacts with the α7 subtype of the nicotinic 
acetylcholine receptor subunit (α7 nAChR, synonym: CHRNA7), which is widely 
expressed throughout the central and peripheral nervous systems, as well as in 
several non-neuronal loci, such as epithelial cells, lymphoid tissues, and peripheral 
blood lymphocytes. Western blot and autoradiographic analyses indicate that the α7 
nAChR subunit protein is up-regulated in human brain samples from Alzheimer’s 
patients, as well as in animal models of AD [411-413]. Nordberg and colleagues 
investigated the expression of nicotinic acetylcholine receptors (nAChRs) on 
astrocytes and neurons in the hippocampus and temporal cortex of subjects carrying 
the Swedish amyloid precursor protein (APP) 670/671 mutation (APPswe) and in 
patients with sporadic Alzheimer's disease (AD), and age-matched control subjects. 
Significant increases in the total number of astrocytes and of astrocytes expressing 
the α7 nAChR subunit, along with significant decreases in the levels of α7 and α4 
nAChR subunits on neurons, were observed in the hippocampus and temporal cortex 
of both APPswe and sporadic AD brains. Furthermore, the number of 125I-α-BTX 
(125I-α bungarotoxin) binding sites (α7 nAChR) in the temporal cortex of the APPswe 
brain was significant lower than in the younger control group, reflecting the lower 
neuronal level of α7 nAChR. The increase in the level of expression of α7 nAChR on 
astrocytes was positively correlated with the extent of neuropathological alternations, 
  Discussion 
 
 
190
especially the number of neuritic plaques, in the AD brain. The elevated expression 
of α7 nAChR on astrocytes might participate in the Aβ cascade and formation of 
neuritic plaques, thereby playing an important role in the pathogenesis of AD [414]. 
Fodero and colleagues demonstrated that Aβ42 was more potent than Aβ40 in its 
ability to increase AChE (acetylcholinesterase) in primary cortical neurons [415]. 
The muscarinic 3 cholinergic receptor (CHRM3) was found to be down-regulated by 
both increased and decreased Aβ42/Aβ40 ratios. Thus, this regulation can be assumed 
to be non-specific for Aβ42. In contrast to this, the nicotinic acetylcholine receptor α7 
(CHRNA7) was  found among the most inversely expressed genes as response to a 
changed Aβ42/Aβ40 ratio: an increased Aβ42/Aβ40 ratio led to 1.8 fold upregulation 
(p=0.061), whereas a decreased Aβ42/Aβ40 ratio led to 1.3 fold downregulation 
(p=0.152) of CHRNA7. Further investigation of the CHRNA7 might provide additional 
useful information about  effects mediated by acetylcholine. 
6.29 Excitatory and inhibitory neurotransmitter receptors 
were affected by a changed Aβ42/Aβ40 ratio  
6.29.1 Glutamate-receptors were differentially expressed in 
response to an increased Aβ42/Aβ40 ratio and might 
influence Ca2+ transport and LTP 
Glutamate receptors, like the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid 
(AMPA) receptors mediate the majority of excitatory synaptic transmission in the 
central nervous system (CNS) and are essential for the induction and maintenance of 
long-term potentiation and long-term depression, two cellular models of learning and 
memory. 
The AMPA receptors are ionotropic transmembrane receptors for glutamate that 
mediate fast synaptic transmission in the CNS. The name is derived from their ability 
to be activated by the artificial glutamate analog AMPA. AMPA receptors are found in 
many parts of the brain and are the most commonly found receptors in the nervous 
system. AMPA receptors are composed of four types of subunits, designated as 
GLUR1 (GRIA1), GLUR2 (GRIA2), GLUR3 (GRIA3), and GLUR4 (GRIA4), which 
combine to form tetramers [416, 417]. Most AMPA receptors are either homo-
tetramers of GluR1 or GluR4, or symmetric 'dimer of dimers' of GluR2 and either 
GluR1, GluR3 or GluR4. 
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The gene encoding the ionotropic glutamate receptor AMPA2 subunit (synonyms: 
GLUR2, GRIA2) was the most strongly up-regulated gene for an increased Aβ42/Aβ40 
ratio (p=0.00034, fold change=8.7, calculated with the GC-RMA algorithm, and the 
third most up-regulated gene, p=0.0331, fold change=2.7, calculated with the PLIER 
algorithm). A decreased ratio did not differentially express AMPA2. It has been 
demonstrated that calcium entry into cells is prevented by activation of AMPA 
receptors containing GLUR2. This was proposed to protect the cells against 
excitotoxicity [418]. I conclude that  the increased Aβ42/Aβ40 ratio triggers an increase 
in intracellular Ca2+ levels, which in turn is limited by upregulation of AMPA2. 
However, a direct upregulation of  AMPA2 by an increased Aβ42/Aβ40 ratio cannot be 
excluded. 
The  ionotropic glutamate receptor AMPA3 subunit (synonyms: GLUR3, GRIA3) has 
been shown to be involved in cognitive impairment. Mutations in AMPA3 alter ion 
channel properties and are associated with moderate cognitive impairment in 
humans [419]. Moreover, AMPA3 has been suggested as a candidate for bipolar 
disorders and X-linked mental retardation [420]. AMPA3 was down-regulated 
(Aβ42/Aβ40↑, C99I45F/C99WT2, p<0.005, more than 3-fold down-regulated), but not 
differentially expressed for a decreased Aβ42/Aβ40 ratio. 
The inverse regulation of  the AMPA2 and AMPA3 subunits of the AMPA receptor is  
interesting. This regulation is not expected to be just by chance because the 
probability of two genes encoding proteins for subunits of the same receptor type 
showing such a strong inverse regulation is low. It can rather be expected that there 
is a functional relationship, for instance an antagonistic one, between AMPA2 and 
AMPA3 subunits. An explanation for such a relation could be increased Ca2+ levels. It 
can be hypothesized that an increased Aβ42/Aβ40 ratio up-regulates intracellular Ca2+ 
levels. The cells may counter regulate this to keep up the Ca2+ homeostasis by up-
regulating the Ca2+ blocking AMPA2 subunit while down-regulating the Ca2+ 
conducting AMPA3 subunit. 
The metabotropic glutamate receptors are a family of G protein-coupled receptors 
that have been divided into 3 groups on the basis of sequence homology, putative 
signal transduction mechanisms and pharmacological properties. Group I includes 
GRM1 and GRM5 and these receptors have been shown to activate phospholipase 
C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, 
GRM7 and GRM8c. The activities of group II and III receptors are mediated by G-
proteins that inhibit adenylate cyclase activity. 
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The metabotropic glutamate receptor 7 (GRM7), was 1.5 fold up-regulated (p=0.005) 
for an increased Aβ42/Aβ40 ratio and validated by another probe set on the 
microarray. Moreover, using another set of triplicates as a baseline experiment 
(comparison C99I45F/C99WT2 instead of C99I45F/C99WT1) confirmed these results 
(p=0.008, fold change=1.6). In contrast to this a decreased Aβ42/Aβ40 ratio did not 
result in differential expression of GRM7. 
The metabotropic glutamate Receptor 8c (GRM8c), measured by real-time PCR,  
appeared to be up-regulated for an increased Aβ42/Aβ40 ratio (fold change=4.4, 
standard errorfold change=3.875,) and less up-regulated for a decreased Aβ42/Aβ40 ratio 
(fold change=2.1, standard errorfold change=0.52,) However, a stronger differential 
expression for Aβ42/Aβ40↑, due to its high standard error, is questionable and could 
be caused by a clonal effect of one of the three measured independent single clones. 
In summary, GRM7 and possibly GRM8 were up-regulated exclusively in 
consequence of an increased Aβ42/Aβ40 ratio. They are known to inhibit adenylate 
cyclase. Adenylate cyclase normally activates CREB1. CREB1 was found less (-
44%) phosphorylated on the activating sites S129 and S133 as a result of an 
increased Aβ42/Aβ40 ratio. CREB1 could be less active by up-regulated GRM7 and 
possibly GRM8 (which could act synergistically) to inhibit adenylate cyclase. 
However, there are further ways of how the activity of CREB1 may be reduced. To 
name a few: cAMP als  exerts its function via PKA to induce CREB1 and 
downregulation of the PI3K/AKT/CREB1 axis may also contribute to reduce CREB1 
activity .  
6.29.2 GABA and glycine receptors were up-regulated exclusively 
in response to an increased Aβ42/Aβ40 ratio and might exert 
inhibitory effects 
The γ-aminobutyric acid (GABA) A receptor beta 3 (GABRB3) was 2.6 fold up-
regulated (p=0.0256) for Aβ42/Aβ40↑ and validated by another probe set (fold 
change=2.4, p=0.0076) but not differentially expressed for Aβ42/Aβ40↓. Moreover, the 
glycine receptor, beta (GLRB) was 2.1 fold up-regulated (p=0.00018) for Aβ42/Aβ40↑, 
but not differentially expressed for Aβ42/Aβ40↓. Both GABA and glycin e receptors, the 
typical inhibitory neurotransmitter receptors, were up-regulated exclusively in 
response to an increased Aβ42/Aβ40 ratio. This argues for inhibitory effects which 
could occur (for instance in neurons of brains from AD patients) on postsynaptic 
membranes: Anion influx (mainly Cl-) into the cells induce hyperpolarization, which 
would make the generation of postsynaptic action potentials more difficult.  
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6.30 Upregulation of Notch-signaling was triggered by an 
increased Aβ42/Aβ40 ratio and might contribute to 
prevention of terminal cell differentiation 
The Notch signaling pathway controls cellular interactions important for the 
specification of a variety of cell fates in both invertebrates and vertebrates. I identified 
Notch-signaling as up-regulated in consequence of an increased Aβ42/Aβ40 ratio. The 
Delta/Notch-like EGF-related receptor (DNER) was found among the 10 most up-
regulated genes in response to an increased Aβ42/Aβ40 ratio. Furthermore, the Notch 
ligand jagged1 was among the most inversely regulated genes (upregulation in 
consequence of an increased Aβ42/Aβ40 ratio, downregulation as response to a 
decreased Aβ42/Aβ40 ratio). The Co-repressors of Notch-signaling TLE1 and TLE2 
were down-regulated (Aβ42/Aβ40↑). Cut-expression was shown to be induced by 
Notch-signaling [421]. Cut-like 2 (CUTL2) was the second most up-regulated gene 
(increased Aβ42/Aβ40 ratio, p<0.005). The Notch-signaling target-gene CD44 was up-
regulated. None of the previously mentioned genes (except for jagged1, which was 
down-regulated for Aβ42/Aβ40↓) were differentially expressed when the Aβ42/Aβ40 ratio 
was decreased. There were even signs indicating that Notch-signaling was down-
regulated in consequence of a decreased Aβ42/Aβ40 ratio, because the Notch inhibitor 
NUMB was up-regulated when the Aβ42/Aβ40 ratio was decreased. 
DNER was identified as a new epidermal growth factor (EGF)-like repeat-containing 
single-pass transmembrane protein that is specifically expressed in the developing 
and mature central nervous system. Thus, it was named Delta/Notch-like EGF-
related receptor (DNER). The DNER protein is strongly expressed in several types of 
post-mitotic neurons, including cortical and hippocampal pyramidal neurons, 
cerebellar granule cells, and Purkinje cells. DNER protein is localized to the dendritic 
plasma membrane and endosomes and is excluded from the axons, even when 
overexpressed. The tyrosine-based sorting motif in the cytoplasmic domain is 
required for dendritic targeting of DNER. DNER also has a single transmembrane 
region and an intracellular C-terminal region containing potential tyrosine kinase 
phosphorylation sites, a typical tyrosine-based sorting signal (YEEF), and a 
dileucine-type sorting signal (LI). Differentiation of glia in the central nervous system 
is regulated by Notch1 signaling through neuron-glia interaction. Eiraku et al.  
identified DNER as a ligand of Notch during cellular morphogenesis of Bergmann glia 
in the mouse cerebellum. DNER bound to Notch1 at cell-cell contacts and activated 
Notch signaling in vitro [422].  
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Human jagged1 (JAG1) is the ligand for the receptor Notch 1. Mutations that alter the 
jagged1 protein cause Alagille syndrome. Binding of jagged 1 to Notch triggers a 
cascade of proteolytic cleavage that eventually leads to the release of the 
intracellular part of the receptor from the membrane, allowing it to translocate to the 
nucleus and activate transcription factors that play key roles in cell differentiation and 
morphogenesis [423]. Loomes et al. found that JAG1 is expressed in cells adjacent 
to those expressing Notch2, suggesting a possible ligand receptor interaction [424]. 
Wild-type JAG1 is inhibitory for HGF expression and mutant JAG1 relieves the 
inhibition. Downregulation of jagged 1 induces cell growth inhibition and S phase 
arrest in prostate cancer cells [425]. Overexpression of the Notch ligand jagged1 
induces human regulatory T-cells [426]. The Notch ligands, jagged and delta, are 
sequentially processed by α-secretase and presenilin/γ-secretase and release 
signaling fragments [427].  
The TLE genes are human homologs of the Drosophila 'groucho' gene and their 
products belong to this pathway. The transcriptional co-repressor Groucho/TLE1 
(TLE1) is expressed in virtually all major cortical subdivisions, hippocampus, 
amygdala, and thalamus, as well as in the cerebellum of the adult rat brain. 
Transcriptional co-repressors of the Groucho (Gro)/TLE family play important roles 
during a variety of developmental pathways, including neuronal differentiation. In 
particular, they act as negative regulators of neurogenesis, together with 
Hairy/Enhancer of split (Hes) DNA-binding proteins.  
Analysis of mutant alleles of members of the Notch cascade showed that Notch 
signaling extends the differentiation-competent state of developmentally immature 
precursor cells, thereby preventing or delaying their differentiation until the correct 
morphogenetic signals become available (reviewed by Artavanis-Tsakonas et al. 
[428]). A number of pathologies resulting from incomplete cellular differentiation due 
to this general inhibitory action during cell determination were shown to be the result 
of alterations in Notch signaling, including both lymphoblastic and epithelial 
neoplasms. Liu et al. studied the expression of individual TLE genes during epithelial 
differentiation. By a combination of in situ hybridization and immunohistochemical 
studies, they showed that TLE1, TLE2, and TLE3 are coexpressed in a number of 
tissues [429]. Sestan et al. demonstrated inhibition of cortical neurite growth 
mediated by upregulation of Notch signaling [430]. This is in line with my observation 
that many genes promoting neurite outgrowth (previously described in this thesis) 
were repressed as a response to an increased Aβ42/Aβ40 ratio. Furthermore, there 
are hints indicating a shift towards glial differentiation of the human neuroblastoma 
cells as a consequence of an increased Aβ42/Aβ40 ratio, but towards neuronal 
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differentiation as a result of a decreased Aβ42/Aβ40 ratio: morphologically the cells, 
treated with retinoic acid (Aβ42/Aβ40↑) slightly resembled preparations of astrocytes 
(Fig. 5.9, 1D), whereas cells with a decreased Aβ42/Aβ40 ratio treated the same way 
adopt a more neuronal shape with budding protrusions. An expression profile of such 
treated cells or search for glial/neuronal markers would help to clarify this issue. 
Increased truncated TrkB immunoreactivity (I observed upregulation of the truncated, 
non-catalytic isoform in consequence of an increased Aβ42/Aβ40 ratio) was observed 
in reactive glial cells in the cerebral cortex and white matter in AD [274].  The glial 
cell line-derived neurotrophic factor receptor α-3 (GDNFα-3) was down-regulated 
(Aβ42/Aβ40↓) possibly arguing at least for a weak tendency of the cells not to 
differentiate into the glial direction. DNER has been shown to bind to Bergmann glial 
cells promoting their glial fate in cell culture [422]. I found DNER among the 10 most 
up-regulated genes (Aβ42/Aβ40↑), but no differential expression was observed in cells 
with reduced Aβ42/Aβ40 ratio. Similar processes might occur for neural stem cells in 
the human brain surrounded by diverse Aβ42/Aβ40 levels which could shift them 
towards a glial or a neuronal cell fate depending on Aβ42 and Aβ40 levels.  
NR2F1 (Nuclear receptor subfamily 2, group F, member 1) was not differentially 
expressed (for Aβ42/Aβ40↑), but up-regulated when the Aβ42/Aβ40 ratio was decreased 
(p=0.064, fold change=1.4). NR2F1 controls Notch regulation of hair cells and 
supports cell differentiation. Notch regulation of hair cell differentiation in NR2F1 (-/-) 
mice was investigated and misregulation of Notch signaling components was 
confirmed. Reduced Notch signaling correlated with increases hair cell differentiation 
[431].  
It has been suggested that Notch signaling is essential for the development of T 
lineage cells [432, 433], whereas it prevents B cell development [434, 435]. Notch 
signaling may influence the survival and lineage commitment of T cell progenitors at 
several discrete stages. Pre-T-α-chain (preTα) mRNAs have been demonstrated to 
be up-regulated upon activated Notch signaling [436]. This is in line with the 
observation that the T-cell receptor α locus was up-regulated in response to an 
increased Aβ42/Aβ40 ratio (shown by transcriptomics and proteomics) and supports 
the view that up-regulated Notch signaling is a consequence of an increased 
Aβ42/Aβ40 ratio.   
Taken together there are strong indications of up-regulated Notch signaling in 
consequence of an increased Aβ42/Aβ40 ratio. In contrast to this, Notch signaling 
might be down-regulated, possibly accompanied by an increased tendency of the 
cells to differentiate when the Aβ42/Aβ40  ratio was decreased. 
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6.31 Upregulation of TGFβ-signaling was triggered by an 
increased Aβ42/Aβ40 ratio 
TGFβ-signaling has been shown to be involved in AD [437]. In humans with AD, 
transforming growth factor-β1 (TGFβ1) mRNA levels in the midfrontal gyrus correlate 
positively with the relative degree of cerebrovascular amyloid deposition in that brain 
region, suggesting a possible role for TGFβ1 in human cerebrovascular 
abnormalities. Transgenic mice overexpressing TGFβ1 in astrocytes develop AD-like 
cerebrovascular abnormalities, including perivascular astrocytosis, microvascular 
basement membrane thickening, and accumulation of thioflavin S-positive amyloid. 
Mice overexpressing TGFβ1 alone or in addition to human APP show selective 
accumulation of human Aβ in blood vessels and develop cerebral hemorrhages in old 
age. In TGFβ1 transgenic mice, cerebral blood flow in the limbic system was 
significantly lower than in non-transgenic littermate controls. Aged TGFβ1 mice also 
showed overall reduced cerebral glucose uptake as a measure of brain activity [438]. 
However, TGFβ1 was also reported to promote microglial Aβ clearance and reduces 
plaque burden in transgenic mice [439]. 
There were signs that TGFβ-signaling was up-regulated by an increased Aβ42/Aβ40 
ratio. The ligand BMP7 was strongly up-regulated (Aβ42/Aβ40↑) and known to activate 
TGFβ-signaling (TGFβ-induced signaling and BMP induced-signaling are known to 
converge in the common signaling transducer smad 4, strong crosstalk and feedback 
loops have been described for these pathways). In contrast to this, BAMBI, an 
inhibitor of this pathway, was strongly up-regulated as a result of a decreased 
Aβ42/Aβ40 ratio. BAMBI is a transmembrane glycoprotein related to the type I 
receptors of the transforming growth factor-β (TGFβ) family, whose members play 
important roles in signal transduction in many developmental and pathological 
processes. BAMBI is known to negatively regulate TGFβ signaling. BAMBI is a 
pseudoreceptor, lacking an intracellular serine/threonine kinase domain required for 
signaling. Similar proteins in frogs, mice and zebrafish function as negative 
regulators of TGFβ, which has led to the suggestion that the encoded protein may 
function to limit the signaling range of the TGFβ family during early embryogenesis.  
TGFβ signaling is involved in Aβ-induced gene expression, which can be seen from 
strong and significant upregulation (Aβ42/Aβ40↑) of transforming growth factor β2 
(TGFβ2) (p=0.00219, fold change=4.0) and TGFβ-inducible nuclear protein 1 (TINP1) 
(p=0.01324, fold change=3.2) and in parallel strong and significant downregulation 
(Aβ42/Aβ40↑) of transforming growth factor β receptor II (70/80kDa) (TGFBR2) 
(p=0.00219, fold change= -5.0). Inverse, significant and strong differential expression 
of ligand and its receptor is a strong indication of an affection of the corresponding 
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pathway ! Downregulation of the receptor is assumed to be a response of the cells to 
increased availability of the ligand (on the other hand it cannot be excluded that up-
regulation of the ligand is a response to downregulation of the receptor). Since 
activation of pathways is usually regulated by the binding of a ligand to its receptor 
and subsequent autophosphorylation of the receptor, I regard the TGFβ pathway as 
up-regulated in consequence of an increased Aβ42/Aβ40 ratio (due to strong ligand 
upregulation and plenty of further data, like upregulation of TGFβ-inducible genes 
and proteins). Hepatocyte growth factor (HGF) was strongly down-regulated 
(Aβ42/Aβ40↑). HGF antagonizes TGFβ1 by stabilizing SMAD transcriptional co-
repressor TGIF [365]. Dermatopontin was found to be among the most up-regulated 
genes (for Aβ42/Aβ40↑) and in parallel, among the most down-regulated ones (for 
Aβ42/Aβ40↓). Dermatopontin augmented the biological activity of TGFβ1, as analysed 
by the expression of luciferase in mink lung epithelial cells transfected with a 
plasminogen activator inhibitor-promoter-luciferase construct [441]. 
Taken together, the results demonstrated that TGFβ signaling and BMP-signaling are 
affected by a changed Aβ42/Aβ40 ratio on the transcript level. There are strong 
indications, that both pathways are up-regulated in consequence of an increased 
Aβ42/Aβ40 ratio and down-regulated in consequence of a decreased Aβ42/Aβ40 ratio. 
However, further work is necessary, focusing on smad proteins, which are 
components of both pathways. This might help to answer unsolved questions about 
feedback loops and cross-talk between TGFβ signaling and BMP-signaling. 
6.32 Wnt-signaling might be inversely regulated by a changed 
Aβ42/Aβ40 ratio 
The Wnt pathway is suggested to be involved in AD [442]. Wnt9a and Wnt6 were 
found to be down-regulated in consequence of an increased Aβ42/Aβ40 ratio. They are 
known to signal through the canonical Wnt/beta-catenin signaling pathway [443]. In 
contrast to this Wnt5a was up-regulated (for an increased Aβ42/Aβ40 ratio). Wnt5a 
inhibits the Wnt pathway by promoting GSK3-independent β-catenin degradation 
[444]. Interestingly, in breast cancer cells the activation/inhibition pattern was 
reversed (Wnt9a, Wnt6 up-regulated, Wnt5a down-regulated), so it can be 
speculated that proliferation (a hallmark of cancer cells) and differentiation processes 
could be involved in this regulation. DKK2 (p=0.05, 2.2 fold up-regulated, increased 
Aβ42/Aβ40 ratio) and DKK4 (p=0.016, 2.5 fold up-regulated, increased Aβ42/Aβ40 ratio), 
both inhibitors of Wnt-signaling [445] were up-regulated, but were not found to be 
differentially expressed when the Aβ42/Aβ40 ratio was decreased. Interestingly, WNT 
antagonist DKK2 is a Notch signaling target in intestinal stem cells [446], supporting 
  Discussion 
 
 
198
the previously provided data of upregulation of Notch signaling in consequence of an 
increased Aβ42/Aβ40. This might trigger a vicious circle starting from an increased 
Aβ42/Aβ40 ratio,  leading to activation of Notch-signaling which ,in turn, expresses the 
WNT-signaling inhibitor DKK2. Suppressed WNT-signaling may lead to decreased 
inhibition of GSK3β, which in turn might lead to stronger tau phosphorylation. 
Targeting this regulation could turn out to be a suitable drug target for interrupting the 
link between Aβ42 overproduction and tau-hyperphosphorylation. 
There were signs indicating an upregulation of Wnt-signaling triggered by a 
decreased Aβ42/Aβ40 ratio: A large number of target genes were induced as a result 
of an increased Aβ42/Aβ40 ratio. These, included: cyclin D1, catenin α2, PKC α, 
NRCAM, Runx2 and Stra6. Interestingly many of these genes were suppressed in 
consequence of an increased Aβ42/Aβ40 ratio, supporting the previously mentioned 
data, arguing for a downregulation of Wnt-signaling in consequence of an increased 
Aβ42/Aβ40 ratio.  
Taken together there are many indications of downregulation (off-state) of Wnt 
signaling in consequence of an increased Aβ42/Aβ40 ratio, but upregulation (on-state) 
of Wnt signaling as a result of a decreased Aβ42/Aβ40 ratio.  
6.33 Strong and significant downregulation of RGS4 by an 
increased Aβ42/Aβ40 ratio argues for activation of G-
protein signaling  
See Chapter 5.4.4, Fig. 5.5 (Volcano plots, pages 42-43). Regulator of G-protein 
signaling 4 (RGS4) showed decreased mRNA levels in AD in a large collection of 
human brain autopsies from prefrontal cortex. It was shown that all splice variants 
were down-regulated in AD patients [447]. In AD parietal cortex, total levels of RGS4 
proteins were significantly lower than age-matched control cases by 40% and 53%, 
respectively [448]. 
Regulator of G-protein signaling 4 (RGS4) was found to be the most significantly 
down-regulated gene (for Aβ42/Aβ40↑), but it was not found to be differentially 
expressed when the Aβ42/Aβ40 ratio was decreased. Furthermore, downregulation 
was confirmed by three probe sets, all of which had a p-value <0.05 (see Volcano 
plots, Chapter 5.4.4, Fig. 5.5, pages 42-43) strongly increasing the reliability of 
downregulation. Most importantly RGS4 also belongs to the genes that were down-
regulated in hippocampi of 22 subjects with AD of varying severity (compared to 
healthy controls) with the downregulation having already started at incipient AD 
stages [449]. This makes RGS4 a promising candidate (especially in combination 
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with further susceptibility genes) for early diagnosis of AD. RGS4 is also discussed 
as one of the top candidate genes for schizophrenia [450] and might be the link 
between clinical symptoms occurring in schizophrenic as well as in AD patients 
(problems with copying of drawings, cognitive impairment, mood disorders etc.). The 
down-regulation of RGS4, a G-protein signaling inhibitor, indicates activation of G-
protein signaling. At the same time, G-protein signaling activators (G protein-coupled 
receptor 64) were up-regulated (Aβ42/Aβ40↑). On the other hand GPR176, another G 
protein-coupled receptor, was down-regulated (Aβ42/Aβ40↓). Taken together, these 
data indicate upregulation of G-protein signaling in consequence of an increased 
Aβ42/Aβ40 ratio and presumably downregulation in consequence of a decreased 
Aβ42/Aβ40 ratio. This might be true, at least for some G-protein signaling pathways in 
which the previously mentioned genes participate. Further research is necessary 
including the investigation of the phosphorylation status of kinases belonging to these 
pathways. 
6.34 The α and δ loci of the T-cell receptor were up-regulated 
in response to increased and decreased Aβ42/Aβ40 ratios, 
whereas C99 overexpression led to their downregulation  
The genes coding for the T-cell receptor (TCR) polypeptide chains are located on 
different chromosomes. The TCR consists of two polypeptide chains. Most of the 
TCRs possess a β and γ-chain. Only a few consist of a α and δ-chain. The α and δ 
locus of the T-cell receptor was significantly down-regulated in consequence of C99 
overexpression (C99WT/mock). Interestingly an increased and decreased Aβ42/Aβ40 
ratio resulted in strong and significant upregulation of these genes (transcript level, 
microarray analysis). This was validated on the protein level by a proteomic 
approach, in which the α and δ locus of the T-cell receptor was found among the first 
20 most differentially expressed proteins. The α and δ genes (both located on 
chr14q11.2) are located in vicinity of the PS1 gene (chr14q24). The genes for the β 
and γ chain are located on chromosome 7. The fact that those TCR genes, which are 
in vicinity of the PS1 gene, were differentially expressed hint at a regulatory process 
between a changed Aβ42/Aβ40 ratio, PS1 and the α and δ genes of the TCR. 
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Furthermore, it might be of importance that only a few TCRs consist of an α and δ-
chain. This argues for a distinct regulatory process rather than a broad regulation. It 
can be speculated that α and δ genes of the TCR participate in immunological 
processes involved in AD and might contribute to explain hitherto open questions 
about the immune response (participation of microglial cells, T cell activation, B 
lymphocytes, cytokines) in brains of AD patients.  
6.35 Dysregulated LRP4 is assumed to influence transcription 
together with Fe65 
There are a plenty of imaginable ways of how Aβ or the AICD could trigger gene 
expression. To name but a few: Extracellular Aβ42 or Aβ40 could bind to a receptor, 
transducing a signal to the nucleus, which in turn could activate transcription. On the 
other hand, intracellular Aβ42 or Aβ40 (even if only present in small amounts 
intracellularly) could be transported to the nucleus, in order to activate transcription. 
More publications, however, point to the AICD as the transcription inducing molecule. 
The intracellular domains cleaved from the membrane-bound precursors APLP1, 
APLP2 and APP translocate to the nucleus and activate transcription [55, 62, 199, 
200]. Nuclear signaling of the AICD is regulated by the APP-adaptor proteins Fe65, 
Jip1b and X11α, as well as the nuclear docking protein Tip60 that might be involved 
in chromatin remodelling. It has been discussed that the AICD regulates the 
expression of its precursor APP and therefore acts as a signal of APP cleavage, 
leading to the replenishment of full-length APP levels [152]. Furthermore, cleavage 
products of the AICD could activate transcription [73, 151, 208]. It is noteworthy that 
AICD-regulated genes may be a subset of a much larger group of genes controlled 
by γ-secretase processing. 
In this thesis I observed downregulation (p=0.05, 1.5 fold) of low density lipoprotein 
receptor-related protein 4 (LRP4) in consequence of a decreased Aβ42/Aβ40 ratio, 
whereas LRP4 was not differentially expressed in consequence of an increased 
Aβ42/Aβ40 ratio. LRP4 is a potential cell surface endocytic receptor, which binds and 
internalizes extracellular ligands for degradation by lysosomes (reviewed in [451]). 
Importantly, LRP4 and APOE were co-immunoprecipitated in Cos7 cells and it has 
been suggested that APOE is an endogenous ligand for LRP4.  Moreover it has been 
suggested that LRP4 may play a role as a receptor for extracellular signals, including 
those from glial cells, in the maintenance of the viability of neurons [451]. Low density 
lipoprotein receptor-related proteins have been demonstrated to bind to FE65, 
translocates to the nucleus and activates/inhibits transcription [69, 452-454]. I 
speculate that decreased Aβ42 or increased Aβ40 (or the corresponding AICDs) down-
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regulates LRP4 and that, consequently, less extracellular LDL binds to LRP4; less 
LDL is then internalized and degraded in lysosomes, which may have an influence on 
gene expression. Since LRP4 was down-regulated (Aβ42/Aβ40↓), there might have 
been less LRP4-FE65 which could have activated transcription, so that transcription 
was assumed to be inhibited. This is in line with the observation that a decreased 
Aβ42/Aβ40 ratio led to general transcriptional downregulation (see Volcano plots, 
Chapter 5.4.4, Fig. 5.5, pages 42-43).  
6.36 Indications of dysregulated Ca2+ levels in consequence 
of a changed Aβ42/Aβ40 ratio 
Nicotinic acetycholine receptors are known to increase intracellular Ca2+ 
concentrations. An increased Aβ42/Aβ40 ratio led to upregulation of CHRNA7 whereas 
a decreased Aβ42/Aβ40 ratio led to downregulation of CHRNA7. Moreover,  the T-cell 
receptor has been reported to increase intracellular Ca2+ concentrations [455]. The 
alpha locus of the T cell receptor was up-regulated (Aβ42/Aβ40↑, p=0.00219, fold 
change=5.0). The calcium channel voltage-dependent L type alpha 1D subunit 
(CACNA1D) conducts Ca2+-influx and was found to be up-regulated (Aβ42/Aβ40↑). 
Also the AMPA2 (GLUR2) subunit of the AMPA receptor was strongly up-regulated 
(Aβ42/Aβ40↑), however, it was shown to rather inhibit Ca2+ influx [418]. Increased 
intracellular Ca2+ concentrations have been reported to induce apoptosis [456]. 
AMPA2 upregulation might be a counter-regulation of the cells as response to 
increased intracellular Ca2+ concentrations and in order to protect themselves from 
Ca2+ induced apoptosis. Enhanced LTP has been observed in AMPA receptor 
GluR2-deficient mice [457-459] and long term depression (LTD) has been associated 
with the presence of AMPA2 containing AMPA receptors [460]. Further indications of 
increased intracellular Ca2+ concentrations are differential expression of specific Ca2+ 
binding proteins: actinin  alpha 1 (ACTN1) was up-regulated (Aβ42/Aβ40↑), but not 
specifically for Aβ42, since it was also found up-regulated when the Aβ42/Aβ40 ratio 
was decreased. Calbindin was found up-regulated in consequence of an increased  
Aβ42/Aβ40 ratio only, whereas it was not differentially expressed when this ratio was 
decreased. Calbindin is a calcium-binding protein belonging to the troponin C 
superfamily. Calbindin contains 4 active calcium-binding domains, and 2 modified 
domains that presumably have lost their calcium-binding capacity. Taken together 
there are indications of increased intracellular Ca2+ levels in consequence of an 
increased Aβ42/Aβ40 ratio. However, it is not clear (since Ca2+ levels were not 
measured directly, Ca2+ levels could also be decreased) whether the genes 
mentioned above were directly dysregulated in consequence of an increased 
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Aβ42/Aβ40 ratio or if an increased Aβ42/Aβ40 ratio first dysregulates Ca2+ levels, which 
in turn dysregulate the genes. The latter case is assumed to be slightly more 
probable (however the direct regulation of the genes cannot be excluded), because 
of observations made in AD brains: In AD brains, both frontal and temporal cortex 
vesicles show elevated Ca2+ content, most evident as an increased peak Ca2+ 
content at 2 min (after stimulation). The AD cerebellar cortex time course was similar 
to controls and did not show an elevated peak at 2 min [461]. This regulation takes 
place within a few minutes. Such a short duration cannot be mediated via gene 
expression but must be directly regulated on the protein level. Increased intracellular 
Aβ42-induced Ca2+ levels have been observed [462]. If an increased Aβ42/Aβ40 ratio 
directly up-regulated AMPA2 (not via dysregulated Ca2+ levels), then Ca2+ influx 
would be expected to be blocked (at least through the AMPA receptor) and 
decreased rather than increased inracellular Ca2+ levels would be expected.  
6.37 CREB1 is assumed to be less active in consequence of 
an increased Aβ42/Aβ40 ratio 
Long term potentiation (LTP) has been shown to be involved in AD. LTP was 
accompanied by robust phosphorylation of the cAMP-responsive element binding 
protein 1 (CREB1) in tissue prepared from entorhinal cortex of both young and old 
rats [281]. 
CREB1 was found among the 20 most significantly down-regulated transcripts, only 
in consequence of an increased Aβ42/Aβ40 ratio, whereas a decreased Aβ42/Aβ40 ratio 
did not effect CREB1 expression. However, CREB1 was found to be only very 
weakly down-regulated which questions a real downregulation. However, it has to be 
taken into consideration that the PLIER algorithm, used here to calculate the fold 
change, is known to slightly underestimates the true fold change, so that a slightly 
stonger downregulation can be expected. Moreover, two different probe sets on the 
microarray showed this very weak but significant downregulation (probe set 
204314_s_at: fold change=-1.1, p=0.0072, 204313_s_at: fold change=-1.1, 
p=0.0144) which make a real down-regulation more probable (the fold change of -1.1 
was calculated with the PLIER algorithm, that is known to slightly underestimate true 
fold changes [194]. Furthermore, CREB1 showed weaker phosphorylation on 
S129+S133 (for Aβ42/Aβ40↑), two sites known to induce transcriptional activation of 
CREB1 upon phosphorylation. Phosphorylation on S133 is accomplished by different 
kinases, like PKB (synonym: AKT; for instance via PI3K/AKT signaling) and PKC. 
PKA, PKB and PKC were hypophosphorylated at distinct sites (shown elsewhere in 
this thesis) and in consequence were expected to be less active (for Aβ42/Aβ40↑). 
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This may have contributed to reduced phosphorylation and activity of CREB1. 
It can be concluded that for an increased Aβ42/Aβ40 ratio CREB1 might be less active 
either via its downregulation on the transcript level or/and its reduced 
phosphorylation status at the activating phosphorylation sites. Both effects have been 
shown to aggravate long term potentiation (LTP) [463].  
6.38 Further inversely regulated genes by a changed 
Aβ42/Aβ40 ratio 
Associations to AD or crucial neural processes were found for the following genes 
and deserve further investigation. Up-regulated (for Aβ42/Aβ40↑) and in parallel down-
regulated (for Aβ42/Aβ40↓) were: PDZK1, PBX1. 
PDZK1 (PDZ domain containing 1), a multi-PDZ domain containing adaptor protein, 
interacts with various membrane proteins, including the high density lipoprotein 
(HDL) receptor scavenger receptor class B type I (SRBI, synonym: CD36L1). 
Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of 
SRBI and altered lipoprotein metabolism [464]. SRBI mediates the selective uptake 
of cholesteryl esters from high density lipoprotein. By coexpressing SRBI with PDZK1 
in Chinese Hamster Ovary cells, Ikemoto et al. observed an increase in the 
expression level of SRBI, a reduction in the deacylation rate of the cholesteryl esters 
taken up from HDL and a change in the intracellular distribution of a fluorescent lipid 
taken up from HDL. Taken together, these data suggest that PDZK1 is associated 
with SRBI and may modulate intracellular transport and metabolism of cholesteryl 
esters taken up from HDL [465]. 
In vitro studies have shown that PBX1 (Pre-B-cell leukemia transcription factor 1) 
regulates the activity of IPF1 (insulin promoter factor 1; IPF1 is a para-Hox 
homeodomain transcription factor required for the development and function of the 
pancreas in mice and humans). To investigate in vivo roles of PBX1 in pancreatic 
development and function, Kim et al. examined pancreatic PBX1 expression, and 
morphogenesis, cell differentiation, and function in mice deficient for PBX1. PBX1 -/- 
embryos had pancreatic hypoplasia and marked defects in exocrine and endocrine 
cell differentiation prior to death at embryonic day 15 or 16. In these embryos, 
expression of ISL1 and ATOH5, essential regulators of pancreatic morphogenesis 
and differentiation, was severely reduced. PBX1 +/- adults had pancreatic islet 
malformations, impaired glucose tolerance, and hypoinsulinemia. Thus, Kim et al. 
concluded that PBX1 is essential for normal pancreatic development and function. 
Analysis of trans-heterozygous PBX1 +/- and IPF1 +/- mice revealed in vivo genetic 
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interactions between PBX1 and IPF1 that are essential for postnatal pancreatic 
function. Mutations affecting the IPF1 protein promote diabetes mellitus in mice and 
humans. Kim et al. concluded that perturbation of PBX1 activity may also promote 
susceptibility to diabetes mellitus [466, 467]. Retinoic acid regulates the expression 
of PBX1, PBX2, and PBX3 in P19 cells both transcriptionally and post-translationally 
[468].  
GATA3, SHOX2 and ADRB1 were down-regulated (for Aβ42/Aβ40↑, comparison 
C99I45F/C99WT1) and in parallel up-regulated (for Aβ42/Aβ40↓, comparison 
C99V50F/C99WT1). 
GATA3 (GATA binding protein3) is a transcriptional activator which binds to the 
enhancer (to the consensus sequence 5'-agatag-3') of the T-cell receptor alpha and 
delta genes [187]. Interestingly the expression (detected on the transcript level by 
microarray analysis and on the protein level by a proteomics approach) of the T-cell 
receptor alpha and delta locus was significantly down-regulated in consequence of 
C99 overexpression (C99WT/mock), while increased and decreased Aβ42/Aβ40 ratios 
resulted in strong and significant upregulation of these genes. Since this cannot be a 
consequence of GATA3 dysregulation (if so, T-cell receptors would be expected to 
be down-regulated for Aβ42/Aβ40↑, because GATA3 was down-regulated for 
Aβ42/Aβ40↑), GATA3 downregulation is assumed to be a consequence of, rather than 
the cause of differential T-cell receptor expression, which maybe limits its own 
expression by GATA3 downregulation (negative feedback loop).  
The SHOX2 (short stature homeobox 2) gene is a member of the homeobox family of 
genes that encodes proteins with a DNA binding domain. Homeobox genes have 
been characterized extensively as transcriptional regulators involved in pattern 
formation in both invertebrate and vertebrate species. Several human genetic 
disorders are caused by aberrations in human homeobox genes. SHOX is thought to 
be responsible for short stature and is implicated in the short stature phenotype of 
Turner syndrome patients. This gene is considered to be a candidate gene for 
Cornelia de Lange syndrome (a disease with strong mental retardation). 
Recent publications associate AD with a dysbalanced stress-response or dysfunction 
of noradrenergic regulation [469]. Dysregulated ADRB1 (adrenergic β-1 receptor, 
direct comparison of both mutants, C99I45F/C99V50F, showed >3-fold down-
regulation for Aβ42/Aβ40↑, p<0.005) may play a role here. However, ADRB1 was 
expressed at low absolute values (expression values in one group). So relative 
values (fold changes, comparisons between two groups), which are usually more 
reliable when absolute values are high, have to be regarded with care. 
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6.39 Miscellaneous genes 
The following genes were found to be significantly (p<0.05) and differentially (fold 
change >2.0) expressed and deserve further investigation in future projects. For 
these genes, an association with AD or a connection to important cellular processes 
or important cerebral functions were found. Depending on the nature of research, the 
opinions about which genes play crucial roles change over the course of time. So the  
genes listed below only represent a small selection of interesting targets or projects 
for future research. It is noteworthy that all the differentially expressed genes 
identified in this thesis (which can be found in Chapter 12, Supplementary 
Information), should be compared with the latest publications and with updated 
databases from time to time.      
The comparison between C99I45F and C99WT (Aβ42/Aβ40↑) revealed the following 
genes as up-regulated: TNC (Tenascin C), NLGN4X (neuroligin 4, X-linked), PAG 
(phosphoprotein associated with glycosphingolipid-enriched microdomains)*, 
TNFAIP6 (tumor necrosis factor, alpha-induced protein 6) and TRAF5 (tumor 
necrosis factor receptor-associated factor 5).  
In contrast to this the following genes were down-regulated (for Aβ42/Aβ40↑): GJA1 
(gap junction protein, alpha 1, synonym: connexin 43) and CD99 (CD99 antigen). 
The comparison between C99V50F and C99WT (Aβ42/Aβ40↓) revealed the following 
genes as up-regulated: SGK (serum/glucocorticoid regulated kinase), CDKN1A 
(cyclin-dependent kinase inhibitor 1A, synonyms: p21, Cip1), VGF (VGF nerve 
growth factor inducible), ID4 (inhibitor of DNA binding 4, dominant negative helix-
loop-helix protein), FOXC1 (forkhead box C1), BCL2 (B-cell CLL/lymphoma 2), 
GAP43 (growth associated protein 43), GDF1 (growth differentiation factor 1), 
MAPK8IP2 (mitogen-activated protein kinase 8 interacting protein 2). 
In contrast to this, the following genes were down-regulated (for Aβ42/Aβ40↓): NAV2 
(neuron navigator 2), PAG*  
*Of special interest are those genes that were inversely regulated by a changed 
Aβ42/Aβ40 ratio, like PAG and other genes listed in Chapter 5.6 (Inversely regulated 
genes). 
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6.40 Chromosomal susceptibility loci 
The following loci were selected according to various criteria. Further association 
studies, like analyses of SNPs (single nucleotide polymorphisms) in affected families 
(families in which AD occurs more often than seems likely to be just by chance) 
should be carried out with special regard to these loci. Focusing on these loci might 
be also beneficial for linkage analyses. Numbering refers to human chromosomes. 
The chromosomal locus and a short description why it was selected are shown: 
 
• chr11p15.5, several genes were found to be co-regulated in this imprinted 
region (down-regulated for an increased Aβ42/Aβ40 ratio, presumably by 
imprinting). 
• chr3p14.3-p14.2, ADAMTS9, the most inversely metalloprotease expressed 
(in consequence of a changed Aβ42/Aβ40 ratio). 
• chr6q22, PREP, prolylendopeptidase, independently identified by two 
laboratories (University of Heidelberg and University of Göttingen) by two 
different methods (transcriptomics, proteomics). 
• chr14q32.33, KIAA0125, see Chapter 6.25. 
• chr1q23 and 1p36, “Chromeron“ effect on this locus, see Chapter 5.15. 
• chr15q24, CRABP1, might have a crucial effect on neurogenesis, 
independently identified by two laboratories (University of Heidelberg and 
University of Göttingen) by two different methods (transcriptomics, 
proteomics). 
• chr2q36, co-regulated genes: DNER (delta-Notch-like EGF repeat-containing 
transmembrane), SGPP2 (Sphingosine-1-phosphate phosphatase 2), IGFBP5 
(insulin-like growth factor binding protein 5). 
• chr10q24.33, co-regulated genes: GRK5 (G protein-coupled receptor kinase 
5), INA (internexin neuronal intermediate filament protein alpha). 
• chr10q23.3, ACTA2, see Chapter 6.11. 
• chr7q21-q22, HGF (hepatocyte growth factor) and TFPI2 (tissue factor 
pathway inhibitor 2), both co-regulated and found in the same signal 
transduction pathway. 
• chr9q22.1,  NTRK2, non-catalytic isoform, assumed to inhibit  BDNF signaling. 
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• chr11q12.1, syntaxin3, among the most inversely regulated genes, also found 
in a PS1/PS2 knockdown approach in our laboratory and as a consequence of 
AICD overexpression [57]. 
• chr10p15, GATA3, dysregulated transcription factor in a pathway that turned 
out to be important (IGF2 signaling). 
• chr17q11, CYB561, cytochrome b-561, transmembrane protein, electron 
transport, among the most strongly down-regulated genes (in consequence of 
an increased Aβ42/Aβ40 ratio), CYB561 supplies electrons to monooxygenases 
(for instance to dopamine beta-hydroxylase). 
• chr22q12.1-q13.2|22q12.3, TIMP3 (tissue inhibitor of metalloproteinase 3), 
inhibits α-secretases. 
• chr8p12, PLAT (plasminogen activator, tissue), altered transcriptional control 
of fibrinolysis. 
• chr17p13.1, SERPINF1 (serine proteinase inhibitor, clade F), altered 
transcriptional control of fibrinolysis. 
• chr14q21.3, CDKL1, cyclin-dependent kinase-like 1 (CDC2-related kinase), 
candidate kinase for tau or GSK3 phosphorylation. 
• chr21q22.13 DYRK1A  Dual-specificity tyrosine-(Y)-phosphorylation regulated 
kinase 1A, candidate kinase for tau or GSK3 phosphorylation. 
6.41 Intersection of genes identified in this thesis as a 
consequence of altered C99 cleavage products and 
genes identified as a result of PS1/PS2 knockdown in 
murine embryonic fibroblasts 
The overlapping genes of both approaches are assumed to be differentially 
expressed due to one common mechanism, namely processing by the γ-secretase 
complex. The probability that the same genes occur by chance in both approaches 
among the 100 most up or 100 most down-regulated genes when such big data sets 
(40,000 transcripts in the human neuroblastoma cells, 12,000 in the murine 
fibroblasts) are compared is extremely low. Here (see Chapter 5.18), 9 genes were 
identified as overlapping genes. Although data from two species (human and mouse) 
were compared, more overlapping genes were found than could be expected just by 
chance, increasing the reliability of a common regulatory process.   
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6.42 Intersection of genes identified in this thesis as a 
consequence of altered C99 cleavage products and 
genes identified as a result of AICD overexpression in 
human neuroblastoma cells 
See Chapter 5.19, page 120. The overlapping genes of both approaches are 
assumed to be differentially expressed by the AICD or cleavage products thereof. 
C99 was overexpressed in the human neuroblastoma cell line SH-SY5Y: Aβ42/Aβ40 
and their respective APP intracellular domains (AICDs) were liberated by processing. 
This special comparison with an approach in which the AICD was overexpressed 
alone and also together with FE65 [57], argues, at least for this small overlapping 
subset of genes, for a mechanism triggered by the AICD. Intriguingly, ACTA2 was 
found to be among the three most dysregulated genes (all with a p-value <0.05) by 
Müller et al. (in the human neuroblastoma cell line SHEP-SF, in consequence of 
AICD overexpression), by our PS1/PS2 knockdown approach with siRNA in murine 
embryonic fibroblasts (presented in the Master thesis of my colleague Laura Busia) 
and by changed C99 cleavage products in the human neuroblastoma cell line SH-
SY5Y (presented in this thesis). Common to all three approaches is the AICD, either 
released by processing (our two approaches: PS1/PS2 knockdown, altered C99 
processing) or overexpressed in human neuroblastoma cells [57]. The fact that 
Müller et al. found the same gene (ACTA2) as a consequence of AICD-
overexpression argues for an effect triggered by the AICD.  
6.43 Concluding remarks and outlook 
In summary, it was shown that C99 cleavage products had a strong impact on gene 
expression. In contrast to many other studies in which Aβ42/Aβ40 is added artificially 
from outside the cells, here, the naturally occurring precursor C99 was 
overexpressed and Aβ42/Aβ40 (and their respective APP intracellular domains) were 
liberated by processing. The goal of this thesis was to obtain information about 
effects of the changed C99 processing, due to point mutations in two C99 mutants 
which resulted in different Aβ42/Aβ40 levels, together with the inherently produced 
AICDs. This approach does not allow distinguishing between effects mediated by 
Aβ42/Aβ40 and the AICDs. Furthermore, it has to be taken into consideration that the 
AICD is further processed and its cleavage products themselves could also influence 
gene expression. 
 
 
  Discussion 
 
 
209
It was demonstrated that in mutants with an increased Aβ42/Aβ40 ratio CRABP1 was 
up-regulated on the transcript level and on the protein level which reduced 
responsiveness of human neuroblastoma cells to retinoic acid. The knockdown of 
CRABP1 rescued the differentiation potential of these cells and could also be an 
important mechanism in vivo, where CRABP1 might prevent the terminal 
differentiation of neural precursor cells into functional neurons.  
IGF2 signaling, via the IGF-Receptor 1, was shown to be down-regulated in 
consequence of an increased Aβ42/Aβ40 ratio and is most probably caused in part by 
imprinting processes. This is in line with previously published in vivo data in which 
IGF2 levels were found to be decreased in the brains of AD patients. The presented 
model (see Chapter 5.9.2, Fig. 5.35, pages 78-79) was created using Pathway 
Architect (Stratagene), a literature mining program used to build biological interaction 
networks among genes/proteins of interest. It accesses over 2 million biological facts 
from the current literature. By a complex filtering procedure this pathway (Fig. 5.35) 
was created, in which all transcripts (except for DDC) were found to be connected in 
a network. Nodes (transcripts and/or proteins) are connected via interconnectivities 
(lines). These lines represent direct interactions, regulatory processes or other kinds 
of associations that have been published. The presented model reveals a hitherto 
unknown network of interactions triggered by a changed Aβ42/Aβ40 ratio. PI3K/AKT 
activating molecules like IGF2 were significantly down-regulated. This 
downregulation was corroborated by the simultaneous downregulation of H19 and 
may have been triggered by imprinting (IGF2-H19 imprinted region on chromosome 
11p15.5). Furthermore, effects mediated by other molecules (effects via the non-
catalytic TrkB-receptor, inhibiting effects by IGFBP5 etc.) may act synergistically to 
down-regulate this pathway (for Aβ42/Aβ40↑). Imprinting may exert a key role here, 
due to the fact that not only IGF2, but also further molecules belonging to the 
imprinted region, were simultaneously down-regulated. Future experiments (for 
instance functional assays, in which insulin or insulin like growth factors are added to 
the cells or using inhibitors for this pathway)  will provide further insight into 
insulin/IGF2 signaling. 
There are indications of increased blood coagulation and presumably decreased 
fibrinolysis as a consequence of an increased Aβ42/Aβ40 ratio, while a decreased 
Aβ42/Aβ40 ratio may result in enhanced fibrinolysis, while blood coagulation might be 
reduced. All differentially expressed genes (described in Figure 5.37, except for F2R, 
F2RL3 and VWCD1) code for secreted proteins. Theoretically,  it seems possible that 
in vivo (in brains of AD patients) an increased Aβ42/Aβ40 ratio triggers the release of 
the previously mentioned factors into the extracellular space and into blood vessels, 
in which a shift towards increased blood coagulation and decreased fibrinolysis may 
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take place. Indeed, clinical data on blood coagulation and fibrinolysis hint at such a 
regulation in Alzheimer patients [313] as well as immunohistochemical and electron 
microscopy data of cerebral cortex and brain microvessels [314]. Such a regulation 
would result in decreased cerebral blood flow and a stronger tendency towards 
having strokes and mental dysfunction. Further research focusing on blood 
coagulation and fibrinolysis is necessary.  
The model “Increased Aβ42/Aβ40 ratio is expected to reduce ATP levels and to induce 
phosphofructokinase upregulation” (see Model, Chapter 5.9.3, Fig. 5.36, page 85) 
provides an explanation for changed glucose and ATP levels in brains of AD patients. 
Up-regulated (for Aβ42/Aβ40↑) phosphofructokinase, which plays a key role in 
glycolysis, may contribute to reduce glucose levels by inducing glycolysis. This could 
be regarded as the ‘attempt’ (by feedback loops) of the cells to restore sufficient ATP 
levels. Phosphofructokinase activity in brains from patients with Alzheimer's disease 
was significantly increased in frontal and temporal cortex when compared with 
control brains [332]. Thus, missing glucose could be inherently connected to 
GSK3/tau phosphorylation (provided PFKP turns out to be a possible tau kinase) via 
PFKP upregulation, so GSK3/tau phosphorylation would be an inherent byproduct of 
reduced glucose/ATP levels. Further research is necessary, which focuses on 
phosphofructokinase, its relation to GSK3β and glucose/ATP levels in brains of AD 
patients.   
As candidate genes encoding kinases possibly phosphorylating tau, I identified 
DYRK1, CDKL5, CDK6, DCAMKL1, ERK1 and PFKP (furthermore, PPP2R4 and 
PPP2R2C two regulatory subunits of protein phosphatase 2A, which may influence 
its phosphatase activity on tau). Concentrating on these candidates might help to 
interrupt the harmful connection between Aβ and tau. Further research should also 
focus on the following areas which were distinctly differentially affected by a changed 
Aβ42/Aβ40 ratio: (metallo) proteases (especially ADAMTS9 and MMP8) and protease 
inhibitors (especially TIMP3, TIMP1), extracellular matrix proteins (especially 
ACTA2), mitochondrial respiratory chain (especially NDUFB9), cytochromes with 
special regard to the cytochromes b-561 and b-245, copper transport/metabolism 
(with special regard to ATP7A), dopamine, serotonin and glutamate-metabolism with 
special regard to DDC, GLS and GLUL, effects of BDNF (non-catalytic isoform of 
TRKB), membrane fusion of neurotransmitter containing vesicles (especially syntaxin 
3 and synapsin 2), Ca2+-metabolism (especially the AMPA2 and AMPA3 subunits of 
AMPA receptors), synaptosomal and axonal transport events (SEMA3A, SEMA3C, 
L1CAM, PTN, SLIT1, DNCLI2), acetylcholine receptors (CHRNA7). Furthermore, 
future research should focus on Notch, Wnt, TGFβ and G protein signaling which 
have been shown to be influenced by a changed Aβ42/Aβ40 ratio. Moreover, strong 
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differential effects of a changed Aβ42/Aβ40 ratio have been observed on receptor 
expression (PTGER2, EGFR, GRM7, GRM8c, GLRB, GABRB3). APP is a 
transmembrane protein which is expected to exert trans-cellular interactions. It can 
be speculated that some of the dysregulated receptors may turn out to be possible 
interaction partners of APP. 
Further research is necessary to provide the possibility of distinguishing between 
effects by Aβ42/Aβ40 and by the AICD (or its cleavage products). It is assumed, even 
though no experimental evidence is provided here, that the AICDs change similarly to 
Aβ42 and Aβ40. Currently, we are investigating this issue together with our 
collaboration partner Stefan Lichtenthaler. I expect that at least some of the identified 
genes in our approach are differentially expressed by different AICD species. It has 
to be taken into consideration that AICD-induced/repressed genes may only be a 
subset of the genes that are regulated by γ-secretase cleavage. Moreover, the AICD 
is further cleaved. Additionally, a signalling function of its cleavage products cannot 
be ruled out. Finally, the possibility that both Aβ42/Aβ40 and the AICDs synergistically 
influence gene expression, cannot be excluded. 
Future research should focus on the most inversely (by an altered Aβ42/Aβ40 ratio) 
expressed genes (Chapter 5.6), because they are expected to show the biggest 
differences in Aβ42 and Aβ40 effects.  
RNA interference experiments (knockdown of up-regulated transcripts) and 
overexpression of down-regulated genes could unravel crucial signal transduction 
pathways and could be helpful in obtaining further insights into the behaviour of the 
cells. Time course experiments with an inducible system (for instance tet-off/on 
system) or by RNA interference would help to distinguish between primary and 
secondary effects initially triggered by Aβ overexpression. 
The genes selected in this thesis are currently being used to generate a subarray 
(oligonucleotide microarray), for example in order to test primary neurons and their 
response to Aβ overexpression or for human post-mortem tissue. This is currently 
carried out in collaboration with the biotechnological company Febit, Heidelberg, 
Germany. 
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7 Materials and Methods 
7.1 Materials 
7.1.1 Cell lines 
• E.coli DH5α and BL21 (DE3)  
• Human neuroblastoma cell line SH-SY5Y:  
This cell line was originally isolated from a metastatic bone tumor. Transformed neural tissue 
(neuroblastoma) from a 4 year old girl was metastasized into the bone marrow from where it was 
isolated. SH-SY5Y is a thrice cloned (SK-N-SH -> SH-SY -> SH-SY5 -> SH-SY5Y) subline of the 
neuroblastoma cell line SK-N-SH which was isolated and established in 1970. This cell line has 47 
chromosomes. The cells possess a unique marker comprised of a chromosome 1 with a complex 
insertion of an additional copy of a 1q segment into the long arm, resulting in trisomy of 1q. SH-SY5Y 
cells are reported to exhibit moderate levels of dopamine beta hydroxylase activity. These cells grow 
as a mixture of floating and adherent cells. The cells grow as clusters of neuroblastic cells with 
multiple, short, fine cell processes (neurites). Cells tend to aggregate, form clumps and float [470, 
471]. 
7.1.2 Gene Chips® (Affymetrix whole genome oligonucleotide 
arrays) 
• Test 3 arrays  
• Gene Chip Human Genome HG-U133 A (22283 probe sets for the detection of approximately 
the corresponding number of transcripts)  
• Gene Chip Human Genome HG-U133 B (22645 probe sets for the detection of approximately 
the corresponding number of transcripts)  
7.1.3 TaqMan® Human Endogenous Control Plate  
The amplification of an endogenous control can be used to normalize the amount of sample RNA or 
cDNA added to a reaction. The TaqMan® Human Endogenous Control Plate is designed to identify an 
endogenous control for gene-expression studies. It consists of an Optical 96-well Reaction Plate 
loaded with TaqMan® probes and primers for 11 candidate control assays and an internal positive 
control (IPC) assay arranged into 12 columns of eight replicate wells. Assays for the endogenous 
controls included on the TaqMan® Human Endogenous Control Plate are conveniently available once 
an appropriate endogenous control has been selected.  
Out of 11 candidate control assays one was excluded (18s rRNA-assay), due to a different preparation 
procedure. The remaining 10 candidate control assays were used to select a suitable endogenous 
control for normalisation:  
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• Acidic ribosomal protein 
• β-actin 
• CyclophilinA 
• Glyceraldehyde-3-phosphate dehydrogenase 
• Phosphoglycerokinase 
• β2-Microglobulin 
• β-Glucuronidase 
• Hypoxanthine ribosyl transferase 
• Transcription factor IID, TATA binding protein 
• Transferrin receptor 
 
The assay was performed according to the manufacturer’s instructions (www.appliedbiosystems.com) 
and measured with a GeneAmp 5700 Sequence Detection System (real-time PCR cycler). 
7.1.4 Primer sequences for quantitative real-time PCR 
All primers for real-time PCR were purchased from Applied Biosystems and were part of the Taq man 
Gene expression assays (assays-on-demand). 
Gene name Assay ID 
peptidylprolyl isomerase A (cyclophilin A) Hs99999904_m1 
actin, beta Hs99999903_m1 
ribosomal protein, large, P0 Hs99999902_m1 
glutamate receptor, metabotropic 7 Hs00356067_m1 
hepatocyte growth factor (hepapoietin A; scatter factor) Hs00300159_m1 
protein tyrosine phosphatase, receptor type, N polypeptide 2 Hs00243067_m1 
neurofilament 3 (150kDa medium) Hs00193572_m1 
endothelin converting enzyme-like 1 Hs00191400_m1 
glutamate receptor, ionotropic, AMPA 2 Hs00181331_m1 
neurotrophic tyrosine kinase, receptor, type 2 Hs00178811_m1 
cellular retinoic acid binding protein 1 Hs00171635_m1 
insulin-like growth factor 2 (somatomedin A) Hs00171254_m1 
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3C Hs00170762_m1 
glutamate receptor, metabotropic 8 Hs00168299_m1 
human GAPD (GAPDH) endogenous control (FAM™ dye/ 
MGB Probe, non-primer limited) 4333764T 
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7.1.5 siRNAs 
All siRNAs were double-stranded Silencer™ siRNAs, purchased from Ambion with the following 
properties: 
Type:   Pre-designed 
Format:   Annealed 
Purity: Standard purity (column purified), the siRNAs for GAPDH, beta-actin, 
Cyclophilin A (positive controls) and non-targeting siRNAs (scrambled 
sequences=negative controls) were HPLC purified.  
Amount:   5 nmol 
Catalogue #:  16708 
Length:   21 nucleotides   
5 nmol siRNA, delivered as a powder, was reconstituted in 100 µl of nuclease-free water to come to a 
stock solution of 50 µM. Once reconstituted in nuclease-free water, the siRNA was ready to transfect 
and were used at a final concentration of 30-90 nM. 
Controls: 
• Negative controls: Validated, non-targeting siRNAs (scrambled sequences) 
• Positive controls: Validated, siRNAs against GAPDH and cyclophilin A 
 
Catalogue # or siRNA ID #: 
• To efficiently knock-down crabp1 three siRNAs were used targeting different exons: 
siRNA ID # 121004 (exons 3, 4), siRNA ID # 121005 (exon 4), siRNA ID # 121006 (exon 4),  
• Positive controls: directed against GAPDH: Catalogue # 4605 and cyclophilin A: Catalogue # 
4616 
7.1.6 Plasmids 
• pCEP4 vector alone, negative control (Invitrogen) 
• pCEP4-spA4ct-DA-WT 
• pCEP4-spA4ct-DA-I45F 
• pCEP4-spA4ct-DA-V50F 
pCEP4-spA4ct-DA constructs were provided by colleagues and have been described previously [148, 
149]. 
7.1.7 Chips for the Bioanalyzer 2100™ (Agilent) 
• RNA 6000 Nano Chips Agilent Technologies. 
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7.1.8 Kits 
 
RNA 6000 Nano Assay Reagent Kit  Agilent, Böblingen, Germany 
SuperscriptTM Double-Stranded cDNA Synthesis Kit Invitrogen, Karlsruhe, Germany 
GeneChip® Sample Clean up Module Affymetrix, Santa Clara (California, USA) 
GeneChip® Eucaryotic Hybrization Control Kit Affymetrix, Santa Clara (California, USA) 
BioArrayTM High YieldTM RNA Labeling Kit (10rct) Enzo Life Sciences, NY (USA) 
QIAshredderTM (50) Qiagen, Hilden, Germany 
RNeasy® Midi Kit (50) Qiagen, Hilden, Germany 
RNeasy®-Free DNase Set Qiagen, Hilden, Germany 
High Capacity cDNA Archive Kit  Applied Biosystems, USA 
GeneChip® Eukaryotic Hybridization Control Kit Affymetrix, Santa Clara (California, USA) 
 
7.1.9 Antibodies 
7.1.9.1 Primary antibodies 
Apart from primary antibodies used for screening of phosphorylated proteins mentioned in Chapter 
5.8.1, the following antibodies were used: 
• W0-2, recognized epitope Aβ (1-16 aa) [472]. 
• G-10 [472]. 
• G-11 [472]. 
• Monoclonal anti-cellular retinoic acid binding protein 1 (Sigma, product number C1608), 1:250 
for immunofluorescence. 
• Anti-β-actin (Abcam, ab8227), 1:5000 as loading control for Western blot.   
7.1.9.2 Secondary antibodies 
 
• Western Blotting: 
For Enhanced Chemical Luminescence (ECL) detection after Western Blotting, Horseradish-
Peroxidase (HRP) coupled anti-mouse (Promega), anti-rabbit (Promega), anti-rat (DAKO) 
antibodies were used with a 1:10 000 dilution. 
• Immunocytochemistry: 
For immunocytochemistry  Alexa 488 goat anti-mouse, Alexa 488 goat anti-rabbit, Alexa 568 goat 
anti-mouse and Alexa 594 goat anti-rabbit (Molecular Probes) were used with a 1:200 dilution.  
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7.1.10 Oligonucleotides 
 
Primer name Sequence (5’→3’) Description Company 
pCEP (forward 
primer) 
5’-AGCAGAGCTC 
GTTTAGTGAACCG 3’ 
Primer for sequencing MWG-Biotech, 
Germany  
pCEP/spa4ct12
79-1260 
5’-GGCGGTGTT GTCATA 
GCGAC-3’ 
Primer for sequencing MWG-Biotech, 
Germany 
pCEP/spa4ct95
2-933 
5’-GCTGTAACAC 
AAGTAGATGC -3’ 
Primer for sequencing MWG-Biotech, 
Germany 
pCEP/spa4ct66
3-642 
5’- GCTTCTCTTGC 
CTAAGTATTCC-3’ 
Primer for sequencing MWG-Biotech, 
Germany 
T7-(dT)24 5’-GGCCAGTGA 
ATTGTAATACGAC 
TCACTATAGGGAGGCGG
TTTTTTTTTTTTTTTT 
TTTTTTTT-3’ 
Primer for cDNA-Synthesis Proligo, Germany 
and France 
Control oligoB2 Confidential information, 
not provided by Affymetrix 
Biotin labelled 
oligonucleotide, added to 
the hybridization solution to 
provide alignment signals 
for image analysis 
Affymetrix, 
England 
 
7.1.11 Chemicals 
 
Agarose (Dnase-, Rnase-free) Serva Heidelberg 
Ammoniumacetate ApliChem, Darmstadt 
Ampicillin Serva Heidelberg 
Antifoam O-30 SIGMA, Deisenhofen 
Bromophenol blue LKB. Broma, Sweeden 
BSA (50 mg/ml) Invitrogen, Karlsruhe 
Complete® Protease Inhibitor Mix Roche, Basel 
Dithiothreitol (DTT) Invitrogen, Karlsruhe 
EDTA Disodium Salt SIGMA, Deisenhofen 
Ethanol (absolute) Riedel-de-Haën Lab Chemicals, Seelze 
Ethidiumbromide (10 mg/ml) SIGMA, Deisenhofen 
Ethylenediaminetetraacetic acid (EDTA) SIGMA, Deisenhofen 
Herring Sperm DNA (10 mg/ml) Invitrogen, Karlsruhe 
Isopropanol Riedel-de-Haën Lab Chemicals, Seelze  
Magnesiumchloride Merk KGaA, Darmstadt 
MES free Acid Monohydrate SIGMA, Deisenhofen 
MES Sodium Salt SIGMA, Deisenhofen 
Methanol Merk KGaA, Darmstadt 
Natriumchloride J. T. Baker, Deventer, Holland 
Potassium-Acetate SIGMA, Deisenhofen 
Retinoic acid SIGMA, Deisenhofen 
Sodium-Acetate SIGMA, Deisenhofen 
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Sodium-Chloride J. T. Baker, Deventer, Holland 
Streptavidin (R-phycoerythrin conjugate) Molecular Probes, Leiden, Holland 
Tricine Biomol, Hamburg 
Tris SIGMA, Deisenhofen 
Tris-Acetate SIGMA, Deisenhofen 
Triton-X-100 Merk KGaA, Darmstadt 
TRIZMA® BASE SIGMA, Deisenhofen 
Trizma® Hydrochloride SIGMA, Deisenhofen 
Tween® 20 SIGMA, Deisenhofen 
β-Mercaptoethanol SIGMA, Deisenhofen 
 
7.1.12 Buffers and solutions 
 
• 12 x MES Stock (1000 ml): 
70.4 g MES Free Acid Monohydrate 
193.3 g MES Sodium Salt 
These components were dissolved 
 in 800 ml H2O and filled up to 1000 ml with H2O. 
pH was adjusted between 6,5 and 6,7. 
This solution was filtered sterile (0.2 µm filter) 
and stored at 4°C (shielded from light). 
 
• 2 x MES hybridisation buffer (50 ml): 
8.3 ml 12 x MES Stock 
17.7 ml 5 M NaCl  
4 ml 0.5 M EDTA 
0.1 ml 10% TWEEN 20 
19.9 ml RNase-free water 
 
• Wash-buffer A (non-stringent buffer) (1000 ml): 
300 ml 20x SSPE 
1 ml 10% TWEEN 20 
698 ml RNase-free water 
This solution was filtered sterile (0.2 µm filter) 
After filtration, 1 ml 5% antifoam was added. 
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• Wash-buffer B (stringent buffer) (1000 ml): 
83.3 ml 2x MES stock 
5.2 ml 5 M NaCl 
1 ml 10% TWEEN 20 
910.5 ml RNase free water 
This solution was filtered sterile (0.2 µm filter) 
 
• 2 x staining buffer (250 ml): 
41.7 ml 12 x MES Stock 
92.5 ml 5 M NaCl 
2.5 ml 10% TWEEN 20 
 
112.8 ml RNase-free water 
This solution was filtered sterile (0.2 µm filter) 
After filtration, 0.5 ml 5% antifoam were added 
 
• SAPE staining solution (1.staining, 3.staining, 1200 µl): 
600 µl 2 x stain buffer 
540 µl RNase free water 
48 µl 50 mg/ml acetylated BSA (final concentration: 2 mg/ml) 
12 µl 1mg/ml SAPE (final concentration: 10 µm/ml) 
This solution was mixed well and centrifuged for 5 min at 14000 rpm, 
The supernatant was aliquoted and stored in light-protected brown tubes. 
 
• Antibody solution (for 2. staining, 600 µl): 
300 µl 2 x stain buffer 
266.4 µl RNase-free water 
24 µl50 mg/ml BSA (final concentration: 2 mg/ml) 
6 µl 10 mg/ml goat IgG (final concentration: 0,1 mg/ml) 
3.6 µl 0.5 mg/ml biotinylated anti-streptavidin antibody (final concentration: 0.3 µg/ml) 
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7.1.13 Enzymes 
 
Enzymes Company 
NheI Biolabs 
BamHI Biolabs 
KpnI Promega 
XhoI Biolabs 
Bgl II Biolabs 
DNaseI Qiagen 
SuperSript II Reverse Transcriptase Invitrogen 
E.coli DNA-Ligase Invitrogen 
E.coli DNA-Polymerase I Invitrogen 
RNase H Invitrogen 
T4 Polymerase Invitrogen 
T7 RNA -Polymerase Invitrogen 
 
7.1.14 Antibiotics 
Hygromycin B, (50 mg/ml) (PAA Laboratories), 300 µg/ml (final concentration) 
7.1.15 Cell culture 
• Medium for human neuroblastoma cells (SH-SY5Y): 
250 ml MEM (Minimun Essential Medium), without L-Glutamine (Sigma) 
250 ml F12 (Nutrient Mixture F-12, HAM) (Sigma) 
57 ml FBS (PAN) 
5.7 ml MEM non essential-amino acids 100x (Sigma) 
5.7 ml L-Glutamine (Sigma) 
3.0 ml Hygromycin B, 50 mg/ml (PAA Laboratories), 300 µg/ml (final concentration) 
 
• Reagents for cell culture: 
Dimethylsulfoxyde (DMSO) SIGMA, Deisenhofen 
Dulbecco’s Modified Eagle’s Medium SIGMA, Deisenhofen 
Fetal Bovine Serum SIGMA, Deisenhofen 
Fetal Bovine Serum PANTM, Biotech GmbH, South America 
Hygromycin B, solution (50 mg/ml) PAA Laboratories GmbH, Pasching 
Minimum Essential Medium Eagle SIGMA, Deisenhofen 
MEM Non-Essential Amino Acid Solution 
100 x 
SIGMA, Deisenhofen 
Nutrient Mixture-F12 HAM SIGMA, Deisenhofen 
OptiMEM® + GlutaMAXTM GIBCOTM Invitrogen, Auckland N.Z. 
Trypsin-EDTA-Solution (1x) SIGMA, Deisenhofen 
L-Glutamine SIGMA, Deisenhofen 
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7.1.16 Devices 
• Agilent 2100 Bioanalyzer® 
• Gene Chip® Hybridization Oven 640 (Affymetrix) 
• Gene Chip® Fluidics Station 400 (Affymetrix) 
• Gene Array® Scanner (Hewlett Packard) 
7.1.17 Nucleic acid and protein molecular weight markers 
• 1 kb (+) DNA-ladder (Invitrogen) 
• RNA 6000 Ladder (Ambion) 
• Prestained protein ladder (Fermentas) 
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7.2 Methods 
7.2.1 DNA methods 
7.2.1.1 Transformation of competent E. coli 
Chemo-competent E.coli DH5α cells were thawed on ice and 50 ng plasmid-DNA was added to a 100 
µl cell aliquot. After incubation on ice for 30 min, cells were heat shocked for 90 s at 42°C and further 
incubated on ice for 5 min. Then 900 µl LB-medium was added to each aliquot and incubated on a 
roller shaker for 45 min at 37°C. Afterwards, 200 µl were plated on agar plates and incubated over 
night at 37°C. 
7.2.1.2 Small scale preparation of plasmid DNA (Mini Prep) 
For small scale preparation of plasmid DNA (Mini Prep), the Qiagen Mini Prep Kit was used: 
S1: 50 mM Tris/HCl, 10 mM EDTA, 100 µg RNase A/ml, pH 8.0 
S2: 200 mM NaOH, 1% SDS 
S3: 2.8 M Potassium acetate pH 5.1 
70% ethanol 
TE-buffer, pH 8.0: 10 mM Tris/HCl pH 8.0, 1mM EDTA pH 8.0 
 
A single bacterial colony was picked from an agar-plate, inoculated into 3 ml LB-medium, 
supplemented with 3 µl ampicillin (100mg/ml) and incubated over night at 37°C under vigorous 
shaking. 1-2 ml of this culture was transferred into an Eppendorf tube and centrifuged at 6.000 rpm for 
5 min. The cells were resuspended in 100 µl S1 buffer and further processed according to the 
manufacturer’s protocol. 
7.2.1.3 Large scale preparation of plasmid DNA (Maxi Prep) 
For large scale preparation of plasmid DNA (Maxi Prep), the Nucleobond AX-500 Kit (Macherey & 
Nagel) was used: 
• N2: 100 mM Tris, 15% ethanol, 900 mM KCL pH 6.3 
• N3: 100 mM Tris, 15% ethanol, 1150 mM KCL pH 6.3 
• N5: 100 mM Tris, 15% ethanol, 1000 mM KCL pH 8.5 
 
3 ml of LB medium (containing 3 µl of 100mg/ml ampicillin) were inoculated with a bacterial colony and 
incubated at 37°C for approximately 6 hours under vigorous shaking. Then this culture was added to 
400 ml (containing 400 µl of 100mg/ml ampicillin) LB medium and incubated at 37°C over night under 
vigorous shaking. This culture was centrifuged for 10 min at 6000 rpm/4°C and further processed 
according to the manufacturer’s protocol. 
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7.2.1.4 Purification and concentration of DNA 
An equal volume of phenol-chloroform-isoamylalcohol (25:24:1) was added to a given volume of DNA 
solution and vortexed thoroughly for at least 1 min. The emulsion was centrifuged for 10 min at 13000 
rpm in a common table centrifuge to achieve a separation of the phases. The aquatic, DNA-containing 
phase on top was carefully transferred into a new Eppendorf tube. This procedure was repeated once 
and the DNA was precipitated as follows: 1/10 volume of sodium acetate (3M, pH 5.2) and 2.5 
volumes of 100% ethanol (-20°C) was added to the given volume of DNA solution, mixed well, and 
incubated for 30 min at -20°C. The precipitated DNA was centrifuged for 5 min at 4°C/13000 rpm. The 
supernatant was removed, the precipitated DNA was air-dried and diluted in a suitable volume of H2O. 
7.2.1.5 Determination of DNA concentration 
DNA concentrations were measured with a spectrophotometer (Biorad Smart Spec 3000) at a 
wavelength of 260nm. The DNA was diluted in a suitable volume of H2O so that the following 
measurements of absorption were in a range of 0.1 -1.0.  
The following equation was used to calculate the concentration from the measured absorption: 
dsDNA:   A260nm(1cm)=1 corresponds to a concentration of approximately 50 µg/ml 
(ssDNA or ssRNA:  A260nm(1cm)=1 corresponds to a concentration of approximately 40 µg/ml) 
 
The purity of the DNA was determined by measuring the absorption at 280 nm and 310 nm which 
corresponds to the absorption maxima of aromatic proteins and polysaccharides. For pure DNA the 
A260nm/A280 ratio should be between 1.8 and 2.1, with no absorption at 310 nm. 
7.2.1.6 Restriction digestion of DNA 
A typical reaction was prepared as follows: 
Plasmid-DNA 1.0 µg 
10 x reaction buffer 3 µl 
Restriction enzyme (5-10 U) 0.5-1.0 µl 
H2O ad 30 µl 
 
The reaction was incubated at the appropriate temperature (generally 37 °C) for 1-2 h. 
7.2.1.7 Analysis of DNA fragments on agarose gels 
1x TAE buffer:  40 mM Tris-acetate 
   1 mM EDTA ph 8.0 
Ethidiumbromide stock: 10 mg/ml (diluted 1:10 000) 
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6x DNA sample buffer:  30 % glycerol (w/v) 
    0.25 % bromophenol-blue 
    0.25 % Xylencyanol 
    50 mM EDTA pH 8.0 
1 % agarose gels were used for separation of DNA. The agarose was dissolved in 1xTAE buffer by 
boiling in a microwave oven. Ethidiumbromide was added to a final concentration of 1 µg/ml and the 
solution was poured into a gel chamber. DNA sample buffer was added to the samples. Then the 
samples and a 1 kb DNA ladder were loaded onto the gel and electrophoresis was performed at 100-
200 V. After separation, photographs were taken of the gels under UV-light and correct cleavage was 
estimated by comparing the fragment sizes with the DNA ladder. 
7.2.1.8 Sequencing of plasmids 
Plasmids mentioned in Chapter 7.1.6 were sent for sequencing to MWG-Biotech using the primers 
listed in Chapter 7.1.10. All constructs showed the expected sequences. 
7.2.2 Cell culture methods 
7.2.2.1 Cultivation of eukaryotic cell lines 
• 1 x PBS:   137 mM NaCl  
    2.7 mM KCl  
10 mM Na2HPO4 
      2 mM KH2PO4 
 PBS was adjusted  to pH 7.4 
 
• Medium for human neuroblastoma cells (SH-SY5Y): 
250 ml MEM (Minimun Essential Medium), without L-Glutamine 
250 ml Nutrient Mixture F-12, HAM 
57 ml FBS  
5.7 ml MEM non essential-amino acids 100x 
5.7 ml L-Glutamine 
3.0 ml Hygromycin B, solution (50 mg/ml) 
 
All cells were cultured at 37°C in cell culture medium described above in a humidified atmosphere with 
5% CO2. The cells were cultivated in 10 cm cell culture dishes (Sarsted®) and passaged with Trypsin-
EDTA at 90-100% confluency. For passaging, cells were washed once with sterile 1x PBS, and 
trypsinized with 1 ml of Trypsin-EDTA for 2-5 min at 37°C. 9 ml fresh growth medium was added and 
detached cells were resuspended until a single cell suspension was obtained. Aliquots (1/20-1/3) of 
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the resuspended cells were plated in dishes containing 10 ml fresh medium and were equally 
distributed by gentle shaking. 
7.2.2.2 Freezing and thawing of eukaryotic cell lines 
• Freezing medium: 
Medium for human neuroblastoma cells (previously mentioned) 
15% (v/v) DMSO 
10% FBS 
without antibiotics 
Cells at 60-90% confluency were used for freezing. Cells from a 10 cm dish were trypsinized as 
described and transferred into a 15 ml tube with 10 ml of fresh medium. The cells were centrifuged at 
300 x g for 5 min, resuspended in 1 ml freezing medium and transferred into cryovials (Nunc). The 
vials were incubated in a crybox (Nunc) containing isopropanol at -80°C, and then transferred into a 
liquid nitrogen tank for long-term storage. 
 
• Thawing cells: 
Cells frozen in liquid nitrogen were quickly thawed at 37°C in a water bath. 
Cells were then transferred to a 10 cm dish with 10 ml fresh growth medium and equally distributed by 
gentle shaking. The next day the medium was replaced in order to remove residual DMSO and non-
viable cells. Cells were further cultured as described above. 
7.2.2.3 Stable transfection of human neuroblastoma cells 
Human neuroblastoma cells (SH-SY5Y) were transfected with the following constructs: 
 
• pCEP4 vector alone, negative control (Invitrogen) 
• pCEP4-spA4ct-DA-WT 
• pCEP4-spA4ct-DA-I45F 
• pCEP4-spA4ct-DA-V50F 
 
OptiMEM (Invitrogen) 
Lipofectamine (Invitrogen) 
Plus-reagent (Invitrogen) 
In an Eppendorf tube, 4 µg plasmid-DNA was mixed with 750 µl OptiMEM and 20 µl Plus-reagent 
(mixture a). Meanwhile, 750 µl OptiMEM was mixed with 30 µl OptiMEM (mixture b). Both mixtures 
were separately incubated for 15 min at room temperature. Afterwards  mixture a and mixture b were 
combined and further incubated for 15 min at room temperature.  A 10 cm dish with SH-SY5Y cells at 
70-80 % confluency was washed with OptiMEM twice and 5 ml OptiMEM were added.  The combined 
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Lipofectamine/DNA mixture was added to 80% confluent cells and incubated for 3 h at 37°C and 5% 
CO2. Afterwards, 4 ml OptiMEM supplemented with 10% FCS was added. The next day, the 
transfection medium was removed and 10 ml of growth medium, described in Chapter 7.2.2.1 
containing hygromycin B (final concentration 300 µg/ml), was added to the cells to select transfected 
cells for stable expression. Single colonies (corresponding to single clones with varying expression 
levels), consisting of 1-7 cells, were selected and transferred to 48 well plates and grown to 100% 
confluency. Then the cells were transferred to 24 well plates, grown again to 100% confluency. 
Afterwards the cells were transferred to 6 well plates, grown again to 100% confluency and finally cells 
were transferred to 10 cm dishes. Within 1-10 passages cells were checked for expression by 
Western-Blotting. Afterwards total-RNA and proteins were extracted from single clones producing 
varying or equal amounts of overexpressed C99.  
C99WT, C99I45F and C99V50F were overexpressed. The same cell line was mock-transfected 
(negative control). Overexpressed C99 was intracellularly processed resulting in different amounts of 
Aβ42 and Aβ40 [148, 149]. 9 clones (3 for C99WT, 3 for C99I45F and 3 for C99V50F) with 
approximately similar expression levels were selected and used for transcriptome analysis and 
analysis of the phosphorylation status of crucial proteins. 
7.2.2.4 RNA interference 
7.2.2.4.1 Transient knockdown by siRNAs 
Long, double-stranded RNAs (dsRNAs; typically >200 nt) can be used to silence the expression of 
target genes in a variety of organisms and cell types (e.g. worms, fruit flies and plants). Upon 
introduction, the long dsRNAs enter a cellular pathway that is commonly referred to as the RNA 
interference (RNAi) pathway. Firstly, the dsRNAs get processed into 20-25 nucleotide (nt) small 
interfering RNAs (siRNAs) by an RNase III-like enzyme called Dicer (initiation step)*. Then, the 
siRNAs assemble into endoribonuclease-containing complexes known as RNA-induced silencing 
complexes (RISCs), unwinding in the process. The siRNA strands subsequently guide the RISCs to 
complementary RNA molecules, where they cleave and destroy the cognate RNA (effecter step). 
Cleavage of cognate RNA takes place near the middle of the region bound by the siRNA strand. In 
mammalian cells, introduction of long dsRNA (>30 nt) initiates a potent antiviral response, exemplified 
by nonspecific inhibition of protein synthesis and RNA degradation. The mammalian antiviral response 
can be bypassed, however, by the introduction or expression of siRNAs.  
 
 
                                            
*Alternatively siRNAs can be directly administered to the cells. In this thesis, siRNAs with 21 nucleotides in length 
were used. This leads to an effective knockdown of target m-RNA while bypassing the mammalian antiviral 
response (473. Tuschl, T., Functional genomics: RNA sets the standard. Nature, 2003. 421(6920): p. 220-1, 
474. Elbashir, S.M., W. Lendeckel, and T. Tuschl, RNA interference is mediated by 21- and 22-nucleotide 
RNAs. Genes Dev, 2001. 15(2): p. 188-200, 475. Elbashir, S.M., J. Harborth, W. Lendeckel, A. Yalcin, K. 
Weber, and T. Tuschl, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. 
Nature, 2001. 411(6836): p. 494-8, 476. Fire, A., S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. 
Mello, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998. 
391(6669): p. 806-11, 477. Tuschl, T., J.B. Thomson, and F. Eckstein, RNA cleavage by small catalytic RNAs. 
Curr Opin Struct Biol, 1995. 5(3): p. 296-302, 478. Tuschl, T., P.D. Zamore, R. Lehmann, D.P. Bartel, and 
P.A. Sharp, Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev, 1999. 13(24): p. 3191-7, 
479. Tuschl, T., Expanding small RNA interference. Nat Biotechnol, 2002. 20(5): p. 446-8.). 
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Optimizing transfection efficiency is crucial for maximizing gene silencing while minimizing cytoxicity. 
The following conditions were adjusted (in order of importance): 
 
• Identification of an effective transfection agent for the used cell type  
• Amount of transfection agent  
• Amount of siRNA  
• Cell density at the time of transfection  
• Order of transfection (pre-plating cells or plating cells/transfecting in tandem)  
• Length of exposure of cells to transfection agent/siRNA complexes 
 
7.2.2.4.2 Transfection of the human neuroblastoma cell line SH-SY5Y 
with siRNAs 
The following three transfection solutions were tested for transfection efficiency of the human 
neuroblastoma cell line SH-SY5Y: 
 
Transfection solution Properties 
siPORT™ NeoFX™ Transfection Agent (Ambion) 
Lipid-based agent that delivers siRNA into 
mammalian cells with minimal cytotoxicity.  
siPORT™ Amine Transfection Agent (Ambion)  
Polyamines that deliver siRNA into mammalian 
cells with minimal cytotoxicity.  
Lipofectamin plus (Invitrogen) 
Cationic-lipid reagent for transfecting a broad 
range of cells. 
 
The volumes and the amounts in the following protocol were for transfections in 10 cm plates. 
• Cell plating 
Approximately 24 h before transfection, cells were plated in normal growth medium so that they were  
approximately 50% confluent after 24 hours. 
The cells were incubated overnight under normal cell culture conditions. 
After 24 hours the normal growth medium was substituted with OPTI-MEM I without serum and the 
cells were incubated for 1-3 hours. 
• Preparing siRNA/transfection agent complexes (si PORT Amine) 
33 µl of the transfection agent siPORT Amine, was diluted in 517 µl OPTI-MEM I without serum to 
reach a final volume of 550 µl. The solution was mixed well and incubated at room temperature for 15 
minutes. 
8.25 µl of 20 µM siRNA (for a final concentration of 30 nM) was diluted in 541.75 OPTI-MEM I to reach 
a final volume of 550 µl. The solution was incubated for 15 minutes at room temperature. 
The diluted siRNA was added to the diluted transfection agent and mixed by gently flicking the tube. 
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The dilution was incubated for 15 minutes at room temperature. 
• Transfecting cells 
12650 µl OPTI-MEM I was added to the solution containing the transfection agent and the siRNA.  
After removing the OPTI-MEM I from the plate containing the cells, the transfection agent/siRNA 
complex in OPTI-MEM I was added dropwise to the cells. 
Without swirling, the dish was gently rocked back and forth to evenly distribute the complexes. 
The cells were incubated under normal cell culture conditions for 24 hr. 
After 24 h, the medium containing the transfection agent/siRNA complex was substituted with normal 
growth medium and the cells were incubated for 24 hours. 
 
• Assay for target gene activity 48 h after transfection 
The total RNA was extracted from the cells 48 hours after the start of transfection and the knock down 
of the gene of interest was measured by real-time PCR. 
 
• Protocol for transfection with Lipofectamin Plus (6-well plate): 
20 µl of Lipofectamin Plus was diluted in 490 µl OPTI-MEM I and the solution was incubated at room 
temperature for 15 minutes. 
After adding 1.5 µl of siRNA to 98.5 µl of OPTI-MEM I, 2.7 µl of Plus Reagent were added to the 
solution and incubated for 15 minutes at room temperature. 
The standard protocol was not modified from this step and continues as above. 
7.2.3 RNA methods 
7.2.3.1 Transcriptome analysis using Affymetrix screening 
7.2.3.1.1 Total RNA preparation from cultured cells 
Total RNA was extracted using the Qiashredder-Kit (Qiagen), RNeasy Midi-columns (Qiagen) and the 
RNase-free DNase set (Qiagen). 
Human neuroblastoma cells (SH-SY5Y) were grown in 10 cm cell culture dishes until they reached 
70% confluency. Cells were washed twice with ice-cold PBS.  Then cells were lysed with 1.8 ml RLT-
buffer per cell culture dish containing β-mercaptoethanol. After 5 min, lysed cells were scraped off and 
put on Qiashredder columns. The columns were centrifuged for 1 min at room temperature at 13000 
rpm in a commonly used table Eppendorf centrifuge. The flow-through was mixed with an equal 
volume of 70% ethanol and put onto RNeasy Midi-columns. The columns were centrifuged for 5 min at 
room temperature at 3000-5000g in a swinging-bucket centrifuge. Directly on the columns any 
remaining DNA was digested by using the RNase-free DNase set (Qiagen) following the 
manufacturer’s instructions. Then 2.5 ml RPE-buffer was put onto the columns. The columns were 
centrifuged for 2 min at room temperature at 3000-5000g in a swinging-bucket centrifuge. 250µl 
RNase-free water was put onto the columns in order to elute the total-RNA. After 10 min columns 
  Materials and Methods 
 
 
228
were centrifuged for 2 min at room temperature at 3000-5000 g in a swinging-bucket centrifuge. The 
eluted total-RNA was immediately stored at -80°C. 
7.2.3.1.2 Quantification of RNA  
For quantitation the BIO-RAD spectrophotometer SmartSpecTM 3000 was used. 
To determine the concentration of total RNA in an aqueous solution, total-RNA was diluted in an 
appropriate volume of RNase-free water (approximately 1:10, depending on RNA yield). The 
absorbance of this solution was measured at wavelengths of 260/280 and 320 nm. 
To ensure significance, absorbance at 260 nm should be between 0.1 and 0.9. An absorbance of 1 
unit at 260 nm corresponds to 40 μg of RNA per ml. This relation is valid for measurements in water 
only.  
dilRNA fml
gAc ⋅⋅= μ40260  dilf  = dilution factor 
RNA samples have to be measured in RNase-free cuvettes, especially if the RNA is to be recovered 
after spectrophotometry. This can be accomplished by washing cuvettes with RNase-free water. It is 
crucial to use the same solution (here: water) in which the RNA was diluted to blank the 
spectrophotometer.   
An example for the calculation of RNA yield is shown below:  
The total amount of RNA in µg resulting from one extraction, was calculated by multiplying the 
calculated concentration in µg/ml with the total volume of water in which the sample was initially 
dissolved. 
Volume of extracted total-RNA= 1.6 ml  
Dilution = 10 μl of RNA sample + 90 μl RNase-free water (1/10 dilution).  
Measured absorbance of diluted sample in a 1 ml cuvette (RNase-free): A260 = 0.75  
Concentration of RNA sample = 40 x A260 x dilution factor  
       = 40 x 0.75 x 10  
       = 296 μg ml
-1  
Total yield = concentration x volume of sample in ml  
    = 296μg ml
-1 
x 1.6 ml  
    = 473.6 μg RNA  
7.2.3.1.3 Precipitation of total-RNA 
A given volume of total-RNA (corresponding to 20 µg total-RNA) was precipitated by adding 10% (v/v) 
sodium-acetate (3 M, pH 5.2) and 2.5 times the volume of absolute ethanol. After mixing by finger 
flicking the precipitate was stored overnight (or at least 1 hour) at -20°C. Then it was centrifuged at 
13000 rpm/4°C. The pellet was washed twice with 80% ice cold ethanol. Then the supernatant was 
carefully removed and the remaining precipitate was air-dried for 15-30 min at room temperature and 
dissolved in 9 µl of RNase-free water. 
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7.2.3.1.4 Reverse transcription of total RNA into cDNA by oligo (dT) 
primers 
20 µg of total RNA was used to generate first-strand cDNA by using the SuperscriptTM Double-
Stranded cDNA Synthesis Kit (Invitrogen). 
1.5 µl T7-linked oligo(dT)24 primer (100 µM) was added to 9 µl total-RNA (precipitated from 20 µg 
total-RNA and dissolved in RNase-free water) and incubated for 10 min at 70°C. Then 4 µl 5x first 
strand cDNA buffer, 2 µl 0.1 M DTT and 1 µl 10 mM dNTP-mix were added and incubated for 2 min at 
45°C.  Afterwards, 3 µl Super Script ІІ RT was added and incubated for 1 h at 45°C. Second strand 
synthesis was performed by adding the following substances and incubated for 2 h at 16°C: 91 µl 
RNase-free water, 30 µl 5 x second strand cDNA buffer, 3 µl 10 mM dNTP mix, 1 µl E.coli DNA ligase 
(10 U/µl), 4 µl E.coli DNA polymerase I and 1 µl RNase H (2 U/µl). Then 2 µl T4 polymerase was 
added and incubated for 5 min at 16°C. The reaction was stopped by adding 10 µl 0.5 M EDTA. 
Finally, the samples were frozen at -80°C. 
7.2.3.1.5 Purification of cDNA 
The purification of previously synthesized cDNA was performed using the GeneChip® Sample Clean 
up Module (Affymetrix) by following the manufacturer’s instructions.  
7.2.3.1.6 In vitro transcription of cDNA into cRNA 
After purification of cDNA, in vitro transcription was performed with biotinylated UTP and CTP using 
the BioArrayTM High YieldTM RNA Labeling Kit (Enzo Life Sciences).  
3.3 µl of purified cDNA was mixed with appropriate volumes of reaction buffer, biotin-labeled 
ribonucleotides, DTT, RNase inhibitor and T7 RNA polymerase in a total volume of 40 µl according to 
the manufacturer’s instructions. This mixture was incubated for 5 h at 37°C and stored at -80°C 
afterwards. 
7.2.3.1.7 Purification of cRNA 
The purification of previously in vitro transcribed cRNA was performed using the GeneChip® Sample 
Clean up Module (Affymetrix) by following the manufacturer’s instructions.  
7.2.3.1.8 Fragmentation of cRNA 
The fragmentation of the cRNA was performed using the GeneChip® Eukaryotic Hybridization Control 
Kit (Affymetrix). 
A given volume of purified cRNA (corresponding to 15 µg of purified cRNA) was mixed with 8 µl 5x 
fragmentation buffer and filled up with RNase-free water to a total volume of 40 µl. This mixture was 
incubated for 35 min at 94°C and stored afterwards at -80°C. (To confirm successful fragmentation 
cRNA could again be checked with the Bioanalyzer 2100™). 
 
 
  Materials and Methods 
 
 
230
7.2.3.1.9 Hybridisation of fragmented cRNA onto the arrays 
Hybridisation controls (spike controls) and the control oligonucleotide B2 (land mark for the scanner) 
were added to 15 µg fragmented cRNA. In detail, the following hybridisation cocktail was prepared:  
40 µl (15 µg) fragmented cRNA, 5.1 µl control oligonucleotide B2 (3nM), 15 µl 20x Eukaryotic 
Hybridisation Controls, 3 µl herring sperm DNA (10 mg/ml), 3 µl BSA (50 mg/ml), 2x MES hybridisation 
buffer and 83.9 µl of RNase-free water. 
Prior to using whole genome arrays, test arrays were used to check sample quality again. After 
checking sample quality with the test array, the same cRNA was hybridized to Affymetrix whole 
genome U-133 A and B oligonucleotide arrays: 
The hybridisation cocktail was incubated for 5 min at 99°C followed by an incubation of 5 min at 45°C.  
• Pre-incubation: 
Meanwhile 240 µl 1x MES hybridisation buffer was filled into the Chip cartridges and the Chips were 
pre-incubated for 10 min/45°C at 60 rpm in a hybridisation oven (Affymetrix).  
• Hybridisation: 
Then the 1x MES hybridisation buffer was removed from the Chip cartridges and 240 µl of the 
incubated hybridisation cocktail was filled into the Chip cartridges. The Chips were incubated for 16 
h/45°C at 60 rpm in the hybridisation oven.   
7.2.3.1.10 Washing and staining of the arrays 
Before washing, 240 µl of the hybridisation cocktail, used for hybridisation, was collected and stored at 
-20°C for eventual reuse. The arrays were then washed by filling the Chip-cartridges with wash buffer 
A (non-stringent wash buffer). The Chips were put into the Fluidics station (Affymetrix) and were 
washed according to the manufacturer’s instructions: 
• wash buffer A: non-stringent wash buffer 
• wash buffer B: stringent wash buffer 
• SAPE: streptavidin-phycoerythrin 
 
Specification Conditions 
Post Hyb Wash#1 10 cycles of 2 mixes/cycle with wash buffer A at 25°C 
Post Hyb Wash#2 8 cycles of 15 mixes/cycle with wash buffer B at 50°C 
Staining Staining of the array for 10 min with SAPE solution at 25°C 
Post Stain Wash 10 cycles of 4 mixes/cycle with wash buffer A at 25°C 
2nd Staining Staining of the array for 10 min with a biotinylated anti-streptavidin 
antibody at 25°C 
3rd Staining Staining of the array for 10 min with SAPE solution at 25°C 
Final Wash 15 cycles of 4 mixes/cycle with wash buffer A at 25°C. Holding 
temperature= 25°C 
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7.2.3.1.11 Scanning of the arrays 
The Chips were scanned twice with a Gene Array Scanner (Hewlett Packard) and the quality of the 
created dat-file images were evaluated by using the Microarray Suite MAS 5.0 (Affymetrix) and the 
Gene Operating Software GCOS1.2 (Affymetrix). 
7.2.3.1.12 Data analysis 
The data analysis was performed with the Microarray Suite MAS 5.0 (Affymetrix) and the Gene 
Operating Software GCOS1.2 (Affymetrix). Further data analysis was performed with the Micro DB 
(Affymetrix), Data Mining Tool (Affymetrix), Array Assist 3.3 (Stratagene), Pathway Assist (Stratagene) 
3.0, Ingenuity Pathway Analysis (Ingenuity Systems) and the PANTHER Gene and Protein 
Classification System (Applied Biosystems). Data analysis was performed at the same time by our 
collaboration partner Carina Ittrich with the open source software “Language R” available at www.r-
project.org. Further information and R-packages are available at www.bioconductor.org 10 
7.2.3.2 Quantitative real-time PCR 
7.2.3.2.1 Preface 
Quantitative real-time PCR can be performed in a one-step reaction (reverse transcription carried out 
in the same tube as PCR) or in two steps (reverse transcription carried out in a separate reaction).  
Here I followed a two-step reverse transcription polymerase chain reaction (RT-PCR) protocol. In the 
first step, total-RNA, extracted from cells, is reverse transcribed into cDNA. In the second step, this 
cDNA acts as a template for DNA amplification, which is measured with a GeneAmp® 5700 Sequence 
Detection System (real-time PCR cycler). Pre-designed and labelled primer/probe sets were selected 
from the Applied Biosystems’ Assays-on-DemandTM product line. 
7.2.3.2.2 Reverse transcription of total RNA into cDNA by using 
random hexamer primers  
The High-Capacity cDNA Archive Kit (Applied Biosystems) was used for reverse transcription (RT) of 
total-RNA into single-stranded cDNA. 
As a first step, a 2 X RT master mix was prepared using the kit ‘s components, already thawed on ice. 
As a second step, a given volume of a total-RNA sample (10-50 ng) was adjusted with RNase-free 
water to a volume of 50 µl. 
 
 
 
 
 
                                            
10 Bioconductor is an open source and open development software project for the analysis and comprehension of 
transcriptomic data. 
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 Volume (µl)/Reaction 
10X Reverse Transcription Buffer 10 
25X dNTPs 4 
10X random primers 10 
MultiScribe™ Reverse Transcriptase, 50 U/µl 5 
Nuclease-free H2O 21 
Total volume of 2 X RT master mix 50 
Total volume of total-RNA sample adjusted to 10-50 
ng/50 µl 
50 
 
Total volume of reaction 
100 
 
Finally the following mix was pipetted into a 96-well reaction plate or single Eppendorf tubes: 
50 µl of 2 X RT master mix was added to 50 µl of total-RNA sample (adjusted to 10-50 ng/50 µl) to 
come to a total volume of 100 µl. The sample was pipetted up and down twice to ensure a 
homogenous mixture. 
The samples were incubated for 120 min at 37°C and subsequently held at 4°C using a common 
thermal cycler (Mastercycler® gradient (Eppendorf)). The obtained cDNA was kept at -20°C for long 
term storage. 
7.2.3.2.3 Real-time detection of amplified cDNA by using an ABI 
cycler 5700 and Taqman probes (Applied Biosystems) 
The quantitative real-time PCR assay was performed using the TaqMan® Gene Expression Assays 
and the TaqMan® Universal PCR Master Mix. The cDNA amplification was measured with a 
GeneAmp® 5700 Sequence Detection System.  
Principle: the special design of TaqMan probes, combined with 5’-3’ nuclease activity of the 
polymerase allows direct detection of PCR products by the release of a fluorescent reporter during the 
PCR on the ABI PRISM Sequencing Detector. 
TaqMan probes consist of an oligonucleotide with a 5’-reporter dye and a downstream, 3’- quencher 
dye. The fluorescent reporter dye, FAM (6-carboxy-fluorescein) is covalently linked to the 5’ end of the 
oligonucleotide. This reporter is quenched by TAMRA (6-carboxy-tetramethyl-rhodamin), typically 
located at the 3’ end. During PCR, if the target of interest is present, the probe specifically anneals 
between the forward and reverse primer sites. The nucleolytic activity of the polymerase only cleaves 
the probe between the reporter and the quencher if this region hybridizes to the target. This cleavage 
between the reporter and the quencher dyes results in an increase of fluorescence of the reporter that 
is proportional to the amount of product accumulated. This process is described in Figure 7.1 
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The fluorescence signal in each reaction is measured in real time at each cycle of the PCR by the ABI 
5700 instrument. Laser light passes through optical fibres to excite the fluorochromes in the samples. 
Emitted fluorescence passes back through the optical fibres and is directed to a spectrograph 
attached to a CCD camera. Fluorescence detection between 500 and 660 nm is possible. The ABI 
5700 can simultaneously measure more than one fluorescence wavelength per well. This means that 
endogenous controls can be run either as parallel reactions in separate wells (singleplex11 PCR)  or 
within the same well as the sample (multiplex12 PCR). Here singleplex PCR was performed. 
 
 
 
 
 
 
 
Figure 7.1 Polymerisation-
associated, 5´ to 
3´nuclease activity of 
AmpliTaq Gold DNA 
Polymerase during PCR. 
(Figure taken from Applied 
Biosystems) 
 
When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression 
of the reporter fluorescence primarily by Förster-type energy transfer (Förster, 1948; Lakowicz, 1983). 
During PCR, if the target of interest is present, the probe specifically anneals between the forward and 
reverse primer sites. The 5´ to 3´ nucleolytic activity of the AmpliTaq Gold enzyme cleaves the probe 
between the reporter and the quencher only if the probe hybridizes to the target. The probe fragments 
are then displaced from the target, and polymerization of the strand continues. The 3´ end of the probe 
is blocked to prevent extension of the probe during PCR. This process occurs in every cycle and does 
not interfere with the exponential accumulation of product. Analysis of the digitized fluorescence 
intensity signal is done by the Sequence Detector software (Applied Biosystems). The reporter signal 
is plotted against the cycle number. The threshold cycle (cT) is the PCR cycle at which a significant 
increase in reporter fluorescence above baseline can be detected. 
 
 
 
 
 
                                            
11 Singleplex PCR: one primer pair is used for the reaction 
12 Multiplex PCR: more than one primer pair are used for the reaction 
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Method: The reaction was carried out in 96 well plates from Applied Biosystems. 
 
TaqMan Universal PCR Master Mix (2 x) 12.5 µl 
Assays-on-DemandTM Gene Expression Assay 
Mix (20x) (containing forward and reverse 
primers and labelled probe) 
1.25 µl 
RNase-free water 1.25 µl 
Total volume of master mix 15 µl 
Total volume of cDNA (corresponding to 10ng-
100ng) 
10 µl 
Total volume of reaction 25 µl/well 
 
For one well, 12.5 µl of TaqMan Universal PCR Master Mix (2 x), 1.25 µl of 20 x Assays-on-DemandTM 
Gene Expression Assay Mix (containing forward and reverse primers and labelled probe) and 1.25 µl 
RNase-free water were mixed. A total volume of 15 µl of this premix, already prepared in batch for 
multiple wells, was distributed in each well together with 10 µl of cDNA sample (10ng-100ng final 
amount) as template. Three control-wells, containing just the premix with primers and Taq Man probe 
but without template, were added to each plate to detect any possible contamination with non specific 
DNA (NTC, No-Template-Control). Amplification of an endogenous control was performed to 
standardize the amount of sample DNA added to the reaction. For the quantification of gene 
expression, cyclophilin A was used as this endogenous control. Three replicates of each sample and 
endogenous control were amplified.  
Relative quantification with data from the ABI PRISM® 5700 Sequence Detection System was 
performed with the comparative method (the MethodTCΔΔ−2 ). 
This method is a convenient way to analyze the relative changes in gene expression from real-time 
quantitative PCR experiments. For the ∆∆CT calculation to be valid, the amplification efficiencies of the 
target (gene of interest) and reference (in all samples equally expressed gene) must be approximately 
equal. A sensitive method for assessing if two amplicons have the same efficiency is to look at how 
∆CT varies with the template dilution. Therefore, standard curves were established for calculating the 
efficiency of amplification. 
The ∆CT value is determined by subtracting the average CT value of the endogenous control from the 
average CT value of the gene of interest. The same is done for a so-called calibrator (this is for 
instance a user-defined baseline experiment). 
 
∆CT1 = CT gene of interest - CT endogenous control (calibrator=baseline experiment) 
∆CT2= CT gene of interest - CT endogenous control  
 
 The fold change of gene expression is: 
2 
-(∆CT2 -∆CT1) 
This is the amount of target, normalized to an endogenous reference and relative to a calibrator. 
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7.2.3.3 RNA interference (siRNAs) 
Refer to Chapter 7.2.2.4, RNA interference. 
7.2.4 Quality control of cells, total-RNA, cRNA and Chips® 
7.2.4.1 Screening of cells for mycoplasma contamination 
Each sample was screened and found to be free from mycoplasma contamination. The Mycoplasma 
Detection Kit (Roche) was used according to the manufacturer’s recommendations. This is an enzyme 
immunoassay for the detection of mycoplasmas/acholeplasmas in cell culture (M. arginini, M. 
hyorhinis, M. orale, A. laidlawii). 
7.2.4.2 Assessment of RNA purity by measuring the 260 nm/280 
nm ratio 
The ratio of the measurements at 260 nm and 280 nm (A260/A280) provides an estimate of the purity 
of RNA with respect to contaminants that absorb in the UV-range, such as proteins and phenol. Pure 
RNA has an A260/A280 ratio of 1.9–2.1. If there is contamination with protein or phenol, the 
A260/A280 will be significantly less than the values given above, and accurate quantification of the 
RNA will not be possible. A more exact ratio is gained by subtracting a previously measured 
background wavelength at 320 nm from the numerical values of A260 and A280. 
The resulting formula for the ratio is: 
 
320280
320260
BgA
BgA
Ratio −
−=  
 
Absorption at 280 nm is caused by aromatic amino acids, mainly by tryptophane and less strongly by 
tyrosine and phenylalanine, depending on their absorption maximum. Absorption at 260 nm is caused 
by nucleic acids. A 260 nm/280 nm ratio < 1.8 is caused by increased amounts of proteins in the 
sample. A 260 nm/280 nm ratio of 1.9-2.1 for Chip experiments and 1.8-2.1 for quantitative real-time 
PCR was accepted.   
7.2.4.3 Agarose gel electrophoresis 
Total-RNA, unfragmented cRNA and fragmented cRNA were checked on 1% agarose gels. For total-
RNA two distinct bands (28s and 18s ribosomal RNA) were expected. The 28 s band should be 
approximately twice as strong as the 18 s band. For unfragmented cRNA a smear of bands, 
representing the different mRNAs, was expected with an accumulation in the centre of the smear. For 
fragmented cRNA bands corresponding to a size of 35-200 bases were expected. 
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7.2.4.4 Checking quality of unfragmented cRNA with the 
Bioanalyzer 2100 (Agilent) 
As described in Chapter 7.2.4.5 the quality of cRNA was checked using RNA Nano Chips. The quality 
of cRNA was evaluated by the distribution of the cRNAs which should result in a characteristic shape 
of the curve generated by the Bioanalyzer 2100™. If the quality was evaluated to be good, 15 µg of 
purified cRNA was used for fragmentation. 
7.2.4.5 Assessment of RNA integrity with the Bioanalyzer 2100 
(Agilent) 
Principle: The integrity of RNA samples is essential in the context of gene expression analysis via 
microarray technology or real-time PCR. Agilent provides RNA assays that enable rapid 
characterization of total or mRNA or cRNA samples, with unmatched sensitivity and with minimal 
sample consumption. 
The quantitative range for total RNA Assay is 25-500 ng/µl, while the qualitative range is 5-500 ng/µl. 
The Agilent 2100 Bioanalyzer is the most successful micro fluidics-based platform for the analysis of 
RNA, DNA and proteins. 
The system uses micro-fabrication technology to transfer laboratory processes onto miniature glass 
chips that contain a network of interconnected channels and reservoirs. Filling the channels with a gel 
matrix and the wells with buffer or sample allows electrophoresis to be carried out on a miniaturized 
scale. Choosing the appropriate LabChip kit (containing chips, buffer, gel, intercalating dye and 
standards) enables the analysis of RNA, DNA or protein samples. 
The electropherogram of the sample well window for total RNA (eukaryotic) consists of 2 ribosomal 
peaks, the 28S and 18S and one marker peak. If the total RNA is undamaged the ratio of 28S: 18S 
RNA is close to the theoretical maximum of 2.5. The respective ribosomal bands should appear as 
sharp bands. 28S ribosomal RNA bands should be present with an intensity approximately twice that 
of the 18S RNA band. If the ribosomal bands in a given lane are not sharp, but appear as a smear of 
smaller sized RNAs, it is likely that the RNA sample suffered major degradation during preparation.  
Method:  
The first step in performing the RNA 6000 Nano assay consisted of centrifuging 550 µl of RNA 6000 
Nano gel matrix in a spin filter at 1500 g ± 20% for 10 minutes. 
65 µl of this filtered gel was mixed with 1 µl of the RNA 6000 Nano dye concentrate, already 
equilibrated to room temperature for 30 min and spinned down. 
The solution was well vortexed and spun down at 13000 g for 10 min at room temperature. A new 
RNA Nano chip was placed on a device for filling the Nano chip with the samples (Chip Priming 
Station) and the gel-dye mix, the RNA 6000 Nano Marker, the Ladder and the samples were pipetted 
into the wells, following the instructions of the RNA 6000 Nano Assay Protocol. 
 
 
 
  Materials and Methods 
 
 
237
7.2.4.6 Assessment of Gene Chip® quality, hybridisation efficiency 
and RNA quality by certain parameters 
After scanning, array images were assessed by several parameters giving information about Chip 
quality, hybridisation efficiency and RNA quality: 
• Array images were assessed by eye to confirm the absence of bubbles or scratches.  
• Scaling factors 
• Background 
• Noise 
• Number of present transcripts 
• 3'/5' ratios for GAPDH and beta-actin 
• Bio spike controls 
 
7.2.5 Protein methods 
7.2.5.1 Protein expression in mammalian cells 
Human neuroblastoma cells (SH-SY5Y) were transfected as described and C99WT, C99I45F and 
C99V50F were overexpressed. The same cell line was mock-transfected (negative control). 
Overexpressed C99 was intracellularly processed resulting in different amounts of Aβ42 and Aβ40 [148, 
149]. 
7.2.5.2 Whole cell protein extraction from mammalian cells 
7.2.5.2.1 Extraction of non-phosphorylated proteins 
• Cell lysis buffer:  
50 mM Tris-HCl pH 7.5 
150 mM NaCl 
5 mM EDTA 
1% Triton X 
1% NP40 
1x Complete® protease inhibitor (freshly added before use) 
1 X PBS 
4 X SDS sample buffer 
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To minimize protein degradation, all steps were carried out on ice. For protein extraction from cell 
cultures, cells were washed once with ice-cold PBS and after adding 1 ml of PBS, cells were scraped 
off, transferred into a 1 ml Eppendorf tube, and centrifuged at 300 g, at 4°C, for 5 min. The 
supernatant was removed and 200 µl of lysis buffer, containing 1x (prepared from a 25x stock 
solution) protease inhibitor was added to the pellet. After incubating for 20 minutes on ice, the solution 
was further centrifuged at 13000 rpm, at 4°C, for 10 minutes and the supernatant was stored at -80°C 
for later use or immediately denatured with the appropriate volume of 4xSDS sample buffer. For 
analyzing proteins by SDS-PAGE, the lysates were boiled for 10 min in 4xSDS sample buffer and 
loaded on a SDS-polaycrylamide gel. 
7.2.5.2.2 Extraction of phosphorylated proteins 
• Screening of phosphorylated proteins using the Kinexus-screening service™: 
Kinexus offers different kinds of screenings for the detection of phosphorylated proteins by SDS-
PAGE. Here the Kinetworks™ Biosource Phospho-Site Neurobiology Screen (KPSS-9.0) and the 
KCPS-1.0 Custom Screen were used. All antibodies used for these screens were intensively tested for 
specificity by Kinexus.  
The human neuroblastoma cell line SH-SY5Y, transfected with C99-spA4CT WT, C99-spA4CT I45F 
or C99-spA4CT V50F was grown to 70% confluency. Protein was extracted by lysing the cell pellet, 
derived from three 10 cm dishes in 250 µl of the following buffer: 
 
20 mM MOPS, pH 7.0 
2 mM EGTA 
5 mM EDTA 
Phosphatase inhibitor cocktail II (Calbiochem), according to the manufacturer’s instructions 
20 mM sodium pyrophosphate 
40 mM β-glycerophosphate, pH 7.2 
Complete® Protease Inhibitor Mix (Roche) (1x final concentration from a 25x stock solution) 
0.5% NonidetP-40 
 
This solution was sonicated on ice for 15 seconds followed by a break of 45 seconds, sonicated again 
for 15 seconds and stored on ice afterwards for 20 min. Then this lysate was ultracentrifuged at 120 
000 g for 30 min at 4°C. The protein concentration of the supernatant was determined using the BCA-
test described elsewhere. 500 µg of protein was added to 125 µl 4x SDS-PAGE sample buffer and 
filled up with double-distilled water to a total volume of 500 µl. This sample was sent to Kinexus for 
screening of the phosphorylation status of important proteins involved in signaling processes. After 
approximately 4 weeks the results were provided from Kinexus as TIFF-files of the scanned Western-
blots and the normalized phosphorylation status was delivered as Microsoft Excel spreadsheets. 
Further data analysis was performed using a student’s t-test. 
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7.2.5.3 Determination of protein concentrations 
Protein concentrations were measured using an ELISA-reader (microplate-reader 450, BIO-RAD) or 
the BIO-RAD spectrophotometer SmartSpecTM 3000 according to the BCA (Bicinchoninic acid) 
method. In an alkaline solution, proteins reduce Copper- ions to Cu1+-ions which form a violet complex 
with BCA. The absorption maximum of this complex is at 562 nm. 
 
BCA, working solution: 1 ml CuSO4 ·5 H2O + 39 ml BCA (Sigma)(1:40 dilution) 
BSA standard solutions (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 mg/ml) 
ELISA 96-well plate (Greiner) 
 
The proteins were diluted approximately 1:10 (dependent on protein yield) with 1 X PBS.  
20 µl of each diluted protein sample were placed in each well and 200 µl of BCA working solution was 
added. 20 µl of standard (BSA), gradual concentrations (as above), were added into each well, 
together with 200 µl of BCA working solution. The plate was covered with aluminium and kept for 15 
minutes at 37°C and subsequently 15 minutes at room temperature on a horizontal shaker. Absorption 
was measured with a microplate-reader (model 450, BIO-RAD) at 550 nm. Protein concentrations 
were calculated with the BSA standard curve. 
7.2.5.4 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
• 4 X loading buffer for SDS-PAGE: 
250 mM Tris/HCl pH 6.8 
8% SDS 
30% Glycerol 
0.02% Bromophenol blue 
Prior to use, 5% β-mercaptoethanol was added 
• 10 X SDS-Running Buffer 
1.92 M Glycine 
0.25 M Tris-base 
1% (w/v) SDS 
• Separating gel: 10 ml (12% Polyacrylamide): 
4 ml 30% Acrylamide + 0,8 ml Bisacrylamide 
2.5 ml 1,5 M Tris, pH 8,8  
0.1 ml 10% SDS 
0.1 ml 10% APS 
0.004 ml TEMED 
3.3 ml double-distilled H2O  
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• Stacking gel: 3 ml (5% Acrylamide) 
0.5 ml 30% Acrylamide + 0,8 ml Bisacrylamide 
0.38 ml 1 M Tris, pH 6,8 
0.03 ml 10% SDS 
0.03 ml 10% APS 
0.003 ml TEMED 
2.1 ml double-distilled H2O 
 
SDS binds to hydrophobic regions of the proteins so that they become negatively charged and migrate 
to the anode. As the amount of SDS bound is proportional to the molecular weight of the proteins, the 
SDS-polypeptide complex moves in the gel according to the size of the proteins. 
Pre-cut glass plates were assembled with Teflon spacers (1mm) and a silicon tube and used for 
casting the gel. After pouring the separating gel, a thin layer of isopropanol was added on top. As soon 
as the separating gel was polymerized (approximately 1 h) the isopropanol was removed, the stacking 
gel was poured and a comb was positioned in the polymerising stacking gel. After polymerisation was 
finished, protein samples were loaded (after boiling for 10 min in 4 X loading buffer) and 
electrophoresis was performed in 1 x running buffer for approximately 2 hours at 160 V. 
7.2.5.5 Western blotting  
 
Transfer of proteins onto nitrocellulose membranes and  their immunological detection 
 
Western blotting was used to identify a protein of interest by its size in a protein extract. 
Proteins are separated by SDS-PAGE and electrophoretically transferred from the gel to a 
nitrocellulose membrane. Specific antibodies can detect the immobilized proteins on the membrane. 
 
• Western Blot Transfer (Wet Blot) 
Transferbuffer (Western blot) pH 8.4: 
20 mM Tris-base 
200 mM Glycine 
20% Methanol 
ad 3000 ml H2O 
 
After separating the proteins by SDS-PAGE the separating gel was equilibrated in transfer buffer for 5 
min. Whatman sheets and a nitrocellulose membrane were cut to the size of the gel and soaked for 5 
min in transfer buffer. The gel and the membrane were sandwiched between soaked pieces of sponge 
pads, Whatman paper, and perforated plastic plates as follows: 
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• Anode (+) 
• Sponge pad 
• 2 Whatman sheets 
• Nitrocellulose 
• SDS gel 
• 2 Whatman sheets 
• Sponge pad 
• Cathode (-) 
 
The proteins were blotted at approximately 1mA/cm2 
The transfer was performed in a blotting tank (Bio-Rad) for 3 hours at 400 mA, 280 V, at 4°C. 
 
• Staining of immobilized proteins  with Ponceau S 
Ponceau S-solution: 
0.2% (w/v) Ponceau-S red 
3% (w/v) sulfonic acid 
0.1% (w/v) glacial acid 
Proteins immobilized on a membrane can be reverse stained with Ponceau S-dye to evaluate the 
efficiency of protein transfer after Western blotting. 
The nitrocellulose membrane was incubated in Ponceau S-solution on a horizontal shaker for 5 min. 
The stained solution was recovered, and unspecifically bound dye was removed with dd H2O. The 
efficiency of protein transfer was evaluated and subsequently the membrane staining was removed by 
incubation with 1 x PBS. 
• Immunological detection of blotted proteins 
1 x TBST: 
100 mM Tris/HCl 
1.5 M NaCl 
0.5% Tween 20 
pH 7.4 
ECL-kit (Amersham) 
 
After Western Blot transfer of proteins to the nitrocellulose membrane, the membrane was blocked for 
1 h in 5% (w/v) skim-milk in 1 x TBST to prevent unspecific binding of antibodies. The primary 
antibody was diluted in 5% (w/v) skim-milk in 1 x TBST to a suitable concentration. The membrane 
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was incubated with the primary antibody either for 2-4 h at room temperature or overnight at 4°C.To 
remove all the traces of unspecifically bound primary antibodies the membrane was washed twice with 
1 x TBST, and further incubated twice in 1 x TBST for 10 min. Incubation of the membrane with the 
secondary antibody conjugated to horseradish peroxidase (HRP, dilution 1:2000-10000 in TBS) was 
carried out for 1h at room temperature. The membrane was again washed twice with 1 x TBST, and 
further incubated three times in 1 x TBST for 5 min. 
The protein of interest was detected by enhanced chemical luminescence (ECL) utilizing the reaction 
of luminol and H2O2, which is catalyzed by HRP. For this purpose, the membrane was incubated with 
the ECL (Amersham) reagent for exactly 1 min and the chemifluorescent signal was immediately 
visualized by exposure to Hyperfilm ECL films (Amersham). 
 
• Stripping and re-probing of Western Blot membranes  
Stripping buffer: 
62.5 mM Tris/HCl pH 6.7 
100 mM β-Mercaptoethanol 
2% SDS 
 
For reprobing the membrane with different antibodies, the previously applied antibodies first had to be 
removed. For this purpose, stripping buffer was preheated to 80°C. The membrane was incubated 
with 100-200 ml preheated stripping buffer on a horizontal shaker until room temperature was reached 
(30-45 min). The membrane was further incubated several times (3-5 times) with 1 x TBST, until 
hardly any residual β-Mercaptoethanol could be detected by smelling. 
The membrane was again blocked in 5% (w/v) skim-milk in 1 x TBST for 1 h, and a new primary 
antibody could be applied as described. 
Normalisation and relative quantification of proteins: 
For normalisation of loaded protein amounts, blotted membranes were stripped as described and re-
probed with an anti-β-actin antibody (Abcam), diluted according to the manufacturer’s instructions. The 
obtained bands on Hyperfilm ECL films (Amersham) were quantified by densitometry using the Image 
Gauge software. 
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7.2.5.6 Immunoprecipitation 
 
• Washing buffer A:  10 mM Tris/HCl pH 7.5, 150 mM NaCl, 2 mM  
EDTA, 0.2% NP40 
• Washing buffer B:  Like washing buffer A, but with 500 mM NaCl instead 
• Washing buffer C:  10 mM Tris/HCl pH 7.5 
• Protein A sepharose (Amersham) 
• Protein G sepharose (Sigma) 
 
Proteins secreted into the medium or extracted from cell lysates were precipitated with appropriate 
antibodies and 30 µl Protein A sepharose (for polyclonal antibodies) or Protein G sepharose (for 
monoclonal antibodies). Protein samples were cleared from cell debris by centrifugation at 15.000 x g 
for 10 min. Samples were pre-incubated for 1 h at 4°C with 10 µl of  Protein A or G- sepharose to 
reduce unspecific binding. Equally, antibodies were prebound to 30 µl of Protein A or G- sepharose in 
500 µl Washing buffer A by incubating on an overhead shaker for 1 h at room temperature. The 
sepharose beads were sedimented at 15.000 x g for 30 s and the supernatant was transferred to the 
prebound antibody beads. The samples were incubated for 2-3 h at room temperature or overnight at 
4°C. The sepharose beads were centrifuged at 5000 x g for 30 s, washed three times with Washing 
buffer A. In case of unspecific binding, additional washing steps with Washing buffer B and C were 
performed. The buffer was completely removed with a Hamilton syringe and the proteins attached to 
the sepharose beads were denatured in 2x SDS sample buffer for 10 min at 70°C. The samples were 
further analyzed by SDS-PAGE and Western blotting. 
7.2.6 Differentiation of human neuroblastoma cells by retinoic 
acid  
A 0.5 M stock solution of all-trans retinoic acid (RA, Sigma R2625) was prepared by dissolving 1 g RA 
in 6.66 ml DMSO. A further stock solution was prepared by diluting the 0.5 M stock solution 1:1000 in 
DMSO. To reach final concentrations of 0.1-1000 nM, this stock solution was further diluted in 
appropriate volumes of cell culture medium in absence or presence of serum. The human 
neuroblastoma cell line SH-SY5Y was treated with 0.1 nM-10 µM RA in cell culture medium, 
mentioned in Chapter 7.1.15, in absence or presence of serum for 2-9 days. All preparation steps of 
RA and cell culture experiments were performed in dim light due to light-sensitiveness of RA. 
Differentiation of cells was checked by light microscopy at appropriate times. 
 
 
 
 
 
  Materials and Methods 
 
 
244
7.2.7 Immunocytochemistry 
7.2.7.1 Immunostaining of cultured cells 
• Preparation of coverslips: 
PLL, 20 µg/ml (Sigma) 
Collagen (Sigma, C7661) 
Neuroclean® Coverslips (Primeglass, Neuherberg, Germany), were distributed in a 24 well plate, 
covered with PLL or collagen for several hours. PLL or collagen was removed and the coverslips were 
air-dried for approximately 30 min. Afterwards human neuroblastoma cells were plated. 
 
• Immunostaining 
 
Mowiol:  2.4 g Mowiol 4-88 (Sigma) 
  6 ml Glycerol (Sigma) 
  6 ml double-distilled H2O 
  12 ml 0.2 M Tris-HCl pH 8.5 
 
Mowiol was incubated for 10 min at 50°C, centrifuged for 15 min at 5000 rpm in a commonly used 
Eppendorf centrifuge, the supernatant was collected in fresh tubes and stored at -20°C. Once 
defrosted, it was stable for at least one month. 
 
4% PFA in PBS 
1 x PBS 
For immunocytochemistry, cells were grown on (PLL or collagen coated) coverslips in 24 well plates 
and fixed with 4% Paraformaldehyde in 1x PBS for 5 min. Cells were permeabilized in 1x PBS + 0.1 % 
NP40 for 10 min and blocked with 5% normal goat serum in 1 x PBS for 1 h. Primary antibodies were 
diluted in 1 x PBS + 5% goat serum (1:50-1:1000). Each coverslip was placed upside down on 
approximately 50 µl antibody solution and incubated at 4°C over night. The next day, cells were 
incubated with the appropriate secondary antibodies coupled with Alexa 488 and Alexa 594 
fluorescent dyes (Molecular probes) for 0.5-1 h at room temperature and mounted with Mowiol. 
Embedded cells were stored, protected from light, until examination under a deconvolution 
fluorescence microscope. 
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7.2.7.2 Immunofluorescence microscopy 
Pictures were taken using the deconvolution microscope Leica DMRXA, equipped with suitable 
software (Openlab). Omission of primary antibodies was used as a control to verify specificity 
(expected to show only very low background staining). Embedded cells were examined with a Leica 
deconvolution microscope by using 10x, 40x and 100x objectives.   
7.2.8 Light microscopy 
For checking differentiation after RA treatment, cells were cultured in a 24-well plate, treated with RA, 
as described, and pictures were taken of the living human neuroblastoma cell line SH-SY5Y. An 
inverse photo-microscope, the Zeiss Axiovert 35 was used, equipped with an Olympus DP50 digital 
colour camera. Pictures were taken using a 20x objective. Afterwards cells were incubated at 37°C to 
induce further differentiation. 
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10 Abbreviations 
A absorption 
aa amino acids 
Aβ amyloid-β peptide 
ACTA2  actin alpha 2 smooth muscle aorta 
ACTN1 actinin alpha 1 
AD Alzheimer's disease 
ADAM a disintegrin-like and metalloprotease 
ADAMTS3 a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif  3
ADAMTS9 a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif  9
ADRB1 adrenergic, beta-1-receptor 
AICD APP intracellular domain 
AKT1 v-akt murine thymoma viral oncogene homolog 1 
AMPA2 glutamate receptor ionotropic AMPA 2 (synonym: gria2) 
AMPA3 glutamate receptor ionotropic AMPA 3 (synonym: gria3) 
APLP amyloid precursor like protein 
APLP1  amyloid beta (A4) precursor-like protein 1 
APLP2 amyloid beta (A4) precursor-like protein 2 
APP amyloid precursor protein (synonym: AβPP) 
ASS argininosuccinate synthase  
ATP7A ATPase, Cu2+ transporting, alpha polypeptide (Menkes syndrome) 
BAMBI BMP and activin membrane-bound inhibitor 
BCA bicinchinonic acid 
BDNF brain-derived neurotrophic factor 
BMP7 bone morphogenetic protein 7 (osteogenic protein 1) 
bp base pairs 
BSA bovine serum albumin 
b-561 cytochrome b-561 (CYB561) 
b-245 cytochrome b-245, alpha polypeptide (CYBA) 
C99 C-terminal fragment of APP comprising 99 aa 
CCND1 cyclin D1 (synonym: PRAD1, parathyroid adenomatosis 1) 
CDK6 cyclin-dependent kinase 6 
CDKL1 cyclin-dependent kinase-like 1 (CDC2-related kinase) 
CDKL5 cyclin-dependent kinase-like 5 
CDKN1A   cyclin-dependent kinase inhibitor 1A (synonym: p21, Cip1) 
CHRNA7 cholinergic receptor nicotinic alpha polypeptide 7  
COL4A1 collagen type IV alpha 1 
COL4A2 collagen type IV alpha 2 
CRABP1 cellular retinoic acid binding protein 1 
CREB1 cAMP responsive element binding protein 1 
CSF cerebro spinal fluid 
CTF C-terminal fragment 
CTSD cathepsin D (lysosomal aspartyl protease) 
CUTL2 cut-like 2 (Drosophila) 
DAPI 4', 6'-diamidino-2-phenylindole dihydrochloride 
DCAMKL1 DCAMKL1, doublecortin and CaM kinase-like 1 
DDC dopa decarboxylase (aromatic L-amino acid decarboxylase) 
DKK2 dickkopf homolog 2 (Xenopus laevis) 
DKK4 dickkopf homolog 4 (Xenopus laevis) 
DMEM Dulbecco's minimal essential medium 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
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DNCLI2 dynein cytoplasmic light intermediate polypeptide 2 
DNER delta-notch-like EGF repeat-containing transmembrane 
dNTPs 2'-deoxyribonucleoside-5'-triphosphates 
DS Down's syndrome 
DTT dithiothreitol 
DYRK1 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B 
ECEL1 endothelin converting enzyme-like 1 
EDTA ethylene diamine tetra acetic acid 
EGFR 
epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene 
homolog, avian) 
ERK1 extracellular regulated protein-serine kinase 1 (p44 MAP kinase)  
et al. et alii, and others 
FAD familial AD 
FBS fetal bovine serum 
FCS fetal calf serum 
FGB fibrinogen B beta polypeptide 
GABRB3 γ-aminobutyric acid (GABA) A receptor beta 3 
GAD1 glutamate decarboxylase 1 (brain 67kDa) 
GATA3 GATA binding protein 3 
GC-RMA robust multichip averaging, regarding GC content 
GLRB glycine receptor, beta 
GLS glutaminase 
GLUL glutamine synthase (synonym: Glutamate-ammonia ligase) 
GRIA2  synonym: glutamate receptor, ionotropic, AMPA 2 
GRIA3  synonym: glutamate receptor, ionotropic, AMPA 3 
GRM7  glutamate receptor, metabotropic 7 
GRM8c glutamate receptor, metabotropic 8c 
GSK3β glycogen synthase kinase 3 β 
H19 H19 imprinted maternally expressed untranslated mRNA 
HCHWAD hereditary cerebral hemorrhages with amyloidosis 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 
HMP19 HMP19 protein (LOC51617) 
HRP horse radish peroxidase 
HS3ST2 heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
IDE insulin degrading enzyme 
IGF1R insulin-like growth factor 1 receptor 
IGF2 insulin-like growth factor 2 (somatomedin A) 
IGFBP5 insulin-like growth factor binding protein 5 
ITGB5 integrin β 5 
JAG1 jagged 1  
JNK c-Jun amino-terminal kinase 
kb kilobase pair 
kDa kilodalton 
L1CAM L1 cell adhesion molecule 
LB Luria-Bertani medium 
LOAD late onset Alzheimer’s disease 
LOD Score logarithm of the odds score 
LRP4 low density lipoprotein receptor-related protein 4 
LTP long-term potentiation 
MAPT microtubule-associated protein tau (synonym: Tau) 
MEK1 MAPK/ERK protein-serine kinase 1 (synonym: MKK1) 
MEM minimal essential medium 
MES 2-morpholinoethane-sulfonic acid 
min minute 
          Abbreviations 
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MMP8 matrix metalloproteinase 8 (neutrophil collagenase) 
MOPS 3-(N-morpholino) propane-sulfonic acid 
MT microtubule 
NDUFB9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 
NFTs neuro fibrillary tangles 
NGF nerve growth factor 
NP-40 nonidet P-40 
NSAIDS non steroidal anti-inflammatory drugs 
NTRK2 neurotrophic tyrosine kinase receptor type 2 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PBX1 pre-B-cell leukemia transcription factor 1 
PD Parkinson’s disease 
PDZK1 PDZ domain containing 1 
PFA paraformaldehyde 
PFKP  phosphofructokinase platelet 
PI3K phosphoinositide-3-kinase 
PKC protein kinase C 
PLAT plasminogen activator tissue 
PLIER probe logarithmic intensity error 
PLL poly-L-Lysine 
PREP prolyl endopeptidase 
PRSS12 protease serine 12 (neurotrypsin, motopsin) 
PS presenilin 
PTGER2, prostaglandin E receptor 2 (subtype EP2), 53kDa 
PTN pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) 
RA retinoic acid 
RELN reelin 
RGS4 regulator of G-protein signaling 4 
RMA robust multichip average 
RNA ribonucleic acid 
RNase ribonuclease 
rpm revolutions per minute 
RT room temperature 
SD standard deviation 
SDS sodium dodecyl sulphate 
SEMA3A  
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 
3A 
SEMA3C 
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 
3C 
SERPINE2 serine proteinase inhibitor clade E member 2 
SERPINF1 serine proteinase inhibitor clade F member 1 
SGK serum/glucocorticoid regulated kinase 
SHOX2 short stature homeobox 2 
siRNA small interfering RNA 
SLIT1 slit homolog 1 (Drosophila) 
STX3A  syntaxin 3A 
SYN2 synapsin 2 
TAE tris acetate EDTA buffer 
tau microtubule-associated protein tau (synonym : MAPT) 
TBE tris borate EDTA buffer 
TFPI2 tissue factor pathway inhibitor 2 
TGFB2 transforming growth factor, beta 2 
TGFBR2 transforming growth factor, beta receptor 2 (70/80kDa) 
          Abbreviations 
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TIMP1 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity collagenase inhibitor) 
TIMP3  tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy pseudoinflammatory) 
TLE1 transducin-like enhancer of split 1 (E(sp1) homolog  Drosophila) 
TLE2 transducin-like enhancer of split 2 (E(sp1) homolog  Drosophila) 
Tris tris (hydroxymethyl) aminomethane 
TRKB tyrosine kinase receptor B, synonym: NTRK2 
3'-UTR 3-prime untranslated region 
5'-UTR 5-prime untranslated region 
v/v volume per volume 
VEGF vascular endothelial growth factor 
VMP vesicular membrane protein p24 
w/v weight per volume 
WNT composition of Wingless und Int1 
WT wild type 
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12 Supplementary Information  
12.1 Preface 
All the data were calculated with three different normalisation algorithms (PLIER, GC-
RMA, MAS 5). The thresholds for the p-values were adjusted to p<0.05 (PLIER), to 
p<0.005 (GC-RMA) and to p<0.05 (MAS 5). However, data slightly greater than these 
thresholds (for instance p=0.058, when the threshold was p<0.05) are also listed 
here (the exact p-value is given in the tables), if they might have crucial biological 
functions. P-values were calculated from three independent single clones. For some 
genes no gene symbols, titles or locations are shown, because this information is not 
available for all probes (for instance for expressed sequence tags) on the Chip. 
Instead, only the probe set ID is shown allowing to get information from public 
databases. 
12.2 Genes identified using different algorithms 
12.2.1 Genes identified using the PLIER-algorithm (Array Assist, 
Stratagene) 
Table 12.1 Most up and down-regulated genes derived from the comparison 
C99I45F/C99WT1 (Aβ42/Aβ40↑, n=3, p<0.05, C99WT1 was the 
baseline experiment) 
Position Probe Set ID p-value 
Fold change 
C99I45F/C99WT1 
Gene 
Symbol Title Location 
1 218623_at 0.0030 3.0 HMP19 
HMP19 protein 
(LOC51617)  chr5q35.2 
2 239293_at 0.0055 2.8 VMP 
vesicular membrane 
protein p24 chr6p22.2 
3 205358_at 0.0331 2.7 GRIA2 
glutamate receptor  
ionotropic  AMPA 2 chr4q32-q33 
4 223672_at 0.0189 2.7 
DKFZp761D
221 
hypothetical protein 
DKFZp761D221 chr1p31.2 
5 205113_at 0.0441 2.6 NEF3 
neurofilament 3 (150kDa 
medium) chr8p21 
6 227690_at 0.0256 2.6 GABRB3 
Gamma-aminobutyric acid 
(GABA) A receptor  beta 3 chr15q11.2-q12 
7 228010_at 0.0201 2.4 PPP2R2C 
protein phosphatase 2 
(formerly 2A)  regulatory 
subunit B (PR 52)  
gamma isoform chr4p16.1 
8 227830_at 0.0076 2.4 GABRB3 
Gamma-aminobutyric acid 
(GABA) A receptor  beta 3 chr15q11.2-q12 
9 226281_at 0.0048 2.3 DNER 
delta-Notch-like EGF 
repeat-containing 
transmembrane chr2q36.3 
10 201939_at 0.0415 2.3 PLK2 polo-like kinase 2 chr5q12.1-q13.2 
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(Drosophila) 
11 226086_at 0.0309 2.3 SYT13 synaptotagmin XIII chr11p12-p11 
12 227210_at 0.0414 2.3 SFMBT2 
Scm-like with four mbt 
domains 2 chr10p14 
13 201341_at 0.0079 2.2 ENC1 
ectodermal-neural cortex 
(with BTB-like domain) chr5q12-q13.3 
14 221916_at 0.0430 2.2 NEFL 
Neurofilament  light 
polypeptide 68kDa chr8p21 
15 221796_at 0.0231 2.2 NTRK2 
neurotrophic tyrosine 
kinase  receptor  type 2, 
non-catalytic isoform chr9q22.1 
16 225111_s_at 0.0157 2.1 NAPB 
N-ethylmaleimide-
sensitive factor 
attachment protein  beta chr20p12.3-p11.21 
17 209755_at 0.0289 2.1 NMNAT2 
nicotinamide nucleotide 
adenylyltransferase 2 chr1q25 
18 212096_s_at 0.0170 2.1 MTUS1 
mitochondrial tumor 
suppressor 1 chr8p22 
19 212314_at 0.0388 2.1 KIAA0746 KIAA0746 protein chr4p15.2 
20 234904_x_at 0.0226 2.1 ELAVL4 
ELAV (embryonic lethal  
abnormal vision  
Drosophila)-like 4 (Hu 
antigen D) chr1p34 
21 206502_s_at 0.0356 2.0 INSM1 insulinoma-associated 1 chr20p11.2 
22 206002_at 0.0076 2.0 GPR64 
G protein-coupled 
receptor 64 chrXp22.13 
23 209591_s_at 0.0114 2.0 BMP7 
bone morphogenetic 
protein 7 (osteogenic 
protein 1) chr20q13 
24 204396_s_at 0.0167 2.0 GRK5 
G protein-coupled 
receptor kinase 5 chr10q24-qter 
25 213338_at 0.0400 2.0 RIS1 
Ras-induced senescence 
1 chr3p21.3 
26 229724_at 0.0462 2.0 GABRB3 
gamma-aminobutyric acid 
(GABA) A receptor  beta 3 chr15q11.2-q12 
27 226814_at 0.0032 2.0 ADAMTS9 
a disintegrin-like and 
metalloprotease 
(reprolysin type) with 
thrombospondin type 1 
motif  9 chr3p14.3-p14.2 
28 213802_at 0.0008 2.0 PRSS12 
Protease  serine  12 
(neurotrypsin  motopsin) chr4q28.1 
29 223500_at 0.0297 2.0 CPLX1 complexin 1 chr4p16.3 
30 226560_at 0.0541 2.0 SGPP2 
Sphingosine-1-phosphate 
phosphotase 2 chr2q36.1 
31 203329_at 0.0189 1.9 PTPRM 
protein tyrosine 
phosphatase  receptor 
type  M chr18p11.2 
32 201621_at 0.0015 1.9 NBL1 
neuroblastoma  
suppression of 
tumorigenicity 1 chr1p36.13-p36.11 
33 221801_x_at 0.0297 1.9 NEFL 
neurofilament  light 
polypeptide 68kDa chr8p21 
34 221933_at 0.0300 1.9 NLGN4X neuroligin 4  X-linked chrXp22.32-p22.31 
35 228347_at 0.0304 1.9 SIX1 
Sine oculis homeobox 
homolog 1 (Drosophila) chr14q23.1 
36 203789_s_at 0.0106 1.9 SEMA3C 
sema domain  
immunoglobulin domain 
(Ig)  short basic domain  
secreted  (semaphorin) 
3C chr7q21-q31 
37 212658_at 0.0180 1.9 LHFPL2 
lipoma HMGIC fusion 
partner-like 2 chr5q14.1 
38 223143_s_at 0.0275 1.9 C6orf166 
chromosome 6 open 
reading frame 166 chr6q15 
39 230112_at 0.0199 1.9 C3HC4 
membrane-associated 
ring finger (C3HC4) 4 chr2q35 
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40 219926_at 0.0134 1.8 POPDC3 
popeye domain 
containing 3 chr6q21 
41 205348_s_at 0.0111 1.8 DNCI1 
dynein  cytoplasmic  
intermediate polypeptide 
1 chr7q21.3-q22.1 
42 210108_at 0.0454 1.8 CACNA1D 
calcium channel  voltage-
dependent  L type  alpha 
1D subunit chr3p14.3 
43 205515_at 0.0132 1.8 PRSS12 
protease  serine  12 
(neurotrypsin  motopsin) chr4q28.1 
44 201645_at 0.0492 1.8 TNC tenascin C (hexabrachion) chr9q33 
45 205068_s_at 0.0093 1.8 ARHGAP26 
Rho GTPase activating 
protein 26 chr5q31 
46 209590_at 0.0190 1.8 BMP7 
Bone morphogenetic 
protein 7 (osteogenic 
protein 1) chr20q13 
47 201037_at 0.0022 1.8 PFKP 
phosphofructokinase  
platelet chr10p15.3-p15.2 
48 206577_at 0.0361 1.8 VIP 
vasoactive intestinal 
peptide chr6q25 
49 213273_at 0.0053 1.8 ODZ4 
odz  odd Oz/ten-m 
homolog 4 (Drosophila) chr11q14.1 
50 219825_at 0.0123 1.8 CYP26B1 
cytochrome P450  family 
26  subfamily B  
polypeptide 1 chr2p13.2 
51 219225_at 0.0068 1.8 PGBD5 
piggyBac transposable 
element derived 5 chr1q42.13 
52 204465_s_at 0.0376 1.8 INA 
internexin neuronal 
intermediate filament 
protein  alpha chr10q24.33 
53 224940_s_at 0.0504 1.8 PAPPA 
pregnancy-associated 
plasma protein A  
pappalysin 1 chr9q33.2 
54 203030_s_at 0.0414 1.8 PTPRN2 
protein tyrosine 
phosphatase  receptor 
type  N polypeptide 2 chr7q36 
55 229576_s_at 0.0514 1.8 TBX3 
T-box 3 (ulnar mammary 
syndrome) chr12q24.1 
56 241872_at 0.0323 1.8 
DKFZp761D
221 
Hypothetical protein 
DKFZp761D221 chr1p31.2 
57 209295_at 0.0220 1.8 TNFRSF10B 
tumor necrosis factor 
receptor superfamily  
member 10b chr8p22-p21 
58 203788_s_at 0.0319 1.8 SEMA3C 
sema domain  
immunoglobulin domain 
(Ig)  short basic domain  
secreted  (semaphorin) 
3C chr7q21-q31 
59 204319_s_at 0.0195 1.8 RGS10 
regulator of G-protein 
signaling 10 chr10q25 
60 205373_at 0.0114 1.7 CTNNA2 
catenin (cadherin-
associated protein)  alpha 
2 chr2p12-p11.1 
61 212841_s_at 0.0271 1.7 PPFIBP2 
PTPRF interacting protein  
binding protein 2 (liprin 
beta 2) chr11p15.4 
62 202507_s_at 0.0236 1.7 SNAP25 
synaptosomal-associated 
protein  25kDa chr20p12-p11.2 
63 219697_at 0.0116 1.7 HS3ST2 
heparan sulfate 
(glucosamine) 3-O-
sulfotransferase 2 chr16p12 
64 213689_x_at 0.0540 1.7 LOC388650 Hypothetical LOC388650 chr1p22.1 
65 212095_s_at 0.0198 1.7 MTUS1 
mitochondrial tumor 
suppressor 1 chr8p22 
66 212311_at 0.0332 1.7 KIAA0746 KIAA0746 protein chr4p15.2 
67 212328_at 0.0003 1.7 KIAA1102 KIAA1102 protein chr4p13 
68 213478_at 0.0021 1.7 KIAA1026 KIAA1026 protein chr1p36.21 
69 202508_s_at 0.0235 1.7 SNAP25 synaptosomal-associated chr20p12-p11.2 
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protein  25kDa 
70 221558_s_at 0.0364 1.7 LEF1 
lymphoid enhancer-
binding factor 1 chr4q23-q25 
71 212843_at 0.0016 1.7 NCAM1 
neural cell adhesion 
molecule 1 chr11q23.1 
72 203029_s_at 0.0530 1.7 PTPRN2 
protein tyrosine 
phosphatase  receptor 
type  N polypeptide 2 chr7q36 
73 205143_at 0.0112 1.7 CSPG3 
chondroitin sulfate 
proteoglycan 3 (neurocan) chr19p12 
74 201150_s_at 0.0263 1.7 TIMP3 
tissue inhibitor of 
metalloproteinase 3 
(Sorsby fundus dystrophy  
pseudoinflammatory) 
chr22q12.1-
q13.2|22q12.3 
75 203130_s_at 0.0109 1.7 KIF5C kinesin family member 5C chr2q23.1 
76 213411_at 0.0074 1.7 ADAM22 
A disintegrin and 
metalloproteinase domain 
22 chr7q21 
77 37005_at 0.0038 1.7 NBL1 
neuroblastoma  
suppression of 
tumorigenicity 1 chr1p36.13-p36.11 
78 212327_at 0.0069 1.7 KIAA1102 KIAA1102 protein chr4p13 
79 206014_at 0.0521 1.6 ACTL6B actin-like 6B chr7q22 
80 215740_at 0.0083 1.6 PTPRN2 
Protein tyrosine 
phosphatase  receptor 
type  N polypeptide 2 chr7q36 
81 205117_at 0.0201 1.6 FGF1 
fibroblast growth factor 1 
(acidic) chr5q31 
82 219610_at 0.0496 1.6 RGNEF 
Rho-guanine nucleotide 
exchange factor chr5q13.2 
83 212325_at 0.0079 1.6 KIAA1102 KIAA1102 protein chr4p13 
84 217028_at 0.0523 1.6 CXCR4 
chemokine (C-X-C motif) 
receptor 4 chr2q21 
85 219277_s_at 0.0133 1.6 OGDHL 
oxoglutarate 
dehydrogenase-like chr10q11.23 
86 204412_s_at 0.0384 1.6 NEFH 
neurofilament  heavy 
polypeptide 200kDa chr22q12.2 
87 211160_x_at 0.0045 1.6 ACTN1 actinin  alpha 1 
chr14q24.1-
q24.2|14q24|14q22
-q24 
88 205721_at 0.0332 1.6 GFRA2 
GDNF family receptor 
alpha 2 chr8p21 
89 219837_s_at 0.0378 1.6 CYTL1 cytokine-like 1 chr4p16-p15 
90 212093_s_at 0.0088 1.6 MTUS1 
mitochondrial tumor 
suppressor 1 chr8p22 
91 203037_s_at 0.0192 1.6 MTSS1 metastasis suppressor 1 chr8p22 
92 202920_at 0.0014 1.6 ANK2 ankyrin 2  neuronal chr4q25-q27 
93 204117_at 0.0025 1.6 PREP prolyl endopeptidase chr6q22 
94 214875_x_at 0.0179 1.6 APLP2 
amyloid beta (A4) 
precursor-like protein 2 
chr11q23-
q25|11q24 
95 209234_at 0.0371 1.6 KIF1B kinesin family member 1B chr1p36.2 
96 206290_s_at 0.0062 1.5 RGS7 
regulator of G-protein 
signaling 7 
chr1q43|1q23.1 
according to Sierra 
(Transcriptomics 
79; 177; 2002) 
[AFS] 
97 216672_s_at 0.0332 1.5 MYT1L 
myelin transcription factor 
1-like chr2p25.3 
98 37950_at 0.0002 1.5 PREP prolyl endopeptidase chr6q22 
99 
203640_at 
 0.0370 1.5 MBNL2 
muscleblind-like 2 
(Drosophila) chr13q32.1 
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100 
215955_x_at 
 
0.0074 
 1.5 
ARHGAP26 
 
Rho GTPase activating 
protein 26 
 
chr5q31 
 
21 204314_s_at 0.0072 -1.1 CREB1 
cAMP responsive element 
binding protein 1 chr2q34 
20 214080_x_at 0.0471 -1.1 PRKCSH 
protein kinase C substrate 
80K-H chr19p13.2 
19 204313_s_at 0.0144 -1.1 CREB1 
cAMP responsive element 
binding protein 1 chr2q34 
18 201337_s_at 0.0327 -1.1 VAMP3 
vesicle-associated 
membrane protein 3 
(cellubrevin) chr1p36.23 
17 221745_at 0.0406 -1.1 HAN11 WD-repeat protein chr17q23.3 
16 201259_s_at 0.0297 -1.2 SYPL synaptophysin-like protein chr7q22.3 
15 206848_at 0.0149 -1.2 HOXA7 homeo box A7   
14 220138_at 0.0277 -1.3 HAND1 
heart and neural crest 
derivatives expressed 1 chr5q33 
13 207966_s_at 0.0106 -1.3 GLG1 golgi apparatus protein 1 chr16q22-q23 
12 201726_at 0.0162 -1.3 ELAVL1 
ELAV (embryonic lethal  
abnormal vision  
Drosophila)-like 1 (Hu 
antigen R) chr19p13.2 
11 200879_s_at 0.0127 -1.4 EPAS1 
endothelial PAS domain 
protein 1 chr2p21-p16 
10 203590_at 0.0066 -1.5 DNCLI2 
dynein  cytoplasmic  light 
intermediate polypeptide 
2 chr16q22.1 
9 200878_at 0.0404 -1.6 EPAS1 
endothelial PAS domain 
protein 1 chr2p21-p16 
8 210816_s_at 0.0343 -1.6 CYB561 cytochrome b-561 chr17q11-qter 
7 202291_s_at 0.0246 -1.7 MGP matrix Gla protein chr12p13.1-p12.3 
6 217200_x_at 0.037 -1.7 CYB561 cytochrome b-561 chr17q11-qter 
5 214020_x_at 0.0446 -1.9 ITGB5 Integrin  beta 5 chr3q21.2 
4 201125_s_at 0.0477 -2 ITGB5 integrin  beta 5 chr3q21.2 
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3 204337_at 0.0124 -2.2 RGS4 
regulator of G-protein 
signaling 4 chr1q23.3 
2 204339_s_at 0.0068 -2.6 RGS4 
regulator of G-protein 
signaling 4 chr1q23.3 
1 204338_s_at 0.0176 -2.7 RGS4 
regulator of G-protein 
signaling 4 chr1q23.3 
Table 12.1 Most up and down-regulated genes derived from the comparison C99I45F/C99WT1 
(n=3, p<0.05), analyzed with the Array Assist software and the PLIER algorithm. 
Table 12.2 Most up and down-regulated genes derived from the comparison 
C99V50F/C99WT1 (Aβ42/Aβ40↓, n=3, p<0.05, C99WT1 was the 
baseline experiment) 
Position Probe Set ID p-value 
Fold change 
C99V50F/C99WT1 Gene Symbol Title Location 
1 209291_at 0.0153 3.0 ID4 
inhibitor of DNA 
binding 4, dominant 
negative helix-loop-
helix protein chr6p22-p21 
2 212092_at 0.0173 2.7 PEG10 
paternally expressed 
10 chr7q21 
3 209278_s_at 0.0272 2.6 TFPI2 
tissue factor pathway 
inhibitor 2 chr7q22 
4 209277_at 0.0186 2.5 TFPI2 
Tissue factor pathway 
inhibitor 2 chr7q22 
5 202479_s_at 0.0217 2.3 TRIB2 
tribbles homolog 2 
(Drosophila) chr2p24.3 
6 205113_at 0.0374 2.3 NEF3 
neurofilament 3 
(150kDa medium) chr8p21 
7 212094_at 0.0077 2.3 PEG10 
paternally expressed 
10 chr7q21 
8 215411_s_at 0.0258 2.2 TRAF3IP2 
TRAF3 interacting 
protein 2 chr6q21 
9 221916_at 0.0315 2.2 NEFL 
Neurofilament, light 
polypeptide 68kDa chr8p21 
10 202478_at 0.0285 2.2 TRIB2 
tribbles homolog 2 
(Drosophila) chr2p24.3 
11 221805_at 0.0425 2.1 NEFL 
neurofilament, light 
polypeptide 68kDa chr8p21 
12 218623_at 0.0139 2.1 HMP19   chr5q35.2 
13 209293_x_at 0.0141 2.1 ID4 
inhibitor of DNA 
binding 4, dominant 
negative helix-loop-
helix protein chr6p22-p21 
14 202284_s_at 0.0453 2.0 CDKN1A 
cyclin-dependent 
kinase inhibitor 1A 
(p21, Cip1) chr6p21.2 
15 205586_x_at 0.0375 2.0 VGF 
VGF nerve growth 
factor inducible chr7q22 
16 201739_at 0.0420 1.9 SGK 
serum/glucocorticoid 
regulated kinase chr6q23 
17 219914_at 0.0368 1.9 ECEL1 
endothelin converting 
enzyme-like 1 chr2q36-q37 
18 203304_at 0.0150 1.9 BAMBI 
BMP and activin 
membrane-bound 
inhibitor chr10p12.3-p11.2 
19 221801_x_at 0.0384 1.9 NEFL 
neurofilament, light 
polypeptide 68kDa chr8p21 
20 206631_at 0.0111 1.8 PTGER2 
prostaglandin E 
receptor 2 (subtype chr14q22 
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EP2), 53kDa 
21 213894_at 0.0474 1.8 KIAA0960 KIAA0960 protein chr7p21.3 
22 209292_at 0.0233 1.8 ID4 
Inhibitor of DNA 
binding 4, dominant 
negative helix-loop-
helix protein chr6p22-p21 
23 204688_at 0.0183 1.8 SGCE sarcoglycan, epsilon chr7q21-q22 
24 203685_at 0.0291 1.7 BCL2 B-cell CLL/lymphoma 2 chr18q21.33|18q21.3
25 209462_at 0.0188 1.7 APLP1 
amyloid beta (A4) 
precursor-like protein 1 chr19q13.1 
26 206478_at 0.0104 1.7 KIAA0125 KIAA0125 chr14q32.33 
27 219093_at 0.0482 1.7 FLJ20701 
hypothetical protein 
FLJ20701 /// 
hypothetical protein 
FLJ20701 chr2q36.3 
28 203662_s_at 0.0065 1.7 TMOD1 tropomodulin 1 chr9q22.3 
29 201341_at 0.0089 1.7 ENC1 
ectodermal-neural 
cortex (with BTB-like 
domain) chr5q12-q13.3 
30 201939_at 0.0299 1.6 PLK2 
polo-like kinase 2 
(Drosophila) chr5q12.1-q13.2 
31 205399_at 0.0459 1.6 DCAMKL1 
doublecortin and CaM 
kinase-like 1 chr13q13 
32 213260_at 0.0428 1.6 FOXC1 Forkhead box C1 chr6p25 
33 220386_s_at 0.0224 1.6 EML4 
echinoderm 
microtubule associated 
protein like 4 chr2p22-p21 
34 203661_s_at 0.0308 1.6 TMOD1 tropomodulin 1 chr9q22.3 
35 205373_at 0.0079 1.5 CTNNA2 
catenin (cadherin-
associated protein), 
alpha 2 chr2p12-p11.1 
36 207260_at 0.0246 1.5 FEV 
FEV (ETS oncogene 
family) chr2q36 
37 202517_at 0.0422 1.5 CRMP1 
collapsin response 
mediator protein 1 chr4p16.1-p15 
38 213601_at 0.0484 1.5 MEGF4   
39 214508_x_at 0.0312 1.5 CREM 
cAMP responsive 
element modulator chr10p11.21 
40 210829_s_at 0.0086 1.5 SSBP2 
single-stranded DNA 
binding protein 2 chr5q14.1 
41 204471_at 0.0409 1.5 GAP43 
growth associated 
protein 43 chr3q13.1-q13.2 
42 208070_s_at 0.0244 1.5 REV3L 
REV3-like, catalytic 
subunit of DNA 
polymerase zeta 
(yeast) chr6q21 
43 205068_s_at 0.0199 1.5 ARHGAP26 
Rho GTPase activating 
protein 26 chr5q31 
44 203787_at 0.0031 1.5 SSBP2 
single-stranded DNA 
binding protein 2 chr5q14.1 
45 204134_at 0.0490 1.5 PDE2A 
phosphodiesterase 2A, 
cGMP-stimulated chr11q13.4 
46 209967_s_at 0.0461 1.5 CREM 
cAMP responsive 
element modulator chr10p11.21 
47 208712_at 0.0249 1.5 CCND1 
cyclin D1 (PRAD1: 
parathyroid 
adenomatosis 1) chr11q13 
48 214326_x_at 0.0350 1.5 JUND jun D proto-oncogene chr19p13.2 
49 200672_x_at 0.0037 1.5 SPTBN1 
spectrin, beta, non-
erythrocytic 1 chr2p21 
50 200671_s_at 0.0015 1.5 SPTBN1 
spectrin, beta, non-
erythrocytic 1 chr2p21 
51 212843_at 0.0089 1.4 NCAM1 
neural cell adhesion 
molecule 1 chr11q23.1 
52 211160_x_at 0.0171 1.4 ACTN1 actinin, alpha 1 chr14q24.1-q24.2 
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53 209197_at 0.0280 1.4 SYT11 synaptotagmin XI chr1q21.2 
54 213093_at 0.0291 1.4 PRKCA protein kinase C, alpha chr17q22-q23.2 
55 208637_x_at 0.0141 1.4 ACTN1 actinin, alpha 1 chr14q24.1-q24.2 
56 208978_at 0.0179 1.4 CRIP2 cysteine-rich protein 2 chr14q32.3 
57 201954_at 0.0145 1.4 ARPC1B 
actin related protein 
2/3 complex, subunit 
1B, 41kDa chr7q22.1 
58 214839_at 0.0398 1.4 LOC157627 
hypothetical protein 
LOC157627 chr8p23.1 
59 218773_s_at 0.0106 1.4 MSRB2 
methionine sulfoxide 
reductase B2 chr10p12 
60 220377_at 0.0079 1.4 C14orf110 
chromosome 14 open 
reading frame 110 chr14q32.33 
61 219451_at 0.0202 1.4 MSRB2 
methionine sulfoxide 
reductase B2 chr10p12 
62 210078_s_at 0.0416 1.4 KCNAB1 
potassium voltage-
gated channel, shaker-
related subfamily, beta 
member 1 chr3q26.1 
63 216963_s_at 0.0473 1.4 GAP43 
growth associated 
protein 43 chr3q13.1-q13.2 
64 208729_x_at 0.0124 1.4 HLA-B 
major 
histocompatibility 
complex, class I, B chr6p21.3 
65 212328_at 0.0260 1.4 KIAA1102 KIAA1102 protein chr4p13 
66 215678_at 0.0016 1.4 LOC440792 
similar to proline 
dehydrogenase 
(oxidase) 1; tumor 
protein p53 inducible 
protein 6; p53 induced 
protein; proline oxidase 
2; proline 
dehydrogenase 
(proline oxidase ) chr22q11.21 
67 213013_at 0.0352 1.3 MAPK8IP1 
mitogen-activated 
protein kinase 8 
interacting protein 1 chr11p12-p11.2 
68 207353_s_at 0.0017 1.3 HMX1 
homeo box (H6 family) 
1 chr4p16.1 
69 212878_s_at 0.0271 1.3 KNS2 kinesin 2 60/70kDa chr14q32.3 
70 202177_at 0.0146 1.3 GAS6 growth arrest-specific 6 chr13q34 
71 212325_at 0.0394 1.3 KIAA1102 KIAA1102 protein chr4p13 
72 204099_at 0.0104 1.3 SMARCD3 
SWI/SNF related, 
matrix associated, 
actin dependent 
regulator of chromatin, 
subfamily d, member 3 chr7q35-q36 
73 219327_s_at 0.0329 1.3 GPRC5C 
G protein-coupled 
receptor, family C, 
group 5, member C chr17q25 
74 218876_at 0.0089 1.3 CGI-38 
brain specific protein /// 
brain specific protein chr16q22.1 
75 208636_at 0.0266 1.3 ACTN1 Actinin, alpha 1 chr14q24.1-q24.2 
76 203409_at 0.0086 1.3 DDB2 /// LHX3 
damage-specific DNA 
binding protein 2, 
48kDa /// LIM 
homeobox 3 
chr11p12-p11 /// 
chr9q34.3 
77 212803_at 0.0164 1.3 NAB2 
NGFI-A binding protein 
2 (EGR1 binding 
protein 2) chr12q13.3-q14.1 
78 214781_at 0.0061 1.3 DKFZp761P19121   
79 211530_x_at 0.0271 1.3 HLA-G 
HLA-G 
histocompatibility 
antigen, class I, G chr6p21.3 
80 200852_x_at 0.0180 1.3 GNB2 
guanine nucleotide 
binding protein (G 
chr7q21.3-
q22.1|7q22 
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protein), beta 
polypeptide 2 
81 203752_s_at 0.0430 1.3 JUND jun D proto-oncogene chr19p13.2 
82 1598_g_at 0.0391 1.3 GAS6 growth arrest-specific 6 chr13q34 
83 206397_x_at 0.0325 1.3 GDF1 /// LASS1 
growth differentiation 
factor 1 /// LAG1 
longevity assurance 
homolog 1 (S. 
cerevisiae) chr19p12 
84 204608_at 0.0021 1.3 ASL 
argininosuccinate 
lyase chr7cen-q11.2 
85 204806_x_at 0.0134 1.3 HLA-F 
major 
histocompatibility 
complex, class I, F chr6p21.3 
86 203149_at 0.0137 1.3 PVRL2 
poliovirus receptor-
related 2 (herpesvirus 
entry mediator B) chr19q13.2-q13.4 
87 207788_s_at 0.0145 1.3 SCAM-1 
vinexin beta (SH3-
containing adaptor 
molecule-1) chr8p21.3 
88 211911_x_at 0.0365 1.3 HLA-B 
major 
histocompatibility 
complex, class I, B /// 
major 
histocompatibility 
complex, class I, B chr6p21.3 
89 222240_s_at 0.0049 1.3 ISYNA1 
myo-inositol 1-
phosphate synthase 
A1 chr19p13.11 
90 200710_at 0.0107 1.3 ACADVL 
acyl-Coenzyme A 
dehydrogenase, very 
long chain chr17p13-p11 
91 212935_at 0.0380 1.3 MCF2L 
MCF.2 cell line derived 
transforming 
sequence-like chr13q34 
92 212071_s_at 0.0077 1.3 SPTBN1 
spectrin, beta, non-
erythrocytic 1 chr2p21 
93 209855_s_at 0.0103 1.3 KLK2 kallikrein 2, prostatic chr19q13.41 
94 207469_s_at 0.0428 1.3 PIR 
pirin (iron-binding 
nuclear protein) chrXp22.2 
95 213201_s_at 0.0216 1.3 TNNT1 
troponin T1, skeletal, 
slow chr19q13.4 
96 202786_at 0.0016 1.3 STK39 
serine threonine kinase 
39 (STE20/SPS1 
homolog, yeast) chr2q24.3 
97 213423_x_at 0.0286 1.2 TUSC3 
tumor suppressor 
candidate 3 chr8p22 
98 208874_x_at 0.0069 1.2 PPP2R4 
protein phosphatase 
2A, regulatory subunit 
B' (PR 53) chr9q34 
99 200989_at 0.0048 1.2 HIF1A 
hypoxia-inducible 
factor 1, alpha subunit 
(basic helix-loop-helix 
transcription factor) chr14q21-q24 
100 
221875_x_at 
 0.0439 1.2 
HLA-F 
 
major 
histocompatibility 
complex, class I, F 
 
chr6p21.3 
 
50 203804_s_at 0.0491 -1.2 CROP 
cisplatin resistance-
associated 
overexpressed protein chr17q21.33 
49 222018_at 0.0465 -1.2 NACA 
nascent-polypeptide-
associated complex 
alpha polypeptide chr12q23-q24.1 
48 209081_s_at 0.0027 -1.2 COL18A1 
collagen, type XVIII, 
alpha 1 chr21q22.3 
47 210387_at 0.0306 -1.2 HIST1H2BG histone 1, H2bg chr6p21.3 
46 206848_at 0.0234 -1.2    
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45 204030_s_at 0.0445 -1.2 SCHIP1 
schwannomin 
interacting protein 1 chr3q25.32-q25.33 
44 209082_s_at 0.0421 -1.2 COL18A1 
collagen, type XVIII, 
alpha 1 chr21q22.3 
43 215338_s_at 0.0173 -1.2 NKTR 
natural killer-tumor 
recognition sequence chr3p23-p21 
42 214469_at 0.045 -1.2 HIST1H2AE histone 1, H2ae chr6p22.2-p21.1 
41 213902_at 0.0345 -1.2 ASAH1 
N-acylsphingosine 
amidohydrolase (acid 
ceramidase) 1 chr8p22-p21.3 
40 204635_at 0.018 -1.2 RPS6KA5 
ribosomal protein S6 
kinase, 90kDa, 
polypeptide 5 chr14q31-q32.1 
39 215919_s_at 0.0206 -1.2 MRPS11 
mitochondrial 
ribosomal protein S11 chr15q25 
38 214805_at 0.0293 -1.2 EIF4A1 
Eukaryotic translation 
initiation factor 4A, 
isoform 1 chr17p13 
37 209007_s_at 0.0163 -1.2 NPD014 NPD014 protein chr1p36.13-p35.1 
36 202202_s_at 0.0231 -1.2 LAMA4 laminin, alpha 4 chr6q21 
35 203989_x_at 0.0266 -1.2 F2R 
coagulation factor II 
(thrombin) receptor chr5q13 
34 210523_at 0.0234 -1.2 BMPR1B 
bone morphogenetic 
protein receptor, type 
IB chr4q22-q24 
33 203781_at 0.0264 -1.2 MRPL33 
mitochondrial 
ribosomal protein L33 chr2p21 
32 213410_at 0.0343 -1.2 C10orf137 
chromosome 10 open 
reading frame 137 chr10q26.13-q26.2 
31 206653_at 0.031 -1.2 POLR3G 
Polymerase (RNA) III 
(DNA directed) 
polypeptide G (32kD) chr5q14.3 
30 202127_at 0.0061 -1.3 PRPF4B 
PRP4 pre-mRNA 
processing factor 4 
homolog B (yeast) chr6p25.2 
29 203259_s_at 0.0351 -1.3 C6orf74 
chromosome 6 open 
reading frame 74 chr6q13-q24.3 
28 201578_at 0.0458 -1.3 PODXL podocalyxin-like chr7q32-q33 
27 204702_s_at 0.0381 -1.3 NFE2L3 
nuclear factor 
(erythroid-derived 2)-
like 3 chr7p15-p14 
26 234729_at 0.0441 -1.3 PHKG1 
phosphorylase kinase  
gamma 1 (muscle) chr7p12-q21 
25 209957_s_at 0.0488 -1.3 NPPA 
natriuretic peptide 
precursor A chr1p36.21 
24 212179_at 0.0259 -1.3 C6orf111 
chromosome 6 open 
reading frame 111 chr6q16.3 
23 203790_s_at 0.0448 -1.4 HRSP12 
heat-responsive 
protein 12 chr8q22 
22 213701_at 0.019 -1.4 DKFZp434N2030 
hypothetical protein 
DKFZp434N2030 chr12q21.33 
21 203726_s_at 0.046 -1.4 LAMA3 laminin, alpha 3 chr18q11.2 
20 208691_at 0.0361 -1.4 TFRC 
transferrin receptor 
(p90, CD71) /// 
transferrin receptor 
(p90, CD71) chr3q29 
19 241271_at 0.0215 -1.4 PKN2 Protein kinase N2 chr1p22.2 
18 212382_at 0.0467 -1.4 TCF4 Transcription factor 4 chr18q21.1 
17 213245_at 0.0426 -1.5 ADCY1 
adenylate cyclase 1 
(brain) chr7p13-p12 
16 209220_at 0.0057 -1.6 GPC3 glypican 3 chrXq26.1 
15 202669_s_at 0.0168 -1.7 EFNB2 ephrin-B2 chr13q33 
14 235957_at 0.0374 -1.7   transcribed locus   
13 206673_at 0.0372 -1.7 GPR 
putative G protein 
coupled receptor chr15q14-q15.1 
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12 209238_at 0.0438 -1.8 STX3A syntaxin 3A chr11q12.1 
11 202283_at 0.0266 -1.8 SERPINF1 
serine (or cysteine) 
proteinase inhibitor, 
clade F (alpha-2 
antiplasmin, pigment 
epithelium derived 
factor), member 1 chr17p13.1 
10 222288_at 0.0164 -1.8   Similar to CG9996-PA chr3p13 
9 209757_s_at 0.0242 -1.9 MYCN 
v-myc 
myelocytomatosis viral 
related oncogene, 
neuroblastoma derived 
(avian) chr2p24.1 
8 242385_at 0.049 -2 RORB 
RAR-related orphan 
receptor B chr9q22 
7 218330_s_at 0.0348 -2 NAV2 neuron navigator 2 chr11p15.1 
6 214596_at 0.0359 -2 CHRM3 
cholinergic receptor, 
muscarinic 3 chr1q41-q44 
5 228978_at 0.0027 -2.2 LOC440450 LOC440450 chr17q23.2 
4 207401_at 0.0303 -2.2 PROX1 
prospero-related 
homeobox 1 chr1q32.2-q32.3 
3 212713_at 0.047 -2.3 MFAP4 
microfibrillar-
associated protein 4 chr17p11.2 
2 243808_at 0.0408 -2.5 CDK6 
Cyclin-dependent 
kinase 6 chr7q21-q22 
1 215632_at 0.0162 -2.5 NEUROG2 neurogenin 2 chr4q25 
Table 12.2 Most up and down-regulated genes derived from the comparison C99V50F/C99WT1 
(n=3, p<0.05), analyzed with the Array Assist software and the PLIER algorithm. 
 
Table 12.3 Most up and down-regulated genes derived from the comparison 
C99WT1/mock (n=3, p<0.05, mock was the baseline experiment) 
Position Probe Set ID P-value 
Fold change 
C99WT1/mock 
Gene 
Symbol Title Location 
1 204239_s_at 0.0079 17.2 NNAT neuronatin 
chr20q11.2-
q12 
2 214953_s_at 0.0011 11.2 APP13 
amyloid beta (A4) precursor protein 
(protease nexin-II  Alzheimer 
disease) 
chr21q21.2|2
1q21.3 
3 215632_at 0.0127 4.6 NEUROG2 neurogenin 2 chr4q25 
4 214596_at 0.0014 4.2 CHRM3 cholinergic receptor  muscarinic 3 chr1q41-q44 
5 212713_at 0.0053 3.6 MFAP4 microfibrillar-associated protein 4 chr17p11.2 
6 221796_at 0.0111 3.3 NTRK2 
neurotrophic tyrosine kinase  
receptor  type 2, non-catalytic isoform chr9q22.1 
7 210414_at 0.0165 2.9 FLRT1 
fibronectin leucine rich 
transmembrane protein 1 
chr11q12-
q13 
8 207401_at 0.0258 2.7 PROX1 prospero-related homeobox 1 
chr1q32.2-
q32.3 
9 221795_at 0.0038 2.7 NTRK2 
neurotrophic tyrosine kinase  
receptor  type 2, non-catalytic isoform chr9q22.1 
10 212226_s_at 0.0140 2.5 PPAP2B 
phosphatidic acid phosphatase type 
2B 
chr1pter-
p22.1 
                                            
13 APP appears as up-regulated. However the over-expressed C99 most probably leads to this effect. C99 and 
APP are both recognized by the same probe set on the Chip. Since the probe set for APP detection is taken from 
the 3’ end by Affymetrix, the C-terminus of APP (C99) is recognized as well. Detection of the strongly up-
regulated C99 (second most up-regulated transcript out of approximately 44,000) is an indicator that 
overexpressed and hence up-regulated transcripts are recognized correctly. A simultaneous detection of putative 
up-regulated APP cannot be completely excluded.  
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11 223940_x_at 0.0520 2.3 MALAT1 
metastasis associated lung 
adenocarcinoma transcript 1 (non-
coding RNA) chr11q13.1 
12 209355_s_at 0.0311 2.3 PPAP2B 
phosphatidic acid phosphatase type 
2B 
chr1pter-
p22.1 
13 202669_s_at 0.0282 2.1 EFNB2 ephrin-B2 chr13q33 
14 221310_at 0.0142 2.1 FGF14 fibroblast growth factor 14 chr13q34 
15 213593_s_at 0.0075 2.1 TRA2A Transformer-2 alpha chr7p15.3 
16 211600_at 0.0059 2.0    
17 213742_at 0.0003 2.0 SFRS11 splicing factor  arginine/serine-rich 11 chr1p31 
18 222344_at 0.0011 2.0 C5orf13 
Chromosome 5 open reading frame 
13 chr5q22.1 
19 213517_at 0.0077 2.0 PCBP2 Poly(rC) binding protein 2 
chr12q13.12-
q13.13 
20 217853_at 0.0196 2.0 TENS1 tensin-like SH2 domain containing 1 
chr7p13-
p12.3 
21 217813_s_at 0.0245 2.0 SPIN spindlin 
chr9q22.1-
q22.3 
22 211454_x_at 0.0511 2.0    
23 214577_at 0.0454 1.9 MAP1B microtubule-associated protein 1B chr5q13 
24 221019_s_at 0.0125 1.9 COLEC12 
collectin sub-family member 12 /// 
collectin sub-family member 12 
chr18pter-
p11.3 
25 242488_at 0.0401 1.9  
CDNA FLJ38396 fis  clone 
FEBRA2007957  
26 222272_x_at 0.0320 1.9 SCIN scinderin chr7p21.3 
27 212230_at 0.0169 1.9 PPAP2B 
phosphatidic acid phosphatase type 
2B 
chr1pter-
p22.1 
28 217342_x_at 0.0043 1.9 FLJ11292 hypothetical protein FLJ11292 chr5q14.3 
29 238549_at 0.0136 1.9 CBFA2T2 
core-binding factor  runt domain  
alpha subunit 2; translocated to  2 chr20q11 
30 211127_x_at 0.0047 1.9 EDA ectodysplasin A 
chrXq12-
q13.1 
31 210511_s_at 0.0050 1.9 INHBA 
inhibin  beta A (activin A  activin AB 
alpha polypeptide) chr7p15-p13 
32 208120_x_at 0.0235 1.9    
33 217321_x_at 0.0009 1.8 ATXN3 Ataxin 3 
chr14q24.3-
q32.2 
34 209144_s_at 0.0309 1.8 CBFA2T2 
core-binding factor  runt domain  
alpha subunit 2; translocated to  2 chr20q11 
35 213229_at 0.0110 1.8 DICER1 Dicer1  Dcr-1 homolog (Drosophila) chr14q32.13 
36 219697_at 0.0143 1.8 HS3ST2 
heparan sulfate (glucosamine) 3-O-
sulfotransferase 2 chr16p12 
37 221234_s_at 0.0327 1.8 BACH2 
BTB and CNC homology 1  basic 
leucine zipper transcription factor 2 /// 
BTB and CNC homology 1  basic 
leucine zipper transcription factor 2 chr6q15 
38 214902_x_at 0.0086 1.8 FLJ42393 FLJ42393 protein chr3q27.3 
39 201309_x_at 0.0549 1.8 C5orf13 
chromosome 5 open reading frame 
13 chr5q22.1 
40 228656_at 0.0289 1.8 PROX1 Prospero-related homeobox 1 
chr1q32.2-
q32.3 
41 211571_s_at 0.0065 1.8 CSPG2 
chondroitin sulfate proteoglycan 2 
(versican) chr5q14.3 
42 203628_at 0.0274 1.8 IGF1R insulin-like growth factor 1 receptor chr15q26.3 
43 207115_x_at 0.0057 1.8 MBTD1 mbt domain containing 1 chr17q21.33 
44 205168_at 0.0199 1.8 DDR2 
discoidin domain receptor family  
member 2 chr1q12-q23 
45 212385_at 0.0177 1.8 TCF4 Transcription factor 4 chr18q21.1 
46 214761_at 0.0046 1.8 ZNF423 zinc finger protein 423 chr16q12 
47 219647_at 0.0245 1.8 POPDC2 popeye domain containing 2 chr3q13.33 
48 206056_x_at 0.0003 1.8 SPN 
sialophorin (gpL115  leukosialin  
CD43) chr16p11.2 
49 203002_at 0.0003 1.8 AMOTL2 angiomotin like 2 chr3q21-q22 
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50 211304_x_at 0.0005 1.8 KCNJ5 
potassium inwardly-rectifying channel  
subfamily J  member 5 chr11q24 
51 218330_s_at 0.0056 1.7 NAV2 neuron navigator 2 chr11p15.1 
52 202379_s_at 0.0028 1.7 NKTR 
natural killer-tumor recognition 
sequence chr3p23-p21 
53 212151_at 0.0299 1.7 PBX1 
Pre-B-cell leukemia transcription 
factor 1 chr1q23 
54 209757_s_at 0.0223 1.7 MYCN 
v-myc myelocytomatosis viral related 
oncogene  neuroblastoma derived 
(avian) chr2p24.1 
55 215063_x_at 0.0074 1.7 FLJ20331 hypothetical protein FLJ20331 chr1p31.1 
56 215615_x_at 0.0216 1.7 RERE 
Arginine-glutamic acid dipeptide (RE) 
repeats 
chr1p36.1-
p36.2 
57 227671_at 0.0360 1.7    
58 219206_x_at 0.0002 1.7 CGI-119 CGI-119 protein 
chr12q14.1-
q15 
59 200879_s_at 0.0119 1.7 EPAS1 endothelial PAS domain protein 1 chr2p21-p16 
60 210368_at 0.0016 1.7 
PCDHGB4 
/// 
PCDHGA8 
protocadherin gamma subfamily B  4 
/// protocadherin gamma subfamily A  
8 chr5q31 
61 213956_at 0.0484 1.7 CAP350 centrosome-associated protein 350 
chr1p36.13-
q41 
62 204913_s_at 0.0105 1.7 SOX11 
SRY (sex determining region Y)-box 
11 chr2p25 
63 222358_x_at 0.0102 1.7  
Transcribed locus  weakly similar to 
XP_517655.1 similar to KIAA0825 
protein [Pan troglodytes]  
64 208238_x_at 0.0146 1.7    
65 211704_s_at 0.0435 1.7 
SPIN2 /// 
SPIN-2 
spindlin family  member 2 /// spindlin 
family  member 2 /// spindlin-like 
protein 2 /// spindlin-like protein 2 chrXp11.1 
66 206061_s_at 0.0048 1.7 DICER1 Dicer1  Dcr-1 homolog (Drosophila) chr14q32.13 
67 217586_x_at 0.0076 1.7    
68 209584_x_at 0.0044 1.7 APOBEC3C 
apolipoprotein B mRNA editing 
enzyme  catalytic polypeptide-like 3C 
chr22q13.1-
q13.2 
87 211160_x_at 0.0045 1.6 ACTN1 actinin  alpha 1 
chr14q24.1-
q24.2|14q24|
14q22-q24 
70 210525_x_at 0.0008 1.7 C14orf143 
chromosome 14 open reading frame 
143 chr14q32.11 
71 207117_at 0.0473 1.6 H-plk Krueppel-related zinc finger protein chr7q11.21 
72 212966_at 0.0263 1.6 HIC2 hypermethylated in cancer 2 chr22q11.21 
73 211936_at 0.0277 1.6 HSPA5 
heat shock 70kDa protein 5 (glucose-
regulated protein  78kDa) 
chr9q33-
q34.1 
74 210172_at 0.0246 1.6 SF1 splicing factor 1 chr11q13 
75 235716_at 0.0456 1.6 TRA2A Transformer-2 alpha chr7p15.3 
76 221387_at 0.0278 1.6 GPR147 G protein-coupled receptor 147 
chr10q21-
q22 
77 213575_at 0.0217 1.6 TRA2A Transformer-2 alpha chr7p15.3 
78 217536_x_at 0.0267 1.6  
Transcribed locus  weakly similar to 
NP_055301.1 neuronal thread 
protein AD7c-NTP [Homo sapiens]  
79 212468_at 0.0342 1.6 SPAG9 sperm associated antigen 9 chr17q21.33 
80 214329_x_at 0.0254 1.6 TNFSF10 
Tumor necrosis factor (ligand) 
superfamily  member 10 /// Tumor 
necrosis factor (ligand) superfamily  
member 10 chr3q26 
81 235060_at 0.0311 1.6 LOC23117 
KIAA0220-like protein /// Similar to 
PI-3-kinase-related kinase SMG-1 
isoform 1; lambda/iota protein kinase 
C-interacting protein; 
phosphatidylinositol 3-kinase-related 
protein kinase 
chr16p12.2 /// 
chr16p12.1 
82 209638_x_at 0.0256 1.6 RGS12 regulator of G-protein signaling 12 chr4p16.3 
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83 223287_s_at 0.0446 1.6 FOXP1 forkhead box P1 chr3p14.1 
84 214707_x_at 0.0080 1.6 ALMS1 Alstrom syndrome 1 chr2p13 
85 207365_x_at 0.0037 1.6 USP34 ubiquitin specific protease 34 chr2p15 
86 200920_s_at 0.0137 1.6 BTG1 
B-cell translocation gene 1  anti-
proliferative chr12q22 
87 220071_x_at 0.0112 1.6 C15orf25 
chromosome 15 open reading frame 
25 chr15q15.1 
88 206551_x_at 0.0301 1.6 DRE1 DRE1 protein chr3q27.1 
89 216882_s_at 0.0512 1.6 NEBL nebulette chr10p12 
90 207625_s_at 0.0473 1.6 CBFA2T2 
core-binding factor  runt domain  
alpha subunit 2; translocated to  2 chr20q11 
91 215179_x_at 0.0082 1.6 PGF 
Placental growth factor  vascular 
endothelial growth factor-related 
protein 
chr14q24-
q31 
92 214594_x_at 0.0467 1.6 ATP8B1 ATPase  Class I  type 8B  member 1 
chr18q21-
q22|18q21.31
93 202971_s_at 0.0075 1.6 DYRK2 
dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 2 chr12q15 
94 216459_x_at 0.0272 1.6    
95 206792_x_at 0.0122 1.6 PDE4C 
phosphodiesterase 4C  cAMP-
specific (phosphodiesterase E1 
dunce homolog  Drosophila) chr19p13.11 
96 205347_s_at 0.0003 1.6 TMSL8 thymosin-like 8 
chrXq21.33-
q22.3 
97 207186_s_at 0.0547 1.6 FALZ fetal Alzheimer antigen chr17q24.3 
98 203308_x_at 0.0006 1.6 HPS1 Hermansky-Pudlak syndrome 1 
chr10q23.1-
q23.3 
99 232168_x_at 0.0244 1.6 MACF1 
microtubule-actin crosslinking factor 
1 chr1p32-p31 
100 210508_s_at 0.0159 1.6 KCNQ2 
potassium voltage-gated channel  
KQT-like subfamily  member 2 chr20q13.3 
101 214989_x_at 0.0002 1.6 PLEKHA5 
Pleckstrin homology domain 
containing  family A member 5 chr12p12 
102 205572_at 0.0450 1.6 ANGPT2 angiopoietin 2 chr8p23.1 
103 207164_s_at 0.0103 1.6 ZNF238 zinc finger protein 238 chr1q44-qter 
104 207173_x_at 0.0418 1.6 CDH11 
cadherin 11  type 2  OB-cadherin 
(osteoblast) chr16q22.1 
105 221728_x_at 0.0101 1.6    
106 208404_x_at 0.0170 1.6    
107 203627_at 0.0007 1.6 IGF1R Insulin-like growth factor 1 receptor chr15q26.3 
108 214683_s_at 0.0478 1.6 CLK1 CDC-like kinase 1 chr2q33 
109 60815_at 0.0212 1.6 MGC13098 hypothetical protein MGC13098 chr7p13 
110 219437_s_at 0.0332 1.6 ANKRD11 ankyrin repeat domain 11 chr16q24.3 
110 226101_at 0.0491 -1.9 PRKCE protein kinase C  epsilon chr2p21 
109 203303_at 0.0010 -2.0 TCTE1L 
t-complex-associated-testis-
expressed 1-like chrXp21 
108 217763_s_at 0.0436 -2.0 RAB31 
RAB31  member RAS oncogene 
family chr18p11.3 
107 207620_s_at 0.0018 -2.0 CASK 
calcium/calmodulin-dependent serine 
protein kinase (MAGUK family) chrXp11.4 
106 208700_s_at 0.0377 -2.0 TKT 
transketolase (Wernicke-Korsakoff 
syndrome) chr3p14.3 
105 202016_at 0.0192 -2.0 MEST 
mesoderm specific transcript 
homolog (mouse) chr7q32 
104 226614_s_at 0.0342 -2.0 C8orf13 
chromosome 8 open reading frame 
13 chr8p23-p22 
103 225817_at 0.0285 -2.0 CGNL1 cingulin-like 1 chr15q21.3 
102 207447_s_at 0.0537 -2.0 GNTIVH 
UDP-N-acetylglucosamine:a-1 3-D-
mannoside beta-1 4-N-
acetylglucosaminyltransferase IV chr12q21 
101 201744_s_at 0.0090 -2.0 LUM lumican 
chr12q21.3-
q22 
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100 213787_s_at 0.0325 -2.0 EBP 
emopamil binding protein (sterol 
isomerase) 
chrXp11.23-
p11.22 
99 214527_s_at 0.0019 -2.0 PQBP1 polyglutamine binding protein 1 chrXp11.23 
98 205324_s_at 0.0108 -2.0 FTSJ1 FtsJ homolog 1 (E. coli) chrXp11.23 
97 236236_at 0.0350 -2.0   
CDNA FLJ30437 fis  clone 
BRACE2009045   
96 223051_at 0.0221 -2.0 HSPC182 HSPC182 protein chr1p36.33 
95 209170_s_at 0.0041 -2.0 GPM6B glycoprotein M6B chrXp22.2 
94 206631_at 0.0102 -2.0 PTGER2 
prostaglandin E receptor 2 (subtype 
EP2)  53kDa chr14q22 
93 201037_at 0.0339 -2.0 PFKP phosphofructokinase  platelet 
chr10p15.3-
p15.2 
92 209191_at 0.0068 -2.1 TUBB6 tubulin  beta 6 chr18p11.21 
91 230547_at 0.0212 -2.1   
CDNA FLJ42249 fis  clone 
TKIDN2007667   
90 204134_at 0.0181 -2.1 PDE2A 
phosphodiesterase 2A  cGMP-
stimulated chr11q13.4 
89 203304_at 0.0308 -2.1 BAMBI 
BMP and activin membrane-bound 
inhibitor 
chr10p12.3-
p11.2 
88 206233_at 0.0125 -2.1 B4GALT6 
UDP-Gal:betaGlcNAc beta 1 4- 
galactosyltransferase  polypeptide 6 chr18q11 
87 222138_s_at 0.0086 -2.1 WDR13 WD repeat domain 13 chrXp11.23 
86 205656_at 0.0197 -2.1 PCDH17 protocadherin 17 chr13q21.1 
85   0.0461 -2.1       
84 223313_s_at 0.0403 -2.1 MAGED4 melanoma antigen family D  4   
83 221910_at 0.0354 -2.1 LOC221810 hypothetical protein LOC221810 chr7p21.3 
82 206837_at 0.0005 -2.1 CART1 
cartilage paired-class homeoprotein 
1 
chr12q21.3-
q22 
81 212457_at 0.0040 -2.1 TFE3 
transcription factor binding to IGHM 
enhancer 3 chrXp11.22 
80 206478_at 0.0006 -2.1 KIAA0125 KIAA0125 chr14q32.33 
79 205068_s_at 0.0104 -2.1 ARHGAP26 Rho GTPase activating protein 26 chr5q31 
78 218532_s_at 0.0120 -2.2 FLJ20152 hypothetical protein FLJ20152 chr5p15.1 
77 228010_at 0.0198 -2.2 PPP2R2C 
protein phosphatase 2 (formerly 2A)  
regulatory subunit B (PR 52)  gamma 
isoform chr4p16.1 
76 243610_at 0.0000 -2.2 LOC138255 OTTHUMP00000021439 chr9q21.11 
75 214913_at 0.0475 -2.2 ADAMTS3 
a disintegrin-like and metalloprotease 
(reprolysin type) with thrombospondin 
type 1 motif  3 chr4q13.3 
74 202284_s_at 0.0192 -2.2 CDKN1A 
cyclin-dependent kinase inhibitor 1A 
(p21  Cip1) chr6p21.2 
73 229110_at 0.0228 -2.2   
CDNA clone IMAGE:4794876  partial 
cds   
72 205857_at 0.0392 -2.2       
71 229576_s_at 0.0257 -2.2 TBX3 T-box 3 (ulnar mammary syndrome) chr12q24.1 
70 216963_s_at 0.0182 -2.2 GAP43 growth associated protein 43 
chr3q13.1-
q13.2 
69 217764_s_at 0.0514 -2.2 RAB31 
RAB31  member RAS oncogene 
family chr18p11.3 
68 219073_s_at 0.0226 -2.2 OSBPL10 oxysterol binding protein-like 10 chr3p22.3 
67 223193_x_at 0.0250 -2.2 E2IG5 
growth and transformation-
dependent protein chr3q21.1 
66 233337_s_at 0.0337 -2.3 SEZ6L2 
seizure related 6 homolog (mouse)-
like 2 chr16p11.2 
65 33767_at 0.0456 -2.3 NEFH 
neurofilament  heavy polypeptide 
200kDa chr22q12.2 
64 204723_at 0.0470 -2.3 SCN3B 
sodium channel  voltage-gated  type 
III  beta chr11q24.1 
63 216047_x_at 0.0098 -2.3 SEZ6L 
seizure related 6 homolog (mouse)-
like chr22q12.1 
62 225029_at 0.0206 -2.3   
CDNA clone IMAGE:4686928  partial 
cds   
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61 224345_x_at 0.0485 -2.3 E2IG5 
growth and transformation-
dependent protein /// growth and 
transformation-dependent protein chr3q21.1 
60 239352_at 0.0121 -2.3 SLC6A15 solute carrier family 6  member 15 chr12q21.3 
59 210319_x_at 0.0139 -2.3 MSX2 
msh homeo box homolog 2 
(Drosophila) chr5q34-q35 
58 225081_s_at 0.0282 -2.4 RAM2 transcription factor RAM2 chr7p15.3 
57 204412_s_at 0.0207 -2.4 NEFH 
neurofilament  heavy polypeptide 
200kDa chr22q12.2 
56 209120_at 0.0362 -2.4 NR2F2 
nuclear receptor subfamily 2  group F  
member 2 chr15q26 
55 221914_at 0.0349 -2.4       
54   0.0190 -2.4       
53 230896_at 0.0490 -2.4   
CDNA FLJ35632 fis  clone 
SPLEN2011678   
52 218623_at 0.0249 -2.5       
51 213664_at 0.0109 -2.5 SLC1A1 
solute carrier family 1 
(neuronal/epithelial high affinity 
glutamate transporter  system Xag)  
member 1 chr9p24 
50 219230_at 0.0215 -2.5 FLJ10970 hypothetical protein FLJ10970 chr17q23.1 
49 213200_at 0.0139 -2.5 SYP synaptophysin 
chrXp11.23-
p11.22 
48 203329_at 0.0013 -2.5 PTPRM 
protein tyrosine phosphatase  
receptor type  M chr18p11.2 
47 221288_at 0.0118 -2.6 GPR22 G protein-coupled receptor 22 
chr7q22-
q31.1 
46 225516_at 0.0156 -2.6 SLC7A2 
solute carrier family 7 (cationic amino 
acid transporter  y+ system)  member 
2 
chr8p22-
p21.3 
45 203430_at 0.0033 -2.6 HEBP2 heme binding protein 2 chr6q24 
44 206376_at 0.0049 -2.7 SLC6A15 solute carrier family 6  member 15 chr12q21.3 
43 238600_at 0.0339 -2.7 MARLIN1 
multiple coiled-coil GABABR1-
binding protein chr4p16.1 
42 235333_at 0.0312 -2.7       
41 226281_at 0.0427 -2.7 DNER 
delta-Notch-like EGF repeat-
containing transmembrane chr2q36.3 
40 212192_at 0.0094 -2.8 KCTD12 
potassium channel tetramerisation 
domain containing 12 chr13q22.3 
39 221801_x_at 0.0384 -2.8 NEFL 
neurofilament  light polypeptide 
68kDa chr8p21 
38 209755_at 0.0433 -2.9 NMNAT2 
nicotinamide nucleotide 
adenylyltransferase 2 chr1q25 
37 221916_at 0.0453 -2.9 NEFL 
Neurofilament  light polypeptide 
68kDa chr8p21 
36 225544_at 0.0205 -2.9 TBX3 T-box 3 (ulnar mammary syndrome) chr12q24.1 
35 212094_at 0.0130 -3 PEG10 paternally expressed 10 chr7q21 
34 230112_at 0.0214 -3 - 
membrane-associated ring finger 
(C3HC4) 4 chr2q35 
33 209278_s_at 0.0153 -3 TFPI2 tissue factor pathway inhibitor 2 chr7q22 
32 219682_s_at 0.0105 -3 TBX3 T-box 3 (ulnar mammary syndrome) chr12q24.1 
31 221805_at 0.0385 -3 NEFL 
neurofilament  light polypeptide 
68kDa chr8p21 
30 209291_at 0.0355 -3 ID4 
inhibitor of DNA binding 4  dominant 
negative helix-loop-helix protein chr6p22-p21 
29 227289_at 0.0389 -3.1 LOC144997 hypothetical protein LOC144997 chr13q14.3 
28 215411_s_at 0.0066 -3.1 TRAF3IP2 TRAF3 interacting protein 2 chr6q21 
27 203824_at 0.0433 -3.1 TSPAN8 tetraspanin 8 
chr12q14.1-
q21.1 
26 204471_at 0.0094 -3.2 GAP43 growth associated protein 43 
chr3q13.1-
q13.2 
25 202242_at 0.0038 -3.2 TSPAN7 tetraspanin 7 chrXp11.4 
24 213609_s_at 0.0063 -3.3 SEZ6L 
seizure related 6 homolog (mouse)-
like chr22q12.1 
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23 209277_at 0.0052 -3.3 TFPI2 Tissue factor pathway inhibitor 2 chr7q22 
22 227198_at 0.0402 -3.4 LAF4 
Lymphoid nuclear protein related to 
AF4 
chr2q11.2-
q12 
21 225996_at 0.0533 -3.4   
CDNA FLJ36725 fis  clone 
UTERU2012230   
20 218858_at 0.0026 -3.4 DEPDC6 DEP domain containing 6 chr8q24.12 
19 206137_at 0.0014 -3.4 RIMS2 
regulating synaptic membrane 
exocytosis 2 chr8q22.3 
18 205113_at 0.0236 -3.4 NEF3 neurofilament 3 (150kDa medium) chr8p21 
17 229823_at 0.0020 -3.4   Transcribed locus   
16 204869_at 0.0104 -3.5 PCSK2 
proprotein convertase subtilisin/kexin 
type 2 chr20p11.2 
15 228863_at 0.0353 -3.5 PCDH17 Hypothetical protein LOC144997 chr13q21.1 
14 212096_s_at 0.0028 -3.5 MTUS1 mitochondrial tumor suppressor 1 chr8p22 
13 210839_s_at 0.0185 -3.6 ENPP2 
ectonucleotide 
pyrophosphatase/phosphodiesterase 
2 (autotaxin) chr8q24.1 
12 205305_at 0.0010 -3.6 FGL1 fibrinogen-like 1 
chr8p22-
p21.3 
11 221245_s_at 0.0207 -4 C2orf31 
chromosome 2 open reading frame 
31 /// chromosome 2 open reading 
frame 31 chr2q34 
10 204035_at 0.0092 -4.1 SCG2 secretogranin II (chromogranin C) chr2q35-q36 
9 204389_at 0.0035 -4.3 MAOA monoamine oxidase A 
chrXp11.4-
p11.3 
8 206805_at 0.0153 -4.3 SEMA3A 
sema domain  immunoglobulin 
domain (Ig)  short basic domain  
secreted  (semaphorin) 3A chr7p12.1 
7 209392_at 0.0081 -4.5 ENPP2 
ectonucleotide 
pyrophosphatase/phosphodiesterase 
2 (autotaxin) chr8q24.1 
6 209205_s_at 0.0131 -4.6 LMO4 LIM domain only 4 chr1p22.3 
5 212741_at 0.0098 -4.6 MAOA monoamine oxidase A 
chrXp11.4-
p11.3 
4 204388_s_at 0.0077 -4.7 MAOA monoamine oxidase A 
chrXp11.4-
p11.3 
3 213847_at 0.0334 -4.9 PRPH peripherin 
chr12q12-
q13 
2 204870_s_at 0.0019 -9.2 PCSK2 
proprotein convertase subtilisin/kexin 
type 2 chr20p11.2 
1 201739_at 0.0023 -10.1 SGK 
serum/glucocorticoid regulated 
kinase chr6q23 
Table 12.3 Most up and down-regulated genes derived from the comparison C99WT1/mock 
(n=3, p<0.05), analyzed with the Array Assist software and the PLIER algorithm. 
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12.2.2 Genes identified using the GC-RMA algorithm (Language 
R, Bioconductor) 
 
Table 12.4 Most up and down-regulated genes derived from the comparison 
C99I45F/C99WT1 (Aβ42/Aβ40↑, n=3, p<0.005, fold change of 
expression >2.0, C99WT1 was the baseline experiment) 
Position Probe Set ID p-value 
Fold change 
C99I45F/ 
C99WT1 
Gene 
Symbol Gene Title 
Chromosomal 
Location 
1 205358_at 0.00034 8.7 GRIA2 glutamate receptor, ionotropic, AMPA 2 chr4q32-q33 
2 213920_at 0.00426 6.9 CUTL2 cut-like 2 (Drosophila) chr12q24.13 
3 209591_s_at 0.00005 6.2 BMP7 
bone morphogenetic protein 7 
(osteogenic protein 1) chr20q13 
4 221933_at 0.00007 5.0 NLGN4X neuroligin 4, X-linked 
chrxp22.32-
p22.31 
5 212096_s_at 0.00100 5.0 MTUS1 mitochondrial tumor suppressor 1 chr8p22 
6 206502_s_at 0.00291 5.0 INSM1 insulinoma-associated 1 chr20p11.2 
7 218623_at 0.00288 4.9    
8 203329_at 0.00139 4.4 PTPRM 
protein tyrosine phosphatase, receptor 
type, M chr18p11.2 
9 213338_at 0.00352 4.3 RIS1 Ras-induced senescence 1 chr3p21.3 
10 203973_s_at 0.00372 3.9 CEBPD 
CCAAT/enhancer binding protein 
(C/EBP), delta 
chr8p11.2-
p11.1 
11 209590_at 0.00110 3.8 BMP7 
bone morphogenetic protein 7 
(osteogenic protein 1) chr20q13 
12 201645_at 0.00210 3.7 TNC tenascin C (hexabrachion) chr9q33 
13 210108_at 0.00113 3.7 CACNA1D 
calcium channel, voltage-dependent, L 
type, alpha 1D subunit chr3p14.3 
14 205348_s_at 0.00176 3.4 DNCI1 
dynein, cytoplasmic, intermediate 
polypeptide 1 
chr7q21.3-
q22.1 
15 206290_s_at 0.00135 3.2 RGS7 regulator of G-protein signaling 7 chr1q43 
16 219225_at 0.00201 3.0 PGBD5 
piggyBac transposable element derived 
5 chr1q42.13 
17 219825_at 0.00262 3.0 CYP26B1 
cytochrome P450, family 26, subfamily 
B, polypeptide 1 chr2p13.2 
18 201341_at 0.00116 2.8 ENC1 
ectodermal-neural cortex (with BTB-like 
domain) chr5q12-q13.3 
19 212658_at 0.00112 2.8 LHFPL2 lipoma HMGIC fusion partner-like 2 chr5q14.1 
20 207076_s_at 0.00470 2.6 ASS argininosuccinate synthetase chr9q34.1 
21 201621_at 0.00002 2.6 NBL1 
neuroblastoma, suppression of 
tumorigenicity 1 
chr1p36.13-
p36.11 
22 212538_at 0.00343 2.6 DOCK9 dedicator of cytokinesis 9 chr13q32.3 
23 213273_at 0.00476 2.6 ODZ4 
odz, odd Oz/ten-m homolog 4 
(Drosophila) chr11q14.1 
24 37005_at 0.00003 2.5 NBL1 
neuroblastoma, suppression of 
tumorigenicity 1 
chr1p36.13-
p36.11 
25 213744_at 0.00138 2.4 ATRNL1 attractin-like 1 chr10q26 
26 205003_at 0.00244 2.4 DOCK4 dedicator of cytokinesis 4 chr7q31.1 
27 219277_s_at 0.00124 2.3 OGDHL oxoglutarate dehydrogenase-like chr10q11.23 
28 37950_at 0.00090 2.2 PREP prolyl endopeptidase chr6q22 
29 213802_at 0.00035 2.2    
30 211259_s_at 0.00481 2.1 BMP7 
bone morphogenetic protein 7 
(osteogenic protein 1) chr20q13 
31 205515_at 0.00486 2.1 PRSS12 
protease, serine, 12 (neurotrypsin, 
motopsin) chr4q28.1 
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32 205279_s_at 0.00018 2.1 GLRB glycine receptor, beta chr4q31.3 
33 204140_at 0.00210 2.1 TPST1 tyrosylprotein sulfotransferase 1 chr7q11.21 
34 212325_at 0.00380 2.1 KIAA1102 KIAA1102 protein chr4p13 
35 201037_at 0.00230 2.1 PFKP phosphofructokinase, platelet 
chr10p15.3-
p15.2 
36 218899_s_at 0.00240 2.0 BAALC brain and acute leukemia, cytoplasmic chr8q22.3 
23 212057_at 0.00110 -2.0 KIAA0182 KIAA0182 protein chr16q24.1 
22 221605_s_at 0.00494 -2.1 PIPOX pipecolic acid oxidase chr17q11.2 
21 219031_s_at 0.00246 -2.1    
20 208424_s_at 0.00433 -2.1 CIAPIN1 cytokine induced apoptosis inhibitor 1 chr16q13-q21 
19 211671_s_at 0.00129 -2.2 NR3C1 
nuclear receptor subfamily 3, group C, 
member 1 (glucocorticoid receptor)  chr5q31 
18 207966_s_at 0.00288 -2.3 GLG1 golgi apparatus protein 1 chr16q22-q23 
17 206848_at 0.00007 -2.3    
16 217200_x_at 0.00034 -2.3    
15 218354_at 0.00424 -2.3 HSPC176 hematopoietic stem/progenitor cells 176 chr16q24.3 
14 209163_at 0.00333 -2.3 CYB561 cytochrome b-561 chr17q11-qter 
13 209560_s_at 0.00430 -2.4 DLK1 delta-like 1 homolog (Drosophila) chr14q32 
12 203028_s_at 0.00028 -2.5 CYBA cytochrome b-245, alpha polypeptide chr16q24 
11 202765_s_at 0.00105 -2.6    
10 219437_s_at 0.00033 -2.6 ANKRD11 ankyrin repeat domain 11 chr16q24.3 
9 40837_at 0.00253 -2.8 TLE2 
transducin-like enhancer of split 2 
(E(sp1) homolog, Drosophila) chr19p13.3 
8 209164_s_at 0.00129 -2.8 CYB561 cytochrome b-561 chr17q11-qter 
7 214347_s_at 0.00496 -3.1 DDC 
dopa decarboxylase (aromatic L-amino 
acid decarboxylase) chr7p11 
6 201667_at 0.00243 -3.5 GJA1 
gap junction protein, alpha 1, 43kDa 
(connexin 43) chr6q21-q23.2 
5 210816_s_at 0.00018 -4.8 CYB561 cytochrome b-561 chr17q11-qter 
4 207074_s_at 0.00199 -5.1 SLC18A1 
solute carrier family 18 (vesicular 
monoamine), member 1 chr8p21.3 
3 208443_x_at 0.00439 -6.1 SHOX2 short stature homeobox 2 chr3q25-q26.1 
2 201028_s_at 0.00403 -12.6 CD99 CD99 antigen 
chrxp22.32; 
yp11.3 
1 201029_s_at 0.00363 -15.7 CD99 CD99 antigen 
chrxp22.32; 
yp11.3 
Table 12.4 Most up and down-regulated genes derived from the comparison C99I45F/C99WT1, 
(n=3, p<0.005, fold change of expression >2.0, C99WT1 was the baseline experiment), analyzed 
with the Language R software and the GC-RMA algorithm. 
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Table 12.5 Most up and down-regulated genes derived from the comparison 
C99V50F/C99WT1 (Aβ42/Aβ40↓, n=3, p<0.005, fold change of expression >2.0, 
C99WT1 was the baseline experiment) 
Table 12.5 Most up and down-regulated genes derived from the comparison 
C99V50F/C99WT1 (p<0.005, n=3), analyzed with the Language R software and the GC-RMA 
algorithm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Position Probe Set ID p-value 
Fold 
change 
C99V50F/ 
C99WT1 
Gene 
Symbol Gene Title 
Chromosomal 
Location 
1 206478_at 0.00142 5.3 KIAA0125 KIAA0125 chr14q32.33 
2 208603_s_at 0.00191 2.5 MAPK8IP2
mitogen-activated protein kinase 8 
interacting protein 2 chr22q13.33 
3 200974_at 0.00115 2.2 ACTA2 actin, alpha 2, smooth muscle, aorta chr10q23.3 
4 216963_s_at 0.00449 2.2 GAP43 growth associated protein 43 
chr3q13.1-
q13.2 
5 201860_s_at 0.00477 2.1 PLAT plasminogen activator, tissue chr8p12 
6 206397_x_at 0.00269 2.1 GDF1 growth differentiation factor 1 chr19p12 
7 204471_at 0.00190 2.1 GAP43 growth associated protein 43 
chr3q13.1-
q13.2 
7 220287_at 0.00110 -2.0 ADAMTS9 
a disintegrin-like and metalloprotease 
(reprolysin type) with thrombospondin type 1 
motif, 9 
chr3p14.3-
p14.2 
6 209220_at 0.00089 -2.5 GPC3 glypican 3 chrxq26.1 
5 212148_at 0.00288 -2.8 PBX1 pre-B-cell leukemia transcription factor 1 chr1q23 
4 209757_s_at 0.00416 -3.0 MYCN 
v-myc myelocytomatosis viral related 
oncogene, neuroblastoma derived (avian) chr2p24.1 
3 202283_at 0.00362 -3.1 SERPINF1
serine (or cysteine) proteinase inhibitor, 
clade F (alpha-2 antiplasmin, pigment 
epithelium derived factor), member 1 chr17p13.1 
2 209238_at 0.00268 -3.7 STX3A syntaxin 3A chr11q12.1 
1 215632_at 0.00166 -12.5 NEUROG2 neurogenin 2 chr4q25 
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Table 12.6 Most up and down-regulated genes derived from the comparison 
C99WT1/mock (n=3, p<0.005, fold change of expression >2.0, 
mock was the baseline experiment) 
Position Probe Set ID p-value 
Fold 
change 
C99WT1/ 
mock 
Gene 
Symbol Gene Title 
Chromosomal 
Location 
1 204239_s_at 0.00161 32.1 NNAT neuronatin chr20q11.2-q12 
2 215632_at 0.00083 15.8 NEUROG2 neurogenin 2 chr4q25 
3 214953_s_at 0.00000 12.1 APP 
amyloid beta (A4) precursor protein 
(protease nexin-II, Alzheimer disease) chr21q21.3 
4 212713_at 0.00367 8.0 MFAP4 microfibrillar-associated protein 4 chr17p11.2 
5 221796_at 0.00051 7.7 NTRK2 
neurotrophic tyrosine kinase, receptor, type 
2, non-catalytic isoform chr9q22.1 
6 214596_at 0.00006 6.1 CHRM3 cholinergic receptor, muscarinic 3 chr1q41-q44 
7 212226_s_at 0.00031 5.7 PPAP2B phosphatidic acid phosphatase type 2B chr1pter-p22.1 
8 222344_at 0.00048 4.6    
9 210414_at 0.00244 4.5 FLRT1 
fibronectin leucine rich transmembrane 
protein 1 chr11q12-q13 
10 221310_at 0.00074 4.1 FGF14 fibroblast growth factor 14 chr13q34 
11 217996_at 0.00026 4.0 PHLDA1 
pleckstrin homology-like domain, family A, 
member 1 chr12q15 
12 213742_at 0.00041 3.8 SFRS11 splicing factor, arginine/serine-rich 11 chr1p31 
13 213593_s_at 0.00062 3.4 TRA2A transformer-2 alpha chr7p15.3 
14 215164_at 0.00120 3.4  
MRNA; cDNA DKFZp564I083 (from clone 
DKFZp564I083)  
15 213517_at 0.00396 3.2 PCBP2 poly(rC) binding protein 2 
chr12q13.12-
q13.13 
16 209144_s_at 0.00244 3.0 CBFA2T2 
core-binding factor, runt domain, alpha 
subunit 2; translocated to, 2 chr20q11 
17 212230_at 0.00025 2.8 PPAP2B phosphatidic acid phosphatase type 2B chr1pter-p22.1 
18 222214_at 0.00289 2.8  CDNA: FLJ21335 fis, clone COL02546  
19 221234_s_at 0.00120 2.8 BACH2 
BTB and CNC homology 1, basic leucine 
zipper transcription factor 2 /// BTB and CNC 
homology 1, basic leucine zipper 
transcription factor 2 chr6q15 
20 209750_at 0.00392 2.6 NR1D2 
nuclear receptor subfamily 1, group D, 
member 2 chr3p24.2 
21 201294_s_at 0.00392 2.5 WSB1 WD repeat and SOCS box-containing 1 chr17q11.1 
22 212966_at 0.00003 2.4 HIC2 hypermethylated in cancer 2 chr22q11.21 
23 60815_at 0.00432 2.4 
MGC1309
8 hypothetical protein MGC13098 chr7p13 
24 213575_at 0.00016 2.4 TRA2A transformer-2 alpha chr7p15.3 
25 212151_at 0.00074 2.4 PBX1 pre-B-cell leukemia transcription factor 1 chr1q23 
26 207598_x_at 0.00393 2.4 XRCC2 
X-ray repair complementing defective repair 
in Chinese hamster cells 2 chr7q36.1 
27 205168_at 0.00392 2.4 DDR2 discoidin domain receptor family, member 2 chr1q12-q23 
28 214251_s_at 0.00467 2.4 NUMA1 nuclear mitotic apparatus protein 1 chr11q13 
29 213956_at 0.00095 2.3 CAP350 centrosome-associated protein 350 chr1p36.13-q41 
30 206848_at 0.00009 2.2    
31 211466_at 0.00445 2.2 NFIB nuclear factor I/B chr9p24.1 
32 211600_at 0.00438 2.1 PTPRO 
protein tyrosine phosphatase, receptor type, 
O /// protein tyrosine phosphatase, receptor 
type, O 
chr12p13.3-
p13.2 
33 214683_s_at 0.00344 2.1 CLK1 CDC-like kinase 1 chr2q33 
34 210655_s_at 0.00406 2.1 FOXO3A forkhead box O3A chr6q21 
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35 208120_x_at 0.00427 2.1    
36 201309_x_at 0.00370 2.1 C5orf13 chromosome 5 open reading frame 13 chr5q22.1 
37 207605_x_at 0.00479 2.1 H-plk Krueppel-related zinc finger protein chr7q11.21 
38 222366_at 0.00497 2.1    
39 211571_s_at 0.00447 2.1 CSPG2 chondroitin sulfate proteoglycan 2 (versican) chr5q14.3 
40 213649_at 0.00353 2.1 SFRS7 splicing factor, arginine/serine-rich 7, 35kDa chr2p22.1 
41 219206_x_at 0.00250 2.0 CGI-119 CGI-119 protein chr12q14.1-q15 
42 218066_at 0.00125 2.0 SLC12A7 
solute carrier family 12 (potassium/chloride 
transporters), member 7 chr5p15 
104 213079_at 0.00080 -2.0 DT1P1A10 hypothetical protein DT1P1A10 chrxp11.22 
103 201673_s_at 0.00357 -2.0 GYS1 glycogen synthase 1 (muscle) chr19q13.3 
102 205541_s_at 0.00002 -2.0 GSPT2 G1 to S phase transition 2 
chrxp11.23-
p11.21 
101 207769_s_at 0.00001 -2.0 PQBP1 polyglutamine binding protein 1 chrxp11.23 
100 209216_at 0.00307 -2.0 WDR45 WD repeat domain 45 chrxp11.23 
99 203814_s_at 0.00003 -2.0 NQO2 NAD(P)H dehydrogenase, quinone 2 chr6pter-q12 
98 208700_s_at 0.00021 -2.1 TKT 
transketolase (Wernicke-Korsakoff 
syndrome) chr3p14.3 
97 203617_x_at 0.00002 -2.1 ELK1 ELK1, member of ETS oncogene family chrxp11.2 
96 219188_s_at 0.00377 -2.1 LRP16 LRP16 protein chr11q11 
95 204639_at 0.00054 -2.1 ADA adenosine deaminase 
chr20q12-
q13.11 
94 213744_at 0.00485 -2.1 ATRNL1 attractin-like 1 chr10q26 
93 218532_s_at 0.00140 -2.1 FLJ20152 hypothetical protein FLJ20152 chr5p15.1 
92 218935_at 0.00078 -2.1 EHD3 EH-domain containing 3 chr2p21 
91 207447_s_at 0.00064 -2.1 
HGNT-IV-
H 
UDP-N-acetylglucosamine:a-1,3-D-
mannoside beta-1,4-N-
acetylglucosaminyltransferase IV chr12q21 
90 203629_s_at 0.00007 -2.1 COG5 component of oligomeric golgi complex 5 chr7q22-q31 
89 218826_at 0.00180 -2.1 SLC35F2 solute carrier family 35, member F2 chr11q22.3 
88 218251_at 0.00014 -2.1 MID1IP1 
MID1 interacting protein 1 (gastrulation 
specific G12-like (zebrafish)) chrxp11.4 
87 203458_at 0.00072 -2.1 SPR 
sepiapterin reductase (7,8-
dihydrobiopterin:NADP+ oxidoreductase) chr2p14-p12 
86 204866_at 0.00005 -2.1 PHF16 PHD finger protein 16 chrxp11.3 
85 201895_at 0.00003 -2.1 ARAF1 
v-raf murine sarcoma 3611 viral oncogene 
homolog 1 chrxp11.4-p11.2
84 219959_at 0.00403 -2.1 MOCOS molybdenum cofactor sulfurase chr18q12 
83 205324_s_at 0.00000 -2.1 FTSJ1 FtsJ homolog 1 (E. coli) chrxp11.23 
82 206339_at 0.00017 -2.1 CART 
cocaine- and amphetamine-regulated 
transcript chr5q13.2 
81 221524_s_at 0.00092 -2.1 RRAGD Ras-related GTP binding D chr6q15-q16 
80 200632_s_at 0.00450 -2.2 NDRG1 N-myc downstream regulated gene 1 chr8q24.3 
79 218625_at 0.00027 -2.2 NRN1 neuritin 1 chr6p25.1 
78 212916_at 0.00005 -2.2 PHF8 PHD finger protein 8 chrxp11.22 
77 202504_at 0.00405 -2.2 TRIM29 tripartite motif-containing 29 chr11q22-q23 
76 212063_at 0.00006 -2.2 CD44 
CD44 antigen (homing function and Indian 
blood group system) chr11p13 
75 204412_s_at 0.00087 -2.2    
74 201136_at 0.00064 -2.2 PLP2 
proteolipid protein 2 (colonic epithelium-
enriched) chrxp11.23 
73 211896_s_at 0.00100 -2.2 DCN decorin chr12q13.2 
72 211894_x_at 0.00079 -2.3 SEZ6L 
seizure related 6 homolog (mouse)-like /// 
seizure related 6 homolog (mouse)-like chr22q12.1 
71 213200_at 0.00149 -2.3 SYP synaptophysin 
chrxp11.23-
p11.22 
70 204513_s_at 0.00192 -2.3 ELMO1 
engulfment and cell motility 1 (ced-12 
homolog, C. elegans) chr7p14.1 
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69 218501_at 0.00087 -2.3 ARHGEF3 
Rho guanine nucleotide exchange factor 
(GEF) 3 chr3p21-p13 
68 213358_at 0.00097 -2.3 KIAA0802 KIAA0802 chr18p11.22 
67 203303_at 0.00184 -2.3 TCTE1L t-complex-associated-testis-expressed 1-like chrxp21 
66 203320_at 0.00003 -2.3 LNK lymphocyte adaptor protein chr12q24 
65 218603_at 0.00015 -2.3 HECA headcase homolog (Drosophila) chr6q23-q24 
64 213107_at 0.00119 -2.3 TNIK TRAF2 and NCK interacting kinase chr3q26.31 
63 208690_s_at 0.00468 -2.3 PDLIM1 PDZ and LIM domain 1 (elfin) chr10q22-q26.3 
62 222138_s_at 0.00002 -2.3 WDR13 WD repeat domain 13 chrxp11.23 
61 217763_s_at 0.00408 -2.4 RAB31 RAB31, member RAS oncogene family chr18p11.3 
60 206016_at 0.00037 -2.4 CXorf37 chromosome X open reading frame 37 chrxp11.23 
59 203386_at 0.00154 -2.4 TBC1D4 TBC1 domain family, member 4 chr13q21.33 
58 213787_s_at 0.00183 -2.4 EBP emopamil binding protein (sterol isomerase) 
chrxp11.23-
p11.22 
57 214527_s_at 0.00000 -2.4 PQBP1 polyglutamine binding protein 1 chrxp11.23 
56 205433_at 0.00002 -2.4 BCHE butyrylcholinesterase 
chr3q26.1-
q26.2 
55 39966_at 0.00322 -2.5 CSPG5 
chondroitin sulfate proteoglycan 5 
(neuroglycan C) chr3p21.3 
54 209191_at 0.00239 -2.5 MGC4083 tubulin beta MGC4083 chr18p11.21 
53 219855_at 0.00000 -2.5 NUDT11 
nudix (nucleoside diphosphate linked moiety 
X)-type motif 11 chrxp11.22 
52 212573_at 0.00198 -2.5 KIAA0830 KIAA0830 protein chr11q21 
51 33767_at 0.00270 -2.5 NEFH neurofilament, heavy polypeptide 200kDa chr22q12.2 
50 203387_s_at 0.00298 -2.6 TBC1D4 TBC1 domain family, member 4 chr13q21.33 
49 205857_at 0.00003 -2.6 SLC18A2 
solute carrier family 18 (vesicular 
monoamine), member 2 chr10q25 
48 213937_s_at 0.00000 -2.6 FTSJ1 FtsJ homolog 1 (E. coli) chrxp11.23 
47 200974_at 0.00024 -2.6 ACTA2 actin, alpha 2, smooth muscle, aorta chr10q23.3 
46 218619_s_at 0.00107 -2.7 SUV39H1 
suppressor of variegation 3-9 homolog 1 
(Drosophila) chrxp11.23 
45 210319_x_at 0.00183 -2.8    
44 205651_x_at 0.00000 -2.9 RAPGEF4 
Rap guanine nucleotide exchange factor 
(GEF) 4 chr2q31-q32 
43 212730_at 0.00016 -2.9 DMN desmuslin chr15q26.3 
42 207813_s_at 0.00027 -3.0 FDXR ferredoxin reductase chr17q24-q25 
41 221914_at 0.00194 -3.0 SYN1 synapsin I chrxp11.23 
40 202735_at 0.00262 -3.1 EBP emopamil binding protein (sterol isomerase) 
chrxp11.23-
p11.22 
39 212457_at 0.00000 -3.1 TFE3 
transcription factor binding to IGHM 
enhancer 3 chrxp11.22 
38 217764_s_at 0.00193 -3.1 RAB31 RAB31, member RAS oncogene family chr18p11.3 
37 203430_at 0.00347 -3.2 HEBP2 heme binding protein 2 chr6q24 
36 219073_s_at 0.00008 -3.2 OSBPL10 oxysterol binding protein-like 10 chr3p22.3 
35 204955_at 0.00054 -3.2 SRPX sushi-repeat-containing protein, X-linked chrxp21.1 
34 206187_at 0.00026 -3.3 PTGIR prostaglandin I2 (prostacyclin) receptor (IP) chr19q13.3 
33 210997_at 0.00204 -3.4 HGF 
hepatocyte growth factor (hepapoietin A; 
scatter factor) chr7q21.1 
32 204471_at 0.00002 -3.4 GAP43 growth associated protein 43 
chr3q13.1-
q13.2 
31 217762_s_at 0.00180 -3.4 RAB31 RAB31, member RAS oncogene family chr18p11.3 
30 205230_at 0.00343 -3.4 RPH3A rabphilin 3A homolog (mouse) chr12q24.13 
29 207620_s_at 0.00001 -3.4 CASK 
calcium/calmodulin-dependent serine protein 
kinase (MAGUK family) chrxp11.4 
28 205656_at 0.00340 -3.5 PCDH17 protocadherin 17 chr13q21.1 
27 216963_s_at 0.00011 -3.5 GAP43 growth associated protein 43 
chr3q13.1-
q13.2 
26 221288_at 0.00174 -3.6 GPR22 G protein-coupled receptor 22 chr7q22-q31.1 
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25 206837_at 0.00012 -3.6 CART1 cartilage paired-class homeoprotein 1 chr12q21.3-q22 
24 205068_s_at 0.00326 -3.6 
ARHGAP2
6 Rho GTPase activating protein 26 chr5q31 
23 218424_s_at 0.00003 -3.6 TSAP6 dudulin 2 chr2q14.2 
22 210519_s_at 0.00066 -3.8 NQO1 NAD(P)H dehydrogenase, quinone 1 chr16q22.1 
21 209627_s_at 0.00153 -4.0 OSBPL3 oxysterol binding protein-like 3 chr7p15 
20 219271_at 0.00131 -4.0 GALNT14 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 (GalNAc-
T14) chr2p23.1 
19 206376_at 0.00482 -4.3 SLC6A15 
solute carrier family 6 (neurotransmitter 
transporter), member 15 chr12q21.3 
18 210675_s_at 0.00160 -4.4 PTPRR 
protein tyrosine phosphatase, receptor type, 
R chr12q15 
17 205305_at 0.00000 -4.5 FGL1 fibrinogen-like 1 chr8p22-p21.3 
16 213664_at 0.00000 -4.9 SLC1A1 
solute carrier family 1 (neuronal/epithelial 
high affinity glutamate transporter, system 
Xag), member 1 chr9p24 
15 213620_s_at 0.00001 -5.2 ICAM2 intercellular adhesion molecule 2 chr17q23-q25 
14 206478_at 0.00103 -5.7 KIAA0125 KIAA0125 chr14q32.33 
13 204035_at 0.00055 -5.9 SCG2 secretogranin II (chromogranin C) chr2q35-q36 
12 213609_s_at 0.00005 -6.2 SEZ6L seizure related 6 homolog (mouse)-like chr22q12.1 
11 212741_at 0.00017 -6.5 MAOA monoamine oxidase A chrxp11.4-p11.3
10 204389_at 0.00001 -6.5 MAOA monoamine oxidase A chrxp11.4-p11.3
9 202242_at 0.00021 -6.9 TM4SF2 transmembrane 4 superfamily member 2 chrxp11.4 
8 204388_s_at 0.00008 -7.0 MAOA monoamine oxidase A chrxp11.4-p11.3
7 221245_s_at 0.00019 -7.1 C2orf31 
chromosome 2 open reading frame 31 /// 
chromosome 2 open reading frame 31 chr2q34 
6 210839_s_at 0.00000 -7.1 ENPP2 
ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
(autotaxin) chr8q24.1 
5 212096_s_at 0.00017 -7.2 MTUS1 mitochondrial tumor suppressor 1 chr8p22 
4 218858_at 0.00001 -7.9 DEPDC6 DEP domain containing 6 chr8q24.12 
3 213847_at 0.00050 -10.4 PRPH peripherin chr12q12-q13 
2 209392_at 0.00000 -17.3 ENPP2 
ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
(autotaxin) chr8q24.1 
1 201739_at 0.00184 -21.8 SGK serum/glucocorticoid regulated kinase chr6q23 
Table 12.6 Most up and down-regulated genes derived from the comparison C99WT1/mock 
(n=3, p≤0.005), analyzed with the Language R software and the GC-RMA algorithm. 
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12.2.3 Genes identified using the MAS 5 algorithm (Array Assist, 
Stratagene)  
 
Table 12.7 Most up and down-regulated genes derived from the comparison 
C99I45F/C99WT1 (Aβ42/Aβ40↑, n=3, p<0.05, C99WT1 was the 
baseline experiment) 
Position Probe Set ID p-value 
Fold 
Change 
C99I45F/ 
C99WT1 
Gene 
Symbol Gene Title 
Chromosomal 
Location 
1 215168_at 0.00653 8.0 TIMM17A 
translocase of inner mitochondrial 
membrane 17 homolog A (yeast) chr1q32.1 
2 238368_at 0.00132 6.3 PVT1 
Pvt1 oncogene homolog, MYC activator 
(mouse) chr8q24 
3 240106_at 0.00132 6.3 MGC4170 MGC4170 protein chr12q23.3 
4 241040_at 0.00132 6.3  Transcribed locus  
5 213174_at 0.00313 6.3 TTC9 tetratricopeptide repeat domain 9 chr14q24.2 
6 213338_at 0.03347 6.3 RIS1 Ras-induced senescence 1 chr3p21.3 
7 207860_at 0.00219 5.0 NCR1 natural cytotoxicity triggering receptor 1 chr19q13.42 
8 217085_at 0.00219 5.0 SLC14A2 
Solute carrier family 14 (urea transporter), 
member 2 
chr18q12.1-
q21.1 
9 217394_at 0.00219 5.0 TRA@ T cell receptor alpha locus chr14q11.2 
10 232825_s_at 0.00219 5.0 C18orf4 chromosome 18 open reading frame 4 chr18q22.1 
11 242758_x_at 0.00219 5.0 JMJD1A Jumonji domain containing 1A chr2p11.2 
12 243169_at 0.00219 5.0  Transcribed locus  
13 227342_s_at 0.02322 5.0 MYEOV 
myeloma overexpressed gene (in a subset 
of t(11;14) positive multiple myelomas) chr11q13 
14 205220_at 0.02490 5.0 GPR109B 
G protein-coupled receptor 109B /// G 
protein-coupled receptor 109B chr12q24.31 
15 211341_at 0.02490 5.0 POU4F1 POU domain, class 4, transcription factor 1 chr13q21.1-q22 
16 239776_at 0.02490 5.0  MRNA; cDNA DKFZp686G0585   
17 242003_at 0.02490 5.0 LOC157697 Hypothetical protein LOC157697 chr8p23.3 
18 244261_at 0.02490 5.0 IL28RA 
interleukin 28 receptor, alpha (interferon, 
lambda receptor) chr1p36.11 
19 209909_s_at 0.00219 4.0 TGFB2 transforming growth factor, beta 2 chr1q41 
20 216994_s_at 0.00219 4.0 RUNX2 runt-related transcription factor 2 chr6p21 
21 219949_at 0.00219 4.0 LRRC2 leucine rich repeat containing 2 chr3p21.31 
22 220190_s_at 0.00219 4.0 
ALF /// 
SALF 
TFIIA-alpha/beta-like factor /// stoned 
B/TFIIA-alpha/beta-like factor chr2p16.3 
23 206575_at 0.02490 4.0 CDKL5 cyclin-dependent kinase-like 5 chrXp22 
24 241177_at 0.02490 4.0  Transcribed locus  
25 242708_at 0.02490 4.0 PEX1 Peroxisome biogenesis factor 1 chr7q21-q22 
26 212942_s_at 0.02572 4.0 KIAA1199 KIAA1199 chr15q24 
27 214343_s_at 0.02572 4.0 ATXN7L1  ataxin 7-like 1 /// ataxin 7-like 4 
chr7q22.1 /// 
chr7q22.3 
28 215559_at 0.02572 4.0 ABCC6 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 6 chr16p13.1 
29 216191_s_at 0.02572 4.0 
TRA@ /// 
TRD@ 
T cell receptor alpha locus /// T cell receptor 
delta locus chr14q11.2 
30 221182_at 0.02572 4.0 FLJ23550 hypothetical protein FLJ23550 chr1q24.3 
31 224506_s_at 0.02572 4.0 C9orf67 
chromosome 9 open reading frame 67 /// 
chromosome 9 open reading frame 67 chr9q34.13 
32 228054_at 0.02572 4.0 TMEM44 transmembrane protein 44 chr3q29 
33 233314_at 0.02572 4.0 PTEN 
phosphatase and tensin homolog (mutated 
in multiple advanced cancers 1) chr10q23.3 
34 241051_at 0.02572 4.0    
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35 243847_at 0.02572 4.0 CLIC4 Chloride intracellular channel 4 chr1p36.11 
36 244604_at 0.02572 4.0 LOC340171 hypothetical LOC340171 chr6q14.1 
37 201645_at 0.00749 3.2 TNC tenascin C (hexabrachion) chr9q33 
38 205302_at 0.00749 3.2 IGFBP1 insulin-like growth factor binding protein 1 chr7p13-p12 
39 206856_at 0.00749 3.2 LILRB5 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 5 chr19q13.4 
40 213317_at 0.00749 3.2 CLIC5 Chloride intracellular channel 5 chr6p12.1-21.1 
41 215351_at 0.00749 3.2 RTCD1 RNA terminal phosphate cyclase domain 1 chr1p21.3 
42 215653_at 0.00749 3.2  Clone IMAGE:205688, mRNA sequence  
43 216541_x_at 0.00749 3.2 
IGHG1 /// 
IGHG3 /// 
MGC27165 
immunoglobulin heavy constant gamma 1 
(G1m marker) /// immunoglobulin heavy 
constant gamma 3 (G3m marker) /// 
hypothetical protein MGC27165 chr14q32.33 
44 217006_x_at 0.00749 3.2    
45 220996_s_at 0.00749 3.2 C1orf14 
chromosome 1 open reading frame 14 /// 
chromosome 1 open reading frame 14 chr1q25 
46 223045_at 0.00749 3.2 EGLN1 egl nine homolog 1 (C. elegans) chr1q42.1 
47 223694_at 0.00749 3.2 TRIM7 tripartite motif-containing 7 chr5q35.3 
48 231797_at 0.00749 3.2 SIX4 
sine oculis homeobox homolog 4 
(Drosophila) chr14q23 
49 234531_at 0.00749 3.2  CDNA FLJ13378 fis, clone PLACE1000931  
50 235519_at 0.00749 3.2    
51 236538_at 0.00749 3.2 GRIA2 glutamate receptor, ionotropic, AMPA 2 chr4q32-q33 
52 238825_at 0.00749 3.2 ACRC acidic repeat containing chrXq13.1 
53 240459_at 0.00749 3.2 YT521 splicing factor YT521-B chr4q13.2 
54 242223_at 0.00749 3.2 MCCC1 
Methylcrotonoyl-Coenzyme A carboxylase 1 
(alpha) chr3q27 
55 244399_at 0.00749 3.2 STAB2 Stabilin 2 chr12q23.3 
56 244528_at 0.00749 3.2 ARMC8 Armadillo repeat containing 8 chr3q22.3 
57 244611_at 0.00749 3.2 THRAP1 
Thyroid hormone receptor associated 
protein 1 chr17q22-q23 
58 206838_at 0.01324 3.2 TBX19 T-box 19 chr1q23-q24 
59 225864_at 0.01324 3.2 NSE2 breast cancer membrane protein 101 chr8q24.21 
60 226560_at 0.01324 3.2 SGPP2 Sphingosine-1-phosphate phosphotase 2 chr2q36.1 
61 228018_at 0.01324 3.2    
62 230394_at 0.01324 3.2 TCP10L t-complex 10 (mouse)-like chr21q22.11 
63 233908_x_at 0.01324 3.2  CDNA FLJ12050 fis, clone HEMBB1002002  
64 233927_at 0.01324 3.2  CDNA FLJ11919 fis, clone HEMBB1000274  
65 241154_x_at 0.01324 3.2 MTSS1 Metastasis suppressor 1 chr8p22 
66 241265_x_at 0.01324 3.2 TINP1 TGF beta-inducible nuclear protein 1 chr5q13.3 
67 241793_at 0.01324 3.2 ZMYND17 zinc finger, MYND domain containing 17 chr10q22.2 
68 242299_at 0.01324 3.2  Transcribed locus  
69 204988_at 0.01613 2.5 FGB fibrinogen, B beta polypeptide chr4q28 
70 206490_at 0.01613 2.5 DLGAP1 
discs, large (Drosophila) homolog-
associated protein 1 chr18p11.3 
71 206619_at 0.01613 2.5 DKK4 dickkopf homolog 4 (Xenopus laevis) chr8p11.2-p11.1
72 206699_x_at 0.01613 2.5 NPAS1 neuronal PAS domain protein 1 
chr19q13.2-
q13.3 
73 206814_at 0.01613 2.5 NGFB nerve growth factor, beta polypeptide chr1p13.1 
74 207766_at 0.01613 2.5 CDKL1 
cyclin-dependent kinase-like 1 (CDC2-
related kinase) chr14q21.3 
75 208007_at 0.01613 2.5    
76 209689_at 0.01613 2.5 FLJ10996 hypothetical protein FLJ10996 chr2q14.1 
77 211128_at 0.01613 2.5 EDA ectodysplasin A chrXq12-q13.1 
78 217199_s_at 0.01613 2.5 STAT2 
signal transducer and activator of 
transcription 2, 113kDa chr12q13.3 
79 217523_at 0.01613 2.5 CD44 
CD44 antigen (homing function and Indian 
blood group system) chr11p13 
80 219059_s_at 0.01613 2.5 XLKD1 extracellular link domain containing 1 chr11p15 
81 221667_s_at 0.01613 2.5 HSPB8 heat shock 22kDa protein 8 chr12q24.23 
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82 223316_at 0.01613 2.5 CCDC3 coiled-coil domain containing 3 chr10p13 
83 223574_x_at 0.01613 2.5 PPP2R2C 
protein phosphatase 2 (formerly 2A), 
regulatory subunit B (PR 52), gamma 
isoform chr4p16.1 
84 224274_at 0.01613 2.5 C14orf155 chromosome 14 open reading frame 155 chr14q21.2 
85 224300_x_at 0.01613 2.5 FTCD formiminotransferase cyclodeaminase chr21q22.3 
86 226220_at 0.01613 2.5 DREV1 DORA reverse strand protein 1 chr16p13-p12 
87 226281_at 0.01613 2.5 DNER 
delta-Notch-like EGF repeat-containing 
transmembrane chr2q36.3 
88 227276_at 0.01613 2.5 PLXDC2 plexin domain containing 2 chr10p12.31 
89 228590_at 0.01613 2.5 FLJ20758 FLJ20758 protein chr2p11.2 
90 232729_at 0.01613 2.5 FBXO32 F-box protein 32 chr8q24.13 
91 234261_at 0.01613 2.5 EB-1 E2a-Pbx1-associated protein chr12q23.1 
92 234717_at 0.01613 2.5    
93 234826_at 0.01613 2.5 LOC375295 Hypothetical gene supported by BC013438 chr2q31.1 
94 234924_s_at 0.01613 2.5 KIAA1441 KIAA1441 protein chr1q21.2 
95 236316_at 0.01613 2.5 FAM3C family with sequence similarity 3, member C chr7q22.1-q31.1
96 236991_at 0.01613 2.5  Transcribed locus  
97 237273_at 0.01613 2.5 KCNU1 potassium channel, subfamily U, member 1 chr8p11.22 
98 237469_at 0.01613 2.5 TOP2A Topoisomerase (DNA) II alpha 170kDa chr17q21-q22 
99 238977_at 0.01613 2.5 MCM6 
MCM6 minichromosome maintenance 
deficient 6 (MIS5 homolog, S. pombe) (S. 
cerevisiae) chr2q21 
100 239064_at 0.01613 2.5  CDNA FLJ36582 fis, clone TRACH2013081  
100 232391_at 0.00749 -3.2 GIOT-1 
gonadotropin inducible transcription 
repressor 1 chr19q13.12 
99 237820_at 0.00749 -3.2    
98 239337_at 0.00749 -3.2    
97 240300_at 0.00749 -3.2 TK2 Thymidine kinase 2, mitochondrial chr16q22-q23.1 
96 241092_at 0.00749 -3.2 BBX Bobby sox homolog (Drosophila) chr3q13.1 
95 241139_at 0.00749 -3.2  Transcribed locus  
94 243353_at 0.00749 -3.2 PDCD8 
Programmed cell death 8 (apoptosis-
inducing factor) chrXq25-q26 
93 206701_x_at 0.02572 -3.2 EDNRB endothelin receptor type B chr13q22 
92 207652_s_at 0.02572 -3.2 CMKLR1 chemokine-like receptor 1 chr12q24.1 
91 210584_s_at 0.02572 -3.2 
POLDIP3 /// 
dJ222E13.2
polymerase (DNA-directed), delta interacting 
protein 3 /// similar to CGI-96 chr22q13.2 
90 213277_at 0.02572 -3.2 ZFP36L1 Zinc finger protein 36, C3H type-like 1 chr14q22-q24 
89 214131_at 0.02572 -3.2 CYorf15B chromosome Y open reading frame 15B chrYq11.222 
88 214374_s_at 0.02572 -3.2 PPFIBP1 
PTPRF interacting protein, binding protein 1 
(liprin beta 1) 
chr12p11.23-
p11.22 
87 216039_at 0.02572 -3.2 PMS2L1 postmeiotic segregation increased 2-like 1 chr7q22.1 
86 221026_s_at 0.02572 -3.2 SCRT1 
scratch homolog 1, zinc finger protein 
(Drosophila) /// scratch homolog 1, zinc 
finger protein (Drosophila) chr8q24.3 
85 223620_at 0.02572 -3.2 GPR34 G protein-coupled receptor 34 
chrXp11.4-
p11.3 
84 223815_at 0.02572 -3.2 LOC90799 hypothetical protein BC009518 chr17q24.2 
83 228533_at 0.02572 -3.2 FNDC3A fibronectin type III domain containing 3A chr13q14.2 
82 228575_at 0.02572 -3.2 FNDC6 fibronectin type III domain containing 6 chr3q22.3 
81 229972_at 0.02572 -3.2    
80 230385_at 0.02572 -3.2 LOC153277 hypothetical protein LOC153277 chr5q23.3 
79 230451_at 0.02572 -3.2    
78 230534_at 0.02572 -3.2 MGC15634 hypothetical protein MGC15634 chr1q42.13 
77 232688_at 0.02572 -3.2 BMP2K BMP2 inducible kinase chr4q21.21 
76 233703_x_at 0.02572 -3.2 FLJ42117 FLJ42117 protein chr3p14.2 
75 233714_at 0.02572 -3.2 ARNT 
Aryl hydrocarbon receptor nuclear 
translocator chr1q21 
74 233997_at 0.02572 -3.2  Hypothetical LOC388790 chr20p11.23 
73 235592_at 0.02572 -3.2 ELL2 Elongation factor, RNA polymerase II, 2 chr5q15 
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72 236783_at 0.02572 -3.2 KCNIP4 Kv channel interacting protein 4 chr4p15.31 
71 239849_at 0.02572 -3.2 EMCN Endomucin chr4q24 
70 239862_at 0.02572 -3.2 TPD52 Tumor protein D52 chr8q21 
69 240936_at 0.02572 -3.2 RARRES1 
Retinoic acid receptor responder 
(tazarotene induced) 1 chr3q25.32 
68 241088_at 0.02572 -3.2 MGC14816 Hypothetical protein MGC14816 chr1p21.3 
67 242542_at 0.02572 -3.2 PHACTR2 Phosphatase and actin regulator 2 chr6q24.2 
66 242815_x_at 0.02572 -3.2  CDNA FLJ32308 fis, clone PROST2002906  
65 242921_at 0.02572 -3.2 RUTBC2 RUN and TBC1 domain containing 2 chr22q11.23 
64 244231_at 0.02572 -3.2    
63 203556_at 0.00219 -5.0 ZHX2 zinc fingers and homeoboxes 2 chr8q24.13 
62 207329_at 0.00219 -5.0 MMP8 
matrix metalloproteinase 8 (neutrophil 
collagenase) chr11q22.3 
61 213094_at 0.00219 -5.0 GPR126 G protein-coupled receptor 126 chr6q24.1 
60 214648_at 0.00219 -5.0 GPX5 
Glutathione peroxidase 5 (epididymal 
androgen-related protein) chr6p22.1 
59 220674_at 0.00219 -5.0 FLJ22814 hypothetical protein FLJ22814 chr19q13.13 
58 224021_at 0.00219 -5.0 RP1 retinitis pigmentosa 1 (autosomal dominant) chr8q11-q13 
57 236419_at 0.00219 -5.0 TGFBR2 
Transforming growth factor, beta receptor II 
(70/80kDa) chr3p22 
56 237314_at 0.00219 -5.0 C10orf63 chromosome 10 open reading frame 63 chr10p12.1 
55 243268_at 0.00219 -5.0 UNQ3112 LVLF3112 chr11q24.2 
54 240853_at 0.00219 -5.0    
53 221433_at 0.01324 -5.0 FGF21 fibroblast growth factor 21 chr19q13.1-qter 
52 234861_at 0.01324 -5.0 LOC93463 hypothetical protein LOC93463 chr2q37.3 
51 236293_at 0.01324 -5.0 RHOH Ras homolog gene family, member H chr4p13 
50 236606_at 0.01324 -5.0 SAV1 Salvador homolog 1 (Drosophila) chr14q13-q23 
49 237216_at 0.01324 -5.0 GARNL1 
GTPase activating Rap/RanGAP domain-
like 1 chr14q13.2 
48 237429_at 0.01324 -5.0  Transcribed locus  
47 242892_at 0.01324 -5.0 PER2 Period homolog 2 (Drosophila) chr2q37.3 
46 243247_at 0.01324 -5.0 MGC27434 Hypothetical LOC401477 chr8q24.21 
45 244318_at 0.01324 -5.0 KIAA0241 KIAA0241 protein chr7p14.3 
44 
AFFX-r2-Bs-
dap-M_at 0.01324 -5.0    
43 241098_at 0.01324 -5.0    
42 208525_s_at 0.02490 -5.0 
OR2F1 /// 
OR2F2 
olfactory receptor, family 2, subfamily F, 
member 1 /// olfactory receptor, family 2, 
subfamily F, member 2 chr7q35 
41 217655_at 0.02490 -5.0 FXYD5 
FXYD domain containing ion transport 
regulator 5 chr19q12-q13.1 
40 224095_at 0.02490 -5.0  PRO2591  
39 225453_x_at 0.02490 -5.0 LOC115098 Hypothetical protein BC013949 chr19p13.11 
38 232415_at 0.02490 -5.0 PCDHB13 protocadherin beta 13 chr5q31 
37 236401_at 0.02490 -5.0    
36 240782_at 0.02490 -5.0  Transcribed locus  
35 241256_at 0.02490 -5.0    
34 211811_s_at 0.00132 -5.0 PCDHA6 protocadherin alpha 6 chr5q31 
33 215325_x_at 0.00132 -5.0 C19orf26 chromosome 19 open reading frame 26 chr19p13.3 
32 228356_at 0.00132 -5.0 ANKRD11 Ankyrin repeat domain 11 chr16q24.3 
31 232958_at 0.00132 -5.0  CDNA FLJ13595 fis, clone PLACE1009595  
30 236399_at 0.00132 -5.0  
Homo sapiens, clone IMAGE:3896086, 
mRNA  
29 236469_at 0.00132 -5.0  
MRNA full length insert cDNA clone 
EUROIMAGE 110216  
28 238808_at 0.00132 -5.0 HOXA13 Homeo box A13 chr7p15-p14 
27 241113_at 0.00132 -5.0 C14orf125 Chromosome 14 open reading frame 125 chr14q12 
26 242893_at 0.00132 -5.0    
25 217267_s_at 0.00776 -5.0    
24 219584_at 0.00776 -5.0 PLA1A phospholipase A1 member A 
chr3q13.13-
q13.2 
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23 238878_at 0.00776 -5.0 ARX aristaless related homeobox 
chrXp22.1-
p21.3 
22 234764_x_at 0.01613 -5.0 IGLC2 
Ig lambda chain V-region (VL-AIG) /// 
Immunoglobulin lambda variable 3-21 chr22q11.2 
21 244306_at 0.01613 -5.0  Transcribed locus  
20 203726_s_at 0.03517 -5.0 LAMA3 laminin, alpha 3 chr18q11.2 
19 240156_at 0.03517 -5.0 RFX2 
Regulatory factor X, 2 (influences HLA class 
II expression) 
chr19p13.3-
p13.2 
18 223596_at 0.03902 -5.0 SLC12A6 
solute carrier family 12 (potassium/chloride 
transporters), member 6 chr15q13-q15 
17 230951_at 0.03902 -5.0 EPB41L5 
Erythrocyte membrane protein band 4.1 like 
5 chr2q14.2 
16 223374_s_at 0.00653 -8.0 B3GALT3 
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 3 chr3q25 
15 242105_at 0.00653 -8.0 CCNE1 Cyclin E1 chr19q12 
14 243528_at 0.00653 -8.0 ZDHHC2 Zinc finger, DHHC domain containing 2 chr8p21.3-p22 
13 240408_at 0.01613 -8.0 TBC1D14 TBC1 domain family, member 14 chr4p16.1 
12 241502_x_at 0.01613 -8.0 MRPS22 Mitochondrial ribosomal protein S22 chr3q23 
11 207430_s_at 0.00056 -8.0 MSMB microseminoprotein, beta- chr10q11.2 
10 243602_at 0.00056 -8.0  Transcribed locus  
9 216045_at 0.00749 -8.0 KIAA0565 KIAA0565 gene product chr17p11.2 
8 210705_s_at 0.01580 -8.0 TRIM5 tripartite motif-containing 5 chr11p15 
7 214488_at 0.01944 -8.0 RAP2B RAP2B, member of RAS oncogene family chr3q25.2 
6 217050_at 0.02322 -8.0 EPAG early lymphoid activation protein  
5 238237_at 0.02322 -8.0  
Transcribed locus, weakly similar to 
NP_064698.1 a disintegrin and 
metalloprotease domain 3 (cyritestin) 
[Rattus norvegicus]  
4 233297_s_at 0.00039 -8.0    
3 241855_s_at 0.01417 -8.0 CUL3 Cullin 3 chr2q36.3 
2 241532_at 0.01944 -8.0    
1 239200_at 0.03800 -8.0    
Table12.7 Most up and down-regulated genes derived from the comparison 
C99I45F/C99WT1 (n=3, p<0.05), analyzed with the Array Assist software and the MAS 5 
algorithm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Supplementary Information 
- S30 - 
 
 
Table 12.8 Most up and down-regulated genes derived from the comparison 
C99V50F/C99WT1 (Aβ42/Aβ40↓, n=3, p<0.05, C99WT1 was the 
baseline experiment) 
 
 
Position Probe Set ID p-value 
Fold 
Change 
C99V50F/ 
C99WT1 
Gene 
Symbol Gene Title Gene Location 
1 226757_at 0.01613 16.0 IFIT2 
interferon-induced protein with 
tetratricopeptide repeats 2 chr10q23-q25 
2 231644_at 0.00749 10.1  Transcribed locus  
3 225664_at 0.00653 8.0 COL12A1 collagen, type XII, alpha 1 chr6q12-q13 
4 242271_at 0.00653 8.0 SLC26A9 solute carrier family 26, member 9 chr1q31-q32 
5 241833_at 0.00749 8.0  Full length insert cDNA clone YY86C01  
6 241436_at 0.03411 8.0 SCNN1G sodium channel, nonvoltage-gated 1, gamma chr16p12 
7 205414_s_at 0.00132 6.3 KIAA0672 KIAA0672 gene product chr17p12 
8 211667_x_at 0.00132 6.3  T-cell receptor alpha chain  
9 217394_at 0.00132 6.3 TRA@ T cell receptor alpha locus chr14q11.2 
10 230643_at 0.00132 6.3 WNT9A 
Wingless-type MMTV integration site family, 
member 9A chr1q42 
11 244399_at 0.00132 6.3 STAB2 Stabilin 2 chr12q23.3 
12 233499_at 0.01580 6.3    
13 204908_s_at 0.01613 6.3 BCL3 B-cell CLL/lymphoma 3 
chr19q13.1-
q13.2 
14 224506_s_at 0.01613 6.3 C9orf67 
chromosome 9 open reading frame 67 /// 
chromosome 9 open reading frame 67 chr9q34.13 
15 225288_at 0.01613 6.3 COL27A1 Collagen, type XXVII, alpha 1 chr9q32 
16 237193_s_at 0.01613 6.3    
17 243530_at 0.01613 6.3 CPSF6 
Cleavage and polyadenylation specific factor 
6, 68kDa chr12q15 
18 237874_at 0.03347 6.3 RNF150 Ring finger protein 150 chr4q31.21 
19 241756_at 0.03347 6.3 SMARCA2
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
a, member 2 chr9p22.3 
20 239776_at 0.03902 6.3  MRNA; cDNA DKFZp686G0585  
21 205829_at 0.00219 5.0 HSD17B1 hydroxysteroid (17-beta) dehydrogenase 1 chr17q11-q21 
22 206229_x_at 0.00219 5.0 PAX2 paired box gene 2 chr10q24 
23 234531_at 0.00219 5.0  CDNA FLJ13378 fis, clone PLACE1000931  
24 244480_at 0.00219 5.0  Transcribed locus  
25 244604_at 0.00219 5.0 
LOC34017
1 hypothetical LOC340171 chr6q14.1 
26 206670_s_at 0.00481 5.0 GAD1 glutamate decarboxylase 1 (brain, 67kDa) chr2q31 
27 216994_s_at 0.00481 5.0 RUNX2 runt-related transcription factor 2 chr6p21 
28 202404_s_at 0.02322 5.0 COL1A2 collagen, type I, alpha 2 chr7q22.1 
29 224213_at 0.02322 5.0 C14orf91 chromosome 14 open reading frame 91 
chr14q22.1-
q23.3 
30 232656_at 0.02322 5.0  CDNA FLJ11692 fis, clone HEMBA1004983  
31 243103_at 0.02322 5.0 TK1 Thymidine kinase 1, soluble 
chr17q23.2-
q25.3 
32 220551_at 0.02490 5.0 SLC17A6 
solute carrier family 17 (sodium-dependent 
inorganic phosphate cotransporter), member 
6 chr11p14.3 
33 221134_at 0.02490 5.0 ANGPT4 angiopoietin 4 chr20p13 
34 230516_at 0.02490 5.0 C7orf30 Chromosome 7 open reading frame 30 chr7p15.3 
35 232729_at 0.02490 5.0 FBXO32 F-box protein 32 chr8q24.13 
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36 237641_at 0.02490 5.0 
LOC38856
3 hypothetical LOC388563 chr19q13.42 
37 237785_at 0.02490 5.0 ASB14 Ankyrin repeat and SOCS box-containing 14 chr3p21.1 
38 240341_at 0.02490 5.0 
LOC33952
9 Hypothetical protein LOC339529 chr1q44 
39 241051_at 0.02490 5.0    
40 241834_at 0.02490 5.0 PAR1 Prader-Willi/Angelman region-1 chr15q11.2 
41 209909_s_at 0.00219 4.0 TGFB2 transforming growth factor, beta 2 chr1q41 
42 220077_at 0.00219 4.0 FLJ22349 hypothetical protein FLJ22349 chr22q13.2 
43 220474_at 0.00219 4.0 SLC25A21
solute carrier family 25 (mitochondrial 
oxodicarboxylate carrier), member 21 chr14q11.2 
44 232277_at 0.00219 4.0 SLC28A3 
Solute carrier family 28 (sodium-coupled 
nucleoside transporter), member 3 chr9q22.2 
45 226959_at 0.02490 4.0 
LOC28307
0 Hypothetical protein LOC283070 chr10p14 
46 233084_s_at 0.02490 4.0 C10orf94 chromosome 10 open reading frame 94 chr10q26.3 
47 237488_at 0.02490 4.0 HNRPC 
Heterogeneous nuclear ribonucleoprotein C 
(C1/C2) chr14q11.2 
48 238289_at 0.02490 4.0 RPGR Retinitis pigmentosa GTPase regulator chrXp11.4 
49 240643_at 0.02490 4.0 TTBK1 tau tubulin kinase 1 chr6p21.1 
50 240711_at 0.02490 4.0 
MGC1219
7 Arginine/serine-rich coiled-coil 1 chr3q25.32 
51 241363_at 0.02490 4.0 FLJ20433 Hypothetical protein FLJ20433 chr9q34.3 
52 242202_at 0.02490 4.0  Hypothetical LOC402532 chr7 
53 242708_at 0.02490 4.0 PEX1 Peroxisome biogenesis factor 1 chr7q21-q22 
54 244163_at 0.02490 4.0 SEMA3A 
Sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 
3A chr7p12.1 
55 244548_at 0.02490 4.0 
ARHGAP2
6 Rho GTPase activating protein 26 chr5q31 
56 202600_s_at 0.02572 4.0 NRIP1 nuclear receptor interacting protein 1 chr21q11.2 
57 206805_at 0.02572 4.0 SEMA3A 
sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 
3A chr7p12.1 
58 207178_s_at 0.02572 4.0 FRK fyn-related kinase chr6q21-q22.3 
59 214146_s_at 0.02572 4.0 PPBP 
pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7) chr4q12-q13 
60 214708_at 0.02572 4.0 SNTB1 
syntrophin, beta 1 (dystrophin-associated 
protein A1, 59kDa, basic component 1) chr8q23-q24 
61 214781_at 0.02572 4.0    
62 216140_at 0.02572 4.0    
63 217085_at 0.02572 4.0 SLC14A2 
Solute carrier family 14 (urea transporter), 
member 2 
chr18q12.1-
q21.1 
64 219327_s_at 0.02572 4.0 GPRC5C 
G protein-coupled receptor, family C, group 
5, member C chr17q25 
65 223858_at 0.02572 4.0 ESRRB estrogen-related receptor beta chr14q24.3 
66 224012_at 0.02572 4.0 ANKRD20 ankyrin repeat domain 20A  
chr9q12 /// 
chr9p11.2 
67 228146_at 0.02572 4.0 
LOC33926
3 hypothetical protein LOC339263 chr17p11.2 
68 228644_s_at 0.02572 4.0 SLC12A4 
Solute carrier family 12 (potassium/chloride 
transporters), member 4 chr16q22.1 
69 229880_at 0.02572 4.0  Full-length cDNA clone CS0DD009YF23   
70 229999_at 0.02572 4.0    
71 232024_at 0.02572 4.0 GIMAP2 GTPase, IMAP family member 2 chr7q36.1 
72 232993_at 0.02572 4.0 SYNJ1 Synaptojanin 1 chr21q22.2 
73 233753_at 0.02572 4.0 SFRS15 splicing factor, arginine/serine-rich 15 chr21q22.1 
74 234283_at 0.02572 4.0 HSPC117 Hypothetical protein HSPC117 chr22q12 
75 235655_at 0.02572 4.0    
76 235995_at 0.02572 4.0 
LOC44200
9 
similar to solute carrier family 7 member 8 
(53.8 kD) (4K364) chr2p24.1 
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77 236295_s_at 0.02572 4.0 NOD3 NOD3 protein chr16p13.3 
78 238368_at 0.02572 4.0 PVT1 
Pvt1 oncogene homolog, MYC activator 
(mouse) chr8q24 
79 238825_at 0.02572 4.0 ACRC acidic repeat containing chrXq13.1 
80 239310_at 0.02572 4.0 DDB2 
Damage-specific DNA binding protein 2, 
48kDa chr11p12-p11 
81 241103_at 0.02572 4.0    
82 242173_at 0.02572 4.0    
83 243091_at 0.02572 4.0 CRYZL1 Crystallin, zeta (quinone reductase)-like 1 chr21q21.3 
84 243919_at 0.02572 4.0    
85 244060_at 0.02572 4.0 ADD2 Adducin 2 (beta) chr2p14-p13 
86 244528_at 0.02572 4.0 ARMC8 Armadillo repeat containing 8 chr3q22.3 
87 241673_x_at 0.03902 4.0    
88 206155_at 0.00749 3.2 ABCC2 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 2 chr10q24 
89 207147_at 0.00749 3.2 DLX2 distal-less homeo box 2 chr2q32 
90 207355_at 0.00749 3.2 SLC1A7 
solute carrier family 1 (glutamate 
transporter), member 7 chr1p32.3 
91 211635_x_at 0.00749 3.2    
92 215496_at 0.00749 3.2 SAMD4 sterile alpha motif domain containing 4 chr14q22.2 
93 220416_at 0.00749 3.2 ATP8B4 ATPase, Class I, type 8B, member 4 chr15q21.2 
94 224043_s_at 0.00749 3.2 UPB1 ureidopropionase, beta chr22q11.2 
95 226646_at 0.00749 3.2 KLF2 Kruppel-like factor 2 (lung) 
chr19p13.13-
p13.11 
96 227371_at 0.00749 3.2 BAIAP2L1 BAI1-associated protein 2-like 1 chr7q21.3-q22.1
97 228434_at 0.00749 3.2 BTNL9 butyrophilin-like 9 chr5q35.3 
98 228599_at 0.00749 3.2 MS4A1 
Membrane-spanning 4-domains, subfamily A, 
member 1 chr11q12 
99 228761_at 0.00749 3.2 
DKFZp547
F072 hypothetical protein DKFZp547F072 chr8q24.3 
100 229910_at 0.00749 3.2 
LOC12666
9 hypothetical protein LOC126669 chr1q21.3 
101 230034_x_at 0.00749 3.2 MRPL41 Mitochondrial ribosomal protein L41 chr9q34.3 
102 230462_at 0.00749 3.2 NUMB numb homolog (Drosophila) chr14q24.3 
101 238647_at 0.01613 -2.5 C14orf28 chromosome 14 open reading frame 28 chr14q21.2 
100 238815_at 0.01613 -2.5 LRRTM1 
leucine rich repeat transmembrane neuronal 
1 chr2p12 
99 239632_at 0.01613 -2.5    
98 239666_at 0.01613 -2.5 PYGO2 Pygopus homolog 2 (Drosophila) chr1q22 
97 240138_at 0.01613 -2.5    
96 240695_at 0.01613 -2.5 SH2D3C SH2 domain containing 3C chr9q34.11 
95 241312_at 0.01613 -2.5    
94 241423_at 0.01613 -2.5   chr5q13.3 
93 242281_at 0.01613 -2.5 GLUL 
Glutamate-ammonia ligase (glutamine 
synthase) chr1q31 
92 242445_at 0.01613 -2.5 FGD4 FYVE, RhoGEF and PH domain containing 4 chr12p11.21 
91 243122_at 0.01613 -2.5 PACRG PARK2 co-regulated chr6q26 
90 243334_at 0.01613 -2.5 CACNA1D 
Calcium channel, voltage-dependent, L type, 
alpha 1D subunit chr3p14.3 
89 243559_at 0.01613 -2.5 ZNF148 Zinc finger protein 148 (pHZ-52) chr3q21 
88 244669_at 0.01613 -2.5 C6orf160 LOC441164 chr6q14.3 
87 238308_at 0.01613 -2.5    
86 238311_at 0.01613 -2.5    
85 206466_at 0.00749 -3.2    
84 206761_at 0.00749 -3.2 CD96 CD96 antigen 
chr3q13.13-
q13.2 
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83 207324_s_at 0.00749 -3.2 DSC1 desmocollin 1 
chr18q12.2|18q
12.1 
82 207977_s_at 0.00749 -3.2 DPT dermatopontin chr1q12-q23 
81 208350_at 0.00749 -3.2 CSN1S1 casein alpha s1 chr4q21.1 
80 217203_at 0.00749 -3.2    
79 221996_s_at 0.00749 -3.2 CLTB Clathrin, light polypeptide (Lcb) chr4q2-q3 
78 224851_at 0.00749 -3.2 CDK6 cyclin-dependent kinase 6 chr7q21-q22 
77 225590_at 0.00749 -3.2 SH3MD2 SH3 multiple domains 2 chr4q32.3-q33 
76 226613_at 0.00749 -3.2 
TBC1D10
A TBC1 domain family, member 10A chr22q12.1-qter 
75 228624_at 0.00749 -3.2 FLJ11155 hypothetical protein FLJ11155 chr4q32.1 
74 229134_at 0.00749 -3.2    
73 229706_at 0.00749 -3.2 TCERG1 transcription elongation regulator 1 chr5q31 
72 230051_at 0.00749 -3.2 C10orf47 chromosome 10 open reading frame 47 chr10p14 
71 230395_at 0.00749 -3.2 DREV1 DORA reverse strand protein 1 chr16p13-p12 
70 232562_at 0.00749 -3.2 
CDNA 
FLJ11554    
69 232903_at 0.00749 -3.2 
CDNA: 
FLJ21199    
68 235401_s_at 0.00749 -3.2 FREB Fc receptor homolog expressed in B cells chr1q23.3 
67 235574_at 0.00749 -3.2 GBP4 guanylate binding protein 4 chr1p22.2 
66 236410_x_at 0.00749 -3.2 
LOC38759
3 TPTE/TPIP pseudogene chr22q13 
65 238752_at 0.00749 -3.2 MRS2L 
MRS2-like, magnesium homeostasis factor 
(S. cerevisiae) chr6p22.3-p22.1
64 238898_at 0.00749 -3.2    
63 239169_at 0.00749 -3.2 RAD52B RAD52 homolog B (S. cerevisiae) chr17q11.2 
62 239299_at 0.00749 -3.2 DDI1 DNA-damage inducible protein 1  
61 241057_x_at 0.00749 -3.2 DDX26 
DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 26 
chr13q14.12-
q14.2 
60 241113_at 0.00749 -3.2 C14orf125 Chromosome 14 open reading frame 125 chr14q12 
59 241270_at 0.00749 -3.2 RHBDL6 Rhomboid, veinlet-like 6 (Drosophila) chr17q25.1 
58 243184_at 0.00749 -3.2 TJP1 Tight junction protein 1 (zona occludens 1) chr15q13 
57 243636_s_at 0.00749 -3.2 EVE1 SH3 domain protein D19 chr4q31.3 
56 240921_at 0.00749 -3.2    
55 240910_at 0.00749 -3.2    
54 206145_at 0.04742 -3.2 RHAG Rhesus blood group-associated glycoprotein chr6p21.1-p11 
53 207008_at 0.04742 -3.2 IL8RB interleukin 8 receptor, beta chr2q35 
52 207221_at 0.04742 -3.2 F2RL3 
coagulation factor II (thrombin) receptor-like 
3 chr19p12 
51 208536_s_at 0.04742 -3.2 BCL2L11 BCL2-like 11 (apoptosis facilitator) chr2q13 
50 214342_at 0.04742 -3.2 
ATXN7L1 
/// 
ATXN7L4 ataxin 7-like 1 /// ataxin 7-like 4 
chr7q22.1 /// 
chr7q22.3 
49 214460_at 0.04742 -3.2 LSAMP limbic system-associated membrane protein chr3q13.2-q21 
48 214680_at 0.04742 -3.2 NTRK2 
neurotrophic tyrosine kinase, receptor, type 
2, non-catalytic isoform chr9q22.1 
47 216131_at 0.04742 -3.2 FRMD4B FERM domain containing 4B chr3p14.1 
46 216558_x_at 0.04742 -3.2    
45 221790_s_at 0.04742 -3.2 LDLRAP1 
low density lipoprotein receptor adaptor 
protein 1 chr1p36-p35 
44 229554_at 0.04742 -3.2 LUM Lumican chr12q21.3-q22 
43 230752_at 0.04742 -3.2 CBX5 
Chromobox homolog 5 (HP1 alpha homolog, 
Drosophila) chr12q13.13 
42 231699_at 0.04742 -3.2 NFKBIA 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, alpha chr14q13 
41 231709_x_at 0.04742 -3.2 MYR8 Myosin heavy chain Myr 8 chr13q33.3 
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40 237640_at 0.04742 -3.2 C14orf138 chromosome 14 open reading frame 138 chr14q21.3 
39 237841_at 0.04742 -3.2 C9orf5 Chromosome 9 open reading frame 5 chr9q31 
38 238170_at 0.04742 -3.2 Cep63 Centrosome protein Cep63 chr3q22.1 
37 239022_at 0.04742 -3.2 SDHAL2 
Succinate dehydrogenase complex, subunit 
A, flavoprotein-like 2 chr3q29 
36 239837_at 0.04742 -3.2 ADAM11 
A disintegrin and metalloproteinase domain 
11 chr17q21.3 
35 244323_at 0.04742 -3.2 BHLHB5 
basic helix-loop-helix domain containing, 
class B, 5 chr8q13 
34 237009_at 0.04742 -3.2    
33 241104_at 0.04742 -3.2    
32 210096_at 0.00749 -4.0 CYP4B1 
cytochrome P450, family 4, subfamily B, 
polypeptide 1 chr1p34-p12 
31 202307_s_at 0.02572 -4.0 TAP1 
transporter 1, ATP-binding cassette, sub-
family B (MDR/TAP) chr6p21.3 
30 208170_s_at 0.02572 -4.0 TRIM31 tripartite motif-containing 31 chr6p21.3 
29 210525_x_at 0.02572 -4.0 C14orf143 chromosome 14 open reading frame 143 chr14q32.11 
28 211907_s_at 0.02572 -4.0 PARD6B 
par-6 partitioning defective 6 homolog beta 
(C. elegans)  chr20q13.13 
27 215487_x_at 0.02572 -4.0   
chr20p11.21-
p11.1 
26 217584_at 0.02572 -4.0 NPC1 Niemann-Pick disease, type C1 chr18q11-q12 
25 220931_at 0.02572 -4.0 MGC5590 hypothetical protein MGC5590 chr13q14.11 
24 221928_at 0.02572 -4.0 ACACB acetyl-Coenzyme A carboxylase beta chr12q24.11 
23 222272_x_at 0.02572 -4.0 SCIN scinderin chr7p21.3 
22 223582_at 0.02572 -4.0 MASS1 
monogenic, audiogenic seizure susceptibility 
1 homolog (mouse) chr5q13 
21 229261_at 0.02572 -4.0 SOS1 Son of sevenless homolog 1 (Drosophila) chr2p22-p21 
20 236399_at 0.02572 -4.0    
19 240242_at 0.02572 -4.0    
18 240421_x_at 0.02572 -4.0    
17 242321_at 0.02572 -4.0    
16 243660_at 0.02572 -4.0 CHD9 
Chromodomain helicase DNA binding protein 
9 chr16q12.2 
15 202235_at 0.00219 -5.0 SLC16A1 
solute carrier family 16 (monocarboxylic acid 
transporters), member 1 chr1p12 
14 206715_at 0.00219 -5.0 TFEC transcription factor EC chr7q31.2 
13 207430_s_at 0.00219 -5.0 MSMB microseminoprotein, beta- chr10q11.2 
12 203902_at 0.01324 -5.0 HEPH hephaestin chrXq11-q12 
11 214479_at 0.01324 -5.0 GFRA3 GDNF family receptor alpha 3 chr5q31.1-q31.3
10 214826_at 0.01324 -5.0 2'-PDE 2'-phosphodiesterase chr3p14.3 
9 233305_at 0.01324 -5.0 EFCBP1 EF hand calcium binding protein 1 chr8q21.3 
8 238555_at 0.01324 -5.0 MRPS31 Mitochondrial ribosomal protein S31 chr13q14.11 
7 234945_at 0.02490 -5.0 FAM54A family with sequence similarity 54, member A chr6q23.3 
6 240894_at 0.02490 -5.0    
5 205380_at 0.00132 -6.3 PDZK1 PDZ domain containing 1 chr1q21 
4 234344_at 0.00132 -6.3 RAP2C RAP2C, member of RAS oncogene family chrXq25 
3 214488_at 0.01613 -6.3 RAP2B RAP2B, member of RAS oncogene family chr3q25.2 
2 244749_at 0.01613 -6.3    
1 240850_at 0.03517 -6.3 DYRK1A 
Dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 1A chr21q22.13 
Table 12.8 Most up and down-regulated genes derived from the comparison 
C99V50F/C99WT1 (n=3, p<0.05), analyzed with the Array Assist software and the MAS 5 
algorithm. 
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Table 12.9 Most up and down-regulated genes derived from the comparison 
C99WT1/mock (n=3, p<0.05, mock was the baseline experiment) 
Position Probe Set ID p-value 
Fold 
change 
C99WT1/ 
mock 
Gene 
Symbol Gene Title 
Chromosomal 
Location 
1 219691_at 0.00015 25.4 SAMD9 sterile alpha motif domain containing 9 chr7q21.2 
2 244621_x_at 0.00039 12.7  Transcribed locus  
3 244820_at 0.00582 12.7 ZNRF3 Zinc and ring finger 3 chr22q12.1 
4 238237_at 0.01417 12.7  
Transcribed locus, weakly similar to 
NP_064698.1 a disintegrin and metalloprotease 
domain 3 (cyritestin) [Rattus norvegicus]  
5 240146_at 0.00056 10.1 CAPZA2 
Capping protein (actin filament) muscle Z-line, 
alpha 2 
chr7q31.2-
q31.3 
6 221795_at 0.00793 10.1 NTRK2 
neurotrophic tyrosine kinase, receptor, type 2, 
non-catalytic isoform chr9q22.1 
7 204239_s_at 0.01944 10.1 NNAT neuronatin 
chr20q11.2-
q12 
8 242631_x_at 0.03411 10.1    
9 214953_s_at 0.00056 8.0 APP 
amyloid beta (A4) precursor protein (protease 
nexin-II, Alzheimer disease) 
chr21q21.2|2
1q21.3 
10 219584_at 0.00653 8.0 PLA1A phospholipase A1 member A 
chr3q13.13-
q13.2 
11 237462_at 0.00653 8.0 
MGC4040
5 Hypothetical protein MGC40405 chr7q21.2 
12 201789_at 0.00132 6.3 DHRS7 
dehydrogenase/reductase (SDR family) 
member 7 chr14q23.1 
13 206142_at 0.00132 6.3 ZNF135 zinc finger protein 135 (clone pHZ-17) chr19q13.4 
14 211466_at 0.00132 6.3 NFIB nuclear factor I/B chr9p24.1 
15 215632_at 0.00132 6.3 NEUROG2 neurogenin 2 chr4q25 
16 218113_at 0.00132 6.3 TMEM2 transmembrane protein 2 chr9q13-q21 
17 229723_at 0.00132 6.3 TAGAP T-cell activation GTPase activating protein chr6q25.3 
18 231281_at 0.00132 6.3  CDNA FLJ13469 fis, clone PLACE1003528  
19 236484_at 0.00132 6.3 STARD7 START domain containing 7 chr2q11.2 
20 237383_at 0.00132 6.3  Transcribed locus  
21 237656_at 0.00132 6.3 BOMB BH3-only member B protein chr4q35.1 
22 238332_at 0.00132 6.3 ANKRD29 ankyrin repeat domain 29 chr18q11.2 
23 240327_at 0.00132 6.3 SEPT6 Septin 6 chrXq24 
24 240472_at 0.00132 6.3  
MRNA; cDNA DKFZp761N2217 (from clone 
DKFZp761N2217)  
25 242036_x_at 0.00132 6.3 ATP2B3 
ATPase, Ca++ transporting, plasma membrane 
3 chrXq28 
26 239465_at 0.00132 6.3    
27 204320_at 0.00313 6.3 COL11A1 collagen, type XI, alpha 1 chr1p21 
28 242433_at 0.00313 6.3    
29 227344_at 0.01613 6.3 ZNFN1A1 Zinc finger protein, subfamily 1A, 1 (Ikaros) 
chr7p13-
p11.1 
30 233295_at 0.01613 6.3  
Pheromone receptor (PHRET) pseudogene, 
partial mRNA sequence  
31 238635_at 0.01613 6.3 FLJ21657 hypothetical protein FLJ21657 chr5p12 
32 240906_at 0.01613 6.3 MRPS36 Mitochondrial ribosomal protein S36 chr5q13.2 
33 243838_at 0.01613 6.3 ATXN2 Ataxin 2 chr12q24.1 
34 233172_at 0.03902 6.3  CDNA FLJ13313 fis, clone OVARC1001489  
35 215188_at 0.00219 5.0 STK24 
serine/threonine kinase 24 (STE20 homolog, 
yeast) 
chr13q31.2-
q32.3 
36 215824_at 0.00219 5.0 NUDT7 
nudix (nucleoside diphosphate linked moiety X)-
type motif 7 chr16q23.1 
37 227266_s_at 0.00219 5.0 FYB FYN binding protein (FYB-120/130) chr5p13.1 
38 229162_s_at 0.00219 5.0 ABTB1 
Ankyrin repeat and BTB (POZ) domain 
containing 1 chr3q21 
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39 233243_at 0.00219 5.0 CBFA2T2 
Core-binding factor, runt domain, alpha subunit 
2; translocated to, 2 chr20q11 
40 234344_at 0.00219 5.0 RAP2C RAP2C, member of RAS oncogene family chrXq25 
41 238481_at 0.00219 5.0 MGP matrix Gla protein 
chr12p13.1-
p12.3 
42 238932_at 0.00219 5.0  CDNA FLJ41867 fis, clone OCBBF2005546  
43 239712_at 0.00219 5.0 C9orf93 Chromosome 9 open reading frame 93 chr9p22.3 
44 244478_at 0.00219 5.0  
Transcribed locus, weakly similar to 
XP_515998.1 similar to SLC39A10 protein [Pan 
troglodytes]  
45 236653_at 0.00481 5.0    
46 236791_at 0.00481 5.0 
AMMECR
1 Hypothetical protein LOC286505 chrXq22.3 
47 243195_s_at 0.00481 5.0 ZNF551 zinc finger protein 551 chr19q13.43 
48 244148_at 0.00481 5.0  Similar to 40S ribosomal protein S20 chr2q23.1 
49 244434_at 0.00481 5.0    
50 210697_at 0.02322 5.0 ZNF257 zinc finger protein 257 chr19q13 
51 227070_at 0.02322 5.0 GLT8D2 glycosyltransferase 8 domain containing 2 chr12q 
52 236293_at 0.02322 5.0 RHOH Ras homolog gene family, member H chr4p13 
53 243325_at 0.02322 5.0 GSTK1 Glutathione S-transferase kappa 1  
54 203902_at 0.02490 5.0 HEPH hephaestin chrXq11-q12 
55 206392_s_at 0.02490 5.0 RARRES1 
retinoic acid receptor responder (tazarotene 
induced) 1 chr3q25.32 
56 215558_at 0.02490 5.0 UBR2 
Ubiquitin protein ligase E3 component n-
recognin 2 chr6p21.1 
57 216766_at 0.02490 5.0 PRKCE Protein kinase C, epsilon chr2p21 
58 228496_s_at 0.02490 5.0 CRIM1 Cysteine-rich motor neuron 1 chr2p21 
59 232343_at 0.02490 5.0  CDNA FLJ12138 fis, clone MAMMA1000331  
60 232473_at 0.02490 5.0 PRPF18 
PRP18 pre-mRNA processing factor 18 
homolog (yeast) chr10p13 
61 232502_at 0.02490 5.0 FLJ34077 weakly similar to zinc finger protein 195 chr10q23-q24 
62 236523_at 0.02490 5.0 
LOC28555
6 hypothetical protein LOC285556 chr4q23 
63 236892_s_at 0.02490 5.0    
64 243421_at 0.02490 5.0    
65 243436_at 0.03347 5.0  Transcribed locus  
66 239938_x_at 0.04742 5.0 MEF2C 
MADS box transcription enhancer factor 2, 
polypeptide C (myocyte enhancer factor 2C) chr5q14 
67 214488_at 0.00219 4.0 RAP2B RAP2B, member of RAS oncogene family chr3q25.2 
68 219955_at 0.00219 4.0    
69 220521_s_at 0.00219 4.0 APG16L APG16 autophagy 16-like (S. cerevisiae) chr2q37.1 
70 232930_at 0.00219 4.0 DOCK1 Dedicator of cytokinesis 1 
chr10q26.13-
q26.3 
71 236837_x_at 0.00219 4.0  Hypothetical LOC387904 chr13q12.11 
72 243602_at 0.00219 4.0  Transcribed locus  
73 206443_at 0.02490 4.0 RORB RAR-related orphan receptor B chr9q22 
74 208577_at 0.02490 4.0 HIST1H3C histone 1, H3c chr6p21.3 
75 210426_x_at 0.02490 4.0 RORA RAR-related orphan receptor A chr15q21-q22 
76 214680_at 0.02490 4.0 NTRK2 
neurotrophic tyrosine kinase, receptor, type 2, 
non-catalytic isoform chr9q22.1 
77 219211_at 0.02490 4.0 USP18 ubiquitin specific protease 18 chr22q11.21 
78 220609_at 0.02490 4.0 
LOC44111
8 
similar to FLJ44216 protein; similar to cell 
surface antigen chr5q35.3 
79 227803_at 0.02490 4.0 ENPP5 
ectonucleotide 
pyrophosphatase/phosphodiesterase 5 
(putative function) 
chr6p21.1-
p11.2 
80 233717_x_at 0.02490 4.0 SMO Smoothened homolog (Drosophila) chr7q32.3 
81 235593_at 0.02490 4.0 ZFHX1B zinc finger homeobox 1b chr2q22 
82 237491_at 0.02490 4.0 MYH10 Myosin, heavy polypeptide 10, non-muscle chr17p13 
83 237951_at 0.02490 4.0 FLJ21628 Hypothetical protein FLJ21628 chr5q35.3 
84 243332_at 0.02490 4.0    
85 244050_at 0.02490 4.0    
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86 205703_at 0.02572 4.0 ATP6V0A2
ATPase, H+ transporting, lysosomal V0 subunit 
a isoform 2 chr12q24.31 
87 208011_at 0.02572 4.0 PTPN22 
protein tyrosine phosphatase, non-receptor type 
22 (lymphoid) 
chr1p13.3-
p13.1 
88 214712_at 0.02572 4.0    
89 215213_at 0.02572 4.0 NUP54 nucleoporin 54kDa chr4q21.1 
90 216157_at 0.02572 4.0  CDNA FLJ14169 fis, clone NT2RP2002056  
91 222966_at 0.02572 4.0    
92 226701_at 0.02572 4.0 GJA5 
gap junction protein, alpha 5, 40kDa (connexin 
40) chr1q21.1 
93 228884_at 0.02572 4.0 
LOC44001
0 similar to leucine rich repeat containing 27 chr10q26.3 
94 231145_at 0.02572 4.0 SLC25A21 
Solute carrier family 25 (mitochondrial 
oxodicarboxylate carrier), member 21 chr14q11.2 
95 231357_at 0.02572 4.0 UNQ5782 macrophage antigen h chr12p13.31 
96 233548_at 0.02572 4.0  Clone IMAGE:35115, mRNA sequence  
97 235438_at 0.02572 4.0  
MRNA; cDNA DKFZp686E22185 (from clone 
DKFZp686E22185) 
 
 
98 239270_at 0.02572 4.0 PLCXD3 
phosphatidylinositol-specific phospholipase C, 
X domain containing 3 chr5p13.1 
99 239448_at 0.02572 4.0    
100 239619_at 0.02572 4.0 ZNF395 Zinc finger protein 395 chr8p21.1 
100 229823_at 0.00749 -3.2  Transcribed locus  
99 230398_at 0.00749 -3.2 CTEN C-terminal tensin-like chr17q21.2 
98 232533_at 0.00749 -3.2  CDNA FLJ31054 fis, clone HSYRA2000706  
97 235108_at 0.00749 -3.2 KCNK3 Potassium channel, subfamily K, member 3 chr2p23 
96 235655_at 0.00749 -3.2  Transcribed locus  
95 235900_at 0.00749 -3.2 
MGC2967
1 hypothetical protein MGC29671 chr17p13.2 
94 236652_at 0.00749 -3.2 
LOC14970
3 hypothetical protein LOC149703 chr20q13.12 
93 237608_at 0.00749 -3.2    
92 237631_at 0.00749 -3.2  Transcribed locus  
91 238600_at 0.00749 -3.2 MARLIN1 multiple coiled-coil GABABR1-binding protein chr4p16.1 
90 240483_at 0.00749 -3.2 
LOC37706
4 kruppel-like zinc finger factor X17 chr3p12.3 
89 242003_at 0.00749 -3.2 
LOC15769
7 Hypothetical protein LOC157697 chr8p23.3 
88 200872_at 0.04742 -3.2 S100A10 
S100 calcium binding protein A10 (annexin II 
ligand, calpactin I, light polypeptide (p11)) chr1q21 
87 202910_s_at 0.04742 -3.2 CD97 CD97 antigen chr19p13 
86 205856_at 0.04742 -3.2 SLC14A1 
solute carrier family 14 (urea transporter), 
member 1 (Kidd blood group) chr18q11-q12 
85 206136_at 0.04742 -3.2 FZD5 frizzled homolog 5 (Drosophila) chr2q33-q34 
84 207860_at 0.04742 -3.2 NCR1 natural cytotoxicity triggering receptor 1 chr19q13.42 
83 207864_at 0.04742 -3.2 SCN7A sodium channel, voltage-gated, type VII, alpha chr2q21-q23 
82 210181_s_at 0.04742 -3.2 CABP1 calcium binding protein 1 (calbrain) chr12q24.31 
81 218484_at 0.04742 -3.2 LOC56901 
NADH:ubiquinone oxidoreductase MLRQ 
subunit homolog chr12q13.3 
80 219478_at 0.04742 -3.2 WFDC1 WAP four-disulfide core domain 1 chr16q24.3 
79 219772_s_at 0.04742 -3.2 SMPX small muscle protein, X-linked chrXp22.1 
78 221312_at 0.04742 -3.2 GLP2R glucagon-like peptide 2 receptor chr17p13.3 
77 221667_s_at 0.04742 -3.2 HSPB8 heat shock 22kDa protein 8 chr12q24.23 
76 222963_s_at 0.04742 -3.2 IL1RAPL1 interleukin 1 receptor accessory protein-like 1 
chrXp22.1-
p21.3 
75 227910_at 0.04742 -3.2 LOC63929 hypothetical protein LOC63929 
chr22q13.31-
q13.33 
74 228590_at 0.04742 -3.2 FLJ20758 FLJ20758 protein chr2p11.2 
73 231760_at 0.04742 -3.2 C20orf51 chromosome 20 open reading frame 51 chr20q13.33 
72 235943_at 0.04742 -3.2 FLJ13197 Hypothetical LOC401126 chr4p14 
71 236151_at 0.04742 -3.2 KIAA1853 KIAA1853 protein chr12q24.23 
70 236638_at 0.04742 -3.2  Transcribed locus  
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69 238133_at 0.04742 -3.2  Transcribed locus  
68 239108_at 0.04742 -3.2 MLSTD1 Male sterility domain containing 1 chr12p11.22 
67 239218_at 0.04742 -3.2  CDNA FLJ43039 fis, clone BRTHA3003023  
66 241756_at 0.04742 -3.2 SMARCA2 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 2 chr9p22.3 
65 242192_at 0.04742 -3.2    
64 242963_at 0.04742 -3.2 
MGC2696
3 hypothetical protein MGC26963 chr4q25 
63 233418_at 0.00749 -4.0 LOC91450 hypothetical protein LOC91450 chr15q24.1 
62 240858_at 0.00749 -4.0 LTBP1 
Latent transforming growth factor beta binding 
protein 1 chr2p22-p21 
61 204388_s_at 0.02572 -4.0 MAOA monoamine oxidase A 
chrXp11.4-
p11.3 
60 206670_s_at 0.02572 -4.0 GAD1 glutamate decarboxylase 1 (brain, 67kDa) chr2q31 
59 209167_at 0.02572 -4.0 GPM6B glycoprotein M6B chrXp22.2 
58 209392_at 0.02572 -4.0 ENPP2 
ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
(autotaxin) chr8q24.1 
57 211324_s_at 0.02572 -4.0 
RANBP2L
1 RAN binding protein 2-like 1 chr2q13 
56 212942_s_at 0.02572 -4.0 KIAA1199 KIAA1199 chr15q24 
55 218858_at 0.02572 -4.0 DEPDC6 DEP domain containing 6 chr8q24.12 
54 221245_s_at 0.02572 -4.0 C2orf31 
chromosome 2 open reading frame 31 /// 
chromosome 2 open reading frame 31 chr2q34 
53 223719_s_at 0.02572 -4.0 RTBDN retbindin chr19p12 
52 223783_s_at 0.02572 -4.0 GEMIN4 Gem (nuclear organelle) associated protein 4 chr17p13 
51 226088_at 0.02572 -4.0 ZDHHC12 zinc finger, DHHC domain containing 12 chr9q34.11 
50 226281_at 0.02572 -4.0 DNER 
delta-Notch-like EGF repeat-containing 
transmembrane chr2q36.3 
49 227198_at 0.02572 -4.0 LAF4 Lymphoid nuclear protein related to AF4 
chr2q11.2-
q12 
48 229197_at 0.02572 -4.0 ING5 inhibitor of growth family, member 5 chr2q37.3 
47 230547_at 0.02572 -4.0  CDNA FLJ42249 fis, clone TKIDN2007667  
46 235180_at 0.02572 -4.0 STYX serine/threonine/tyrosine interacting protein  
45 240129_at 0.02572 -4.0 UBE2V1 Ubiquitin-conjugating enzyme E2 variant 1 chr20q13.2 
44 243103_at 0.02572 -4.0 TK1 Thymidine kinase 1, soluble 
chr17q23.2-
q25.3 
43 243994_at 0.02572 -4.0    
42 244465_at 0.02572 -4.0  Transcribed locus  
41 237219_at 0.02572 -4.0    
40 
AFFX-
HUMRGE/M1
0098_M_at 0.02572 -4.0    
39 221134_at 0.00219 -5.0 ANGPT4 angiopoietin 4 chr20p13 
38 222061_at 0.00219 -5.0 CD58 
CD58 antigen, (lymphocyte function-associated 
antigen 3) chr1p13 
37 224012_at 0.00219 -5.0 ANKRD20 ankyrin repeat domain 20A  
chr9q12 /// 
chr9p11.2 
36 231849_at 0.00219 -5.0 
LOC14450
1 hypothetical protein LOC144501 chr12q13.13 
35 240106_at 0.00219 -5.0 MGC4170 MGC4170 protein chr12q23.3 
34 243232_at 0.00219 -5.0    
33 244261_at 0.00219 -5.0 IL28RA 
interleukin 28 receptor, alpha (interferon, 
lambda receptor) chr1p36.11 
32 204803_s_at 0.01324 -5.0 RRAD Ras-related associated with diabetes chr16q22 
31 211642_at 0.01324 -5.0  
Rheumatoid factor RF-ET11 /// Rheumatoid 
factor RF-ET11  
30 219607_s_at 0.01324 -5.0 MS4A4A 
membrane-spanning 4-domains, subfamily A, 
member 4 chr11q12 
29 229471_s_at 0.01324 -5.0 SRP46 Splicing factor, arginine/serine-rich, 46kD chr11q22 
28 238419_at 0.01324 -5.0 PHLDB2 
pleckstrin homology-like domain, family B, 
member 2 
chr3q13.2 
 
27 241765_at 0.01324 -5.0 CPM carboxypeptidase M chr12q14.3 
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26 204389_at 0.02490 -5.0 MAOA monoamine oxidase A 
chrXp11.4-
p11.3 
25 211667_x_at 0.02490 -5.0  
T-cell receptor alpha chain (TCRAV2S1J22) /// 
T-cell receptor alpha chain (TCRAV2S1J22)  
24 213174_at 0.02490 -5.0 TTC9 tetratricopeptide repeat domain 9 chr14q24.2 
23 214562_at 0.02490 -5.0 HIST1H4L histone 1, H4l 
chr6p22-
p21.3 
22 213620_s_at 0.02490 -5.0    
21 224162_s_at 0.02490 -5.0 FBXO31 F-box protein 31 chr16q24.2 
20 227229_at 0.02490 -5.0  Homo sapiens, clone IMAGE:5303499, mRNA  
19 243610_at 0.02490 -5.0 
LOC13825
5 OTTHUMP00000021439 chr9q21.11 
18 207178_s_at 0.00132 -6.3 FRK fyn-related kinase 
chr6q21-
q22.3 
17 225664_at 0.00776 -6.3 COL12A1 collagen, type XII, alpha 1 chr6q12-q13 
16 229070_at 0.00776 -6.3 C6orf105 chromosome 6 open reading frame 105 chr6p24.1 
15 209309_at 0.01613 -6.3 AZGP1 alpha-2-glycoprotein 1, zinc chr7q22.1 
14 208791_at 0.03902 -6.3 CLU 
clusterin (complement lysis inhibitor, SP-40,40, 
sulfated glycoprotein 2, testosterone-repressed 
prostate message 2, apolipoprotein J) chr8p21-p12 
13 209120_at 0.03902 -6.3 NR2F2 
nuclear receptor subfamily 2, group F, member 
2 chr15q26 
12 237193_s_at 0.03902 -6.3    
11 242939_at 0.03902 -6.3 TFDP1 transcription factor Dp-1 chr13q34 
10 204908_s_at 0.00653 -8.0 BCL3 B-cell CLL/lymphoma 3 
chr19q13.1-
q13.2 
9 225516_at 0.00653 -8.0 SLC7A2 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 2 
chr8p22-
p21.3 
8 209357_at 0.01613 -8.0 CITED2 
Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2 chr6q23.3 
7 244849_at 0.02131 -8.0 SEMA3A 
Sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3A chr7p12.1 
6 220884_at 0.02490 -8.0    
5 215161_at 0.00056 -10.1 CAMK1G 
calcium/calmodulin-dependent protein kinase 
IG chr1q32-q41 
4 224506_s_at 0.00749 -10.1 C9orf67 
chromosome 9 open reading frame 67 /// 
chromosome 9 open reading frame 67 chr9q34.13 
3 240724_at 0.01417 -12.7  Transcribed locus  
2 201739_at 0.02572 -16.0 SGK serum/glucocorticoid regulated kinase chr6q23 
1 204870_s_at 0.01235 -32.0 PCSK2 proprotein convertase subtilisin/kexin type 2 chr20p11.2 
Table 12.9 Most up and down-regulated genes derived from the comparison C99WT1/mock 
(n=3, p<0.05), analyzed with the Array Assist software and the MAS 5 algorithm. 
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12.3 Gene annotations 
12.3.1 Preface 
Information about genes is taken and modified from several databases (http://harvester.embl.de, 
www.ncbi.nlm.nih.gov/omim, www.ncbi.nlm.nih.gov/sites/entrez?db=gene, www.ihop-net.org and 
others). Due to the inherent properties of such databases, which are updated regularly, the given 
information is what was available when the databases were last accessed (August 2007-January 
2008). It is important to look for the latest information updates from time to time. Some data are 
managed automatically and extracted by specialized computer programs and consequently a 
reference is not provided for all information, but can be obtained from the databases mentioned 
above.  
12.3.2 Annotations for differentially expressed genes  
(volcano plots)  
 
See results, Chapter 5.4.4, volcano plots, Fig. 5.5 
Selection of down-regulated genes, C99I45F/C99WT1 (volcano plot) 
G
en
e 
Sy
m
bo
l 
G
en
e 
N
am
e 
C
hr
om
os
om
al
 
Lo
ca
tio
n Annotations 
D
O
K
4 
D
O
C
KI
N
G
 
P
R
O
TE
IN
 4
 
ch
r1
6q
13
 Cai et al. (2003) found that both DOK4 and DOK5 are tyrosine-phosphorylated in response to insulin and insulin-like growth factor-1 (IGF1) in transfected cells. DOK4 is 
rapidly and heavily phosphorylated in response to insulin and, once phosphorylated, 
binds a set of SH2 domain proteins, including RasGAP, CRK and the nonreceptor 
tyrosine kinases SRS and FYN. DOK4 also activates MAPK in cells.  
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The protein encoded by this gene is the major procollagen II N-propeptidase. 
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Putative single-pass type I membrane protein involved in cell adhesion and leukocyte 
transendothelial migration. 
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4 The muscarinic cholinergic receptors belong to a larger family of G protein-coupled 
receptors. The functional diversity of these receptors is defined by the binding of 
acetylcholine and includes cellular responses such as adenylate cyclase inhibition, 
phosphoinositide degeneration, and potassium channel mediation. Muscarinic receptors 
influence many effects of acetylcholine in the central and peripheral nervous system.  
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The protein encoded by this gene belongs to the highly conserved cyclin family, whose 
members are characterized by a strong periodicity in protein abundance throughout the 
cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct 
expression and degradation patterns which contribute to the temporal coordination of 
each mitotic event. This cyclin forms a complex with, and functions as, a regulatory 
subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This 
protein has been shown to interact with tumor suppressor protein Rb and the expression 
of this gene is regulated positively by Rb. Mutations, amplification and overexpression of 
this gene, which alters cell cycle progression, are observed frequently in a variety of 
tumors and may contribute to tumorigenesis. Brisken et al. (2002) found that prolactin  
induced Igf2 mRNA and Igf2 induced cyclin D1 protein expression in mouse mammary 
epithelial cultures. 
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Cyclin-dependent kinase inhibitor 1C is a tight-binding inhibitor of several G1 cyclin/Cdk 
complexes and a negative regulator of cell proliferation. Hatada and Mukai (1995) 
showed that a mouse homolog of p57(KIP2) is genomically imprinted. Matsuoka et al. 
(1996) demonstrated that the p57(KIP2) gene is imprinted in humans as well. 
Upregulation of p57 mRNA and protein occurred before TGF-beta-induced G1 cell cycle 
arrest, required transcription, and was mediated via a highly conserved region of the 
proximal p57 promoter.  
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Cytochrome b561 is a major transmembrane protein that is specific to catecholamine and 
neuropeptide secretory vesicles of the adrenal medulla, pituitary gland, and other 
neuroendocrine tissues. This 30kD cytochrome is present in both the small synaptic 
vesicles and the large dense core vesicles (chromaffin granules) of the tissues. Its role is 
to supply reducing equivalents to 2 monooxygenases, dopamine beta-hydroxylase in 
chromaffin granules and peptidylglycine monooxygenase in neurosecretory vesicles. The 
cytochrome fulfillls this role by catalyzing the transfer of electrons from a cytoplasmic 
donor, ascorbate, across a phospholipid bilayer to the luminal acceptor, 
semidehydroascorbate, in the interior of the vesicles. The continuously regenerated 
ascorbate within these vesicles is the immediate donor for the monooxygenases within 
the neuroendocrine secretory vesicles. Thus, cytochrome b561 is a transmembrane 
electron channel. b561 is assumed to binds 2 heme groups non-covalently.  
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DDC catalyzes the decarboxylation of l-3,4- dihydroxyphenylalanine (dopa) to dopamine, 
l-5-hydroxytryptophan to serotonin and l-tryptophan to tryptamine. Defects in DDC are the 
cause of aadc (aromatic L-amino acid decarboxylase deficiency). Aadc deficiency is an 
inborn error in neurotransmitter metabolism that leads to combined serotonin and 
catecholamine deficiency. it causes developmental and psychomotor delay, poor feeding, 
lethargy, ptosis, intermittent hypothermia, gastrointestinal disturbances. The onset is early 
in infancy and inheritance is autosomal recessive. DOPA decarboxylase (EC 4.1.1.28) is 
an enzyme implicated in 2 metabolic pathways, synthesizing 2 important 
neurotransmitters, dopamine and serotonin (Christenson et al., 1972). Following the 
hydroxylation of tyrosine to form L-dihydroxyphenylalanine (L-DOPA), catalyzed by 
tyrosine hydroxylase (TH), DDC decarboxylates L-DOPA to form dopamine. This 
neurotransmitter is found in different areas of the brain and is particularly abundant in 
basal ganglia. Dopamine is also produced by DDC in the sympathetic nervous system 
and is the precursor of the catecholaminergic hormones, noradrenaline and adrenaline in 
the adrenal medulla. In the nervous system, tryptophan hydroxylase produces 5-OH 
tryptophan, which is decarboxylated by DDC, giving rise to serotonin. DDC is a 
homodimeric, pyridoxal phosphate-dependent enzyme. Ichinose et al. (1989) prepared a 
cDNA clone for the coding region of human aromatic L-amino acid decarboxylase by 
screening a human pheochromocytoma cDNA library with an oligonucleotide probe that 
corresponded to a partial amino acid sequence of the enzyme purified from the tumor. 
The cDNA clone encoded a protein of 480 amino acids, with a calculated molecular mass 
of 53.9 kD. The amino acid sequence asn-phe-asn-pro-his-lys-trp around a possible 
pyridoxal phosphate cofactor binding site was shown to be identical in human, 
Drosophila, and pig enzymes. The protein encoded by hepatoma cells is the same as that 
encoded by adrenal chromaffin-derived pheochromocytoma cells. De Luca et al. (2003) 
found that variation in the dopa decarboxylase gene is related to longevity in Drosophila. 
They pointed out that DDC is only one of the enzymes in the biosynthetic pathways for 
bioamines and catecholamines. A polymorphism in tyrosine hydroxylase, the rate-limiting 
enzyme in the synthesis of catecholamines, is associated with variation in human 
longevity (De Benedictis et al., 1998; De Luca et al., 2001). 
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DNCLI2 may play a role in regulating interactions between dynein and p150-glued, and 
the cellular substrates for dynein- mediated motility (such as organelles). 
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Fibrillins are structural components of 10-12 nm extracellular calcium-binding microfibrils, 
which occur either in association with elastin or in elastin-free bundles. Fibrillin-1 
containing microfibrils provide long-term force bearing structural support. The FBN1gene 
encodes a member of the fibrillin family. The encoded protein is a large, extracellular 
matrix glycoprotein that serves as a structural component of 10-12 nm calcium-binding 
microfibrils. These microfibrils provide force bearing structural support in elastic and non-
elastic connective tissue throughout the body. Mutations in this gene are associated with 
Marfan syndrome, isolated ectopia lentis, autosomal dominant Weill-Marchesani 
syndrome, MASS syndrome, and Shprintzen-Goldberg craniosynostosis syndrome. 
Fibrillin-1 sequence encoded by exons 44-49 releases endogenous TGFbeta1, thereby 
stimulating TGFbeta receptor-mediated Smad2 signaling (J Cell Biol. 2007 Jan 
29;176(3):355-67). 
G
A
TA
3 
G
A
TA
 b
in
di
ng
 p
ro
te
in
 3
 
ch
r1
0p
15
 
Transcriptional activator which binds to the enhancer of the t-cell receptor alpha and delta 
genes. Binds to the consensus sequence 5'-agatag-3'. Fields et al. (2002) noted that high 
levels of histone acetylation at particular loci correlate with transcriptional activity, 
whereas reduced levels correlate with silencing. GATA3 regulated FUT7 transcription by 
recruiting histone deacetylase-3 (HDAC3) and HDAC5 in a phosphorylation-dependent 
manner,  and by competing with CBP (CREBBP)/p300 (EP300) in binding to the N 
terminus of TBET. Maximal expression of FUT7 and sialyl Lewis x in T cells was obtained 
by ROG (ZBTB32)-mediated suppression of GATA3. Chen et al. (2006) concluded that 
the GATA3/TBET transcription factor complex regulates cell lineage-specific expression 
of lymphocyte homing receptors and that glycoconjugates are regulated by this complex 
to attain cell lineage-specific expression in Th1 and Th2 lymphocyte subsets. Zhu et al. 
(2004) generated mice with a conditional deletion of Gata3 and Gata3-deficient mouse T-
cell lines and found that both Il4-dependent and -independent Th2 differentiation was 
diminished, permitting Th1 differentiation in the absence of IFNγ and Il12. Deletion of 
Gata3 from established Th2 cells stopped production of Il5 and Il13, but not of Il4. Mice 
lacking Gata3 produced IFNγ rather than Th2 cytokines in response to infection with 
Nippostrongylus brasiliensis. Zhu et al. (2004) concluded that Gata3 serves as a principal 
switch in determining Th1-Th2 responses. 
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The human H19 gene is 2.7 kb long and includes 4 small introns. Zhang and Tycko 
(1992) found restriction site polymorphisms in the human H19 gene and, by examination 
of the representation of these polymorphisms in cDNAs from fetal organs, demonstrated 
that H19 expression was largely or exclusively from a single allele. The H19 gene and 2 
other genes, insulin-like growth factor II (IGF2) and insulin-like growth factor II receptor, 
show monoallelic expression in mice. IGF2 is, like H19, located in 11p15. Zhang and 
Tycko (1992) commented that if IGF2 also shows monoallelic expression, it may indicate 
that that region is a 'hotspot' for this phenomenon. Mutter et al. (1993) found that normal 
gestations only express H19 from the maternal allele and express IGF2 from the paternal 
allele, whereas neither is expressed from the maternal genome of gynogenetic 
gestations, and both are expressed from the paternal genome of androgenetic gestations. 
The imprinted H19 gene, which encodes an untranslated RNA, lies at the end of a cluster 
of imprinted genes. Imprinted genes are expressed from only 1 of the parental alleles and 
are marked epigenetically by DNA methylation and histone modifications. The paternally 
expressed gene Igf2 is separated by approximately 100 kb from the maternally expressed 
noncoding gene H19 on mouse distal chromosome 7. Differentially methylated regions in 
Igf2 and H19 contain chromatin boundaries, silencers, and activators, and regulate the 
reciprocal expression of the 2 genes in a methylation-sensitive manner.  
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Negative regulator of the heat shock response. Negatively affects HSF1 DNA-binding 
activity. May have a role in the suppression of the activation of the stress response during 
the aging process. 
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Hepatocyte growth factor regulates cell growth, cell motility, and morphogenesis by 
activating a tyrosine kinase signaling cascade after binding to the proto-oncogenic c-Met 
receptor. Hepatocyte growth factor is secreted by mesenchymal cells and acts as a multi-
functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, 
cell motility, and matrix invasion gives it a central role in angiogenesis, tumorigenesis and 
tissue regeneration. It is secreted as a single inactive polypeptide and is cleaved by 
serine proteases into a 69-kDa alpha-chain and 34-kDa beta-chain. A disulfide bond 
between the alpha and beta chains produces the active, heterodimeric molecule. The 
protein belongs to the plasminogen subfamily of S1 peptidases but has no detectable 
protease activity. Alternative splicing of this gene produces multiple transcript variants 
encoding different isoforms. The cytokine hepatocyte growth factor/scatter factor inhibits 
apoptosis and enhances DNA repair by a common mechanism involving signaling 
through phosphatidyl inositol 3' kinase-, HGF/SF induced the phosphorylation of c-Akt 
(protein kinase-B), a PI3K substrate implicated in apoptosis inhibition;  HGF/SF activates 
a cell survival and DNA repair pathway that involves signaling through PI3K and c-Akt 
and stabilization of the expression of Bcl-XL; and they implicate Bcl-XL in the DNA repair 
process (Oncogene. 2000 Apr 27;19(18):2212-23). Scatter factor/hepatocyte growth 
factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-
kinase- and AKT-dependent pathways (Cancer Res. 2000 Aug 1;60(15):4277-83). 
Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-
kinase/Akt and mitogen-activated protein kinase pathways (Proc Natl Acad Sci U S A. 
2001 Jan 2;98(1):247-52). Neuroprotection by scatter factor/hepatocyte growth factor and 
FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/akt-dependent and 
MAPK/CREB-independent (J Neurochem. 2002 Apr;81(2):365-78).The receptor tyrosine 
kinase Met and its ligand hepatocyte growth factor are clustered at excitatory synapses 
and can enhance clustering of synaptic proteins (Cell Cycle. 2006 Jul;5(14):1560-8). 
Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced 
signal transduction through the receptor tyrosine kinase c-Met (J Biol Chem. 1999 Mar 
5;274(10):6499-506). Activation mechanisms of the urokinase-type plasminogen activator 
promoter by hepatocyte growth factor/scatter factor (J Biol Chem. 1999 Jun 
4;274(23):16377-86). Gene transfer of hepatocyte growth factor gene into rat brains 
improves learning and memory in the chronic stage of cerebral infarction; 
immunohistochemical analysis for Cdc42 and synaptophysin in the peri-infarct region 
revealed that HGF enhanced the neurite extension and increased the number of 
synapses. These data demonstrated that HGF plays a pivotal role in the functional 
recovery after cerebral infarction through neuritogenesis, improved microcirculation, and 
the prevention of gliosis (Eur J Biochem. 2001 Aug;268(16):4423-9). Hepatocyte growth 
factor/scatter factor (HGF/SF) antagonizes TGF-beta1 by stabilizing SMAD transcriptional 
co-repressor TGIF (Regul Pept. 2005 Aug 15;130(1-2):75-80). Human platelets express 
HGF receptor, the tyrosine kinase encoded by c-MET gene. At physiological 
concentrations HGF was found to inhibit both glycoprotein (alpha)IIb(beta)3 activation and 
thrombin-dependent platelet aggregation in a dose- and time-dependent manner. These 
results suggest that circulating HGF may counteract thrombogenesis by negatively 
modulating platelet functions (FEBS Lett. 2005 Aug 15;579(20):4550-4). Exogenous HGF 
promoted a highly significant increase in dendritic growth and branching of layer 2 
pyramidal neurons, whereas inactivation of endogenous HGF with function-blocking, anti-
HGF antibody caused a marked reduction in size and complexity of the dendritic arbors of 
these neurons. Likewise, pyramidal neurons transfected with an MET dominant-negative 
mutant receptor had much smaller and less complex dendritic arbors than control 
transfected neurons did. These results indicate that HGF plays a role in regulating 
dendritic morphology in the developing cerebral cortex (Development. 2004 
Aug;131(15):3717-26.). Expression of c-Met in developing rat hippocampi: evidence for 
HGF as a neurotrophic factor for calbindin D-expressing neurons (Eur J Neurosci. 2000 
Oct;12(10):3453-61). It is known that HGF/SF induces in vitro expression of vascular 
endothelial growth factor (VEGF), a key agonist of tumor angiogenesis; by contrast, 
thrombospondin 1 (TSP-1) is a negative regulator of angiogenesis. It was shown that  in 
the very same tumor cells, in addition to inducing VEGF expression, HGF/SF dramatically 
down-regulates TSP-1 expression. These studies identify HGF/SF as a key switch for 
turning on angiogenesis (Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23). 
Autocrine and/or paracrine trophic support of the HGF-c-Met system contributes to the 
attenuation of the degeneration of residual anterior horn cells in ALS, while disruption of 
the neuronal HGF-c-Met system at an advanced disease stage accelerates cellular 
degeneration and/or the process of cell death (Acta Neuropathol (Berl). 2003 
Aug;106(2):112-20). PKC, p42/44 MAPK and p38 MAPK regulate hepatocyte growth 
factor secretion from human astrocytoma cells (Brain Res Mol Brain Res. 2002 Jun 
15;102(1-2):73-82). It was reported that APP level, soluble APP (sAPP) secretion, and A 
beta production in HEK293 cells transfected with either wild-type APP(751) or APP(751) 
carrying the Swedish mutation are all elevated by hepatocyte growth factor (HGF) (Exp 
Cell Res. 2003 Jul 15;287(2):387-96). 
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This gene encodes a member of the insulin family of polypeptide growth factors that is 
involved in development and growth. It is an imprinted gene and is expressed only from 
the paternally inherited allele. Interaction of insulin-like growth factor II (IGF-II) with 
multiple plasma proteins: high affinity binding of plasminogen to IGF-II and IGF-binding 
protein-3 (Biol Chem. 2005 Mar 18;280(11):9994-10000). Transferrin binds insulin-like 
growth factors and affects binding properties of insulin-like growth factor binding protein-3 
(FEBS Lett. 2001 Dec 14;509(3):395-8). 
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Transcription corepressor activity, zinc ion binding. Insulinoma-associated protein-2 is a 
major autoantigen in type 1 diabetes that occurs through autoimmune-mediated beta-cell 
destruction (Diabetes. 2007 Jan;56(1):41-8). 
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Membrane; single-pass type I membrane protein. Heterodimer of an alpha and a beta 
subunit. Beta-5 associates with alpha-v. Integrin alpha-v/beta-5 is a receptor for 
fibronectin. It recognizes the sequence r-g-d in its ligand. 
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Millevoi et al. (1998) showed that nebulette binds to actin and plays an  important role in 
the assembly of the Z-disc.  
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1 This gene encodes a cytoplasmic protein that contains epidermal growth factor (EGF)-like repeats. The encoded heterotrimeric protein may be involved in cell growth regulation and 
differentiation. It is believed to be a secreted protein and to bind to pkc beta-1. 
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Cytoskeletal protein that may act as an adapter that brings other proteins (like kinases) to 
the cytoskeleton. It is thought to interact with alpha-actinins 1, 2 and 4. It has 1 lim zinc-
binding domain. The ZASP-like motif in actinin-associated LIM protein is required for 
interaction with the alpha-actinin rod and for targeting to the muscle Z-line (J Biol Chem. 
2004 Jun 18;279(25):26402-10). The Z-line is a specialized structure connecting adjacent 
sarcomeres in muscle cells. Alpha-Actinin cross-links actin filaments in the Z-line. Several 
PDZ-LIM domain proteins localize to the Z-line and interact with alpha-actinin. Actinin-
associated LIM protein (ALP), C-terminal LIM domain protein (CLP36), and Z band 
alternatively spliced PDZ-containing protein (ZASP) have a conserved region named the 
ZASP-like motif (ZM) between PDZ and LIM domains. It is suggested that the two 
interaction sites of ALP (PDZ domain and ZM motif) would stabilize certain conformations 
of alpha-actinin 2 that would strengthen the Z-line integrity. 
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POU3F3 is a member of the class III POU family of transcription factors (see POU3F1; 
602479) that are expressed in the central nervous system. The POU domain in these 
proteins is required for high affinity binding to octamer DNA sequences (Sumiyama et al. 
(1996)). Overexpression experiments in vivo indicate that Brn2 (a POU protein), like 
Mash1, regulates additional aspects of neurogenesis, including the division of progenitors 
and the differentiation and migration of neurons.  
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Prox1 is a transcription factor with two highly conserved domains, a homeobox and a 
prospero domain. Dyer et al. (2003) found that the  Prox1 regulates the exit of progenitor 
cells from the cell cycle in the embryonic mouse retina. Cells lacking Prox1 are less likely 
to stop dividing, and ectopic expression of Prox1 forces progenitor cells to exit the cell 
cycle. Other observations indicated that Prox1 activity is both necessary and sufficient for 
progenitor-cell proliferation and cell-fate determination in the vertebrate retina. Prox1 
inactivation caused abnormal cellular proliferation, down-regulated expression of the cell 
cycle inhibitors Cdkn1b and Cdkn1c, misexpression of E-cadherin, and inappropriate 
apoptosis.  
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The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) 
family. PTPs are known to be signaling molecules that regulate a variety of cellular 
processes including cell growth, differentiation, mitotic cycle, and oncogenic 
transformation. This PTP possesses an extracellular region, a single transmembrane 
region, and two tandem catalytic domains, and thus represents a receptor-type PTP. The 
extracellular region contains a meprin-A5 antigen-PTP mu (MAM) domain, an Ig-like 
domain and four fibronectin type III-like repeats. This PTP was shown to mediate 
homophilic intercellular interaction, possibly through the interaction with beta- and 
gamma-catenin at adherens junctions. Expression of this gene was found to be 
stimulated by TGF-beta 1, which may be important for the inhibition of keratinocyte 
proliferation. 
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This gene encodes a member of the insulin family of polypeptide growth factors that is 
involved in development and growth. It is an imprinted gene and is expressed only from 
the paternally inherited allele. It is a candidate gene for eating disorders. There is a read-
through, INS-IGF2, which aligns to this gene at the 3' region and to the upstream INS 
gene at the 5' region. Two alternatively spliced transcript variants encoding the same 
protein have been found for this gene. 
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Regulator of G protein signaling (RGS) family members are regulatory molecules that act 
as GTPase activating proteins (GAPs) for G alpha subunits of heterotrimeric G proteins. 
RGS proteins are able to deactivate G protein subunits of the Gi alpha, Go alpha and Gq 
alpha subtypes. They drive G proteins into their inactive GDP-bound forms. Regulator of 
G protein signaling 4 belongs to this family. All RGS proteins share a conserved 120-
amino acid sequence termed the RGS domain. Regulator of G protein signaling 4 protein 
is 37% identical to RGS1 and 97% identical to rat Rgs4. This protein negatively regulates 
signaling upstream or at the level of the heterotrimeric G protein and is localized in the 
cytoplasm. In AD parietal cortex, total levels of G(q/11) and RGS4 proteins were 
significantly lower than age-matched control cases by 40% and 53% respectively 
(Synapse. 2003 Jan;47(1):58-65). DNA microarray studies of postmortem brain samples 
have shown RGS4 underexpression in the dorsolateral prefrontal cortex, motor and visual 
cortices in schizophrenia patients relative to control subjects (Mol Psychiatry. 2005 
Feb;10(2):213-9). Support for RGS4 as a susceptibility gene for schizophrenia (Biol 
Psychiatry. 2004 Jan 15;55(2):192-5). 
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Synonyms: glial-derived neurite promoting factor p, protease nexin I , protease inhibitor 7. 
Protease nexin I (PN-I) is a 44-kD thrombin and urokinase inhibitor released by human 
foreskin fibroblasts. PN-I shares several features with antithrombin III, an abundant 
plasma thrombin inhibitor. Both PN-I and AT-III have high affinities for heparin, and 
heparin accelerates their rate of thrombin inhibition. In addition, the published sequence 
of 28 amino acids at the N-terminus of PN-I is identical to the N-terminal amino acid 
sequence of a glial-derived neurite promoting factor. Protease nexin I is the most 
important physiologic regulator of alpha-thrombin in tissues (Carter et al., 1995). PN1 is 
highly expressed and developmentally regulated in the nervous system where it is 
concentrated at neuromuscular junctions and also central synapses in the hippocampus 
and striatum. Approximately 10% of identified proteins at mammalian neuromuscular 
junctions are serine protease inhibitors, consistent with their central role in balancing 
serine protease activity to develop, maintain, and remodel synapses. Pericyte expression 
of protease nexin 1 may provide endogenous anticoagulant activity (J Cereb Blood Flow 
Metab. 2006 Feb;26(2):209-17). Protease nexin 1 is a potent urinary plasminogen 
activator inhibitor in the presence of collagen type IV. Protease nexin 1 (PN1) in solution 
forms inhibitory complexes with thrombin or urokinase, which have opposing effects on 
the blood coagulation cascade. An initial report supported the idea that PN1 target 
protease specificity is under the influence of collagen type IV (1). Although collagen type 
IV demonstrated no effect on the association rate between PN1 and thrombin, the study 
reported that the association rate between PN1 and urokinase was allosterically reduced 
10-fold. This has led to the generally accepted idea that the primary role of PN1 in the 
brain is to act as a rapid thrombin inhibition and clearance mechanism during trauma and 
loss of vascular integrity. In studies to identify the structural determinants of PN1 that 
mediate the allosteric interaction with collagen type IV, it was found that protease 
specificity was only affected after transient exposure of PN1 to acidic conditions that 
mimic the elution protocol from a monoclonal antibody column. Because PN1 used in 
previous studies was purified over a monoclonal antibody column, it was proposed that 
the allosteric regulation of PN1 target protease specificity by collagen type IV is a result of 
the purification protocol. Both biochemical and kinetic data support this conclusion. This 
finding is significant because it implies that PN1 may play a much larger role in the 
modeling and remodeling of brain tissues during development and is not simply a 
thrombin clearance mechanism as previously suggested (J Biol Chem. 2002 Dec 
6;277(49):47285-91). 
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This gene is a member of the homeo box family of genes that encode proteins containing 
a 60-amino acid residue motif that represents a DNA binding domain. Homeo box genes 
have been characterized extensively as transcriptional regulators involved in pattern 
formation in both invertebrate and vertebrate species. Several human genetic disorders 
are caused by aberrations in human homeo box genes. SHOX is a pseudoautosomal 
homeo box gene that is thought to be responsible for idiopathic short stature and 
implicated to play a role in the short stature phenotype of Turner syndrome patients. This 
gene is considered to be a candidate gene for Cornelia de Lange syndrome.  
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Tissue factor pathway inhibitor is an important regulator of the extrinsic pathway of blood 
coagulation through its ability to inhibit factor Xa and factor VIIa-tissue factor activity. It 
was originally identified by Siiteri et al. (1982) and Butzow et al. (1988) as a placental 
glycoprotein that inhibits plasmin, trypsin, and thrombin (Miyagi et al., 1996). Sprecher et 
al. (1994) described the molecular cloning and expression of a full-length cDNA that 
encodes a molecule, designated TFPI2 that has a similar overall domain organization and 
considerable primary amino acid sequence homology to TFPI. After a 22-residue signal 
peptide, the mature TFPI2 protein contains 213 amino acids with 18 cysteines and 2 
canonical N-linked glycosylation sites. The deduced sequence of mature TFPI2 revealed 
a short acidic N-terminal region, 3 tandem Kunitz-type domains, and a C-terminal tail 
highly enriched in basic amino acids. It may play a role in the regulation of plasmin-
mediated matrix remodeling.  
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Synonym: Collagenase inhibitor. This gene belongs to the TIMP gene family. The proteins 
encoded by this gene family are natural inhibitors of the matrix metalloproteinases 
(MMPs), a group of peptidases involved in degradation of the extracellular matrix. In 
addition to its inhibitory role against most of the known MMPs, the encoded protein is able 
to promote cell proliferation in a wide range of cell types, and may also have an anti-
apoptotic function. Transcription of this gene is highly inducible in response to many 
cytokines and hormones. In addition, the expression from some but not all inactive X 
chromosomes suggests that this gene inactivation is polymorphic in human females. This 
gene is located within intron 6 of the synapsin I gene and is transcribed in the opposite 
direction. 
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Synonym: enhancer of split groucho 4, transcriptional corepressor that binds to a number 
of transcription factors. Inhibits the transcriptional activation mediated by pax5, and by 
ctnnb1 and tcf family members in wnt signaling. 
 
 
Selection of up-regulated genes, C99V50F/C99WT1 (volcano plot) 
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This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs) protein family. Members of this family share several distinct protein 
modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, 
and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number 
of C-terminal TS motifs, and some have unique C-terminal domains. Members of the ADAMTS 
family have been implicated in the cleavage of proteoglycans, the control of organ shape during 
development, and the inhibition of angiogenesis. Knockdown of ADAMTS9 resulted in 
diminished production of collagen in A549 cells exposed to TGF-beta1. ADAMTS9 is a 
secreted, cell-surface-binding metalloprotease that cleaves the proteoglycans versican and 
aggrecan. Unlike most precursor proteins, the ADAMTS9 zymogen (pro-ADAMTS9) is resistant 
to intracellular processing. Instead, pro-ADAMTS9 is processed by furin at the cell surface. 
Observations suggest that, unlike other metalloproteases, furin processing of the ADAMTS9 
propeptide reduces its catalytic activity. Observations suggest that the propeptide is a key 
functional domain of ADAMTS9, mediating an unusual regulatory mechanism that may have 
evolved to ensure maximal activity of this protease at the cell surface. ADAMTS proteins are 
structurally homologous to ADAM proteins, but they also contain at least 1 C-terminal 
thrombospondin type 1 (TSP1) repeat and are secreted rather than membrane bound. 
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The human amyloid precursor-like protein APLP2 is a highly conserved homolog of a sequence-
specific DNA-binding mouse protein with an important function in the cell cycle.  It may play a 
role in the regulation of hemostasis, may have inhibitory properties towards coagulation factors 
and may interact with cellular G-protein signaling pathways. APLP2 interact with CP2 
transcription factor in  the nucleus and induce glycogen synthase kinase-3beta expression Cell 
Death Differ. 2007 Jan;14(1):79-91,  FASEB J. 2004 Aug;18(11):1288-90. 
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1 The avian ARHGAP26 protein binds to the C-terminal domain of pp125, one of the tyrosine kinases predicted to be a critical component of the integrin signaling transduction pathway in an 
SH3 domain-dependent manner and stimulates the GTPase activity of the GTP-binding protein 
RhoA. Thus, ARHGAP26 acts as a negative regulator of RhoA. 
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 The bone morphogenetic proteins are members of the transforming growth factor-beta 
superfamily. BMP7 induced SMAD1, both of which were inhibited by follistatin. Transfection with 
antisense SMAD2/SMAD3 prevented activin-induced expression and accumulation of alpha-
smooth muscle actin. 
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Voltage-dependent Ca(2+) channels are multisubunit complexes found in the membrane of 
many excitable cells that regulate calcium entry. N-type calcium channels, which control 
neurotransmitter release from neurons, are dihydropyridine-insensitive and omega-conotoxin-
sensitive. The alpha-1 subunit forms the pore through which calcium enters the cell, and is 
encoded by a family of at least 5 genes. Using binding and immunoprecipitation assays on adult 
rat cortical tissue, Maeno-Hikichi et al. (2003) showed that the enigma-like LIM domain protein 
(ENH) interacts specifically with protein kinase C-epsilon (PRKCE) and the C terminus of 
CACNA1B to form a macromolecular complex. Functional studies in Xenopus oocytes indicated 
that expression of ENH resulted in increased rapid and specific modulation of N-type calcium 
channels by PKCE. The authors concluded that through interactions with a common adaptor 
protein, the formation of a kinase-substrate complex is the molecular basis for the specificity 
and efficiency of cellular signaling. 
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Davare et al. (2001) found that the beta-2 adrenergic receptor is directly associated with one of 
its ultimate effectors, CACNA1D. This complex also contains a G protein, an adenylyl cyclase , 
cAMP-dependent kinase, and the counterbalancing phosphatase PP2A. Davare et al. (2001) 
used electrophysiologic recordings from hippocampal neurons to demonstrate highly localized 
signal transduction from the receptor to the channel. The assembly of this signaling complex 
provides a mechanism that ensures specific and rapid signaling by a G protein-coupled 
receptor. 
C
E
B
P
D
 
C
C
A
A
T/
en
ha
nc
er
 b
in
di
ng
 
pr
ot
ei
n 
(C
/E
B
P
)  
de
lta
 
ch
r8
p1
1.
2-
p1
1.
1 Transcriptional activator; activity is stimulated by sepsis, keratinocyte growth factor, and may be 
involved in glucose-mediated regulation of iNOS. 
C
H
R
N
A
7 
C
ho
lin
er
gi
c 
re
ce
pt
or
  n
ic
ot
in
ic
  a
lp
ha
 p
ol
yp
ep
tid
e 
7 
ch
r1
5q
14
 
The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated 
ion (Na+, K+, Ca2+) channels that mediate fast signal transmission at synapses. The nAChRs are 
thought to be hetero-pentamers composed of homologous subunits. The proposed structure for 
each subunit is a conserved N-terminal extracellular domain followed by three conserved 
transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane 
domain, and a short C-terminal extracellular region. The protein encoded by this gene forms a 
homo-oligomeric channel, displays marked permeability to calcium ions and is a major 
component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-
bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in 
conformation that affects all subunits and leads to opening of an ion-conducting channel across 
the plasma membrane. Significant increases in the total numbers of astrocytes and of 
astrocytes expressing the alpha7 nAChR subunit, along with significant decreases in the levels 
of alpha7 and alpha4 nAChR subunits on neurons, were observed in the hippocampus and 
temporal cortex of both APPswe and sporadic AD brains. Both of these phenomena were more 
pronounced in APPswe than sporadic AD cases. The increase in the level of expression of 
alpha7 nAChR on astrocytes was positively correlated with the extent of neuropathological 
alternations, especially the number of neuritic plaques, in the AD brain. The elevated expression 
of alpha7 nAChR on astrocytes might participate in causing Abeta cascade and formation of 
neuritic plaques, thereby playing an important role in the pathogenesis of AD. 
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5 This gene encodes a member of a family of cytosolic phosphoproteins expressed exclusively in 
the nervous system. The encoded protein is thought to be a part of the semaphorin signal 
transduction pathway implicated in semaphorin-induced growth cone collapse during neural 
development. Alternative splicing results in multiple transcript variants. Synonym: 
Dihydropyrimidinase-related protein 1 (DRP-1). CRMP1 is a predicted functional partner of 
CDK5. 
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Cell-cell and cell-matrix adhesions involve transmembrane glycoproteins such as cell adhesion 
molecules and integrins, which are thought to function via interactions of their cytoplasmic 
domains with proteins associated with the cytoskeleton. Vinculin and talin are examples. The 
activity of cadherins, which mediate homophilic cell-cell Ca2+-dependent association, depends 
on their anchorage to cytoskeleton via proteins termed catenins. 
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 Homeobox protein cut-like 2 (Cux2). In drosophila it may act as a transcription factor involved in neural specification. Binds to DNA in a sequence-specific manner. CUX2 is a potential regulator 
of NCAM expression: Genomic characterization and analysis as a positional candidate 
susceptibility gene for bipolar disorder. 
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This gene encodes a protein that is a member of the dickkopf family. The secreted protein 
contains two cysteine rich regions and is involved in embryonic development through its 
interactions with the Wnt signaling pathway. It can act as either an agonist or antagonist of 
Wnt/beta-catenin signaling, depending on the cellular context and the presence of the co-factor 
kremen 2. Activity of this protein is also modulated by binding to the Wnt co-receptor LDL-
receptor related protein 6 (LRP6). 
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1 Belongs to the dynein intermediate chain family. The intermediate chains seem to help dynein bind to dynactin 150 kDa component. May play a role in mediating the interaction of cytoplasmic 
dynein with membranous organelles and kinetochores. 
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DNER was identified as a new epidermal growth factor (EGF)-like repeat-containing single-pass 
transmembrane protein that is specifically expressed in the developing and mature central 
nervous system. Sequence analysis revealed that the 10 EGF-like repeats in the extracellular 
domain are closely related to those of the developmentally important receptor Notch and its 
ligand Delta. Thus it was named Delta/Notch-like EGF-related receptor (DNER). DNER protein 
is strongly expressed in several types of post-mitotic neurons, including cortical and 
hippocampal pyramidal neurons, cerebellar granule cells, and Purkinje cells. DNER protein is 
localized to the dendritic plasma membrane and endosomes and is excluded from the axons, 
even when overexpressed. The tyrosine-based sorting motif in the cytoplasmic domain is 
required for dendritic targeting of DNER. DNER contains an N-terminal signal sequence and 10 
distinct EGF-like motifs. The final EGF-like repeat displays a typical signature of a calcium-
binding domain important for molecular orientation. DNER also has a single transmembrane 
region and an intracellular C-terminal region containing potential tyrosine kinase 
phosphorylation sites, a typical tyrosine-based sorting signal (YEEF), and a dileucine-type 
sorting signal (LI). Using coimmunoprecipitation techniques, it was found to bind directly  
between DNER and the clathrin coat-associated protein complex Ap1, and Dner and Ap1 were 
found to be colocalized  within mouse Purkinje cells. Eiraku et al. (2002) concluded that DNER 
undergoes Ap1-dependent sorting to the somatodendritic compartments from the trans-Golgi 
network. Differentiation of glia in the central nervous system is regulated by Notch signaling 
through neuron-glia interaction. Eiraku et al. (2005) identified DNER as a ligand of Notch during 
cellular morphogenesis of Bergmann glia in the mouse cerebellum. Dner bound to Notch1 at 
cell-cell contacts and activated Notch signaling in vitro. In the developing cerebellum, Dner was 
highly expressed in Purkinje cell dendrites, which were tightly associated with radial fibers of 
Bergmann glia expressing Notch. Dner specifically bound to Bergmann glia in culture and 
induced process extension by activating gamma-secretase and Dtx1-dependent Notch 
signaling. Inhibition of Dtx1-dependent but not Rbpj (RBPSUH)-dependent Notch signaling in 
Bergmann glia suppressed formation and maturation of radial fibers in organotypic slice 
cultures. Additionally, deficiency of DNER retarded the formation of radial fibers and resulted in 
abnormal arrangement of Bergmann glia. 
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Synonym: p53-induced gene 10. DNA damage and/or hyperproliferative signals activate 
wildtype p53 tumor suppressor protein (TP53), inducing cell cycle arrest or apoptosis. Mutations 
that inactivate p53 occur in 50% of all tumors. Polyak et al. (1997) used serial analysis of gene 
expression (SAGE) to evaluate cellular mRNA levels in a colorectal cancer cell line transfected 
with p53. Of 7,202 transcripts identified, only 14 were expressed at levels more than 10-fold 
higher in p53-expressing cells than in control cells. Polyak et al. (1997) termed these genes 
'p53-induced genes,' or PIGs, several of which were predicted to encode redox-controlling 
proteins. They noted that reactive oxygen species (ROS) are potent inducers of apoptosis. Flow 
cytometric analysis showed that p53 expression induces ROS production, which increases as 
apoptosis progresses under some conditions. The authors stated that the PIG10 gene, also 
called ENC1, encodes an actin-binding protein. 
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 This gene encodes a member of the ligand-gated ionic channel family. The encoded protein is 
one of at least 13 distinct subunits of a multisubunit chloride channel that serves as the receptor 
for gamma-aminobutyric acid, the major inhibitory transmitter of the nervous system. This gene 
is located on the long arm of chromosome 15 in a cluster with two genes encoding related 
subunits of the family. Mutations in this gene may be associated with the pathogenesis of 
Angelman syndrome, Prader-Willi syndrome, and autism. Alternatively spliced transcript 
variants encoding isoforms with distinct signal peptides have been described.  
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G-protein-coupled receptor proteolytic site domain 
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Glutamate receptors sensitive to alpha-amino-3-hydroxy-5-methyl-4-isoxazolpropionate (AMPA) 
are ligand-activated cation channels that mediate the fast component of excitatory postsynaptic 
currents in neurons of the central nervous system. These channels are assembled from 4 
related subunits, GLURA (GRIA1; 138248), GLURB (GRIA2), GLURC (GRIA3), GLURD 
(GRIA4), with the GLURB subunit rendering the channel almost impermeable to Ca2+ (Hollmann 
et al., 1991). Long-term depression was absent in cultured cerebellar Purkinje cells from mutant 
mice lacking the AMPAR GluR2 subunit and could be rescued by transient transfection with the 
wildtype GluR2 subunit. Transfection with GluR2 carrying a point mutation that eliminated PKC 
phosphorylation of ser880 in the carboxy-terminal PDZ ligand of GluR2 failed to restore long-
term depression. In contrast, transfection with GluR2 carrying a point mutation that mimicked 
phosphorylation on ser880 occluded subsequent long-term depression. Thus, PKC 
phosphorylation of GluR2 on ser880 is a critical event in the induction of cerebellar long-term 
depression. Passafaro et al. (2003) demonstrated that overexpression of GLUR2 increases 
dendritic spine size and density in hippocampal neurons, and more remarkably, induces spine 
formation in GABA-releasing interneurons that normally lack spines. The extracellular N-
terminal domain of GLUR2 is responsible for this effect, and heterologous fusion proteins of the 
N-terminal domain of GLUR2 inhibit spine morphogenesis. Passafaro et al. (2003) proposed 
that the N-terminal domain of GLUR2 functions at the cell surface as part of a receptor-ligand 
interaction that is important for spine growth and/or stability. 
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This gene encodes a member of the guanine nucleotide-binding protein (G protein)-coupled 
receptor kinase subfamily of the Ser/Thr protein kinase family. The protein phosphorylates the 
activated forms of G protein-coupled receptors, thus initiating their deactivation. It has also been 
shown to play a role in regulating the motility of polymorphonuclear leukocytes (PMNs). 
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Heparan sulfate biosynthetic enzymes are key components in generating a myriad of distinct 
heparan sulfate fine structures that carry out multiple biological activities. The enzyme encoded 
by this gene is a member of the heparan sulfate biosynthetic enzyme family. It is a type II 
integral membrane protein and possesses heparan sulfate glucosaminyl 3-O-sulfotransferase 
activity. This gene is expressed predominantly in the brain and may play a role in the nervous 
system. 
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Class-IV neuronal intermediate filament that is able to self-assemble. It is involved in the 
morphogenesis of neurons. It may form an independent structural network without the 
involvement of other neurofilaments or it may cooperate with NF-L to form the filamentous 
backbone to which NF-M and NF-H attach to form the cross-bridges. Abnormal neuronal 
intermediate filament (IF) inclusions immunopositive for the type IV IF alpha-internexin have 
been identified as the pathological hallmark of neuronal intermediate filament inclusion disease 
(NIFID) (Eur J Neurol. 2006 May;13(5):528-32). Abnormal neuronal aggregates of alpha-
internexin and the three neurofilament (NF) subunits, NF-L, NF-M, and NF-H have recently 
been identified as the pathological hallmarks of neuronal intermediate filament (IF) inclusion 
disease (NIFID), an early onset neurological disease with a variable clinical phenotype including 
frontotemporal dementia, pyramidal and extrapyramidal signs (Acta Neuropathol (Berl). 2004 
Sep;108(3):213-23). 
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Insulinoma-associated 1 (INSM1) gene is intronless and encodes a protein containing both a 
zinc finger DNA-binding domain and a putative prohormone domain. This gene is a sensitive 
marker for neuroendocrine differentiation of human lung tumors. Coimmunoprecipitation assays 
of mammalian cells revealed that INSM1 interacted with HDAC1 and HDAC3 and that the 
interaction was mediated through cyclin D1. Cyclin D1 cooperated with INSM1 to suppress 
Neurod1 promoter activity, and overexpression of cyclin D1 and HDAC3 significantly enhanced 
the transcriptional repression activity of INSM1 on the Neurod1 promoter. A chromatin 
immunoprecipitation assay showed that HDAC3 occupied the same region of the Neurod1 
promoter by forming a transcription complex with INSM1. Liu et al. (2006) concluded that INSM1 
recruits cyclin D1 and HDACs, which confer transcriptional repressor activity. 
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Genes encodes a protein with LIM domain. Actin binding, zinc ion binding. The LIM domain is a 
cysteine and histidine rich, zinc-coordinating domain composed of two tandemly repeated zinc 
fingers. The domain consists of two orthogonally arranged antiparallel beta-sheets with the 
carboxy-terminal zinc finger motif terminated by an alpha helix. The two zinc fingers pack 
together via a hydrophobic interface formed by conservatively substituted residues 
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The protein encoded by this gene is a member of the kinesin family. This protein is very similar 
to mouse heavy chain kinesin member 1A protein which is an anterograde motor protein 
transporting membranous organelles along axonal microtubules. It is thought that this protein 
may play a critical role in the development of axonal neuropathies resulting from impaired 
axonal transport. There are multiple polyadenylation sites found in this gene.  
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Marszalek et al. (1999) demonstrated that mouse Kif21a bound strongly to microtubules in the 
presence of a nonhydrolyzable ATP analog. They found that Kif21a accumulated on the 
proximal side of a sciatic nerve ligation, consistent with Kif21a being a plus end-directed motor. 
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This gene encodes a protein which contains a C-terminal domain able to interact with the 
angiotension II (AT2) receptor and a large coiled-coil region allowing dimerization. Multiple 
alternatively spliced transcript variants encoding different isoforms have been found for this 
gene. One of the transcript variants has been shown to encode a mitochondrial protein that acts 
as a tumor suppressor and participates in AT2 signaling pathways. Other variants may encode 
nuclear or transmembrane proteins but it has not been determined whether they also participate 
in AT2 signaling pathways. 
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The protein encoded by this gene is a transcription factor that may function as an inhibitor or 
repressor in cell growth and/or maintenance, and plays a role in the negative regulation of the 
cell cycle. It has a possible tumor suppressive activity when over expressed. Alternative splicing 
occurs at this locus and two transcript variants encoding the same protein have been identified. 
These proteins are secreted, and act as BMP (bone morphogenetic protein) antagonists by 
binding to BMPs and preventing them from interacting with their receptors. Thus they may play 
an important role during growth and development. Alternatively spliced transcript variants 
encoding distinct isoforms have been identified for this gene. NBL1 was identified as a binding 
partner for APP (770aa) and ubiquilin-1 (UBQLN1). (UBQLN1 modulates amyloid precursor 
protein trafficking and Abeta secretion. 
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Synonym: Neurofilament, medium polypeptide. Kinesin participates in axonal transport of 
neurofilaments (NFs). It was indicated that phosphorylation of NF-H dissociates NFs from 
kinesin and provides a mechanism by which NF-H phosphorylation can contribute to the slowing 
of NF axonal transport (Brain Res Mol Brain Res. 2005 Nov 30;141(2):151-5). The high 
molecular weight subunits of neurofilaments, NF-H and NF-M, have distinctive long carboxyl-
terminal domains that become highly phosphorylated after newly formed neurofilaments enter 
the axon (J Cell Biol. 1994 Aug;126(4):1031-46). 
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Neurofilaments usually contain three intermediate filament proteins: L, M, and H, which are 
involved in the maintenance of neuronal caliber. .Accumulations of neurofilaments are a 
pathological feature of several neurodegenerative diseases, including amyotrophic lateral 
sclerosis (ALS), Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and 
diabetic neuropathy. The authors concluded that their results demonstrated that aberrant 
neurofilament assembly and transport can induce neurologic disease and further implicated 
defective neurofilament metabolism in the pathogenesis of human neurodegenerative diseases. 
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This gene encodes a member of a family of neuronal cell surface proteins. Members of this 
family may act as splice site-specific ligands for beta-neurexins and may be involved in the 
formation and remodeling of central nervous system synapses. The encoded protein interacts 
with discs, large (Drosophila) homolog 4 (DLG4). Mutations in this gene have been associated 
with autism and Asperger syndrome. Two transcript variants encoding the same protein have 
been identified for this gene. 
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The  gene (for the full length receptor) encodes a member of the neurotrophic tyrosine receptor 
kinase (NTRK) family. This kinase is a membrane-bound receptor that, upon neurotrophin 
binding, phosphorylates itself and members of the MAPK pathway. Signaling through this kinase 
leads to cell differentiation. Alternate transcriptional splice variants encoding different isoforms 
have been found for this gene, but only two of them have been characterized to date. Receptor 
for brain-derived neurotrophic factor (BDNF), neurotrophin-3 and neurotrophin-4/5 but not nerve 
growth factor (NGF). Known substrates for the Trk receptors are shc1, pi-3 kinase, and plc-
gamma-1. 
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2 PFK catalyzes the irreversible conversion of fructose-6-phosphate to fructose-1,6-bisphosphate 
and is a key regulatory enzyme in glycolysis. PFK is found in platelets, brain and fibroblasts.  
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 The protein encoded by this gene catalyzes the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This reaction uses calcium as a 
cofactor and plays an important role in the intracellular transduction of many extracellular 
signals. This gene is activated by two G-protein alpha subunits, alpha-q and alpha-11. Two 
transcript variants encoding different isoforms have been found for this gene. 
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Serum-inducible kinase is a member of the 'polo' family of serine/threonine protein kinases that 
have a role in normal cell division. 
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The product of this gene belongs to the phosphatase 2 regulatory subunit B family. Protein 
phosphatase 2 is one of the four major Ser/Thr phosphatases, and it is implicated in the 
negative control of cell growth and division. It consists of a common heteromeric core enzyme, 
which is composed of a catalytic subunit and a constant regulatory subunit which associates 
with a variety of regulatory subunits. The B regulatory subunit might modulate substrate 
selectivity and catalytic activity. This gene encodes a gamma isoform of the regulatory subunit 
B55 subfamily. Alternatively spliced transcript variants encoding different isoforms have been 
identified. PP2a consists of a common heterodimeric core enzyme, composed of a 36 kDa 
catalytic subunit (subunit c) and a 65 kDa constant regulatory subunit (pr65 or subunit a) that 
associates with a variety of regulatory subunits. Proteins that associate with the core dimer 
include three families of regulatory subunits b (the r2/b/pr55/b55, r3/b''/pr72/pr130/pr59 and 
r5/b'/b56 families), the 48 kDa variable regulatory subunit, viral proteins, and cell signaling 
molecules. 
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The protein encoded by this gene is a cytosolic prolyl endopeptidase that cleaves peptide bonds 
on the C-terminal side of prolyl residues within peptides that are up to approximately 30 amino 
acids long. Prolyl endopeptidases have been reported to be involved in the maturation and 
degradation of peptide hormones and neuropeptides. PREP is believed to deactivate 
neuropeptides that are present in the extracellular space. However, the intracellular localization 
of PREP suggests additional, as yet unidentified physiological functions for this enzyme. 
Immunocytochemical double-labelling procedures and localization of PREP-enhanced green 
fluorescent protein fusion proteins that PREP is mainly localized to the perinuclear space, and is 
associated with the microtubulin cytoskeleton in human neuroblastoma and glioma cell lines. 
Disassembly of the microtubules by nocodazole treatment disrupts both the fibrillar tubulin and 
PREP labelling. Furthermore, in a two-hybrid screen, PREP was identified as a binding partner 
of tubulin. These findings indicate novel functions for PREP in axonal transport and/or protein 
secretion. In the brains of young APP transgenic Tg2576 mice, hippocampal PREP activity was 
increased compared to wild-type littermates in the pre-plaque phase, but not in aged mice with 
beta-amyloid plaque pathology. This "accelerated aging" with regard to hippocampal PREP 
expression in young APP transgenic mice might be one factor contributing to the observed 
cognitive deficits in these mice in the pre-plaque phase and could also explain, in part, the 
cognition-enhancing effects of PREP inhibitors in several experimental paradigms (Neurochem 
Res. 2005 Jun-Jul;30(6-7):695-702). Prolyl endopeptidase (PREP) is a proline-specific 
oligopeptidase with a reported effect on learning and memory in different rat model systems. 
Measuring different second-messenger concentrations revealed an inverse correlation between 
inositol 1,4,5-triphosphate [Ins(1,4,5)P3] concentration and PREP expression. 
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This gene encodes a member of the trypsin family of  secreted serine proteases. Studies in 
mice suggest that the encoded enzyme may be involved in structural reorganizations associated 
with learning and memory. Plays a role in neuronal plasticity and the proteolytic action may 
subserve structural reorganizations associated with learning and memory operations. Defects in 
prss12 are a cause of autosomal recessive nonsyndromic mental retardation. This kind of 
mental retardation is a mental disorder characterized by significantly subaverage general 
intellectual functioning associated with impairments in adaptative behavior and manifested 
during the developmental period. 
P
TP
R
M
 
pr
ot
ei
n 
ty
ro
si
ne
 
ph
os
ph
at
as
e 
 re
ce
pt
or
 
ty
pe
  M
 
ch
r1
8p
11
.2
 
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family 
and a membrane single-pass type I membrane protein. PTPs are known to be signaling 
molecules that regulate a variety of cellular processes including cell growth, differentiation, 
mitotic cycle, and oncogenic transformation. PTPRM possesses an extracellular region, a single 
transmembrane region, and two tandem catalytic domains, and thus represents a receptor-type 
PTP. The extracellular region contains a meprin-A5 antigen-PTP mu (MAM) domain, an Ig-like 
domain and four fibronectin type III-like repeats. PTPRM has been shown to mediate cell-cell 
aggregation through the interaction with another molecule of this PTP on an adjacent cell. 
PTPRM can interact with scaffolding protein RACK1/GNB2L1, which may be necessary for the 
downstream signaling in response to cell-cell adhesion. 
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The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) 
family. PTPs are known to be signaling molecules that regulate a variety of cellular processes 
including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP 
possesses an extracellular region, a single transmembrane region, and a single intracellular 
catalytic domain, and thus represents a receptor-type PTP. The catalytic domain of this PTP is 
most closely related to PTPRN/IA-2beta. This PTP and PTPRN are both found to be major 
autoantigens associated with insulin-dependent diabetes mellitus. Three alternatively spliced 
transcript variants of this gene encoding different proteins have been reported. 
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This gene encodes a large secreted extracellular matrix protein thought to control cell-cell 
interactions critical for cell positioning and neuronal migration during brain development. This 
protein may be involved in schizophrenia, autism, bipolar disorder, major depression and in 
migration defects associated with temporal lobe epilepsy. Mutations of this gene are associated 
with autosomal recessive lissencephaly with cerebellar hypoplasia. Two transcript variants 
encoding distinct isoforms have been identified for this gene. Other transcript variants have also 
been described. Extracellular matrix serine protease that plays a role in layering of neurons in 
the cerebral cortex and cerebellum. Regulates microtubule function in neurons and neuronal 
migration. Affects migration of sympathetic preganglionic neurons in the spinal cord, where it 
seems to act as a barrier to neuronal migration. Enzymatic activity is important for the 
modulation of cell adhesion. Binding to the extracellular domains of lipoprotein receptors VLDLR 
and APOER2 induces tyrosine phosphorylation of dab1 and modulation of tau phosphorylation. 
Abundantly produced during brain ontogenesis by the Cajal-retzius cells and other pioneer 
neurons located in the telencephalic marginal zone and by granule cells of the external granular 
layer of the cerebellum. In adult brains, RELN is preferentially expressed in gabaergic 
interneurons of prefrontal cortices, temporal cortices, hippocampi and glutamatergic granule 
cells of cerebellum. Also expressed in fetal and adult livers. 
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Transmembrane protein. 
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Semaphorins are a large family, including both secreted and membrane associated proteins, 
many of which have been implicated as inhibitors or chemorepellents in axon pathfinding, 
fasciculation and branching, and target selection. All semaphorins possess a semaphorin 
(Sema) domain and a PSI domain (found in plexins, semaphorins and integrins) in the N-
terminal extracellular portion. Additional sequence motifs C-terminal to the semaphorin domain 
allow classification into distinct subfamilies. Results demonstrate that transmembrane 
semaphorins, like the secreted ones, can act as repulsive axon guidance cues. This gene 
encodes a class 6 vertebrate transmembrane semaphorin that demonstrates alternative 
splicing. Six transcript variants have been identified and expression of the distinct encoded 
isoforms is thought to be regulated in a tissue- and development-dependent manner. Qu et al. 
(2002) exposed chicken embryo dorsal root ganglion explants and neonatal rat cortical and 
hippocampal neurons to SEMA6D secreted from transfected COS-7 cells and found that 
SEMA6D induced growth cone collapse. SEMA6D also inhibited axonal extension in a nerve 
growth factor (NGF)-differentiated rat pheochromocytoma cell line.  
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Semaphorins, or collapsins, constitute a family characterized by the presence of a conserved 
semaphorin domain at the N terminus. Secreted protein, may be involved in diverse cell survival 
mechanisms. All glioma cell lines express SEMA3A and SEMA3C and exhibit SEMA3A binding 
sites. 
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Synaptic vesicle membrane docking and fusion is mediated by SNAREs (soluble N-
ethylmaleimide-sensitive factor attachment protein receptors) located on the vesicle membrane 
(v-SNAREs) and the target membrane (t-SNAREs). The assembled v-SNARE/t-SNARE 
complex consists of a bundle of four helices, one of which is supplied by v-SNARE and the 
other three by t-SNARE. For t-SNAREs on the plasma membrane, the protein syntaxin supplies 
one helix and the protein encoded by this gene contributes the other two. Therefore, this gene 
product is a presynaptic plasma membrane protein involved in the regulation of neurotransmitter 
release. Two alternative transcript variants encoding different protein isoforms have been 
described for this gene. Elevated cerebrospinal fluid SNAP-25 in schizophrenia (Biol Psychiatry. 
2003 Jun 15;53(12):1132-7). Increased RNA levels of the 25 kDa synaptosomal associated 
protein in brain samples of adult patients with Down Syndrome (Neurosci Lett. 2003 Jan 
16;336(2):77-80). The heavy chain of kinesin interacts with the SNARE proteins SNAP25 and 
SNAP23 (Biochemistry. 2002 Dec 17;41(50):14906-15). 
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Sphingosine-1-phosphatase is an intracellular enzyme located in the endoplasmic reticulum, 
which regulates the level of sphingosine-1-phosphate (S1P), a bioactive lipid.  
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SYT13 belongs to the large synaptotagmin protein family. All synaptotagmins show type I 
membrane topology, with an extracellular N terminus, a single transmembrane region, and a 
cytoplasmic C terminus containing tandem C2 domains. Major functions of synaptotagmins 
include vesicular traffic, exocytosis, and secretion. 
TN
C
 
te
na
sc
in
 C
 
(h
ex
ab
ra
ch
io
n)
 
ch
r9
q3
3 
TenascinC is part of a specialized extracellular matrix in the region of the horizontal myoseptum 
(in zebrafish) that influences the growth of motor axons. In situ hybridization and 
immunocytochemistry experiments revealed that tenascin-C, one candidate molecule which was 
suspected to be involved in neonatal learning, is expressed in the forebrain of domestic chicks 
around the sensitive period during which auditory filial imprinting takes place (Neuroscience. 
2006 Sep 15;141(4):1709-19). 
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The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains 
an intracelluar death domain. This receptor can be activated by tumor necrosis factor-related 
apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces apoptosis signal. Studies 
with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is 
required for the apoptosis mediated by this protein. Receptor for the cytotoxic ligand 
TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The 
resulting death-inducing signaling complex (disc) performs caspase-8 proteolytic activation 
which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) 
mediating apoptosis. Promotes the activation of NF- kappa-b. 
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2 VMP contains two putative membrane spanning domains and a hydrophilic tail homologous to 
the microtubule-binding domain of MAPs. So it is speculated that VMP may associate with 
microtubules through its C-terminal and plays an important role in vesicular organelles transport 
and nerve signals. 
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The WNT gene family consists of structurally related genes which encode secreted signaling 
proteins. These proteins have been implicated in oncogenesis and in several developmental 
processes, including regulation of cell fate and patterning during embryogenesis. This gene is a 
member of the WNT gene family. It encodes a protein which shows 98%, 98% and 87% amino 
acid identity to the mouse, rat and the xenopus Wnt5A protein, respectively. The experiments 
performed in Xenopus laevis embryos identified that human frizzled-5 (hFz5) is the receptor for 
the Wnt5A ligand and the Wnt5A/hFz5 signaling mediates axis induction. Wnt-5a inhibits the 
Wnt pathway by promoting GSK-3-independent beta-catenin degradation. The Wnt antagonist 
DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is down-regulated in human 
colon cancer (Oncogene. 2005 Feb 3;24(6):1098-103). 
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2 D1 dopamine receptor-interacting protein. 
 
 
 
Selection of down-regulated genes, C99V50F/C99WT1 (volcano plot): 
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Previously described in Chapter 12.3 
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2 ADCY1 is the founding member of the adenylate cyclase (EC 4.6.1.1) family of enzymes 
responsible for the synthesis of cAMP (Ludwig and Seuwen, 2002). In transgenic mice with 
specific overexpression of Adcy1 in the forebrain, Wang et al. (2004) found a tendency 
towards increased long-term potentiation, increased memory for object recognition, and 
slower rates of loss of contextual memory compared to wildtype mice. 
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The protein encoded by this gene is a lysosomal aspartyl protease composed of a dimer of 
disulfide-linked heavy and light chains, both produced from a single protein precursor. This 
proteinase is a member of the peptidase C1 family. Transcription of this gene is initiated from 
several sites, including one which is a start site for an estrogen-regulated transcript. Mutations 
in this gene are involved in the pathogenesis of several diseases, including breast cancer and 
possibly Alzheimer’s disease. Acid protease active in intracellular protein breakdown. involved 
in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer’s 
disease. Localized in lysosomes. The val-58 allele is significantly overrepresented in 
demented patients (11.8%) compared with nondemented controls (4.9%). Carriers of the val-
58 allele have a 3.1-fold increased risk for developing AD than noncarriers. 
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The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. 
The functional diversity of these receptors is defined by the binding of acetylcholine and 
includes cellular responses such as adenylate cyclase inhibition, phosphoinositide 
degeneration, and potassium channel mediation. Muscarinic receptors influence many effects 
of acetylcholine in the central and peripheral nervous system. The muscarinic acetylcholine 
receptor mediates various cellular responses, including inhibition of adenylate cyclase, 
breakdown of phosphoinositides and modulation of potassium channels through the action of 
g proteins. 
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The cyclin-dependent protein kinases (CDKs) regulate major cell cycle transitions in 
eukaryotic cells. In primary T cells that were stimulated to enter the cell cycle, cellular CDK6 
kinase activity first appeared in mid-G1, prior to the activation of any previously characterized 
CDK. Meyerson and Harlow (1994) suggested that CDK6, and the homologous CDK4, link 
growth factor stimulation with the onset of cell cycle progression. Guan et al. (1994) proposed 
that CDK4 and CDK6 are physiologic RB1 kinases that are inhibited by the p14 (600431), p16 
(600160), and p18 (603369) CDK inhibitors. This inhibition prevents the phosphorylation of 
RB1 and keeps RB1 in its active growth-suppressing state.  
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Previously described in Chapter 12.3 
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DYRK2 belongs to a family of protein kinases whose members are presumed to be involved in 
cellular growth and/or development. The family is defined by structural similarity of their kinase 
domains and their capability to autophosphorylate on tyrosine residues. DYRK2 has 
demonstrated tyrosine autophosphorylation and catalyzed phosphorylation of histones H3 and 
H2B in vitro. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in 
the apoptotic response to DNA damage (Mol Cell. 2007 Mar 9;25(5):725-38). Taira et al. 
(2007) found that DYRK2 phosphorylated p53 (TP53) on ser46 in vitro and in human cells. 
Upon exposure to genotoxic stress, DYRK2 translocated into the nucleus and phosphorylated 
p53 on ser46, inducing P53AIP1 expression and apoptosis in a ser46 phosphorylation-
dependent manner. Taira et al. (2007) concluded that DYRK2 regulates p53 to induce 
apoptosis in response to DNA damage. 
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This gene encodes a member of the ephrin (EPH) family. The ephrins and EPH-related 
receptors comprise the largest subfamily of receptor protein-tyrosine kinases and have been 
implicated in mediating developmental events, especially in the nervous system and in 
erythropoiesis. Based on their structures and sequence relationships, ephrins are divided into 
the ephrin-A (EFNA) class, which are anchored to the membrane by a 
glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are 
transmembrane proteins. This gene encodes an EFNB class ephrin which binds to the EPHB4 
and EPHA3 receptors. EFNB2 binds to the receptor tyrosine kinases ephb4 and epha3 and 
may play a role in constraining the orientation of longitudinally projecting axons. 
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3 Glial  cell line-derived neurotrophic factor receptor alpha-3. The protein encoded by this gene 
is a glycosylphosphatidylinositol(GPI)-linked cell surface receptor and a member of the GDNF 
receptor family. It forms a signaling receptor complex with RET tyrosine kinase receptor and 
binds the ligand artemin. Glial cell line-derived neurotrophic factor (GDNF) and neurturin 
(NRTN) promote the survival and maintenance of different neuronal cell types. GDNF signals 
through a receptor complex composed of a GDNF family receptor and the membrane-bound 
protein tyrosine-kinase receptor RET. 
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Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein 
core substituted with a variable number of heparan sulfate chains. Members of the glypican-
related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the 
cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a 
role in the control of cell division and growth regulation. Deletion mutations in this gene are 
associated with Simpson-Golabi-Behmel syndrome. Cell surface proteoglycan that bears 
heparan sulfate may be involved in the suppression/modulation of growth in the predominantly 
mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its 
receptor and thereby modulate its function. May regulate growth and tumor predisposition. 
Predicted functional partners are IGF2, Insulin precursor, WNT5A, CDKN1C, WNT3A, 
WNT7B. 
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Insulinoma-associated protein-2  is a major autoantigen in type 1 diabetes that occurs through 
autoimmune-mediated beta-cell destruction (Diabetes. 2007 Jan;56(1):41-8). 
LR
P
4 
lo
w
 d
en
si
ty
 
lip
op
ro
te
in
 
re
ce
pt
or
-r
el
at
ed
 
pr
ot
ei
n 
4 
ch
r1
1p
11
.2
-p
12
 
Potential cell surface endocytic receptor, which binds and internalizes extracellular ligands for 
degradation by lysosomes. 
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This gene encodes a protein with similarity to a bovine microfibril-associated protein. The 
protein has binding specificities for both collagen and carbohydrate. It is thought to be an 
extracellular matrix protein which is involved in cell adhesion or intercellular interactions. The 
gene is located within the Smith-Magenis syndrome region. Although the precise function of 
this protein is not known, it has been suggested that it could be a Ca2+-dependent adhesive 
protein that is associated with elastin (ELN) microfibrils in the extracellular matrix. MFAP4 has 
a fibrinogen-like domain. The N-terminus of the protein contains an arg-gly-asp sequence that 
serves as the ligand motif for cell surface receptor integrin.  
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The protein encoded by this gene is a proteolipid that may be involved in the regulation of ion 
channels during brain development. The encoded protein may also play a role in forming and 
maintaining the structure of the nervous system. This gene is found within an intron of the 
BLCAP gene, but on the opposite strand. This gene is imprinted and is expressed only from 
the paternal allele, while BLCAP is not imprinted. Two transcript variants encoding two 
different isoforms have been found for this gene. The NNAT gene contains in its 5-prime 
flanking region a neural restrictive silencer element that was thought to govern neuron-specific 
expression. The deduced protein is a proteolipid that may function as a regulator of ion 
channels during brain development. 
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Previously described in Chapter 12.3 
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Belongs to the G-protein coupled receptor 1 family. Orphan receptor. Membrane; multi-pass 
membrane protein. 
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Neurotrophic protein; induces extensive neuronal differentiation in retinoblastoma cells. Potent 
inhibitor of angiogenesis. As it does not undergo the s (stressed) to r (relaxed) conformational 
transition characteristic of active serpins, it exhibits no serine protease inhibitory activity 
expressed in quiescent cells. The N-terminal (aa 44-121) exhibits neurite outgrowth- inducing 
activity. The C-terminal exposed loop (aa 382-418) is essential for serpin activity, secreted 
protein. Natural inhibitors of angiogenesis are able to block pathologic neovascularization 
without harming the pre-existing vasculature. Volpert et al. (2002) demonstrated that 2 such 
inhibitors, thrombospondin I and SERPINF1, derive specificity for remodeling vessels from 
their dependence on Fas/Fas ligand (FasL)-mediated apoptosis to block angiogenesis. Both 
inhibitors up-regulated FasL on endothelial cells. Expression of the essential partner of FasL, 
Fas receptor, was low on quiescent endothelial cells and vessels but greatly enhanced by 
inducers of angiogenesis, thereby specifically sensitizing the stimulated cells to apoptosis by 
inhibitor-generated FasL. The antiangiogenic activity of thrombospondin I and SERPINF1 both 
in vitro and in vivo was dependent on this dual induction of Fas and FasL and the resulting 
apoptosis. Volpert et al. (2002) concluded that this example of cooperation between pro- and 
antiangiogenic factors in the inhibition of angiogenesis provides one explanation for the ability 
of inhibitors to select remodeling capillaries for destruction. 
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 Potentially involved in docking of synaptic vesicles at presynaptic active zones,  contains 1 t-snare coiled-coil homology domain. 
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Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin 
receptor into specialized endosomes, endosomal acidification leads to iron release. The 
apotransferrin-receptor complex is then recycled to the cell surface with a return to neutral pH 
and the concomitant loss of affinity of apotransferrin for its receptor. Transferrin receptor 
(TFR) is necessary for development of erythrocytes and the nervous system. The 
relationships between iron metabolism and type 2 diabetes are bidirectional: Iron affects 
glucose metabolism and glucose metabolism impinges on several iron metabolic pathways. 
Both insulin sensitivity and glucose tolerance status are strongly associated with serum TFR 
concentrations (Diabetes Care. 2007 Mar;30(3):604-8). The early endosome is organised into 
domains to ensure the separation of cargo. Activated mitogenic receptors, such as the 
epidermal growth factor (EGF) receptor, are concentrated into vesicles enriched for the small 
GTPase Rab5, which progressively exclude nutrient receptors, such as transferrin receptor, 
into neighbouring tubules. These vesicles become enlarged, increase their content of 
intralumenal vesicles as EGF receptors are sorted from the limiting membrane, and eventually 
mature to late endosomes. Maturation is governed by the loss of Rab5 and is accompanied by 
the movement of endosomes along microtubules towards the cell centre. It has been shown 
that EGF relocates to the cell centre in a dynein-dependent fashion, concomitant with the 
sorting away of transferrin receptors, although it remains in Rab5-positive early endosomes. 
When dynein function is acutely disrupted, efficient recycling of transferrin from EGF-
containing endosomes is retarded, loss of Rab5 is slowed and endosome enlargement is 
reduced (Nat Cell Biol. 2007 Jan;9(1):113-20). Transferrin receptor 1 is required for iron 
delivery from transferrin to cells. It was established as a gatekeeper for regulating iron uptake 
by most cells. TFRC is regulated by cellular iron levels through binding of the iron regulatory 
proteins, IRP1 and IRP2, to iron-responsive elements in the 3'-utr. Up-regulated upon 
mitogenic stimulation. 
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1 This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix 
(bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH 
protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, 
most notably neuroblastomas. 
 
 
Selection of up-regulated genes, C99V50F/C99WT1 (volcano plot): 
ID
4 
in
hi
bi
to
r o
f D
N
A
 b
in
di
ng
 
4,
 d
om
in
an
t n
eg
at
iv
e 
he
lix
-lo
op
-h
el
ix
 p
ro
te
in
 
ch
r6
p2
2-
p2
1 
Transcription factors containing a basic helix-loop-helix (bHLH) motif regulate expression of 
tissue-specific genes in a number of mammalian and insect systems. DNA-binding activity 
of the bHLH proteins is dependent on formation of homo- and/or heterodimers. Dominant-
negative HLH proteins encoded by Id-related genes (inhibitor of DNA binding), such as ID4, 
also contain the HLH-dimerization domain but lack the DNA-binding basic domain. 
Consequently, Id proteins inhibit binding to DNA and transcriptional transactivation by 
heterodimerization with bHLH proteins (Pagliuca et al., 1995). Downregulation of ID4 by 
promoter hypermethylation in gastric adenocarcinoma (Oncogene. 2003 Oct 9;22(44):6946-
53). HLH proteins lack a basic DNA-binding domain but are able to form heterodimers with 
other hlh proteins, thereby inhibiting DNA binding. 
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This gene is a member of the semaphorin family and encodes a protein with an Ig-like C2-
type (immunoglobulin-like) domain, a PSI domain and a Sema domain. This secreted 
protein can function as a chemoattractive agent, stimulating the growth of apical dendrites. 
The protein is vital for normal neuronal pattern development. Also, aberrant release of this 
protein is associated with the progression of Alzheimer's disease.  SEMA3A is a secreted 
protein and could serve as a ligand that guides specific growth cones by a motility-inhibiting 
mechanism. It binds to the complex neuropilin-1/plexin-1. Polleux et al. (2000) 
demonstrated that the growth of apical dendrites toward the pial surface is regulated by a 
diffusible chemoattractant present at high levels near the marginal zone. A major 
component of the signal is SEMA3A, which was previously characterized as a 
chemorepellant for cortical axons. Soluble guanylate cyclase is asymmetrically localized to 
the developing apical dendrite, and is required for the chemoattractive effect of SEMA3A. 
Thus, the asymmetric localization of soluble guanylate cyclase confers distinct SEMA3A 
responses to axons and dendrites. Polleux et al. (2000) concluded that these observations 
reveal a mechanism by which a single chemotropic signal can pattern both axons and 
dendrites during development. Loss of neuropilin function increases the number of 
interneurons that migrate into the striatum. Marin et al. (2001) concluded that their 
observations reveal a mechanism by which neuropilins mediate sorting of distinct neuronal 
populations into different brain structures, and provide evidence that, in addition to guiding 
axons, these receptors also control neuronal migration in the central nervous system. 
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This gene includes two overlapping reading frames of the same transcript encoding distinct 
isoforms. The shorter isoform has a CCHC-type zinc finger motif containing a sequence 
characteristic of gag proteins of most retroviruses and some retrotransposons, and it 
functions in part by interacting with members of the TGF-beta receptor family. The longer 
isoform has the active-site DSG consensus sequence of the protease domain of pol 
proteins. The longer isoform is the result of -1 translational frameshifting that is also seen in 
some retroviruses. Expression of these two isoforms only comes from the paternal allele 
due to imprinting. Increased gene expression (as observed by an increase in mRNA levels) 
is associated with hepatocellular carcinomas. By yeast 2-hybrid analysis and 
coimmunoprecipitation experiments, Lux et al. (2005) determined that human PEG10-RF1 
and PEG10-RF1/RF2 interacted with the cytoplasmic domain of ALK1, a TGF-beta 
(TGFB1) receptor. 
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Previously described in Chapter 12.3 
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Neurofascin is an L1 family immunoglobulin cell adhesion molecule (see L1CAM) involved 
in axon subcellular targeting and synapse formation during neural development (Ango et al., 
2004). 
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Previously described in Chapter 12.3 
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The protein encoded by this gene belongs to the subtilisin-like proprotein convertase family. 
The members of this family are proprotein convertases that process latent precursor 
proteins into their biologically active products. This encoded protein is a proinsulin-
processing enzyme that plays a key role in regulating insulin biosynthesis. It is also known 
to cleave proopiomelanocortin, proenkephalin, prodynorphin and proluteinizing-hormone-
releasing hormone. The use of alternate polyadenylation sites has been found for this gene. 
The proprotein convertase PC2 is involved in the maturation of prosomatostatin to 
somatostatin-14 but not in the somatostatin deficit in Alzheimer's disease  (Neuroscience. 
2003;122(2):437-47). 
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This gene encodes a protein involved in regulating responses to cytokines by members of 
the Rel/NF-kappaB transcription factor family. These factors play a central role in innate 
immunity in response to pathogens, inflammatory signals and stress. This gene product 
interacts with TRAF proteins (tumor necrosis factor receptor-associated factors) and either 
I-kappaB kinase or MAP kinase to activate either NF-kappaB or Jun kinase. Two alternative 
transcripts encoding different proteins have been identified. A third transcript, which does 
not encode a protein and is transcribed in the opposite orientation, has also been identified. 
Overexpression of this transcript has been shown to reduce expression of at least one of 
the protein encoding transcripts, suggesting it has a regulatory role in the expression of this 
gene. 
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Previously described in Chapter 12.3 
N
E
FL
 
ne
ur
of
ila
m
en
t, 
lig
ht
 
po
ly
pe
pt
id
e 
68
kD
a 
ch
r8
p2
1 
Previously described in Chapter 12.3 
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Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and 
block myogenic differentiation (Oncogene. 2002 May 30;21(24):3827-35). 
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This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to 
and inhibits the activity of cyclin CDK2 or -CDK4 complexes, and thus functions as a 
regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by 
the tumor suppressor protein p53, through which this protein mediates the p53-dependent 
cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact 
with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and 
plays a regulatory role in S phase DNA replication and DNA damage repair. This protein 
was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a 
dramatic activation of CDK2, and may be instrumental in the execution of apoptosis 
following caspase activation. Two alternatively spliced variants, which encode an identical 
protein have been reported. This gene encodes a potent cyclin-dependent kinase inhibitor. 
The encoded protein binds to and inhibits the activity of cyclin CDK2 or -CDK4 complexes, 
and thus functions as a regulator of cell cycle progression at G1. The expression of this 
gene is tightly controlled by the tumor suppressor protein p53, through which this protein 
mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress 
stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA 
polymerase accessory factor, and plays a regulatory role in S phase DNA replication and 
DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like 
caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in 
the execution of apoptosis following caspase activation. Two alternatively spliced variants, 
which encode an identical protein have been reported. Transforming growth factor-beta 
(TGF-beta) inhibits epithelial cell growth, in part via transcriptional induction of the cell cycle 
inhibitor p21(WAF1/Cip1) (p21). It has been shown that bone morphogenetic protein (BMP)-
7 induces higher p21 expression than TGF-beta1 in various epithelial cells. Despite this, 
BMP-7 only weakly suppresses epithelial cell proliferation, as Id2, a cell cycle-promoting 
factor, becomes concomitantly induced by BMP-7. Signaling studies with all type I receptors 
of the TGF-beta superfamily show that BMP receptors induce higher p21 expression than 
TGF-beta/activin receptors. Smad4 is essential for p21 regulation by all receptor pathways. 
Based on the previously known ability of c-Myc to block p21 expression and epithelial 
growth arrest in response to TGF-beta1, it has been demonstrated that ectopic c-Myc 
expression can abrogate Smad-mediated p21 induction by all TGF-beta and BMP 
receptors. Furthermore, p21 induction by all receptor pathways can be blocked by the 
natural inhibitors of the TGF-beta superfamily, p21 is a common target of all TGF-beta 
superfamily pathways. (J Cell Physiol. 2005 Jul;204(1):260-72). 
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This gene is specifically expressed in a subpopulation of neuroendocrine cells, and is up-
regulated by nerve growth factor. The structural organization of this gene is similar to that of 
the rat gene, and both the translated and the untranslated regions show a high degree of 
sequence similarity to the rat gene. The encoded secretory protein also shares similarities 
with the secretogranin/chromogranin family, however, its exact function is not known. VGF 
levels were found to be significantly lower in the CSF from patients with ALS and suggested 
as biomarkers (in combination with others) for ALS (amyotrophic lateral sclerosis). VGF 
may be involved in the regulation of cell-cell interactions or in synatogenesis during the 
maturation of the nervous system and may be stored in secretory vesicles and then 
secreted. Targeted deletion of the Vgf gene indicates that the encoded secretory peptide 
precursor plays a role in the regulation of energy balance (Neuron 23: 537-548, 1999). 
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 This gene encodes a cytoplasmic protein that contains epidermal growth factor (EGF) -like 
repeats. The encoded heterotrimeric protein may be involved in cell growth regulation and 
differentiation. Secreted protein, binds to pkc beta-1. 
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Transforming growth factor-beta (TGFB1) participates in the pathophysiology of diabetic 
complications. Lang et al. (2000) demonstrated markedly enhanced transcription of SGK in 
diabetic nephropathy, with particularly high expression in mesangial cells, interstitial cells, 
and cells in the thick ascending limbs of the loop of Henle and distal tubules. The enhanced 
SGK transcription, which results from excessive extracellular glucose concentrations, 
stimulates renal tubular Na+ transport. These observations disclosed an additional element 
in the pathophysiology of diabetic nephropathy. Gamper et al. (2002) found that expression 
of SGK1, SGK2, and SGK3 in human embryonic kidney cells and Xenopus oocytes 
significantly stimulated voltage-gated K+ channels. Arteaga et al. (2006) found that mouse 
SGK1 is a short-lived protein with a significantly shorter half-life than SGK2 or Akt. SGK1 
was ubiquitinated and degraded at the endoplasmic reticulum (ER) membrane by the action 
of the ER-associated ubiquitin-conjugating enzymes Ubc6 and Ubc7 and the ligase Hrd1. A 
hydrophobic alpha helix located within the N terminus of SGK1 serves as the signal for 
targeting the protein to the ER for ubiquitination and subsequent degradation. This kinase 
has been shown to be important in activating certain potassium, sodium, and chloride 
channels. Expression of this gene in hepatocytes is stimulated by transforming growth 
factor-beta (TGF-beta) which participates in the pathophysiology of diabetic complications. 
Since both TGF-beta expression and SGK expression are elevated in diabetic nephropathy, 
this suggests an involvement of SGK in the development of this condition. Mediates cell 
survival signals. SGK phosphorylates and negatively regulates pro-apoptotic foxo3a. SGK 
is induced by serum and/or glucocorticoids, by excessive extracellular glucose and by tgf-
beta, in cultured cells. It is regulated by phosphorylation: phosphoinositide 3-kinase (PI3K- 
kinase) pathway promotes phosphorylation on ser-422 which in turn increases the 
phosphorylation of thr-256 by pdpk1. Ubiquitinated by nedd4l, which promotes proteasomal 
degradation. 
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This gene encodes a member of the neutral endopeptidase (NEP)-related family. It is 
expressed specifically in the nervous system. It may contribute to the degradation of 
peptide hormones and be involved in the inactivation of neuronal peptides. It is assumed to 
bind 1 zinc ion. The gene disruption in mouse embryonic stem cells results in neonatal 
mortality due to respiratory failure shortly after birth. Based on the specific expression of 
this gene and the phenotype of the gene deficiency in mouse embryos, it is suggested that 
the protein encoded by this gene plays a critical role in the nervous regulation of the 
respiratory system. 
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 This gene encodes a transmembrane glycoprotein related to the type I receptors of the 
transforming growth factor-beta (TGF-beta) family, whose members play important roles in 
signal transduction in many developmental and pathological processes. The encoded 
protein However, is a pseudoreceptor, lacking an intracellular serine/threonine kinase 
domain required for signaling. Similar proteins in frog, mouse and zebrafish function as 
negative regulators of TGF-beta, which has led to the suggestion that the encoded protein 
may function to limit the signaling range of the TGF-beta family during early embryogenesis. 
Negatively regulates tgf-beta signaling. 
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Diacylglycerol kinases (DGKs) are regulators of the intracellular concentration of the second 
messenger diacylglycerol (DAG) and thus play a key role in cellular processes. Nine 
mammalian isotypes have been identified, which are encoded by separate genes. 
Mammalian DGK isozymes contain a conserved catalytic (kinase) domain and a cysteine-
rich domain (CRD). The protein encoded by this gene is a diacylglycerol kinase, beta 
isotype. Two alternatively spliced transcript variants have been found for this gene. 
Diacylglycerol kinases (DGKs) are regulators of the intracellular concentration of the second 
messenger diacylglycerol (DAG) and thus play a key role in cellular processes. Nine 
mammalian isotypes have been identified, which are encoded by separate genes. 
Mammalian DGK isozymes contain a conserved catalytic (kinase) domain and a cysteine-
rich domain (CRD). The protein encoded by this gene is a diacylglycerol kinase, beta 
isotype. 
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Previously described in Chapter 12.3 
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Membrane; single-pass type I membrane protein. The protein encoded by this gene is an 
axonal glycoprotein belonging to the immunoglobulin supergene family. The ectodomain, 
consisting of several immunoglobulin-like domains and fibronectin-like repeats (type III), is 
linked via a single transmembrane sequence to a conserved cytoplasmic domain. This cell 
adhesion molecule plays an important role in nervous system development, including 
neuronal migration and differentiation.  L1CAM is a cell adhesion molecule with an 
important role in the development of the nervous system. Involved in neuron-neuron 
adhesion, neurite fasciculation, outgrowth of neurites, etc.. Binds to axonin on neurons. 
Mutations in the gene cause three X-linked neurological syndromes known by the acronym 
CRASH (corpus callosum hypoplasia, retardation, aphasia, spastic paraplegia and 
hydrocephalus). Defects in Hydrocephalus due to stenosis of the aqueduct of sylvius  is 
characterized by mental retardation and enlarged brain ventricles. Kenwrick et al. (2000) 
reviewed the various functions of L1CAM, including guidance of neurite outgrowth in 
development, neuronal cell migration, axon bundling, synaptogenesis, myelination, 
neuronal cell survival, and long-term potentiation. On differentiated neurons, L1 is found at 
regions of contact between neighbouring axons and on the growth cones, the structures at 
the leading tip of axons that are responsible for sensing extracellular growth and guidance 
cues. This distribution supports the suggestion from in vitro studies that L1 adhesive inter-
actions may mediate axon bundling (fasciculation) (6,7) and that L1 acts as a growth cone 
receptor for signals that induce the extension of processes (neurites) from neurons in 
culture (8). Neurite outgrowth is likened to axon growth and is taken as evidence that L1 
may be involved in axon growth during development (Human Molecular Genetics, 2000, 
Vol. 9, No. 6, 879-886). 
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Cell adhesion molecules (CAMs) are members of the immunoglobulin superfamily. This 
gene encodes a neuronal cell adhesion molecule with multiple immunoglobulin-like C2-type 
domains and fibronectin type-III domains. This ankyrin-binding protein is involved in neuron-
neuron adhesion and promotes directional signaling during axonal cone growth. This gene 
is also expressed in non-neural tissues and may play a general role in cell-cell 
communication via signaling from its intracellular domain to the actin cytoskeleton during 
directional cell migration. Allelic variants of this gene have been associated with autism and 
addiction vulnerability. 
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Receptor for prostaglandin e2. The activity of this receptor is mediated by g(s) proteins that 
stimulate adenylate cyclase. The subsequent raise in intracellular camp is responsible for 
the relaxing effect of this receptor on smooth muscle. How cyclooxygenase-2 (COX-2) and 
its proinflammatory metabolite prostaglandin E2 (PGE2) enhance colon cancer progression 
remains poorly understood. It has been shown that PGE2 stimulates colon cancer cell 
growth through its heterotrimeric guanine nucleotide-binding protein (G protein)-coupled 
receptor, EP2, by a signaling route that involves the activation of phosphoinositide 3-kinase 
and the protein kinase Akt by free G protein beta/gamma subunits and the direct 
association of the G protein alphas subunit with the regulator of G protein signaling (RGS) 
domain of axin. This leads to the inactivation and release of glycogen synthase kinase 
3beta from its complex with axin, thereby relieving the inhibitory phosphorylation of beta-
catenin and activating its signaling pathway (Science. 2005 Dec 2;310(5753):1504-10). 
Recent studies suggest a neuroprotective function of the PGE2 EP2 receptor in excitotoxic 
neuronal injury. The function of the EP2 receptor was examined at time points after 
excitotoxicity in an organotypic hippocampal model of N-methyl-D-aspartate (NMDA) 
challenge and in a permanent model of focal forebrain ischemia. Activation of EP2 led to 
significant neuroprotection in hippocampal slices up to 3 hours after a toxic NMDA stimulus. 
Genetic deletion of EP2 resulted in a marked increase in the number of strokes in the 
permanent middle cerebral artery occlusion model. These findings support further 
investigation into therapeutic strategies targeting the EP2 receptor in strokes (Ann Neurol. 
2005 May;57(5):758-61). Neuroprotective function of the PGE2 EP2 receptor was observed 
in cerebral ischemia (J Neurosci. 2004 Jan 7;24(1):257-68). Cyclo-oxygenases (COXs) 
catalyze the first committed step in the synthesis of the prostaglandins PGE(2), PGD(2), 
PGF(2alpha), PGI(2) and thomboxane A(2). Expression and enzymatic activity of COX-2, 
the inducible isoform of COX, are observed in several neurological diseases and result in 
significant neuronal injury. The neurotoxic effect of COX-2 is believed to occur through 
downstream effects of its prostaglandin products. In this study, the function of PGD(2) and 
its two receptors DP1 and chemoattractant receptor-homologous molecule expressed on 
Th2 cells (CRTH2) (DP2) was examined in neuronal survival. PGD(2) is the most abundant 
prostaglandin in the brain and regulates sleep, temperature and nociception. It signals 
through two distinct G protein-coupled receptors, DP1 and DP2 that have opposite effects 
on cyclic AMP (cAMP) production. Physiological concentrations of PGD(2) potently and 
unexpectedly rescued neurons in paradigms of glutamate toxicity in cultured hippocampal 
neurons and organotypic slices (J Neurochem. 2005 Feb;92(3):477-86). 
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Synonym: THSD7A thrombospondin, type I, domain containing 7A. Membrane; single-pass 
type I membrane protein.   
  Supplementary Information 
- S61 - 
 
 
P
R
P
H
 
pe
rip
he
rin
 
ch
r1
2q
12
-q
13
 
This gene encodes a cytoskeletal protein found in neurons of the peripheral nervous 
system. The encoded protein is a type III intermediate filament protein with homology to 
other cytoskeletal proteins such as desmin, and is a different protein that the peripherin 
found in photoreceptors. Mutations in this gene have been associated with susceptibility to 
amyotrophic lateral sclerosis. Peripherin overexpression in transgenic mice can cause 
defective transport of type IV neurofilament proteins, a phenomenon that may account for 
the progressive formation of amyotrophic lateral sclerosis-like spheroids in axons (J 
Neurochem. 2006 Aug;98(3):926-38).  
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This gene encodes an integral outer mitochondrial membrane protein that blocks the 
apoptotic death of some cells such as lymphocytes. It suppresses apoptosis in a variety of 
cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates 
cell death by controlling the mitochondrial membrane permeability. Appears to function in a 
feedback loop system with caspases. Inhibits caspase activity either by preventing the 
release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating 
factor (apaf-1). Forms homodimers, and heterodimers with bax, bad, bak and bcl-x(l). 
Heterodimerization with bax requires intact bh1 and bh2 motifs, and is necessary for anti-
apoptotic activity. Phosphorylation/dephosphorylation on ser-70 regulates bcl2 anti-
apoptotic activity. Growth factor-stimulated phosphorylation on ser-70 by pkc is required for 
the anti-apoptosis activity and occurs during the g2/m phase of the cell cycle. In the 
absence of growth factors, bcl2 appears to be phosphorylated by other protein kinases such 
as ERKS and stress-activated kinases. Dephosphorylated by protein phosphatase 2a 
(pp2a). BCL2 is proteolytically cleaved by caspases during apoptosis. The cleaved protein, 
lacking the bh4 motif, has pro-apoptotic activity and causes the release of cytochrome c into 
the cytosol, promoting further caspase activity. Farlie et al. (1995) reported observations in 
transgenic mice expressing BCL2 under the control of the neuron-specific enolase 
promoter, suggesting that the role of BCL2 is wider than merely its role in lymphocytes. 
Sensory neurons isolated from dorsal ganglia of newborn mice normally require nerve 
growth factor for their survival in culture, but those from the BCL2 transgenic mice showed 
enhanced survival in its absence. Furthermore, apoptotic death of motor neurons after 
axotomy of the sciatic nerve was inhibited in these mice. The number of neurons in the 2 
neuronal populations from the central and peripheral nervous system was increased by 
30%, indicating that BCL2 expression can protect neurons from cell death during 
development. Thus, BCL2 may play an important role in survival of neurons both during 
development and throughout adult life. 
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This gene encodes a member of the highly conserved amyloid precursor protein gene 
family. The encoded protein is a membrane-associated glycoprotein that is cleaved by 
secretases in a manner similar to amyloid beta A4 precursor protein cleavage. This 
cleavage liberates an intracellular cytoplasmic fragment that may act as a transcriptional 
activator. The encoded protein may also play a role in synaptic maturation during cortical 
development. APLP1 may interact with cellular G-protein signaling pathways. It can 
regulate neurite outgrowth through binding to components of the extracellular matrix such 
as heparin and collagen I. See Discussion for further information. 
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This gene localizes to the immunoglobulin heavy chain locus (IGH@) on chromosome 14. 
The function of its protein product has not been determined. 
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TMOD1 binds to the n-terminus of isoforms 2/3 of tpm3 and to actin. Blocks the elongation 
and depolymerization of the actin filaments at the pointed end. The TMOD/TM complex 
contributes to the formation of the short actin protofilament, which in turn defines the 
geometry of the membrane skeleton. May play an important role in regulating the 
organization of actin filaments by preferentially binding to a specific tropomyosin isoform at 
its N-terminus. 
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This gene is a member of the guanine nucleotide-binding protein (G protein) gamma family 
and encodes a lipid-anchored, cell membrane protein. As a member of the heterotrimeric G 
protein complex, this protein plays a role in this transmembrane signaling system.  
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Similar to Collagen alpha-1(I) chain [Precursor] 
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Voltage-gated sodium channels are transmembrane glycoprotein complexes composed of a 
large alpha subunit and one or more regulatory beta subunits. They are responsible for the 
generation and propagation of action potentials in neurons and muscle. This gene encodes 
one member of the sodium channel beta subunit gene family, and influences the 
inactivation kinetics of the sodium channel. SCN3B association with neurofascin may target 
the sodium channels to the nodes of ranvier of developing axons and retain these channels 
at the nodes in mature myelinated axons. 
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ENC1 expression increased dramatically in a neuroblastoma cell line undergoing retinoic 
acid-induced differentiation. By differential display, Zhao et al. (2000) identified rat Enc1 as 
a transcript associated with differentiation of rat preadipocytes in primary culture. Kim et al. 
(1998) showed that expression of ENC1 induced neuronal process formation, whereas 
antisense treatment inhibited neurite development. Immunoblot analysis showed that ENC1 
is a nuclear matrix protein, can be phosphorylated and binds to the functionally active 
hypophosphorylated form of the nuclear matrix protein RB1 during neuronal differentiation. 
Using primary cell culture of rat stroma-vascular cells, Zhao et al. (2000) found that 
transient early expression of Enc1 preceded the conversion of the fibroblastic preadipocytes 
to mature adipose. Enc1 expression also preceded expression of adipocyte-specific 
markers, including transcription factors known to activate adipocyte genes. Antisense 
transfection blocked differentiation to the mature adipocyte morphology.  
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This gene encodes a membrane bound protein with several transient phosphorylation sites 
and PEST motifs. Conservation of proteins with PEST sequences among different species 
supports their functional significance. PEST sequences typically occur in proteins with high 
turnover rates. Immunological characteristics of this protein are species specific. This 
protein also undergoes N-terminal myristoylation. Intercellular signaling and nerve 
outgrowth are influenced by a number of proteins expressed at nerve endings and 
synapses. GAP43 (162060) is a determinant of neurite outgrowth and plasticity. The rat 22-
kD neuronal tissue-enriched acidic protein (Nap22, synonym:BASP1), like GAP43, binds 
calmodulin , is phosphorylated by protein kinase C, and is expressed specifically in nervous 
tissue. 
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P
LK
2 
po
lo
-li
ke
 
ki
na
se
 2
 
(D
ro
so
ph
i
la
) 
ch
r5
q1
2.
1
-q
13
.2
 
Previously described in Chapter 12.3 
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NR2F1 belongs to the nuclear hormone receptor family. Coup (chicken ovalbumin upstream 
promoter) transcription factor binds to the ovalbumin promoter and, in conjunction with 
another protein (TFIIB) stimulates initiation of transcription. Binds to both direct repeats and 
palindromes of the 5'-aggtca-3' motif. The transcription factor NR2F1, an orphan member of 
the nuclear receptor superfamily, is an important regulator of neurogenesis, cellular 
differentiation and cell migration. NR2F1 is required for proper axonal growth and guidance 
of all major forebrain commissures.  Moreover, hippocampal neurons lacking COUP-TFI 
have a defect in neurite outgrowth and show an abnormal axonal morphology. Armentano 
et al., Development (2006). Suppression of Notch signaling by the COUP-TFII transcription 
factor (NR2F2) regulates vein identity (Nature. 2005 May 5;435(7038):98-104). COUP-TFI 
(NR2F1) controls Notch regulation of hair cell and support cell differentiation. Notch 
regulation of hair cell differentiation in COUP-TFI(-/-) mice was investigated and 
misregulation of Notch signaling components was confirmed. Reduced Notch signaling 
correlated with increased hair cell differentiation. (Development. 2006 Sep;133(18):3683-
93). 
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DCAMKL1 belongs to the ser/thr protein kinase family, this kinase is probably involved in a 
calcium-signaling pathway controlling neuronal migration in the developing brain. 
DCAMKL1 is a microtubule-associated protein that phosphorylates itself and myelin basic 
protein (MBP). DCAMKL1 has microtubule polymerizing activity that is independent of its 
protein kinase activity (Lin et al., 2000). It may also participate in functions of the mature 
nervous system. DCAMKL1 contains 2 doublecortin and 1 protein kinase domains. Purified 
DCAMKL1 associates with microtubules and stimulates polymerization of purified tubulin 
and the formation of aster-like microtubule structures. Overexpressed DCAMKL1 leads to 
striking microtubule bundling in cell lines and cultured primary neural cells. (J Neurosci. 
2000 Dec 15;20(24):9152-61). 
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Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion (Nature. 1997 Aug 
7;388(6642):593-8). Binding to Rab3A-interacting molecule RIM regulates the presynaptic 
recruitment of Munc13-1 and ubMunc13-2. Transmitter release at synapses between nerve 
cells is spatially restricted to active zones, where synaptic vesicle docking, priming, and 
Ca2+-dependent fusion take place in a temporally highly coordinated manner. Munc13s are 
essential for priming synaptic vesicles to a fusion competent state, and their specific active 
zone localization contributes to the active zone restriction of transmitter release and the 
speed of excitation-secretion coupling. (J Biol Chem. 2006 Jul 14;281(28):19720-31. Epub 
2006 May 1). 
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 This gene belongs to the protocadherin gene family, a subfamily of the cadherin 
superfamily. The encoded protein contains six extracellular cadherin domains, a 
transmembrane domain, and a cytoplasmic tail differing from those of the classical 
cadherins. The encoded protein may play a role in the establishment and function of 
specific cell-cell connections in the brain. 
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Synonym: neurite growth-promoting factor 1, pleiotrophin (Ptn). Ptn is a heparin binding 
mitogenic protein. It has neurite extension activity. Heparin-binding neurite outgrowth-
promoting factor is a member of a highly conserved human gene family of proteins. It 
exhibits neurite outgrowth-promoting activity and may play a role in nervous tissue 
development and/or maintenance. Expression of this factor is developmentally regulated, 
increasing in the brain during embryogenesis and reaching its maximum expression at the 
time of birth. The gene codes for a 168-residue protein that is a precursor for a previously 
described brain-derived heparin-binding protein of 136 amino acids (Eddy et al., 1991). 
Using cDNA microarray analysis, Mi et al. (2007) found that Ptn mRNA was up-regulated in 
acutely denervated rat Schwann cells from sciatic nerve. High levels of Ptn mRNA peaked 
at day 7 but were not maintained, returning to baseline levels by 3 months. In a spinal cord 
explant system, Ptn caused increased outgrowth of spinal motor axons and protected spinal 
motor neurons against chronic excitotoxic injury. In neonatal mice, Ptn protected facial 
motor neurons against cell death induced by deprivation of growth factors. In adult rats, Ptn 
enhanced regeneration of myelinated axons across a graft in transected sciatic nerve. 
Further studies suggested that Alk may mediate trophic activities of Ptn. The findings 
indicated that Ptn has a neurotrophic role in peripheral nerves. Pleiotrophin is a 
neurotrophic factor for spinal motor neurons (Proc Natl Acad Sci U S A. 2007 Mar 
13;104(11):4664-9). 
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Secretogranin II belongs to a class of secretory proteins contained in large dense core 
vesicles of many endocrine cells and neurons (Kirchmair et al., 1993). A 33-amino acid 
neuropeptide derived from secretogranin II, termed secretoneurin, is involved in chemotaxis 
of monocytes and endothelial cells and in regulation of endothelial cell proliferation 
(Dunzendorfer et al., 1998). Kirchmair et al. (2004) found that secretoneurin had potent 
angiogenic activity in vivo in a mouse cornea model of neovascularization. Treatment of 
human umbilical vein endothelial cells (HUVECs) with secretoneurin inhibited apoptosis, 
stimulated proliferation. Stimulation of HUVECs with secretoneurin led to activation of ERK  
and, to a lesser extent, AKT, and inhibition of these pathways abrogated the effects of 
secretoneurin. Studies in rodents suggest that the full length protein, secretogranin II, is 
involved in the packaging or sorting of peptide hormones and neuropeptides into secretory 
vesicles. Secretogranin-2 is a neuroendocrine secretory granule protein, which is the 
precursor for biologically active peptides. 
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Transient transfection of a fusion construct of full-length mouse Eml4 with green fluorescent 
protein (GFP-Eml4) into Cos7 and HeLa cells resulted in colocalization of GFP-Eml4 with 
microtubules. This colocalization was observed both with microtubules of non-dividing cells 
and with the mitotic spindle of dividing cells. In addition, transient overexpression of GFP-
Eml4 in Cos7 cells resulted in microtubules that were resistant to nocodazole treatment 
suggesting that Eml4 stabilizes microtubules (Houtman SH, Rutteman M, De Zeeuw CI, 
French PJ). Eml4 belongs to the wd repeat emap family. 
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Synonym: IA-2beta.The protein encoded by this gene is a member of the protein tyrosine 
phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a 
variety of cellular processes including cell growth, differentiation, mitotic cycle, and 
oncogenic transformation. This PTP possesses an extracellular region, a single 
transmembrane region, and a single intracellular catalytic domain, and thus represents a 
receptor-type PTP. The catalytic domain of this PTP is most closely related to PTPRN/IA-
2beta. This PTP and PTPRN are both found to be major autoantigens associated with 
insulin-dependent diabetes mellitus. Three alternatively spliced transcript variants of this 
gene, which encode distinct proteins, have been reported. Targeted disruption of the IA-
2beta gene causes glucose intolerance and impairs insulin secretion but does not prevent 
the development of diabetes in NOD mice. Diabetes. 2004 Jul;53(7):1684-91. Protein 
tyrosine phosphatases (PTP) catalyze the dephosphorylation of phosphotyrosine peptides; 
they regulate phosphotyrosine levels in signal transduction pathways. 
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Synaptic vesicles store neurotransmitters that are released during calcium-regulated 
exocytosis. The specificity of neurotransmitter release requires the localization of both 
synaptic vesicles and calcium channels to the presynaptic active zone. Syntaxins function in 
this vesicle fusion process. Syntaxins also serve as a substrate for botulinum neurotoxin 
type C, a metalloprotease that blocks exocytosis and has high affinity for a molecular 
complex that includes the alpha-latrotoxin receptor  which produces explosive exocytosis 
(Zhang et al., 1995). Bennett et al. (1992) identified two 35-kD proteins (p35 or syntaxins) 
that interact with synaptic vesicle protein p65 (synaptotagmin; 185605). The p35 proteins 
are expressed only in the nervous system. The 2 proteins are 84% identical, include C-
terminal membrane anchors, and are concentrated on the plasma membrane at synaptic 
sites. The authors speculated that the p35 proteins may function in docking synaptic 
vesicles near calcium channels at presynaptic active zones. The priming step of synaptic 
vesicle exocytosis is thought to require the formation of the SNARE complex, which 
comprises the proteins synaptobrevin, SNAP25, and syntaxin. In solution, syntaxin adopts a 
default, closed configuration that is incompatible with formation of the SNARE complex. 
Specifically, the amino terminus of syntaxin binds the SNARE motif and occludes 
interactions with the other SNARE proteins. The N terminus of syntaxin also binds the 
presynaptic protein UNC13 (605836). Studies in mouse, Drosophila, and Caenorhabditis 
elegans suggest that UNC13 functions at a post-docking step of exocytosis, most likely 
during synaptic vesicle priming. Therefore, UNC13 binding to the N terminus of syntaxin 
may promote the open configuration of syntaxin. To test this model, Richmond et al. (2001) 
engineered mutations into C. elegans syntaxin that caused the protein to adopt the open 
configuration constitutively. Richmond et al. (2001) demonstrated that the open form of 
syntaxin can bypass the requirement for UNC13 in synaptic vesicle priming. Thus, 
Richmond et al. (2001) concluded that it is likely that UNC13 primes synaptic vesicles for 
fusion by promoting the open configuration of syntaxin. Neuronal exocytosis is triggered by 
calcium and requires 3 SNARE proteins: synaptobrevin on the synaptic vesicle, and 
syntaxin and SNAP25 on the plasma membrane. 
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Neuronal SNARE proteins form a parallel 4-helix bundle that is thought to drive the fusion of 
opposing membranes. Hu et al. (2002) demonstrated that whereas syntaxin and SNAP25 in 
target membranes are freely available for SNARE complex formation, availability of 
synaptobrevin on synaptic vesicles is very limited. Calcium at micromolar concentrations 
triggers SNARE complex formation and fusion between synaptic vesicles and reconstituted 
target membranes. Although calcium does promote interaction of SNARE proteins between 
opposing membranes, it does not act by releasing synaptobrevin from synaptic vesicle 
restriction. Hu et al. (2002) concluded that their data suggests a mechanism in which 
calcium-triggered membrane apposition enables syntaxin and SNAP25 to engage 
synaptobrevin, leading to membrane fusion. SNARE proteins normally face the cytoplasm, 
within which their helical domains can pair to link membranes for fusion. To ascertain 
whether SNAREs can fuse cells, Hu et al. (2003) flipped their orientation and engineered 
cognate cells to express either the v or t-SNAREs. Hu et al. (2003) found that cells 
expressing the interacting domains of v (VAMP2) and t-SNAREs (syntaxin 1A and SNAP25) 
on the cell surface fused spontaneously, demonstrating that SNAREs are sufficient to fuse 
biological membranes. Tucker et al. (2004) investigated the effect of synaptotagmin I 
(SYT1) on membrane fusion mediated by neuronal SNARE proteins SNAP25, syntaxin, and 
synaptobrevin, which were reconstituted into vesicles. In the presence of calcium, the 
cytoplasmic domain of SYT1 strongly stimulated membrane fusion when synaptobrevin 
densities were similar to those found in native synaptic vesicles. The calcium dependence 
of SYT1-stimulated fusion was modulated by changes in lipid composition of the vesicles 
and by a truncation that mimics cleavage of SNAP25 by botulinum neurotoxin A. 
Stimulation of fusion was abolished by disrupting the calcium-binding activity, or by severing 
the tandem C2 domains, of SYT1. Thus, SYT1 and SNAREs are likely to represent the 
minimal protein complement for calcium-triggered exocytosis. Syntaxin-1A plays a central 
role in neurotransmitter release through multiple protein-protein interactions. To investigate 
the 3-dimensional structure Fernandez et al. (1998) used nuclear magnetic resonance 
spectroscopy and identified an autonomously folded N-terminal domain in syntaxin-1A. This 
120-residue N-terminal domain is conserved in plasma membrane syntaxins but not in other 
syntaxins, indicating a specific role in exocytosis. The domain contains 3 long alpha helices 
that form an up-and-down bundle with a left-handed twist. A striking residue conservation is 
observed throughout a long groove that is likely to provide a specific surface for protein-
protein interactions. A highly acidic region binds to the C(2)A domain of synaptotagmin-1 in 
a Ca2+-dependent interaction that may serve as an electrostatic switch in neurotransmitter 
release. The dopamine transporter (DAT) regulates the extent and duration of dopamine 
receptor activation through sodium-dependant reuptake of dopamine into presynaptic 
neurons, resulting in termination of dopaminergic neurotransmission. Using the yeast two-
hybrid system, new interactions between DAT, the SNARE protein syntaxin 1A, and the 
receptor for activated C kinases (RACK1) have been identified (Neurochem Res. 2004 
Jul;29(7):1405-9). Association between schizophrenia and the syntaxin 1A gene has been 
shown (Biol Psychiatry. 2004 Jul 1;56(1):24-9). 
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Synonym: Bone morphogenetic protein, placental TGF-beta. Bone morphogenetic proteins 
are members of the transforming growth factor-beta superfamily and regulate tissue 
differentiation and maintenance. They are synthesized as precursor molecules that are 
processed at a dibasic cleavage site to release C-terminal domains containing a 
characteristic motif of 7 conserved cysteines in the mature protein. GDF15 is a secreted 
homodimeric protein that is disulfide-linked. GDF15 is not expressed in undifferentiated 
cells but is progressively up-regulated upon differentiation with retinoic acid followed by 
phorbol ester or cytokine treatment. Exposure of macrophages to MIC1 or TGFB1, followed 
by stimulation with lipopolysaccharide, suppressed the production of TNFA 
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2 Potential single-pass type I membrane protein, may play a role in Notch signaling. It has 
27% similarity with SEL-1 homolog precursor (Mus musculus). It contains one fibronectin 
type-II domain. SEL-1 functions as a negative regulator of the LIN-12/GLP-1 Notch-like 
signaling pathway in C. elegans. 
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Previously described in Chapter 12.3 
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Glutamate decarboxylase (GAD; L-glutamate-1-carboxylyase; EC 4.1.1.15) catalyzes the 
conversion of glutamic acid to gamma-aminobutyric acid (GABA), the major inhibitory 
neurotransmitter in the vertebral central nervous system. This gene encodes one of several 
forms of glutamic acid decarboxylase, identified as a major autoantigen in insulin-
dependent diabetes. The enzyme encoded is responsible for catalyzing the production of 
gamma-aminobutyric acid from L-glutamic acid. A pathogenic role for this enzyme has been 
identified in the human pancreas since it has been identified as an autoantigen and an 
autoreactive T cell target in insulin-dependent diabetes. This gene may also play a role in 
the stiff man syndrome. Deficiency in this enzyme has been shown to lead to pyridoxine 
dependency with seizures. Alternative splicing of this gene results in two products, the 
predominant 67-kD form and a less-frequent 25-kD form. Autoantibodies to insulin and GAD 
are features of preclinical type 1 diabetes in children. For insulin autoantibodies, the 
antibody affinity and epitope specificity predict which children progress to diabetes 
(Diabetes. 2007 Jun; 56(6):1527-33). Its phosphorylation by protein kinase C correlates with 
long-term potentiation.  
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The protein encoded by this gene has been termed a 'growth' or 'plasticity' protein because 
it is expressed at high levels in neuronal growth cones during development and axonal 
regeneration. This encoded protein is considered a crucial component of an effective 
regenerative response in the nervous system. GAP43 binds calmodulin with a greater 
affinity in the absence of ca(2+) than in its presence. Phosphorylation of this protein by 
protein kinase c is specifically correlated with certain forms of synaptic plasticity. 
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Previously described in Chapter 12.3 
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Synonym: von Willebrand factor type A and cache domain containing 1, calcium channel 
protein which plays an important role in excitation-contraction coupling. The L-type calcium 
channel is supposed to be composed of several subunits. Alpha-2 and delta subunits form 
heterodimers that are disulfide-linked. Alpha-2 and delta subunits are supposed to be 
proteolytically processed from a precursor form . 
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BOC is a cell surface receptor of the immunoglobulin (Ig)/fibronectin type III repeat family 
involved in myogenic differentiation.  
R
A
M
2 
tra
ns
cr
ip
tio
n 
fa
ct
or
 R
A
M
2 
Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and 
produces reactive oxygen that may cause neuronal cell death. The transcription factor R1 
(RAM2/CDCA7L/JPO2) inhibits the MAO A promoter and enzymatic activities. Using R1 
overexpression, R1 small interfering RNA, and a MAO A inhibitor, it was found that R1 and 
MAO A act upstream of cyclin D1 and E2F1. In summary, this study demonstrated the 
functions of MAO A and its repressor R1 in apoptotic signaling pathways (Proc Natl Acad Sci 
U S A. 2006 Jul 18;103(29):10923-8). 
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Contactins mediate cell surface interactions during nervous system development. CNTN3 is 
assumed to have neurite outgrowth-promoting activity. CNTN3 contains 4 fibronectin type-iii 
domains. It contains 6 ig-like c2-type (immunoglobulin-like) domains. 
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0 A gene in close vicinity to LOC440450 (chr. 17q23) is for instance: APPBP2 (amyloid beta 
precursor protein binding protein 2) on chr. 17q21-q23.  
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 This gene encodes a member of a subclass of the HSP40/DnaJ protein family. Members of 
this family of proteins are associated with complex assembly, protein folding, and export. 
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NDUFB9 transfers electrons from NADH to the respiratory chain. The immediate electron 
acceptor for the enzyme is believed to be ubiquinone, mitochondrion; mitochondrial inner 
membrane; matrix side. NADH + ubiquinone = NAD+ + ubiquinol. 
  Supplementary Information 
- S67 - 
 
 
LO
C
14
39
03
 
la
yi
lin
 
Layilin, a novel integral membrane protein, is a hyaluronan receptor. Layilin's ability to bind 
hyaluronan, a ubiquitous extracellular matrix component, reveals an interesting parallel 
between layilin and CD44, because both can bind to cytoskeleton-membrane linker proteins 
through their cytoplasmic domains and to hyaluronan through their extracellular domains. This 
parallelism suggests a role for layilin in cell adhesion and motility (Bono P, Rubin K, Higgins 
JM, Hynes RO, Mol. Biol. Cell (2001)).  
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 This gene is a member of the Abd-B homeobox family and encodes a protein with a 
homeobox DNA-binding domain. It is included in a cluster of homeobox D genes located on 
chromosome 2. The encoded nuclear protein functions as a sequence-specific transcription 
factor that is expressed in the developing limb buds and is involved in differentiation and limb 
development. Mutations in this gene have been associated with Wilm's tumor and congenital 
vertical talus (also known as "rocker-bottom foot" deformity or congenital convex pes valgus) 
and/or a foot deformity resembling that seen in Charcot-Marie-Tooth disease. 
D
K
FZ
p7
61
D
22
1 
H
yp
ot
he
tic
a
l p
ro
te
in
 
D
K
FZ
p7
61
D
22
1 
Synonym: SH3-domain GRB2-like (endophilin) interacting protein 1, belongs to the family of 
fibril-associated collagens with interrupted helices. Has 28% similarity to Collagen alpha-1(XII) 
chain. type xii collagen interacts with type I collagen- containing fibrils 
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Previously described in Chapter 12.3 
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 Unknown function,  hypothetical protein MGC33530 (V-set and transmembrane domain 
containing 2), 23% similarity to T-cell receptor alpha chain, protein coding. 
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The GALNT13 protein is a member of the UDP-N-acetyl-alpha-D-galactosamine-polypeptide 
N-acetylgalactosaminyltransferase (GalNAcT; EC 2.4.1.41) family, which initiates O-linked 
glycosylation of mucins by the initial transfer of N-acetylgalactosamine (GalNAc) with an 
alpha-linkage to a serine or threonine residue, localized in the golgi apparatus. 
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Previously described in Chapter 12.3 
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MASK is a protein kinase, potential mediator of cell growth and is pro-apoptotic, localized in 
the cytoplasm and golgi apparatus. Interaction with golgi matrix protein golga2 leading to 
autophosphorylation on thr-178, possibly as a consequence of stabilization of dimer formation. 
May also be activated by C- terminal cleavage.  
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Previously described in Chapter 12.3 
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 The protein encoded by this gene is a type III transmembrane adaptor protein that binds to the 
tyrosine kinase csk protein. It is thought to be involved in the regulation of T cell activation. 
Negatively regulates TCR (T-cell antigen receptor)- mediated signaling in T-cells and FCER1 
(high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Promotes 
CSK activation and recruitment to lipid rafts, which results in LCK inhibition. Inhibits 
immunological synapse formation by preventing dynamic arrangement of lipid raft proteins. 
May be involved in cell adhesion signaling. Subunit interacts with FYN. Phosphorylated by 
FYN on Tyr-317 in resting T-cells; which promotes interaction with CSK. Dephosphorylated by 
PTPRC/CD45 upon TCR activation; which leads to CSK dissociation. May also be 
dephosphorylated by PTPN11. Hyperphosphorylated in mast cells upon FCER1 activation. 
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) This gene encodes a C3H-type zinc finger protein, which is similar to the Drosophila 
melanogaster muscleblind B protein. Drosophila muscleblind is a gene required for 
photoreceptor differentiation. MBNL proteins regulate alternative splicing of two pre-mRNAs 
that are misregulated in myotonic dystrophy, cardiac troponin T (cTNT) and insulin receptor 
(IR). 
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t Strong similarity to Insulin-like growth factor-binding protein complex acid labile chain precursor, may have an important role in regulating the access of circulating insulin growth 
factors to the tissues. KIAA0644 is assumed to form a ternary complex of about 140 to 150 
kDa with IGF2 or IGFBP-3. 
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Previously described in Chapter 12.3 
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PDZK1, a multi-PDZ domain containing adaptor protein, interacts with various membrane 
proteins, including the high density lipoprotein (HDL) receptor scavenger receptor class B type 
I (SR-BI). Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of 
the high density lipoprotein receptor scavenger receptor class B type I, and an altered 
lipoprotein metabolism (J Biol Chem. 2003 Dec 26;278(52):52820-5). The scavenger receptor 
class B type I (SRBI or CD36L1), mediates the selective uptake of cholesteryl esters from high 
density lipoprotein and cholesterol secretion into bile in the liver. By coexpressing SRBI with 
PDZK1 in Chinese hamster ovary cells, Ikemoto et al. (2000) observed an increase in the 
expression level of SRBI, a reduction in the deacylation rate of the cholesteryl esters taken up 
from HDL, and a change in the intracellular distribution of a fluorescent lipid taken up from 
HDL. Taken together, these data suggested that PDZK1 is associated with SRBI in the liver 
sinusoidal plasma membranes and may modulate intracellular transport and metabolism of 
cholesteryl esters taken up from HDL. 
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In vitro studies have shown that PBX1 regulates the activity of IPF1 (insulin promoter factor 1, 
IPF1; IPF1 is a para-Hox homeodomain transcription factor required for the development and 
function of the pancreas in mice and humans). To investigate in vivo roles of PBX1 in 
pancreatic development and function, Kim et al. (2002) examined pancreatic Pbx1 expression, 
and morphogenesis, cell differentiation, and function in mice deficient for Pbx1. Pbx1 -/- 
embryos had pancreatic hypoplasia and marked defects in exocrine and endocrine cell 
differentiation prior to death at embryonic day 15 or 16. In these embryos, expression of Isl1 
and Atoh5, essential regulators of pancreatic morphogenesis and differentiation, was severely 
reduced. Pbx1 +/- adults had pancreatic islet malformations, impaired glucose tolerance, and 
hypoinsulinemia. Thus, Kim et al. (2002) concluded that PBX1 is essential for normal 
pancreatic development and function. Analysis of trans-heterozygous Pbx1 +/- and Ipf1 +/- 
mice revealed in vivo genetic interactions between Pbx1 and Ipf1 that are essential for 
postnatal pancreatic function. Trans-heterozygous mice developed age-dependent overt 
diabetes mellitus, unlike Pbx1 +/- or Ipf1 +/- mice. Mutations affecting the Ipf1 protein promote 
diabetes mellitus in mice and humans. Kim et al. (2002) concluded that perturbation of PBX1 
activity may also promote susceptibility to diabetes mellitus. Retinoic acid regulates the 
expression of PBX1, PBX2, and PBX3 in P19 cells both transcriptionally and post-
translationally (J Cell Biochem. 2004 May 1;92(1):147-63). 
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OSAP is a hypothetical conserved protein with strong similarity to cell death 8 (apoptosis-
inducing factor). 
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Dermatopontin is an extracellular (secreted) matrix protein with possible functions in cell-
matrix interactions and matrix assembly. The protein is found in various tissues and many of 
its tyrosine residues are sulphated. Dermatopontin is postulated to modify the behavior of 
TGF-beta through interaction with decorin. Seems to mediate adhesion by cell surface integrin 
binding, DPT may serve as a communication link between the dermal fibroblast cell surface 
and its extracellular matrix environment. Dermatopontin, a recently found low-molecular-mass 
component of the extracellular matrix, was studied for its interaction with decorin and 
transforming growth factor beta (TGF-beta) and its influence on TGF-beta bioactivity. 
Dermatopontin reacted with decorin with an apparent Kd of 100 nM in a solid-phase assay. 
Dermatopontin inhibited the formation of the decorin-TGF-beta1 complex. Decorin also 
competed with dermatopontin for the binding of this cytokine. The dermatopontin-decorin 
complex bound 3 times more TGF-beta1 than each individual component did, and binding was 
more strongly inhibited by decorin pre-incubated with dermatopontin than by dermatopontin or 
decorin alone. Dermatopontin augmented the biological activity of TGF-beta1, as analysed by 
the expression of luciferase in mink lung epithelial cells transfected with a plasminogen 
activator inhibitor-promoter-luciferase construct, although dermatopontin itself did not show 
apparent induction of luciferase. Dermatopontin showed weak inhibitory activity on the 
proliferation of mink lung epithelial cells, and it enhanced the growth-inhibitory activity of TGF-
beta on these cells. Thus dermatopontin increases the cellular response to TGF-beta. These 
findings strongly suggest that dermatopontin modifies the behaviour of TGF-beta through 
interaction with decorin in the microenvironment of the extracellular matrix in vivo 
(Dermatopontin interacts with transforming growth factor beta and enhances its biological 
activity." Biochem J, 1999). 
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Synonyms: Proliferation-inducing protein 38, ecto-NOX disulfide-thiol exchanger 1, candidate 
growth-related and time keeping constitutive hydroquinone (NADH) oxidase with a strong 
similarity to tumor-associated hydroquinone oxidase,  hydroquinone [NADH] oxidase and 
protein disulfide-thiol oxidoreductase isoform 2. The cytochrome bc complexes found in 
mitochondria, chloroplasts and many bacteria play critical roles in their respective electron 
transport chains. The quinol oxidase (Q(o)) site in this complex oxidizes a hydroquinone 
(quinol), reducing two one-electron carriers, a low potential cytochrome b heme and the 
"Rieske" iron-sulfur cluster. The overall electron transfer reactions are coupled to 
transmembrane translocation of protons via a "Q-cycle" mechanism, which generates proton 
motive force for ATP synthesis. Since semiquinone intermediates of quinol oxidation are 
generally highly reactive, one of the key questions in this field is how does the Q (o) site 
oxidize quinol without the production of harmful side reactions including superoxide 
production? Similar transition states mediate the Q-cycle and superoxide production by the 
cytochrome bc1 complex (J Biol Chem. 2006 Dec 15;281(50):38459-65). 
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Previously described in Chapter 12.3 
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This gene is a member of the synapsin gene family. Synapsins encode neuronal 
phosphoproteins which associate with the cytoplasmic surface of synaptic vesicles. Family 
members are characterized by common protein domains, and they are implicated in 
synaptogenesis and the modulation of neurotransmitter release, suggesting a potential role in 
several neuropsychiatric diseases. The synapsins are a family of 4 synaptic vesicle-
associated proteins, synapsins Ia, Ib, IIa, and IIb that have been implicated in modulation of 
neurotransmitter release and in synaptogenesis (Greengard et al., 1993). They are products 
from alternative splicing of 2 distinct genes, SYN1 and SYN2. SYN2 encodes a neuron-
specific phosphoprotein that selectively binds to small synaptic vesicles in the presynaptic 
nerve terminal. The TIMP4 gene is located within an intron of this gene and is transcribed in 
the opposite direction. Mutations in this gene may be associated with abnormal presynaptic 
function and schizophrenia. Alternative splicing of this gene results in two transcripts. SYN2 is 
a neuronal phosphoprotein that coats synaptic vesicles, binds to the cytoskeleton, and is 
believed to function in the regulation of neurotransmitter release. By use of microarray 
expression profiling of prefrontal cortex from matched pairs of patients with schizophrenia and 
control subjects and hierarchical data analysis, Mirnics et al. (2000) found that levels of 
transcripts encoding proteins involved in the regulation of presynaptic function were 
decreased in all subjects with schizophrenia. Genes of presynaptic function showed different 
combinations of decreased expressions across subjects. Over 250 other gene groups did not 
show altered expression. Selected presynaptic function gene microarray observations were 
verified by in situ hybridization. Two of the most consistently changed transcripts in the 
presynaptic functional gene group, N-ethylmaleimide-sensitive factor and synapsin-2, were 
decreased in 10 out of 10 and 9 out of 10 subjects with schizophrenia respectively. The 
combined data suggested that subjects with schizophrenia share a common abnormality in 
presynaptic function. Predicted Functional Partners:TIMP2, 3 and 4.  Using a cDNA 
microarray representing 6794 distinct human genes, candidate genes whose expression is 
altered in cerebral cortex of cases of early Alzheimer's disease (AD) were identified; among 
these was the synaptic vesicle protein synapsin II, which plays an important role in 
neurotransmitter release. A selective decrease in the expression of the synapsin splice 
variants I-III of the a-type isoform in the entorhinal but not in the visual cortex of cases 
characterized by the earliest clinically detectable stage of AD was found. In contrast, no 
changes in synapsin splice variant II of the b-type isoform was found. Alteration of synapsin 
expression at the earliest clinical stage of AD may suggest new strategies for improved 
treatment (Ho et al., Neurosci. Lett. (2001). 
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The jagged 1 protein encoded by JAG1 is the human homolog of the Drosophilia jagged 
protein. Human jagged 1 is the ligand for the receptor Notch 1, the latter a human homolog of 
the Drosophilia jagged receptor Notch. Mutations that alter the jagged 1 protein cause Alagille 
syndrome. Jagged 1 signaling through Notch 1 has also been shown to play a role in 
hematopoiesis. Jagged-1 is a ligand of the Notch receptor and its binding triggers a cascade 
of proteolytic cleavage that eventually leads to the release of the intracellular part of the 
receptor from the membrane, allowing it to translocate to the nucleus and activate 
transcription factors that play key roles in cell differentiation and morphogenesis (Guarnaccia 
et al., 2004). Loomes et al. (2002) found that JAG1 is expressed in cells adjacent to those 
expressing Notch2, suggesting a possible ligand receptor interaction. Guarnaccia et al. (2004) 
stated that JAG1 is a type I, membrane- anchored, multidomain protein. The extracellular part 
is made of a DSL domain, followed by a series of 16 EGF-like repeats, and a von Willebrand 
factor type C domain. Li et al. (2006) found that Jag1 activated Notch signaling in rats and 
enhanced the differentiation of mesenchymal stem cells into cardiomyocytes. Wild-type JAG1 
is inhibitory for HGF expression and mutant JAG1s relieve the inhibition. AG1 controls HGF 
expression by a dosage-dependent regulation and Notch2 signaling seems to mediate JAG1 
function. Given that HGF plays a critical role in differentiation of hepatic stem cells, 
overexpression of HGF acts on off-balanced cell fate determination in AGS (Alagille 
syndrome) patients. Downregulation of Jagged-1 induces cell growth inhibition and S phase 
arrest in prostate cancer cells (Int J Cancer. 2006 Nov 1;119(9):2071-7). Downregulation of 
Notch-1, Delta-like-1, or Jagged-1 by RNA interference induces apoptosis and inhibits 
proliferation in multiple glioma cell lines (Cancer Res. 2005 Mar 15;65(6):2353-63). The 
soluble form of Jagged1 when present in the cell culture medium, was sufficient to induce 
keratinocyte differentiation (J Cell Biochem. 2004 Aug 15;92(6):1271-81). Jagged1-selective 
Notch signaling induces smooth muscle differentiation via a RBP-Jkappa-dependent pathway 
(J Biol Chem. 2006 Sep 29;281(39):28555-64). Overexpression of the Notch ligand Jagged-1 
induces alloantigen-specific human regulatory T cells  (Blood. 2003 Nov 15;102(10):3815-21). 
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by 
human B lymphocytes (J Virol. 2003 Oct;77(20):10872-80).The Notch ligands jagged and 
delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and 
release signaling fragments (J Biol Chem. 2003 Sep 5;278(36):34427-37.). The Notch ligand 
Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells (J Immunol. 
2002 Oct 15;169(8):4273-8). Jagged-1 mediated activation of Notch signaling induces 
complete maturation of human keratinocytes through NF-kappaB and PPARgamma (Cell 
Death Differ. 2002 Aug;9(8):842-55). Jagged1 was expressed at high levels by hypertrophic 
astrocytes. Experiments in vitro showed that Jagged1 signaling inhibited process outgrowth 
from primary human oligodendrocytes (Nat Med. 2002 Oct;8(10):1075-6). 
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12.3.4 Annotations for clustered genes 
 
C99WT1, C99I45F, C99V50F: 
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This gene encodes a member of a family of neuronal cell surface proteins. Members of this family 
may act as splice site-specific ligands for beta-neurexins and may be involved in the formation and 
remodeling of central nervous system synapses. The encoded protein interacts with discs, large 
(Drosophila) homolog 4 (DLG4). Mutations in this gene have been associated with autism and 
Asperger’s syndrome. Two transcript variants encoding the same protein have been identified for this 
gene. 
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Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian 
brain and are activated in a variety of normal neurophysiologic processes. This gene product belongs 
to a family of glutamate receptors that are sensitive to alpha-amino-3-hydroxy-5-methyl-4-isoxazole 
propionate (AMPA), and function as ligand-activated cation channels. These channels are 
assembled from 4 related subunits, GRIA1-4. The subunit encoded by this gene (GRIA2) is subject 
to RNA editing (CAG->CGG; Q->R) within the second transmembrane domain, which is thought to 
render the channel impermeable to Ca2+. Human and animal studies suggest that pre-mRNA editing 
is essential for brain function, and defective GRIA2 RNA editing at the Q/R site may be relevant to 
amyotrophic lateral sclerosis (ALS) etiology. Alternative splicing has been noted for this gene 
resulting in transcript variants encoding different isoforms, including the generation of flip and flop 
isoforms that vary in their signal transduction properties. 
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Neuro-p24/Neurensin-1, a protein containing a microtubule-associated domain at the carboxyl-
terminus and exclusively localized to small vesicles of neurons. Neurensin-1 was found mainly in 
neuritic processes. 
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The bone morphogenetic proteins (BMPs) are a family of secreted signaling molecules that can 
induce ectopic bone growth. Many BMPs are part of the transforming growth factor-beta (TGFB) 
superfamily. BMPs were originally identified by the ability of demineralized bone extract to induce 
endochondral osteogenesis in vivo in an extraskeletal site. Based on its expression early in 
embryogenesis, the BMP encoded by this gene has a proposed role in early development.  
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Uncharacterized gene, 37% similarity to ADAMTS-1 precursor (Rattus norvegicus): ADAMTS-1 
precursor cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. Flj13710 
is expected to have angiogenic inhibitor activity. Active metalloprotease, which may be associated 
with various inflammatory processes. 
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Previously described in Chapter 12.3 
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Protein coding, unknown function. 
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The inhibitory glycine receptor mediates postsynaptic inhibition in the spinal cord and other regions of 
the central nervous system. It is a pentameric receptor composed of alpha (GLRA1, GLRA2) and 
beta subunits. 
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This gene encodes a member of the trypsin family of serine proteases. A 4-base pair deletion in the 
neuronal serine protease neurotrypsin gene was associated with autosomal recessive nonsyndromic 
mental retardation (MR). In situ hybridization experiments on human fetal brains showed that 
neurotrypsin was highly expressed in brain structures involved in learning and memory. Immuno-
electron microscopy on adult human brain sections revealed that neurotrypsin is located in 
presynaptic nerve endings, particularly over the presynaptic membrane lining the synaptic cleft. 
These findings suggest that neurotrypsin-mediated proteolysis is required for normal synaptic 
function and suggest potential association with mental retardation. 
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ANKRD11 is a  9kb gene encoding nuclear-located protein with ankyrin domains. May recruit histone 
deacetylases to the p160 coactivators/nuclear receptor complex to inhibit ligand-dependent 
transactivation. 
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Cytochrome b561 is a major transmembrane protein that is specific to catecholamine and 
neuropeptide secretory vesicles of the adrenal medulla, pituitary gland, and other neuroendocrine 
tissues. This 30-kD cytochrome is present in both the small synaptic vesicles and the large dense 
core vesicles (chromaffin granules) of the tissues. Its role is to supply reducing equivalents to 2 
monooxygenases, dopamine beta-hydroxylase in chromaffin granules and peptidylglycine 
monooxygenase in neurosecretory vesicles. The cytochrome fulfillls this role by catalyzing the 
transfer of electrons from a cytoplasmic donor, ascorbate, across a phospholipid bilayer to the 
luminal acceptor, semidehydroascorbate, in the interior of the vesicles. The continuously regenerated 
ascorbate within these vesicles is the immediate donor for the monooxygenases within the 
neuroendocrine secretory vesicles. Thus, cytochrome b561 is a transmembrane electron channel. 
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In vertebrates, the genes encoding the class of transcription factors called homeobox genes are 
found in clusters named A, B, C, and D on four separate chromosomes. Expression of these proteins 
is spatially and temporally regulated during embryonic development. This gene is part of the A cluster 
on chromosome 7 and encodes a DNA-binding transcription factor which may regulate gene 
expression, morphogenesis, and differentiation. For example, the encoded protein represses the 
transcription of differentiation-specific genes during keratinocyte proliferation, but this repression is 
then overcome by differentiation signals. This gene is very similar to the antennapedia (Antp) gene of 
Drosophila. 
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Cytochrome b is comprised of a light chain (alpha) and a heavy chain (beta). This gene encodes the 
light, alpha subunit which has been proposed as a primary component of the microbicidal oxidase 
system of phagocytes. Mutations in this gene are associated with autosomal recessive chronic 
granulomatous disease (CGD) that is characterized by the failure of activated phagocytes to 
generate superoxide, important for the microbicidal activity of these cells. 
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Refer to 217200_x_at, same transcript detected by a different probe set. 
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The conserved septin protein family was first identified in yeast and subsequently shown to 
play an important role in cytoskeletal organization and cytokinesis. This gene is a member 
of the septin family of GTPases. Members of this family are required for cytokinesis. This 
gene encodes four transcript variants encoding three distinct isoforms. An additional 
transcript variant has been identified, but its biological validity has not been determined. 
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This gene is a member of the lipoma HMGIC fusion partner (LHFP) gene family, which is a 
subset of the superfamily of tetraspan transmembrane protein encoding genes. Mutations in 
one LHFP-like gene result in deafness in humans and mice, and a second LHFP-like gene 
is fused to a high-mobility group gene in a translocation-associated lipoma. Alternatively 
spliced transcript variants have been found, but their biological validity has not been 
determined. 
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Involved in the initial immune cell clustering during inflammatory response and may regulate 
chemotactic activity of chemokines. Low-affinity receptor for agouti, has a critical role in 
normal myelination in the central nervous system. 
ca
lb
1 
ca
lb
in
di
n 
1 
8q
21
.3
-q
22
.1
 Calbindin is a calcium-binding protein belonging to the troponin C superfamily. It was 
originally described as a 27-kD protein induced by vitamin D in the duodenum of the chick. 
In the brain, its synthesis is independent of vitamin-D-derived hormones. Calbindin contains 
4 active calcium-binding domains, and 2 modified domains that presumably have lost their 
calcium-binding capacity. The neurons in brains of patients with Huntington’s disease are 
calbindin-depleted. 
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The scaffold protein encoded by this gene is a member of the tumor necrosis factor 
receptor-associated factor (TRAF) protein family and contains a meprin and TRAF 
homology (MATH) domain, a RING-type zinc finger, and two TRAF-type zinc fingers. TRAF 
proteins are associated with, and mediate signal transduction from, members of the TNF 
receptor superfamily. This protein is one of the components of a multiple protein complex 
which binds to tumor necrosis factor (TNF) receptor cytoplasmic domains and mediates 
TNF-induced activation. Alternate transcriptional splice variants have been characterized. 
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 CYR61 is a secreted, cysteine-rich, heparin-binding protein encoded by a growth factor-
inducible immediate-early gene. Acting as an extracellular, matrix-associated signaling 
molecule, CYR61 promotes the adhesion of endothelial cells through interaction with 
integrin and augments growth factor-induced DNA synthesis in the same cell type. 
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Previously described in Chapter 12.3 
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BOC is a cell surface receptor of the immunoglobulin (Ig)/fibronectin type III  repeat family 
involved in myogenic differentiation.  
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This gene is a member of the Abd-B homeobox family and encodes a protein with a 
homeobox DNA-binding domain. It is included in a cluster of homeobox D genes located on 
chromosome 2. The encoded nuclear protein functions as a sequence-specific transcription 
factor that is expressed in the developing limb buds and is involved in differentiation and 
limb development. Mutations in this gene have been associated with Wilm's tumor and 
congenital vertical talus (also known as "rocker-bottom foot" deformity or congenital convex 
pes valgus) and/or a foot deformity resembling that seen in Charcot-Marie-Tooth disease. 
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The intermediate chains seem to help dynein bind to dynactin 150 kDa component. May 
play a role in mediating the interaction of cytoplasmic dynein with membranous organelles 
and kinetochores. There is experimental evidence of an association between dnci1 and 
internexin neuronal intermediate filament protein, alpha (INA).  
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Conserved hypothetical protein. This amino acid sequence is of soluble protein. 
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Previously described in Chapter 12.3 
po
pd
c3
 
po
pe
ye
 
do
m
ai
n 
co
nt
ai
ni
ng
 3
 
6q
21
 This gene encodes a member of the POP family of proteins containing three putative 
transmembrane domains. This gene is expressed in cardiac and skeletal muscles and may 
play an important role in these tissues during development. 
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Previously described in Chapter 12.3 
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Cux-1 and Cux-2 represent early markers of neuronal differentiation; both genes are 
expressed in postmitotic cortical neurons, from embryonic stages to adulthood and in the 
proliferative regions of the developing cortex. Cux-2 mRNA expression is also found in the 
embryonic SVZ (subventricular zone), overlapping with BrdU-positive dividing precursors, 
but it is not expressed in the VZ (ventricular zone). Cux2 is an ortholog of the Drosophila cut 
gene, which encodes a homeodomain protein involved in neuronal specification. During 
cortical development Cux2 identifies two subpopulations with different spatial origins, 
migratory behaviours and phenotypic characteristics: 1. A population of interneurons, which 
invades the pallium from the subpallium; 2. A neuronal population produced in the pallium 
around embryonic day 11.5  (in mice), which divides in the SVZ and accumulates in the 
intermediate zone (IZ). Subsequently, Cux2 is a marker of upper cortical layers. Using 
different molecular markers and Pax6-deficient mice,  data were provided suggesting 
relationship between the early-determined Cux2-positive neuronal precursors in the SVZ/IZ 
and upper layer neurons. This suggests that laminar determination of upper cortical layer 
neurons occurs during the earliest stages of corticogenesis. 
tle
2 
tra
ns
du
ci
n-
lik
e 
en
ha
nc
er
 o
f s
pl
it 
2 
(E
(s
p1
) h
om
ol
og
, D
ro
so
ph
ila
) 
19
p1
3.
3 
The Notch signaling pathway controls cellular interactions important for the specification of 
a variety of fates in both invertebrates and vertebrates. The TLE genes are human 
homologs of the Drosophila 'groucho' gene and their products belong to this pathway. 
Analysis of mutant alleles of members of the Notch cascade showed that Notch signaling 
extends the differentiation-competent state of developmentally immature precursor cells, 
thereby preventing or delaying their differentiation until the correct morphogenetic signals 
become available (reviewed by Artavanis-Tsakonas et al., 1995). A number of pathologies 
resulting from incomplete cellular differentiation due to this general inhibitory action during 
cell determination were shown to be the result of alterations in Notch signaling, including 
both lymphoblastic and epithelial neoplasms. Liu et al. (1996) studied the expression of 
individual TLE genes during epithelial differentiation. By a combination of in situ 
hybridization and immunohistochemical studies, they showed that TLE1, TLE2 and TLE3 
are coexpressed in a number of tissues. Moreover, they showed that the expression is 
elevated in cervical squamous metaplasias and carcinomas. 
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Uncharacterized gene, belongs to the AB hydrolase superfamily 
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Synonyms: membrane sialoglycoprotein of the Golgi apparatus, cysteine-rich fibroblast 
growth factor receptor, unknown function.  
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Phosphatidylcholine (PC) transfer protein (PCTP) is a cytosolic protein first purified from 
bovine and rat liver that catalyzes intermembrane transfer of PC. In mammalian cells, these 
insoluble molecules are transferred between membranes by a highly specific 
phosphatidylcholine transfer protein (PC-TP) belonging to the steroidogenic acute 
regulatory protein related transfer (START) domain superfamily of hydrophobic ligand-
binding proteins. 
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The transcription co-repressor TLE1 interacts with the intracellular region of gpl30 through 
its Q domain. The transcription factor Groucho/TLE1 (TLE1) is expressed in virtually all 
major cortical subdivisions, hippocampus, amygdala, and thalamus, as well as in the 
cerebellum of the adult rat brain. In both neocortex and subcortical structures, TLE1 
expression was mostly localized to neurons. Transcriptional corepressors of the Groucho 
(Gro)/TLE family play important roles during a variety of developmental pathways, including 
neuronal differentiation. In particular, they act as negative regulators of neurogenesis, 
together with Hairy/Enhancer of split (Hes) DNA-binding proteins. The interaction with Hes1 
leads to Gro/TLE hyperphosphorylation and increased transcription repression activity in 
mammalian cells, but the underlying molecular mechanisms are poorly characterized. 
Gro/TLE1 is phosphorylated in vivo by protein kinase CK2. This phosphorylation occurs at 
serine 239 within the conserved CcN domain present in all Gro/TLE family members. 
Mutation of serine 239 into alanine decreases Hes1-induced hyperphosphorylation of 
Gro/TLE1 and also reduces its nuclear association and transcription repression activity. It 
was further demonstrated that Gro/TLE1 inhibits the transition of cortical neural progenitors 
into neurons and that its antineurogenic activity is inhibited by a serine-239-alanine 
mutation, but not by a serine-239-glutamate mutation. These results suggest that CK2 
phosphorylation of serine 239 of Gro/TLE1 is important because of its function during 
neuronal differentiation. 
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12.4 Mathematical background 
12.4.1 Preface 
Microarray analysis provides the possibility of measuring several thousands of 
transcripts in parallel. Analyzing such a large number of transcripts simultaneously 
provides information about the interplay between genes. Processing such an amount 
of data is accompanied by difficulties in its interpretation. There are features which 
have to be considered in the context of the whole experiment to obtain reliable 
results, such as: Quality control of Chips and target-RNA, normalisation algorithms, 
suitable statistical methods and filtering of data. Here, the most important 
background information is presented. For detailed information refer to the “Statistical 
Algorithms Description Document” at www.affymetrix.com. 
12.4.2 Background calculation 
Background and noise are distinct phenomena which are calculated separately by 
the Gene Chip software. The background calculation is a measurement of the 
intensity of the autofluorescence of the array surface and of the non-specific binding 
of target or stain molecules (streptavidin-phycoerythrin). The calculation is performed 
as follows: 
The array is divided into sectors (16 by default) 
The software ranks probe cells by fluorescence intensity, identifies the lowest  
2% (by default) for each sector and calculates their average (=sector’s background) 
The sector’s background is subtracted from the average intensities of all probe cells 
within that sector. This subtraction here is described simplified.  
12.4.3 Noise calculation 
Noise (Q) results from small variations in the digitized signal observed by the scanner 
as it scans the probe array’s surface. The level of noise is calculated and then used 
as one of the parameters in determining the significance of differences in probe set 
intensities across two probe arrays. Noise is the extent of pixel to pixel variation of 
the signal intensities. It is calculated using the standard deviations of pixel intensities 
of the background probe cells. The noise is scaled or normalized along with the rest 
of the data according to the following equation: 
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Q= noise for a given probe array 
N= total number of background cells for an array 
stdevi= standard deviation of the intensities of the pixels making up  
 background cell i 
pixeli= total number of pixels in cell i 
SF=  scaling factor 
NF=  normalization factor 
 
Noise Q is not used anywhere in the statistical algorithm. However, since it is based 
on pixels it provides a useful quality measure of how well the grid was placed on the 
array to calculate the CEL file. All other calculations are derived from the CEL files. 
Hence, if errors occur at this step (which can be recognized by increased noise or an 
increased scale factor), this error can systematically influence the entire following 
data analysis (systematic bias leads to systematic error). 
12.4.4 Match/Mismatch system™ of Affymetrix 
A specific feature of Affymetrix microarrays are the so-called MisMatch (MM) 
probes14. Each of the 16-20 probe pairs (ten of those are shown in Figure 12.1) in a 
probe set has a Perfect Match (PM) and a MisMatch probe. One probe set is 
designed to detect one kind of transcript. Its probe pairs are distributed randomly 
over the microarray (although in Figure 12.1 they are shown adjacent to each other), 
however, PM and MM are located next to each other on the microarray. The PM 
probes are designed to bind perfectly to the transcript of interest and the MM probes 
have a mismatching base at position 13 (of a 25 oligomer, not shown in Figure 12.1) 
with the intention of measuring non-specific binding [480]. 
 
                                            
14 Information is mainly based on www.Affymetrix.com and modified. 
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Figure. 12.1  Match/Mismatch System (Affymetrix). A complete probe set is designed to detect one 
kind of transcript and consists of 16-20 probe pairs (here a probe set of 10 probe pairs is shown). A 
probe cell is a square-shaped feature with a unique sequence. Its size ranges from 18-50 µm per side, 
depending on the array type. Each of the probe pairs has a Perfect Match (PM) and a MisMatch (MM) 
probe. The probes are 25-mer oligocucleotides. MM probes have a mismatching base at position 13 
with the intention of measuring non-specific binding. (Figure taken from www.affymetrix.com).  
12.4.5 Normalisation algorithms 
12.4.5.1 Absolute analysis algorithms 
Signal algorithm 
Signal is a quantitative metric calculated for each probe set, which represents the 
relative level of expression of a transcript. Signal is calculated using the One-Step 
Tukey’s Biweight Estimate which yields a robust weighted mean that is relatively 
insensitive to outliers. The MisMatch intensity is used to estimate stray signal. The 
real signal is estimated by taking the log of the Perfect Match intensity after 
subtracting the stray signal estimate. 
The Signal value is calculated from the combined, background-adjusted PM and MM 
values of the probe set. It represents the amount of transcript in solution. 
 
Signal is calculated as follows: 
1. Cell intensities are pre-processed for global background. 
2. An ideal MisMatch value is calculated and subtracted to adjust the PM intensity. 
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3. The adjusted PM intensities are log-transformed to stabilize the variance. 
4. The biweight estimator is used to provide a robust mean of the resulting values. 
Signal is output as the antilog of the resulting value. 
5. Finally, signal is scaled using a trimmed mean. 
 
Detection algorithm 
The detection algorithm assesses probe pair saturation, uses probe pair intensities to 
generate a detection p-value15 and assign a Present, Marginal, or Absent call. Each 
probe pair in a probe set is considered as having a potential vote in determining 
whether the measured transcript is detected (Present) or not detected (Absent). The 
vote is described by a value called the discrimination score [R]. The discrimination 
score is a basic property of a probe pair that describes its ability to detect its intended 
target. It measures the target-specific intensity difference of the probe pair (PM-MM) 
relative to its overall hybridization intensity (PM+MM): R = (PM - MM) / (PM + MM). 
For example, if the PM is much larger than the MM, the discrimination score for that 
probe pair will be close to 1.0. If the discrimination scores are close to 1.0 for the 
majority of the probe pairs, the calculated detection p-value will be lower (more 
significant). A lower p-value is a reliable indicator that the result is valid and that the 
probability of error in the calculation is small. Conversely, if the MM is larger than or 
equal to the PM, then the discrimination score for that probe pair will be negative or 
zero. If the discrimination scores are low for the majority of the probe pairs, the 
calculated detection p-value will be higher (less significant).  
 
Detection calls: 
1. Saturated probe pairs are removed. 
2. Discrimination scores are calculated (this gives information about how different 
the PM and MM cells are). 
3. The Wilcoxon’s rank test is used to calculate a detection p-value (this gives 
information about how confident one can be that a transcript is really 
absent/present). 
4. The detection p-value is compared with a preset significance level to make the 
decision. 
                                            
15 The detection p-value must not be mixed up with the statistical p-value which is calculated at later steps. 
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If a MisMatch cell is saturated, the corresponding probe pair is excluded from further 
data analysis.  
12.4.5.2 Relative analysis algorithms 
Previously mentioned in the Introduction, Chapter 3.6. 
12.4.6 Derivation of the 2-∆∆ CT Method  
Relative quantification with data from the ABI PRISM® 5700 Sequence Detection 
System was performed with the comparative method (the MethodTCΔΔ−2 ). 
This method is a convenient way of analyzing the relative changes in gene 
expression from real-time quantitative PCR experiments. For the ∆∆CT calculation to 
be valid, the amplification efficiencies of the target and reference must be 
approximately equal. A sensitive method for assessing if two amplicons have the 
same efficiency is to look at how ∆CT varies with the template dilution. Therefore, 
standard curves were established for calculating the efficiency of amplification. 
The equation that describes the exponential amplification of PCR is given by 
 
       [1] 
   
where nX  is the number of target molecules at cycle n of the reaction, oX is the initial 
number of target molecules. EX is the efficiency of target amplification, and n is the 
number of cycles. The threshold cycle (CT) indicates the fractional cycle number at 
which the amount of amplified target reaches a fixed threshold. 
Thus, 
X
C
XOT KEXX XT =+×= ,)1(      [ ]2  
 
where XT is the threshold number of target molecules, CT,X  is the threshold cycle for 
target amplification, and Kx is a constant. 
 
A similar equation for endogenous reference (internal control gene) reaction is given 
by 
,)1( nXon EXX +×=
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   [ ]3  
 
where RT is the threshold number of reference molecules, RO is the initial number of 
reference molecules, ER is the efficiency of reference amplification, CT,R is the 
threshold cycle for reference amplification, and KR is a constant.  
Dividing XT by RT gives the expression 
 
     [ ]4  
 
For real-time amplification using TaqMan probes, the exact values of XT and RT 
depend on a number of factors including the reporter dye used in the probe, the 
sequence context effects on the fluorescence properties of the probe cleavage, purity 
of the probe, and setting of the fluorescence threshold. 
Therefore, the constant K does not have to be equal to one. 
Assuming efficiencies of the target and the reference are the same, 
EX = ER = E 
 
 [ ]5  
or 
 
    [ ]6  
 
Where XN is equal to the normalized amount of target ( )RTXT CC ,, − . 
Rearranging gives the expression 
( ) .1 TCN EKX Δ−+×=         [ ]7  
The final step is to divide the XN for any sample q by the XN for the calibrator (cb): 
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Here ( ).,, cbTqTT CCC Δ−Δ−=ΔΔ−  
For amplicons designed to be less than 150 bp and for which the primer and Mg2+ 
concentrations have been properly optimized, the efficiency is close to one. 
Therefore, the amount of target, normalized to an endogenous reference and relative 
to calibrator, is given by 
Amount of target = .2 TCΔΔ−        [ ]9  
For the ∆∆CT calculation to be valid, the amplification efficiencies of the target and 
reference must be approximately equal. 
A sensitive method for assessing if two amplicons have the same efficiency is to look 
at how ∆CT varies with the template dilution. 
 
Standard deviation calculation using the comparative method 
 
The ∆CT value is determined by subtracting the average of the endogenous control 
gene CT values from the average of the gene of interest CT values. 
The standard deviation of the difference is calculated from the standard deviations of 
the gene of interest and endogenous control gene values using the following formula: 
 
 
Where: 
σ = std dev 
 
The fold change of gene expression is calculated as follows: 
The ∆CT value is determined by subtracting the average of the endogenous control 
gene CT value from the average of the gene of interest CT value. The same is done 
for a so-called calibrator (this is for instance a user-defined baseline experiment) 
( ) 
( ) ( ) [ ]8  1 1 
1 
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∆CT1 = CT gene of interest - CT endogenous control (calibrator=baseline experiment,  
         for instance wildtype) 
∆CT2= CT gene of interest - CT endogenous control (for instance mutant) 
 
 The fold change (fc) of gene expression is: 
 
fc=2
-(∆CT2 -∆CT1) 
 
This is the amount of target, normalized to an endogenous reference and relative to a 
calibrator (baseline experiment). 
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12.5 Quality control 
12.5.1 Quality control of cells, target-RNA and arrays 
Each sample was screened and found to be free from mycoplasma contamination. 
The 260 nm/280 nm ratio for total-RNA was between 1.9-2.1 for Chip experiments 
and 1.8-2.1 for quantitative real-time PCR. Total-RNA and unfragmented cRNA was 
checked with a Bioanalyzer 2100™. For total-RNA, two distinct bands (28s and 18s 
ribosomal RNA) were detected with the 28 s band approximately twice as strong as 
the 18 s band. For unfragmented cRNA a distribution of bands representing the 
different m-RNAs, was detected with an accumulation in the centre of each lane. For 
fragmented cRNA, bands corresponding to a size of 35-200 bases were detected. 
After scanning, array images were assessed by eye to confirm the absence of 
bubbles or scratches. The mean of all Chips are shown, the highest and lowest value 
is indicated in brackets. Target intensities of 100 (HG-U133 A Chip) and 20 (HG-
U133 B Chip) were used. Only Chips with equal target intensities were compared to 
each other (using Affymetrix MAS 5.0 array analysis software and Gene Chip 
operating software GCOS). Scaling factors for A-Chips were within acceptable limits 
0,91 (0.8-1.4), as were background 75,1(60.7-97.7), noise (rawQ) 2,7 (2.4-3.3) and 
number of present transcripts 51% (47,4-52.9%). 3'/5' ratios for GAPDH and β-actin 
were confirmed to be within acceptable limits (GAPDH: 0.92 (0,79-1.81), β-actin: 1.26 
(1.03-2.29), and BioB spike controls were found to be present on 100% of all the 
Chips, with BioC, BioD and CreX also present in increasing intensity. Scaling factors 
for all B-Chips were within acceptable limits 1.24 (0.9-1.6), as were background 
63.87 (43.9-112), noise (raw Q) 2.6 (2.0-3.6) and number of present transcripts (30% 
(14.3-38,4%). 3'/5' ratios for GAPDH and β-actin were confirmed to be within 
acceptable limits (GAPDH: 1.1 (0.88-2.03), β-actin: 1.3 (0.92-2.95), and BioB spike 
controls were found to be present on 95% of all the Chips, with BioC, BioD and CreX 
also present in increasing intensity.  
12.5.2 Quality control of RNA by a test Chip prior to the whole 
genome Chip 
Prior to using the whole genome array, a test array had been used, in order to check 
sample quality. Parameters like scaling factors, background, noise, number of 
present transcripts, 3'/5' ratios for GAPDH and beta-actin and detection of Bio spike 
controls were evaluated. If these parameters were in a suitable range, the same 
sample was used for whole genome arrays. 
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12.5.3 RNA-quality assessed using the Agilent 2100 Bioanalyzer  
 
A 
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B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.2 Total-RNA (A) and unfragmented cRNA (B) were checked with a Bioanalyzer 2100™ 
(Agilent). The Bioanalyzer generates an artificial gel and electropherograms, providing information 
about RNA quality. A) For total-RNA, two distinct bands (28s and 18s ribosomal RNA) were detected 
with the 28 s band approximately twice as strong as the 18 s band. The two distinct bands appear 
slightly shifted from lane to lane due to an unfixed Bioanalyzer or software problem but this does not 
affect the quality of information. B) For unfragmented cRNA a distribution of bands representing the 
different mRNAs, was detected with an accumulation in the center of each lane. Notice the wide range 
of size distribution in each lane showing unfragmented cRNA and the characteristic curves of the 
electropherograms. Only samples satisfying the highest quality standards (a selection of such samples 
is shown here) were used for analysis.  
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12.6  Extended view of connectivities 
 
 
Figure 12.3 Extended view of interconnectivities created with Pathway Architect (Stratagene). 
Pathway Architect is a literature mining program used to build biological interaction networks among 
genes/proteins of interest. It accesses over 2 million biological facts from the current literature. 
IGF2/IGF1R/PKC and PI3K/AKT signaling were influenced by an altered Aβ42/Aβ40ratio. Crucial 
differentially expressed genes (transcripts and partially proteins, if protein information was available) 
were selected and integrated into the Pathway Architect software. By a complex filtering procedure 
this pathway was created, in which all transcripts (except for DDC) were found to be connected in a 
network. Nodes (transcripts and/or proteins, orange-coloured) are connected via interconnectivities 
(lines). These lines represent direct interactions, regulatory processes or other kinds of associations 
that have been published.  
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12.7 CRABP1 knockdown, larger scale of Figure 5.9 D 
 
Figure 12.4 Phase contrast images showing living 
human neuroblastoma cells (SH-SY5Y, mutant C99I45F, 
Aβ42/Aβ40↑), grown on collagen coated glass cover slips 
and treated with 1 nM RA. Differentiation was evaluated by 
the number, shape and length of outgrowing protrusions. 30 
nM siRNA was administered to the cells for 24 h in 
combination with a treatment of 1 nM RA for 4 days. After 4 
days, the effects of >50% knockdown of CRABP1 was 
compared to a nonsense sequence (negative control).  
